FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Long, C Jones, TF Vugia, DJ Scheftel, J Strockbine, N Ryan, P Shiferaw, B Tauxe, RV Gould, LH AF Long, Cherie Jones, Timothy F. Vugia, Duc J. Scheftel, Joni Strockbine, Nancy Ryan, Patricia Shiferaw, Beletshachew Tauxe, Robert V. Gould, L. Hannah TI Yersinia pseudotuberculosis and Y. enterocolitica Infections, FoodNet, 1996-2007 SO EMERGING INFECTIOUS DISEASES LA English DT Letter ID PASTEURELLA-PSEUDOTUBERCULOSIS; OUTBREAK C1 [Strockbine, Nancy; Tauxe, Robert V.; Gould, L. Hannah] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Long, Cherie] Georgia Dept Human Resources, Atlanta, GA USA. [Long, Cherie] Atlanta Res & Educ Fdn, Atlanta, GA USA. [Jones, Timothy F.] Tennessee Dept Hlth, Nashville, TN USA. [Vugia, Duc J.] Calif Dept Publ Hlth, Richmond, CA USA. [Scheftel, Joni] Minnesota Dept Hlth, St Paul, MN USA. [Ryan, Patricia] Maryland Dept Hlth & Mental Hyg, Baltimore, MD USA. [Shiferaw, Beletshachew] Oregon Dept Human Serv, Portland, OR USA. RP Gould, LH (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop F22, Atlanta, GA 30333 USA. EM lgould@cdc.gov NR 10 TC 24 Z9 25 U1 0 U2 7 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD MAR PY 2010 VL 16 IS 3 BP 566 EP 567 DI 10.3201/eid1603.091106 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 566WR UT WOS:000275404700040 PM 20202449 ER PT J AU Kelly, PJ Lucas, H Eremeeva, ME Dirks, KG Rolain, JM Yowell, C Thomas, R Douglas, T Dasch, GA Raoult, D AF Kelly, Patrick J. Lucas, Helene Eremeeva, Marina E. Dirks, Kathryn G. Rolain, Jean Marc Yowell, Charles Thomas, Reginald Douglas, Trevrone Dasch, Gregory A. Raoult, Didier TI Rickettsia felis, West Indies SO EMERGING INFECTIOUS DISEASES LA English DT Letter ID CATS; FLEAS; FEVER C1 [Kelly, Patrick J.; Lucas, Helene] Ross Univ, Sch Vet Med, W Farm, St Kitts & Nevi. [Eremeeva, Marina E.; Dirks, Kathryn G.; Dasch, Gregory A.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Rolain, Jean Marc; Raoult, Didier] Unite Rech Malad Infect & Trop Emergentes, Marseille, France. [Yowell, Charles] Univ Florida, Gainesville, FL USA. [Thomas, Reginald; Douglas, Trevrone] Div Agr, Roseau, Dominica. RP Kelly, PJ (reprint author), Ross Univ, Sch Vet Med, POB 334, W Farm, St Kitts & Nevi. EM pkelly@rossvet.edu.kn OI Dasch, Gregory/0000-0001-6090-1810 NR 10 TC 7 Z9 7 U1 1 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD MAR PY 2010 VL 16 IS 3 BP 570 EP 571 DI 10.3201/eid1603.091431 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 566WR UT WOS:000275404700043 PM 20202452 ER PT J AU Potter, P AF Potter, Polyxeni TI Untitled SO EMERGING INFECTIOUS DISEASES LA English DT Editorial Material C1 Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Potter, P (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop D61, Atlanta, GA 30333 USA. EM PMP1@cdc.gov NR 7 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD MAR PY 2010 VL 16 IS 3 BP 583 EP 584 DI 10.3201/eid1603.000000 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 566WR UT WOS:000275404700050 PM 20202459 ER PT J AU Eskenazi, B Warner, M Marks, AR Samuels, S Needham, L Brambilla, P Mocarelli, P AF Eskenazi, Brenda Warner, Marcella Marks, Amy R. Samuels, Steven Needham, Larry Brambilla, Paolo Mocarelli, Paolo TI Serum Dioxin Concentrations and Time to Pregnancy SO EPIDEMIOLOGY LA English DT Article ID 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN TCDD; POLYCHLORINATED-BIPHENYLS; LACTATIONAL EXPOSURE; REGIONAL DIFFERENCES; OVARIAN-FUNCTION; SEMEN QUALITY; WAITING TIME; FEMALE RATS; IN-UTERO; SEVESO AB Background: Pollution may play a role in population trends of declining semen quality and regional differences in time to pregnancy (TTP) in industrialized societies. Dioxins including 2,3,7,8-tetrachlorodibenzo-p-dioxin ( TCDD) have been suspected. In 1976, an explosion near Seveso, Italy resulted in the highest TCDD exposure known in residential populations. Twenty years later, we conducted a retrospective cohort study, the Seveso Women's Health Study. Methods: Of 981 participants, 472 women attempted pregnancy after the explosion, and 278 delivered a livebirth not associated with contraceptive failure. Individual serum TCDD levels were measured from samples collected soon after the explosion and extrapolated to the conception attempt. We examined the relation of TCDD levels to time to pregnancy (parameterized as the monthly probability of conception within the first 12 months of trying) and to infertility (defined as conception after at least 12 months of trying). We modeled fecundability with discrete-time Cox proportional hazards regression, and we modeled fertility with logistic regression. We tested the sensitivity of the conclusions to differing definitions of eligibility and outcome. Results: Median TCDD level was 50 parts per trillion, median time to pregnancy was 2 months, and 17% reported taking 12 or more months to conceive. For every 10-fold increase in serum TCDD, we observed a 25% increase in time to pregnancy (adjusted-fecundability odds ratio = 0.75 [95% confidence interval (CI) = 0.60-0.95]) and about a doubling in odds of infertility ( adjusted odds ratio = 1.9 [95% CI = 1.1-3.2]). Results were similar for extrapolated TCDD and sensitivity analyses. Conclusions: We found dose-related increases in TTP and infertility associated with individual serum TCDD levels in the women from Seveso, Italy. These findings may have implications for fertility in industrialized areas. C1 [Eskenazi, Brenda; Warner, Marcella; Marks, Amy R.] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA. [Samuels, Steven] SUNY Albany, Sch Publ Hlth, Dept Epidemiol, Albany, NY 12222 USA. [Needham, Larry] Ctr Dis Control & Prevent, Div Environm Hlth Lab Sci, Natl Ctr Environm Hlth, Atlanta, GA USA. [Brambilla, Paolo; Mocarelli, Paolo] Univ Milano Bicocca, Sch Med, Hosp Desio, Dept Lab Med, Desio, Italy. RP Eskenazi, B (reprint author), Univ Calif Berkeley, Sch Publ Hlth, 2150 Shattuck Ave,Suite 600, Berkeley, CA 94720 USA. EM eskenazi@berkeley.edu RI Needham, Larry/E-4930-2011; OI Marks, Amy/0000-0002-3047-5379 FU U.S. Environmental Protection Agency [R82471]; National Institutes of Health [R01 ES07171, F06 TW02075-01]; Endometriosis Association [EA-M1977]; National Institute of Environmental Health Sciences [2P30-ESO01896-17]; Regione Lombardia and Fondazione Lombardia Ambiente, Milan, Italy [2896] FX Supported by Grant Numbers R82471 from the U.S. Environmental Protection Agency, R01 ES07171 and F06 TW02075-01 from the National Institutes of Health, EA-M1977 from the Endometriosis Association, 2P30-ESO01896-17 from the National Institute of Environmental Health Sciences, and #2896 from Regione Lombardia and Fondazione Lombardia Ambiente, Milan, Italy. NR 41 TC 15 Z9 18 U1 2 U2 10 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1044-3983 J9 EPIDEMIOLOGY JI Epidemiology PD MAR PY 2010 VL 21 IS 2 BP 224 EP 231 DI 10.1097/EDE.0b013e3181cb8b95 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 567EM UT WOS:000275426000010 PM 20124903 ER PT J AU Waller, DK Gallaway, MS Taylor, LG Ramadhani, TA Canfield, MA Scheuerle, A Hernandez-Diaz, S Louik, C Correa, A AF Waller, Dorothy Kim Gallaway, Michael Shayne Taylor, Lockwood G. Ramadhani, Tunu A. Canfield, Mark A. Scheuerle, Angela Hernandez-Diaz, Sonia Louik, Carol Correa, Adolfo CA Natl Birth Defects Prevention Stud TI Use of Oral Contraceptives in Pregnancy and Major Structural Birth Defects in Offspring SO EPIDEMIOLOGY LA English DT Article ID LIMB REDUCTION DEFORMITIES; SEX-HORMONE EXPOSURE; CONGENITAL-MALFORMATIONS; ISOLATED HYPOSPADIAS; INTRAUTERINE-DEVICE; ETIOLOGIC FACTORS; RISK; ASSOCIATION; SPERMICIDES; GASTROSCHISIS AB Background: Oral contraceptives (OCs) are the most commonly used reversible contraceptive method among US women. Although the majority of previous studies have reported no association between OC use during pregnancy and birth defects, some studies have reported increased occurrence of neural tube defects, limb reduction defects, and urinary tract anomalies. Methods: We assessed OC use among mothers who participated in the multisite, case-control, National Birth Defects Prevention Study. Mothers of 9986 infants with 32 types of birth defects and 4000 infants without birth defects were included. Results: Maternal OC use during the first 3 months of pregnancy was associated with an increased odds ratio for 2 of 32 birth defects: hypoplastic left heart syndrome (adjusted odds ratio = 2.3 [95% confidence interval = 1.3-4.3) and gastroschisis (1.8 [1.3-2.7]). Conclusion: Previous reports of associations between OC use and specific types of anomalies were not corroborated. Given that associations were assessed for 32 types of birth defects, our findings of 2 increased associations between OC use and gastroschisis and hypoplastic left heart syndrome should be interpreted as hypotheses until they can be evaluated further. Overall, our findings are consistent with the majority of previous studies that found women who use OCs during early pregnancy have no increased risk for most types of major congenital malformations. C1 [Waller, Dorothy Kim; Gallaway, Michael Shayne; Taylor, Lockwood G.] Univ Texas Houston, Hlth Sci Ctr, Sch Publ Hlth, Houston, TX 77030 USA. [Ramadhani, Tunu A.; Canfield, Mark A.; Scheuerle, Angela] Texas Dept State Hlth Serv, Birth Defects Epidemiol & Surveillance Branch, Austin, TX USA. [Scheuerle, Angela] Tesserae Genet, Dallas, TX USA. [Hernandez-Diaz, Sonia; Louik, Carol] Boston Univ, Slone Epidemiol Ctr, Boston, MA 02215 USA. [Hernandez-Diaz, Sonia] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Correa, Adolfo] Ctr Dis Control & Prevent, Natl Birth Defects Ctr & Dev Disabil, Atlanta, GA USA. RP Waller, DK (reprint author), Univ Texas Houston, Hlth Sci Ctr, Sch Publ Hlth, 1200 Hermann Pressler Dr,Suite E-619, Houston, TX 77030 USA. EM Kim.Waller@uth.tmc.edu RI Publications, NBDPS/B-7692-2013; OI Louik, Carol/0000-0001-5429-5084 FU CDC [U50/CCU613232, PA 02081]; Centers of Birth Defects Research and Prevention FX Supported in part by the CDC-funded Texas Center for Birth Defects Research and Prevention by a Cooperative Agreement with the Centers for Disease Control and Prevention, Grant Number: U50/CCU613232, PA 02081, Centers of Birth Defects Research and Prevention. NR 41 TC 18 Z9 19 U1 1 U2 13 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1044-3983 J9 EPIDEMIOLOGY JI Epidemiology PD MAR PY 2010 VL 21 IS 2 BP 232 EP 239 DI 10.1097/EDE.0b013e3181c9fbb3 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 567EM UT WOS:000275426000011 PM 20087193 ER PT J AU Clarkson, LS Tobin-D'Angelo, M Shuler, C Hanna, S Benson, J Voetsch, AC AF Clarkson, L. S. Tobin-D'Angelo, M. Shuler, C. Hanna, S. Benson, J. Voetsch, A. C. TI Sporadic Salmonella enterica serotype Javiana infections in Georgia and Tennessee: a hypothesis-generating study SO EPIDEMIOLOGY AND INFECTION LA English DT Article DE Epidemiology; Salmonella; Salmonella enterica; salmonellosis; zoonoses ID UNITED-STATES; FOODNET SITES; RISK-FACTORS; OUTBREAK; CONSUMPTION; SURVIVAL; HEALTH; WATER AB From 1996 to 2004, the incidence of Salmonella Javiana infections increased in FoodNet, the U.S. national active foodborne disease surveillance programme. Contact with amphibians and consumption of tomatoes have been associated with outbreaks of S. Javiana infection. To generate and test hypotheses about risk factors associated with sporadic S. Javiana infections, we interviewed patients with laboratory-confirmed S. Javiana infection identified in Georgia and Tennessee during August-October 2004. We collected data on food and water consumption, animal contact, and environmental exposure from cases. Responses were compared with population-based Survey exposure data. Seventy-two of 117 identified S. Javiana case-patients were interviewed. Consumption of well water [adjusted odds ratio (aOR) 4.3, 95% confidence interval (Cl) 1.6-11.2] and reptile or amphibian contact (aOR 2.6, 95%, CI 0.9-7.1) were associated with infection. Consumption of tomatoes (aOR 0.5, 95% CI 0.3-0.9) and poultry (aOR 0.5, 95 % CI 0.2-1.0) were protective. Our study suggests that environmental factors are associated with S. Javiana infections in Georgia and Tennessee. C1 [Clarkson, L. S.] Georgia Div Publ Hlth, Epidemiol Branch, Atlanta, GA 30303 USA. [Hanna, S.] Tennessee State Hlth Dept, Nashville, TN USA. [Benson, J.] Georgia Publ Hlth Lab, Atlanta, GA USA. [Voetsch, A. C.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Clarkson, LS (reprint author), Georgia Div Publ Hlth, Epidemiol Branch, 2 Peachtree St NW, Atlanta, GA 30303 USA. EM lsclarkson@dhr.state.ga.us FU Foodborne Diseases Active Surveillance Network (FoodNet) at the Centers for Disease Control and Prevention FX The authors thank Dana Cole, DVM, Dipl. ACVIM, PhD. State Public Health Veterinarian, Georgia Division of Public Health for manuscript review and comments; Julie Schlegel, MSP, Foodborne Epidemiologist, South Carolina Department of Health and Environmental Control for Study and questionnaire design and implementation; and C. P. Kanwat, MBBS, MPH, Foodborne Epidemiologist, South Carolina Department of Health and Environmental Control for Study and questionnaire design and implementation. This work was funded by the Foodborne Diseases Active Surveillance Network (FoodNet) at the Centers for Disease Control and Prevention. NR 26 TC 11 Z9 11 U1 1 U2 4 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0950-2688 J9 EPIDEMIOL INFECT JI Epidemiol. Infect. PD MAR PY 2010 VL 138 IS 3 BP 340 EP 346 DI 10.1017/S0950268809990586 PG 7 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 560CD UT WOS:000274878500006 PM 19723360 ER PT J AU Li, Y Liao, YL Fan, A Zhang, XZ Balluz, L AF Li, Yan Liao, Youlian Fan, Amy Zhang, Xinzhi Balluz, Lina TI ASIAN AMERICAN/PACIFIC ISLANDER PARADOX IN DIABETIC RETINOPATHY: FINDINGS FROM THE BEHAVIORAL RISK FACTOR SURVEILLANCE SYSTEM, 2006-2008 SO ETHNICITY & DISEASE LA English DT Article DE Diabetic Retinopathy; Prevalence; Racial Difference; Diabetes Care ID SOUTH ASIANS; UNITED-STATES; PREVALENCE; POPULATION; EUROPEANS; UK; COMPLICATIONS; NEPHROPATHY; CAUCASIANS; COMMUNITY AB Objectives: To compare the self-reported prevalence of diabetic retinopathy (DR) between Asian Americans/Pacific Islanders (AAPIs) and Whites in the United States. Methods: We analyzed data from 70,209 adults aged >= 18 years with diabetes derived from the 2006-2008 Behavioral Risk Factor Surveillance System (BRFSS), including 1,499 AAPIs and 68,710 White individuals. Results: Compared with Whites with diabetes, AAPIs with diabetes had higher socioeconomic status, fewer risk factors leg, smoking) and coexisting chronic diseases leg, cardiovascular disease [CVD]). Diabetes duration and percentage of persons using insulin were similar between the 2 populations. However, AAPIs had a much higher prevalence of DR (27.6%) than Whites (18.2%) (P < .001). Comparing AAPIs to Whites, the age- and gender-adjusted odds ratio of DR was 1.97 (1.48-2.62). The adjusted odds ratio was 2.21 (1.63-3.00) after adjustment for sociodemographic (education and marital status), chronic conditions (CVD and smoking), severity of diabetes and diabetes care (age of diabetes onset, frequency of self-checking blood sugar, and frequency of dilated eye exam). Conclusions: Despite their favorable socio- and health-related profiles, AAPIs had significantly higher prevalence of DR compared with Whites. (Ethn Dis. 2010;20:111-117) C1 [Li, Yan; Liao, Youlian; Fan, Amy; Zhang, Xinzhi; Balluz, Lina] Ctr Dis Control & Prevent, Div Adults & Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Li, Y (reprint author), 4770 Buford Hwy NE,Mail Stop E-65, Atlanta, GA 30341 USA. EM yli6@cdv.gov NR 22 TC 4 Z9 6 U1 0 U2 1 PU INT SOC HYPERTENSION BLACKS-ISHIB PI ATLANTA PA 100 AUBURN AVE NE STE 401, ATLANTA, GA 30303-2527 USA SN 1049-510X J9 ETHNIC DIS JI Ethn. Dis. PD SPR PY 2010 VL 20 IS 2 BP 111 EP 117 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 598EJ UT WOS:000277815700005 PM 20503889 ER PT J AU Peralta, RH Espindola, NM Pardini, AX Iha, AH Moura, H Barr, JR Vaz, AJ Peralta, JM AF Peralta, Regina H. Espindola, Noeli M. Pardini, Alessandra X. Iha, Alberto H. Moura, Hercules Barr, John R. Vaz, Adelaide J. Peralta, Jose M. TI Taenia crassiceps cysticerci: Characterization of the 14-kDa glycoprotein with homologies to antigens from Taenia solium cysticerci SO EXPERIMENTAL PARASITOLOGY LA English DT Article DE Cysticercosis; Taenia solium; Taenia crassiceps; Glycoprotein antigen; Protein sequence ID CEREBROSPINAL-FLUID; MOLECULAR CHARACTERIZATION; INFECTED MICE; NEUROCYSTICERCOSIS; SERUM; IMMUNODIAGNOSIS; SERODIAGNOSIS; METACESTODES; SAMPLES; REACTIVITIES AB Glycoproteins from the total vesicular fluid of Taenia crassiceps (VF-Tc) were prepared using three different purification methods, consisting of ConA-lectin affinity chromatography (ConA-Tc), preparative electrophoresis (SDS-PAGE) (14gp-Tc), and monoclonal antibody immunoaffinity chromatography (18/14-Tc). The complex composition represented by the VF-Tc and ConA-Tc antigens revealed peptides ranging from 101 - to 14-kDa and from 92- to 12-kDa, respectively. Immunoblotting using lectins confirmed glucose/mannose (glc/man) residues in the 18- and 14-kDa peptides, which are considered specific and immunodominant for the diagnosis of cysticercosis, and indicated that these fractions are glycoproteins. Serum antibodies from a patient with neurocysticercosis that reacted to the 14gp band from T. crassiceps (Tc) were eluted from immunoblotting membranes and showed reactivity to 14gp from Taenia solium. In order to determine the similar peptide sequence, the N-terminal amino acid was determined and analyzed with sequences available in public databases. This sequence revealed partial homology between T. crassiceps and T solium peptides. In addition, mass spectrometry along with theoretical M-r and pI of the 14gp-Tc point suggested a close relationship to some peptides of a 150-kDa protein complex of the T solium previously described. The identification of these common immunogenic sites will contribute to future efforts to develop recombinant antigens and synthetic peptides for immunological assays. (C) 2009 Elsevier Inc. All rights reserved. C1 [Peralta, Jose M.] Univ Fed Rio de Janeiro, Inst Microbiol, Dept Imunol, BR-21941590 Rio De Janeiro, Brazil. [Peralta, Regina H.] Univ Fed Fluminense, Fac Med, Dept Patol, Rio De Janeiro, Brazil. [Espindola, Noeli M.; Pardini, Alessandra X.; Iha, Alberto H.; Vaz, Adelaide J.] Univ Sao Paulo, Fac Ciencias Farmaceut, Lab Imunol Clin, Sao Paulo, Brazil. [Moura, Hercules; Barr, John R.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. RP Peralta, JM (reprint author), Univ Fed Rio de Janeiro, Inst Microbiol, Dept Imunol, BR-21941590 Rio De Janeiro, Brazil. EM peralta@micro.ufrj.br FU FAPESP [02-12061-0]; FAPERJ; CNPq, Brazil; CNPq FX Research supported by FAPESP (Grant 02-12061-0), FAPERJ, and CNPq, Brazil. Alessandra Xavier Pardini had a fellowship from CNPq. NR 40 TC 6 Z9 8 U1 0 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0014-4894 EI 1090-2449 J9 EXP PARASITOL JI Exp. Parasitol. PD MAR PY 2010 VL 124 IS 3 BP 295 EP 300 DI 10.1016/j.exppara.2009.10.016 PG 6 WC Parasitology SC Parasitology GA 558CJ UT WOS:000274717600007 PM 19896939 ER PT J AU Berry, RJ Bailey, L Mulinare, J Bower, C AF Berry, Robert J. Bailey, Lynn Mulinare, Joe Bower, Carol CA Folic Acid Working Grp TI Fortification of flour with folic acid SO FOOD AND NUTRITION BULLETIN LA English DT Article; Proceedings Paper CT 2nd Technical Workshop on Wheat Flour Fortification CY MAR 30-APR 03, 2008 CL Atlanta, GA ID NEURAL-TUBE DEFECTS; PERICONCEPTIONAL VITAMIN SUPPLEMENTATION; TANDEM MASS-SPECTROMETRY; IN-VITRO FERTILIZATION; CEREAL-GRAIN PRODUCTS; FOOD FORTIFICATION; MICROBIOLOGICAL ASSAY; FOLATE CONCENTRATIONS; DIETARY-FOLATE; SERUM FOLATE AB Background: After randomized, controlled trials established that consumption of folic acid before pregnancy and during the early weeks of gestation reduces the risk of a neural tube defect (NTD)-affected pregnancy, the United States Public Health Service recommended in 1992 that all women capable of becoming pregnant consume 400 mu g folic acid daily. In 1998, folic acid fortification of all enriched cereal grain product flour was fully implemented in the United States and Canada. Objective. To provide guidance on national fortification of wheat and maize flours to prevent 50 to 70% of the estimated 300,000 NTD-affected pregnancies worldwide. Methods: An expert workgroup reviewed the latest evidence of effectiveness of folic acid flour fortification and the safety of folic acid. Results: Recent estimates show that in the United States and Canada, the additional intake of about 100 to 150 mu g/day of folic acid through food fortification has been effective in reducing the prevalence of NTDs at birth and increasing blood folate concentrations in both countries. Most potential adverse effects associated with folic acid are associated with extra supplement use not mandatory fortification Fortification of wheat flour has a proven record of prevention in other developed countries. In 2009, 51 countries had regulations written for mandatory wheat flour fortification programs that included folic acid Conclusions: NTDs remain an important cause of perinatal mortality and infantile paralysis worldwide. Mandatory fortification of flour with folic acid has proved to be one of the most successful public health interventions in reducing the prevalence of NTD-affected pregnancies Most developing countries have few, if any, common sources of folic acid, unlike many developed countries, which have folic acid available from ready-to-eat cereals and supplements. Expanding the number of developed and developing countries with folic acid flour fortification has tremendous potential to safely eliminate most folic acid-preventable NTDs. C1 [Berry, Robert J.; Mulinare, Joe] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Bailey, Lynn] Univ Florida, Gainesville, FL USA. [Bower, Carol] Univ Western Australia, Perth, WA 6009, Australia. RP Berry, RJ (reprint author), Ctr Dis Control & Prevent, Mail Stop E-86,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM RJBerry@cdc.gov NR 138 TC 57 Z9 59 U1 0 U2 27 PU INT NUTRITION FOUNDATION PI BOSTON PA 150 HARRISON AVE, BOSTON, MA 02111 USA SN 0379-5721 J9 FOOD NUTR BULL JI Food Nutr. Bull. PD MAR PY 2010 VL 31 IS 1 SU S BP S22 EP S35 PG 14 WC Food Science & Technology; Nutrition & Dietetics SC Food Science & Technology; Nutrition & Dietetics GA 588WH UT WOS:000277104800003 PM 20629350 ER PT J AU Serdula, M AF Serdula, Mary TI Maximizing the impact of flour fortification to improve vitamin and mineral nutrition in populations SO FOOD AND NUTRITION BULLETIN LA English DT Editorial Material ID FOLIC-ACID FORTIFICATION; CARDIOVASCULAR DEFECTS; CONTROLLED-TRIAL; UNITED-STATES; FOLATE; IRON; ZINC; WOMEN; AGE C1 Ctr Dis Control & Prevent, Int Micronutrient Malnutr Prevent & Control Progr, Div Nutr Phys Act & Obes, Atlanta, GA 30341 USA. RP Serdula, M (reprint author), Ctr Dis Control & Prevent, Int Micronutrient Malnutr Prevent & Control Progr, Div Nutr Phys Act & Obes, 4770 Buford Hwy NE,MS K-25, Atlanta, GA 30341 USA. NR 31 TC 10 Z9 10 U1 0 U2 0 PU INT NUTRITION FOUNDATION PI BOSTON PA 150 HARRISON AVE, BOSTON, MA 02111 USA SN 0379-5721 J9 FOOD NUTR BULL JI Food Nutr. Bull. PD MAR PY 2010 VL 31 IS 1 SU S BP S86 EP S93 PG 8 WC Food Science & Technology; Nutrition & Dietetics SC Food Science & Technology; Nutrition & Dietetics GA 588WH UT WOS:000277104800008 PM 20629355 ER PT J AU Serdula, M Pena-Rosas, JP Maberly, GF Parvanta, I AF Serdula, Mary Pena-Rosas, J. P. Maberly, Glen F. Parvanta, Ibrahim TI The opportunity of flour fortification: Building on the evidence to move forward SO FOOD AND NUTRITION BULLETIN LA English DT Editorial Material ID NEURAL-TUBE DEFECTS; FOLIC-ACID; DEFICIENCY; PREVENTION; VITAMIN; SUPPLEMENTATION C1 [Serdula, Mary] Ctr Dis Control & Prevent, Int Micronutrient Malnutr Prevent & Control Progr, Div Nutr Phys Act & Obes, Atlanta, GA 30341 USA. RP Serdula, M (reprint author), Ctr Dis Control & Prevent, Int Micronutrient Malnutr Prevent & Control Progr, Div Nutr Phys Act & Obes, 4770 Buford Hwy NE,MS K-25, Atlanta, GA 30341 USA. NR 22 TC 7 Z9 7 U1 0 U2 2 PU INT NUTRITION FOUNDATION PI BOSTON PA 150 HARRISON AVE, BOSTON, MA 02111 USA SN 0379-5721 J9 FOOD NUTR BULL JI Food Nutr. Bull. PD MAR PY 2010 VL 31 IS 1 SU S BP S3 EP S6 PG 4 WC Food Science & Technology; Nutrition & Dietetics SC Food Science & Technology; Nutrition & Dietetics GA 588WH UT WOS:000277104800001 PM 20629348 ER PT J AU Halpin, JL Garrett, NM Ribot, EM Graves, LM Cooper, KL AF Halpin, Jessica L. Garrett, Nancy M. Ribot, Efrain M. Graves, Lewis M. Cooper, Kara L. TI Re-evaluation, Optimization, and Multilaboratory Validation of the PulseNet-Standardized Pulsed-Field Gel Electrophoresis Protocol for Listeria monocytogenes SO FOODBORNE PATHOGENS AND DISEASE LA English DT Article ID UNITED-STATES; SURVEILLANCE; OUTBREAK; NETWORK; USA AB The PulseNet Methods Development and Validation Laboratory began a re-evaluation of the standardized pulsed-field gel electrophoresis (PFGE) protocols with the goal of optimizing their overall performance and robustness. Herein, we describe a stepwise evaluation of the PulseNet-standardized PFGE protocol for Listeria monocytogenes that led to the modification of several steps which significantly improved the overall appearance and reproducibility of the resulting PFGE data. These improvements included the following: (1) reducing the cell suspension concentration, (2) increasing lysozyme incubation temperature from 37 degrees C to 56 degrees C, and (3) decreasing the number of units of restriction enzymes AscI and ApaI. These changes were incorporated into a proposed protocol that was evaluated by 16 PulseNet participating laboratories, including 2 international participants. Results from the validation study indicated that the updated L. monocytogenes protocol is more robust than the original PulseNet-standardized protocol established in 1998 and this resulted in the official adoption of the new protocol into the PulseNet system in the spring of 2008. The modifications not only represent an improvement to the protocol but also describe procedural improvements that could be potentially applied to the PFGE analysis of other Gram-positive organisms. C1 [Halpin, Jessica L.; Garrett, Nancy M.; Ribot, Efrain M.; Graves, Lewis M.; Cooper, Kara L.] Ctr Dis Control & Prevent, Enter Dis Lab Branch, Atlanta, GA USA. RP Halpin, JL (reprint author), EDLB, DFBMD, NCZVED, CCID,PulseNet Methods & Reference Unit, 1600 Clifton Rd,Mail Stop CO3, Atlanta, GA 30329 USA. EM fzv8@cdc.gov RI Ducey, Thomas/A-6493-2011 FU Connecticut Department of Public Health Laboratory; Hawaii State Department of Health; Los Angeles County Public Health Lab; Massachusetts Department of Public Health; New York City Department of Health and Mental Hygiene; New York State Department of Health; Ohio Department of Health; South Carolina Department of Health and Environmental Control; Tennessee Department of Health Laboratory Services; Virginia Division of Consolidated Laboratories; United States Department of Agriculture/Food Safety Inspection Service/Outbreak Section of Eastern Laboratory; FDA Pacific Regional Lab NW; FDA PulseNet Team; FDA Southeast Regional Lab; Centers for Disease Control Taiwan; Public Health Laboratory Center (Hong Kong); Oak Ridge Institute for Science and Education FX The authors acknowledge the support from the Connecticut Department of Public Health Laboratory, the Hawaii State Department of Health, the Los Angeles County Public Health Lab, the Massachusetts Department of Public Health, the New York City Department of Health and Mental Hygiene, the New York State Department of Health, the Ohio Department of Health, South Carolina Department of Health and Environmental Control, Tennessee Department of Health Laboratory Services, Virginia Division of Consolidated Laboratories, the United States Department of Agriculture/Food Safety Inspection Service/Outbreak Section of Eastern Laboratory, the FDA Pacific Regional Lab NW, the FDA PulseNet Team, the FDA Southeast Regional Lab, the Centers for Disease Control Taiwan, and the Public Health Laboratory Center (Hong Kong). Jessica L. Halpin was supported by a fellowship from the Oak Ridge Institute for Science and Education. NR 13 TC 27 Z9 27 U1 1 U2 5 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1535-3141 J9 FOODBORNE PATHOG DIS JI Foodborne Pathog. Dis. PD MAR PY 2010 VL 7 IS 3 BP 293 EP 298 DI 10.1089/fpd.2009.0394 PG 6 WC Food Science & Technology SC Food Science & Technology GA 562XL UT WOS:000275089100010 PM 19911934 ER PT J AU McMahon, BJ Bruden, D Bruce, MG Livingston, S Christensen, C Homan, C Hennessy, TW Williams, J Sullivan, D Rosen, HR Gretch, D AF McMahon, Brian J. Bruden, Dana Bruce, Michael G. Livingston, Stephen Christensen, Carol Homan, Chriss Hennessy, Thomas W. Williams, James Sullivan, Daniel Rosen, Hugo R. Gretch, David TI Adverse Outcomes in Alaska Natives Who Recovered From or Have Chronic Hepatitis C Infection SO GASTROENTEROLOGY LA English DT Article DE Hepatitis C Virus; Hepatitis C Population Outcome Study; Hepatitis C in Alaska Natives; Hepatitis C Liver Related Decompensation and Death ID STAGE LIVER-DISEASE; VIRUS-INFECTION; NATURAL-HISTORY; HEPATOCELLULAR-CARCINOMA; UNITED-STATES; CIRRHOSIS; MORTALITY; ALCOHOL; PROGRESSION; RISK AB BACKGROUND & AIMS: The factors associated with adverse outcome from hepatitis C virus (HCV) infection are incompletely understood. To determine the incidence and risk factors associated with the development of endstage liver disease (ESLD) and liver-related death (LRD), we conducted a retrospective/prospective population-based study in a cohort of Alaska Native persons chronically infected with HCV from 1994 to 2005. METHODS: We followed 960 persons prospectively for an average of 7.2 years and retrospectively for 12.1 years with data from medical records and serum samples. We compared data from subjects that were chronically infected with those who recovered from HCV infection, stratified by alcohol use. Survival models were used to examine factors associated with ESLD and LRD in chronically infected patients. RESULTS: During prospective follow-up, 80 (8.8%) and 47 (5.2%) patients developed ESLD and LRD, respectively. In examining incidence per 100 person-years, no difference was found among heavy alcohol users in the incidence of LRD (2.28 versus 3.50; P = .34) or ESLD (3.21 versus 5.69; P = .13) in persons with chronic HCV compared with those recovered from HCV infection. In subjects that consumed <50 g alcohol/d, the incidences of LRD were 0.77 and 0.09 (P = .01) and of ESLD were 1.58 versus 0.36 (P = .002), respectively, in subjects with chronic infection versus those that recovered. Multivariate analysis showed that older age, heavy alcohol use, and HCV genotype 3 were associated with ESLD. CONCLUSIONS: A history of heavy alcohol use is associated with the highest incidence of LRD and ESLD, regardless of whether patients are chronically infected or recover from HCV infection. C1 [McMahon, Brian J.; Livingston, Stephen; Christensen, Carol; Homan, Chriss; Williams, James] Alaska Native Tribal Hlth Consortium, Liver Dis & Hepatitis Program, Anchorage, AK 99508 USA. [Hennessy, Thomas W.] Ctr Dis Control & Prevent, Natl Ctr Preparedness Detect & Control Infect Dis, Div Emerging Infect & Surveillance Serv, Arctic Invest Program, Anchorage, AK USA. [Sullivan, Daniel; Gretch, David] Univ Washington, Sch Med, Seattle, WA USA. [Rosen, Hugo R.] Univ Colorado, Sch Med, Denver, CO USA. RP McMahon, BJ (reprint author), Alaska Native Tribal Hlth Consortium, Liver Dis & Hepatitis Program, 4315 Diplomacy Dr, Anchorage, AK 99508 USA. EM bdm9@cdc.gov FU National Institutes of Health [AI 48214, R01 AI 66209]; Alaska Native Tribal Health Consortium; Arctic Investigations Program, CDC FX Supported by the National Institutes of Health ( grant AI 48214 and R01 AI 66209) and by the Alaska Native Tribal Health Consortium and the Arctic Investigations Program, CDC. NR 27 TC 24 Z9 24 U1 0 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 J9 GASTROENTEROLOGY JI Gastroenterology PD MAR PY 2010 VL 138 IS 3 BP 922 EP U157 DI 10.1053/j.gastro.2009.10.056 PG 11 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 563EF UT WOS:000275109900023 PM 19909749 ER PT J AU Calonge, N Green, NS Rinaldo, P Lloyd-Puryear, M Dougherty, D Boyle, C Watson, M Trotter, T Terry, SF Howell, RR AF Calonge, Ned Green, Nancy S. Rinaldo, Piero Lloyd-Puryear, Michele Dougherty, Denise Boyle, Coleen Watson, Michael Trotter, Tracy Terry, Sharon F. Howell, R. Rodney CA Advisory Comm Heritable Disorders TI Committee report: Method for evaluating conditions nominated for population-based screening of newborns and children SO GENETICS IN MEDICINE LA English DT Editorial Material DE newborn screening; evidence review; nomination; rare condition; advisory committee AB The Secretary's Advisory Committee on Heritable Disorders in Newborns and Children is charged with evaluating conditions nominated for addition to the uniform screening panel and consequently making recommendations to the secretary of the US Department of Health and Human Services. This report describes the framework by which the committee approaches its task. Key decision nodes include initial review of every nomination to determine whether conditions are amenable for systematic evidence review, review of systematic evidence reviews conducted by the committee's external review group, and deliberation and formal recommendation for addition or exclusion to the uniform panel. Data analyzed include the accuracy and specificity of screening and diagnostic tests for nominated disorders, the extent of predicted health benefits, harms impact on disease course, and cost from early diagnosis and treatment. The committee process is guided by approaches used by similar entities, but more flexible criteria are sometimes needed to accommodate data limitations stemming from the rarity of many of these conditions. Possible outcomes of committee review range from recommendation to add a nominated condition to the uniform panel; provide feedback on specific gaps in evidence that must be addressed before making a decision; or rejection of a nomination (e. g., because of identified harms). The committee's structured evidence-based assessment of nominated conditions supports a consistently rigorous, iterative and transparent approach to its making recommendations regarding broad population-based screening programs for rare conditions in infants and children. Genet Med 2010:12(3):153-159. C1 [Green, Nancy S.] Columbia Univ, Med Ctr, Dept Pediat, New York, NY 10032 USA. [Calonge, Ned] Colorado Dept Publ Hlth & Environm, Denver, CO USA. [Rinaldo, Piero] Mayo Clin, Coll Med, Dept Lab Med & Pathol, Rochester, MN USA. [Lloyd-Puryear, Michele] US Hlth Resources & Serv Adm, US Dept HHS, Rockville, MD 20857 USA. [Dougherty, Denise] Agcy Healthcare Res & Qual, HHS, Rockville, MD USA. [Boyle, Coleen] Ctr Dis Control & Prevent, HHS, Rockville, MD USA. [Watson, Michael] Amer Coll Med Genet, Bethesda, MD USA. [Trotter, Tracy] San Ramon Valley Primary Care Med Grp, San Ramon, CA USA. [Terry, Sharon F.] Genet Alliance, Washington, DC USA. [Howell, R. Rodney] Univ Miami, Miller Sch Med, Dept Pediat, Miami, FL 33136 USA. RP Green, NS (reprint author), Columbia Univ, Med Ctr, Dept Pediat, 630 W 168 St,Black Bldg 2-241, New York, NY 10032 USA. EM nsg11@columbia.edu OI Green, Nancy/0000-0002-9877-1561 NR 11 TC 39 Z9 40 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1098-3600 J9 GENET MED JI Genet. Med. PD MAR PY 2010 VL 12 IS 3 BP 153 EP 159 DI 10.1097/GIM.0b013e3181d2af04 PG 7 WC Genetics & Heredity SC Genetics & Heredity GA 574VU UT WOS:000276023100004 PM 20154628 ER PT J AU Ahluwalia, IB Robinson, D Vallely, L Gieseker, KE Kabakama, A AF Ahluwalia, Indu B. Robinson, Dorcas Vallely, Lisa Gieseker, Karen E. Kabakama, Alfreda TI Sustainability of community-capacity to promote safer motherhood in northwestern Tanzania: what remains? SO GLOBAL HEALTH PROMOTION LA English DT Article DE community; emergency obstetric care; maternal health; sustainability; transport AB Objective. To examine the remains of the Community-Based Reproductive Health Project (CBRHP) implemented by CARE-Tanzania to address high maternal mortality in two rural districts. Methods. In early 2007, data were collected from 29 villages and used to assess sustainability of emergency transport systems, retention of village health workers (VHWs), and their potential impact on maternal health. Surveillance data from the Ministry of Health were reviewed to assess changes in prenatal and service use indicators. Results. From 2001 through 2006, the CBRHP-trained VHWs have continued to provide education and referrals to women in their communities including prenatal and emergency obstetric care; six villages with emergency transport systems have continued for more than 5 years providing free or low-cost transport to health facilities. Selected maternal and infant health indicators, such as early prenatal care, identification of pregnancy-related danger signs, and data on maternal and infant outcomes, improved in the two targeted districts over time. Conclusions. The two components of CBRHP, work of VHWs and community-financing for emergency transport systems in six villages, have continued. Both of these promote maternal health and linkages with the health delivery systems. Surveillance data show changes in maternal health indicators that were targeted by the district-wide CBRHP interventions. Programs such as CBRHP, with focus on capacity-building and empowerment, can assist in mobilizing the formal and informal systems in communities, components of which may be sustained over time. (Global Health Promotion, 2010; 17(1): pp. 39-49) C1 [Ahluwalia, Indu B.] Ctr Dis Control & Prevent, Div Adult & Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Robinson, Dorcas] CARE Int Tanzania, Dar Es Salaam, Tanzania. [Gieseker, Karen E.] Georgia State Univ, Inst Publ Hlth, Atlanta, GA 30303 USA. RP Ahluwalia, IB (reprint author), Ctr Dis Control & Prevent, Div Adult & Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy NE,Mailstop K-66, Atlanta, GA 30341 USA. EM Iahluwalia@cdc.gov OI Vallely, Lisa/0000-0002-8247-7683 NR 28 TC 14 Z9 14 U1 1 U2 13 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1757-9759 J9 GLOB HEALTH PROMOT JI Glob. Health Promot. PD MAR PY 2010 VL 17 IS 1 BP 39 EP 49 DI 10.1177/1757975909356627 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA V24SX UT WOS:000208431200006 PM 20357351 ER PT J AU Frieden, TR Dietz, W Collins, J AF Frieden, Thomas R. Dietz, William Collins, Janet TI Reducing Childhood Obesity Through Policy Change: Acting Now To Prevent Obesity SO HEALTH AFFAIRS LA English DT Article ID PHYSICAL-ACTIVITY; UNITED-STATES; ENERGY-INTAKE; RISK-FACTORS; US CHILDREN; ADOLESCENTS; HEALTH; TELEVISION; SCHOOL; CONSUMPTION AB Childhood obesity is epidemic in the United States, and is expected to increase the rates of many chronic diseases. Increasing physical activity and improving nutrition are keys to obesity prevention and control. But changing individual behavior is difficult. A comprehensive, coordinated strategy is needed. Policy interventions that make healthy dietary and activity choices easier are likely to achieve the greatest benefits. There is emerging evidence on how to address childhood obesity, but we must take action now to begin to reverse the epidemic. C1 [Dietz, William] CDC, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Frieden, Thomas R.] Ctr Dis Control & Prevent CDC, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Frieden, TR (reprint author), Ctr Dis Control & Prevent CDC, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM txf2@cdc.gov NR 70 TC 67 Z9 68 U1 1 U2 18 PU PROJECT HOPE PI BETHESDA PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA SN 0278-2715 J9 HEALTH AFFAIR JI Health Aff. PD MAR-APR PY 2010 VL 29 IS 3 BP 357 EP 363 DI 10.1377/hlthaff.2010.0039 PG 7 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 562EC UT WOS:000275031300004 PM 20194973 ER PT J AU Klein, JD Dietz, W AF Klein, Jonathan D. Dietz, William TI Childhood Obesity: The New Tobacco SO HEALTH AFFAIRS LA English DT Article ID PUBLIC-POLICY; UNITED-STATES; WEIGHT STATUS; HEALTH; OVERWEIGHT; CHILDREN; IMPACT; RACE AB Overcoming the childhood obesity epidemic will require changes on the scale of a social movement similar to the shift in attitudes and regulations toward smoking and tobacco. Tobacco control became a successful public health movement because of shifts in social norms and because cigarette companies came to be perceived by many as a common enemy. In contrast, obesity advocates have not identified a common threat or mobilized grass-roots change, nor have they identified strategies that resonate across diverse settings and constituencies. Framing obesity as a common threat can lead to consensus regarding the interventions needed to achieve healthier children and communities. C1 [Klein, Jonathan D.] Amer Acad Pediat, Julius B Richmond Ctr Excellence, Elk Grove Village, IL USA. [Dietz, William] Ctr Dis Control & Prevent, Div Nutr & Phys Act, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Klein, JD (reprint author), Amer Acad Pediat, Julius B Richmond Ctr Excellence, Elk Grove Village, IL USA. EM jklein@aap.org NR 38 TC 22 Z9 22 U1 0 U2 2 PU PROJECT HOPE PI BETHESDA PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA SN 0278-2715 J9 HEALTH AFFAIR JI Health Aff. PD MAR-APR PY 2010 VL 29 IS 3 BP 388 EP 392 DI 10.1377/hlthaff.2009.0736 PG 5 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 562EC UT WOS:000275031300008 PM 20194977 ER PT J AU Asfaw, A Lamanna, F Klasen, S AF Asfaw, Abay Lamanna, Francesca Klasen, Stephan TI GENDER GAP IN PARENTS' FINANCING STRATEGY FOR HOSPITALIZATION OF THEIR CHILDREN: EVIDENCE FROM INDIA SO HEALTH ECONOMICS LA English DT Article DE gender discrimination; health-care finance; hospitalization; India ID SEX-SELECTIVE ABORTIONS; HEALTH-CARE; COPING-STRATEGIES; ENDOGENOUS ILLNESS; MISSING WOMEN; RURAL INDIA; SRI-LANKA; MORTALITY; BIAS; BANGLADESH AB The 'missing women' dilemma in India has sparked great interest ill investigating gender discrimination in the provision of health care in the country. No studies, however, have directly examined discrimination in health-care financing strategies in the case of severe illness of Sons versus daughters. In this paper, we hypothesize that households Who face tight budget constraints are more likely to spend their meager resources on hospitalization or boys rather than girls. We use the 60th round of the Indian National Sample Survey (2004) and a multinomial logit model to test this hypothesis and to throw, some light on this important but overlooked issue. The results reveal that boys are much more likely to be hospitalized than girls. When it comes to financing, the gap in the usage of household income and savings is relatively small, while the gender gap in the probability of hospitalization and usage of more onerous financing strategies is very high. Ceteris paribus, the probability of boys to be hospitalized by financing from borrowing,, sale of assets, help from friends, etc. is much higher than that of girls. Moreover, in line with our theoretical framework, the results indicate that the gender gap intensifies as we move from the richest to poorest households. Copyright (C) 2009 John Wiley & Sons, Ltd. C1 [Asfaw, Abay] Ctr Dis Control & Prevent, Natl Inst Occupat Safety & Hlth, Washington, DC USA. [Lamanna, Francesca] World Bank, Washington, DC 20433 USA. [Lamanna, Francesca; Klasen, Stephan] Univ Gottingen, Gottingen, Germany. [Klasen, Stephan] IZA, Bonn, Germany. RP Asfaw, A (reprint author), Ctr Dis Control & Prevent, Natl Inst Occupat Safety & Hlth, Washington, DC USA. EM agetahun@cdc.gov FU International Food Policy Research Institute (IFPRI); German Research Foundation FX We would like to thank Monica Das Gupta, Michael Grimm, Elisabeth Sadoulet, Joachim Winter, and participants at workshops and conferences at UC Berkeley, IZA (Bonn), RWI (Essen), Mannheim, and Gottingen for helpful comments and discussion. Funding from the International Food Policy Research Institute (IFPRI) and the German Research Foundation in support of this work is gratefully acknowledged. NR 59 TC 20 Z9 20 U1 1 U2 7 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND SN 1057-9230 J9 HEALTH ECON JI Health Econ. PD MAR PY 2010 VL 19 IS 3 BP 265 EP 279 DI 10.1002/hec.1468 PG 15 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA 569KG UT WOS:000275594700003 PM 19267357 ER PT J AU Franzini, L Taylor, W Elliott, MN Cuccaro, P Tortolero, SR Gilliland, MJ Grunbaum, J Schuster, MA AF Franzini, Luisa Taylor, Wendell Elliott, Marc N. Cuccaro, Paula Tortolero, Susan R. Gilliland, M. Janice Grunbaum, JoAnne Schuster, Mark A. TI Neighborhood characteristics favorable to outdoor physical activity: Disparities by socioeconomic and racial/ethnic composition SO HEALTH & PLACE LA English DT Article DE Neighborhoods; Physical activity; Socioeconomic disparities; Racial disparities; Physical environment; Social environment ID BODY-MASS INDEX; UNITED-STATES; FAST-FOOD; OBESITY; WALKING; HEALTH; AVAILABILITY; ASSOCIATIONS; WALKABILITY; MULTILEVEL AB This paper uses a socioecological framework to investigate socioeconomic and racial/ethnic disparities in neighborhood characteristics that are associated with outdoor physical activity. We surveyed 632 parents of 5th graders about perceptions of their neighborhood social processes and collected systematic observations of the physical environment on their block-face of residence. Higher poverty neighborhoods and non-White neighborhoods have better accessibility: however, they are less safe, less comfortable, and less pleasurable for outdoor physical activity, and have less favorable social processes. Interventions to reduce disparities in physical activity should address not only the physical environment, but also social processes favorable to physical activity. (C) 2009 Elsevier Ltd. All rights reserved. C1 [Franzini, Luisa; Taylor, Wendell; Cuccaro, Paula; Tortolero, Susan R.] Univ Texas Sch Publ Hlth, Houston, TX 77030 USA. [Elliott, Marc N.; Schuster, Mark A.] RAND Hlth, Santa Monica, CA USA. [Gilliland, M. Janice] Univ Utah, Dept Pediat, Salt Lake City, UT USA. [Grunbaum, JoAnne] Ctr Dis Control & Prevent, Atlanta, GA USA. [Schuster, Mark A.] Childrens Hosp, Boston, MA 02115 USA. [Schuster, Mark A.] Harvard Univ, Sch Med, Boston, MA USA. RP Franzini, L (reprint author), Univ Texas Sch Publ Hlth, 1200 Pressler Dr, Houston, TX 77030 USA. EM Luisa.Franzini@uth.tmc.edu; Wendell.C.Taylor@uth.tmc.edu; Elliott@rand.org; Paula.M.Cuccaro@uth.tmc.edu; Susan.Tortolero@uth.tmc.edu; janice.gilliland@hsc.utah.edu; jgrunbaum@cdc.gov; mark.schuster@childrens.harvard.edu OI Cuccaro, Paula/0000-0002-9551-4789 FU NCCDPHP CDC HHS [U19 DP002664, U48 DP000056, U48 DP000057] NR 56 TC 53 Z9 53 U1 1 U2 18 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 1353-8292 J9 HEALTH PLACE JI Health Place PD MAR PY 2010 VL 16 IS 2 BP 267 EP 274 DI 10.1016/j.healthplace.2009.10.009 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 554UQ UT WOS:000274461100011 PM 19896408 ER PT J AU Chen, Z Roy, K Haddix, AC Thacker, SB AF Chen, Zhuo Roy, Kakoli Haddix, Anne C. Thacker, Stephen B. TI Factors associated with differences in mortality and self-reported health across states in the United States SO HEALTH POLICY LA English DT Article DE Econometric models; Mortality; Physicians; Socioeconomic factors; United States ID INCOME INEQUALITY; POPULATION HEALTH; PUBLIC-HEALTH; PRIMARY-CARE; US COUNTIES; DISPARITIES; DETERMINANTS; COUNTRIES; AMERICA; OBESITY AB Objective: Recent studies indicate continuing health disparities across geographic units in the US. This paper provides updated estimates of the association between socioeconomic factors and population health using a new state-level dataset and panel econometric methods that account for state-specific effects and autoregressive error structure. Methods: Data from multiple sources for the 50 US states and the District of Columbia are merged. The dependent variables are age-adjusted all-cause mortality, self-assessed health status, and number of healthy days. Panel econometric models are used to accommodate state-specific unobserved factors and to incorporate autoregressive random disturbances to provide consistent and robust estimates. Results: A 1-unit increase in the number of physicians per 1000 population is associated with a reduction in mortality by 30/100,000. The effects of physician-to-population ratio on self-reported health measures are mixed. Socioeconomic, demographic, as well as the prevalence of smoking and obesity have varying effects on mortality and self-reported measures of health. Conclusions:The new estimate of the association between physician supply and lower mortality suggests continuing efforts to assess the need for policies and incentives to induce physician labor supply in underserved states. Strategies and policies to reduce health disparities should address social, economic and individual risk factors. Published by Elsevier Ireland Ltd. C1 [Chen, Zhuo; Roy, Kakoli; Haddix, Anne C.; Thacker, Stephen B.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Chen, Z (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM zchen1@cdc.gov NR 45 TC 2 Z9 2 U1 1 U2 2 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0168-8510 J9 HEALTH POLICY JI Health Policy PD MAR PY 2010 VL 94 IS 3 BP 203 EP 210 DI 10.1016/j.healthpol.2009.09.011 PG 8 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 564CM UT WOS:000275189600003 PM 19854529 ER PT J AU Rowe, AK Onikpo, F Lama, M Deming, MS AF Rowe, Alexander K. Onikpo, Faustin Lama, Marcel Deming, Michael S. TI The rise and fall of supervision in a project designed to strengthen supervision of Integrated Management of Childhood Illness in Benin SO HEALTH POLICY AND PLANNING LA English DT Article DE Benin; child health; developing country; health services research; supervision ID PRIMARY-HEALTH-CARE; PUBLIC-HEALTH; QUALITY; IMPLEMENTATION; GUIDELINES; ADHERENCE; SERVICES; ACHIEVE; WORKERS AB Objective In developing countries, supervision is a widely recognized strategy for improving health worker performance; and anecdotally, maintaining regular, high-quality supervision is difficult. However, remarkably little research has explored in depth why supervision is so challenging. Methods In the context of a trial to improve health worker adherence to Integrated Management of Childhood Illness (IMCI) guidelines and strengthen supervision in southeastern Benin, we used record reviews, focus group discussions, key informant interviews, and cross-sectional surveys to examine the supervision process. Findings Initially, little IMCI supervision occurred. The frequency increased substantially after implementing a series of workshops, but then deteriorated. Quantitative and qualitative data revealed obstacles to supervision at multiple levels of the health system. Based on supervisors' opinions, the main problems were: poor coordination; inadequate management skills and ineffective management teams; a lack of motivation; problems related to decentralization; health workers sometimes resisting IMCI implementation; and less priority given to IMCI supervision because of incentives for non-supervision activities, a lack of leadership, and an expectation of integrated supervision. To this list, based on our observations, we add: the increasing supervision workload, time required for non-supervision activities, project interventions not always being implemented as planned, and the loss of particularly effective supervisors. In terms of correctly completing steps of the supervision process, the quality of supervision was generally good. Conclusions Managers should monitor supervision, understand the evolving influences on supervision, and use their resources and authority to both promote supervision and remove impediments to supervision. Support from leaders can be crucial, thus donors and politicians should help make supervision a true priority. As with front-line clinicians, supervisors are health workers who need support. We emphasize the importance of research to identify effective and affordable strategies for improving supervision frequency and quality. (ClinicalTrials.gov number NCT00510679.). C1 [Rowe, Alexander K.; Deming, Michael S.] Ctr Dis Control & Prevent, Malaria Branch AKR, Div Parasit Dis, Atlanta, GA 30341 USA. [Rowe, Alexander K.; Deming, Michael S.] Ctr Dis Control & Prevent, Parasit Dis Branch MSD, Div Parasit Dis, Atlanta, GA 30341 USA. [Onikpo, Faustin] Minist Hlth, Direct Dept Sante Publ Oueme & Plateau, Porto Novo, Benin. [Lama, Marcel] Africare Benin, Porto Novo, Benin. RP Rowe, AK (reprint author), Ctr Dis Control & Prevent, Malaria Branch AKR, Div Parasit Dis, Mailstop F22,4770 Buford Highway, Atlanta, GA 30341 USA. EM axr9@cdc.gov NR 32 TC 29 Z9 29 U1 1 U2 9 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0268-1080 J9 HEALTH POLICY PLANN JI Health Policy Plan. PD MAR PY 2010 VL 25 IS 2 BP 125 EP 134 DI 10.1093/heapol/czp054 PG 10 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 558YZ UT WOS:000274786800007 PM 19923206 ER PT J AU Esona, MD Foytich, K Wang, YH Shin, G Wei, G Gentsch, JR Glass, RI Jiang, BM AF Esona, Mathew D. Foytich, Kimberly Wang, Yuhuan Shin, Gary Wei, Gang Gentsch, Jon R. Glass, Roger I. Jiang, Baoming TI Molecular characterization of human rotavirus vaccine strain CDC-9 during sequential passages in Vero cells SO HUMAN VACCINES LA English DT Article DE rotavirus; rotavirus vaccine; CDC-9 ID NONSTRUCTURAL GLYCOPROTEIN NSP4; POLYMERASE CHAIN-REACTION; GROUP-A; PORCINE ROTAVIRUS; ATTENUATED VACCINE; NUCLEIC-ACID; VIRUS; GENE; IDENTIFICATION; DIARRHEA AB We have developed several candidate human rotavirus vaccine strains with common serotypes via adaptation in Vero cells, adhering to the Good Laboratory Practice (GLP) guidelines. We sequenced the entire genome of a G1P[8] strain CDC-9 in original stool and passaged materials from Vero cells and examined its genetic relatedness to the prototype human rotavirus KU and other strains. With the exception of VP3 gene which was closely related to that of strain DS-1, the culture-adapted CDC-9 strain shared moderate to high nt (range 83.4%-95.1%) and deduced aa (range 81.3%-97.9%) sequence identities with the KU and other G1P[8] strains. Alignments of the deduced aa sequences of 11 gene segments of the wild-type and culture-adapted CDC-9 showed complete sequence identity in genes encoding NSP2, NSP3, NSP4, VP1, VP2, VP3 and VP7, a single aa change in genes coding for NSP1, NSP5 and VP6 and several scattered aa changes in the VP4 gene during the passage in Vero cells. Two of the VP4 aa substitutions (385 and 388) are within sites associated with neutralization resistant mutants selected by cross-reactive monoclonal antibodies. Although some sequence changes were evident, we do not know if these changes contribute to the possible attenuation of this strain. Further testing of this vaccine strain in clinical trials is justified. C1 [Esona, Mathew D.; Foytich, Kimberly; Wang, Yuhuan; Shin, Gary; Wei, Gang; Gentsch, Jon R.; Glass, Roger I.; Jiang, Baoming] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA 30333 USA. [Glass, Roger I.] NIH, Fogerty Int Ctr, Bethesda, MD 20892 USA. RP Jiang, BM (reprint author), Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA 30333 USA. EM bxj4@cdc.gov FU Cooperative Research and Development Agreement with Sanofi Pasteur, Lyon, France FX We thank Charles Humphrey for performing electron microscope analysis. This study was supported in part by a Cooperative Research and Development Agreement with Sanofi Pasteur, Lyon, France. NR 51 TC 8 Z9 9 U1 0 U2 0 PU LANDES BIOSCIENCE PI AUSTIN PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA SN 1554-8600 J9 HUM VACCINES JI Hum. Vaccines PD MAR PY 2010 VL 6 IS 3 BP 247 EP 253 PG 7 WC Biotechnology & Applied Microbiology; Immunology SC Biotechnology & Applied Microbiology; Immunology GA 589VZ UT WOS:000277183600011 ER PT J AU Dubberke, ER Butler, AM Yokoe, DS Mayer, J Hota, B Mangino, JE Khan, YM Popovich, KJ Stevenson, KB McDonald, LC Olsen, MA Fraser, VJ AF Dubberke, Erik R. Butler, Anne M. Yokoe, Deborah S. Mayer, Jeanmarie Hota, Bala Mangino, Julie E. Khan, Yosef M. Popovich, Kyle J. Stevenson, Kurt B. McDonald, L. Clifford Olsen, Margaret A. Fraser, Victoria J. CA Ctr Dis Control Prevention TI Multicenter Study of Surveillance for Hospital-Onset Clostridium difficile Infection by the Use of ICD-9-CM Diagnosis Codes SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID DISEASE; DIARRHEA; EPIDEMIC; OUTBREAK; COHORT AB OBJECTIVE. To compare incidence of hospital-onset Clostridium difficile infection (CDI) measured by the use of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) discharge diagnosis codes with rates measured by the use of electronically available C. difficile toxin assay results. METHODS. Cases of hospital-onset CDI were identified at 5 US hospitals during the period from July 2000 through June 2006 with the use of 2 surveillance definitions: positive toxin assay results (gold standard) and secondary ICD-9-CM discharge diagnosis codes for CDI. The chi(2) test was used to compare incidence, linear regression models were used to analyze trends, and the test of equality was used to compare slopes. RESULTS. Of 8,670 cases of hospital-onset CDI, 38% were identified by the use of both toxin assay results and the ICD-9-CM code, 16% by the use of toxin assay results alone, and 45% by the use of the ICD-9-CM code alone. Nearly half (47%) of cases of CDI identified by the use of a secondary diagnosis code alone were community-onset CDI according to the results of the toxin assay. The rate of hospital-onset CDI found by use of ICD-9-CM codes was significantly higher than the rate found by use of toxin assay results overall (P < .001), as well as individually at 3 of the 5 hospitals (P < .001 for all). The agreement between toxin assay results and the presence of a secondary ICD-9-CM diagnosis code for CDI was moderate, with an overall kappa value of 0.509 and hospital-specific kappa values of 0.489-0.570. Overall, the annual increase in CDI incidence was significantly greater for rates determined by the use of ICD-9-CM codes than for rates determined by the use of toxin assay results (Pp. 006). CONCLUSIONS. Although the ICD-9-CM code for CDI seems to be adequate for measuring the overall CDI burden, use of the ICD-9-CM discharge diagnosis code for CDI, without present-on-admission code assignment, is not an acceptable surrogate for surveillance for hospital-onset CDI. Infect Control Hosp Epidemiol 2010;31:262-268 C1 [Dubberke, Erik R.; Butler, Anne M.; Olsen, Margaret A.; Fraser, Victoria J.] Washington Univ, Sch Med, St Louis, MO USA. [Yokoe, Deborah S.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Yokoe, Deborah S.] Harvard Univ, Sch Med, Boston, MA USA. [Mayer, Jeanmarie] Univ Utah Hosp, Salt Lake City, UT USA. [Hota, Bala; Popovich, Kyle J.] Rush Univ, Med Ctr, Stroger Hosp Cook Cty, Chicago, IL 60612 USA. [Mangino, Julie E.; Khan, Yosef M.; Stevenson, Kurt B.] Ohio State Univ, Med Ctr, Columbus, OH 43210 USA. [McDonald, L. Clifford] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Dubberke, ER (reprint author), Box 8051,660 S Euclid, St Louis, MO 63110 USA. EM edubberk@im.wustl.edu FU Centers for Disease Control and Prevention [UR8/CCU715087-06/1, 5U01C1000333]; Eastern Massachusetts Prevention Epicenter [5U01CI000344]; Ohio State University Prevention Epicenter [5U01CI000328]; Stroger Hospital of Cook County/Rush University Medical Center Prevention Epicenter [5U01CI000327]; University of Utah Prevention Epicenter [5U01CI000334]; National Institutes of Health [K12RR02324901, K24AI06779401, K01AI065808]; Viropharma; Sage Products FX Financial support. Centers for Disease Control and Prevention (grants UR8/CCU715087-06/1 and 5U01C1000333 to Washington University Prevention Epicenter, 5U01CI000344 to Eastern Massachusetts Prevention Epicenter, 5U01CI000328 to Ohio State University Prevention Epicenter, 5U01CI000327 to Stroger Hospital of Cook County/Rush University Medical Center Prevention Epicenter, and 5U01CI000334 to University of Utah Prevention Epicenter) and the National Institutes of Health (grants K12RR02324901, K24AI06779401, and K01AI065808 to Washington University).; Potential conflicts of interest. E. R. D. has served as a consultant to Merck, Salix, and Becton-Dickinson and has received research funding from Viropharma. D. S. Y. has received research funding from Sage Products. All other authors report no conflicts of interest relevant to this article. NR 16 TC 36 Z9 36 U1 0 U2 0 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD MAR PY 2010 VL 31 IS 3 BP 262 EP 268 DI 10.1086/650447 PG 7 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 549UJ UT WOS:000274079500006 PM 20100085 ER PT J AU Mukherjee, A Chattopadhyay, S Bagchi, P Dutta, D Singh, NB Arora, R Parashar, UD Gentsch, JR Chawla-Sarkar, M AF Mukherjee, Anupam Chattopadhyay, Shiladitya Bagchi, Parikshit Dutta, Dipanjan Singh, Ng. Brajachand Arora, Rashmi Parashar, Umesh D. Gentsch, Jon R. Chawla-Sarkar, Mamta TI Surveillance and molecular characterization of rotavirus strains circulating in Manipur, North-Eastern India: Increasing prevalence of emerging G12 strains SO INFECTION GENETICS AND EVOLUTION LA English DT Article DE Group A rotavirus; G12 strains; Genotype P[19]; Interspecies transmission; Vaccine ID CLOSE RELATIONSHIP; G9 STRAINS; CHIANG-MAI; PSI-BLAST; CHILDREN; EMERGENCE; THAILAND; DIARRHEA; SEROTYPE; EPIDEMIOLOGY AB To determine the frequency and genotypes of rotavirus strains, samples were collected from children hospitalized with acute diarrhea at the Regional Institute of Medical Sciences, Manipur. The globally common genotypes G1P[8] and G2P[4] constituted 58% of the total positive strains, while 3% and 8% strains were emerging genotypes, G9P[6] and G12P[6]. This is the first report of genotype G12 in Manipur. The G12 strains clustered with lineage III strains and had >98% identity with corresponding rotaviruses from Bangladesh, Thailand and the USA. Other uncommon G-P combinations including G4P[4], G4P[6], G10P[6] and G9P[9], along with a few strains that could not be typed were also found. The VP7 genes of G4 and G10 strains clustered with porcine and bovine strains, indicating possible zoonotic transmission. High frequency (36-62%) of rotavirus infection and predominance of G1P[8] and G2P[4] among children with acute diarrhea emphasized the need for implementation of currently available vaccines to reduce the burden of rotavirus induced diarrhea in India. (C) 2010 Elsevier B.V. All rights reserved. C1 [Chawla-Sarkar, Mamta] Natl Inst Cholera & Enter Dis, Div Virol, Kolkata 700010, W Bengal, India. [Singh, Ng. Brajachand] Reg Inst Med Sci, Imphal, Manipur, India. [Arora, Rashmi] Indian Council Med Res, New Delhi 110029, India. [Parashar, Umesh D.; Gentsch, Jon R.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Chawla-Sarkar, M (reprint author), Natl Inst Cholera & Enter Dis, Div Virol, P-33,CIT Rd,Scheme XM, Kolkata 700010, W Bengal, India. EM chawlam70@gmail.com FU Indian Council of Medical Research (ICMR), New Delhi; Center for Disease Control (CDC), Atlanta; ICMR and University Grant Commision, Govt. of India FX The study was supported by financial assistance from Indian Council of Medical Research (ICMR), New Delhi and Center for Disease Control (CDC), Atlanta. A. Mukherjee and D. Dutta are supported by Senior Research Fellowship from ICMR and University Grant Commision, Govt. of India, respectively. NR 45 TC 39 Z9 39 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1567-1348 EI 1567-7257 J9 INFECT GENET EVOL JI Infect. Genet. Evol. PD MAR PY 2010 VL 10 IS 2 BP 311 EP 320 DI 10.1016/j.meegid.2010.01.002 PG 10 WC Infectious Diseases SC Infectious Diseases GA 573PJ UT WOS:000275926400021 PM 20083233 ER PT J AU Vincent, AL Lager, KM Faaberg, KS Harland, M Zanella, EL Ciacci-Zanella, JR Kehrli, ME Janke, BH Klimov, A AF Vincent, Amy L. Lager, Kelly M. Faaberg, Kay S. Harland, Michelle Zanella, Eraldo L. Ciacci-Zanella, Janice R. Kehrli, Marcus E., Jr. Janke, Bruce H. Klimov, Alexander TI Experimental inoculation of pigs with pandemic H1N1 2009 virus and HI cross-reactivity with contemporary swine influenza virus antisera SO INFLUENZA AND OTHER RESPIRATORY VIRUSES LA English DT Article DE H1N1 2009; hemagglutination inhibition assay; influenza A virus; pathogenesis; swine ID A VIRUSES; UNITED-STATES; REASSORTANT H1N2; ORIGIN H1N1; HUMANS; CANADA; IDENTIFICATION; RECEPTORS; INFECTION; PCR AB Background A novel A/H1N1 was identified in the human population in North America in April 2009. The gene constellation of the virus was a combination from swine influenza A viruses (SIV) of North American and Eurasian lineages that had never before been identified in swine or other species. Objectives The objectives were to (i) evaluate the clinical response of swine following experimental inoculation with pandemic H1N1 2009; (ii) assess serologic cross-reactivity between H1N1 2009 and contemporary SIV antisera; and (iii) develop a molecular assay to differentiate North American-lineage SIV from H1N1 2009. Methods Experiment 1: Weaned pigs were experimentally infected with A/California/04/2009 (H1N1). Experiment 2: The cross-reactivity of a panel of US SIV H1N1 or H1N2 antisera with three isolates of pandemic A/H1N1 was evaluated. Experiment 3: A polymerase chain reaction (PCR)-based diagnostic test was developed and validated on samples from experimentally infected pigs. Results and Conclusions In experiment 1, all inoculated pigs demonstrated clinical signs and lesions similar to those induced by endemic SIV. Viable virus and antigen were only detected in the respiratory tract. In experiment 2, serologic cross-reactivity was limited against H1N1 2009 isolates, notably among virus antisera from the same HA phylogenetic cluster. The limited cross-reactivity suggests North American pigs may not be fully protected against H1N1 2009 from previous exposure or vaccination and novel tests are needed to rapidly diagnose the introduction of H1N1 2009. In experiment 3, an RT-PCR test that discriminates between H1N1 2009 and endemic North American SIV was developed and validated on clinical samples. C1 [Vincent, Amy L.; Lager, Kelly M.; Faaberg, Kay S.; Harland, Michelle; Zanella, Eraldo L.; Ciacci-Zanella, Janice R.; Kehrli, Marcus E., Jr.] ARS, Virus & Prion Dis Res Unit, Natl Anim Dis Ctr, USDA, Ames, IA 50010 USA. [Zanella, Eraldo L.] Univ Passo Fundo, Fac Agron & Med Vet, BR-1920 Passo Fundo, RS, Brazil. [Ciacci-Zanella, Janice R.] EMBRAPA Brazilian Agr Res Corp, Labex USA, Brasilia, DF, Brazil. [Janke, Bruce H.] Iowa State Univ, Coll Vet Med, Dept Vet Diagnost & Prod Anim Med, Ames, IA USA. [Klimov, Alexander] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. RP Vincent, AL (reprint author), ARS, Virus & Prion Dis Res Unit, Natl Anim Dis Ctr, USDA, 1920 Dayton Ave, Ames, IA 50010 USA. EM amy.vincent@ars.usda.gov RI Zanella, Janice/C-3632-2014 FU USDA-ARS; DHHS-CDC FX The authors thank David Michael and Hillary Horst for technical assistance and Dr Becky Jepsen, Brian Pottebaum, and Jason Huegel for assistance with animal studies. We thank Dr Crystal Loving for critical review of the manuscript and Dr Marie Gramer (University of Minnesota) for providing SIV isolates. Mention of trade names or commercial products in this article is solely for the purpose of providing specific information and does not imply recommendation or endorsement by the US Department of Agriculture. Funding was provided by USDA-ARS and DHHS-CDC. NR 26 TC 52 Z9 53 U1 1 U2 5 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1750-2640 J9 INFLUENZA OTHER RESP JI Influenza Other Respir. Viruses PD MAR PY 2010 VL 4 IS 2 BP 53 EP 60 DI 10.1111/j.1750-2659.2009.00121.x PG 8 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA 554BR UT WOS:000274411000002 PM 20167045 ER PT J AU Nakao, M Li, TY Han, XM Ma, XM Xiao, N Qiu, JM Wang, H Yanagida, T Mamuti, W Wen, H Moro, PL Giraudoux, P Craig, PS Ito, A AF Nakao, Minoru Li, Tiaoying Han, Xiumin Ma, Xiumin Xiao, Ning Qiu, Jiamin Wang, Hu Yanagida, Tetsuya Mamuti, Wulamu Wen, Hao Moro, Pedro L. Giraudoux, Patrick Craig, Philip S. Ito, Akira TI Genetic polymorphisms of Echinococcus tapeworms in China as determined by mitochondrial and nuclear DNA sequences SO INTERNATIONAL JOURNAL FOR PARASITOLOGY LA English DT Article DE Echinococcus; Mitochondrial DNA; Genetic diversity; Population genetic structure; China ID NORTH-WESTERN CHINA; ALVEOLAR ECHINOCOCCOSIS; CYSTIC ECHINOCOCCOSIS; POPULATION-GENETICS; QINGHAI-PROVINCE; TIBETAN PLATEAU; GRANULOSUS; MULTILOCULARIS; IDENTIFICATION; EPIDEMIOLOGY AB The genetic polymorphisms of Echinococcus spp. in the eastern Tibetan Plateau and the Xinjiang Uyghur Autonomous Region were evaluated by DNA sequencing analyses of genes for mitochondrial cytochrome c oxidase subunit 1 (cox1) and nuclear elongation factor-1 alpha (ef1a). We collected 68 isolates of Echinococcus granulosus sensu stricto (s.s.) from Xinjiang and 113 isolates of E. granulosus s. s., 49 isolates of Echinococcus multilocularis and 34 isolates of Echinococcus shiquicus from the Tibetan Plateau. The results of molecular identification by mitochondrial and nuclear markers were identical, suggesting the infrequency of introgressive hybridization. A considerable intraspecific variation was detected in rnitochondrial cox1 sequences. The parsimonious network of cox1 haplotypes showed star-like features in E. granulosus s. s. and E. multilocularis, but a divergent feature in E shiquicus. The cox1 neutrality indexes Computed by Tajima's D and Fu's Fs tests showed high negative values in E. granulosus s. s. and E multilocularis, indicating significant deviations from neutrality. In contrast, the low positive values of both tests were obtained in E. shiquicus. These results suggest the following hypotheses: (i) recent founder effects arose in E. granulosus and E. multilocularis after introducing particular individuals into the endemic areas by anthropogenic movement or natural migration of host mammals, and (ii) the ancestor of E shiquicus was segregated into the Tibetan Plateau by colonising alpine mammals and its mitochondrial locus has evolved without bottleneck effects. (C) 2009 Australian Society for Parasitology Inc. Published by Elsevier Ltd. All rights reserved. C1 [Nakao, Minoru; Li, Tiaoying; Han, Xiumin; Ma, Xiumin; Xiao, Ning; Yanagida, Tetsuya; Mamuti, Wulamu; Ito, Akira] Asahikawa Med Coll, Dept Parasitol, Asahikawa, Hokkaido 0788510, Japan. [Li, Tiaoying; Xiao, Ning; Qiu, Jiamin] Sichuan Ctr Dis Control & Prevent, Inst Parasit Dis, Chengdu 610041, Peoples R China. [Han, Xiumin; Wang, Hu] Qinghai Prov Inst Endem Dis Control, Xining 811602, Qinghai, Peoples R China. [Ma, Xiumin; Mamuti, Wulamu] Xinjiang Med Univ, Dept Microbiol & Parasitol, Urumqi 830054, Peoples R China. [Ma, Xiumin; Wen, Hao] Xinjiang Med Univ, Affiliated Hosp 1, Xinjiang Hydatid Clin Res Inst, Urumqi 830054, Peoples R China. [Moro, Pedro L.] Ctr Dis Control & Prevent, Immunizat Safety Off, Div Healthcare Qual Promot, Atlanta, GA 30333 USA. [Giraudoux, Patrick] Univ Franche Comte, CNRS, UMR Aff INRA 6249, Dept Chronoenvironm, F-25030 Besancon, France. [Craig, Philip S.] Univ Salford, Biosci Res Inst, Cestode Zoonoses Res Grp, Great Manchester M5 4WT, England. [Craig, Philip S.] Univ Salford, Sch Environm & Life Sci, Great Manchester M5 4WT, England. RP Nakao, M (reprint author), Asahikawa Med Coll, Dept Parasitol, Asahikawa, Hokkaido 0788510, Japan. EM nakao@asahikawa-med.ac.jp RI Giraudoux, Patrick/B-9274-2011; ito, akira/E-9377-2014 OI Giraudoux, Patrick/0000-0003-2376-0136; ito, akira/0000-0002-5070-9187 FU US National Institutes of Health Funds [1565]; Japan Society for the Promotion of Science (JSPS) [17256002, 21256003]; JSPS-Asia/Africa Science Platform Fund FX This study was supported by the US National Institutes of Health Funds (the NIH/NSF Ecology and Infectious Diseases Program, # TWO 1565, Principal Investigator: P.S. Craig), the Japan Society for the Promotion of Science (JSPS) (17256002, 21256003) and JSPS-Asia/Africa Science Platform Fund (2006-2011) to A. Ito. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Fogarty International Center or the National Institutes of Health. The authors thank many colleagues and Held workers who collected the isolates of E. granulosus s. s., E. multilocularis and E. shiquicus in China. NR 37 TC 50 Z9 57 U1 5 U2 42 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0020-7519 J9 INT J PARASITOL JI Int. J. Parasit. PD MAR PY 2010 VL 40 IS 3 BP 379 EP 385 DI 10.1016/j.ijpara.2009.09.006 PG 7 WC Parasitology SC Parasitology GA 568MN UT WOS:000275526600013 PM 19800346 ER PT J AU Seaman, V Dearwent, SM Gable, D Lewis, B Metcalf, S Orloff, K Tierney, B Zhu, J Logue, J Marchetto, D Ostroff, S Hoffman, R Xu, MJ Carey, D Erlich, P Gerhard, G Roda, P Iannuzzo, J Lewis, R Mellow, J Mulvihill, L Myles, Z Wu, MX Frank, A Gross-Davis, CA Klotz, J Lynch, A Weissfeld, J Weinberg, R Cole, H AF Seaman, Vincent Dearwent, Steve M. Gable, Debra Lewis, Brian Metcalf, Susan Orloff, Ken Tierney, Bruce Zhu, Jane Logue, James Marchetto, David Ostroff, Stephen Hoffman, Ronald Xu, Mingjiang Carey, David Erlich, Porat Gerhard, Glenn Roda, Paul Iannuzzo, Joseph Lewis, Robert Mellow, John Mulvihill, Linda Myles, Zachary Wu, Manxia Frank, Arthur Gross-Davis, Carol Ann Klotz, Judith Lynch, Adam Weissfeld, Joel Weinberg, Rona Cole, Henry TI A Multidisciplinary Investigation of a Polycythemia Vera Cancer Cluster of Unknown Origin SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH LA English DT Article DE polycythemia vera; cancer cluster; environmental exposure; Pennsylvania ID MYELOPROLIFERATIVE NEOPLASMS; JAK2 HAPLOTYPE; DISORDERS; PATHOGENESIS AB Cancer cluster investigations rarely receive significant public health resource allocations due to numerous inherent challenges and the limited success of past efforts. In 2008, a cluster of polycythemia vera, a rare blood cancer with unknown etiology, was identified in northeast Pennsylvania. A multidisciplinary group of federal and state agencies, academic institutions, and local healthcare providers subsequently developed a multifaceted research portfolio designed to better understand the cause of the cluster. This research agenda represents a unique and important opportunity to demonstrate that cancer cluster investigations can produce desirable public health and scientific outcomes when necessary resources are available. C1 [Seaman, Vincent; Dearwent, Steve M.; Gable, Debra; Lewis, Brian; Metcalf, Susan; Orloff, Ken; Tierney, Bruce; Zhu, Jane] Agcy Tox Subst & Dis Registry, Atlanta, GA 30341 USA. [Logue, James; Marchetto, David; Ostroff, Stephen] Penn Dept Hlth, Harrisburg, PA 17120 USA. [Hoffman, Ronald; Xu, Mingjiang] Mt Sinai Sch Med, New York, NY 10029 USA. [Carey, David; Erlich, Porat; Gerhard, Glenn; Roda, Paul] Geisinger Hlth Syst Clin, Danville, PA 17822 USA. [Iannuzzo, Joseph; Lewis, Robert; Mellow, John] Penn Dept Environm Protect, Wilkes Barre, PA 18711 USA. [Mulvihill, Linda; Myles, Zachary; Wu, Manxia] Ctr Dis Control & Prevent, Natl Program Canc Registries, Atlanta, GA 30333 USA. [Frank, Arthur; Gross-Davis, Carol Ann; Klotz, Judith; Lynch, Adam] Drexel Univ, Sch Publ Hlth, Philadelphia, PA 19102 USA. [Weissfeld, Joel] UPMC Canc Pavil, Pittsburgh, PA 15232 USA. [Weinberg, Rona] New York Blood Ctr, New York, NY 10065 USA. [Cole, Henry] Henry S Cole & Associates, Upper Marlboro, MD 20772 USA. RP Seaman, V (reprint author), Agcy Tox Subst & Dis Registry, 4770 Buford Highway NE, Atlanta, GA 30341 USA. EM VSeaman@cdc.gov; sed7@cdc.gov; dfg0@cdc.gov; bkl9@cdc.gov; swm1@cdc.gov; keo1@cdc.gov; bgt2@cdc.gov; jcz8@cdc.gov; jlogue@state.pa.us; dmarchetto@state.pa.us; sostroff@state.pa.us; ronald.hoffman@mssm.edu; mingjiang.xu@mssm.edu; djcarey@geisinger.edu; pmerlich@geisinger.edu; gsgerhard@geisinger.edu; proda1@geisinger.edu; jiannuzzo@state.pa.us; robelewis@state.pa.us; mellow5n2@aol.com; lmulvihill@cdc.gov; hkt4@cdc.gov; mwu@cdc.gov; ALF13@drexel.edu; CG48@drexel.edu; Judith.Klotz@comcast.net; jwepid@pitt.edu; rweinberg@nybloodcenter.org; hcole@hcole-environmental.com NR 13 TC 3 Z9 3 U1 0 U2 3 PU MOLECULAR DIVERSITY PRESERVATION INTERNATIONAL-MDPI PI BASEL PA KANDERERSTRASSE 25, CH-4057 BASEL, SWITZERLAND SN 1660-4601 J9 INT J ENV RES PUB HE JI Int. J. Environ. Res. Public Health PD MAR PY 2010 VL 7 IS 3 BP 1139 EP U11 DI 10.3390/ijerph7031139 PG 15 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 573XZ UT WOS:000275951600026 PM 20617023 ER PT J AU Stefaniak, AB Virji, MA Harvey, CJ Sbarra, DC Day, GA Hoover, MD AF Stefaniak, Aleksandr B. Virji, M. Abbas Harvey, Christopher J. Sbarra, Deborah C. Day, Gregory A. Hoover, Mark D. TI Influence of artificial gastric juice composition on bioaccessibility of cobalt- and tungsten-containing powders SO INTERNATIONAL JOURNAL OF HYGIENE AND ENVIRONMENTAL HEALTH LA English DT Article DE Dissolution; Gastric juice; Ingestion; Cobalt; Cemented tungsten carbide ID IN-VITRO DISSOLUTION; ORAL BIOAVAILABILITY; BIOLOGICAL LEVELS; PARTICLES; EXPOSURE; HEALTH; TESTS; SOIL; CHROMIUM; DISEASE AB The dissolution of metal-containing particles in the gastric compartment is poorly understood. The purpose of this study was to elucidate the influence of artificial gastric juice chemical composition on bioaccessibility of metals associated with ingestion-based health concerns. Dissolution rates were evaluated for well-characterized feedstock cobalt, tungsten metal, and tungsten carbide powders, chemically bonded pre-sintered (spray dryer material) and post-sintered (chamfer grinder) cemented tungsten carbide materials, and an admixture of pure cobalt and pure tungsten carbide, prepared by mechanically blending the two feedstock powders. Dissolution of each study material was evaluated in three different formulations of artificial gastric juice (from simplest to most chemically complex): American Society of Testing Materials (ASTM), U.S. Pharmacopoeia (USP), and National Institute for Occupational Safety and Health (NIOSH). Approximately 20% of cobalt dissolved in the first dissolution phase (t(1/2) = 0.02 clays) and the remaining 80% was released in the second long-term dissolution phase (t(1/2) = 0.5 to 1 days). Artificial gastric juice chemical composition did not influence dissolution rate constant values (k, g/cm(2) day) of cobalt powder, either alone or as an admixture. Approximately 100% of the tungsten and tungsten carbide that dissolved was released in a single dissolution phase: k-values of each material differed significantly in the solvents: NIOSH > ASTM > LISP (p < 0.05). The k-values of cobalt and tungsten carbide in pre- and post-sintered cemented tungsten carbide powders were significantly different from values for the pure feedstock powders. Solvent composition had little influence on oral bioaccessibility of highly soluble cobalt and our data support consideration of the oral exposure route as a contributing pathway to total-body exposure. Solvent composition appeared to influence bioaccessibility of the low soluble tungsten compounds, though differences may be due to variability in the data associated with the small masses of materials that dissolved. Nonetheless, ingestion exposure may not contribute appreciably to total body burden given the short residence time of material in the stomach and relatively long dissolution half-times of these materials (tip = 60 to 380 days). Published by Elsevier GmbH. C1 [Stefaniak, Aleksandr B.; Virji, M. Abbas; Harvey, Christopher J.; Sbarra, Deborah C.; Day, Gregory A.; Hoover, Mark D.] Ctr Dis Control & Prevent, NIOSH, Morgantown, WV 26505 USA. RP Stefaniak, AB (reprint author), Ctr Dis Control & Prevent, NIOSH, Mailstop H-2703, Morgantown, WV 26505 USA. EM astefaniak@cdc.gov RI Stefaniak, Aleksandr/I-3616-2012; Hoover, Mark/I-4201-2012 OI Hoover, Mark/0000-0002-8726-8127 NR 44 TC 7 Z9 7 U1 0 U2 15 PU ELSEVIER GMBH, URBAN & FISCHER VERLAG PI JENA PA OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY SN 1438-4639 EI 1618-131X J9 INT J HYG ENVIR HEAL JI Int. J. Hyg. Environ. Health. PD MAR PY 2010 VL 213 IS 2 BP 107 EP 115 DI 10.1016/j.ijheh.2009.12.006 PG 9 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 582QJ UT WOS:000276612500005 PM 20096630 ER PT J AU Aiello, AE Coulborn, RM Perez, V Davis, BM Uddin, M Murray, GF Shay, DK Waterman, SH Monto, AS AF Aiello, A. E. Coulborn, R. M. Perez, V. Davis, B. M. Uddin, M. Murray, G. F. Shay, D. K. Waterman, S. H. Monto, A. S. TI A randomized intervention trial of mask use and hand hygiene to reduce seasonal influenza-like illness and influenza infections among young adults in a university setting SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES LA English DT Meeting Abstract C1 [Aiello, A. E.; Coulborn, R. M.; Perez, V.; Davis, B. M.; Uddin, M.; Monto, A. S.] Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA. [Murray, G. F.] Univ S Alabama, Mobile, AL 36688 USA. [Shay, D. K.; Waterman, S. H.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1201-9712 J9 INT J INFECT DIS JI Int. J. Infect. Dis. PD MAR PY 2010 VL 14 SU 1 BP E320 EP E320 DI 10.1016/j.ijid.2010.02.2201 PG 1 WC Infectious Diseases SC Infectious Diseases GA 578MQ UT WOS:000276298201288 ER PT J AU Ansari, J Salman, M Safdar, RM Ikram, N Mahmood, T Zaheer, HA Kazi, BM Walke, H Asghar, RJ AF Ansari, J. Salman, M. Safdar, R. M. Ikram, N. Mahmood, T. Zaheer, H. A. Kazi, B. M. Walke, H. Asghar, R. J. TI Outbreak investigation of HIV/AIDS in Jalalpur Jattan (JPJ), Pakistan-2008 SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES LA English DT Meeting Abstract C1 [Ansari, J.; Salman, M.] Natl Inst Hlth, Publ Hlth Div, Islamabad, Pakistan. [Safdar, R. M.] Publ Hlth Labs Div, Islamabad, Pakistan. [Ikram, N.; Zaheer, H. A.] NACP, Islamabad, Pakistan. [Mahmood, T.] Dept Hlth, Islamabad, Pakistan. [Walke, H.] Ctr Dis Control & Prevent, Iatlanta, GA USA. [Asghar, R. J.] CDC, Ctr Dis Control & Prevent, Islamabad, Pakistan. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1201-9712 J9 INT J INFECT DIS JI Int. J. Infect. Dis. PD MAR PY 2010 VL 14 SU 1 BP E74 EP E74 DI 10.1016/j.ijid.2010.02.1653 PG 1 WC Infectious Diseases SC Infectious Diseases GA 578MQ UT WOS:000276298200174 ER PT J AU Arguin, P AF Arguin, P. TI Need for chemoprophylaxis for travelers to the Americas: Yes SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES LA English DT Meeting Abstract C1 [Arguin, P.] CDC, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1201-9712 J9 INT J INFECT DIS JI Int. J. Infect. Dis. PD MAR PY 2010 VL 14 SU 1 BP E23 EP E23 DI 10.1016/j.ijid.2010.02.1536 PG 1 WC Infectious Diseases SC Infectious Diseases GA 578MQ UT WOS:000276298200058 ER PT J AU Arvelo, W Reyes, L Estevez, A Gray, J Lindstrom, S Fry, A Olsen, S Ardon, F Frenkel, G Gordillo, B Lindblade, K AF Arvelo, W. Reyes, L. Estevez, A. Gray, J. Lindstrom, S. Fry, A. Olsen, S. Ardon, F. Frenkel, G. Gordillo, B. Lindblade, K. TI Population-based surveillance for 2009 pandemic influenza A H1N1 Virus in Guatemala, 2009 SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES LA English DT Meeting Abstract C1 [Arvelo, W.; Lindstrom, S.; Fry, A.; Olsen, S.; Lindblade, K.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Reyes, L.; Ardon, F.; Gordillo, B.] Minist Publ Hlth & Social Assistance, Guatemala City, Guatemala. [Estevez, A.; Gray, J.; Frenkel, G.] Univ Valle Guatemala, Guatemala City, Guatemala. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1201-9712 J9 INT J INFECT DIS JI Int. J. Infect. Dis. PD MAR PY 2010 VL 14 SU 1 BP E320 EP E321 DI 10.1016/j.ijid.2010.02.2202 PG 2 WC Infectious Diseases SC Infectious Diseases GA 578MQ UT WOS:000276298201289 ER PT J AU Balaban, V Marano, C AF Balaban, V. Marano, C. TI Medical tourism research: A systematic review SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES LA English DT Meeting Abstract C1 [Balaban, V.; Marano, C.] CDC, Atlanta, GA 30333 USA. NR 0 TC 7 Z9 7 U1 0 U2 13 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1201-9712 J9 INT J INFECT DIS JI Int. J. Infect. Dis. PD MAR PY 2010 VL 14 SU 1 BP E135 EP E135 DI 10.1016/j.ijid.2010.02.1784 PG 1 WC Infectious Diseases SC Infectious Diseases GA 578MQ UT WOS:000276298200305 ER PT J AU Sesquen, YC Gilman, RH Verastegui, M Yauri, V Angulo, N Portocarrero, DEV Bern, C AF Castro Sesquen, Y. Gilman, R. H. Verastegui, M. Yauri, V. Angulo, N. Velasquez Portocarrero, D. E. Bern, C. TI Cavia porcellus as a model for experimental infection by Trypanosoma cruzi SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES LA English DT Meeting Abstract C1 [Castro Sesquen, Y.; Verastegui, M.; Yauri, V.; Angulo, N.; Velasquez Portocarrero, D. E.] Univ Peruana Cayetano Heredia, Lima, Peru. [Gilman, R. H.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Bern, C.] CDC, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1201-9712 J9 INT J INFECT DIS JI Int. J. Infect. Dis. PD MAR PY 2010 VL 14 SU 1 BP E342 EP E342 DI 10.1016/j.ijid.2010.02.380 PG 1 WC Infectious Diseases SC Infectious Diseases GA 578MQ UT WOS:000276298201340 ER PT J AU Cetron, M AF Cetron, M. TI The Changing Patterns of Global Migration and the Impact on Infectious Diseases SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES LA English DT Meeting Abstract C1 [Cetron, M.] CDC, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 1 U2 4 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1201-9712 J9 INT J INFECT DIS JI Int. J. Infect. Dis. PD MAR PY 2010 VL 14 SU 1 BP E18 EP E19 DI 10.1016/j.ijid.2010.02.1526 PG 2 WC Infectious Diseases SC Infectious Diseases GA 578MQ UT WOS:000276298200048 ER PT J AU Coronado, F Griffith, M Tondella, ML Bonkosky, M Landaverde, M Clark, T AF Coronado, F. Griffith, M. Tondella, M. L. Bonkosky, M. Landaverde, M. Clark, T. TI Pertussis in Latin America: Developing the tools to face the challenge ahead SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES LA English DT Meeting Abstract C1 [Coronado, F.; Griffith, M.; Tondella, M. L.; Bonkosky, M.; Clark, T.] CDC, Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Landaverde, M.] Pan Amer Hlth Org, Washington, DC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1201-9712 J9 INT J INFECT DIS JI Int. J. Infect. Dis. PD MAR PY 2010 VL 14 SU 1 BP E283 EP E283 DI 10.1016/j.ijid.2010.02.2114 PG 1 WC Infectious Diseases SC Infectious Diseases GA 578MQ UT WOS:000276298201203 ER PT J AU Cortes, J Arvelo, W Lopez, B Reyes, L Gordillo, B Parashar, U Lindblade, K AF Cortes, J. Arvelo, W. Lopez, B. Reyes, L. Gordillo, B. Parashar, U. Lindblade, K. TI The epidemiology of rotavirus disease among children < 5 years of age - Santa Rosa, Guatemala, 2007-2009 SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES LA English DT Meeting Abstract C1 [Cortes, J.; Arvelo, W.; Lindblade, K.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Lopez, B.] Ctr Dis Control & Prevent, Guatemala City, Guatemala. [Reyes, L.] Guatemala Minist Publ Hlth & Social Assistance, Guatemala City, Guatemala. [Gordillo, B.] Minist Publ Hlth & Social Assistance, Guatemala City, Guatemala. [Parashar, U.] CDC, Atlanta, GA 30333 USA. OI Lopez, Beatriz/0000-0003-1353-9948 NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1201-9712 J9 INT J INFECT DIS JI Int. J. Infect. Dis. PD MAR PY 2010 VL 14 SU 1 BP E176 EP E176 DI 10.1016/j.ijid.2010.02.1876 PG 1 WC Infectious Diseases SC Infectious Diseases GA 578MQ UT WOS:000276298200395 ER PT J AU Cortes, J Esposito, D Cortese, M Bartlett, D Tate, J Payne, D Patel, M Curns, A Gentsch, J Parashar, U AF Cortes, J. Esposito, D. Cortese, M. Bartlett, D. Tate, J. Payne, D. Patel, M. Curns, A. Gentsch, J. Parashar, U. TI Uptake and impact of Rotavirus vaccines in US Children SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES LA English DT Meeting Abstract C1 [Cortese, M.; Bartlett, D.; Tate, J.; Payne, D.; Patel, M.; Curns, A.; Gentsch, J.] NCIRD, CDC, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1201-9712 J9 INT J INFECT DIS JI Int. J. Infect. Dis. PD MAR PY 2010 VL 14 SU 1 BP E175 EP E176 DI 10.1016/j.ijid.2010.02.1875 PG 2 WC Infectious Diseases SC Infectious Diseases GA 578MQ UT WOS:000276298200394 ER PT J AU Costa, P Orlosky, P Blanton, J Briggs, D Williams, C Tumpey, A AF Costa, P. Orlosky, P. Blanton, J. Briggs, D. Williams, C. Tumpey, A. TI World Rabies Day Campaign: Evaluating a global initiative SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES LA English DT Meeting Abstract C1 [Costa, P.; Williams, C.] Global Alliance Rabies Control, Manhattan, KS USA. [Orlosky, P.; Blanton, J.; Tumpey, A.] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Briggs, D.] Kansas State Coll Vet Med, Manhattan, KS USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1201-9712 J9 INT J INFECT DIS JI Int. J. Infect. Dis. PD MAR PY 2010 VL 14 SU 1 BP E431 EP E432 DI 10.1016/j.ijid.2010.02.578 PG 2 WC Infectious Diseases SC Infectious Diseases GA 578MQ UT WOS:000276298201538 ER PT J AU Davis, X Jentes, E Han, P Pollard, W Marano, C AF Davis, X. Jentes, E. Han, P. Pollard, W. Marano, C. TI Characteristics of travelers to developing countries: Findings from the 2008 consumer styles survey SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES LA English DT Meeting Abstract C1 [Davis, X.; Han, P.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Jentes, E.; Pollard, W.; Marano, C.] CDC, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1201-9712 J9 INT J INFECT DIS JI Int. J. Infect. Dis. PD MAR PY 2010 VL 14 SU 1 BP E130 EP E131 DI 10.1016/j.ijid.2010.02.1774 PG 2 WC Infectious Diseases SC Infectious Diseases GA 578MQ UT WOS:000276298200295 ER PT J AU Drobeniuc, J Meng, J Reuter, G Khudyakov, N Le, NT Greene-Montfort, T Dimitrova, Z Kamili, S Teo, CG AF Drobeniuc, J. Meng, J. Reuter, G. Khudyakov, N. Le, N. -T Greene-Montfort, T. Dimitrova, Z. Kamili, S. Teo, C. -G TI Performance of serologic assays specific to IgM antibodies against hepatitis E virus: pangenotypic evaluation SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES LA English DT Meeting Abstract C1 [Drobeniuc, J.; Meng, J.; Khudyakov, N.; Le, N. -T; Greene-Montfort, T.; Dimitrova, Z.; Kamili, S.; Teo, C. -G] Ctr Dis Control & Prevent, Atlanta, GA USA. [Reuter, G.] State Publ Hlth Serv, ANTSZ Reg Inst, Reg Lab Virol, Pecs, Hungary. RI Reuter, Gabor/I-7412-2013 OI Reuter, Gabor/0000-0002-5857-4934 NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1201-9712 J9 INT J INFECT DIS JI Int. J. Infect. Dis. PD MAR PY 2010 VL 14 SU 1 BP E239 EP E239 DI 10.1016/j.ijid.2010.02.2020 PG 1 WC Infectious Diseases SC Infectious Diseases GA 578MQ UT WOS:000276298201109 ER PT J AU Ehimiyein, A Niezgoda, M Orciari, L Kuzmin, I Osinubi, M Ehimiyein, IO Adawa, D Abdullahi, S Ogunkoya, A Rupprecht, CE AF Ehimiyein, A. Niezgoda, M. Orciari, L. Kuzmin, I. Osinubi, M. Ehimiyein, I. O. Adawa, D. Abdullahi, S. Ogunkoya, A. Rupprecht, C. E. TI Rabies cases in dog markets in Kaduna state, northern Nigeria SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES LA English DT Meeting Abstract C1 [Ehimiyein, A.; Niezgoda, M.; Orciari, L.; Kuzmin, I.; Osinubi, M.; Rupprecht, C. E.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Ehimiyein, I. O.; Adawa, D.; Abdullahi, S.; Ogunkoya, A.] Ahmadu Bello Univ, Zaria, KD, Nigeria. NR 0 TC 0 Z9 0 U1 0 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1201-9712 J9 INT J INFECT DIS JI Int. J. Infect. Dis. PD MAR PY 2010 VL 14 SU 1 BP E476 EP E476 DI 10.1016/j.ijid.2010.02.675 PG 1 WC Infectious Diseases SC Infectious Diseases GA 578MQ UT WOS:000276298201636 ER PT J AU Esposito, D Gardner, TJ Schneider, E Stockman, LJ Tate, J Panozzo, CA Robbins, CL Jenkerson, SA Thomas, L Watson, CM Curns, A Erdman, DD Lu, X Cromeans, T Westcott, M Humphries, C Ballantyne, J Fischer, GE McLaughlin, JB Armstrong, G Anderson, LJ AF Esposito, D. Gardner, T. J. Schneider, E. Stockman, L. J. Tate, J. Panozzo, C. A. Robbins, C. L. Jenkerson, S. A. Thomas, L. Watson, C. M. Curns, A. Erdman, D. D. Lu, X. Cromeans, T. Westcott, M. Humphries, C. Ballantyne, J. Fischer, G. E. McLaughlin, J. B. Armstrong, G. Anderson, L. J. TI An outbreak of pneumonia associated with emergent human adenovirus serotype 14-Southeast Alaska, 2008 SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES LA English DT Meeting Abstract C1 [Esposito, D.; Schneider, E.; Stockman, L. J.; Tate, J.; Panozzo, C. A.; Robbins, C. L.; Curns, A.; Erdman, D. D.; Lu, X.; Cromeans, T.; Fischer, G. E.; Armstrong, G.; Anderson, L. J.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Gardner, T. J.; Jenkerson, S. A.; McLaughlin, J. B.] Alaska Dept Hlth & Social Serv, Anchorage, AK USA. [Thomas, L.] Alicia Roberts Med Ctr, Klawock, AK USA. [Watson, C. M.] Craig Publ Hlth Ctr, Craig, AK USA. [Westcott, M.; Humphries, C.; Ballantyne, J.] Alaska State Publ Hlth Virol Lab, Fairbanks, AK USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1201-9712 J9 INT J INFECT DIS JI Int. J. Infect. Dis. PD MAR PY 2010 VL 14 SU 1 BP E175 EP E175 DI 10.1016/j.ijid.2010.02.1874 PG 1 WC Infectious Diseases SC Infectious Diseases GA 578MQ UT WOS:000276298200393 ER PT J AU Fiore, AE AF Fiore, A. E. TI Influenza vaccination: Where do we stand? SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES LA English DT Meeting Abstract C1 [Fiore, A. E.] Natl Ctr Infect Dis, CDC, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1201-9712 J9 INT J INFECT DIS JI Int. J. Infect. Dis. PD MAR PY 2010 VL 14 SU 1 BP E12 EP E12 DI 10.1016/j.ijid.2010.02.1507 PG 1 WC Infectious Diseases SC Infectious Diseases GA 578MQ UT WOS:000276298200029 ER PT J AU Gargano, LM Pazol, K Painter, JE Sales, JM Murray, D Morfaw, C Jones, LM Weiss, P Orenstein, WA DiClemente, RJ Hughes, JM AF Gargano, L. M. Pazol, K. Painter, J. E. Sales, J. M. Murray, D. Morfaw, C. Jones, L. M. Weiss, P. Orenstein, W. A. DiClemente, R. J. Hughes, J. M. TI Influenza vaccine delivery to adolescents: Assessment of two multicomponent interventions SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES LA English DT Meeting Abstract C1 [Painter, J. E.; Sales, J. M.; Jones, L. M.; Weiss, P.; DiClemente, R. J.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Pazol, K.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Murray, D.] Med Coll Georgia, Dept Pediat Infect Dis, Augusta, GA 30912 USA. [Morfaw, C.] Richmond Cty Hlth Dept, Augusta, GA USA. [Orenstein, W. A.] Bill & Melinda Gates Fdn, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1201-9712 J9 INT J INFECT DIS JI Int. J. Infect. Dis. PD MAR PY 2010 VL 14 SU 1 BP E319 EP E320 DI 10.1016/j.ijid.2010.02.2200 PG 2 WC Infectious Diseases SC Infectious Diseases GA 578MQ UT WOS:000276298201287 ER PT J AU Han, P Yanni, E Jentes, E Davis, X Pollard, W Marano, C AF Han, P. Yanni, E. Jentes, E. Davis, X. Pollard, W. Marano, C. TI Attitudes towards Avian influenza and sources of media information in travelers to developing countries SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES LA English DT Meeting Abstract C1 [Han, P.; Yanni, E.; Davis, X.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Jentes, E.; Pollard, W.; Marano, C.] CDC, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1201-9712 J9 INT J INFECT DIS JI Int. J. Infect. Dis. PD MAR PY 2010 VL 14 SU 1 BP E131 EP E131 DI 10.1016/j.ijid.2010.02.1775 PG 1 WC Infectious Diseases SC Infectious Diseases GA 578MQ UT WOS:000276298200296 ER PT J AU Kesavachandran, U Hurst, S Gade, L Balajee, A AF Kesavachandran, U. Hurst, S. Gade, L. Balajee, A. TI Assessment of a novel region of the 28S rRNA operon for identification of clinically significant Mucormycota SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES LA English DT Meeting Abstract C1 [Kesavachandran, U.; Hurst, S.; Gade, L.; Balajee, A.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1201-9712 J9 INT J INFECT DIS JI Int. J. Infect. Dis. PD MAR PY 2010 VL 14 SU 1 BP E119 EP E120 DI 10.1016/j.ijid.2010.02.1750 PG 2 WC Infectious Diseases SC Infectious Diseases GA 578MQ UT WOS:000276298200271 ER PT J AU LaRocque, R Rao, S Lawton, T Tsibris, A Schoenfeld, D Barry, A Yanni, E Marano, N Gallagher, N Marano, C Brunette, G Ryan, E AF LaRocque, R. Rao, S. Lawton, T. Tsibris, A. Schoenfeld, D. Barry, A. Yanni, E. Marano, N. Gallagher, N. Marano, C. Brunette, G. Ryan, E. TI Use and sources of medical information among departing international travelers to low and middle income countries at Logan International Airport-Boston, MA, 2009 SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES LA English DT Meeting Abstract C1 [LaRocque, R.; Rao, S.; Lawton, T.; Tsibris, A.; Schoenfeld, D.; Ryan, E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Barry, A.] Boston Publ Hlth Commiss, Boston, MA USA. [Yanni, E.; Marano, N.; Gallagher, N.; Marano, C.; Brunette, G.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1201-9712 J9 INT J INFECT DIS JI Int. J. Infect. Dis. PD MAR PY 2010 VL 14 SU 1 BP E132 EP E132 DI 10.1016/j.ijid.2010.02.1777 PG 1 WC Infectious Diseases SC Infectious Diseases GA 578MQ UT WOS:000276298200298 ER PT J AU LaRocque, R Rao, S Yanni, E Marano, N Gallagher, N Marano, C Brunette, G Lee, J Ansdell, V Schwartz, BS Knouse, M Cahill, J Hagmann, S Vinetz, J Hoffman, R Alvarez, S Goad, J Franco-Paredes, C Kozarsky, P Schoenfeld, D Ryan, E AF LaRocque, R. Rao, S. Yanni, E. Marano, N. Gallagher, N. Marano, C. Brunette, G. Lee, J. Ansdell, V. Schwartz, B. S. Knouse, M. Cahill, J. Hagmann, S. Vinetz, J. Hoffman, R. Alvarez, S. Goad, J. Franco-Paredes, C. Kozarsky, P. Schoenfeld, D. Ryan, E. TI Demographics, medical conditions, and use of immunizations and chemoprophylaxis among international travelers within the Global TravEpiNet US National Clinic Network SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES LA English DT Meeting Abstract C1 [LaRocque, R.; Rao, S.; Schoenfeld, D.; Ryan, E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Yanni, E.; Marano, N.; Gallagher, N.; Marano, C.; Brunette, G.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Lee, J.] NW Mem Hosp, Travel & Immunizat Ctr, Chicago, IL 60611 USA. [Ansdell, V.] Kaiser Permanente Honolulu Travel Med Clin, Honolulu, HI USA. [Schwartz, B. S.] Univ Calif San Francisco, Travel Med & Immunizat Ctr, San Francisco, CA 94143 USA. [Knouse, M.] Lehigh Valley Med Ctr, Allenton, PA USA. [Cahill, J.] Travel & Immunizat Ctr, New York, NY USA. [Hagmann, S.] Bronx Lebanon Hosp Ctr, Neighborhod Clin Travel Hlth, Bronx, NY 10456 USA. [Vinetz, J.] Univ Calif, San Diego Travel Clin, La Jolla, CA USA. [Hoffman, R.] Univ Calif Los Angeles, Travel & Trop Med Clin, Los Angeles, CA USA. [Alvarez, S.] Mayo Clin, Jacksonville, FL 32224 USA. [Goad, J.] USC Int Travel Med Clin, Los Angeles, CA USA. [Franco-Paredes, C.; Kozarsky, P.] Emory TravelWell, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1201-9712 J9 INT J INFECT DIS JI Int. J. Infect. Dis. PD MAR PY 2010 VL 14 SU 1 BP E131 EP E132 DI 10.1016/j.ijid.2010.02.1776 PG 2 WC Infectious Diseases SC Infectious Diseases GA 578MQ UT WOS:000276298200297 ER PT J AU Moreno, AT Ferreira, DM Pimenta, FC Santos, SR Martinez, MB Miyaji, E AF Moreno, A. T. Ferreira, D. M. Pimenta, F. C. Santos, S. R. Martinez, M. B. Miyaji, E. TI Variability of PspC (Pneumococcal surface protein C) in strains isolated in the University Hospital of the University of Sao Paulo (Brazil) SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES LA English DT Meeting Abstract C1 [Moreno, A. T.; Ferreira, D. M.; Miyaji, E.] Inst Butantan, Sao Paulo, Brazil. [Pimenta, F. C.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Santos, S. R.; Martinez, M. B.] Univ Hosp, Sao Paulo, Brazil. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1201-9712 J9 INT J INFECT DIS JI Int. J. Infect. Dis. PD MAR PY 2010 VL 14 SU 1 BP E444 EP E444 DI 10.1016/j.ijid.2010.02.606 PG 1 WC Infectious Diseases SC Infectious Diseases GA 578MQ UT WOS:000276298201566 ER PT J AU Nguyen, A Cohen, N Lipman, H Brown, C Fishbein, D AF Nguyen, A. Cohen, N. Lipman, H. Brown, C. Fishbein, D. TI Mass screening for fever: A comparison of three infrared thermal dectection systems and selfreported fever SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES LA English DT Meeting Abstract C1 [Nguyen, A.; Lipman, H.; Brown, C.; Fishbein, D.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Cohen, N.] Ctr Dis Control & Prevent, Chicago, IL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1201-9712 J9 INT J INFECT DIS JI Int. J. Infect. Dis. PD MAR PY 2010 VL 14 SU 1 BP E130 EP E130 DI 10.1016/j.ijid.2010.02.1773 PG 1 WC Infectious Diseases SC Infectious Diseases GA 578MQ UT WOS:000276298200294 ER PT J AU Nunez, S Mayta, H Verastegui, M Lafuente, C Bern, C Gilman, R AF Nunez, S. Mayta, H. Verastegui, M. Lafuente, C. Bern, C. Gilman, R. TI Trypanosoma cruzi expressing luciferase for drug screening using a bolivian strain SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES LA English DT Meeting Abstract C1 [Nunez, S.] Prisma, Lima 31, Peru. [Mayta, H.; Verastegui, M.] Univ Peruana Cayetano Heredia, Lima 31, Peru. [Lafuente, C.] Hosp Univ Japones, Santa Cruz, Bolivia. [Bern, C.] CDC, Atlanta, GA USA. [Gilman, R.] Johns Hopkins Univ, Baltimore, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1201-9712 J9 INT J INFECT DIS JI Int. J. Infect. Dis. PD MAR PY 2010 VL 14 SU 1 BP E443 EP E443 DI 10.1016/j.ijid.2010.02.603 PG 1 WC Infectious Diseases SC Infectious Diseases GA 578MQ UT WOS:000276298201563 ER PT J AU Oleribe, O Mosha, F Mohammed, M Mghamba, J Mmbuji, P Nsubuga, P Mukanga, D AF Oleribe, O. Mosha, F. Mohammed, M. Mghamba, J. Mmbuji, P. Nsubuga, P. Mukanga, D. TI From strategy to action: The vital roles of trained field epidemiologists and laboratory management professionals in epidemic control and prevention in Tanzania SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES LA English DT Meeting Abstract C1 [Oleribe, O.; Mosha, F.; Mohammed, M.; Mghamba, J.] TFELTP, Dar Es Salaam, Tanzania. [Mmbuji, P.] Tanzanian Minist Hlth & Social Welf, Dar Es Salaam, Tanzania. [Nsubuga, P.] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Mukanga, D.] AFENET, Kampala, Uganda. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1201-9712 J9 INT J INFECT DIS JI Int. J. Infect. Dis. PD MAR PY 2010 VL 14 SU 1 BP E432 EP E432 DI 10.1016/j.ijid.2010.02.579 PG 1 WC Infectious Diseases SC Infectious Diseases GA 578MQ UT WOS:000276298201539 ER PT J AU Szymanowski, P Lipman, H Fishbein, D Chandra, C AF Szymanowski, P. Lipman, H. Fishbein, D. Chandra, C. TI Epidemiology of varicella among passengers and crew on international conveyances, United States, 2005-2008 SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES LA English DT Meeting Abstract C1 [Szymanowski, P.] CDC, SRA Int, Atlanta, GA 30333 USA. [Lipman, H.; Fishbein, D.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Chandra, C.] CDC Internship Program, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1201-9712 J9 INT J INFECT DIS JI Int. J. Infect. Dis. PD MAR PY 2010 VL 14 SU 1 BP E177 EP E177 DI 10.1016/j.ijid.2010.02.1878 PG 1 WC Infectious Diseases SC Infectious Diseases GA 578MQ UT WOS:000276298200397 ER PT J AU van Eijk, AM Brooks, JT Adcock, PM Garrett, V Eberhard, M Rosen, DH Ayisi, JG Ochieng, JB Kumar, L Gentsch, JR Nahlen, BL Mintz, ED Slutsker, L AF van Eijk, Anna M. Brooks, John T. Adcock, Penny M. Garrett, Valerie Eberhard, Mark Rosen, Daniel H. Ayisi, John G. Ochieng, John B. Kumar, Lata Gentsch, Jon R. Nahlen, Bernard L. Mintz, Eric D. Slutsker, Laurence TI Diarrhea in children less than two years of age with known HIV status in Kisumu, Kenya SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE Diarrhea; HIV infection; Children; Kenya ID HUMAN-IMMUNODEFICIENCY-VIRUS; COTRIMOXAZOLE PROPHYLAXIS; ZINC SUPPLEMENTATION; WESTERN KENYA; SOUTH-AFRICA; INFECTION; MORBIDITY; INFANTS; UGANDA; MORTALITY AB Objective: To compare the frequency and etiology of diarrhea in children aged less than 2 years with known HIV status. Methods: This was a nested cohort study, whereby children were followed during monthly routine and unscheduled visits. The HIV status of children was determined with PCR. A stool culture was obtained from children with diarrhea. A subset of stool samples was examined for parasites and tested for rotavirus. Results: Between 1997 and 2001, 682 children (51.0% male) contributed observation periods with a mean of 47 weeks. Overall there were 198 episodes of diarrhea per 100 child-years of observation (CYO); diarrhea was more common among HIV-positive children than among HIV-negative children (321 vs. 183 episodes/100 CYO, respectively, p < 0.01) and was not statistically different for HIV-negative children born to HIV-positive compared with HIV-negative mothers (182 vs. 187 episodes/100 CYO, respectively, p = 0.36). For 66.5% of the acute episodes a stool culture was obtained; 27.8% of stool cultures yielded a bacterial pathogen. A positive stool culture was less likely among HIV-positive children compared to children of HIV-negative mothers (20.5% vs. 34.3%, p = 0.01). Susceptibility of Salmonella and Shigella to commonly used antibiotics was low. Rotavirus was detected in 13.9% of 202 examined stool samples, and a stool parasite in 3.8% of 394 samples. Diarrhea was associated with 37.8% of child deaths. Conclusions: Diarrhea was more common among HIV-infected children, but was not associated with specific bacterial pathogens. Measures that reduce diarrhea will benefit all children, but may benefit HIV-infected children in particular. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. C1 [van Eijk, Anna M.] Univ Amsterdam, Acad Med Ctr, Dept Infect Dis Trop Med & AIDS, NL-1105 AZ Amsterdam, Netherlands. [Brooks, John T.] Ctr Dis Control & Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA USA. [Adcock, Penny M.; Garrett, Valerie; Kumar, Lata; Mintz, Eric D.] Ctr Dis Control & Prevent, Enter Dis Epidemiol Branch, Div Bacterial Foodborne & Mycot Dis, Natl Ctr Zoonot Vectorborne & Enter Dis, Atlanta, GA USA. [Eberhard, Mark; Rosen, Daniel H.; Nahlen, Bernard L.; Slutsker, Laurence] Ctr Dis Control & Prevent, Div Parasit Dis, Natl Ctr Zoonot Vectorborne & Enter Dis, Atlanta, GA USA. [Ayisi, John G.; Ochieng, John B.] Kenya Govt Med Res Ctr, Ctr Vector Biol & Control Res, Kisumu, Kenya. [Gentsch, Jon R.] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP van Eijk, AM (reprint author), Univ Amsterdam, Acad Med Ctr, Dept Infect Dis Trop Med & AIDS, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands. EM amvaneijk@yahoo.com FU Centers for Disease Control and Prevention; United States Agency for International Development [AOT0483-PH1-2171, HRN-A-00-04-00010-02]; The Netherlands Foundation for the Advancement of Tropical Research, The Hague, The Netherlands FX This study was supported by the Centers for Disease Control and Prevention and grant number AOT0483-PH1-2171, HRN-A-00-04-00010-02 from the United States Agency for International Development and by The Netherlands Foundation for the Advancement of Tropical Research, The Hague, The Netherlands. The funding agencies had no role in the design, collection, analysis and interpretation of data, or in the decision to submit the manuscript for publication. NR 21 TC 15 Z9 15 U1 0 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1201-9712 J9 INT J INFECT DIS JI Int. J. Infect. Dis. PD MAR PY 2010 VL 14 IS 3 BP E220 EP E225 DI 10.1016/j.ijid.2009.06.001 PG 6 WC Infectious Diseases SC Infectious Diseases GA 568HN UT WOS:000275513300006 PM 19664950 ER PT J AU Yanni, E Berro, A Han, P Lawson, C Gallagher, N Liske, K Houck, P Lipman, H Brunette, G Marano, N Brown, C AF Yanni, E. Berro, A. Han, P. Lawson, C. Gallagher, N. Liske, K. Houck, P. Lipman, H. Brunette, G. Marano, N. Brown, C. TI Influenza-like illness among US pilgrims returning from the Hajj in the Kingdom of Saudi Arabia compared to other US-bound Travelers: Data from the CDC quarantine activity reporting system (QARS), 2006-2008 SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES LA English DT Meeting Abstract C1 [Yanni, E.; Han, P.; Lawson, C.; Gallagher, N.; Liske, K.; Houck, P.; Lipman, H.; Marano, N.; Brown, C.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Berro, A.; Brunette, G.] CDC, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1201-9712 J9 INT J INFECT DIS JI Int. J. Infect. Dis. PD MAR PY 2010 VL 14 SU 1 BP E270 EP E270 DI 10.1016/j.ijid.2010.02.2088 PG 1 WC Infectious Diseases SC Infectious Diseases GA 578MQ UT WOS:000276298201177 ER PT J AU Dye, BA Arevalo, O Vargas, CM AF Dye, Bruce A. Arevalo, Oscar Vargas, Clemencia M. TI Trends in paediatric dental caries by poverty status in the United States, 1988-1994 and 1999-2004 SO INTERNATIONAL JOURNAL OF PAEDIATRIC DENTISTRY LA English DT Article ID ORAL-HEALTH COMPONENT; EXAMINATION SURVEY NHANES; BEVERAGE CONSUMPTION; NATIONAL-HEALTH; QUALITY-ASSURANCE; YOUNG-CHILDREN; NUTRITION; INSURANCE; PATTERNS; CARE AB Background. Recent reports have suggested that dental caries among some young children is increasing in the United States. Aim. To describe changes in paediatric caries prevalence by poverty status in the United States. Design. National Health and Nutrition Examination Survey (NHANES) data for children aged 2-11 years for 1988-1994 and 1999-2004 were used. Results. Caries in the primary dentition increased among poor and non-poor boys aged 2-8 years (45-53% and 23-31%, respectively) and among non-poor boys aged 2-5 years (13-21%) from 1988-1994 to 1999-2004. Caries experience also increased on buccal-lingual, mesio-distal, and occlusal primary dental surfaces among poor children aged 2-8 years and this increase may be attributed to an increase in the number of dental surfaces restored. In the mixed dentition, caries remains relatively unchanged. Caries continues to decline in the permanent dentition for many children, but is increasing among poor non-Hispanic whites aged 6-8 years (8-22%) and poor Mexican-Americans aged 9-11 years (38-55%). Conclusions. For many older children, caries continues to decline or remain unchanged. Nevertheless, for a subgroup of younger children, caries is increasing and this increase is impacting some traditionally low-risk groups of children. C1 [Dye, Bruce A.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, NHANES Programme, Hyattsville, MD 20782 USA. [Arevalo, Oscar] Univ Kentucky, Coll Dent, Div Dent Publ Hlth, Lexington, KY USA. [Vargas, Clemencia M.] Univ Maryland, Sch Dent, Dept Hlth Promot & Policy, Baltimore, MD 21201 USA. RP Dye, BA (reprint author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, NHANES Programme, 3311 Toledo Rd,Room 4416, Hyattsville, MD 20782 USA. EM bfd1@cdc.gov NR 32 TC 53 Z9 57 U1 2 U2 17 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0960-7439 J9 INT J PAEDIATR DENT JI Int. J. Paediatr. Dent. PD MAR PY 2010 VL 20 IS 2 BP 132 EP 143 DI 10.1111/j.1365-263X.2009.01029.x PG 12 WC Dentistry, Oral Surgery & Medicine; Pediatrics SC Dentistry, Oral Surgery & Medicine; Pediatrics GA 557LX UT WOS:000274671700007 PM 20384828 ER PT J AU Cain, KP Nelson, LJ Cegielski, JP AF Cain, K. P. Nelson, L. J. Cegielski, J. P. TI Global policies and practices for managing persons exposed to multidrug-resistant tuberculosis SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE LA English DT Article DE tuberculosis; contact tracing; tuberculosis, multidrug-resistant; child ID CONTACT INVESTIGATIONS; HOUSEHOLD CONTACTS; MYCOBACTERIUM-TUBERCULOSIS; PULMONARY TUBERCULOSIS; LATENT TUBERCULOSIS; PREVENTIVE THERAPY; CONTROLLED TRIAL; YOUNG-CHILDREN; UNITED-STATES; HONG-KONG AB SETTING: In the 1960s, treatment for latent tuberculosis infection (LTBI) with isoniazid proved to be so effective, safe, and inexpensive that research into alternative treatments virtually ceased. Now that multidrug-resistant tuberculosis (MDR-TB) is widespread, no data are available to guide the management of persons exposed to MDR-TB (contacts). METHODS: We surveyed National TB Program directors and MDR-TB program managers about current practices for managing MDR-TB contacts in countries with an MDR-TB prevalence of >2% in new patients and those with programs for managing MDR-TB. RESULTS: Of 35 countries that met the survey criteria, 25 (71%) responded; 24 of these (96%) have a guideline for managing TB contacts. Of these, 19 (76%) usually or always evaluated contacts and treated LTBI. In contrast, 10 (40%) countries reported having a guideline for managing MDR-TB contacts, 11 (44%) usually or always evaluated MDR-TB contacts, and 9 (36%) treated LTBI. Only two (8%) used a regimen that has activity against MDR-TB. Lack of evidence or guidelines was the main reason for not treating MDR-TB contacts. CONCLUSIONS: Management of MDR-TB contacts is inconsistent and ineffective due to lack of evidence-based guidelines. There is an urgent need to generate evidence to guide policy. C1 [Cain, K. P.; Nelson, L. J.; Cegielski, J. P.] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA. [Cain, K. P.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Off Workforce & Career Dev, Atlanta, GA USA. RP Cain, KP (reprint author), CDC, Div TB Eliminat, 1600 Clifton Rd,MS-E-10, Atlanta, GA 30333 USA. EM kcain@cdc.gov NR 45 TC 13 Z9 13 U1 2 U2 6 PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) PI PARIS PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE SN 1027-3719 J9 INT J TUBERC LUNG D JI Int. J. Tuberc. Lung Dis. PD MAR PY 2010 VL 14 IS 3 BP 269 EP 274 PG 6 WC Infectious Diseases; Respiratory System SC Infectious Diseases; Respiratory System GA 565AL UT WOS:000275260300008 PM 20132616 ER PT J AU Bloss, E Kuksa, L Holtz, TH Riekstina, V Skripconoka, V Kammerer, S Leimane, V AF Bloss, E. Kuksa, L. Holtz, T. H. Riekstina, V. Skripconoka, V. Kammerer, S. Leimane, V. TI Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000-2004 SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE LA English DT Article DE tuberculosis; multidrug resistance; adverse events; Latvia AB SETTING: Latvia has one of the highest rates of multidrug-resistant tuberculosis (MDR-TB) globally. Clinical management of MDR-TB requires lengthy multidrug regimens that often cause adverse events. DESIGN: We retrospectively reviewed records of patients who began MDR-TB treatment between 2000 and 2004. Treatment-related adverse events and factors associated with experiencing adverse events were evaluated. We also examined the frequency of and reasons for changing drug regimens. RESULTS: Among 1027 cases, 807 (79%) experienced at least one adverse event, with a median of three events per case. The most commonly reported events were nausea (58%), vomiting (39%) and abdominal pain (24%). More serious events, such as psychiatric episodes (13%), hepatitis (9%) and renal failure (4%), were relatively frequent. A change in drug dose due to an adverse event occurred in 201 (20%) cases, while 661 (64%) had at least one drug discontinued temporarily or permanently. Being older, female, having bilateral lung cavities and a greater number of TB symptoms at baseline were associated with an increased number of events. CONCLUSION: Adverse events were prevalent among MDR-TB cases treated in Latvia, with over two thirds requiring discontinuation of at least one drug. MDR-TB patients who are female, older or have severe TB disease should be closely monitored for treatment-related adverse events. C1 [Bloss, E.; Holtz, T. H.; Kammerer, S.] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA 30333 USA. [Kuksa, L.; Riekstina, V.; Skripconoka, V.; Leimane, V.] State Agcy TB & Lung Dis, Riga, Latvia. RP Bloss, E (reprint author), Ctr Dis Control & Prevent, Div TB Eliminat, 1600 Clifton Rd,MS E-10, Atlanta, GA 30333 USA. EM dpu2@cdc.gov FU Latvian Ministry of Health; US Agency for International Development (USAID) FX Funding for the study was provided by the Latvian Ministry of Health. The US Agency for International Development (USAID) contributed funding to support technical assistance to the project on behalf of the US Centers for Disease Control and Prevention. USAID had no role in the conduct of the study. NR 20 TC 34 Z9 37 U1 0 U2 2 PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) PI PARIS PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE SN 1027-3719 J9 INT J TUBERC LUNG D JI Int. J. Tuberc. Lung Dis. PD MAR PY 2010 VL 14 IS 3 BP 275 EP 281 PG 7 WC Infectious Diseases; Respiratory System SC Infectious Diseases; Respiratory System GA 565AL UT WOS:000275260300009 PM 20132617 ER PT J AU Agizew, T Bachhuber, MA Nyirenda, S Makwaruzi, VZSAM Tedla, Z Tallaksen, RJ Parker, JE Mboya, JJ Samandari, T AF Agizew, T. Bachhuber, M. A. Nyirenda, S. Makwaruzi, V. Z. S. A. M. Tedla, Z. Tallaksen, R. J. Parker, J. E. Mboya, J. J. Samandari, T. TI Association of chest radiographic abnormalities with tuberculosis disease in asymptomatic HIV-infected adults SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE LA English DT Article DE tuberculosis; HIV; screening; chest radiograph ID HUMAN-IMMUNODEFICIENCY-VIRUS; T-LYMPHOCYTE COUNT; PULMONARY TUBERCULOSIS; PREVENTIVE THERAPY; SUBCLINICAL TUBERCULOSIS; ACTIVE TUBERCULOSIS; GOLD MINERS; MANIFESTATIONS; BOTSWANA; UGANDA AB SETTING: Francistown and Gaborone, Botswana. OBJECTIVE: Chest radiography is used to screen for tuberculosis (TB) in asymptomatic persons living with the human immunodeficiency virus (PLWH) seeking isoniazid preventive therapy (IPT). We describe radiographic features in PLWH in a TB-endemic setting and identify features associated with TB disease. DESIGN: Asymptomatic PLWH seeking IPT under program conditions for a clinical trial between 2004 and 2006 received chest radiographs (CXRs) that were read using the standardized Chest Radiograph Reading and Recording System (CRRS). Clinical characteristics, including TB disease, were compared with the radiographic findings. RESULTS: From 2732 screening CXRs, 183 had one or more abnormalities and were scored using CRRS, with 42% having infiltrates (36% upper lobes), 35% parenchymal fibrosis and 32% adenopathy. TB disease status was determined in 129 (70%) PLWH, of whom 22 (17%) had TB disease. TB disease was associated with upper lobe infiltrates (relative risk [RR] 3.0, 95%CI 1.5-6.2) and mediastinal adenopathy (RR 3.9, 95%CI 1.8-8.4). The sensitivity and specificity of either upper lobe infiltrates or mediastinal lymphadenopathy for TB disease were respectively 64% and 82%. CONCLUSION: A combination of CXR features was useful for predicting TB disease in asymptomatic PLWH. CRRS should be used more frequently in similar studies. C1 [Samandari, T.] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA 30333 USA. [Makwaruzi, V. Z. S. A. M.] Nyangabgwe Referral Hosp, Francistown, Botswana. [Agizew, T.; Bachhuber, M. A.; Nyirenda, S.; Tedla, Z.; Samandari, T.] BOTUSA, Gaborone, Botswana. [Tallaksen, R. J.; Parker, J. E.] W Virginia Univ, Sch Med, Morgantown, WV 26506 USA. [Mboya, J. J.] Minist Hlth, Dis Control Unit, Gaborone, Botswana. RP Samandari, T (reprint author), Ctr Dis Control & Prevent, Div TB Eliminat, 1600 Clifton Rd N E,Mailstop E-10, Atlanta, GA 30333 USA. EM tsamandari@cdc.gov RI Mitchell, Ellen/H-5475-2013 FU CDC, Atlanta, Georgia, USA; United States Agency for International Development FX The authors gratefully acknowledge the services of the research nurses, health educators and laboratory technicians, data manager, data clerks, as well as the Botswana volunteers in the IPT trial, for making this study possible. The trial was funded by the CDC, Atlanta, Georgia, USA, and the United States Agency for International Development. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the funding agencies. NR 37 TC 11 Z9 12 U1 0 U2 1 PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) PI PARIS PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE SN 1027-3719 J9 INT J TUBERC LUNG D JI Int. J. Tuberc. Lung Dis. PD MAR PY 2010 VL 14 IS 3 BP 324 EP 331 PG 8 WC Infectious Diseases; Respiratory System SC Infectious Diseases; Respiratory System GA 565AL UT WOS:000275260300016 PM 20132624 ER PT J AU Ohkado, A Pevzner, E Sugiyama, T Murakami, K Yamada, N Cavanaugh, S Ishikawa, N Harries, AD AF Ohkado, A. Pevzner, E. Sugiyama, T. Murakami, K. Yamada, N. Cavanaugh, S. Ishikawa, N. Harries, A. D. TI Evaluation of an international training course to build programmatic capacity for tuberculosis control SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE LA English DT Article DE evaluation; international training; operations research; electronic mail; tuberculosis ID OPERATIONAL-RESEARCH AB We evaluated the international training course of the Research Institute of Tuberculosis, Kiyose, Japan, by e-mailing structured questionnaires to participants who attended the course from 2001 to 2007. Of 62 responding participants, 34 developed action plan projects (APPs) and 28 developed operations research projects (ORPs). Among respondents drafting APPs, 27 (79%) started implementing projects, and 24 (88%) completed over half of their planned activities. Among respondents drafting ORPs, 11 (39%) started projects but no scientific papers were published. The main reasons for the failure to implement ORPs were due to lack of time, funds, and disapproval by supervisors. A sequential training model may better address barriers to teaching and assisting ORPs. C1 [Ohkado, A.] Japan AntiTB Assoc, Dept Epidemiol & Clin Res, Res Inst TB, Kiyose, Tokyo 2048533, Japan. [Pevzner, E.; Cavanaugh, S.] US Ctr Dis Control & Prevent, Natl Ctr HIV Hepatitis STD & TB Prevent, Div TB Eliminat, Atlanta, GA USA. [Murakami, K.; Yamada, N.] JATA, RIT, Int Cooperat Dept, Kiyose, Japan. [Harries, A. D.] Int Union TB & Lung Dis, Paris, France. [Harries, A. D.] London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1, England. RP Ohkado, A (reprint author), Japan AntiTB Assoc, Dept Epidemiol & Clin Res, Res Inst TB, Matsuyama 3-1-24, Kiyose, Tokyo 2048533, Japan. EM ohkadoa@jata.or.jp FU Japan International Cooperation Agency; JATA FX The authors thank the Japan International Cooperation Agency for continuous financial support of the international training Course at the RIT. This Study was funded mainly by the Double-Barred Cross Seal Donation Fund of JATA. NR 8 TC 7 Z9 7 U1 0 U2 0 PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) PI PARIS PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE SN 1027-3719 J9 INT J TUBERC LUNG D JI Int. J. Tuberc. Lung Dis. PD MAR PY 2010 VL 14 IS 3 BP 371 EP 373 PG 3 WC Infectious Diseases; Respiratory System SC Infectious Diseases; Respiratory System GA 565AL UT WOS:000275260300023 PM 20132631 ER PT J AU Spradling, PR Richardson, JT Buchacz, K Moorman, AC Finelli, L Bell, BP Brooks, JT AF Spradling, Philip R. Richardson, James T. Buchacz, Kate Moorman, Anne C. Finelli, Lyn Bell, Beth P. Brooks, John T. CA HIV Outpatient Study Investigators TI Trends in Hepatitis C Virus Infection Among Patients in the HIV Outpatient Study, 1996-2007 SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE coinfection; HCV; HIV; prevalence; testing ID HUMAN-IMMUNODEFICIENCY-VIRUS; INJECTION-DRUG USERS; ACTIVE ANTIRETROVIRAL THERAPY; CLINICAL-TRIALS GROUP; UNITED-STATES; LIVER-DISEASE; PREVALENCE; MORTALITY; COINFECTION; MORBIDITY AB Background: Coinfection with hepatitis C virus (HCV) contributes increasingly to the morbidity and mortality of persons infected with HIV. We assessed HCV infection screening practices and determined trends in the prevalence of HCV infection in the HIV Outpatient Study (HOPS) from 1996 to 2007. Methods: We calculated the proportion of patients eligible to be tested for HCV infection (i.e., never tested or previously tested negative) and the prevalence of HCV infection annually from 1996 to 2007 by sociodemographic, clinical, and HIV risk category characteristics. We used multiple logistic regression analyses to evaluate factors independently associated with HCV testing. Results: A total of 7618 patients were active in the HOPS from 1996 through 2007. The proportion of eligible patients tested for HCV infection increased from 10.7% in 1996 to 76.6% in 2007 and increased among all demographic and risk groups. Overall HCV prevalence decreased from 36.7% in 1996 to 19.7% in 2007; decreases in prevalence occurred among all groups except for injection drug users (IDUs). In multivariable analysis, age older than 35 years, nonwhite race, Hispanic ethnicity, high-risk heterosexual and IDU risk categories, and at least 3 years of enrollment in the HOPS were associated with increased odds of having been tested for HCV infection. Conclusions: Screening for HCV infection in the HOPS has improved, although a sizable fraction of patients remain unscreened. The decline in overall HCV infection prevalence from 1996 to 2007 resulted primarily from a decline in the fraction of all prevalent infections in the cohort attributable to IDU patients. C1 [Spradling, Philip R.; Finelli, Lyn; Bell, Beth P.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. [Richardson, James T.] Cerner Corp, Vienna, VA USA. [Buchacz, Kate; Moorman, Anne C.; Brooks, John T.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. RP Spradling, PR (reprint author), Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV Hepatitis STD & TB Prevent, Mailstop G37,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM pspradling@cdc.gov FU Centers for Disease Control and Prevention [200-2001-00133, 200-2006-2879] FX Supported by Contract 200-2001-00133 and 200-2006-2879-Centers for Disease Control and Prevention. NR 52 TC 23 Z9 23 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD MAR 1 PY 2010 VL 53 IS 3 BP 388 EP 396 DI 10.1097/QAI.0b013e3181b67527 PG 9 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 565VX UT WOS:000275324500014 PM 19738485 ER PT J AU Catalano, RF Gavin, LE Markham, CM AF Catalano, Richard F. Gavin, Lorrie E. Markham, Christine M. TI Future Directions for Positive Youth Development as a Strategy to Promote Adolescent Sexual and Reproductive Health SO JOURNAL OF ADOLESCENT HEALTH LA English DT Editorial Material ID MENTAL-HEALTH; PREVENTION; CHILDHOOD C1 [Catalano, Richard F.] Univ Washington, Sch Social Work, Social Dev Res Grp, Seattle, WA 98195 USA. [Gavin, Lorrie E.] US Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA. [Markham, Christine M.] Univ Texas Hlth Sci Ctr Houston, Univ Texas Prevent Res Ctr, Houston, TX USA. RP Catalano, RF (reprint author), Univ Washington, Sch Social Work, Social Dev Res Grp, Seattle, WA 98195 USA. NR 18 TC 12 Z9 12 U1 0 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD MAR PY 2010 VL 46 IS 3 SU 1 BP S92 EP S96 DI 10.1016/j.jadohealth.2009.12.026 PG 5 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA 559WY UT WOS:000274860500007 PM 20172463 ER PT J AU Gavin, LE Catalano, RF David-Ferdon, C Gloppen, KM Markham, CM AF Gavin, Loretta E. Catalano, Richard F. David-Ferdon, Corinne Gloppen, Kari M. Markham, Christine M. TI A Review of Positive Youth Development Programs That Promote Adolescent Sexual and Reproductive Health SO JOURNAL OF ADOLESCENT HEALTH LA English DT Review DE Adolescent; Sexual and reproductive health; Positive youth development ID TEEN OUTREACH PROGRAM; PREGNANCY PREVENTION PROGRAM; RANDOMIZED CONTROLLED-TRIAL; CHANGING TEACHING PRACTICES; SERVICE LEARNING-PROGRAM; GATEHOUSE PROJECT; RISK BEHAVIORS; FOLLOW-UP; SCHOOLS; OUTCOMES AB Purpose: Positive youth development (PYD) may be a promising strategy for promoting adolescent health. A systematic review of the published data was conducted to identify and describe PYD programs that improve adolescent sexual and reproductive health. Methods: Eight databases were searched for articles about PYD programs published between 1985 and 2007. Programs included met the following criteria: fostered at least one of 12 PYD goals in multiple socialization domains (i.e., family, school, community) or addressed two or more goals in at least one socialization domain; allocated at least half of the program activities to promoting general PYD outcomes (as compared with a focus on direct sexual health content); included youth younger than 20 years old; and used an experimental or quasi-experimental evaluation design. Results: Thirty programs met the inclusion criteria, 15 of which had evidence of improving at least one adolescent sexual and reproductive health outcome. Program effects were moderate and well-sustained. Program goals addressed by approximately 50% or more of the effective programs included promoting prosocial bonding, cognitive competence, social competence, emotional competence, belief in the future, and self-determination. Effective programs were significantly more likely than those that did not have an impact to strengthen the school context and to deliver activities in a supportive atmosphere. Effective programs were also more likely to build skills, enhance bonding, strengthen the family, engage youth in real roles and activities, empower youth, communicate expectations, and be stable and relatively long-lasting, although these differences between effective and ineffective programs were not statistically significant. Conclusion: PYD programs can promote adolescent sexual and reproductive health, and tested, effective PYD programs should be part of a comprehensive approach to promoting adolescent health. However, more research is needed before a specific list of program characteristics can be viewed as a "recipe'' for success. Published by Elsevier Inc. C1 [Gavin, Loretta E.; David-Ferdon, Corinne; Gloppen, Kari M.] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Catalano, Richard F.] Univ Washington, Sch Social Work, Social Dev Res Grp, Seattle, WA 98195 USA. [Markham, Christine M.] Univ Texas Hlth Sci Ctr Houston, Univ Texas Prevent Res Ctr, Houston, TX USA. RP Gavin, LE (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. EM lcg6@cdc.gov FU NIAID NIH HHS [P30 AI036211] NR 59 TC 63 Z9 63 U1 5 U2 37 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD MAR PY 2010 VL 46 IS 3 SU 1 BP S75 EP S91 DI 10.1016/j.jadohealth.2009.11.215 PG 17 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA 559WY UT WOS:000274860500006 PM 20172462 ER PT J AU Gavin, LE Catalano, RF Markham, CM AF Gavin, Lorrie E. Catalano, Richard F. Markham, Christine M. TI Positive Youth Development as a Strategy to Promote Adolescent Sexual and Reproductive Health SO JOURNAL OF ADOLESCENT HEALTH LA English DT Editorial Material ID DEVELOPMENT PROGRAMS; UNITED-STATES; PREVENTION; RISK C1 [Gavin, Lorrie E.] US Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA. [Catalano, Richard F.] Univ Washington, Sch Social Work, Social Dev Res Grp, Seattle, WA 98195 USA. [Markham, Christine M.] Univ Texas Hlth Sci Ctr Houston, Univ Texas Prevent Res Ctr, Houston, TX USA. RP Gavin, LE (reprint author), US Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA. NR 21 TC 13 Z9 13 U1 0 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD MAR PY 2010 VL 46 IS 3 SU 1 BP S1 EP S6 DI 10.1016/j.jadohealth.2009.12.017 PG 6 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA 559WY UT WOS:000274860500001 PM 20172457 ER PT J AU Gloppen, KM David-Ferdon, C Bates, J AF Gloppen, Kari M. David-Ferdon, Corinne Bates, Jessica TI Confidence as a Predictor of Sexual and Reproductive Health Outcomes for Youth SO JOURNAL OF ADOLESCENT HEALTH LA English DT Review DE Adolescent; HIV prevention; STD prevention; Unintended pregnancy; Youth development; Confidence; Belief in the future; Self-efficacy; Self-determination; Identity ID AFRICAN-AMERICAN ADOLESCENTS; HIGH-SCHOOL-STUDENTS; CONTRACEPTIVE SELF-EFFICACY; CONSISTENT CONDOM USE; RISK BEHAVIOR; TRANSMITTED-DISEASES; GENDER-DIFFERENCES; HIV-INFECTION; PSYCHOSOCIAL PREDICTORS; JUVENILE-OFFENDERS AB Purpose: To assess the association between four positive youth development (PYD) constructs of confidence and adolescent sexual and reproductive health (ASRH) outcomes. Methods: We searched nine online databases to locate behavioral research that examined the association between four constructs of confidence (belief in the future, self-determination, clear and positive identity, and self-efficacy) and ASRH outcomes (e. g., ever had sex, condom use, contraception use, number of partners, pregnancy/birth, and sexually transmitted infection). Findings were coded as "protective,'' "risk,'' or "no association.'' The presence of at least two longitudinal studies reporting consistent significant associations for at least one ASRH outcome indicated evidence for a protective or risk association. Results: We found evidence to support two of the four PYD constructs of confidence (belief in the future and self-determination) as protective factors for ASRH outcomes. Evidence was insufficient to draw conclusions about clear and positive identity as a protective factor, and was mixed for self-efficacy. Measures of confidence varied considerably across the studies reviewed, reflecting varying definitions; often, the measures used had limited information on reliability. Few longitudinal investigations were identified, and available studies were inconsistent in how they examined the association between the PYD constructs and ASRH outcomes. Evidence for most constructs was insufficient to identify their influence on specific sub-groups of youth. Conclusions: Despite the need for additional research, this review suggests that belief in the future and self-determination are promising protective factors. Further research is needed to better understand the potential for self-efficacy and clear and positive identity as protective factors. Published by Elsevier Inc. C1 [Gloppen, Kari M.] CDC, Div Adolescent & Sch Hlth, Atlanta, GA 30333 USA. [David-Ferdon, Corinne] CDC, Coordinating Ctr Environm Hlth & Injury Prevent, Atlanta, GA 30333 USA. [Bates, Jessica] CDC, Div Reprod Hlth, Atlanta, GA 30333 USA. RP Gloppen, KM (reprint author), 4770 Buford Hwy NE MS K 12, Atlanta, GA 30341 USA. EM kgloppen@cdc.gov NR 174 TC 16 Z9 16 U1 0 U2 24 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD MAR PY 2010 VL 46 IS 3 SU 1 BP S42 EP S58 DI 10.1016/j.jadohealth.2009.11.216 PG 17 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA 559WY UT WOS:000274860500004 PM 20172459 ER PT J AU House, LD Mueller, T Reininger, B Brown, K Markham, CM AF House, Lawrence Duane Mueller, Trisha Reininger, Belinda Brown, Kathryn Markham, Christine M. TI Character as a Predictor of Reproductive Health Outcomes for Youth: A Systematic Review SO JOURNAL OF ADOLESCENT HEALTH LA English DT Review DE Character; Adolescent; Sexual behavior; Reproductive health ID ADOLESCENT SEXUAL-BEHAVIOR; AFRICAN-AMERICAN ADOLESCENTS; HIGH-SCHOOL-STUDENTS; CONDOM USE; FEMALE ADOLESCENTS; RISK BEHAVIOR; CONTRACEPTIVE USE; 1ST INTERCOURSE; TRANSMITTED-DISEASES; PARENTAL COMMUNICATION AB To review research examining the influence of character on adolescent sexual and reproductive health (ASRH). We defined character as comprising two positive youth development constructs: prosocial norms and spirituality. We conducted a systematic review of behavioral research published from 1985 through 2007 that examined the association between two character constructs (prosocial norms and spirituality) and ASRH outcomes. We coded results as showing a protective association, risk association, or no association, and as longitudinal, or cross-sectional. We considered consistent associations from at least two longitudinal studies for a given outcome to be sufficient evidence for a protective or risk association. There is sufficient evidence to indicate that prosocial norms and spirituality can be protective factors for some ASRH outcomes including intention to have sex, early sex or ever having sex, contraceptive and condom use, frequency of sex, and pregnancy. The generalizability of findings by age, race/ethnicity, and gender was unclear. Findings suggest that some character sub-constructs are associated with a reduced likelihood of several adverse ASRH outcomes and with an increased likelihood of using contraceptives and intending to use condoms. Further research is needed to better understand mixed results and results showing some character sub-constructs, such as religious affiliation, to be associated with adverse ASRH outcomes. Published by Elsevier Inc. C1 [House, Lawrence Duane; Mueller, Trisha] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA. [Reininger, Belinda] Univ Texas Sch Publ Hlth, Univ Texas Prevent Res Ctr, Brownsville, TX USA. [Brown, Kathryn] Ctr Dis Control & Prevent, Coordinating Ctr Environm Hlth & Injury Prevent, Atlanta, GA USA. [Markham, Christine M.] Univ Texas Hlth Sci Ctr, Univ Texas Prevent Res Ctr, Houston, TX USA. RP House, LD (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, 4770 Buford Highway, Atlanta, GA 30341 USA. EM Lhouse1@cdc.gov NR 214 TC 9 Z9 9 U1 3 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD MAR PY 2010 VL 46 IS 3 SU 1 BP S59 EP S74 DI 10.1016/j.jadohealth.2009.11.218 PG 16 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA 559WY UT WOS:000274860500005 PM 20172460 ER PT J AU House, LD Bates, J Markham, CM Lesesne, C AF House, Lawrence Duane Bates, Jessica Markham, Christine M. Lesesne, Catherine TI Competence as a Predictor of Sexual and Reproductive Health Outcomes for Youth: A Systematic Review SO JOURNAL OF ADOLESCENT HEALTH LA English DT Review DE Competence; Adolescent; Sexual behavior; Reproductive health ID HIGH-SCHOOL-STUDENTS; CONDOM USE; CONTRACEPTIVE USE; ADOLESCENT MALES; 1ST INTERCOURSE; RISK BEHAVIOR; INCARCERATED ADOLESCENTS; AMERICAN ADOLESCENTS; RACE DIFFERENCES; NONPREGNANT ADOLESCENTS AB To examine the association between "competence'' and adolescent sexual and reproductive health (ASRH) outcomes. Competence refers to the development of skills to perform tasks successfully in four areas including social and behavioral, cognitive, emotional, and moral competence. We conducted a systematic review of research published from 1985 through 2007. Inclusion criteria included use of multivariate analyses, a sample size of >= 100, publication in a peer-reviewed journal, and measurement of an ASRH outcome. We coded findings as protective, risk, or no association and as longitudinal or cross-sectional. We considered the presence of two longitudinal studies with consistent findings for at least one outcome to be sufficient evidence for a risk or protective association. We identified 77 studies that examined cognitive competence, 27 studies that examined social and behavioral competence, 12 studies that examined emotional competence, and no studies that met inclusion criteria for moral competence. The evidence indicated that cognitive competence and social and behavioral competence can be protective factors for ASRH, with findings from at least two longitudinal studies demonstrating a protective association with an ASRH outcome. Findings across cognitive, social and behavioral subconstructs and ASRH outcomes were more mixed. There was insufficient evidence to draw conclusions about emotional and moral competence and ASRH. Helping adolescents to achieve cognitive, social, and behavioral competence may reduce the likelihood of sexual activity and teen pregnancy, and increase contraceptive use. Additional research is needed to examine other outcomes and the generalizability of findings. Published by Elsevier Inc. C1 [House, Lawrence Duane; Bates, Jessica; Lesesne, Catherine] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA 30341 USA. [Markham, Christine M.] Univ Texas Hlth Sci Ctr, Univ Texas Prevent Res Ctr, Houston, TX USA. RP House, LD (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, 4770 Buford Highway, Atlanta, GA 30341 USA. EM Lhouse1@cdc.gov NR 141 TC 20 Z9 21 U1 5 U2 18 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD MAR PY 2010 VL 46 IS 3 SU 1 BP S7 EP S22 DI 10.1016/j.jadohealth.2009.12.003 PG 16 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA 559WY UT WOS:000274860500002 PM 20172461 ER PT J AU Markham, CM Lormand, D Gloppen, KM Peskin, MF Flores, B Low, B House, LD AF Markham, Christine M. Lormand, Donna Gloppen, Kari M. Peskin, Melissa F. Flores, Belinda Low, Barbara House, Lawrence Duane TI Connectedness as a Predictor of Sexual and Reproductive Health Outcomes for Youth SO JOURNAL OF ADOLESCENT HEALTH LA English DT Review DE Connectedness; Bonding; Adolescent; Sexual behavior; Reproductive health ID RISK-TAKING BEHAVIORS; AFRICAN-AMERICAN ADOLESCENTS; PARENT-CHILD RELATIONSHIP; CONDOM USE; FEMALE ADOLESCENTS; 1ST INTERCOURSE; HISPANIC ADOLESCENTS; TRANSMITTED-DISEASES; GENDER-DIFFERENCES; TEENAGE PREGNANCY AB To review research examining the influence of "connectedness'' on adolescent sexual and reproductive health (ASRH). Connectedness, or bonding, refers to the emotional attachment and commitment a child makes to social relationships in the family, peer group, school, community, or culture. A systematic review of behavioral research (1985-2007) was conducted. Inclusion criteria included examination of the association between a connectedness sub-construct and an ASRH outcome, use of multivariate analyses, sample size of >= 100, and publication in a peer-reviewed journal. Results were coded as protective, risk, or no association, and as longitudinal, or cross sectional. Findings from at least two longitudinal studies for a given outcome with consistent associations were considered sufficient evidence for a protective or risk association. Eight connectedness sub-constructs were reviewed: family connectedness (90 studies), parent-adolescent general communication (16 studies), parent-adolescent sexuality communication (58 studies), parental monitoring (61 studies), peer connectedness (nine studies), partner connectedness (12 studies), school connectedness (18 studies), and community connectedness (four studies). There was sufficient evidence to support a protective association with ASRH outcomes for family connectedness, general and sexuality-specific parent-adolescent communication, parental monitoring, partner connectedness, and school connectedness. Sufficient evidence of a risk association was identified for the parent overcontrol sub-construct of parental monitoring. Connectedness can be a protective factor for ASRH outcomes, and efforts to strengthen young people's pro-social relationships are a promising target for approaches to promote ASRH. Further study regarding specific sub-constructs as well as their combined influence is needed. Published by Elsevier Inc. C1 [Markham, Christine M.; Lormand, Donna; Peskin, Melissa F.; Flores, Belinda; Low, Barbara] Univ Texas Hlth Sci Ctr Houston, Univ Texas Prevent Res Ctr, Houston, TX 77030 USA. [Gloppen, Kari M.] Ctr Dis Control & Prevent, Div Adolescent & Sch Hlth, Atlanta, GA USA. [House, Lawrence Duane] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA. RP Markham, CM (reprint author), Univ Texas Hlth Sci Ctr Houston, Univ Texas Prevent Res Ctr, 7000 Fannin,26th Floor, Houston, TX 77030 USA. EM christine.markham@uth.tmc.edu FU NIAID NIH HHS [P30 AI036211] NR 201 TC 116 Z9 117 U1 6 U2 28 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD MAR PY 2010 VL 46 IS 3 SU 1 BP S23 EP S41 DI 10.1016/j.jadohealth.2009.11.214 PG 19 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA 559WY UT WOS:000274860500003 PM 20172458 ER PT J AU Roy, SR McGinty, EE Hayes, SC Zhang, L AF Roy, Sitesh Ranen McGinty, Emma Elizabeth Hayes, Sandra Carr Zhang, Lei TI Regional and racial disparities in asthma hospitalizations in Mississippi SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Article DE Asthma; hospitalization; race; urban; rural; disparity ID UNITED-STATES; HEALTH-INSURANCE; CHILDREN; READMISSIONS; CARE; ADMISSIONS; CHILDHOOD; OUTCOMES; RISK; CITY AB Background: In the United States, asthma hospitalization rates are disproportionately high among blacks compared with other racial/ethnic groups and vary by geographic region. These disparities among asthma hospitalizations might be affected by social, environmental, and health-care access factors. Objective: To determine demographic risk factors for asthma hospitalizations in urban versus rural areas of Mississippi. Methods: A cross-sectional study using data from the Mississippi Asthma Surveillance System was conducted to compare asthma hospitalizations in the urban Jackson metropolitan statistical area and rural Delta regions of Mississippi from 2003 to 2005. Factors including race, sex, age, and household income that might be associated with multiple hospitalizations for asthma (3 or more during the study period) were assessed using logistic regression. Results: Asthma hospitalization rates were significantly higher among all demographic groups in the rural Delta region compared with the urban Jackson Metropolitan Statistical Area (P < .001). In both regions, hospitalization rates were higher among blacks and females (P < .001). Asthma hospitalization rates were highest among children (0-17 years) and older adults (>= 65 years). In both regions, blacks were more likely to have 3 or more asthma hospitalizations (P < .001). Residents of the Delta had higher odds for multiple hospitalizations controlling for race, sex, age, and household income (P < .05). Conclusion: Blacks with asthma are more likely to have multiple asthma hospitalizations in Mississippi. Higher odds of multiple asthma discharges for Delta residents were not explained by race, sex, age, or income, indicating that other contributing factors (eg, environmental, social, and access to care factors) need further investigation. (J Allergy Clin Immunol 2010;125:636-42.) C1 [Zhang, Lei] Mississippi Dept Hlth, Off Hlth Data & Res, Jackson, MS 39215 USA. [Roy, Sitesh Ranen] Univ Mississippi, Dept Pediat, Med Ctr, Div Allergy Immunol, Jackson, MS USA. [McGinty, Emma Elizabeth] Ctr Dis Control & Prevent, Publ Hlth Prevent Serv, Atlanta, GA USA. [Hayes, Sandra Carr] Tougaloo Coll, Cent Mississippi Area Hlth Educ Ctr, Tougaloo, MS USA. RP Zhang, L (reprint author), Mississippi Dept Hlth, Off Hlth Data & Res, 570 E Woodrow Wilson,POB 1700, Jackson, MS 39215 USA. EM Lei.Zhang@msdh.state.ms.us FU Centers for Disease Control and Prevention (CDC), National Center for Environmental Health, Air Pollution and Respiratory Health Branch [5U59EH000208-03] FX Collection of asthma hospital discharge data used in this research was supported by Cooperative Agreement Number 5U59EH000208-03 from the Centers for Disease Control and Prevention (CDC), National Center for Environmental Health, Air Pollution and Respiratory Health Branch. The contents of the article are solely responsibility of the authors and do not necessarily represent the official views of the CDC or the Mississippi State Department of Health. NR 43 TC 16 Z9 16 U1 0 U2 2 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD MAR PY 2010 VL 125 IS 3 BP 636 EP 642 DI 10.1016/j.jaci.2009.11.046 PG 7 WC Allergy; Immunology SC Allergy; Immunology GA 573BK UT WOS:000275883200019 PM 20226297 ER PT J AU Luis, AD Douglass, RJ Mills, JN Bjornstad, ON AF Luis, Angela D. Douglass, Richard J. Mills, James N. Bjornstad, Ottar N. TI The effect of seasonality, density and climate on the population dynamics of Montana deer mice, important reservoir hosts for Sin Nombre hantavirus SO JOURNAL OF ANIMAL ECOLOGY LA English DT Article DE rodent; small mammal; SNV; temporal variation; trophic cascade hypothesis ID SOUTHWESTERN UNITED-STATES; CAPTURE-RECAPTURE DATA; LYME-DISEASE RISK; PEROMYSCUS-MANICULATUS; RODENT POPULATIONS; PULMONARY SYNDROME; LONG-TERM; WEATHER-MODIFICATION; FEEDBACK STRUCTURE; MOUSE-POPULATIONS AB P>1. Since Sin Nombre virus was discovered in the U.S. in 1993, longitudinal studies of the rodent reservoir host, the deer mouse (Peromyscus maniculatus) have demonstrated a qualitative correlation among mouse population dynamics and risk of hantavirus pulmonary syndrome (HPS) in humans, indicating the importance of understanding deer mouse population dynamics for evaluating risk of HPS. 2. Using capture-mark-recapture statistical methods on a 15-year data set from Montana, we estimated deer mouse survival, maturation and recruitment rates and tested the relative importance of seasonality, population density and local climate in explaining temporal variation in deer mouse demography. 3. From these estimates, we designed a population model to simulate deer mouse population dynamics given climatic variables and compared the model to observed patterns. 4. Month, precipitation 5 months previously, temperature 5 months previously and to a lesser extent precipitation and temperature in the current month, were important in determining deer mouse survival. Month, the sum of precipitation over the last 4 months, and the sum of the temperature over the last 4 months were important in determining recruitment rates. Survival was more important in determining the growth rate of the population than recruitment. 5. While climatic drivers appear to have a complex influence on dynamics, our forecasts were good. Our quantitative model may allow public health officials to better predict increased human risk from basic climatic data. C1 [Luis, Angela D.; Bjornstad, Ottar N.] Penn State Univ, Dept Biol, University Pk, PA 16801 USA. [Douglass, Richard J.] Univ Montana, Dept Biol, Butte, MT 59701 USA. [Mills, James N.] Ctr Dis Control & Prevent, Div Viral & Rickettsial Dis, Natl Ctr Zoonot Vector Borne & Enter Dis, Atlanta, GA 30333 USA. RP Luis, AD (reprint author), Penn State Univ, Dept Biol, University Pk, PA 16801 USA. EM ADL12@psu.edu RI Bjornstad, Ottar/I-4518-2012 FU National Institutes of Health (NIH) [P20RR16455-05]; U.S. Centres for Disease Control and Prevention, Atlanta, GA [US3/CCU813599]; Academic Computing Fellowship, Penn State University FX We thank Kent Wagoner for data base management and design of specialty software and the private ranch owner, Dr. David Cameron, in Cascade County for the use of his property. Kevin Hughes, Arlene Alvarado, Farrah Arneson, Karoun Bagamian, Jessica Bertoglio, Brent Lonner, Jonnae Lumsden, Bill Semmons, and Amy Skypala provided valuable assistance in the field. Thanks also to Scott Carver for field mentoring and ponderings. Financial support was provided by the National Institutes of Health (NIH) grant # P20RR16455-05 from the INBRE - BRIN program, the U.S. Centres for Disease Control and Prevention, Atlanta, GA, through cooperative agreement # US3/CCU813599, and an Academic Computing Fellowship, Penn State University. NR 68 TC 25 Z9 28 U1 4 U2 50 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0021-8790 J9 J ANIM ECOL JI J. Anim. Ecol. PD MAR PY 2010 VL 79 IS 2 BP 462 EP 470 DI 10.1111/j.1365-2656.2009.01646.x PG 9 WC Ecology; Zoology SC Environmental Sciences & Ecology; Zoology GA 552VH UT WOS:000274321200019 PM 20015212 ER PT J AU Hawkins, NA Smith, T Zhao, LH Rodriguez, J Berkowitz, Z Stein, KD AF Hawkins, Nikki A. Smith, Tenbroeck Zhao, Luhua Rodriguez, Juan Berkowitz, Zahava Stein, Kevin D. TI Health-related behavior change after cancer: results of the American Cancer Society's studies of cancer survivors (SCS) SO JOURNAL OF CANCER SURVIVORSHIP LA English DT Article DE Cancer survivors; Health behavior; Behavior change; Spiritual well-being ID QUALITY-OF-LIFE; BREAST-CANCER; NECK-CANCER; STYLE BEHAVIORS; PROSTATE-CANCER; UNITED-STATES; LONG-TERM; PSYCHOLOGICAL DISTRESS; COLORECTAL-CANCER; PHYSICAL-ACTIVITY AB Introduction Cancer survivors are known to make positive health-related behavior changes after cancer, but less is known about negative behavior changes and correlates of behavior change. The present study was undertaken to examine positive and negative behavior changes after cancer and to identify medical, demographic, and psychosocial correlates of changes. Methods We analyzed data from a cross-sectional survey of 7,903 cancer survivors at 3, 6, and 11 years after diagnosis. Results Of 15 behaviors assessed, survivors reported 4 positive and 1 or 0 negative behavior changes. Positive change correlated with younger age, greater education, breast cancer, longer time since diagnosis, comorbidities, vitality, fear of recurrence, and spiritual well-being, while negative change correlated with younger age, being non-Hispanic African American, being widowed, divorced or separated, and lower physical and emotional health. Faith mediated the relationship between race/ethnicity and positive change. Conclusions Cancer survivors were more likely to make positive than negative behavior changes after cancer. Demographic, medical, and psychosocial variables were associated with both types of changes. Implications for cancer survivors Results provide direction for behavior interventions and illustrate the importance of looking beyond medical and demographic variables to understand the motivators and barriers to positive behavior change after cancer. C1 [Hawkins, Nikki A.; Rodriguez, Juan; Berkowitz, Zahava] Ctr Dis Control & Prevent CDC, Div Canc Prevent & Control, Atlanta, GA 30341 USA. [Smith, Tenbroeck; Zhao, Luhua; Stein, Kevin D.] Amer Canc Soc, Behav Res Ctr, Atlanta, GA 30329 USA. RP Hawkins, NA (reprint author), Ctr Dis Control & Prevent CDC, Div Canc Prevent & Control, 4770 Buford Hwy NE,MS K-55, Atlanta, GA 30341 USA. EM cyt4@cdc.gov FU ACS Behavioral Research Center FX The American Cancer Society (ACS) Studies of Cancer Survivors (SCS) were funded as an intramural program of research conducted by the ACS Behavioral Research Center. We wish to acknowledge the cooperation and efforts of the cancer registries and public health departments from the states of Arizona, California (Regions 2-6), Colorado, Delaware, Illinois, Iowa, Maine, Massachusetts, Michigan, Nebraska, New Jersey, Pennsylvania, Washington, and Wyoming. We also thank the staff of the hundreds of hospitals that reported cases to the participating cancer registries. Lastly, we are grateful to the thousands of cancer survivors, their physicians, and their loved ones who contributed to the collection of these data. The authors assume full responsibility for analyses and interpretation of these data. NR 69 TC 42 Z9 42 U1 4 U2 23 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1932-2259 EI 1932-2267 J9 J CANCER SURVIV JI J. Cancer Surviv.-Res. Pract. PD MAR PY 2010 VL 4 IS 1 BP 20 EP 32 DI 10.1007/s11764-009-0104-3 PG 13 WC Oncology; Social Sciences, Biomedical SC Oncology; Biomedical Social Sciences GA 788TV UT WOS:000292468200003 PM 19902360 ER PT J AU Winchell, JM Wolff, BJ Tiller, R Bowen, MD Hoffmaster, AR AF Winchell, Jonas M. Wolff, Bernard J. Tiller, Rebekah Bowen, Michael D. Hoffmaster, Alex R. TI Rapid Identification and Discrimination of Brucella Isolates by Use of Real-Time PCR and High-Resolution Melt Analysis SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID SINGLE-NUCLEOTIDE POLYMORPHISMS; SPECIES LEVEL; MELITENSIS; DIFFERENTIATION; OVIS AB Definitive identification of Brucella species remains a challenge due to the high degree of genetic homology shared within the genus. We report the development of a molecular technique which utilizes real-time PCR followed by high-resolution melt (HRM) curve analysis to reliably type members of this genus. Using a panel of seven primer sets, we tested 153 Brucella spp. isolates with >99% accuracy compared to traditional techniques. This assay provides a useful diagnostic tool that can rapidly type Brucella isolates and has the potential to detect novel species. This approach may also prove helpful for clinical, epidemiological and veterinary investigations. C1 [Winchell, Jonas M.; Wolff, Bernard J.; Bowen, Michael D.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Tiller, Rebekah; Hoffmaster, Alex R.] Ctr Dis Control & Prevent, Natl Ctr Zoonot Vector Borne & Enter Dis, Atlanta, GA 30333 USA. RP Winchell, JM (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE,MS G-03, Atlanta, GA 30333 USA. EM jwinchell@cdc.gov NR 22 TC 18 Z9 23 U1 0 U2 3 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD MAR PY 2010 VL 48 IS 3 BP 697 EP 702 DI 10.1128/JCM.02021-09 PG 6 WC Microbiology SC Microbiology GA 561RL UT WOS:000274996200003 PM 20053863 ER PT J AU Lonsway, DR Jevitt, LA Uhl, JR Cockerill, FR Anderson, ME Sullivan, MM De, BK Edwards, JR Patel, JB AF Lonsway, David R. Jevitt, Laura A. Uhl, James R. Cockerill, Franklin R., III Anderson, Mary E. Sullivan, Maureen M. De, Barun K. Edwards, Jonathan R. Patel, Jean B. TI Effect of Carbon Dioxide on Broth Microdilution Susceptibility Testing of Brucella spp. SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID IN-VITRO ACTIVITIES; LABORATORY-ACQUIRED BRUCELLOSIS; ANTIMICROBIAL AGENTS; MELITENSIS; ANTIBIOTICS; CIPROFLOXACIN; BIOTERRORISM; PREVENTION; STRAINS AB Since some strains of Brucella species may require carbon dioxide for growth, a multilaboratory study was conducted to compare broth microdilution susceptibility results using ambient air (AA) and 5% CO(2) incubation conditions. Six antimicrobial agents were tested against 39 Brucella isolates. Aminoglycoside MICs tended to be 1 log(2) dilution higher in CO(2) than in AA; tetracycline-class MICs to be 1 log(2) dilution lower in CO(2). C1 [Lonsway, David R.; Jevitt, Laura A.; Edwards, Jonathan R.; Patel, Jean B.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30333 USA. [De, Barun K.] Ctr Dis Control & Prevent, Div Foodborne Bacterial & Mycot Dis, Atlanta, GA 30333 USA. [Uhl, James R.; Cockerill, Franklin R., III] Mayo Clin, Rochester, MN 55905 USA. [Anderson, Mary E.; Sullivan, Maureen M.] Minnesota State Publ Hlth Lab, Minneapolis, MN 55414 USA. RP Lonsway, DR (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Mailstop G08,1600 Clifton Rd, Atlanta, GA 30333 USA. EM dul7@cdc.gov NR 28 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD MAR PY 2010 VL 48 IS 3 BP 952 EP 956 DI 10.1128/JCM.01860-09 PG 5 WC Microbiology SC Microbiology GA 561RL UT WOS:000274996200043 PM 20032255 ER PT J AU Dingle, KE Blaser, MJ Tu, ZC Pruckler, J Fitzgerald, C van Bergen, MAP Lawson, AJ Owen, RJ Wagenaar, JA AF Dingle, Kate E. Blaser, Martin J. Tu, Zheng-Chao Pruckler, Janet Fitzgerald, Collette van Bergen, Marcel A. P. Lawson, Andrew J. Owen, Robert J. Wagenaar, Jaap A. TI Genetic Relationships among Reptilian and Mammalian Campylobacter fetus Strains Determined by Multilocus Sequence Typing SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID PATHOGENESIS; JEJUNI; RECOMBINATION; INFECTIONS; HOMOLOGS; LOCUS AB Reptile Campylobacter fetus isolates and closely related strains causing human disease were characterized by multilocus sequence typing. They shared similar to 90% nucleotide sequence identity with classical mammalian C. fetus, and there was evidence of recombination among members of these two groups. The reptile group represents a possible separate genomospecies capable of infecting humans. C1 [Dingle, Kate E.] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Lab Sci, Oxford OX3 9DU, England. [Blaser, Martin J.; Tu, Zheng-Chao] NYU, Sch Med, Dept Med, New York, NY 10016 USA. [Pruckler, Janet; Fitzgerald, Collette] CDC, Enter Dis Lab Branch, Atlanta, GA 30333 USA. [van Bergen, Marcel A. P.; Wagenaar, Jaap A.] Cent Vet Inst Wageningen UR, NL-8200 AB Lelystad, Netherlands. [Lawson, Andrew J.; Owen, Robert J.] Hlth Protect Agcy, Lab Enter Pathogens, Ctr Infect, London, England. [Wagenaar, Jaap A.] Univ Utrecht, Fac Vet Med, Dept Immunol & Infect Dis, Utrecht, Netherlands. [van Bergen, Marcel A. P.; Wagenaar, Jaap A.] WHO Collaborating Ctr Campylobacter, Lelystad, Netherlands. [van Bergen, Marcel A. P.; Wagenaar, Jaap A.] OIE Reference Lab Campylobacteriosis, Lelystad, Netherlands. [van Bergen, Marcel A. P.; Wagenaar, Jaap A.] WHO Collaborating Ctr Campylobacter, Utrecht, Netherlands. [van Bergen, Marcel A. P.; Wagenaar, Jaap A.] OIE Reference Lab Campylobacteriosis, Utrecht, Netherlands. RP Dingle, KE (reprint author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Lab Sci, Oxford OX3 9DU, England. EM kate.dingle@ndcls.ox.ac.uk FU Wellcome Trust; Department for Environment, Food and Rural Affairs [OZ0611, OZ0615]; NIHR Oxford Biomedical Research Centre, John Radcliffe Hospital, Oxford, United Kingdom; Diane Belfer Program in Human Microbial Ecology FX This study used the Internet-accessible databases located at http: //pubmlst.org/campylobacter/, the maintenance, development, and stewardship of which is supported by funding from the Wellcome Trust and the Department for Environment, Food and Rural Affairs Research Contract numbers OZ0611 and OZ0615. Kate Dingle is supported by the NIHR Oxford Biomedical Research Centre, John Radcliffe Hospital, Oxford, United Kingdom. This study was supported in part by the Diane Belfer Program in Human Microbial Ecology. NR 16 TC 9 Z9 9 U1 0 U2 3 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD MAR PY 2010 VL 48 IS 3 BP 977 EP 980 DI 10.1128/JCM.01439-09 PG 4 WC Microbiology SC Microbiology GA 561RL UT WOS:000274996200050 PM 20053851 ER PT J AU Luquez, C Dykes, JK Yu, PA Raphael, BH Maslanka, SE AF Luquez, Carolina Dykes, Janet K. Yu, Patricia A. Raphael, Brian H. Maslanka, Susan E. TI First Report Worldwide of an Infant Botulism Case Due to Clostridium botulinum Type E (vol 48, pg 326, 2010) SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Correction C1 [Luquez, Carolina; Dykes, Janet K.; Yu, Patricia A.; Raphael, Brian H.; Maslanka, Susan E.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Luquez, C (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. NR 1 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD MAR PY 2010 VL 48 IS 3 BP 1017 EP 1017 DI 10.1128/JCM.00051-10 PG 1 WC Microbiology SC Microbiology GA 561RL UT WOS:000274996200063 ER PT J AU Ford, ES Schulze, MB Kroger, J Pischon, T Bergmann, MM Boeing, H AF Ford, Earl S. Schulze, Matthias B. Kroeger, Janine Pischon, Tobias Bergmann, Manuela M. Boeing, Heiner TI Television watching and incident diabetes: Findings from the European Prospective Investigation into Cancer and Nutrition-Potsdam Study SO JOURNAL OF DIABETES LA English DT Article DE body mass index; diabetes; exercise; leisure activities; prospective studies; television AB Background: The aim of the present study was to examine whether the amount of time spent watching television is a potential risk factor for incident diabetes and to what extent this association may be explained by obesity. Methods: We used data for 23 855 men and women from the European Prospective Investigation into Cancer and Nutrition-Potsdam Study. During an average of 7.8 years of follow-up, 927 participants developed diabetes. Incident diabetes was identified on the basis of self-report and was verified by contacting the patient's attending physician. The amount of time spent watching television was self-reported. Results: The mean time that the participants who developed diabetes watched television was 2.4 h /week, compared with 2.0 h /week for those who did not develop diabetes (P < 0.001). After adjusting for age, sex, educational status, smoking status, alcohol use, occupational activity, physical activity, the intake of various foods, and systolic blood pressure, the adjusted hazard ratio for diabetes among participants who watched 4 h/day of television compared with those who watched < 1 h/day was 1.63 [95% confidence interval (CI): 1.17-2.27]. After additional adjustment for waist circumference and body mass index, the hazard ratio was reduced to 1.14 (95% CI: 0.81-1.61). Conclusions: In the present study, the amount of time spent watching television was an independent predictor of incident diabetes only in models that adjusted for sociodemographic characteristics, lifestyle behaviors, and systolic blood pressure. The attenuation of the association after adjusting for anthropometric measures may represent an explanatory mechanism for our findings. C1 [Ford, Earl S.] Ctr Dis Control & Prevent, Div Adult & Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Schulze, Matthias B.] Tech Univ Munich, Publ Hlth Nutr Unit, Ctr Life & Food Sci, Freising Weihenstephan, Germany. [Kroeger, Janine; Pischon, Tobias; Bergmann, Manuela M.; Boeing, Heiner] German Inst Human Nutr Potsdam Rehbrucke, Dept Epidemiol, Potsdam, Nuthetal, Germany. RP Ford, ES (reprint author), Ctr Dis Control & Prevent, Div Adult & Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway,MS K66, Atlanta, GA 30341 USA. EM eford@cdc.gov OI Kroger, Janine/0000-0002-7496-3665; Schulze, Matthias B./0000-0002-0830-5277; Pischon, Tobias/0000-0003-1568-767X FU Federal Ministry of Science, Germany [01 EA 9401]; European Union [SOC 95201408 05F02]; German Cancer Aid [70-2488-Ha I]; European Community [SOC 98200769 05F02]; German Research Foundation (DFG) [KFO 114] FX The recruitment phase of the EPIC-Potsdam Study was supported by the Federal Ministry of Science, Germany (01 EA 9401) and the European Union (SOC 95201408 05F02). The follow-up of the EPIC-Potsdam Study was supported by the German Cancer Aid (70-2488-Ha I) and the European Community (SOC 98200769 05F02). The study was also supported by a grant from the German Research Foundation (DFG, KFO 114). NR 12 TC 32 Z9 33 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1753-0393 J9 J DIABETES JI J. Diabetes PD MAR PY 2010 VL 2 IS 1 BP 23 EP 27 DI 10.1111/j.1753-0407.2009.00047.x PG 5 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA V24MU UT WOS:000208415300006 PM 20923471 ER PT J AU Reeves, WC Gurbaxani, BM Lin, JMS Unger, ER AF Reeves, William C. Gurbaxani, Brian M. Lin, Jin-Mann S. Unger, Elizabeth R. TI A Response to Jason et al. (2009), "Evaluating the Centers for Disease Control's Empirical Chronic Fatigue Syndrome Case Definition" SO JOURNAL OF DISABILITY POLICY STUDIES LA English DT Editorial Material DE chronic fatigue syndrome; CFS; case definition; depression AB The recent article by Jason, Najar, Porter, and Reh, "Evaluating the Centers for Disease Control's Empirical Chronic Fatigue Syndrome Case Definition" (2009; Journal of Disability Policy Studies, 20:2, 93-100) attempted to critically explore several pertinent issues concerning diagnosing chronic fatigue syndrome (CFS). Most of these issues have been brewing since international adoption of the 1994 CFS case definition by Fukuda et al., and it is high time to address them in a peer-reviewed and public forum. C1 [Reeves, William C.; Lin, Jin-Mann S.; Unger, Elizabeth R.] Ctr Dis Control & Prevent, Chron Viral Dis Branch, Natl Ctr Zoonot Vector Borne & Enter Dis, Atlanta, GA 30333 USA. RP Reeves, WC (reprint author), Ctr Dis Control & Prevent, Chron Viral Dis Branch, Natl Ctr Zoonot Vector Borne & Enter Dis, Atlanta, GA 30333 USA. EM wcr1@cdc.gov OI Unger, Elizabeth/0000-0002-2925-5635 NR 11 TC 1 Z9 1 U1 0 U2 1 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1044-2073 J9 J DISABIL POLICY STU JI J. Disabil. Policy Stud. PD MAR PY 2010 VL 20 IS 4 BP 229 EP 232 DI 10.1177/1044207309346310 PG 4 WC Rehabilitation SC Rehabilitation GA V26RL UT WOS:000208562600004 ER PT J AU Lemke, AA Trinidad, SB Edwards, KL Starks, H Wiesner, GL AF Lemke, Amy A. Trinidad, Susan B. Edwards, Karen L. Starks, Helene Wiesner, Georgia L. CA GRRIP Consortium TI ATTITUDES TOWARD GENETIC RESEARCH REVIEW: RESULTS FROM A NATIONAL SURVEY OF PROFESSIONALS INVOLVED IN HUMAN SUBJECTS PROTECTION SO JOURNAL OF EMPIRICAL RESEARCH ON HUMAN RESEARCH ETHICS LA English DT Review DE institutional review board; research ethics committee; genetics; genetic research; human subjects protection ID MULTICENTER; CHALLENGES; APPROVAL; BOARDS AB THE RECENT EXPANSION OF HUMAN genetics research has raised complex ethical and regulatory issues. However, few published reports describe the views of professionals involved in human subjects protection (HSP) regarding the risks and benefits of genetic research. This anonymous, web-based study elicited the opinions of 208 HSP professionals about review of genetic research. The majority of respondents felt that different guidance is needed for various aspects of genetic protocol review compared with other types of human subjects research. Importantly, opinions were divided on specific genetic research issues, such as what constitutes human subjects research, when to re-consent, and the likelihood and risks of research participant identification. Findings from this study illustrate the need for a collaborative approach to ethics oversight in the review and conduct of genetic research. C1 [Lemke, Amy A.] Northwestern Univ, Ctr Genet Med, Feinberg Sch Med, Chicago, IL 60611 USA. [Trinidad, Susan B.] Univ Washington, Sch Med, Dept Bioeth & Humanities, Seattle, WA 98195 USA. [Edwards, Karen L.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Edwards, Karen L.] Univ Washington, Inst Publ Hlth Genet, Seattle, WA 98195 USA. [Edwards, Karen L.] Univ Washington, CDC Funded, Ctr Genom & Publ Hlth, Seattle, WA 98195 USA. [Wiesner, Georgia L.] Case Western Reserve Univ, Sch Med, Cleveland, OH 44106 USA. RP Lemke, AA (reprint author), Northwestern Univ, Ctr Genet Med, Feinberg Sch Med, 676 N St Clair St,Suite 1260, Chicago, IL 60611 USA. EM a-lemke@northwestern.edu OI Trinidad, Susan Brown/0000-0002-5956-6557 FU National Human Genome Research Institute [P50 HG003374, P50 HG003390, U01 HG004609] FX Supplementary material (survey instrument) is available onlineathttp://caliber.ucpress.net/doi/suppl/10.1525/jer.2010.5.1.83. Support for this research comes from National Human Genome Research Institute grants P50 HG003374, P50 HG003390, and U01 HG004609. This work was presented in part at the American Society of Human Genetics Annual Meeting in Honolulu, Hawaii in October 2009, and at the Public Responsibility in Medicine and Research Advancing Ethical Research Conference in Nashville, Tennessee in November 2009. NR 25 TC 15 Z9 15 U1 0 U2 6 PU UNIV CALIFORNIA PRESS PI BERKELEY PA C/O JOURNALS DIVISION, 2000 CENTER ST, STE 303, BERKELEY, CA 94704-1223 USA SN 1556-2646 J9 J EMPIR RES HUM RES JI J. Empir. Res. Hum. Res. Ethics PD MAR PY 2010 VL 5 IS 1 BP 83 EP 91 DI 10.1525/jer.2010.5.1.83 PG 9 WC Ethics; Medical Ethics SC Social Sciences - Other Topics; Medical Ethics GA 579CE UT WOS:000276343600009 PM 20235866 ER PT J AU Schultz, MG Sapp, JH Cusack, CD Fink, JM AF Schultz, Myron G. Sapp, James H., II Cusack, Caroline D. Fink, Jennifer M. TI The National Exposure Registry: History and Lessons Learned SO JOURNAL OF ENVIRONMENTAL HEALTH LA English DT Article ID SUBSTANCES AB The National Exposure Registry (NER) was created as a comprehensive group of data repositories that sought, over time, to relate specific environmental exposures to dioxin, trichloroethylene (TCE), benzene, and trichloroethane (TCA) to registrants' health conditions. Some parts of the NER were well conceived, whereas others were not. The most important design deficiency of the NER was its inability to adequately assess exposure. This was the key missing element and the Achilles heel of the NER program. At least three other important issues were never satisfactorily resolved in the design of the NER. They were unverified self-reporting, appropriate control groups, and the use of biomarkers. The many health effects that were observed to be in excess when compared with national norms might be explained by methodological differences in data analysis and reliance on self-reported nonverified data. Creating and maintaining a population-based chemical exposure registry is a more difficult challenge than creating and maintaining an outcome registry, such as a cancer registry. C1 [Schultz, Myron G.] Ctr Dis Control & Prevent, Div Hlth Studies, NCEH ATSDR, Atlanta, GA 30341 USA. RP Schultz, MG (reprint author), Ctr Dis Control & Prevent, Div Hlth Studies, NCEH ATSDR, 4770 Buford Highway NE,MS F-57, Atlanta, GA 30341 USA. EM mgs1@cdc.gov NR 12 TC 4 Z9 4 U1 0 U2 0 PU NATL ENVIRON HEALTH ASSOC PI DENVER PA 720 S COLORADO BLVD SUITE 970, SOUTH TOWER, DENVER, CO 80246 USA SN 0022-0892 J9 J ENVIRON HEALTH JI J. Environ. Health PD MAR PY 2010 VL 72 IS 7 BP 20 EP 25 PG 6 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 563TE UT WOS:000275156300004 PM 20235405 ER PT J AU Bhatti, P Blair, A Bell, EM Rothman, N Lan, Q Barr, DB Needham, LL Portengen, L Figgs, LW Vermeulen, R AF Bhatti, Parveen Blair, Aaron Bell, Erin M. Rothman, Nathaniel Lan, Qing Barr, Dana B. Needham, Larry L. Portengen, Lutzen Figgs, Larry W. Vermeulen, Roel TI Predictors of 2,4-dichlorophenoxyacetic acid exposure among herbicide applicators SO JOURNAL OF EXPOSURE SCIENCE AND ENVIRONMENTAL EPIDEMIOLOGY LA English DT Article DE 2,4-D; biomonitoring; herbicide; exposure determinants ID PROFESSIONAL TURF APPLICATORS; HUMAN URINE; METABOLITES; PESTICIDES; MODELS AB To determine the major factors affecting the urinary levels of 2,4-dichlorophenoxyacetic acid (2,4-D) among county noxious weed applicators in Kansas, we used a regression technique that accounted for multiple days of exposure. We collected 136 12-h urine samples from 31 applicators during the course of two spraying seasons (April to August of 1994 and 1995). Using mixed-effects models, we constructed exposure models that related urinary 2,4-D measurements to weighted self-reported work activities from daily diaries collected over 5 to 7 days before the collection of the urine sample. Our primary weights were based on an earlier pharmacokinetic analysis of turf applicators; however, we examined a series of alternative weighting schemes to assess the impact of the specific weights and the number of days before urine sample collection that were considered. The derived models accounting for multiple days of exposure related to a single urine measurement seemed robust with regard to the exact weights, but less to the number of days considered; albeit the determinants from the primary model could be fitted with marginal losses of fit to the data from the other weighting schemes that considered a different numbers of days. In the primary model, the total time of all activities (spraying, mixing, other activities), spraying method, month of observation, application concentration, and wet gloves were significant determinants of urinary 2,4-D concentration and explained 16% of the between-worker variance and 23% of the within-worker variance of urinary 2,4-D levels. As a large proportion of the variance remained unexplained, further studies should be conducted to try to systematically assess other exposure determinants. Journal of Exposure Science and Environmental Epidemiology (2010) 20, 160-168; doi: 10.1038/jes.2009.14; published online 25 March 2009 C1 [Bhatti, Parveen; Blair, Aaron; Rothman, Nathaniel; Lan, Qing] NCI, Div Canc Epidemiol & Genet, Rockville, MD USA. [Bell, Erin M.] SUNY Albany, Dept Epidemiol, Sch Publ Hlth, Rensselaer, NY USA. [Barr, Dana B.; Needham, Larry L.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. [Portengen, Lutzen; Vermeulen, Roel] Univ Utrecht, Inst Risk Assessment Sci, Utrecht, Netherlands. [Figgs, Larry W.] Univ Kentucky, Dept Prevent Med & Environm Hlth, Coll Publ Hlth, Lexington, KY USA. [Vermeulen, Roel] Univ Med Ctr Utrecht, Julius Ctr, Utrecht, Netherlands. RP Bhatti, P (reprint author), NCI, Div Canc Epidemiol & Genet, 6120 Execut Blvd,EPS 7049,MSC 7238, Bethesda, MD 20892 USA. EM bhattip@mail.nih.gov RI Needham, Larry/E-4930-2011; Barr, Dana/E-6369-2011; Barr, Dana/E-2276-2013; Vermeulen, Roel/F-8037-2011 OI Vermeulen, Roel/0000-0003-4082-8163 FU Intramural NIH HHS [Z01 CP010119-12] NR 11 TC 1 Z9 1 U1 1 U2 7 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1559-0631 J9 J EXPO SCI ENV EPID JI J. Expo. Sci. Environ. Epidemiol. PD MAR-APR PY 2010 VL 20 IS 2 BP 160 EP 168 DI 10.1038/jes.2009.14 PG 9 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 557DQ UT WOS:000274649700007 PM 19319162 ER PT J AU Curwin, BD Hein, MJ Barr, DB Striley, C AF Curwin, Brian D. Hein, Misty J. Barr, Dana B. Striley, Cynthia TI Comparison of immunoassay and HPLC-MS/MS used to measure urinary metabolites of atrazine, metolachlor, and chlorpyrifos from farmers and non-farmers in Iowa SO JOURNAL OF EXPOSURE SCIENCE AND ENVIRONMENTAL EPIDEMIOLOGY LA English DT Article DE biomonitoring; pesticides; analytical methods; immunoassay; HPLC; censored data ID LINKED-IMMUNOSORBENT-ASSAY; PESTICIDE APPLICATORS; LIQUID-CHROMATOGRAPHY; QUANTIFICATION; HERBICIDES; EXPOSURE; WATER AB Urine samples were collected from 51 participants in a study investigating pesticide exposure among farm families in Iowa. Aliquots from the samples were sent to two different labs and analyzed for metabolites of atrazine (atrazine mercapturate), metolachlor (metolachlor mercapturate) and chlorpyrifos (TCP) by two different analytical methods: immunoassay and high performance liquid chromatography tandem mass spectrometry (HPLC-MS/MS). HPLC-MS/MS methods tend to be highly specific, but are costly and time consuming. Immunoassay methods are cheaper and faster, but can be less sensitive due to cross reactivity and matrix effects. Three statistical methods were employed to compare the two analytical methods. Each statistical method differed in how the samples that had results below the limit of detection (LOD)were treated. The first two methods involved an imputation procedure and the third method used maximum likelihood estimation (MLE). A fourth statistical method that modeled each lab separately using MLE was used for comparison. The immunoassay and HPLC-MS/MS methods were moderately correlated (correlation 0.40-0.49), but the immunoassay methods consistently had significantly higher geometric mean (GM) estimates for each pesticide metabolite. The GM estimates for atrazine mercapturate, metolachlor mercapturate, and TCP by immunoassay ranged from 0.16-0.98 mu g l(-1), 0.24-0.45 mu g l(-1) and 14-14 mu g l(-1), respectively and by HPLC-MS/ MS ranged from 0.0015-0.0039 mu g l(-1), 0.12-0.16 mu g l(-1), and 2.9-3.0 mu g l(-1), respectively. Immunoassays tend to be cheaper and faster than HPLC-MS/ MS, however, they may result in an upward bias of urinary pesticide metabolite levels. Journal of Exposure Science and Environmental Epidemiology (2010) 20, 205-212; doi: 10.1038/jes.2009.15; published online 11 March 2009 C1 [Curwin, Brian D.; Hein, Misty J.] NIOSH, Ctr Dis Control & Prevent, Div Surveillance Hazard Evaluat & Field Studies, Cincinnati, OH 45226 USA. [Barr, Dana B.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. [Striley, Cynthia] NIOSH, Ctr Dis Control & Prevent, Div Appl Res & Technol, Cincinnati, OH 45226 USA. RP Curwin, BD (reprint author), NIOSH, Ctr Dis Control & Prevent, Div Surveillance Hazard Evaluat & Field Studies, 4676 Columbia Pkwy,MS R-14, Cincinnati, OH 45226 USA. EM bcurwin@cdc.gov RI Barr, Dana/E-6369-2011; Barr, Dana/E-2276-2013 NR 18 TC 6 Z9 7 U1 1 U2 21 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1559-0631 J9 J EXPO SCI ENV EPID JI J. Expo. Sci. Environ. Epidemiol. PD MAR-APR PY 2010 VL 20 IS 2 BP 205 EP 212 DI 10.1038/jes.2009.15 PG 8 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 557DQ UT WOS:000274649700012 PM 19277069 ER PT J AU Ma, L Zhang, GD Gerner-Smidt, P Tauxe, RV Doyle, MP AF Ma, Li Zhang, Guodong Gerner-Smidt, Peter Tauxe, Robert V. Doyle, Michael P. TI Survival and Growth of Salmonella in Salsa and Related Ingredients SO JOURNAL OF FOOD PROTECTION LA English DT Article ID RAW TOMATOES; ALLICIN; STORAGE; TEMPERATURE; ENTERITIDIS; STABILITY; OUTBREAK; CILANTRO; FATE AB A large outbreak of Salmonella Saintpaul associated with raw jalapeno peppers, serrano peppers, and possibly tomatoes was reported in the United States in 2008. During the outbreak, two clusters of illness investigated among restaurant patrons were significantly associated with eating salsa. Experiments were performed to determine the survival and growth characteristics of Salmonella in salsa and related major ingredients, i.e., tomatoes, jalapeno peppers, and cilantro. Intact and chopped vegetables and different formulations of salsas were inoculated with a five-strain mixture of Salmonella and then stored at 4, 12, and 21 degrees C for up to 7 days. Salmonella populations were monitored during storage. Salmonella did not grow, but survived on intact tomatoes and jalapeno peppers, whereas significant growth at 12 and 21 degrees C was observed on intact cilantro. In general, growth of Salmonella occurred in all chopped vegetables when stored at 12 and 21 degrees C, with chopped jalapeno peppers being the most supportive of Salmonella growth. Regardless of differences in salsa formulation, no growth of Salmonella (initial inoculation ca. 3 log CFU/g) was observed in salsa held at 4 degrees C; however, rapid or gradual decreases in Salmonella populations were only observed in formulations that contained both fresh garlic and lime juice. Salmonella grew at 12 and 21 degrees C in salsas, except for those formulations that contained both fresh garlic and lime juice, in which salmonellae were rapidly or gradually inactivated, depending on salsa formulation. These results highlight the importance of preharvest pathogen contamination control of fresh produce and proper formulation and storage of salsa. C1 [Ma, Li; Zhang, Guodong; Doyle, Michael P.] Univ Georgia, Ctr Food Safety, Griffin, GA 30223 USA. [Ma, Li; Gerner-Smidt, Peter; Tauxe, Robert V.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Doyle, MP (reprint author), Univ Georgia, Ctr Food Safety, 1109 Expt St, Griffin, GA 30223 USA. EM mdoyle@uga.edu NR 18 TC 18 Z9 19 U1 0 U2 12 PU INT ASSOC FOOD PROTECTION PI DES MOINES PA 6200 AURORA AVE SUITE 200W, DES MOINES, IA 50322-2863 USA SN 0362-028X J9 J FOOD PROTECT JI J. Food Prot. PD MAR PY 2010 VL 73 IS 3 BP 434 EP 444 PG 11 WC Biotechnology & Applied Microbiology; Food Science & Technology SC Biotechnology & Applied Microbiology; Food Science & Technology GA 570LB UT WOS:000275677900004 PM 20202327 ER PT J AU Whichard, JM Medalla, F Hoekstra, RM McDermott, PF Joyce, K Chiller, T Barrett, TJ White, DG AF Whichard, Jean M. Medalla, Felicita Hoekstra, Robert M. McDermott, Patrick F. Joyce, Kevin Chiller, Tom Barrett, Timothy J. White, David G. TI Evaluation of Antimicrobial Resistance Phenotypes for Predicting Multidrug-Resistant Salmonella Recovered from Retail Meats and Humans in the United States SO JOURNAL OF FOOD PROTECTION LA English DT Article ID SEROTYPE TYPHIMURIUM; NONTYPHOIDAL SALMONELLA; ANIMAL ORIGIN; INFECTIONS; ILLNESS; BURDEN; DEATH AB Although multidrug-resistant (MDR) non-Typhi Salmonella (NTS) strains are a concern in food production, determining resistance to multiple antimicrobial agents at slaughter or processing may be impractical. Single antimicrobial resistance results for predicting multidrug resistance are desirable. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value were used to determine each antimicrobial agent's ability to predict MDR phenotypes of human health significance: ACSSuT (resistance to at least ampicillin, chloramphenicol, streptomycin, sulfamethoxazole, tetracycline) in NTS isolates, and MDR-AmpC-SN (resistance to ACSSuT, additional resistance to amoxicillin-clavulanate and to ceftiofur, and decreased Susceptibility [MIC >= 2 mu g/ml] to ceftriaxone) in NTS serotype Newport. The U.S. National Antimicrobial Resistance Monitoring System determined MICs to 15 or more antimicrobial agents for 9,955 NTS isolates from humans from 1999 to 2004 and 689 NTS isolates from retail meat from 2002 to 2004. A total of 847 (8.5%) human and 26 (3.8%) retail NTS isolates were ACSSuT; 995 (10.0%) human and 16 (2.3%) retail isolates were serotype Newport. Among Salmonella Newport. 204 (20.5%) human and 9 (56.3%) retail isolates were MDR-AmpC-SN. Chloramphenicol resistance provided the highest PPVs for ACSSuT among human (90.5%; 95% confidence interval, 88.4 to 92.3) and retail NTS isolates (96.3%; 95% confidence interval, 81.0 to 99.9). Resistance to ceftiofur and to amoxicillin-clavulanate and decreased susceptibility to ceftriaxone provided the highest PPVs (97.1, 98.1, and 98.6%, respectively) for MDR-AmpC-SN from humans. High PPVs for these agents applied to retail meat MDR-AmpC-SN, but isolate numbers were lower. Variations in MIC results may complicate ceftriaxone's predictive utility. Selecting specific antimicrobial resistance offers practical alternatives for predicting MDR phenotypes. Chloramphenicol resistance works best for ACSSuT-NTS, and resistance to ceftiofur, amoxicillin-clavulanate, or chloramphenicol works best for MDR-AmpC-SN. C1 [Whichard, Jean M.; Medalla, Felicita; Hoekstra, Robert M.; Joyce, Kevin; Chiller, Tom; Barrett, Timothy J.] Ctr Dis Control & Prevent, Div Foodborne Bacterial & Mycot Dis, Atlanta, GA 30333 USA. [McDermott, Patrick F.; White, David G.] US FDA, Div Anim & Food Microbiol, Res Off, Ctr Vet Med, Laurel, MD 20708 USA. RP Whichard, JM (reprint author), Ctr Dis Control & Prevent, Div Foodborne Bacterial & Mycot Dis, Atlanta, GA 30333 USA. EM zyr3@cdc.gov FU Food and Drug Administration; CDC FX We thank the state and local laboratories for participating in the NARMS surveillance program and the USDA-FSIS and Agricultural Research Set-vice for technical review of this manuscript, This work was funded by an Interagency Agreement between the Food and Drug Administration and the CDC. NR 31 TC 6 Z9 6 U1 0 U2 5 PU INT ASSOC FOOD PROTECTION PI DES MOINES PA 6200 AURORA AVE SUITE 200W, DES MOINES, IA 50322-2863 USA SN 0362-028X J9 J FOOD PROTECT JI J. Food Prot. PD MAR PY 2010 VL 73 IS 3 BP 445 EP 451 PG 7 WC Biotechnology & Applied Microbiology; Food Science & Technology SC Biotechnology & Applied Microbiology; Food Science & Technology GA 570LB UT WOS:000275677900005 PM 20202328 ER PT J AU Heneine, W AF Heneine, Walid TI When Do Minority Drug-Resistant HIV-1 Variants Have a Major Clinical Impact? SO JOURNAL OF INFECTIOUS DISEASES LA English DT Editorial Material ID SINGLE-DOSE NEVIRAPINE; ANTIRETROVIRAL TREATMENT; MUTATIONS; THERAPY; POPULATIONS; INHIBITORS; EFAVIRENZ; WOMEN; ASSAY C1 [Heneine, Walid] Ctr Dis Control & Prevent, Branch Lab, Div HIV AIDS Prevent, Atlanta, GA USA. RP Heneine, W (reprint author), CDC, 1600 Clifton Rd NE,Mail Stop G45, Atlanta, GA 30333 USA. EM wmh2@cdc.gov NR 19 TC 9 Z9 9 U1 0 U2 0 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD MAR 1 PY 2010 VL 201 IS 5 BP 647 EP 649 DI 10.1086/650545 PG 3 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 552MW UT WOS:000274296600002 PM 20102273 ER PT J AU Gubareva, LV Fry, AM AF Gubareva, Larisa V. Fry, Alicia M. TI Current Challenges in the Risk Assessment of Neuraminidase Inhibitor-Resistant Influenza Viruses SO JOURNAL OF INFECTIOUS DISEASES LA English DT Editorial Material ID IN-VITRO; A(H1N1) VIRUS; ACTIVE-SITE; OSELTAMIVIR; TRANSMISSION; SENSITIVITY; INFECTIONS; MUTATIONS; FITNESS; FERRETS C1 [Gubareva, Larisa V.; Fry, Alicia M.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Resp Infect Dis & Immunizat, Coordinated Ctr Infect Dis, Atlanta, GA USA. RP Gubareva, LV (reprint author), CDC, 1600 Clifton St NE,MS G16, Atlanta, GA 30333 USA. EM LGubareva@cdc.gov NR 19 TC 6 Z9 7 U1 0 U2 0 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD MAR 1 PY 2010 VL 201 IS 5 BP 656 EP 658 DI 10.1086/650465 PG 3 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 552MW UT WOS:000274296600005 PM 20100087 ER PT J AU Gertz, RE Li, ZY Pimenta, FC Jackson, D Juni, BA Lynfield, R Jorgensen, JH Carvalho, MD Beall, BW AF Gertz, Robert E. Li, Zhongya Pimenta, Fabiana C. Jackson, Delois Juni, Billie A. Lynfield, Ruth Jorgensen, James H. Carvalho, Maria da Gloria Beall, Bernard W. CA Active Bacterial Core Surveillance TI Increased Penicillin Nonsusceptibility of Nonvaccine-Serotype Invasive Pneumococci Other than Serotypes 19A and 6A in Post-7-Valent Conjugate Vaccine Era SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID UNITED-STATES; STREPTOCOCCUS-PNEUMONIAE; DISEASE; CHILDREN; ADULTS; CLONE AB According to population-based invasive pneumococcal surveillance in the United States during 2007, 898 (26%) of 3,511 isolates were penicillin nonsusceptible. Non-7-valent pneumococcal conjugate vaccine (PCV7) serotypes other than 19A accounted for 40% of these penicillin-nonsusceptible isolates; of these, serotypes 15A (11%), 23A (8%), 35B (8%), and 6C (5%) were most common (cumulatively 32% of penicillin-nonsusceptible isolates). Each except 6C represented a single serotype and clonal complex combination that predated the introduction of PCV7. We evaluated the genetic characteristics and nonsusceptibility to penicillin of non-PCV7 serotypes, and we found increased proportions of specific penicillin-nonsusceptible clones in serotypes 15A, 23A, 35B, and 6C, which potentially indicates a basic change of population structure within these individual serotypes. C1 [Gertz, Robert E.; Li, Zhongya; Pimenta, Fabiana C.; Jackson, Delois; Beall, Bernard W.] Ctr Dis Control & Prevent, Resp Dis Branch, Atlanta, GA 30333 USA. [Juni, Billie A.; Lynfield, Ruth] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Jorgensen, James H.] Minnesota Dept Hlth, Minneapolis, MN USA. RP Beall, BW (reprint author), Ctr Dis Control & Prevent, Resp Dis Branch, 1600 Clifton Rd,MS C02, Atlanta, GA 30333 USA. EM bbeall@cdc.gov FU Centers for Disease Control and Prevention Emerging Infections Program; Centers for Disease Control and Prevention Antimicrobial Working Group; National Vaccine Program Office FX Financial support: Centers for Disease Control and Prevention Emerging Infections Program; Centers for Disease Control and Prevention Antimicrobial Working Group; National Vaccine Program Office. NR 15 TC 66 Z9 68 U1 0 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD MAR 1 PY 2010 VL 201 IS 5 BP 770 EP 775 DI 10.1086/650496 PG 6 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 552MW UT WOS:000274296600019 PM 20178139 ER PT J AU Tatte, VS Gentsch, JR Chitambar, SD AF Tatte, Vaishali S. Gentsch, Jon R. Chitambar, Shobha D. TI Characterization of Group A Rotavirus Infections in Adolescents and Adults From Pune, India: 1993-1996 and 2004-2007 SO JOURNAL OF MEDICAL VIROLOGY LA English DT Article DE epidemiology; adult diarrhea; G and P types; rotavirus ID POLYMERASE CHAIN-REACTION; PHYLOGENETIC ANALYSIS; HIGH-FREQUENCY; VP4 GENE; MOLECULAR CHARACTERIZATION; SEQUENCE ALIGNMENT; NSP4 GENES; STRAINS; DIVERSITY; CHILDREN AB A total of 1,591 fecal specimens were collected in 1993-1996 and 2004-2007 from adolescents and adults with acute gastroenteritis in Pune, India for detection and characterization of rotavirus. At the two time points, group A rotavirus was detected in 8.6% and 16.2% of the adolescents and 5.2% and 17.2% of the adults, respectively. Reverse transcription-PCR with consensus primers followed by multiplex genotyping PCR detected common strains G1P[8], G2P[4], GPM, and G4P[8] in a total of 53.1% of the samples from 1993 to 1996, while the only prevalent strain identified in 2004-2007 was G2P[4] (23.5% of total). Uncommon rotavirus strains (G1P[4], G2P[8] G9P[6]/P[4]) increased from 7.8% (1993-1996) to 41.2% (2004-2007), while the prevalence of mixed rotavirus infections was high (39%/35%) at both time points. Mixed infections detected by multiplex PCR were confirmed by sequencing two or more individual genotype-specific PCR products of the VP7 and VP4 genes from the same sample. Phylogenetic analysis of the sequences showed circulation of a heterogeneous rotavirus strain population comprising genotypes G1 (lineages I and IIb), G2 (lineages I and IIb),G4(lineage la), P[4] (lineages P[4]-5 and P[4]-1), P[8] (lineages P[8]-II and P[8]-III), and P[6] (M37-like lineage). The VP6 gene sequences of the nontypeable strains were most homologous to animal strains. This study documents the molecular epidemiology of rotavirus strains in adolescents and adults in India, and suggests that it may be important to monitor these strains over time for the potential impact on rotavirus vaccines under development for use in the Indian population. J. Med. Virol. 82:519-527, 2010. (C) 2010 Wiley-Liss, Inc. C1 [Tatte, Vaishali S.; Chitambar, Shobha D.] Natl Inst Virol, Rotavirus Dept, Pune 411001, Maharashtra, India. [Gentsch, Jon R.] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Chitambar, SD (reprint author), Natl Inst Virol, Rotavirus Dept, 20-A Dr Ambedkar Rd, Pune 411001, Maharashtra, India. EM chitambars@hotmail.com NR 52 TC 28 Z9 28 U1 0 U2 0 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0146-6615 J9 J MED VIROL JI J. Med. Virol. PD MAR PY 2010 VL 82 IS 3 BP 519 EP 527 DI 10.1002/jmv.21708 PG 9 WC Virology SC Virology GA 548IP UT WOS:000273955000022 PM 20087938 ER PT J AU Durazo-Arvizu, RA Dawson-Hughes, B Sempos, CT Yetley, EA Looker, AC Cao, GC Harris, SS Burt, VL Carriquiry, AL Picciano, MF AF Durazo-Arvizu, Ramon A. Dawson-Hughes, Bess Sempos, Christopher T. Yetley, Elizabeth A. Looker, Anne C. Cao, Guichan Harris, Susan S. Burt, Vicki L. Carriquiry, Alicia L. Picciano, Mary Frances TI Three-Phase Model Harmonizes Estimates of the Maximal Suppression of Parathyroid Hormone by 25-Hydroxyvitamin D in Persons 65 Years of Age and Older SO JOURNAL OF NUTRITION LA English DT Article ID LOCALLY WEIGHTED REGRESSION; VITAMIN-D STATUS; HYPOVITAMINOSIS D; SERUM; WOMEN AB The concentration or threshold of 25-hydroxyvitamin D [25(OH)D] needed to maximally suppress intact serum parathyroid hormone (iPTH) has been suggested as a measure of optimal vitamin D status. Depending upon the definition of maximal suppression of iPTH and the 2-phase regression approach used, 2 distinct clusters for a single 25(OH)D threshold have been reported: 16-20 ng/mL (40-50 nmol/L) and 30-32 ng/mL (75-80 nmol/L). To rationalize the apparently disparate published results, we compared thresholds from several regression models including a 3-phase one to estimate simultaneously 2 thresholds before and after adjusting for possible confounding for age, BMI, glomerular filtration rate, dietary calcium, and season (April-September vs. October-March) within a single data set, i.e. data from the Tufts University Sites Testing Osteoporosis Prevention/Intervention Treatment study, consisting of 181 men and 206 women (total n = 387) ages 65-87 y. Plasma 25(OH)D and serum iPTH concentrations were (mean +/- SD) 22.1 +/- 7.44 ng/mL (55.25 +/- 18.6 nmol/L) and 36.6 +/- 16.03 pg/mL (3.88 +/- 1.7 pmol/L), respectively. The 3-phase model identified 2 thresholds of 12 ng/mL (30 nmol/L) and 28 ng/mL (70 nmol/L); similar results were found from the 2-phase models evaluated, i.e. 13-20 and 27-30 ng/mL (32.5-50 and 67.5-75 nmol/L) and with previous results. Adjusting for confounding did not change the results substantially. Accordingly, the 3-phase model appears to be superior to the 2-phase approach, because it simultaneously estimates the 2 threshold clusters found from the 2-phase approaches along with estimating confidence limits. If replicated, it may be of both clinical and public health importance. J. Nutr. 140: 595-599, 2010. C1 [Sempos, Christopher T.; Yetley, Elizabeth A.; Picciano, Mary Frances] Natl Inst Hlth, Off Dietary Supplements, Bethesda, MD 20816 USA. [Durazo-Arvizu, Ramon A.; Cao, Guichan] Loyola Univ Chicago, Dept Prevent Med & Epidemiol, Stritch Sch Med, Maywood, IL 60153 USA. [Dawson-Hughes, Bess; Harris, Susan S.] Tufts Univ, Jean Mayer USDA Human Nutr Res Ctr Aging, Bone Metab Lab, Boston, MA 02111 USA. [Looker, Anne C.; Burt, Vicki L.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Carriquiry, Alicia L.] Iowa State Univ, Dept Stat, Ames, IA 50011 USA. RP Sempos, CT (reprint author), Natl Inst Hlth, Off Dietary Supplements, Bethesda, MD 20816 USA. EM semposch@mail.nih.gov FU National Institute on Aging, NIH, Bethesda, MD [AG10353]; Office of Dietary Supplements [5R37 HL045508-17] FX Supported by a grant from the National Institute on Aging, NIH, Bethesda, MD, grant number AG10353, and by an Office of Dietary Supplements administrative supplement to NIH grant number 5R37 HL045508-17. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the CDC, the NIH, or the US Department of Health and Human Services. NR 23 TC 32 Z9 36 U1 0 U2 2 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-3166 EI 1541-6100 J9 J NUTR JI J. Nutr. PD MAR PY 2010 VL 140 IS 3 BP 595 EP 599 DI 10.3945/jn.109.116681 PG 5 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 559FJ UT WOS:000274807800023 PM 20089790 ER PT J AU DeJoy, DM Wilson, MG Vandenberg, RJ McGrath-Higgins, AL Griffin-Blake, CS AF DeJoy, David M. Wilson, Mark G. Vandenberg, Robert J. McGrath-Higgins, Allison L. Griffin-Blake, C. Shannon TI Assessing the impact of healthy work organization intervention SO JOURNAL OF OCCUPATIONAL AND ORGANIZATIONAL PSYCHOLOGY LA English DT Article ID PSYCHOLOGICAL EMPOWERMENT; EMPLOYEE PARTICIPATION; OCCUPATIONAL STRESS; WORKPLACE; PERFORMANCE; DIMENSIONS; PROMOTION; BEHAVIOR; SAFETY; DETERMINANTS AB This research evaluates a healthy work organization intervention implemented in a retail setting. Using a participatory process, employee teams in 11 intervention stores developed customized plans for improving work organization at their sites. Ten comparable stores served as controls. Employee surveys were administered prior to the intervention and twice again at 12-month intervals. Business results were compiled monthly for each store. The baseline data were used by the teams to identify needs and establish action priorities for their stores. Most study outcomes declined across time for all stores, due primarily to internal corporate events and a generally adverse economic environment. However, the intervention process appeared to buffer some of these declines; intervention stores fared better in terms of selected aspects of organizational climate and psychological work adjustment. Intervention stores also performed better than controls on general indices of perceived health and safety and two of the four business outcomes: employee turnover and sales per labour hour. These results are discussed in terms of the challenges involved in evaluating organizational-level interventions in work settings. C1 [DeJoy, David M.; Wilson, Mark G.] Univ Georgia, Workplace Hlth Grp, Dept Hlth Promot & Behav, Coll Publ Hlth, Athens, GA 30602 USA. [Vandenberg, Robert J.] Univ Georgia, Workplace Hlth Grp, Dept Management, Terry Coll Business, Athens, GA 30602 USA. [McGrath-Higgins, Allison L.] Raytheon Co, Waltham, MA USA. [Griffin-Blake, C. Shannon] US Ctr Dis Control & Prevent, Atlanta, GA USA. RP DeJoy, DM (reprint author), Univ Georgia, Workplace Hlth Grp, Dept Hlth Promot & Behav, Coll Publ Hlth, Athens, GA 30602 USA. EM dmdejoy@uga.edu RI Vandenberg, Robert/Q-2180-2015 NR 70 TC 23 Z9 24 U1 2 U2 37 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0963-1798 J9 J OCCUP ORGAN PSYCH JI J. Occup. Organ. Psychol. PD MAR PY 2010 VL 83 IS 1 BP 139 EP 165 DI 10.1348/096317908X398773 PG 27 WC Psychology, Applied; Management SC Psychology; Business & Economics GA 582WU UT WOS:000276631800008 ER PT J AU Powell, K Braun, KV Singh, R Shapira, SK Olney, RS Yeargin-Allsopp, M AF Powell, Kimberly Braun, Kim Van Naarden Singh, Rani Shapira, Stuart K. Olney, Richard S. Yeargin-Allsopp, Marshalyn TI Prevalence of Developmental Disabilities and Receipt of Special Education Services among Children with an Inborn Error of Metabolism SO JOURNAL OF PEDIATRICS LA English DT Article ID LONG-TERM TREATMENT; PROPIONIC ACIDEMIA; LYASE DEFICIENCY; VERBAL DYSPRAXIA; GALACTOSEMIA; MANAGEMENT; DISORDERS; SPECTRUM; OUTCOMES; ACIDURIA AB Objective To examine the presence of developmental disabilities and receipt of special education services in children with an inborn error of metabolism. Study design The study population was children born from 1988 through 2001 in whom a metabolic disorder was diagnosed after identification by newborn screening (n = 97) or after clinical identification (n = 34). These children were linked to the Metropolitan Atlanta Development Disability Surveillance Program (MADDSP) and Special Education Database of Metropolitan Atlanta (SEDMA) to determine developmental outcomes at 8 years of age and 3 through 10 years of age, respectively. Medical and educational records were examined to consider factors contributing to developmental outcomes. Results Of 97 children with a metabolic disorder identified with newborn screening, 12 (12.4%) were identified by SEDMA as receiving special education services and 2 (2.7%) were identified by MADDSP as having a developmental disability. Of the 34 children with a clinically identified metabolic disorder, 8 (23.5%) were identified with SEDMA, and 5 (17.2%) were identified with a MADDSP developmental disability. Conclusion Early identification and treatment have been successful in limiting the impact of severe developmental disabilities. Continued surveillance and research are needed to monitor less severe developmental outcomes. (J Pediatr 2010;156:420-6). C1 [Powell, Kimberly] Assoc Univ Ctr Disabil, Silver Spring, MD USA. [Powell, Kimberly; Braun, Kim Van Naarden; Yeargin-Allsopp, Marshalyn] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Dev Disabil Branch, Atlanta, GA USA. [Singh, Rani; Olney, Richard S.] Emory Univ, Div Med Genet, Sch Med, Dept Human Genet, Atlanta, GA 30322 USA. [Shapira, Stuart K.; Olney, Richard S.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Pediat Genet Team, Atlanta, GA USA. RP Braun, KV (reprint author), 1600 Clifton Rd,MS E-86, Atlanta, GA 30333 USA. EM kbn5@cdc.gov NR 25 TC 2 Z9 2 U1 2 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-3476 J9 J PEDIATR-US JI J. Pediatr. PD MAR PY 2010 VL 156 IS 3 BP 420 EP 426 DI 10.1016/j.jpeds.2009.09.068 PG 7 WC Pediatrics SC Pediatrics GA 559XO UT WOS:000274863800020 PM 19914633 ER PT J AU Park, SY Van Beneden, CA Pilishvili, T Martin, M Facklam, RR Whitney, CG AF Park, Sarah Y. Van Beneden, Chris A. Pilishvili, Tamara Martin, Michael Facklam, Richard R. Whitney, Cynthia G. CA Active Bacterial Core Surveillance TI Invasive Pneumococcal Infections among Vaccinated Children in the United States SO JOURNAL OF PEDIATRICS LA English DT Article ID CONJUGATE VACCINE; EFFICACY; DISEASE; IMMUNOGENICITY; SAFETY; TRIAL; ERA AB Objective Because 7-valent pneumococcal conjugate vaccine (PCV7) is highly efficacious, pneumococcal infections in vaccinated children raise concerns about immunologic disorders. We characterized a case series of US children in whom invasive pneumococcal infections developed despite vaccination. Study design We reviewed invasive ( sterile site) pneumococcal infections in children aged <5 years who had received >= 1 PCV7 dose as identified from October 2001 to February 2004 through national passive surveillance and the Centers for Disease Control and Prevention's Active Bacterial Core surveillance. Vaccine serotype infections were considered breakthrough cases; the subset of breakthrough cases occurring in children who completed an age-appropriate vaccination series were considered PCV7 failures. Results We identified 753 invasive infections; 155 infections (21%) were breakthrough cases, predominantly caused by serotypes 6B (n = 50, 32%) and 19F (n = 45, 29%). The proportion of breakthrough cases decreased with the increasing number of PCV7 doses received (P < .001, X(2) for linear trend). Children with co-morbid conditions accounted for 31% of breakthrough infections. Twenty-seven cases (4%) were classified as vaccine failures. Most failures (71%) occurred in children who were vaccinated according to catch-up schedules; 37% had co-morbid conditions. Conclusion Invasive pneumococcal infections identified in vaccinated U. S. children were primarily caused by disease resulting from serotypes not covered with PCV7, rather than failure of the vaccine. Incomplete vaccination and co-morbid conditions likely contribute to breakthrough vaccine-type pneumococcal infections. (J Pediatr 2010; 156:478-83). C1 [Park, Sarah Y.; Martin, Michael] Ctr Dis Control & Prevent, Off Workforce & Career Dev, Atlanta, GA USA. [Park, Sarah Y.; Van Beneden, Chris A.; Pilishvili, Tamara; Martin, Michael; Facklam, Richard R.; Whitney, Cynthia G.] Ctr Dis Control & Prevent, Resp Dis Branch, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Park, SY (reprint author), Hawaii Dept Hlth, 1132 Bishop St,Suite 1900, Honolulu, HI 96813 USA. EM sarah.park@doh.hawaii.gov NR 15 TC 30 Z9 30 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-3476 J9 J PEDIATR-US JI J. Pediatr. PD MAR PY 2010 VL 156 IS 3 BP 478 EP U185 DI 10.1016/j.jpeds.2009.10.008 PG 8 WC Pediatrics SC Pediatrics GA 559XO UT WOS:000274863800033 PM 19962156 ER PT J AU Moore, LV Fulton, J Kruger, J McDivitt, J AF Moore, Latetia V. Fulton, Janet Kruger, Judy McDivitt, Judith TI Knowledge of Physical Activity Guidelines Among Adults in the United States, Health Styles 2003-2005 SO JOURNAL OF PHYSICAL ACTIVITY & HEALTH LA English DT Article DE knowledge; health messages; communication strategies ID COMMUNICATION; RECOMMENDATIONS; EXERCISE AB Background: We estimated percentages of US adults (18 years) who knew that prior federal physical activity (PA) guidelines call for a minimum of 30 minutes of moderate-intensity PA most days(>= 5)/week using 2003 to 2005 Health Styles, an annual mail survey. Methods: 10,117 participants identified "the minimum amount of moderate-intensity PA the government recommends to get overall health benefits." Response options included 30/>= 5, 20/>= 3, 30/7, and 60/7 (minutes/days per week), "none of these," and "don't know." The odds of correctly identifying the guideline was modeled by participant sex, age, race/ethnicity, income, education, marital status, body mass index, physical activity level, and survey year using logistic regression. Results: 25.6% of respondents correctly identified the guideline. Women were 30% more likely to identify the guideline than men (Odds Ratio [95% Confidence Limits] (OR) = 1.28 [1.15, 1.44]). Regular PA was positively associated with identifying the guideline versus inactivity (OR = 2.08 [1.73, 2.50]). Blacks and those earning <$15,000 annually were 24% to 32% less likely to identify the guideline than whites and those earning >$60,000, respectively. Conclusions: Most adults did not know the previous moderate-intensity PA recommendation, which indicates a need for effective communication strategies for the new 2008 Physical Activity Guidelines for Adults. C1 [Moore, Latetia V.; Fulton, Janet; Kruger, Judy; McDivitt, Judith] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA 30333 USA. RP Moore, LV (reprint author), Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA 30333 USA. NR 32 TC 16 Z9 16 U1 3 U2 8 PU HUMAN KINETICS PUBL INC PI CHAMPAIGN PA 1607 N MARKET ST, PO BOX 5076, CHAMPAIGN, IL 61820-2200 USA SN 1543-3080 J9 J PHYS ACT HEALTH JI J. Phys. Act. Health PD MAR PY 2010 VL 7 IS 2 BP 141 EP 149 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 636LT UT WOS:000280737900001 PM 20484752 ER PT J AU Evenson, KR Wen, F Lee, SM Heinrich, KM Eyler, A AF Evenson, Kelly R. Wen, Fang Lee, Sarah M. Heinrich, Katie M. Eyler, Amy TI National Study of Changes in Community Access to School Physical Activity Facilities: The School Health Policies and Programs Study SO JOURNAL OF PHYSICAL ACTIVITY & HEALTH LA English DT Article DE community use; exercise; physical activity; policy; school ID INTERVENTIONS; PREVENTION; EDUCATION AB Background: A Healthy People 2010 developmental objective (22-12) was set to increase the proportion of the nation's public and private schools that provide access to their physical activity spaces and facilities for all persons outside of normal school hours The purpose of this study was to describe the prevalence of indoor and outdoor facilities at schools and the availability of those facilities to the public in 2000 and 2006. Methods: In 2000 and 2006, the School Health Policies and Programs Study (SHPPS) was conducted in each state and in randomly selected districts, schools, and classrooms. This analysis focused on the school level questionnaire from a nationally representative sample of public and nonpublic elementary, middle, and high schools (n = 921 in 2000 and n = 984 in 2006). Results: No meaningful changes in the prevalence of access to school physical activity facilities were found from 2000 to 2006, for youth or adult community sports teams, classes, or open gym Conclusions: These national data indicate a lack of progress from 2000 and 2006 toward increasing the proportion of the nation's public and private schools that provide access to their physical activity facilities for all persons outside of normal school hours. C1 [Evenson, Kelly R.; Wen, Fang] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27515 USA. [Lee, Sarah M.] Ctr Dis Control & Prevent, Div Adolescent & Sch Hlth, Atlanta, GA USA. [Heinrich, Katie M.] Univ Hawaii, Dept Publ Hlth Sci, Honolulu, HI 96822 USA. [Eyler, Amy] Washington Univ, Prevent Res Ctr, St Louis, MO USA. RP Evenson, KR (reprint author), Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27515 USA. RI Heinrich, Katie/B-4782-2013 OI Heinrich, Katie/0000-0002-6837-408X FU NCCDPHP CDC HHS [U48 DP000059, U48 DP000060, U48 DP001903, U48-DP000059, U48-DP000060] NR 23 TC 9 Z9 9 U1 1 U2 9 PU HUMAN KINETICS PUBL INC PI CHAMPAIGN PA 1607 N MARKET ST, PO BOX 5076, CHAMPAIGN, IL 61820-2200 USA SN 1543-3080 J9 J PHYS ACT HEALTH JI J. Phys. Act. Health PD MAR PY 2010 VL 7 SU 1 BP S20 EP S30 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 636LX UT WOS:000280738300008 PM 20440007 ER PT J AU Eyler, A Lankford, T Chriqui, J Evenson, KR Kruger, J Tompkins, N Voorhees, C Zieff, S Aytur, S Brownson, R AF Eyler, Amy Lankford, Tina Chriqui, Jamie Evenson, Kelly R. Kruger, Judy Tompkins, Nancy Voorhees, Carolyn Zieff, Susan Aytur, Semra Brownson, Ross TI An Analysis of State Legislation on Community Trails SO JOURNAL OF PHYSICAL ACTIVITY & HEALTH LA English DT Article DE trails; state legislation; policy; environment ID PHYSICAL-ACTIVITY; POLICY; WALKING; HEALTH AB Background: Trails provide opportunities for recreation, transportation and activity. The purpose of this article is to describe state legislation related to community trails, to analyze legislation content, and to evaluate legislation on inclusion of evidence-informed elements Methods: State trail legislation from 2001 to 2008 was identified using online legislative databases. An analysis of evidence-informed elements included in the legislation was conducted. These elements included funding, liability, accessibility, connectivity, and maintenance. Results: Of the total 991 trail bills, 516 (52 0%) were appropriations bills, of which 167 (32 2%) were enacted. We analyzed 475 (48%) nonappropriation trail bills of which 139 (29.3%) were enacted. The percentage of enactment of appropriations bills decreased over time while enactment of nonappropriations trail bills increased. Over half of the nonappropriations trail bills included at least I evidence-informed element, most commonly funding. Few bills contained liability, connectivity, accessibility, or maintenance. Conclusions: There is opportunity for providing evidence-informed information to policy-makers to potentially influence bill content The number of bills with a funding element demonstrates that fiscal support for trails is an important policy lever that state legislatures may use to support trails. Lastly, trails should be considered in over-all state-level physical activity legislation to provide opportunities for communities to be active. C1 [Eyler, Amy] Washington Univ, Prevent Res Ctr, St Louis, MO 63130 USA. [Lankford, Tina] Ctr Dis Control & Prevent, Phys Act & Hlth Branch, Atlanta, GA USA. [Chriqui, Jamie] Univ Illinois, Inst Hlth Res & Policy, Chicago, IL USA. [Evenson, Kelly R.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA. [Kruger, Judy] Ctr Dis Control & Prevent, Div Nutr & Phys Act, Atlanta, GA USA. [Tompkins, Nancy] W Virginia Univ, Dept Community Med, Morgantown, WV 26506 USA. [Voorhees, Carolyn] Univ Maryland, Dept Publ & Community Health, College Pk, MD 20742 USA. [Zieff, Susan] San Francisco State Univ, Dept Kinesiol, San Francisco, CA 94132 USA. [Aytur, Semra] Univ New Hampshire, Dept Hlth Management & Policy, Durham, NH 03824 USA. [Brownson, Ross] Washington Univ, George Warren Brown Sch Social Work, Prevent Res Ctr, Dept Surg, St Louis, MO 63130 USA. [Brownson, Ross] Washington Univ, Sch Med, Alvin J Siteman Canc Ctr, St Louis, MO 63130 USA. RP Eyler, A (reprint author), Washington Univ, Prevent Res Ctr, St Louis, MO 63130 USA. FU NCCDPHP CDC HHS [U48/DP000060] NR 26 TC 5 Z9 5 U1 0 U2 3 PU HUMAN KINETICS PUBL INC PI CHAMPAIGN PA 1607 N MARKET ST, PO BOX 5076, CHAMPAIGN, IL 61820-2200 USA SN 1543-3080 J9 J PHYS ACT HEALTH JI J. Phys. Act. Health PD MAR PY 2010 VL 7 SU 1 BP S40 EP S47 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 636LX UT WOS:000280738300010 PM 20440011 ER PT J AU Eyler, A Brownson, R Schmid, T Pratt, M AF Eyler, Amy Brownson, Ross Schmid, Tom Pratt, Michael TI Understanding Policies and Physical Activity: Frontiers of Knowledge to Improve Population Health INTRODUCTION SO JOURNAL OF PHYSICAL ACTIVITY & HEALTH LA English DT Editorial Material ID PUBLIC-HEALTH; UNITED-STATES; IMPACT AB With Increasing evidence of the detrimental effects of physical inactivity, there is interest in enhancing research on policies that may influence physical activity in communities. Given the potential policy impact, a framework that organized and conceptualized policy interventions and priorities for public health efforts to promote physical activity was developed. In addition, the Physical Activity Policy Research Network (PAPRN) was formed as a way to operationalize the contents of the framework. Recommendations for future work in this area include enhancing transdisciplinary collaborations, raising the priority of policy evaluation, studying policies at all levels, and emphasizing dissemination of findings. C1 [Eyler, Amy; Brownson, Ross] Washington Univ, Prevent Res Ctr, St Louis, MO 63130 USA. [Schmid, Tom; Pratt, Michael] Ctr Dis Control, Dept Phys Act & Hlth, Atlanta, GA 30333 USA. RP Eyler, A (reprint author), Washington Univ, Prevent Res Ctr, St Louis, MO 63130 USA. NR 22 TC 10 Z9 10 U1 0 U2 3 PU HUMAN KINETICS PUBL INC PI CHAMPAIGN PA 1607 N MARKET ST, PO BOX 5076, CHAMPAIGN, IL 61820-2200 USA SN 1543-3080 J9 J PHYS ACT HEALTH JI J. Phys. Act. Health PD MAR PY 2010 VL 7 SU 1 BP S9 EP S12 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 636LX UT WOS:000280738300006 PM 20440018 ER PT J AU Ryman, T Macauley, R Nshimirimana, D Taylor, P Shimp, L Wilkins, K AF Ryman, T. Macauley, R. Nshimirimana, D. Taylor, P. Shimp, L. Wilkins, K. TI Reaching every district (RED) approach to strengthen routine immunization services: evaluation in the African region, 2005 SO JOURNAL OF PUBLIC HEALTH LA English DT Article DE health services; immunization AB Background This evaluation was undertaken in 2005, in the African region, to better understand the reaching every district (RED) implementation process that provides a framework for strengthening immunization services at the district level Methods In June 2005, a convenience sample of five countries was selected to evaluate the implementation of RED Evaluation teams consisting of key partners conducted site visits to the national, district and health facility levels using standardized qualitative questionnaires Results RED was implemented in a similar manner in all five countries, i e starting with training and micro-planning All RED components were Implemented to some degree in the countries Common implementation factors included development of plans, expanding outreach services (defined as services provided in sites outside fixed immunization sites), planning of supervisory visits and efforts to link with communities and utilize community volunteers Monitoring tools such as wall charts and maps were observed and reportedly used Conclusions Evaluation of the RED implementation process provided evidence of improvement in delivery of routine immunization services The RED framework should continue to be used to strengthen the immunization delivery system to meet continuing new demands, such as the introduction of new vaccines and integrated delivery of other child survival interventions C1 [Ryman, T.; Wilkins, K.] US Ctr Dis Control & Prevent, Global Immunizat Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Macauley, R.; Nshimirimana, D.] World Hlth Org Reg Off Africa, Div Prevent & Control Communicable Dis, Brazzaville, Congo. [Taylor, P.; Shimp, L.] JSI Res & Training Inst Inc, IMMUNIZATIONbasies, Arlington, VA 22209 USA. RP Ryman, T (reprint author), US Ctr Dis Control & Prevent, Global Immunizat Div, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd,MS-E05, Atlanta, GA 30333 USA. FU World Health Organization; Regional Office for Africa; United States Agency For International Development; Centers for Disease Control and Prevention FX Funding for this evaluation was provided by the World Health Organization, Regional Office for Africa, the United States Agency For International Development through IMMUNIZATIONbasics and the Centers for Disease Control and Prevention. NR 7 TC 16 Z9 18 U1 0 U2 3 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1741-3842 J9 J PUBLIC HEALTH-UK JI J. Public Health PD MAR PY 2010 VL 32 IS 1 BP 18 EP 25 DI 10.1093/pubmed/fdp048 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 576PG UT WOS:000276156600008 PM 19542268 ER PT J AU Sarmiento, K Mitchko, J Klein, C Wong, S AF Sarmiento, Kelly Mitchko, Jane Klein, Cynthia Wong, Sharon TI Evaluation of the Centers for Disease Control and Prevention's Concussion Initiative for High School Coaches: "Heads Up: Concussion in High School Sports" SO JOURNAL OF SCHOOL HEALTH LA English DT Article DE health communication; concussion prevention; physical fitness and sport; public health; high school coaches; tool kit AB METHODS: A mail questionnaire was administered to all eligible high school coaches who received the tool kit. Follow-up focus groups were conducted for additional information. Both quantitative data from the surveys and qualitative data from the focus groups were analyzed to support the objectives of the study. RESULTS: Respondents self-reported favorable changes in knowledge, attitudes, and practices toward the prevention and management of concussions. Qualitative responses augmented the quantitative data. CONCLUSION: Barriers to concussion prevention and management are complex; however, these results highlight the role that coaches can play in school settings in establishing a safe environment for their athletes. C1 [Sarmiento, Kelly] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Div Injury Response, Atlanta, GA 30341 USA. [Klein, Cynthia] SRA Int Inc, Survey & Evaluat Res Div, Atlanta, GA 30329 USA. RP Sarmiento, K (reprint author), Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Div Injury Response, 4770 Buford Hwy NE,Mail Stop F-62, Atlanta, GA 30341 USA. EM KSarmiento@cdc.gov; jpmitchko@cdc.gov; Cynthia_Klein@sra.com; SWong1@cdc.gov NR 6 TC 50 Z9 50 U1 2 U2 7 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0022-4391 J9 J SCHOOL HEALTH JI J. Sch. Health PD MAR PY 2010 VL 80 IS 3 BP 112 EP 118 PG 7 WC Education & Educational Research; Education, Scientific Disciplines; Health Care Sciences & Services; Public, Environmental & Occupational Health SC Education & Educational Research; Health Care Sciences & Services; Public, Environmental & Occupational Health GA 557KW UT WOS:000274669000002 PM 20236412 ER PT J AU Howie, LD Lukacs, SL Pastor, PN Reuben, CA Mendola, P AF Howie, LaJeana D. Lukacs, Susan L. Pastor, Patricia N. Reuben, Cynthia A. Mendola, Pauline TI Participation in Activities Outside of School Hours in Relation to Problem Behavior and Social Skills in Middle Childhood SO JOURNAL OF SCHOOL HEALTH LA English DT Article DE middle childhood; activity participation; behavior problems; social skills ID LEISURE ACTIVITIES; PHYSICAL-ACTIVITY; AMERICAN; CHILDREN; YOUTH AB METHODS: Estimates were based on 25,797 children from the 2003-2004 National Survey of Children's Health. Outside of school activity was defined as participating in sports teams/lessons, clubs/organizations, or both at least once in the past year. Analysis of variance was used to evaluate the differences in behavior problems and social skills adjusting for sociodemographic factors, among children classified by participation in outside of school activities. RESULTS: Seventy-five percent of children participated in outside of school activities: 23% in sports, 16% in clubs, and 36% in both clubs and sports. Activity participation differed by gender, race/ethnicity, type of school, poverty status, family structure, household education, and school and community safety. Children participating in both sports and clubs had higher social skills index scores, but no significant difference in problem behavior scores compared with children who did not participate in any outside of school activity. CONCLUSION: Children participating in both sports and clubs had greater social competence during middle childhood compared with children who did not participate in any outside of school activities. C1 [Howie, LaJeana D.; Lukacs, Susan L.; Pastor, Patricia N.; Reuben, Cynthia A.; Mendola, Pauline] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. RP Howie, LD (reprint author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, 3311 Toledo Rd,RM6110, Hyattsville, MD 20782 USA. EM LHOWIE@CDC.GOV; SLUKACS@CDC.GOV; PPASTOR@CDC.GOV; CREUBEN@CDC.GOV; PMENDOLA@CDC.GOV OI Mendola, Pauline/0000-0001-5330-2844 NR 26 TC 18 Z9 19 U1 3 U2 21 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0022-4391 J9 J SCHOOL HEALTH JI J. Sch. Health PD MAR PY 2010 VL 80 IS 3 BP 119 EP 125 PG 7 WC Education & Educational Research; Education, Scientific Disciplines; Health Care Sciences & Services; Public, Environmental & Occupational Health SC Education & Educational Research; Health Care Sciences & Services; Public, Environmental & Occupational Health GA 557KW UT WOS:000274669000003 PM 20236413 ER PT J AU Pardo, C Pineros, M Jones, NR Warren, CW AF Pardo, Constanza Pineros, Marion Jones, Nathan R. Warren, Charles W. TI Results of Global Youth Tobacco Surveys in Public Schools in Bogota, Colombia SO JOURNAL OF SCHOOL HEALTH LA English DT Article DE smoking; tobacco; adolescents; surveillance ID DISEASES AB METHODS: GYTS was implemented in public schools in Bogota, Colombia, by the Colombian National Cancer Institute. Data were collected from students in classrooms using self-administered procedures. RESULTS: Between 2001 and 2007, ever having smoked cigarettes decreased along with exposure to secondhand smoke (SHS) at home, having an object with a tobacco logo on it, and having been offered free cigarettes by a tobacco company representative. Prevalence of current cigarette smoking did not change from 2001 to 2007 (32.9% and 29.9%). Exposure to pro-tobacco advertising increased, reaching 71.4%, and 73.4% respectively, in 2007. Having been taught about the harmful effects of tobacco use did not change over time. CONCLUSIONS: The government of Colombia ratified the WHO FCTC in 2008. However, Colombia has one of the highest levels of cigarette smoking among 13-15 year olds in the Region of the Americas. The tobacco control effort in Colombia has much work to do, including recognition that the levels of smoking among adolescents are already as high as those of adults. Future declines in tobacco use among adolescents in Bogota will likely depend on development of a comprehensive tobacco control program. C1 [Pardo, Constanza] Natl Canc Inst, Canc Epidemiol Surveillance Grp, Bogota, DC, Colombia. [Pineros, Marion] Natl Canc Inst, Publ Hlth Unit, Bogota, DC, Colombia. [Jones, Nathan R.] Univ Wisconsin Madison, Paul P Carbone Comprehens Canc Ctr, Survey Res Shared Serv, Madison, WI 53726 USA. [Warren, Charles W.] Ctr Dis Control & Prevent, Off Smoking & Hlth, Atlanta, GA 30341 USA. RP Pardo, C (reprint author), Natl Canc Inst, Canc Epidemiol Surveillance Grp, Calle 1 9-85, Bogota, DC, Colombia. EM cpardo@cancer.gov.co; mpineros@cancer.gov.co; njones@uwccc.wisc.edu; wcw1@cdc.gov NR 17 TC 3 Z9 4 U1 0 U2 1 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0022-4391 J9 J SCHOOL HEALTH JI J. Sch. Health PD MAR PY 2010 VL 80 IS 3 BP 141 EP 145 PG 5 WC Education & Educational Research; Education, Scientific Disciplines; Health Care Sciences & Services; Public, Environmental & Occupational Health SC Education & Educational Research; Health Care Sciences & Services; Public, Environmental & Occupational Health GA 557KW UT WOS:000274669000006 PM 20236416 ER PT J AU Steindel, SJ AF Steindel, Steven J. TI OIDs: how can I express you? Let me count the ways SO JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION LA English DT Article AB An object identifier (OID) has a central utility in providing a traceable source for the meaning of an identifier appearing in a cross-system communication. The views in this paper illustrate the problems with using the present OID registration system as a reliable source for the identifier, the confusion that the use of an OID introduces in messages, and the redundancy that the OID introduces at the expense of increased message size and no new content. In promoting clearly defined cross-system communication identifiers, Health Level 7 developed a standard that required use of OIDs outside of network addressing. This standard and its propagation by others may have paradoxically added more confusion than clarity. C1 [Steindel, Steven J.] Ctr Dis Control & Prevent, Natl Ctr Publ Hlth Informat, Atlanta, GA USA. RP Steindel, SJ (reprint author), 1021 Wadsworth Dr NW, Atlanta, GA 30318 USA. EM stevejs@mindspring.com NR 13 TC 1 Z9 1 U1 0 U2 0 PU HANLEY & BELFUS-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 1067-5027 J9 J AM MED INFORM ASSN JI J. Am. Med. Inf. Assoc. PD MAR PY 2010 VL 17 IS 2 BP 144 EP 147 DI 10.1136/jamia.2009.000265 PG 4 WC Computer Science, Information Systems; Computer Science, Interdisciplinary Applications; Information Science & Library Science; Medical Informatics SC Computer Science; Information Science & Library Science; Medical Informatics GA 567ZH UT WOS:000275488100005 PM 20190056 ER PT J AU Bhavsar, TR Kim, HJ Yu, Y AF Bhavsar, Tina R. Kim, Hye-Joo Yu, Yon TI Roles and contributions of pharmacists in regulatory affairs at the Centers for Disease Control and Prevention for public health emergency preparedness and response SO JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION LA English DT Article DE Centers for Disease Control and Prevention; bioterrorism; emergency preparedness; influenza ID USE AUTHORIZATION; UNITED-STATES AB Objective: To provide a general description of the roles and contributions of three pharmacists from the Regulatory Affairs program (RA) at the Centers for Disease Control and Prevention (CDC) who are involved in emergency preparedness and response activities, including the 2009 pandemic influenza A (H1N1) public health emergency. Setting: Atlanta, GA. Practice description: RA consists of a staff of nine members, three of whom are pharmacists. The mission of RA is to support CDC's preparedness and emergency response activities and to ensure regulatory compliance for critical medical countermeasures against potential threats from natural, chemical, biological, radiological, or nuclear events. Conclusion: RA was well involved in the response to the H1N1 outbreak through numerous activities, such as submitting multiple Emergency Use Authorization (EUA) requests to the Food and Drug Administration, including those for medical countermeasures to be deployed from the Strategic National Stockpile, and developing the CDC EUA website (www.cdc.gov/h1n1flu/eua). RA will continue to support current and future preparedness and emergency response activities by ensuring that the appropriate regulatory mechanisms are in place for the deployment of critical medical countermeasures from the Strategic National Stockpile against threats to public health. C1 [Bhavsar, Tina R.; Kim, Hye-Joo; Yu, Yon] Ctr Dis Control & Prevent, Off Director, Natl Ctr Emerging & Zoonot Infect Dis Proposed, Atlanta, GA USA. RP Bhavsar, TR (reprint author), 1600 Clifton Rd NE,MS C-12, Atlanta, GA 30333 USA. EM asn2@cdc.gov NR 5 TC 3 Z9 3 U1 0 U2 0 PU AMER PHARMACEUTICAL ASSOC PI WASHINGTON PA 2215 CONSTITUTION AVE NW, WASHINGTON, DC 20037 USA SN 1544-3191 J9 J AM PHARM ASSOC JI J. Am. Pharm. Assoc. PD MAR-APR PY 2010 VL 50 IS 2 BP 165 EP 168 DI 10.1331/JAPhA.2010.09220 PG 4 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 585EG UT WOS:000276806600009 PM 20199957 ER PT J AU Pisu, M Richardson, LC Kim, YI Krontiras, H Martin, MY Salas, M Pollack, LA AF Pisu, Maria Richardson, Lisa C. Kim, Young-Il Krontiras, Helen Martin, Michelle Y. Salas, Maribel Pollack, Lori A. TI Less-Than-Standard Treatment in Rectal Cancer Patients: Which Patients Are at Risk? SO JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION LA English DT Article DE cancer; rectum; tumor; chemotherapy; treatment ID COLORECTAL-CANCER; ADJUVANT THERAPY; UNITED-STATES; COLON-CANCER; STAGE-II; SURVIVAL; CHEMOTHERAPY; RADIOTHERAPY; POPULATION; OUTCOMES AB Objective: Guidelines recommend that patients with non-metastatic rectal cancer receive surgery and adjuvant chemotherapy and/or radiation therapy (XRT) after surgery (especially if stage II and III). Studies reported that 90% of stage II and III patients received surgery, and 70% received adjuvant treatment. In states where socioeconomics and limited medical resources may hinder treatment, cancer care is understudied. The objective is to describe initiation and completion of rectal cancer treatment in Alabama. Methods: Medicare claims were obtained for 675 stage I to III rectal cancer patients diagnosed in 1999-2003, enrolled in fee-for-service Medicare, and with at least 9 months of follow-up. Logistic regressions were used to identify significant differences by sex, age, and race in the likelihood of initiating treatment and receiving an incomplete course of chemotherapy or XRT (120 days of chemotherapy and 28 days of XRT). Results: Overall, 90% received surgery, of which 43% received some adjuvant treatment. Among stage II to III patients, 58.8% received adjuvant treatment. Except for patients aged 75 years and greater being less likely to start chemotherapy, there were no significant differences in initiation by age, sex, and race. Depending on concurrent administration of chemotherapy and XRT, 29% to 35% received incomplete chemotherapy, and 16% to 23% incomplete XRT. Women were more likely to have incomplete chemotherapy than men. Conclusions: Adjuvant treatment was less than reported in previous studies. Treatment initiation and completion did not differ across demographic factors. Future studies should explore reasons why older rectal cancer patients in Alabama are less likely to receive recommended treatment. C1 [Pisu, Maria; Kim, Young-Il; Martin, Michelle Y.] Univ Alabama, Dept Med, Div Prevent Med, Birmingham, AL 35294 USA. [Krontiras, Helen] Univ Alabama, Dept Surg, Gen Surg Oncol Sect, Birmingham, AL 35294 USA. [Richardson, Lisa C.; Pollack, Lori A.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth, Div Canc Prevent & Control, Atlanta, GA USA. [Salas, Maribel] AstraZeneca LP, US Patient Safety, Wilmington, DE USA. RP Pisu, M (reprint author), Univ Alabama, Dept Med, Div Prevent Med, 1530 3rd Ave S,MT 628, Birmingham, AL 35294 USA. EM mpisu@uab.edu FU Centers for Disease Control and Prevention Prevention Research Centers Program [U48 DP000225-01] FX This study was supported by cooperative agreement U48 DP000225-01 from the Centers for Disease Control and Prevention Prevention Research Centers Program. NR 24 TC 7 Z9 8 U1 0 U2 0 PU NATL MED ASSOC PI WASHINGON PA 1012 10TH ST, N W, WASHINGON, DC 20001 USA SN 0027-9684 J9 J NATL MED ASSOC JI J. Natl. Med. Assoc. PD MAR PY 2010 VL 102 IS 3 BP 190 EP 198 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 574CV UT WOS:000275967000004 PM 20355348 ER PT J AU Borresen, ML Olsen, OR Ladefoged, K McMahon, BJ Hjuler, T Panum, I Simonetti, J Jones, C Krarup, H Koch, A AF Borresen, M. L. Olsen, O. R. Ladefoged, K. McMahon, B. J. Hjuler, T. Panum, I. Simonetti, J. Jones, C. Krarup, H. Koch, A. TI Hepatitis D outbreak among children in a hepatitis B hyper-endemic settlement in Greenland SO JOURNAL OF VIRAL HEPATITIS LA English DT Article DE children; Greenland; hepatitis B; hepatitis D; outbreak; vaccination ID VIRUS-INFECTION; HEPATOCELLULAR-CARCINOMA; VIRAL LOAD; GENOTYPES; DELTA; CIRRHOSIS; FULMINANT; ANTIGEN; CORE AB Hepatitis B virus (HBV) infection is endemic in Greenland with 5-10% of the population being HBsAg-positive (chronic carriers). Surprisingly, despite of the high prevalence of HBV infection, acute and chronic hepatitis B, liver cirrhosis and primary hepatocellular carcinoma appear much less frequently than expected. The reasons for the low frequencies are unknown, but as a consequence implementation of a childhood HBV vaccination programme, though debated for years, has never been instituted. We describe an outbreak of hepatitis D (HDV) infection among children in a hepatitis B hyper-endemic settlement of 133 inhabitants on the west coast of Greenland. In 2006 a total of 27% of the inhabitants were HBsAg-positive (chronic carriers) and 83% were HBcAb-positive (previously exposed). Forty-six percent of the HBsAg-positive persons were below 20 years of age. On follow-up 1 year later a total of 68% of the HBsAg-positive persons were HDV-IgG positive. Five children, who were HBsAg-positive in 2006, had HDV-seroconverted from 2006 to 2007, indicating a HDV-super-infection. Most of the HDV-IgG positive children had markedly elevated liver enzymes. In the multivariate analysis, among the HBV and HDV markers, presence of HDV-IgG was most strongly associated with elevation of liver enzymes. In conclusion, the HBV-HDV super-infection and presumed HDV outbreak in this settlement challenges the notion that HBV infection may not be as harmless in Greenland as previously anticipated. The findings strongly suggest that HBV vaccination should be included in the child-immunization program in Greenland. C1 [Borresen, M. L.; Hjuler, T.; Koch, A.] Statens Serum Inst, Dept Epidemiol Res, DK-2300 Copenhagen, Denmark. [Olsen, O. R.] Sisimiut Hlth Clin & Hosp, Sisimiut, Greenland. [Ladefoged, K.] Dronning Ingrids Hosp, Dept Internal Med, Nuuk, Greenland. [McMahon, B. J.; Simonetti, J.; Jones, C.] Ctr Dis Control & Prevent, Liver Dis & Hepatitis Program, Alaska Native Med Ctr, Anchorage, AK USA. [McMahon, B. J.; Simonetti, J.; Jones, C.] Ctr Dis Control & Prevent, Arctic Invest Program, Anchorage, AK USA. [Panum, I.] Statens Serum Inst, Dept Virol, DK-2300 Copenhagen, Denmark. [Krarup, H.] Alborg Univ Hosp, Dept Clin Biochem, Aalborg, Denmark. RP Borresen, ML (reprint author), Statens Serum Inst, Dept Epidemiol Res, Artillerivej 5, DK-2300 Copenhagen, Denmark. EM mlb@ssi.dk OI Koch, Anders/0000-0001-9205-1048 FU Danish agency for science, technology and innovation [22-04-0644] FX None of the authors have any financial interest in the subject matter. The study was supported by the Danish agency for science, technology and innovation, Grant number 22-04-0644. NR 31 TC 19 Z9 19 U1 0 U2 1 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1352-0504 J9 J VIRAL HEPATITIS JI J. Viral Hepatitis PD MAR PY 2010 VL 17 IS 3 BP 162 EP 170 DI 10.1111/j.1365-2893.2009.01159.x PG 9 WC Gastroenterology & Hepatology; Infectious Diseases; Virology SC Gastroenterology & Hepatology; Infectious Diseases; Virology GA 545ID UT WOS:000273724800002 PM 19780937 ER PT J AU Witko, SE Johnson, JE Kalyan, NK Felber, BK Pavlakis, GN Sidhu, MK Hendry, RM Udem, SA Parks, CL AF Witko, Susan E. Johnson, J. Erik Kalyan, Narender K. Felber, Barbara K. Pavlakis, George N. Sidhu, Maninder K. Hendry, R. Michael Udem, Stephen A. Parks, Christopher L. TI Refined methods for propagating vesicular stomatitis virus vectors that are defective for G protein expression SO JOURNAL OF VIROLOGICAL METHODS LA English DT Article DE Negative-strand RNA virus; VSV; Vero cells; Electroporation; Heat shock; Non-propagating ID RESPIRATORY SYNCYTIAL VIRUS; ATTENUATED RECOMBINANT VACCINE; REPLICATION-COMPETENT VECTOR; MESSENGER-RNA DEGRADATION; IMMEDIATE-EARLY GENE; STRUCTURAL FEATURES; NONHUMAN-PRIMATES; ENDOGENOUS VIRUS; MAMMALIAN-CELLS; REV DEPENDENCE AB Propagation-defective vesicular stomatitis virus (VSV) vectors that encode a truncated G protein (VSV-Gstem) or lack the G gene entirely (VSV-Delta G) are attractive vaccine vectors because they are immunogenic, cannot replicate and spread after vaccination, and do not express many of the epitopes that elicit neutralizing anti-VSV immunity. To consider advancing non-propagating VSV vectors towards clinical assessment, scalable technology that is compliant with human vaccine manufacturing must be developed to produce clinical trial material. Accordingly, two propagation methods were developed for VSV-Gstem and VSV-Delta G vectors encoding HIV gag that have the potential to support large-scale production. One method is based on transient expression of G protein after electroporating plasmid DNA into Vero cells and the second is based on a stable Vero cell line that contains a G gene controlled by a heat shock-inducible transcription unit. Both methods reproducibly supported production of 1 x 10(7) to 1 x 10(8) infectious units (I.U.s) of vaccine vector per milliliter. Results from these studies also showed that optimization of the G gene is necessary for abundant G protein expression from electroporated plasmid DNA or from DNA integrated in the genome of a stable cell line, and that the titers of VSV-Gstem vectors generally exceeded VSV-Delta G. (C) 2009 Elsevier B.V. All rights reserved. C1 [Witko, Susan E.; Johnson, J. Erik; Kalyan, Narender K.; Sidhu, Maninder K.; Hendry, R. Michael; Udem, Stephen A.; Parks, Christopher L.] Pfizer Vaccine Res, Pearl River, NY 10965 USA. [Felber, Barbara K.] NCI, Human Retrovirus Pathogenesis Sect, Vaccine Branch, Ctr Canc Res, Frederick, MD 21702 USA. [Pavlakis, George N.] NCI, Human Retrovirus Sect, Vaccine Branch, Ctr Canc Res, Frederick, MD 21702 USA. [Hendry, R. Michael] Ctr Dis Control, Div HIV AIDS Prevent, Atlanta, GA 30329 USA. [Parks, Christopher L.] Int AIDS Vaccine Initiat, Vaccine Design & Dev Lab, Brooklyn, NY 11220 USA. RP Kalyan, NK (reprint author), Pfizer Vaccine Res, 401 N Middletown Rd, Pearl River, NY 10965 USA. EM kalyann@wyeth.com FU National Institutes of Health, National Institute of Allergy and Infectious Diseases [HVDDT NO1-A1-25458]; National Cancer Institute, Center for Cancer Research FX This work was sponsored in part by an HIV-1 Vaccine Design and Development Team contract from the National Institutes of Health and the National Institute of Allergy and Infectious Diseases (HVDDT NO1-A1-25458), and the National Cancer Institute Intramural Research Program at the Center for Cancer Research. We thank Julia Li for performing statistical analysis, Alan Gordon for insightful comments and suggestions and Ellen Murphy and Yury Matsuka for critical review of the manuscript. NR 82 TC 6 Z9 6 U1 0 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0166-0934 J9 J VIROL METHODS JI J. Virol. Methods PD MAR PY 2010 VL 164 IS 1-2 BP 43 EP 50 DI 10.1016/j.jviromet.2009.11.023 PG 8 WC Biochemical Research Methods; Biotechnology & Applied Microbiology; Virology SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Virology GA 585JD UT WOS:000276820500008 PM 19941901 ER PT J AU Pau, CP Wells, SK Rudolph, DL Owen, SM Granade, TC AF Pau, Chou-Pong Wells, Susan K. Rudolph, Donna L. Owen, S. Michele Granade, Timothy C. TI A rapid real-time PCR assay for the detection of HIV-1 proviral DNA using double-stranded primer SO JOURNAL OF VIROLOGICAL METHODS LA English DT Article DE HIV-1; Proviral DNA; Double-stranded primer; Real-Time PCR ID DRIED BLOOD SPOTS; QUANTITATIVE DETECTION; RT-PCR; WHOLE-BLOOD; INFECTION; DIAGNOSIS; INFANTS; CELLS; LOAD; AMPLIFICATION AB In this study, a rapid real-time PCR assay to detect HIV-1 proviral DNA in whole blood was developed using a novel double-stranded primer that does not require a target-specific fluorescent probe or intercalating dye systems. Co-amplification of a human gene RNase P served as the internal control to monitor the efficiency of the DNA extraction and PCR amplification. The HIV-1 amplification efficiency was 100% and could amplify 1 copy of HIV-1 DNA 64% of the time and all attempts to amplify 4 copies were successful in less than 51 min. All 22 HIV-1 sero-positive and 20 sero-negative whole blood specimens tested were classified correctly by this assay. In addition, 22 cultured PBMC specimens infected with various HIV-1 subtypes or CRF (A = 2, AC = 1, B = 4, C = 3, D = 3, AE = 2, F = 1, BF = 2, G = 4) were amplified equally well with a similar threshold cycle (C(t)) number (22.9 +/- 1.2). The high amplification efficiency and short PCR cycles were in part due to the short target sequence amplified by eliminating the probe-binding sequence between the primers. This assay may be useful as an alternative confirmation test in a variety of HIV testing venues. Published by Elsevier B.V. C1 [Pau, Chou-Pong; Wells, Susan K.; Rudolph, Donna L.; Owen, S. Michele; Granade, Timothy C.] Ctr Dis Control & Prevent, Branch Lab, Div HIV AIDS Prevent, Natl Ctr HIV STD & TB Prevent, Atlanta, GA 30333 USA. RP Pau, CP (reprint author), Ctr Dis Control & Prevent, Branch Lab, Div HIV AIDS Prevent, Natl Ctr HIV STD & TB Prevent, Atlanta, GA 30333 USA. EM chp3@cdc.gov NR 30 TC 9 Z9 10 U1 4 U2 7 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0166-0934 J9 J VIROL METHODS JI J. Virol. Methods PD MAR PY 2010 VL 164 IS 1-2 BP 55 EP 62 DI 10.1016/j.jviromet.2009.11.027 PG 8 WC Biochemical Research Methods; Biotechnology & Applied Microbiology; Virology SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Virology GA 585JD UT WOS:000276820500010 PM 19948189 ER PT J AU Lazaryan, A Song, W Lobashevsky, E Tang, JM Shrestha, S Zhang, K Gardner, LI McNicholl, JM Wilson, CM Klein, RS Rompalo, A Mayer, K Sobel, J Kaslow, RA AF Lazaryan, Aleksandr Song, Wei Lobashevsky, Elena Tang, Jianming Shrestha, Sadeep Zhang, Kui Gardner, Lytt I. McNicholl, Janet M. Wilson, Craig M. Klein, Robert S. Rompalo, Anne Mayer, Kenneth Sobel, Jack Kaslow, Richard A. CA HIV Epidemiology Res Study Reachin TI Human Leukocyte Antigen Class I Supertypes and HIV-1 Control in African Americans SO JOURNAL OF VIROLOGY LA English DT Article ID IMMUNODEFICIENCY-VIRUS TYPE-1; HLA CLASS-I; T-LYMPHOCYTE RESPONSES; DISEASE PROGRESSION; MULTIPLE IMPUTATION; SELECTION PRESSURE; CELL RESPONSES; VIRAL LOAD; INFECTION; AIDS AB ;The role of human leukocyte antigen (HLA) class I supertypes in controlling human immunodeficiency virus type 1 (HIV-1) infection in African Americans has not been established. We examined the effects of the HLA-A and HLA-B alleles and supertypes on the outcomes of HIV-1 clade B infection among 338 African American women and adolescents. HLA-B58 and -B62 supertypes (B58s and B62s) were associated with favorable HIV-1 disease control (proportional odds ratio [POR] of 0.33 and 95% confidence interval [95% CI] of 0.21 to 0.52 for the former and POR of 0.26 and 95% CI of 0.09 to 0.73 for the latter); B7s and B44s were associated with unfavorable disease control (POR of 2.39 and 95% CI of 1.54 to 3.73 for the former and POR of 1.63 and 95% CI of 1.08 to 2.47 for the latter). In general, individual alleles within specific B supertypes exerted relatively homogeneous effects. A notable exception was B27s, whose protective influence (POR, 0.58; 95% CI, 0.35 to 0.94) was masked by the opposing effect of its member allele B*1510. The associations of most B supertypes (e. g., B58s and B7s) were largely explained either by well-known effects of constituent B alleles or by effects of previously unimplicated B alleles aggregated into a particular supertype (e. g., B44s and B62s). A higher frequency of HLA-B genotypic supertypes correlated with a higher mean viral load (VL) and lower mean CD4 count (Pearson's r = 0.63 and 0.62, respectively; P = 0.03). Among the genotypic supertypes, B58s and its member allele B*57 contributed disproportionately to the explainable VL variation. The study demonstrated the dominant role of HLA-B supertypes in HIV-1 clade B-infected African Americans and further dissected the contributions of individual class I alleles and their population frequencies to the supertype effects. C1 [Lazaryan, Aleksandr; Song, Wei; Lobashevsky, Elena; Tang, Jianming; Shrestha, Sadeep; Zhang, Kui; Wilson, Craig M.; Kaslow, Richard A.] Univ Alabama, Birmingham, AL 35294 USA. [Gardner, Lytt I.; McNicholl, Janet M.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Klein, Robert S.] Mt Sinai Sch Med, New York, NY USA. [Rompalo, Anne] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Mayer, Kenneth] Brown Univ, Sch Med, Providence, RI 02912 USA. [Sobel, Jack] Wayne State Univ, Sch Med, Detroit, MI USA. RP Kaslow, RA (reprint author), Univ Alabama, 220A Ryals Bldg,1665 Univ Blvd, Birmingham, AL 35294 USA. EM rkaslow@uab.edu OI Tang, Jianming/0000-0003-0137-7486 FU National Institute of Child Health and Human Development [U01 HD32830]; National Institute on Drug Abuse; National Institute of Allergy and Infectious Diseases; National Institute of Mental Health; Centers for Disease Control and Prevention; National Institute of Allergy and Infectious Diseases (NIAID); Agency for Health Care Policy and Research; National Institutes of Health Office for Women's Research; National Institute of Allergy and Infectious Diseases [R01 AI071906] FX REACH was supported by grant U01 HD32830 from the National Institute of Child Health and Human Development, with additional funding from the National Institute on Drug Abuse, National Institute of Allergy and Infectious Diseases, and National Institute of Mental Health. HERS was supported by the Centers for Disease Control and Prevention, the National Institute of Allergy and Infectious Diseases (NIAID), the National Institute on Drug Abuse, the Agency for Health Care Policy and Research, and the National Institutes of Health Office for Women's Research. Genetic analysis was supported by grant R01 AI071906 from the National Institute of Allergy and Infectious Diseases. NR 45 TC 13 Z9 15 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD MAR PY 2010 VL 84 IS 5 BP 2610 EP 2617 DI 10.1128/JVI.01962-09 PG 8 WC Virology SC Virology GA 552YD UT WOS:000274330300038 PM 20032191 ER PT J AU Li, Y Chan, EY Li, JN Ni, C Peng, XX Rosenzweig, E Tumpey, TM Katze, MG AF Li, Yu Chan, Eric Y. Li, Jiangning Ni, Chester Peng, Xinxia Rosenzweig, Elizabeth Tumpey, Terrence M. Katze, Michael G. TI MicroRNA Expression and Virulence in Pandemic Influenza Virus-Infected Mice SO JOURNAL OF VIROLOGY LA English DT Article ID RNA-POLYMERASE-II; A VIRUS; CELLULAR MICRORNAS; IMMUNE-RESPONSE; MIR-200 FAMILY; PROTEIN; GENE; TRANSCRIPTION; DEGRADATION; MODULATION AB The worst known H1N1 influenza pandemic in history resulted in more than 20 million deaths in 1918 and 1919. Although the underlying mechanism causing the extreme virulence of the 1918 influenza virus is still obscure, our previous functional genomics analyses revealed a correlation between the lethality of the reconstructed 1918 influenza virus (r1918) in mice and a unique gene expression pattern associated with severe immune responses in the lungs. Lately, microRNAs have emerged as a class of crucial regulators for gene expression. To determine whether differential expression of cellular microRNAs plays a role in the host response to r1918 infection, we compared the lung cellular "microRNAome" of mice infected by r1918 virus with that of mice infected by a nonlethal seasonal influenza virus, A/Texas/36/91. We found that a group of microRNAs, including miR-200a and miR-223, were differentially expressed in response to influenza virus infection and that r1918 and A/Texas/36/91 infection induced distinct microRNA expression profiles. Moreover, we observed significant enrichment in the number of predicted cellular target mRNAs whose expression was inversely correlated with the expression of these microRNAs. Intriguingly, gene ontology analysis revealed that many of these mRNAs play roles in immune response and cell death pathways, which are known to be associated with the extreme virulence of r1918. This is the first demonstration that cellular gene expression patterns in influenza virus-infected mice may be attributed in part to microRNA regulation and that such regulation may be a contributing factor to the extreme virulence of the r1918. C1 [Li, Yu; Chan, Eric Y.; Ni, Chester; Peng, Xinxia; Rosenzweig, Elizabeth; Katze, Michael G.] Univ Washington, Dept Microbiol, Seattle, WA 98195 USA. [Katze, Michael G.] Univ Washington, Washington Natl Primate Res Ctr, Seattle, WA 98195 USA. [Li, Jiangning] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA. [Tumpey, Terrence M.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Katze, MG (reprint author), Univ Washington, Dept Microbiol, Box 358070, Seattle, WA 98195 USA. EM honey@u.washington.edu FU National Institute of Allergy and Infectious Diseases [P01AI058113] FX We thank Marcus Korth for critically reading the manuscript. We also thank Robert Palermo, Lynn Law, and Sean Proll for their helpful discussions.; This work was supported by the Public Health Service grant P01AI058113 from the National Institute of Allergy and Infectious Diseases.; The findings and conclusions in this report are those of the author(s) and do not necessarily represent the views of the funding agency. NR 40 TC 86 Z9 88 U1 0 U2 6 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD MAR PY 2010 VL 84 IS 6 BP 3023 EP 3032 DI 10.1128/JVI.02203-09 PG 10 WC Virology SC Virology GA 565VG UT WOS:000275322300037 PM 20071585 ER PT J AU Krause, JC Tumpey, TM Huffman, CJ McGraw, PA Pearce, MB Tsibane, T Hai, R Basler, CF Crowe, JE AF Krause, Jens C. Tumpey, Terrence M. Huffman, Chelsey J. McGraw, Patricia A. Pearce, Melissa B. Tsibane, Tshidi Hai, Rong Basler, Christopher F. Crowe, James E., Jr. TI Naturally Occurring Human Monoclonal Antibodies Neutralize both 1918 and 2009 Pandemic Influenza A (H1N1) Viruses SO JOURNAL OF VIROLOGY LA English DT Article ID ANTIGENIC STRUCTURE; H-1 SUBTYPE; DETERMINANTS; MICE AB The 2009 pandemic influenza A (H1N1) virus exhibits hemagglutinin protein sequence homology with the 1918 pandemic influenza virus. We found that human monoclonal antibodies recognized the Sa antigenic site on the head domains of both 1918 and 2009 hemagglutinins, a site that is hypervariable due to immune selection. These antibodies exhibited high potency against the 2009 virus in vitro, and one exerted a marked therapeutic effect in vivo. C1 [Crowe, James E., Jr.] Vanderbilt Univ, Med Ctr, Program Vaccine Sci, T2220 Med Ctr N,Dept Pediat, Nashville, TN 37232 USA. [Krause, Jens C.; Huffman, Chelsey J.; McGraw, Patricia A.; Crowe, James E., Jr.] Vanderbilt Univ, Med Ctr, Dept Microbiol & Immunol, Nashville, TN 37232 USA. [Tumpey, Terrence M.; Pearce, Melissa B.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA. [Tsibane, Tshidi; Hai, Rong; Basler, Christopher F.] Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA. RP Crowe, JE (reprint author), Vanderbilt Univ, Med Ctr, Program Vaccine Sci, T2220 Med Ctr N,Dept Pediat, 1161 21st Ave S, Nashville, TN 37232 USA. EM james.crowe@vanderbilt.edu RI Crowe, James/B-5549-2009 OI Crowe, James/0000-0002-0049-1079 FU Pediatric Infectious Diseases Society Fellowship Award; Burroughs Wellcome Fund Clinical Scientist in Translational Research; [U19 AI057229]; [U54 AI057157]; [P01 AI058113] FX This work was supported by grants U19 AI057229, U54 AI057157, and P01 AI058113. J. C. K. was supported by a Pediatric Infectious Diseases Society Fellowship Award. J. E. C. is a Burroughs Wellcome Fund Clinical Scientist in Translational Research.; We thank Bryan Shepherd for help with the statistical analysis and Damian Ekiert for helpful discussions. Clinical isolates of the 2009 A (H1N1) virus (CA04 and A/Mexico/4108/2009 strains) were obtained from Alexander Klimov (Centers for Disease Control and Prevention).; The findings and conclusions in this report are those of the authors and do not necessarily reflect the views of the funding agency. NR 21 TC 58 Z9 63 U1 1 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD MAR PY 2010 VL 84 IS 6 BP 3127 EP 3130 DI 10.1128/JVI.02184-09 PG 4 WC Virology SC Virology GA 565VG UT WOS:000275322300049 PM 20042511 ER PT J AU Wong, C Krashin, J Rue-Cover, A Saraiya, M Unger, E Calugar, A Markowitz, L AF Wong, Charlene Krashin, Jamie Rue-Cover, Alison Saraiya, Mona Unger, Elizabeth Calugar, Angela Markowitz, Lauri TI Invasive and In Situ Cervical Cancer Reported to the Vaccine Adverse Event Reporting System (VAERS) SO JOURNAL OF WOMENS HEALTH LA English DT Article ID HUMAN-PAPILLOMAVIRUS VACCINATION; PARTICLE VACCINE; YOUNG-WOMEN; QUADRIVALENT VACCINE; HPV VACCINATION; INFECTION; RECOMMENDATIONS; DISEASES; SAFETY; TRIAL AB The quadrivalent human papillomavirus (HPV) vaccine was recommended in 2006 for routine vaccination of 11 or 12-year-old girls, with catchup through age 26 years, for the prevention of genital HPV-related diseases. The Vaccine Adverse Event Reporting System (VAERS) is a national spontaneous surveillance system of adverse events following vaccination in the United States. The objective of this study was to identify and review VAERS reports of invasive and in situ cervical cancer in women immunized with the quadrivalent HPV vaccine. A VAERS database search was performed to identify such cases reported in the United States from January 1, 2006, through April 9, 2009. Medical Dictionary for Regulatory Activities (MedDRA) search terms used were "cervix carcinoma,'' "cervix carcinoma stage 0,'' "cervix carcinoma stage III,'' "carcinoma in situ,'' and "cervical dysplasia.'' Case inclusion required a report to contain a clear statement of a cervical carcinoma or carcinoma in situ diagnosis on any screening or diagnostic test after at least one dose of the HPV vaccine. All reports were reviewed by two investigators. Four VAERS reports for MedDRA term "cervix carcinoma,'' one for "cervix carcinoma stage 0,'' none for "cervix carcinoma stage III,'' three for "carcinoma in situ,'' and 53 for "cervical dysplasia'' were identified. Of these, three cases of carcinoma in situ and one case of microinvasive cervical cancer met study inclusion criteria. Cases of cervical cancer and precancers are not unexpected in vaccinated women. Cervical cancer screening continues to be important, even for women who have received the HPV vaccine. C1 [Wong, Charlene; Saraiya, Mona] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Krashin, Jamie; Markowitz, Lauri] Ctr Dis Control & Prevent, Div Sexually Transmitted Dis Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30341 USA. [Rue-Cover, Alison; Calugar, Angela] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Natl Ctr Preparedness Detect & Control Infect Dis, Atlanta, GA 30341 USA. [Unger, Elizabeth] Ctr Dis Control & Prevent, Div Viral & Rickettsial Dis, Natl Ctr Zoonot Vector Borne & Enter Dis, Atlanta, GA 30341 USA. RP Saraiya, M (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway,MS K-55, Atlanta, GA 30341 USA. EM yzs2@cdc.gov OI Krashin, Jamie/0000-0002-7463-6672; Unger, Elizabeth/0000-0002-2925-5635 FU External Medical Affairs, Pfizer Inc FX Charlene Wong and Jamie Krashin completed this project during their 1-year fellowship, The CDC Experience, a public/private partnership supported by a grant to the CDC Foundation from External Medical Affairs, Pfizer Inc.; The findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention. NR 36 TC 3 Z9 3 U1 0 U2 1 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD MAR PY 2010 VL 19 IS 3 BP 365 EP 370 DI 10.1089/jwh.2009.1891 PG 6 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 574IS UT WOS:000275983200001 PM 20141382 ER PT J AU Duwe, KN Reefhuis, J Honein, MA Schieve, LA Rasmussen, SA AF Duwe, Kara N. Reefhuis, Jennita Honein, Margaret A. Schieve, Laura A. Rasmussen, Sonja A. CA Natl Birth Defects Prevention Stud TI Epidemiology of Fertility Treatment Use Among US Women with Liveborn Infants, 1997-2004 SO JOURNAL OF WOMENS HEALTH LA English DT Article ID ASSISTED REPRODUCTIVE TECHNOLOGY; IN-VITRO FERTILIZATION; INTRACYTOPLASMIC SPERM INJECTION; BIRTH-DEFECTS PREVENTION; INSURANCE MANDATES; PRENATAL-DIAGNOSIS; MULTIPLE GESTATION; PERINATAL OUTCOMES; UNITED-STATES; INFERTILITY AB Objective: This study assessed reported use of assisted reproductive technology (ART) and other (non-ART) fertility treatments among a population-based sample and examined factors related to use. Methods: The data for this study were collected as part of the National Birth Defects Prevention Study (NBDPS), limited to women from the control group who delivered liveborn infants with no major birth defects. We described prevalence of the use of ART and clomiphene citrate (the most commonly used non-ART treatment) by demographic and lifestyle factors and examined associations among use of fertility treatments and pregnancy outcomes, timing of prenatal care initiation, and use of prenatal testing technologies. Results: Overall, 4.2% of women reported any type of maternal fertility treatment use; 1.0% reported ART use, 1.6% reported clomiphene citrate use without ART, and 1.7% reported other fertility treatments. Women who reported any fertility treatment type were more likely than women with an unassisted conception to be non-Hispanic white, >30 years of age, and more highly educated. Overall, women who reported ART use were more likely than women who reported unassisted pregnancy to have an amniocentesis; however, this association was no longer evident after adjustment for maternal age. Conclusions: Fertility treatment use and type of treatment vary by maternal characteristics. This information may be useful to inform a broad maternal and child health audience about the growing use of fertility treatments, including who is using the treatments and the choices they are making about prenatal care. C1 [Duwe, Kara N.; Reefhuis, Jennita; Honein, Margaret A.; Schieve, Laura A.; Rasmussen, Sonja A.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Duwe, Kara N.] Oak Ridge Inst Sci & Educ, Oak Ridge, TN USA. RP Duwe, KN (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd,MS E-86, Atlanta, GA 30333 USA. EM Kduwe@cdc.gov RI Reefhuis, Jennita/E-1793-2011; Publications, NBDPS/B-7692-2013 OI Reefhuis, Jennita/0000-0002-4747-4831; FU Research Participation Program for the Centers for Disease Control FX We thank all collaborators from the Centers for Birth Defects Research and Prevention in Arkansas, California, Georgia, Iowa, Massachusetts, New Jersey, New York, North Carolina, Texas, and Utah for their significant contributions. We also thank the families that participated in the NBDPS. This project was supported in part by an appointment to the Research Participation Program for the Centers for Disease Control and Prevention administered by the Oak Ridge Institute for Science and Education through an agreement between the Department of Energy and CDC. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.; K.N.D. was supported by an appointment to the Research Participation Program for the Centers for Disease Control and Prevention administered by the Oak Ridge Institute for Science and Education through an agreement between the Department of Energy and CDC. NR 57 TC 13 Z9 13 U1 0 U2 4 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD MAR PY 2010 VL 19 IS 3 BP 407 EP 416 DI 10.1089/jwh.2009.1499 PG 10 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 574IS UT WOS:000275983200006 PM 20141369 ER PT J AU Ahluwalia, IB Tessaro, I Greenlund, KJ Ford, ES AF Ahluwalia, Indu B. Tessaro, Irene Greenlund, Kurt J. Ford, Earl S. TI Factors Associated with Control of Hypertension, Hypercholesterolemia, and Diabetes Among Low-Income Women in West Virginia SO JOURNAL OF WOMENS HEALTH LA English DT Article ID HEALTH-CARE ACCESS; UNITED-STATES; UNCONTROLLED HYPERTENSION; BLOOD-PRESSURE; US ADULTS; PREVALENCE; AWARENESS; TRENDS; OUTCOMES; DISEASE AB Background: Adequate control of cardiovascular risk factors, such as hypertension, hypercholesterolemia, and diabetes, requires management. Low-income women living in rural areas with limited health services may experience special challenges in managing chronic conditions. Methods: In 2008, we conducted an analysis of the baseline, cross-sectional survey of 733 uninsured, low-income, rural women aged 40-64 years participating in the Well-Integrated Screening and Evaluation for Women Across the Nation (WISEWOMAN) project in West Virginia to characterize prevalence, treatment, and control of hypertension, hypercholesterolemia, and diabetes. Data were collected from 2004 to 2007. Results: About 56% of the women had hypertension (38% of which was untreated or uncontrolled), 45% had hypercholesterolemia (31% of which was untreated or uncontrolled), and 19% had diabetes (26% of which was untreated or uncontrolled). Multivariable analyses showed that those with a regular physician were less likely than those without a physician to have uncontrolled hypertension (adjusted odds ratio [AOR] 0.34, 95% CI 0.13-0.88) and hypercholesterolemia (AOR 0.14, 95% CI 0.04-0.47). Education level was also a significant predictor for uncontrolled hypertension, and physical activity level (measured by total metabolic equivalent [ MET] hours) significantly predicted uncontrolled hypercholesterolemia (AOR 1.01, 95% CI 1.001-1.02). For diabetes, race/ethnicity was the main predictor; white women were less likely than other groups to have untreated or uncontrolled diabetes. Conclusions: High proportions of women in the WV-WISEWOMAN project had uncontrolled hypertension, hypercholesterolemia, and diabetes at baseline. These study results should be used to inform programs seeking to increase access to health services in order to reduce consequences of uncontrolled chronic conditions. C1 [Ahluwalia, Indu B.; Greenlund, Kurt J.; Ford, Earl S.] Ctr Dis Control & Prevent, Div Adult & Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Tessaro, Irene] W Virginia Univ, Sch Nursing, Morgantown, WV 26506 USA. RP Ahluwalia, IB (reprint author), Ctr Dis Control & Prevent, Div Adult & Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway NE,Mailstop K-22, Atlanta, GA 30341 USA. EM Iahluwalia@cdc.gov NR 22 TC 12 Z9 12 U1 0 U2 3 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD MAR PY 2010 VL 19 IS 3 BP 417 EP 424 DI 10.1089/jwh.2009.1590 PG 8 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 574IS UT WOS:000275983200007 PM 20156080 ER PT J AU Ahluwalia, I Jamieson, D Rasmussen, S D'Angelo, D Goodman, D Hoban, C Kim, H Cain, R AF Ahluwalia, Indu Jamieson, Denise Rasmussen, Sonja D'Angelo, Denise Goodman, Dave Hoban, Carol Kim, Hanna Cain, Rachel TI Correlates of Seasonal Influenza Vaccine Uptake by Women During Pregnancy, Evidence from the Pregnancy Risk Assessment and Monitoring System SO JOURNAL OF WOMENS HEALTH LA English DT Meeting Abstract C1 [Ahluwalia, Indu; Jamieson, Denise; Rasmussen, Sonja; D'Angelo, Denise] CDC, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD MAR PY 2010 VL 19 IS 3 MA 01 BP 603 EP 603 PG 1 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 574IS UT WOS:000275983200029 ER PT J AU Beckles, GL Tierney, E Owens-Gary, M AF Beckles, Gloria L. Tierney, Ed Owens-Gary, Michelle TI Vitamin Deficiency among Women with and without Diagnosed Diabetes, U. S., 2001-2006 SO JOURNAL OF WOMENS HEALTH LA English DT Meeting Abstract C1 [Beckles, Gloria L.; Tierney, Ed; Owens-Gary, Michelle] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD MAR PY 2010 VL 19 IS 3 MA 09 BP 606 EP 606 PG 1 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 574IS UT WOS:000275983200037 ER PT J AU Friedman, A Bloodgood, B Bender, J Levine, E AF Friedman, Allison Bloodgood, Bonny Bender, Jim Levine, Elyse TI Tapping into Women's Values: How Can We Promote Infertility Prevention to Young Women? SO JOURNAL OF WOMENS HEALTH LA English DT Meeting Abstract C1 [Friedman, Allison] Ctr Dis Control & Prevent, Div Std HIV Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD MAR PY 2010 VL 19 IS 3 MA 28 BP 613 EP 613 PG 1 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 574IS UT WOS:000275983200056 ER PT J AU Luncheon, C Zack, M AF Luncheon, Cecily Zack, Matthew TI Health-Related Quality of Life among Asian Women, 18-64 years old, by Nationality and Birthplace-2005 California Health Interview Survey SO JOURNAL OF WOMENS HEALTH LA English DT Meeting Abstract C1 [Luncheon, Cecily; Zack, Matthew] Ctr Dis Control & Prevent, Div Adult & Community Hlth, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD MAR PY 2010 VL 19 IS 3 MA 58 BP 623 EP 624 PG 2 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 574IS UT WOS:000275983200086 ER PT J AU O'Neil, ME D'Angelo, D Ahluwalia, I AF O'Neil, Mary Elizabeth D'Angelo, Denise Ahluwalia, Indu TI Perceived Need and Receipt of Services During Pregnancy among Women with Live Births - Oklahoma and South Carolina, 2004-2007 SO JOURNAL OF WOMENS HEALTH LA English DT Meeting Abstract C1 [O'Neil, Mary Elizabeth; D'Angelo, Denise; Ahluwalia, Indu] CDC, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD MAR PY 2010 VL 19 IS 3 MA 64 BP 625 EP 626 PG 2 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 574IS UT WOS:000275983200092 ER PT J AU Schlehofer, D Ross, DS AF Schlehofer, Deirdre Ross, Danielle S. TI Identifying Health Disparities for Deaf Women: the Deaf Health Survey in American Sign Language SO JOURNAL OF WOMENS HEALTH LA English DT Meeting Abstract C1 [Schlehofer, Deirdre] Univ Rochester, Med Ctr, Dept Community & Prevent Med, Rochester Res Prevent Ctr,NCDHR, Rochester, NY 14627 USA. [Ross, Danielle S.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD MAR PY 2010 VL 19 IS 3 MA 77 BP 630 EP 630 PG 1 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 574IS UT WOS:000275983200105 ER PT J AU Kroeger, K Taylor, M Mickey, T Sangaramoorthy, T Ramachandran, S Loosier, P Pordell, P Herrington, S Bloom, F AF Kroeger, Karen Taylor, Melanie Mickey, Tom Sangaramoorthy, Thurka Ramachandran, Shruti Loosier, Penny Pordell, Paran Herrington, Samantha Bloom, Fred TI Political, Economic and Social Factors Related to Persistent High Rates of Congenital Syphilis (CS) among Latinos in Maricopa County, Arizona: Results from a Rapid Ethnographic Assessment SO JOURNAL OF WOMENS HEALTH LA English DT Meeting Abstract C1 [Kroeger, Karen; Sangaramoorthy, Thurka; Ramachandran, Shruti; Loosier, Penny; Pordell, Paran; Herrington, Samantha; Bloom, Fred] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. [Taylor, Melanie] Arizona Dept Hlth Serv, Off HIV, STD Serv, Phoenix, AZ 85007 USA. [Taylor, Melanie] Arizona Dept Hlth Serv, Off HIV, Hepatitis Serv, Phoenix, AZ 85007 USA. [Mickey, Tom] Maricopa Cty Dept Publ Hlth, STD Program, Phoenix, AZ USA. NR 0 TC 0 Z9 0 U1 0 U2 4 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD MAR PY 2010 VL 19 IS 3 MA 83 BP 632 EP 632 PG 1 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 574IS UT WOS:000275983200111 ER PT J AU Watson, LC Townsend, JS Basile, KC Richardson, LC AF Watson, Lisa C. Townsend, Julie S. Basile, Kathleen C. Richardson, Lisa C. TI The Association of Breast Cancer Screening and Healthcare Utilization among Women Who Report Sexual Violence Victimization SO JOURNAL OF WOMENS HEALTH LA English DT Meeting Abstract C1 [Watson, Lisa C.; Townsend, Julie S.; Basile, Kathleen C.; Richardson, Lisa C.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD MAR PY 2010 VL 19 IS 3 MA 100 BP 638 EP 639 PG 2 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 574IS UT WOS:000275983200128 ER PT J AU White, CM Ressler-Maerlender, J Thornton-Evans, G AF White, Carrie M. Ressler-Maerlender, Jessamyn Thornton-Evans, Gina TI Oral Health During Pregnancy: A Comparative Analysis Reviewing Qualitative Data from the 2005 and 2008 Pregnancy Risk Assessment Monitoring System (PRAMS) Surveys SO JOURNAL OF WOMENS HEALTH LA English DT Meeting Abstract C1 [White, Carrie M.; Thornton-Evans, Gina] Ctr Dis Control & Prevent, GINN Grp, Div Oral Hlth, Atlanta, GA USA. [Ressler-Maerlender, Jessamyn] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD MAR PY 2010 VL 19 IS 3 MA 101 BP 639 EP 639 PG 1 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 574IS UT WOS:000275983200129 ER PT J AU Turmelle, AS Allen, LC Schmidt-French, BA Jackson, FR Kunz, TH McCracken, GF Rupprecht, CE AF Turmelle, Amy S. Allen, Louise C. Schmidt-French, Barbara A. Jackson, Felix R. Kunz, Thomas H. McCracken, Gary F. Rupprecht, Charles E. TI RESPONSE TO VACCINATION WITH A COMMERCIAL INACTIVATED RABIES VACCINE IN A CAPTIVE COLONY OF BRAZILIAN FREE-TAILED BATS (TADARIDA BRASILIENSIS) SO JOURNAL OF ZOO AND WILDLIFE MEDICINE LA English DT Article DE Bat; rabies virus; Tadarida brasiliensis; vaccination; virus neutralizing antibodies ID VIRUS-INFECTION; NEW-MEXICO; PREVALENCE; FUSCUS AB A captive colony of Brazilian five-tailed bats (Tadarida brasiliensis was vaccinated with a commercial monovalent inactivated rabies virus (RAM) vaccine (RABVAC 1). Baseline rabies virus neutralizing antibodies (VNA) and the response to vaccination were measured in 50 bats. Rabies VNA was detected in the plasma of 64% (27/42) of bats that had been vaccinated 1 yr prior, but only 19% (8/42) had levels considered adequate. Rabies VNA was detected in the plasma of 63% (5/8) of bats with no record of previous vaccination, suggesting natural RABV exposure before captivity. All bats demonstrated a VNA response by 10 days postvaccination, and baseline titer significantly predicted immoral response to vaccination. No adverse reactions to vaccination or clinical signs of RABV infection were observed in the bats during a 6-mo observation period. Annual vaccination may maintain immunity against RABV infection in captive colonies of bats. C1 [Turmelle, Amy S.; McCracken, Gary F.] Univ Tennessee, Dept Ecol & Evolutionary Biol, Knoxville, TN 37996 USA. [Allen, Louise C.; Kunz, Thomas H.] Boston Univ, Ctr Ecol & Conservat Biol, Boston, MA 02215 USA. [Schmidt-French, Barbara A.] Bat Conservat Int, Austin, TX 78746 USA. [Turmelle, Amy S.; Jackson, Felix R.; Rupprecht, Charles E.] Ctr Dis Control & Prevent, Div Viral & Rickettsial Dis, Atlanta, GA 30333 USA. RP Turmelle, AS (reprint author), Univ Tennessee, Dept Ecol & Evolutionary Biol, Knoxville, TN 37996 USA. EM ATurmelle@cdc.gov OI McCracken, Gary/0000-0002-2493-8103 FU PHS HHS [0430418] NR 22 TC 2 Z9 2 U1 0 U2 8 PU AMER ASSOC ZOO VETERINARIANS PI YULEE PA 581705 WHITE OAK ROAD, YULEE, FL 32097 USA SN 1042-7260 J9 J ZOO WILDLIFE MED JI J. Zoo Wildl. Med. PD MAR PY 2010 VL 41 IS 1 BP 140 EP 143 DI 10.1638/2008-0161.1 PG 4 WC Veterinary Sciences SC Veterinary Sciences GA 580QL UT WOS:000276464200022 PM 20722268 ER PT J AU Rotstein, DS West, K Levine, G Lockhart, SR Raverty, S Morshed, MG Rowles, T AF Rotstein, David S. West, Kristi Levine, Gregg Lockhart, Shawn R. Raverty, Stephen Morshed, Muhammad G. Rowles, Teri TI CRYPTOCOCCUS GATTII VGI IN A SPINNER DOLPHIN (STENELLA LONGIROSTRIS) FROM HAWAII SO JOURNAL OF ZOO AND WILDLIFE MEDICINE LA English DT Article DE cryptococcosis; Cryptococcus; gattii; VGI; granulomatous; Hawaii; Stenella longirostris ID BRITISH-COLUMBIA; VANCOUVER-ISLAND; PULMONARY CRYPTOCOCCOSIS; TURSIOPS-TRUNCATUS; NEOFORMANS; OUTBREAK; CANADA AB A spinner dolphin (Stenella longirostris) was found stranded in Hawaii with cutaneous nodules and enlarged lymph nodes. Numerous Cryptococcus gattii VGI yeast were observed in multiple organs with minimal inflammation. This case represents the first reported infection of C. gattii in a dolphin from Hawaii. C1 [Rotstein, David S.; Rowles, Teri] NOAA, Silver Spring, MD 20910 USA. [West, Kristi] Hawaii Pacific Univ, Kaneohe, HI 96744 USA. [Levine, Gregg] NOAA, Honolulu, HI 96822 USA. [Lockhart, Shawn R.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Morshed, Muhammad G.] Univ British Columbia, Vancouver, BC V5Z 4R4, Canada. RP Rotstein, DS (reprint author), NOAA, 1315 EW Highway, Silver Spring, MD 20910 USA. EM dave.rotstein@noaa.gov FU National Oceanic and Atmospheric Administration Prescott Stranding FX We thank Justin Viezbicke, the Hawaii Pacific University stranding response team, and the North Carolina State University College of Veterinary Medicine Histopathology Laboratory. We also thank Sultana Mithani and Min-Kuang Lee from the BC Centre for Disease Control Laboratory Services for technical assistance. This work was partially supported by a National Oceanic and Atmospheric Administration Prescott Stranding grant to Hawaii Pacific University. The findings and conclusions of this article are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. NR 12 TC 7 Z9 7 U1 0 U2 4 PU AMER ASSOC ZOO VETERINARIANS PI YULEE PA 581705 WHITE OAK ROAD, YULEE, FL 32097 USA SN 1042-7260 J9 J ZOO WILDLIFE MED JI J. Zoo Wildl. Med. PD MAR PY 2010 VL 41 IS 1 BP 181 EP 183 DI 10.1638/2009-0145.1 PG 3 WC Veterinary Sciences SC Veterinary Sciences GA 580QL UT WOS:000276464200032 PM 20722278 ER PT J AU Reed, C Katz, JM AF Reed, Carrie Katz, Jacqueline M. TI Serological surveys for 2009 pandemic influenza A H1N1 SO LANCET LA English DT Editorial Material ID VIRUSES C1 [Reed, Carrie; Katz, Jacqueline M.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA. RP Reed, C (reprint author), Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA. EM ggj2@cdc.gov NR 13 TC 17 Z9 19 U1 1 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0140-6736 J9 LANCET JI Lancet PD MAR-APR PY 2010 VL 375 IS 9720 BP 1062 EP 1063 DI 10.1016/S0140-6736(09)62194-2 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 578ZB UT WOS:000276334600008 PM 20096449 ER PT J AU Menacker, F MacDorman, MF Declercq, E AF Menacker, Fay MacDorman, Marian F. Declercq, Eugene TI Neonatal Mortality Risk for Repeat Cesarean Compared to Vaginal Birth after Cesarean (VBAC) Deliveries in the United States, 1998-2002 Birth Cohorts SO MATERNAL AND CHILD HEALTH JOURNAL LA English DT Article DE Cesarean delivery; Repeat cesarean delivery; Vaginal birth after cesarean (VBAC); Neonatal mortality; Low-risk births ID LABOR; PREGNANCY; TRIAL; OUTCOMES; WOMEN AB To examine trends in repeat cesarean delivery, the characteristics of women who have repeat cesareans, and the risk of neonatal mortality for repeat cesarean birth compared to vaginal birth after cesarean (VBAC). Trends and characteristics of repeat cesareans were examined for: the period 1998-2002 for [1] all births, [2] low-risk births (singleton, term, vertex births) and [3] "no indicated risk" (NIR) births (singleton, term, vertex presentation births with no reported medical risks or complications). For low-risk and NIR births, neonatal mortality rates for repeat cesareans and VBACs were compared. Multivariate logistic regression was used to examine the risk of neonatal mortality for repeat cesareans and VBACs, after controlling for demographic and health factors. In 2002 the repeat cesarean rate was 87.4%, and varied little by maternal risk status or by demographic and health characteristics. From 1998-2002 rates increased by 20% for low risk and by 21% for NIR births, respectively. For low-risk women for the 1998-2002 birth cohorts, the adjusted odds ratio for neonatal mortality associated with repeat cesarean delivery (compared with VBAC) was 1.36 (95% C.I. 1.20-1.55). For NIR women, the adjusted odds ratio was 1.24 (0.99-1.55). The experience of a prior cesarean has apparently become a major indication for a repeat cesarean. Regardless of maternal risk status, almost 90% of women with a prior cesarean have a subsequent (i.e., repeat) cesarean delivery. This is the case even if there was no other reported medical indication. Our findings do not support the widely-held belief that neonatal mortality risk is significantly lower for repeat cesarean compared to VBAC delivery. C1 [Menacker, Fay; MacDorman, Marian F.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Div Vital Stat, Hyattsville, MD 20782 USA. [Declercq, Eugene] Boston Univ, Sch Publ Hlth, Dept Maternal & Child Hlth, Boston, MA USA. RP Menacker, F (reprint author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Div Vital Stat, CDC 3311 Toledo Rd,Room 7413, Hyattsville, MD 20782 USA. EM ffm4@cdc.gov OI Declercq, Eugene/0000-0001-5411-3033 NR 33 TC 12 Z9 13 U1 1 U2 6 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1092-7875 J9 MATERN CHILD HLTH J JI Matern. Child Health J. PD MAR PY 2010 VL 14 IS 2 BP 147 EP 154 DI 10.1007/s10995-009-0551-5 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 558HE UT WOS:000274730900001 PM 20044789 ER PT J AU Reeves, WK Peiris, KHS Scholte, EJ Wirtz, RA Dowell, FE AF Reeves, W. K. Peiris, K. H. S. Scholte, E. -J. Wirtz, R. A. Dowell, F. E. TI Age-grading the biting midge Culicoides sonorensis using near-infrared spectroscopy SO MEDICAL AND VETERINARY ENTOMOLOGY LA English DT Article DE Culicoides; age-grading; bluetongue; near-infrared spectroscopy ID VIRUS; TRANSMISSION; VARIIPENNIS; CERATOPOGONIDAE; DIPTERA AB Age-grading of insects is important in the control and monitoring of both insect populations and vector-borne diseases. Microscopy and morphological techniques exist to age-grade most blood-feeding flies, but these techniques are laborious, often destructive to the insects, and slow. Near-infrared spectroscopy (NIRS) can be automated and is a non-destructive technique for age-grading. We applied NIRS techniques to age-grade females of the biting midge, Culicoides sonorensis Wirth & Jones (Diptera: Ceratopogonidae), the vector of bluetongue and other arboviruses in North America. Female flies of five known age cohorts (1, 3, 6, 9 and 12 days post-emergence) from three laboratory colonies were used. The data indicate that NIRS can be used to differentiate age groups of C. sonorensis. C1 [Dowell, F. E.] ARS, USDA, Ctr Grain & Anim Hlth Res, Engn & Wind Eros Res Unit, Manhattan, KS 66502 USA. [Reeves, W. K.] ARS, USDA, Arthropod Borne Anim Dis Res Lab, Laramie, WY USA. [Peiris, K. H. S.] Kansas State Univ, Dept Grain Sci & Ind, Manhattan, KS 66506 USA. [Scholte, E. -J.] Natl Reference Lab Fytosanit Pests & Dis Plant Pr, Wageningen, Netherlands. [Wirtz, R. A.] CDC, Entomol Branch, Atlanta, GA 30333 USA. RP Dowell, FE (reprint author), ARS, USDA, Ctr Grain & Anim Hlth Res, Engn & Wind Eros Res Unit, 1515 Coll Ave, Manhattan, KS 66502 USA. EM floyd.dowell@ars.usda.gov NR 17 TC 9 Z9 9 U1 0 U2 6 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0269-283X J9 MED VET ENTOMOL JI Med. Vet. Entomol. PD MAR PY 2010 VL 24 IS 1 BP 32 EP 37 PG 6 WC Entomology; Veterinary Sciences SC Entomology; Veterinary Sciences GA 555CG UT WOS:000274484100005 PM 20377729 ER PT J AU Meissner, HI Tiro, JA Yabroff, KR Haggstrom, DA Coughlin, SS AF Meissner, Helen I. Tiro, Jasmin A. Yabroff, K. Robin Haggstrom, David A. Coughlin, Steven S. TI Too Much of a Good Thing? Physician Practices and Patient Willingness for Less Frequent Pap Test Screening Intervals SO MEDICAL CARE LA English DT Article DE cancer screening; cervical cancer; guidelines; health service; behavior change ID CERVICAL-CANCER; HORMONE-THERAPY; UNITED-STATES; HUMAN-PAPILLOMAVIRUS; NEWSPAPER COVERAGE; WOMEN; CARE; OLDER; INTERVENTIONS; PREFERENCES AB Background: Recent guidelines recommend longer Pap test intervals. However, physicians and patients may not be adopting these recommendations. Objectives: Identify (1) physician and practice characteristics associated with recommending a less frequent interval, and (2) characteristics associated with women's willingness to adhere to a 3-year interval. Research Design: We used 2 national surveys: (1) a 2006/2007 National Survey of Primary Care Physicians for physician cervical cancer screening practices (N = 1114), and (2) the 2005 Health Information Trends Survey for women's acceptance of longer Pap intervals (N = 2206). Measures and Methods: Physician recommendation regarding Pap intervals was measured using a clinical vignette involving a 35-year-old with no new sexual partners and 3 consecutive negative Pap tests; associations with independent variables were evaluated with logistic regression. In parallel models, we evaluated women's willingness to follow a 3-year Pap test interval. Results: A minority of physicians (32%) have adopted-but more than half of women are willing to adopt-3-year Pap test intervals. In adjusted models, physician factors associated with less frequent screening were: serving a higher proportion of Medicaid patients, white, non-Hispanic race, fewer years since medical school graduation, and US Preventive Services Task Force being very influential in physician clinical practice. Women were more willing to follow a 3-year interval if they were older, but less willing if they had personal or family experiences with cancer or followed an annual Pap test schedule. Conclusions: Many women are accepting of a 3-year interval for Pap tests, although most primary care physicians continue to recommend shorter intervals. C1 [Meissner, Helen I.] NIH, Off Behav & Social Sci Res, Bethesda, MD 20892 USA. [Tiro, Jasmin A.] Univ Texas SW Med Ctr Dallas, Dept Clin Sci, Dallas, TX 75390 USA. [Yabroff, K. Robin] NCI, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA. [Haggstrom, David A.] Dept Vet Affairs Med Ctr, Hlth Serv Res & Dev Ctr Implementing Evidence Bas, Indianapolis, IN USA. [Haggstrom, David A.] Regenstrief Inst Hlth Care, IU Ctr Hlth Serv & Outcomes Res, Indianapolis, IN USA. [Haggstrom, David A.] Indiana Univ, Sch Med, Dept Med, Div Gen Internal Med & Geriatr, Indianapolis, IN USA. [Coughlin, Steven S.] Ctr Dis Control & Prevent, Epidemiol & Appl Res Branch, Div Canc Prevent & Control, Atlanta, GA USA. RP Meissner, HI (reprint author), NIH, Off Behav & Social Sci Res, 31 Ctr Dr,Bldg 31,Room B1C19, Bethesda, MD 20892 USA. EM meissneh@od.nih.gov OI Yabroff, K. Robin/0000-0003-0644-5572; Tiro, Jasmin/0000-0001-8300-0441 FU National Cancer Institute [N02-PC-51308]; Centers for Disease Control and Prevention [Y3-PC-6017-01]; Agency for Healthcare Research and Quality [Y3-PC-5019-01, Y3-PC-5019-02] FX Supported by the National Cancer Institute (contract number N02-PC-51308), the Centers for Disease Control and Prevention (interagency agreement number Y3-PC-6017-01), and the Agency for Healthcare Research and Quality ( interagency agreement numbers Y3-PC-5019-01 and Y3-PC-5019-02). NR 46 TC 31 Z9 31 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD MAR PY 2010 VL 48 IS 3 BP 249 EP 259 DI 10.1097/MLR.0b013e3181ca4015 PG 11 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 564FH UT WOS:000275198200009 PM 20182268 ER PT J AU Culler, SD Schieb, L Casper, M Nwaise, I Yoon, PW AF Culler, Steven D. Schieb, Linda Casper, Michele Nwaise, Isaac Yoon, Paula W. TI Is There an Association Between Quality of In-Hospital Cardiac Care and Proportion of Low-Income Patients? SO MEDICAL CARE LA English DT Article DE heart failure; myocardial infarction; quality indicators; hospitals ID PROSPECTIVE PAYMENT SYSTEM; OF-CARE; US HOSPITALS; SAFETY-NET; MORTALITY; PRESSURE AB Background: Process measures have been developed and implemented to evaluate the quality of care patients receive in the hospital. This study examines whether there is an association between the quality of in-hospital cardiac care and a hospital's proportion of low-income patients. Methods and Results: A retrospective analysis of 1979 hospitals submitting information on 12 quality of care (QoC) process measures for acute myocardial infarction (AMI) and congestive heart failure (CHF) patients to the Hospital Quality Alliance during 2005 and 2006 and meeting all study inclusion criteria. Mean hospital performance ranged from 84.2% (ACE inhibitor for left ventricular systolic dysfunction) to 95.9% (aspirin on arrival) for AMI QoC process measures and from 64.4% (discharge instructions) to 92.4% ( left ventricular function assessment) for CHF QoC process measures. Regression analyses indicated a statistically significant negative association between the proportion of low-income patients and hospital performance for 10 of the 12 cardiac QoC process measures, after controlling for selected hospital characteristics. Conclusions: Hospital adherence to QoC process measures for AMI and CHF patients declined as the proportion of low-income patients increased. Future research is needed to examine the role of community characteristics and market forces on the ability of hospitals with a disproportionate share of low-income patients to maintain the staffing, equipment, and policies necessary to provide the recommended standards of care for AMI and CHF patients. C1 [Culler, Steven D.] Emory Univ, Dept Hlth Policy & Management, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Schieb, Linda; Casper, Michele; Nwaise, Isaac; Yoon, Paula W.] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Culler, SD (reprint author), Emory Univ, Dept Hlth Policy & Management, Rollins Sch Publ Hlth, 1518 Clifton Rd NE, Atlanta, GA 30322 USA. EM sculler@sph.emory.edu NR 24 TC 5 Z9 5 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0025-7079 J9 MED CARE JI Med. Care PD MAR PY 2010 VL 48 IS 3 BP 273 EP 278 DI 10.1097/MLR.0b013e3181c161ba PG 6 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 564FH UT WOS:000275198200012 PM 20182270 ER PT J AU Templeton, SP Buskirk, AD Green, BJ Beezhold, DH Schmechel, D AF Templeton, Steven P. Buskirk, Amanda D. Green, Brett J. Beezhold, Donald H. Schmechel, Detlef TI Murine models of airway fungal exposure and allergic sensitization SO MEDICAL MYCOLOGY LA English DT Review DE mouse models; fungal allergy; spores; hyphae; inhalation ID ASPERGILLUS-FUMIGATUS SPORES; REGULATORY T-CELLS; PENICILLIUM-CHRYSOGENUM CONIDIA; TH2 EFFECTOR FUNCTIONS; DUST MITE ALLERGEN; DENDRITIC CELLS; STACHYBOTRYS-CHARTARUM; MOUSE MODEL; BRONCHOPULMONARY ASPERGILLOSIS; TRYPTOPHAN CATABOLISM AB Inhalation of common indoor filamentous fungi has been associated with the induction or exacerbation of allergic respiratory disease. The understanding of fungal inhalation and allergic sensitization has significantly advanced with the use of small animal models, especially mouse models. Numerous studies have employed different animal exposure and sensitization techniques, each with inherent advantages and disadvantages that are addressed in this review. In addition, most studies involve exposure of animals to fungal spores or spore extracts while neglecting the influence of hyphal or subcellular fragment exposures. Recent literature examining the potential for hyphae and fungal fragments to induce or exacerbate allergy is discussed. Innate immune recognition of fungal elements and their contribution to lung allergic inflammation in animal models are also reviewed. Though physical properties of fungi play an important role following exposure, host immune development is also critical in airway inflammation and allergy. We discuss the importance of environmental factors that influence early immune development and subsequent susceptibility to allergy. Murine studies that examine the role of intestinal microflora and prenatal or early life environmental factors that promote allergic sensitization are also evaluated. Future studies will require animal models that accurately reflect natural fungal exposures and identify environmental factors that influence immune development and thus promote respiratory fungal allergy and disease. C1 [Templeton, Steven P.; Buskirk, Amanda D.; Green, Brett J.; Beezhold, Donald H.; Schmechel, Detlef] Ctr Dis Control & Prevent, Allergy & Clin Immunol Branch, Hlth Effects Lab Div, NIOSH, Morgantown, WV 26505 USA. [Buskirk, Amanda D.] W Virginia Univ, Sch Med, Dept Microbiol Immunol & Cell Biol, Morgantown, WV 26506 USA. RP Templeton, SP (reprint author), Ctr Dis Control & Prevent, Allergy & Clin Immunol Branch, Hlth Effects Lab Div, NIOSH, 1095 Willowdale Rd M-S 4020, Morgantown, WV 26505 USA. EM stempleton@cdc.gov RI Templeton, Steven/I-6635-2013 OI Templeton, Steven/0000-0003-3430-7011 NR 117 TC 9 Z9 10 U1 0 U2 4 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1369-3786 J9 MED MYCOL JI Med. Mycol. PD MAR PY 2010 VL 48 IS 2 BP 217 EP 228 DI 10.3109/13693780903420658 PG 12 WC Infectious Diseases; Mycology; Veterinary Sciences SC Infectious Diseases; Mycology; Veterinary Sciences GA 560CK UT WOS:000274879300001 PM 20055736 ER PT J AU Stiefel, MC Perla, RJ Zell, BL AF Stiefel, Matthew C. Perla, Rocco J. Zell, Bonnie L. TI A Healthy Bottom Line: Healthy Life Expectancy as an Outcome Measure for Health Improvement Efforts SO MILBANK QUARTERLY LA English DT Article DE Population surveillance; life expectancy; epidemiologic measurement; health promotion ID DISABILITY-FREE LIFE; POPULATION HEALTH; COMPRESSION; MORBIDITY; DISEASES; CARE AB Methods: This article critically reviews the literature and practices around the world for measuring and improving HLE and synthesizes that information as a basis for recommendations for the adoption and adaptation of HLE as an outcome measure in the United States. Findings: This article makes the case for adoption of HLE as an outcome measure at the national, state, community, and health care system levels in the United States to compare the effectiveness of alternative practices, evaluate disparities, and guide resource allocation. Conclusions: HLE is a clear, consistent, and important population health outcome measure that can enable informed judgments about value for investments in health care. C1 [Stiefel, Matthew C.] Kaiser Permanente, Care & Serv Qual, Oakland, CA 94612 USA. Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Stiefel, MC (reprint author), Kaiser Permanente, Care & Serv Qual, 1 Kaiser Plaza,18th Floor, Oakland, CA 94612 USA. EM matt.stiefel@kp.org NR 74 TC 26 Z9 26 U1 0 U2 2 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0887-378X J9 MILBANK Q JI Milbank Q. PD MAR PY 2010 VL 88 IS 1 BP 30 EP 53 PG 24 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA 573NA UT WOS:000275919400002 PM 20377757 ER PT J AU Chen, B Ragin, A Greene, C AF Chen, Bin Ragin, Angela Greene, Carol TI GOOD LABORATORY PRACTICES FOR GENETIC TESTING-NEW CDC GUIDELINE FOR MOLECULAR GENETIC TESTING AND UPCOMING RECOMMENDATIONS FOR BIOCHEMICAL GENETIC TESTING AND NEWBORN SCREENING SO MOLECULAR GENETICS AND METABOLISM LA English DT Meeting Abstract CT 33rd Annual Meeting of the Society-for-Inherited-Metabolic-Disorders (SIMD 2010) CY MAR 28-31, 2010 CL Albuquerque, NM SP Soc Inherited Metabol Disorders, Genzyme, Abbott Metabol, Shire, ARUP Labs, Cytonet LLC, GeneDx, Hyperion Therapeut, Nautricia N Amer, Vitaflo, Ucyclyd Pharma, RDT, BIOMARIN, Applid Nutr Corp, CamBrooke Foods, Hitachi, Mead Johnson, PreventionGenetics, Canadian PKU & Allied Disorders Inc, Transgenomic, Emory Genet Lab, FOD, Kakkis EveryLife Fdn, Natl PKU Alliance, Organ Acidemia Assoc C1 [Chen, Bin; Ragin, Angela] Ctr Dis Control & Prevent, Atlanta, GA USA. [Greene, Carol] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1096-7192 J9 MOL GENET METAB JI Mol. Genet. Metab. PD MAR PY 2010 VL 99 IS 3 BP 210 EP 210 PG 1 WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research & Experimental SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental Medicine GA 563OB UT WOS:000275140900035 ER PT J AU Chen, B Greene, C AF Chen, Bin Greene, Carol TI Promoting quality of genetic testing with guidelines for good laboratory practices SO MOLECULAR GENETICS AND METABOLISM LA English DT Editorial Material ID UNITED-STATES C1 [Chen, Bin] Ctr Dis Control & Prevent, Div Lab Syst, Atlanta, GA 30333 USA. [Greene, Carol] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. RP Chen, B (reprint author), Ctr Dis Control & Prevent, Div Lab Syst, 1600 Clifton Rd NE,MS G-23, Atlanta, GA 30333 USA. EM bkc1@cdc.gov NR 17 TC 1 Z9 1 U1 0 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1096-7192 J9 MOL GENET METAB JI Mol. Genet. Metab. PD MAR PY 2010 VL 99 IS 3 BP 238 EP 243 DI 10.1016/j.ymgme.2010.01.002 PG 6 WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research & Experimental SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental Medicine GA 563OB UT WOS:000275140900100 PM 20196208 ER PT J AU Magiatis, P Polychronopoulos, P Skaltsounis, AL Lozach, O Meijer, L Miller, DB O'Callaghan, JP AF Magiatis, Prokopios Polychronopoulos, Panagiotis Skaltsounis, Alexios-Leandros Lozach, Olivier Meijer, Laurent Miller, Diane B. O'Callaghan, James P. TI Indirubins deplete striatal monoamines in the Intact and MPTP-treated mouse brain and block kainate-induced striatal astrogliosis SO NEUROTOXICOLOGY AND TERATOLOGY LA English DT Article DE Indirubin; MPTP; Kainate; Astrogliosis; Dopamine; Serotonin ID ARYL-HYDROCARBON RECEPTOR; CYCLIN-DEPENDENT KINASES; GLYCOGEN-SYNTHASE KINASE-3-BETA; FIBRILLARY ACIDIC PROTEIN; IN-VIVO; PARKINSONS-DISEASE; SIGNALING PATHWAY; C57BL/6J MICE; KAINIC ACID; INHIBITORS AB The indirubins long have been used in Chinese medicine for treatment of myelocytic leukemia. Among the many more recently described biological activities of the indirubins, attention has been directed toward the ability of these compounds to inhibit GSK-3 and CDKs, kinases implicated in neurodegenerative conditions. Little information is available on effects of indirubins on chemically-induced neurodegeneration. Here we examined the influence of three indirubins on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)- and kainic acid (KA)-induced neurotoxicity in the mouse. The three indirubins examined were 6-bromoindirubin-3'-oxime (6BIO), 5-bromoindirubin-3'-oxime (5BIO) and 5-amino-6-bromoindirubin (5A6BI). The first two derivatives were previously described indirubins with low nanomolar inhibitory activity against GSK-3 and CDKs. The third compound was synthesized by the dimerization of 5-amino-6-bromoisatin with 3-acetoxyindol. The synthesis of the key compound 5-amino-6-bromoisatin was based on the bromination of the ketal of 5-amino-isatin. All indirubins examined decreased various measures associated with dopaminergic neurotransmission in striatum. These effects occurred alone or over and above the decrements seen following administration of the dopaminergic neurotoxicant, MPTP. Striatal serotonin and serotonin turnover were decreased by the indirubins in MPTP-treated mice. None of these striatal effects of the indirubins alone were associated with evidence of astrogliosis, an indicator of underlying neuropathology, nor did they potentiate the astrogliosis accompanying administration of MPTP. In general, the indirubins reduced KA-associated mortality and striatal but not hippocampal astrogliosis due to this toxicant. The data suggest that indirubins affect striatal biogenic amine levels and turnover in intact mice. The data do not indicate a neuroprotective action of indirubins in mice treated with MPTP but that they do suggest that they may be neuroprotective against KA-induced injury of the neostriatum. Published by Elsevier Inc. C1 [Miller, Diane B.; O'Callaghan, James P.] NIOSH, Mol Neurotoxicol Lab, Hlth Effects Lab Div, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. [Magiatis, Prokopios; Polychronopoulos, Panagiotis; Skaltsounis, Alexios-Leandros] Univ Athens, Fac Pharm, Lab Pharmacognosy, GR-15771 Athens, Greece. [Lozach, Olivier; Meijer, Laurent] CNRS, Biol Stn, Prot Phosphorylat & Human Dis Grp, F-29682 Roscoff, Bretagne, France. [Miller, Diane B.; O'Callaghan, James P.] NIOSH, Chron Stress & Neurotoxicol Lab, Hlth Effects Lab Div, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. RP O'Callaghan, JP (reprint author), NIOSH, Mol Neurotoxicol Lab, Hlth Effects Lab Div, Ctr Dis Control & Prevent, 1095 Willowdale Rd, Morgantown, WV 26505 USA. EM skaltsounis@pharm.uoa.gr; jdo5@cdc.gov RI O'Callaghan, James/O-2958-2013 FU CDC-NIOSH; EEC [FP6-2002] FX This research was supported by intramural funds from CDC-NIOSH (J.O. and D.M.) and grants from the EEC (FP6-2002-Life Sciences & Health, PRO-KINASE Research Project) (LM.) and the Canceropole Grand-Ouest (LM.). The authors thank Fang Ma, Christopher Felton and Brenda Billig for excellent technical assistance. The critical review of the manuscript by Dr. Lawrence P. Wennogle is gratefully acknowledged. NR 35 TC 9 Z9 10 U1 0 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0892-0362 J9 NEUROTOXICOL TERATOL JI Neurotoxicol. Teratol. PD MAR-APR PY 2010 VL 32 IS 2 BP 212 EP 219 DI 10.1016/j.ntt.2009.12.005 PG 8 WC Neurosciences; Toxicology SC Neurosciences & Neurology; Toxicology GA 583TJ UT WOS:000276702500013 PM 20034560 ER PT J AU Krieg, EF Butler, MA Chang, MH Liu, TB Yesupriya, A Dowling, N Lindegren, ML AF Krieg, Edward F., Jr. Butler, Mary Ann Chang, Man-huei Liu, Tiebin Yesupriya, Ajay Dowling, Nicole Lindegren, Mary Lou CA CDC NCI NHANES III Genomics Workin TI Lead and cognitive function in VDR genotypes in the third National Health and Nutrition Examination Survey SO NEUROTOXICOLOGY AND TERATOLOGY LA English DT Article DE Blood lead; Cognitive function; VDR; Homocysteine; NHANES III ID VITAMIN-D-RECEPTOR; PROTEIN-KINASE-C; BLOOD LEAD; GENE VARIANTS; MICE; HOMOCYSTEINE; MECHANISMS; EXPRESSION; HAPLOTYPES; CELLS AB The relationship between the blood lead concentration and cognitive function in children and adults with different VDR genotypes who participated in the third National Health and Nutrition Examination Survey was investigated. The relationship between blood lead and serum homocysteine concentrations was also investigated. In children 12 to 16 years old, performance on the digit span and arithmetic tests as a function of the blood lead concentration varied by VDR rs2239185 and VDR rs731236 genotypes. Decreases in performance occurred in some genotypes, but not in others. In adults 20 to 59 years old, performance on the symbol-digit substitution test as a function of the blood lead concentration varied by VDR rs2239185-rs731236 haplotype. In the 12 to 16 year old children and adults 60 or more years old, the relationship between the serum homocysteine and blood lead concentrations varied by VDR genotype. The mean blood lead concentrations of the children and adults did not vary by VDR genotype. Published by Elsevier Inc. C1 [Krieg, Edward F., Jr.] NIOSH, Robert A Taft Labs, Cincinnati, OH 45226 USA. [Chang, Man-huei; Liu, Tiebin; Yesupriya, Ajay; Dowling, Nicole] Ctr Dis Control & Prevent, Natl Off Publ Hlth Genom, Atlanta, GA 30341 USA. [Lindegren, Mary Lou] Natl Ctr HIV Hepatitis STD & TB Prevent, Global AIDS Program, Atlanta, GA 30333 USA. RP Krieg, EF (reprint author), NIOSH, Robert A Taft Labs, 4676 Columbia Pkwy,MS C-22, Cincinnati, OH 45226 USA. EM erk3@cdc.gov NR 47 TC 12 Z9 12 U1 0 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0892-0362 EI 1872-9738 J9 NEUROTOXICOL TERATOL JI Neurotoxicol. Teratol. PD MAR-APR PY 2010 VL 32 IS 2 BP 262 EP 272 DI 10.1016/j.ntt.2009.12.004 PG 11 WC Neurosciences; Toxicology SC Neurosciences & Neurology; Toxicology GA 583TJ UT WOS:000276702500020 PM 20006704 ER PT J AU Taha, TE Kumwenda, J Cole, SR Hoover, DR Kafulafula, G Fowler, MG Thigpen, MC Li, Q Kumwenda, NI Mofenson, L AF Taha, Taha E. Kumwenda, Johnstone Cole, Stephen R. Hoover, Donald R. Kafulafula, George Fowler, Mary Glenn Thigpen, Michael C. Li, Qing Kumwenda, Newton I. Mofenson, Lynne TI Postnatal Human Immunodeficiency Virus-1 Transmission After Cessation of Infant Extended Antiretroviral Prophylaxis and Effect of Maternal Highly Active Antiretroviral Therapy EDITORIAL COMMENT SO OBSTETRICAL & GYNECOLOGICAL SURVEY LA English DT Editorial Material C1 [Taha, Taha E.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. Johns Hopkins Med Inst, Baltimore, MD 21205 USA. Kennedy Shriver Natl Inst Child Hlth & Human Dev, NIH, Bethesda, MD USA. Univ N Carolina, Sch Publ Hlth, Chapel Hill, NC USA. Rutgers State Univ, Piscataway, NJ USA. Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIVAIDS Viral Hepatitis STD & TB Prevent, Atlanta, GA USA. Univ Malawi, Coll Med, Blantyre, Malawi. RP Taha, TE (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. OI Mofenson, Lynne/0000-0002-2818-9808 NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-7828 J9 OBSTET GYNECOL SURV JI Obstet. Gynecol. Surv. PD MAR PY 2010 VL 65 IS 3 BP 150 EP 151 PG 2 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 575UQ UT WOS:000276095000004 ER PT J AU Schieve, LA Devine, O Boyle, CA Petrini, JR Warner, L AF Schieve, Laura A. Devine, Owen Boyle, Coleen A. Petrini, Joann R. Warner, Lee TI Estimation of the Contribution of Nonassisted Reproductive Technology Ovulation Stimulation Fertility Treatments to US Singleton and Multiple Births EDITORIAL COMMENT SO OBSTETRICAL & GYNECOLOGICAL SURVEY LA English DT Editorial Material C1 [Schieve, Laura A.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. Danbury Hosp, Danbury, CT USA. March Dimes Fdn, White Plains, NY USA. Yeshiva Univ, Dept Obstet & Gynecol & Womens Hlth, Albert Einstein Coll Med, New York, NY 10033 USA. Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Schieve, LA (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-7828 J9 OBSTET GYNECOL SURV JI Obstet. Gynecol. Surv. PD MAR PY 2010 VL 65 IS 3 BP 154 EP 156 PG 3 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 575UQ UT WOS:000276095000006 ER PT J AU Saraiya, M Martinez, G Glaser, K Kulasingam, S AF Saraiya, Mona Martinez, Gladys Glaser, Katherine Kulasingam, Shalini TI Pap Testing and Sexual Activity Among Young Women in the United States EDITORIAL COMMENT SO OBSTETRICAL & GYNECOLOGICAL SURVEY LA English DT Editorial Material C1 [Saraiya, Mona] Ctr Dis Control & Prevent, Natl Coordinating Ctr Hlth Promot, Div Canc Prevent & Control, Epidemiol & Appl Res Branch, Atlanta, GA 30333 USA. Natl Ctr Hlth Stat, Natl Coordinating Ctr Hlth Mkt, Div Vital Stat, Reprod Stat Branch, Atlanta, GA USA. Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN USA. RP Saraiya, M (reprint author), Ctr Dis Control & Prevent, Natl Coordinating Ctr Hlth Promot, Div Canc Prevent & Control, Epidemiol & Appl Res Branch, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-7828 J9 OBSTET GYNECOL SURV JI Obstet. Gynecol. Surv. PD MAR PY 2010 VL 65 IS 3 BP 167 EP 169 PG 3 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 575UQ UT WOS:000276095000013 ER PT J AU Hoover, KW Tao, GY Kent, CK AF Hoover, Karen W. Tao, Guoyu Kent, Charlotte K. TI Trends in the Diagnosis and Treatment of Ectopic Pregnancy in the United States SO OBSTETRICS AND GYNECOLOGY LA English DT Article ID RISK-FACTORS; SPONTANEOUS RESOLUTION; TUBAL PREGNANCY; DISEASE; WOMEN; SURVEILLANCE; METAANALYSIS AB OBJECTIVE: To estimate trends in the rates of diagnosis and treatment of ectopic pregnancy in the United States. METHODS: We analyzed data from a large administrative claims database of more than 200 U. S. commercial health plans, and estimated time trends in the rate and incidence of ectopic pregnancy among girls and women aged 15-44 years by 5-year age groups and by region from 2002 to 2007. We also estimated time trends in the proportion of cases that were treated surgically, either by laparoscopy or laparotomy, or medically with methotrexate. RESULTS: We identified 11,989 ectopic pregnancies during the period from 2002 to 2007. The overall rate of ectopic pregnancy among pregnant girls and women aged 15-44 years during the 6-year study period was 0.64%. We did not observe a trend in the rate of ectopic pregnancy by 5-year age group or by geographic region. The ectopic pregnancy rate increased with age; it was 0.3% among girls and women aged 15-19 years and 1.0% among women aged 35-44 years. Methotrexate treatment increased from 11.1% in 2002 to 35.1% in 2007 (P<.001); the methotrexate failure rate was 14.7% over the 6-year study period. Surgical management with laparotomy decreased over the study period from 40.0% to 33.1% (P<.001). CONCLUSION: We did not find an increasing or decreasing trend in the rate of ectopic pregnancy among U. S. commercially insured women from 2002 to 2007. The use of administrative claims data are likely the most feasible method for estimating the rate and monitoring trends of ectopic pregnancy in the United States. (Obstet Gynecol 2010;115:495-502) C1 [Hoover, Karen W.; Tao, Guoyu; Kent, Charlotte K.] Ctr Dis Control & Prevent, Div Sexually Transmitted Dis Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP Hoover, KW (reprint author), Ctr Dis Control & Prevent, Div Sexually Transmitted Dis Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd,NE MS E-80, Atlanta, GA 30333 USA. EM khoover@cdc.gov NR 32 TC 70 Z9 76 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-7844 J9 OBSTET GYNECOL JI Obstet. Gynecol. PD MAR PY 2010 VL 115 IS 3 BP 495 EP 502 DI 10.1097/AOG.0b013e3181d0c328 PG 8 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 563LA UT WOS:000275132300004 PM 20177279 ER PT J AU Kuo, TM Benard, VB Berkman, ND Martin, CK Richardson, LC AF Kuo, Tzy-Mey Benard, Vicki B. Berkman, Nancy D. Martin, Carolyn K. Richardson, Lisa C. TI Timing of Colposcopy After Cervical Cytologic Abnormalities SO OBSTETRICS AND GYNECOLOGY LA English DT Article ID FOLLOW-UP CARE; PAP TESTS; CANCER; WOMEN; ADHERENCE; RECOMMENDATIONS; SEGREGATION; MANAGEMENT; MORTALITY; ACCESS AB OBJECTIVE: To examine the length of time from Pap test (index Pap) screening to follow-up colposcopy for women with abnormal Pap test results of low-grade squamous intraepithelial lesions (LSIL); atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesions (ASC-H); or high-grade squamous intraepithelial lesions (HSIL). METHODS: We identified 4,824 women aged 18 to 64 years with the index Pap test results of LSIL, HSIL, or ASC-H from health insurance claims in a large U. S. health care organization and who had a routine Pap test in 2004. We used a survival regression model to estimate factors related to the length of time (days) from the index Pap test to a follow-up colposcopy. RESULTS: The expected length of time from an abnormal Pap test to a colposcopy differed by age and Pap test result. For women with an ASC-H result, those who were older were more likely to delay colposcopy compared with the younger women. For women with LSIL and HSIL results, the timing of colposcopy did not differ by age; however, the time was shorter compared with ASC-H. We found that physician specialties, health care settings, and area-level racial and ethnic density were related to timing of receiving follow-up procedures after an abnormal index Pap test result. CONCLUSION: Women with LSIL and HSIL received a colposcopy in 3-4 months, but women with ASC-H were more likely to receive the procedure at a later time. (Obstet Gynecol 2010;115:629-36) C1 [Benard, Vicki B.] Ctr Dis Control & Prevent, Epidemiol & Appl Res Branch, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. Res Triangle Inst Int, Res Triangle Pk, NC USA. Ctr Hlth Care Policy & Evaluat, Minneapolis, MN USA. RP Benard, VB (reprint author), Ctr Dis Control & Prevent, Epidemiol & Appl Res Branch, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Mailstop K-55,4770 Buford Highway NE, Atlanta, GA 30341 USA. EM vdb9@cdc.gov NR 26 TC 7 Z9 9 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-7844 J9 OBSTET GYNECOL JI Obstet. Gynecol. PD MAR PY 2010 VL 115 IS 3 BP 629 EP 636 DI 10.1097/AOG.0b013e3181cec0b5 PG 8 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 563LA UT WOS:000275132300021 PM 20177296 ER PT J AU Paulozzi, LJ AF Paulozzi, L. J. TI Does inadequate diet during childhood explain the higher high fracture rates in the Southern United States? SO OSTEOPOROSIS INTERNATIONAL LA English DT Article DE Calcium; Cohort; Hip fracture; Osteoporosis; Rickets; Vitamin D ID BONE-MINERAL DENSITY; HIP FRACTURE; NUTRITIONAL RICKETS; VITAMIN-D; GEOGRAPHIC-VARIATION; SERUM 25-HYDROXYVITAMIN-D; OLDER-ADULTS; RISK; CALCIUM; WOMEN AB Southern states have the highest age-adjusted hip fracture rates among older adults in the United States. Regional hip fracture rates in the United States in 1986-1993 correlate with death rates from rickets in the 1940s. Historical patterns of bone nutrition early in life might explain contemporary geographic patterns in bone fragility. State of residence early in life is a better predictor of the risk of hip fracture after age 65 than state of current residence. Therefore, the geography of rickets mortality in the United States before 1950 was compared with the geography of hip fracture rates among older adults in the United States during 1986-1993. Vital statistics data for the US white population for 1942-1948 allowed calculation of the ratio of deaths from rickets to live births for each geographic division of the USA. These ratios were correlated with previously published, standardized hip fracture rates among whites 65-89 years old during 1986-1993 by census division. During 1942-1948, the rickets mortality ratio among whites was 3.11 in the South, 1.91 in the Northeast, 1.75 in the Midwest, and 1.04 in the West. The correlation of mortality with risk of hip fracture was 0.71 (p = 0.03) for both sexes combined and 0.86 (p = 0.01) for women. Inadequate nutrition during skeletal formation early in life might explain the higher incidence of hip fracture among older adults in the South. C1 Ctr Dis Control & Prevent, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA. RP Paulozzi, LJ (reprint author), Ctr Dis Control & Prevent, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, 4770 Buford Highway NE,MS F62, Atlanta, GA 30341 USA. EM lbp4@cdc.gov NR 54 TC 3 Z9 3 U1 1 U2 4 PU SPRINGER LONDON LTD PI ARTINGTON PA ASHBOURNE HOUSE, THE GUILDWAY, OLD PORTSMOUTH ROAD, ARTINGTON GU3 1LP, GUILDFORD, ENGLAND SN 0937-941X J9 OSTEOPOROSIS INT JI Osteoporosis Int. PD MAR PY 2010 VL 21 IS 3 BP 417 EP 423 DI 10.1007/s00198-009-0997-8 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 552ZM UT WOS:000274333800007 PM 19557494 ER PT J AU Santos, HLC Bandea, R Martins, LAF de Macedo, HW Peralta, RHS Peralta, JM Ndubuisi, MI da Silva, AJ AF Carneiro Santos, Helena Lucia Bandea, Rebecca Fernandes Martins, Luci Ana de Macedo, Heloisa Werneck Saramago Peralta, Regina Helena Peralta, Jose Mauro Ndubuisi, Mackevin I. da Silva, Alexandre J. TI Differential identification of Entamoeba spp. based on the analysis of 18S rRNA SO PARASITOLOGY RESEARCH LA English DT Article ID LINKED-IMMUNOSORBENT-ASSAY; LABORATORY DIAGNOSIS; HISTOLYTICA; AMEBIASIS; PCR; DISPAR; MICROSCOPY; MULTIPLEX; SAMPLES AB Entamoeba histolytica is known to cause intestinal and extra-intestinal disease while the other Entamoeba species are not considered to be pathogenic. However, all Entamoeba spp. should be reported when identified in clinical samples. Entamoeba polecki, Entamoeba coli, and Entamoeba hartmanii can be differentiated morphologically from E. histolytica, but some of their diagnostic morphologic features overlap. E. histolytica, Entamoeba dispar, and Entamoeba moshkovskii are morphologically identical but can be differentiated using molecular tools. We developed a polymerase chain reaction (PCR) procedure followed by DNA sequencing of specific regions of 18S rRNA gene to differentiate the Entamoeba spp. commonly found in human stools. This approach was used to analyze 45 samples from cases evaluated for the presence of Entamoeba spp. by microscopy and a real-time PCR method capable of differential detection of E. histolytica and E. dispar. Our results demonstrated an agreement of approximately 98% (45/44) between the real-time PCR for E. histolytica and E. dispar and the 18S rRNA analysis described here. Five previously negative samples by microscopy revealed the presence of E. dispar, E. hartmanii, or E. coli DNA. In addition, we were able to detect E. hartmanii in a stool sample that had been previously reported as negative for Entamoeba spp. by microscopy. Further microscopic evaluation of this sample revealed the presence of E. hartmanii cysts, which went undetected during the first microscopic evaluation. This PCR followed by DNA sequencing will be useful to refine the diagnostic detection of Entamoeba spp. in stool and other clinical specimens. C1 [Carneiro Santos, Helena Lucia; Peralta, Jose Mauro] Univ Fed Rio de Janeiro, Rio De Janeiro, Brazil. [Fernandes Martins, Luci Ana; de Macedo, Heloisa Werneck; Saramago Peralta, Regina Helena] Univ Fed Fluminense, Rio De Janeiro, Brazil. [Bandea, Rebecca; da Silva, Alexandre J.] Ctr Dis Control & Prevent, Div Parasit Dis, Coordinating Ctr Infect Dis, Natl Ctr Zoonot Vector Borne & Enter Dis, Atlanta, GA 30333 USA. [Ndubuisi, Mackevin I.] Georgia Hlth Lab, Decatur, GA USA. [Carneiro Santos, Helena Lucia] Fundacao Oswaldo Cruz, Rio De Janeiro, Brazil. RP da Silva, AJ (reprint author), Ctr Dis Control & Prevent, Div Parasit Dis, Coordinating Ctr Infect Dis, Natl Ctr Zoonot Vector Borne & Enter Dis, Atlanta, GA 30333 USA. EM abs8@cdc.gov FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) programa/Brazil; National Food Safety Initiative FX The author thanks Dr. Edward da Silva for providing cultures of E. histolytica and E. moshkovskii. Helena L C Santos was supported by a fellowship from Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) programa/Brazil. This work was also supported with funds from the National Food Safety Initiative. NR 20 TC 17 Z9 17 U1 0 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0932-0113 J9 PARASITOL RES JI Parasitol. Res. PD MAR PY 2010 VL 106 IS 4 BP 883 EP 888 DI 10.1007/s00436-010-1728-y PG 6 WC Parasitology SC Parasitology GA 567BH UT WOS:000275416800017 PM 20169364 ER PT J AU Miller, RL Garfinkel, R Lendor, C Hoepner, L Li, Z Romanoff, L Sjodin, A Needham, L Perera, FP Whyatt, RM AF Miller, Rachel L. Garfinkel, Robin Lendor, Cynthia Hoepner, Lori Li, Zheng Romanoff, Lovisa Sjodin, Andreas Needham, Larry Perera, Frederica P. Whyatt, Robin M. TI Polycyclic aromatic hydrocarbon metabolite levels and pediatric allergy and asthma in an inner-city cohort SO PEDIATRIC ALLERGY AND IMMUNOLOGY LA English DT Article DE polycyclic aromatic hydrocarbons; inner-city asthma; allergen-specific IgE ID DIESEL EXHAUST PARTICLES; AIR-POLLUTION; RESPIRATORY SYMPTOMS; AMBIENT AIR; URINARY 1-HYDROXYPYRENE; US POPULATION; BIRTH COHORT; EXPOSURE; CHILDREN; AGE AB Exposure to polycyclic aromatic hydrocarbons (PAH) has been associated with allergic sensitization and asthma. We hypothesized that increased urinary PAH metabolites are associated with allergy or asthma among children age 5 yrs in an inner-city birth cohort. As part of an ongoing prospective birth cohort under the auspices of the Columbia Center for Children's Environmental Health (CCCEH), urine was collected from 5-yr-old children (n = 222) of Dominican American and African American mothers in Northern Manhattan and South Bronx of New York City. Twenty-four PAH metabolites were measured in these specimens, and their levels (unadjusted and specific gravity corrected) were evaluated with IgE levels and asthma outcomes. Ten metabolites were detected in urine from all children. Concentrations ranged higher than those in representative samples of US children ages 6-11 in the National Health and Nutrition Examination Survey (NHANES). Among CCCEH children, compared with African Americans, the Dominican children had higher 2-hydroxynaphthalene but lower 9-hydroxyfluorene and 4-hydroxyphenanthrene concentrations. Increased 3-hydroxyfluorene and 3-hydroxyphenanthrene levels were associated with higher anti-mouse IgE levels (p < 0.05). These plus 2-hydroxynaphthalene, 2-hydroxyflourene and 1-hydroxyphenanthrene concentrations were associated with higher anti-mouse IgE levels on multivariate analyzes. Increased 2-hydroxyphenanthrene, 3-hydroxyphenanthrene and 4-hydroxyphenanthrene levels were associated with higher anti-cat IgE levels (p < 0.05) in univariate, but not multivariate, analyzes. Levels of PAH metabolites were not associated with respiratory symptoms. Measures of PAH metabolites suggest considerable exposure in an urban pediatric population, and possible associations with allergic sensitization to mouse. C1 [Miller, Rachel L.; Lendor, Cynthia] Columbia Univ, Div Pulm Allergy & Crit Care Med, New York, NY USA. [Miller, Rachel L.; Garfinkel, Robin; Lendor, Cynthia; Perera, Frederica P.; Whyatt, Robin M.] Columbia Univ, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, New York, NY USA. [Li, Zheng; Romanoff, Lovisa; Sjodin, Andreas; Needham, Larry] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, Organ Analyt Toxicol Branch, Atlanta, GA USA. RP Miller, RL (reprint author), Columbia Univ Coll Phys & Surg, PH8E,630 W 168th St, New York, NY 10032 USA. EM rlm14@columbia.edu RI Needham, Larry/E-4930-2011; Sjodin, Andreas/F-2464-2010; OI Hoepner, Lori/0000-0002-4404-8140 FU U. S. Environmental Protection Agency (EPA) [RD832096, R827027]; National Institute of Environmental Health Sciences (NIEHS) [R01 ES013163, P01 ES09600, RO1 ES08977, P30 ES009089]; Irving General Clinical Research Center [RR00645]; Gladys & Roland Harriman Foundation; New York Community Trust; Educational Foundation of America; V. Kann Rasmussen Foundation; Trustees of the Blanchette Hooker Rockefeller Fund FX U. S. Environmental Protection Agency (EPA) (STAR Grant RD832096, R827027), The National Institute of Environmental Health Sciences (NIEHS) (grant #'s R01 ES013163, P01 ES09600, RO1 ES08977, P30 ES009089), Irving General Clinical Research Center (grant # RR00645), Gladys & Roland Harriman Foundation, New York Community Trust, Educational Foundation of America, V. Kann Rasmussen Foundation, and Trustees of the Blanchette Hooker Rockefeller Fund. NR 40 TC 27 Z9 27 U1 1 U2 13 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0905-6157 J9 PEDIATR ALLERGY IMMU JI Pediatr. Allergy Immunol. PD MAR PY 2010 VL 21 IS 2 BP 260 EP 267 DI 10.1111/j.1399-3038.2009.00980.x PN 1 PG 8 WC Allergy; Immunology; Pediatrics SC Allergy; Immunology; Pediatrics GA 575AA UT WOS:000276034200003 PM 20003063 ER PT J AU Brooks, WA Goswami, D Rahman, M Nahar, K Fry, AM Balish, A Iftekharuddin, N Azim, T Xu, XY Klimov, A Bresee, J Bridges, C Luby, S AF Brooks, W. Abdullah Goswami, Doli Rahman, Mustafizur Nahar, Kamrun Fry, Alicia M. Balish, Amanda Iftekharuddin, Nadia Azim, Tasnim Xu, Xiyan Klimov, Alexander Bresee, Joseph Bridges, Carolyn Luby, Stephen TI Influenza is a Major Contributor to Childhood Pneumonia in a Tropical Developing Country SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Article DE influenza; pneumonia; children; urban ID INVASIVE PNEUMOCOCCAL DISEASE; CHILDREN YOUNGER; CONTROLLED-TRIAL; VACCINE POLICY; UNITED-STATES; VIRUS; HOSPITALIZATIONS; BANGLADESH; MORTALITY; BURDEN AB Background: Pneumonia is the leading cause of child mortality worldwide. The role of influenza in childhood pneumonia in tropical developing countries is poorly understood. We undertook population-based surveillance among low-income urban preschool children to determine its role in childhood pneumonia. Methods: Longitudinal prospective active surveillance was conducted among randomly selected households in a poor urban area of Dhaka. Nasopharyngeal washes were collected from 1 in 5 children for influenza culture isolation. Clinical data were collected at clinical presentation and through the illness course. Results: From April 1, 2004 through December 31, 2007, 12,062 children presented in clinic with eligible febrile and respiratory illnesses, from whom 321 influenza isolates were obtained from 2370 nasopharyngeal washes (13.5%), representing 16,043 child-years of observation (adjusted influenza incidence 102 episodes/1000 child-years). There were 8198 pneumonia episodes during the period (pneumonia incidence 511 episodes/1000 child-years). Ninety influenza-positive children (28%) developed pneumonia during their illness. Among influenza culture-positive children, those with pneumonia were younger than those without (23.4 vs. 29.7 months, ANOVA: P < 0.001). Pneumonia was more commonly associated with Influenza A (H3N2) than either A (H1N1) or B infections (age-adjusted relative odds (RO) 2.98, [95% CI: 1.56, 5.71] and 2.75, [95% CI: 1.52, 4.98], respectively). Influenza was associated with 10% all childhood pneumonia. Conclusions: Influenza is a major contributor to childhood pneumonia both through high influenza infection incidence and high pneumonia prevalence among infected children. Its contribution to early childhood pneumonia appears under-appreciated in high pneumonia-endemic tropical settings. Influenza vaccine trials against childhood pneumonia are warranted. C1 [Brooks, W. Abdullah; Goswami, Doli; Rahman, Mustafizur; Nahar, Kamrun; Iftekharuddin, Nadia; Azim, Tasnim; Luby, Stephen] Int Ctr Diarrhoeal Dis Res, Dhaka 1000, Bangladesh. [Fry, Alicia M.; Balish, Amanda; Xu, Xiyan; Klimov, Alexander; Bresee, Joseph; Bridges, Carolyn] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. RP Brooks, WA (reprint author), Int Ctr Diarrhoeal Dis Res, GPO Box 128 Mohakhali, Dhaka 1000, Bangladesh. EM abrooks@icddrb.org RI rahman, mustafizur/E-6918-2010 FU US Centers for Disease Control and Prevention Cooperative Agreement with the International Centre for Diarrheal Disease Research, Bangladesh (ICDDR, B); US Department of Health and Human Services; PneumoADIP Project at the Johns Hopkins Bloomberg School of Public Health; Thrasher Research Fund; Bill and Melinda Gates Foundation FX Supported by the US Centers for Disease Control and Prevention Cooperative Agreement with the International Centre for Diarrheal Disease Research, Bangladesh (ICDDR, B), and by grants from the US Department of Health and Human Services, the PneumoADIP Project at the Johns Hopkins Bloomberg School of Public Health, the Thrasher Research Fund and the Bill and Melinda Gates Foundation and core donors to ICDDR, B. NR 33 TC 72 Z9 73 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0891-3668 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD MAR PY 2010 VL 29 IS 3 BP 216 EP 221 DI 10.1097/INF.0b013e3181bc23fd PG 6 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA 563MG UT WOS:000275136000005 PM 20190613 ER PT J AU Fisher, BT Chiller, TM Prasad, PA Beveridge, M Walsh, TJ Zaoutis, TE AF Fisher, Brian T. Chiller, Tom M. Prasad, Priya A. Beveridge, Mara Walsh, Thomas J. Zaoutis, Theoklis E. TI Hospitalizations for Coccidioidomycosis at Forty-One Children's Hospitals in the United States SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Article DE coccidioidomycosis; children's hospital; hospitalization ID COMPLEX CHRONIC CONDITIONS; PULMONARY COCCIDIOIDOMYCOSIS; KERN COUNTY; CALIFORNIA; POSACONAZOLE; INFECTION; THERAPY; ARIZONA; CLIMATE; TRENDS AB Background: Coccidioidomycosis is often a self-limiting pulmonary infection, but it can cause more clinically apparent disease leading to hospitalization. We describe the characteristics of initial and subsequent hospitalizations in children with coccidioidomycosis. Methods: Using the Pediatric Health Information System (PHIS), an inpatient database, we identified retrospectively a cohort of patients hospitalized between April 1, 2002 and June 30, 2007 at children's hospitals across the United States. Demographic, clinical, and therapeutic data for the initial and subsequent hospitalizations were collected and analyzed. Results: We identified 199 children who had 295 hospitalizations for coccidioidomycosis. The median hospital length of stay was 7 days (interquartile range: 3-14 days). Hospital incidence rates were stable from 2003 to 2005 but increased significantly from 2005 to 2006 (8.31/100,000 discharges vs. 12.95/100,000 discharges; chi(2) = 4.65, P = 0.031). Fluconazole was the most commonly used antifungal agent, but 17.1% of patients were initially managed without antifungal therapy. The presence of an underlying comorbid condition was common (34.2%) as was the need for surgical intervention (41%). In-hospital mortality was low (1.5%). Conclusions: The increase in hospitalization rates associated with coccidioidomycosis from 2005 to 2006 mirrors the increase in cases reported to the Centers for Disease Control and Prevention during the same time period. Hospital admission for coccidioidomycosis seems to be more common in patients with underlying comorbid conditions and frequently necessitates surgical intervention. C1 [Fisher, Brian T.; Prasad, Priya A.; Zaoutis, Theoklis E.] Childrens Hosp Philadelphia, Div Infect Dis, Philadelphia, PA 19104 USA. [Fisher, Brian T.; Prasad, Priya A.; Zaoutis, Theoklis E.] Childrens Hosp Philadelphia, Ctr Pediat Clin Effectiveness, Philadelphia, PA 19104 USA. [Chiller, Tom M.] Ctr Dis Control & Prevent, Mycot Dis Branch, Atlanta, GA USA. [Beveridge, Mara] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Walsh, Thomas J.] NCI, Pediat Oncol Branch, Bethesda, MD 20892 USA. RP Fisher, BT (reprint author), Childrens Hosp Philadelphia, Div Infect Dis, 12th Floor Abramson Res Bldg,34th St & Civ Ctr Bl, Philadelphia, PA 19104 USA. EM fisherbria@email.chop.edu NR 23 TC 8 Z9 8 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0891-3668 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD MAR PY 2010 VL 29 IS 3 BP 243 EP 247 DI 10.1097/INF.0b013e3181bcfd7f PG 5 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA 563MG UT WOS:000275136000010 PM 19934792 ER PT J AU Wenger, JD Zulz, T Bruden, D Singleton, R Bruce, MG Bulkow, L Parks, D Rudolph, K Hurlburt, D Ritter, T Klejka, J Hennessy, T AF Wenger, Jay D. Zulz, Tammy Bruden, Dana Singleton, Rosalyn Bruce, Michael G. Bulkow, Lisa Parks, Debbie Rudolph, Karen Hurlburt, Debby Ritter, Troy Klejka, Joseph Hennessy, Thomas TI Invasive Pneumococcal Disease in Alaskan Children Impact of the Seven-Valent Pneumococcal Conjugate Vaccine and the Role of Water Supply SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Article DE invasive pneumococcal disease; water; pneumococcal conjugate vaccine; Streptococcus pneumoniae ID CONJUGATE VACCINE; RISK-FACTORS; NONVACCINE SEROTYPES; NATIVE CHILDREN; RESPIRATORY-TRACT; INFECTIONS; POPULATION; EPIDEMIOLOGY; EMERGENCE; WATER AB Background: Alaska Native (AN) children, especially those in the Yukon-Kuskokwim region (YK-AN children), suffer some of the highest rates of invasive pneumococcal disease (IPD) in the world. Rates of IPD declined after statewide introduction of the 7-valent pneumococcal conjugate vaccine (PCV7) in 2001, but increased in subsequent years. Methods: Population-based laboratory surveillance data (1986-2007) for invasive Streptococcus pneumoniae infection in Alaskan children <5 years old were used to evaluate the association of IPD rates and serotype distribution with immunization, socioeconomic status, and in-home water service. Results: Introduction of PCV7 vaccine resulted in elimination of IPD caused by vaccine serotypes, but was followed by increasing rates of IPD caused by nonvaccine serotypes. Among YK-AN children IPD rates dropped by 60%, but then rose due to non-PCV7 serotypes to levels 5- to 10-fold higher than rates in non-YK-AN children and non-AN children. IPD rates in YK-AN children were twice as high in villages where <10% of houses had in-home piped water compared with villages where more than 80% of houses had in-home piped water (390 cases/100,000 vs. 146 cases/100,000, P = 0.008). Conclusions: High IPD rates in Alaska are associated with lack of in-home piped water (controlling for household crowding and per capita income). The effect of in-home piped water is most likely mediated through reduced water supply leading to limitations on handwashing. C1 [Wenger, Jay D.; Zulz, Tammy; Bruden, Dana; Singleton, Rosalyn; Bruce, Michael G.; Bulkow, Lisa; Parks, Debbie; Rudolph, Karen; Hurlburt, Debby; Hennessy, Thomas] Ctr Dis Control & Prevent, Arctic Invest Program, Natl Ctr Preparedness Detect & Control Infect Dis, Anchorage, AK 99508 USA. [Ritter, Troy] Alaska Native Tribal Hlth Consortium, Div Environm Hlth & Engn, Anchorage, AK USA. [Klejka, Joseph] Yukon Kuskokwim Hlth Corp, Bethel, AK USA. RP Wenger, JD (reprint author), Ctr Dis Control & Prevent, Arctic Invest Program, Natl Ctr Preparedness Detect & Control Infect Dis, 4055 Tudor Ctr Dr, Anchorage, AK 99508 USA. EM jdw2@cdc.gov NR 32 TC 52 Z9 53 U1 3 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0891-3668 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD MAR PY 2010 VL 29 IS 3 BP 251 EP 256 DI 10.1097/INF.0b013e3181bdbed5 PG 6 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA 563MG UT WOS:000275136000012 PM 19952861 ER PT J AU Payne, DC Szilagyi, PG Staat, MA Edwards, KM Gentsch, JR Weinberg, GA Hall, CB Curns, AT Clayton, H Griffin, MR Fairbrother, G Parashar, UD AF Payne, Daniel C. Szilagyi, Peter G. Staat, Mary Allen Edwards, Kathryn M. Gentsch, Jon R. Weinberg, Geoffrey A. Hall, Caroline B. Curns, Aaron T. Clayton, Haley Griffin, Marie R. Fairbrother, Gerry Parashar, Umesh D. TI Corrected 2007 Rotavirus Hospitalization Rates SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Letter C1 [Payne, Daniel C.; Curns, Aaron T.; Clayton, Haley; Parashar, Umesh D.] Ctr Dis Control & Prevent, Epidemiol Branch, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Szilagyi, Peter G.; Weinberg, Geoffrey A.; Hall, Caroline B.] Univ Rochester, Sch Med & Dent, Dept Pediat, Rochester, NY 14642 USA. [Staat, Mary Allen; Fairbrother, Gerry] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Cincinnati, OH 45221 USA. [Edwards, Kathryn M.] Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN USA. [Gentsch, Jon R.] Ctr Dis Control & Prevent, Gastroenteritis & Resp Viruses Lab Branch, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Griffin, Marie R.] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA. [Griffin, Marie R.] Vanderbilt Univ, Med Ctr, Dept Prevent Med, Nashville, TN USA. RP Payne, DC (reprint author), Ctr Dis Control & Prevent, Epidemiol Branch, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. NR 0 TC 5 Z9 5 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0891-3668 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD MAR PY 2010 VL 29 IS 3 BP 287 EP 288 DI 10.1097/INF.0b013e3181d40e76 PG 2 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA 563MG UT WOS:000275136000028 PM 20190618 ER PT J AU Nuss, AB Forschler, BT Crim, JW TeBrugge, V Pohl, J Brown, MR AF Nuss, Andrew B. Forschler, Brian T. Crim, Joe W. TeBrugge, Victoria Pohl, Jan Brown, Mark R. TI Molecular characterization of neuropeptide F from the eastern subterranean termite Reticulitermes flavipes (Kollar) (Isoptera: Rhinotermitidae) SO PEPTIDES LA English DT Article DE Neuropeptide Y; Insect; Gut motility ID JUVENILE-HORMONE SYNTHESIS; AFRICAN MALARIA MOSQUITO; PANCREATIC-POLYPEPTIDE; ANOPHELES-GAMBIAE; FOOD-INTAKE; Y-LIKE; RHODNIUS-PROLIXUS; MIGRATORY LOCUST; CEPHALIC GANGLIA; PEPTIDE-HORMONES AB Neuropeptide F (NPF)-like immunoreactivity was previously found to be abundant in the eastern subterranean termite, Reticulitermes flavipes. Purification of the NPF from a whole body extract of worker termites was accomplished in the current study by HPLC and heterologous radioimmunoassay for an NPF-related peptide, Helicoverpa zea Midgut Peptide-I. A partial amino acid sequence allowed determination of the corresponding cDNA that encoded an open reading frame deduced for authentic R. flavipes NPF (Ref NPF): KPSDPEQLADTLKYLEELDRFYSQVARPRFa. Effects of synthetic NPFs on muscle contractions were investigated for isolated foreguts and hindguts of workers, with Drill NPF inhibiting spontaneous contractions of hindguts. Phylogenetic analysis of invertebrate NPF sequences reveals two separate groupings, with Ref NPF occurring within a clade composed exclusively of arthropods. (C) 2009 Elsevier Inc. All rights reserved. C1 [Nuss, Andrew B.; Forschler, Brian T.; Brown, Mark R.] Univ Georgia, Dept Entomol, Athens, GA 30602 USA. [Crim, Joe W.] Univ Georgia, Dept Cellular Biol, Athens, GA 30602 USA. [TeBrugge, Victoria] Univ Toronto, Dept Biol, Mississauga, ON L5L 1C6, Canada. [Pohl, Jan] Ctr Dis Control & Prevent, Biotechnol Branch, Atlanta, GA 30333 USA. RP Nuss, AB (reprint author), Univ Georgia, Dept Entomol, 413 Biol Sci Bldg, Athens, GA 30602 USA. EM nuss8@uga.edu FU Microchemical and Proteomics Core of the Emory University School of Medicine, Atlanta, GA FX This research project was supported in part by the Microchemical and Proteomics Core of the Emory University School of Medicine, Atlanta, GA. We thank Stephen Garczynski for assistance with the RIA, Kevin Clark for synthesis of Ref NPFs and Drm NPF, and Ian Orchard and Ronald Gonzalez for facilitation of gut motility assays. NR 53 TC 19 Z9 21 U1 1 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-9781 J9 PEPTIDES JI Peptides PD MAR PY 2010 VL 31 IS 3 SI SI BP 419 EP 428 DI 10.1016/j.peptides.2009.09.001 PG 10 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy SC Biochemistry & Molecular Biology; Endocrinology & Metabolism; Pharmacology & Pharmacy GA 574MQ UT WOS:000275994100009 PM 19747517 ER PT J AU Huang, WT Chang, S Miller, ER Woo, EJ Hoffmaster, AR Gee, JE Clark, TA Iskander, JK Ball, R Broder, KR AF Huang, Wan-Ting Chang, Soju Miller, Elaine R. Woo, Emily Jane Hoffmaster, Alex R. Gee, Jay E. Clark, Thomas A. Iskander, John K. Ball, Robert Broder, Karen R. TI Safety assessment of recalled Haemophilus influenzae type b (Hib) conjugate vaccines-United States, 2007-2008 SO PHARMACOEPIDEMIOLOGY AND DRUG SAFETY LA English DT Article DE vaccine safety; Bacillus cereus; Haemophilus vaccines ID EVENT REPORTING SYSTEM; BACILLUS-CEREUS; VACCINATION; VAERS AB Purpose On 13 December 2007, Merck & Co., Inc. voluntarily recalled 1.2 million doses of Haemophilus influenzae type b (Hib) vaccines that had been distributed since April 2007 for concerns regarding potential Bacillus cereus contamination. Enhanced postrecall surveillance was conducted to detect vaccine-associated B. cereus infections. Methods We reviewed reports involving recalled Hib vaccines received by the Vaccine Adverse Event Reporting System (VAERS) during 1 April 2007-29 February 2008. For each reported death, autopsy review sought evidence of B. cereus infections, For each specified outcome, the proportional reporting ratios (PRRs) were calculated to compare the recalled I-lib vaccines with the manufacturer's nonrecalled Hib vaccines in the VAERS databases. On 20 December 2007, we used the Epidemic Information Exchange (Epi-X) to solicit nongastrointestinal vaccine-associated B. cereus infections, and requested B. cereus isolates for genotyping to compare with the manufacturing facility isolate. Results VAERS received 75 reports involving recalled Hib vaccines; none described a confirmed B. cereus infection. Comparative analyses did not reveal disproportionate reporting of specified outcomes for recalled Hib vaccines. The Epi-X posting triggered one report of vaccine-associated B. cereus bacteremia from a child who received a nonrecalled Hib vaccine manufactured by Merck; the genotypes of isolates from the patient and the manufacturing facility differed. Conclusions No evidence of vaccine-associated B. cereus infection had been found in recipients of recalled Hib vaccines. Conducting laboratory surveillance through Epi-X was feasible and may enhance public health response capacities for future vaccine safety emergencies. Published in 2010 by John Wiley & Sons, Ltd. C1 [Huang, Wan-Ting] CDC, Epidemic Intelligence Serv, Career Dev Div, Off Workforce & Career Dev,Ctr Dis Control & Prev, Atlanta, GA 30333 USA. [Huang, Wan-Ting; Miller, Elaine R.; Iskander, John K.; Broder, Karen R.] CDC, Immunizat Safety Off, Div Healthcare Qual Promot Proposed, Natl Ctr Preparedness Detect & Control Infect Dis, Atlanta, GA 30333 USA. [Chang, Soju; Woo, Emily Jane; Ball, Robert] US FDA, Div Epidemiol, Off Biostat & Epidemiol, Ctr Biol Evaluat & Res, Rockville, MD 20857 USA. [Hoffmaster, Alex R.; Gee, Jay E.] CDC, Bacterial Zoonoses Branch, Div Foodborne Bacterial & Mycot Dis, Natl Ctr Zoonot Vector Borne & Enter Dis, Atlanta, GA 30333 USA. [Clark, Thomas A.] CDC, Meningitis & Vaccine Preventable Dis Branch, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Broder, KR (reprint author), Ctr Dis Control & Prevent, Immunizat Safety Off, Div Healthcare Qual Promot Proposed, 1600 Clifton Rd NE,MS D26, Atlanta, GA 30333 USA. EM kbroder@cdc.gov RI Huang, Wan-Ting/E-3497-2010 OI Huang, Wan-Ting/0000-0002-4344-9567 FU US Department of Health and Human Services FX We thank Merck for voluntarily providing an isolate of B. cereus from the manufacturing equipment to CDC for genotyping. We also thank Christopher Paddock, MD, MPHTM (CDC Infectious Disease Pathology Branch), state health department staff and local medical examiners for their contributions to the autopsy reviews. The following CDC staff assisted in the surveillance through the Vaccine Adverse Event Reporting System: Penina Haber, MPH, Beth Hibbs, RN, MPH, Susan Duderstadt, MD, MPH, and Tracy Thomas, MPH. This work was financially supported by US Department of Health and Human Services. NR 15 TC 2 Z9 2 U1 0 U2 0 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1053-8569 J9 PHARMACOEPIDEM DR S JI Pharmacoepidemiol. Drug Saf. PD MAR PY 2010 VL 19 IS 3 BP 306 EP 310 DI 10.1002/pds.1909 PG 5 WC Public, Environmental & Occupational Health; Pharmacology & Pharmacy SC Public, Environmental & Occupational Health; Pharmacology & Pharmacy GA 570QT UT WOS:000275693700012 PM 20084617 ER PT J AU Ma, Q AF Ma, Qiang TI Transcriptional responses to oxidative stress: Pathological and toxicological implications SO PHARMACOLOGY & THERAPEUTICS LA English DT Review DE Reactive oxygen species; Oxidative stress; Transcription factor; Gene regulation; Disease; Chemical toxicity ID NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; HEAT-SHOCK RESPONSE; PROTEIN-KINASE-C; HYPOXIA-INDUCIBLE FACTOR; GROWTH-FACTOR RECEPTOR; CUL3-BASED E3 LIGASE; FACTOR-I MTF-1; REACTIVE OXYGEN; HYDROGEN-PEROXIDE AB The utilization of molecular oxygen as the terminal electron acceptor for energy production has in many ways shaped the evolution of complex life, physiology, and certain disease processes. The generation of reactive oxygen species (ROS), either as by-products of O(2) metabolism or by specialized enzymes, has the potential to damage cellular components and functions. Exposure to a variety of exogenous toxicants also promotes ROS production directly or through indirect means to cause toxicity. Oxidative stress activates the expression of a wide range of genes that mediate the pathogenic effect of ROS or are required for the detection and detoxification of the oxidants. In many cases, these are mediated by specific transcription factors whose expression, structure, stability, nuclear targeting, or DNA-binding affinity is regulated by the level of oxidative stress. This review examines major transcription factors that mediate transcriptional responses to oxidative stress, focusing on recent progress in the signaling pathways and mechanisms of activation of transcription factors by oxidative stress and the implications of this regulation in the development of disease and chemical toxicity. Published by Elsevier Inc. C1 [Ma, Qiang] NIOSH, Receptor Biol Lab, Toxicol & Mol Biol Branch, Hlth Effects Lab Div,Ctr Dis Control & Prevent, Washington, DC 20201 USA. [Ma, Qiang] W Virginia Univ, Dept Biochem, Sch Med, Morgantown, WV 26505 USA. RP Ma, Q (reprint author), Mailstop 3014,1095 Willowdale Rd, Morgantown, WV 26505 USA. EM qam1@cdc.gov NR 225 TC 83 Z9 92 U1 2 U2 10 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0163-7258 J9 PHARMACOL THERAPEUT JI Pharmacol. Ther. PD MAR PY 2010 VL 125 IS 3 BP 376 EP 393 DI 10.1016/j.pharmthera.2009.11.004 PG 18 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 574MR UT WOS:000275994200002 PM 19945483 ER PT J AU Black, CL Mwinzi, PNM Muok, EMO Abudho, B Fitzsimmons, CM Dunne, DW Karanja, DMS Secor, WE Colley, DG AF Black, Carla L. Mwinzi, Pauline N. M. Muok, Erick M. O. Abudho, Bernard Fitzsimmons, Colin M. Dunne, David W. Karanja, Diana M. S. Secor, W. Evan Colley, Daniel G. TI Influence of Exposure History on the Immunology and Development of Resistance to Human Schistosomiasis Mansoni SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID T-HELPER-2 CYTOKINE RESPONSES; VIRUS TYPE-1 COINFECTION; ADULT WORM ANTIGENS; IMMUNE-RESPONSES; HUMAN IGE; ISOTYPE RESPONSES; LAKE VICTORIA; REINFECTION; ASSOCIATION; HAEMATOBIUM AB Background: Previous studies suggest that humans can acquire immunity to reinfection with schistosomes, most probably due to immunologic mechanisms acquired after exposure to dying schistosome worms. Methodology/Principal Findings: We followed longitudinally two cohorts of adult males occupationally exposed to Schistosoma mansoni by washing cars (120 men) or harvesting sand (53 men) in Lake Victoria. Men were treated with praziquantel each time S. mansoni infection was detected. In car washers, a significant increase in resistance to reinfection, as measured by the number of cars washed between cure and reinfection, was observed after the car washers had experienced, on average, seven cures. In the car washers who developed resistance, the level of schistosome-specific IgE increased between baseline and the time at which development of resistance was first evidenced. In the sand harvesters, a significant increase in resistance, as measured by the number of days worked in the lake between cure and reinfection, was observed after only two cures. History of exposure to S. mansoni differed between the two cohorts, with the majority of sand harvesters being lifelong residents of a village endemic for S. mansoni and the majority of car washers having little exposure to the lake before they began washing cars. Immune responses at study entry were indicative of more recent infections in car washers and more chronic infections in sand harvesters. Conclusions/Significance: Resistance to reinfection with S. mansoni can be acquired or augmented by adults after multiple rounds of reinfection and cure, but the rate at which resistance is acquired by this means depends on immunologic status and history of exposure to S. mansoni infection. C1 [Black, Carla L.; Colley, Daniel G.] Univ Georgia, Ctr Trop & Emerging Global Dis, Athens, GA 30602 USA. [Black, Carla L.; Colley, Daniel G.] Univ Georgia, Dept Microbiol, Athens, GA 30602 USA. [Mwinzi, Pauline N. M.; Muok, Erick M. O.; Abudho, Bernard; Karanja, Diana M. S.] Kenya Govt Med Res Ctr, Ctr Global Hlth Res, Kisumu, Kenya. [Fitzsimmons, Colin M.; Dunne, David W.] Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England. [Secor, W. Evan] Ctr Dis Control & Prevent, Div Parasit Dis, Atlanta, GA USA. RP Black, CL (reprint author), Univ Georgia, Ctr Trop & Emerging Global Dis, Athens, GA 30602 USA. EM blackc@uga.edu RI Greenberg, Robert/D-1091-2009; OI Dunne, David/0000-0002-8940-9886 FU US National Institutes of Health NAIAD [R01 AI053695, T32 AI060546]; Wellcome Trust FX This work was supported by US National Institutes of Health NAIAD grants R01 AI053695 and T32 AI060546 and funding from the Wellcome Trust. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 35 TC 41 Z9 41 U1 1 U2 8 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1935-2727 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD MAR PY 2010 VL 4 IS 3 AR e637 DI 10.1371/journal.pntd.0000637 PG 11 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA 578RG UT WOS:000276312200010 PM 20351784 ER PT J AU Boyd, A Won, KY McClintock, SK Donovan, CV Laney, SJ Williams, SA Pilotte, N Streit, TG de Rochars, MVEB Lammie, PJ AF Boyd, Alexis Won, Kimberly Y. McClintock, Shannon K. Donovan, Catherine V. Laney, Sandra J. Williams, Steven A. Pilotte, Nils Streit, Thomas G. de Rochars, Madsen V. E. Beau Lammie, Patrick J. TI A Community-Based Study of Factors Associated with Continuing Transmission of Lymphatic Filariasis in Leogane, Haiti SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID BANCROFTIAN FILARIASIS; GLOBAL PROGRAM; MASS TREATMENT; RURAL-AREAS; TAMIL-NADU; ELIMINATION; INDIA; IMPACT; ADMINISTRATIONS; PARTICIPATION AB Seven rounds of mass drug administration (MDA) have been administered in Leogane, Haiti, an area hyperendemic for lymphatic filariasis (LF). Sentinel site surveys showed that the prevalence of microfilaremia was reduced to,1% from levels as high as 15.5%, suggesting that transmission had been reduced. A separate 30-cluster survey of 2- to 4-year-old children was conducted to determine if MDA interrupted transmission. Antigen and antifilarial antibody prevalence were 14.3% and 19.7%, respectively. Follow-up surveys were done in 6 villages, including those selected for the cluster survey, to assess risk factors related to continued LF transmission and to pinpoint hotspots of transmission. One hundred houses were mapped in each village using GPS-enabled PDAs, and then 30 houses and 10 alternates were chosen for testing. All individuals in selected houses were asked to participate in a short survey about participation in MDA, history of residence in Leogane and general knowledge of LF. Survey teams returned to the houses at night to collect blood for antigen testing, microfilaremia and Bm14 antibody testing and collected mosquitoes from these communities in parallel. Antigen prevalence was highly variable among the 6 villages, with the highest being 38.2% (Dampus) and the lowest being 2.9% (Corail Lemaire); overall antigen prevalence was 18.5%. Initial cluster surveys of 2- to 4-year-old children were not related to community antigen prevalence. Nearest neighbor analysis found evidence of clustering of infection suggesting that LF infection was focal in distribution. Antigen prevalence among individuals who were systematically noncompliant with the MDAs, i.e. they had never participated, was significantly higher than among compliant individuals (p<0.05). A logistic regression model found that of the factors examined for association with infection, only noncompliance was significantly associated with infection. Thus, continuing transmission of LF seems to be linked to rates of systematic noncompliance. C1 [Boyd, Alexis; Won, Kimberly Y.; McClintock, Shannon K.; Lammie, Patrick J.] Ctr Dis Control & Prevent, Div Parasit Dis, Atlanta, GA 30333 USA. [Donovan, Catherine V.; Streit, Thomas G.] Univ Notre Dame, Dept Biol Sci, Notre Dame, IN 46556 USA. [Laney, Sandra J.; Williams, Steven A.; Pilotte, Nils] Smith Coll, Dept Biol Sci, Northampton, MA 01063 USA. [de Rochars, Madsen V. E. Beau] Hop Ste Croix, Leogane, Haiti. RP Boyd, A (reprint author), Ctr Dis Control & Prevent, Div Parasit Dis, Atlanta, GA 30333 USA. EM kwon@cdc.gov RI Pileggi, Shannon/L-1320-2016 OI Pileggi, Shannon/0000-0002-7732-4164 FU US Centers for Disease Control and Prevention (CDC) Emerging Infectious Diseases; Association of Public Health Laboratories; Bill & Melinda Gates Foundation; Division of Parasitic Diseases, National Center for Zoonotic Vector-Borne and Enteric Disease, CDC, Atlanta, Georgia, USA; Atlanta Research and Education Foundation, Decatur, Georgia, USA FX This project was funded by the US Centers for Disease Control and Prevention (CDC) Emerging Infectious Diseases funds, by the Association of Public Health Laboratories, and by a grant from the Bill & Melinda Gates Foundation awarded to the University of Notre Dame, Indiana. SKM's research is supported by an appointment at the Division of Parasitic Diseases, National Center for Zoonotic Vector-Borne and Enteric Disease, CDC, Atlanta, Georgia, USA and the support of the Atlanta Research and Education Foundation, Decatur, Georgia, USA. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript NR 36 TC 33 Z9 34 U1 1 U2 9 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1935-2727 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD MAR PY 2010 VL 4 IS 3 AR e640 DI 10.1371/journal.pntd.0000640 PG 10 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA 578RG UT WOS:000276312200013 PM 20351776 ER PT J AU Tennant, SM Diallo, S Levy, H Livio, S Sow, SO Tapia, M Fields, PI Mikoleit, M Tamboura, B Kotloff, KL Nataro, JP Galen, JE Levine, MM AF Tennant, Sharon M. Diallo, Souleymane Levy, Haim Livio, Sofie Sow, Samba O. Tapia, Milagritos Fields, Patricia I. Mikoleit, Matthew Tamboura, Boubou Kotloff, Karen L. Nataro, James P. Galen, James E. Levine, Myron M. TI Identification by PCR of Non-typhoidal Salmonella enterica Serovars Associated with Invasive Infections among Febrile Patients in Mali SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID COMMUNITY-ACQUIRED BACTEREMIA; POLYMERASE-CHAIN-REACTION; INFLUENZAE TYPE-B; SUBSP ENTERICA; MULTIPLEX PCR; SELECTIVE AMPLIFICATION; MALAWIAN CHILDREN; CONJUGATE VACCINE; UNITED-STATES; TYPHIMURIUM AB Background: In sub-Saharan Africa, non-typhoidal Salmonella (NTS) are emerging as a prominent cause of invasive disease (bacteremia and focal infections such as meningitis) in infants and young children. Importantly, including data from Mali, three serovars, Salmonella enterica serovar Typhimurium, Salmonella Enteritidis and Salmonella Dublin, account for the majority of non-typhoidal Salmonella isolated from these patients. Methods: We have extended a previously developed series of polymerase chain reactions (PCRs) based on O serogrouping and H typing to identify Salmonella Typhimurium and variants (mostly I 4,[5],12:i:-), Salmonella Enteritidis and Salmonella Dublin. We also designed primers to detect Salmonella Stanleyville, a serovar found in West Africa. Another PCR was used to differentiate diphasic Salmonella Typhimurium and monophasic Salmonella Typhimurium from other O serogroup B, H: i serovars. We used these PCRs to blind-test 327 Salmonella serogroup B and D isolates that were obtained from the blood cultures of febrile patients in Bamako, Mali. Principal Findings: We have shown that when used in conjunction with our previously described O-serogrouping PCR, our PCRs are 100% sensitive and specific in identifying Salmonella Typhimurium and variants, Salmonella Enteritidis, Salmonella Dublin and Salmonella Stanleyville. When we attempted to differentiate 171 Salmonella Typhimurium (I 4,[ 5], 12: i: 1,2) strains from 52 monophasic Salmonella Typhimurium (I 4,[ 5], 12: i:-) strains, we were able to correctly identify 170 of the Salmonella Typhimurium and 51 of the Salmonella I 4,[5],12:i:-strains. Conclusion: We have described a simple yet effective PCR method to support surveillance of the incidence of invasive disease caused by NTS in developing countries. C1 [Tennant, Sharon M.; Levy, Haim; Livio, Sofie; Tapia, Milagritos; Kotloff, Karen L.; Nataro, James P.; Galen, James E.; Levine, Myron M.] Univ Maryland, Sch Med, Ctr Vaccine Dev, Baltimore, MD 21201 USA. [Diallo, Souleymane; Sow, Samba O.; Tapia, Milagritos; Tamboura, Boubou] CVD Mali, Bamako, Mali. [Diallo, Souleymane] Hop Gabriel Toure, Bamako, Mali. [Levy, Haim] Israel Inst Biol Res, IL-70450 Ness Ziona, Israel. [Fields, Patricia I.; Mikoleit, Matthew] Ctr Dis Control & Prevent, Natl Salmonella Reference Lab, Atlanta, GA USA. RP Tennant, SM (reprint author), Univ Maryland, Sch Med, Ctr Vaccine Dev, Baltimore, MD 21201 USA. EM mlevine@medicine.umaryland.edu RI kotloff, karen/E-7768-2012; OI kotloff, karen/0000-0003-1808-6431; Mikoleit, Matthew/0000-0002-4582-6733 FU Bill & Melinda Gates Foundation; Optimus Foundation; National Institute of Allergy and Infectious Diseases (NIAID), USA; The Gates Foundation [1187, 32470]; NIAID [R01 AI029471, U54 AI057168-06] FX This work was supported by grants from the Bill & Melinda Gates Foundation, the Optimus Foundation and the National Institute of Allergy and Infectious Diseases (NIAID), USA. The Gates Foundation grants (# 1187 and # 32470, to MML) supported surveillance to detect invasive bacterial infections in infants and children ( in particular, Haemophilus influenzae type b [Hib]) and to see the impact of introduction of Hib conjugate on invasive Hib disease (# 32470). The grant from the Optimus Foundation ( to SOS) supported systematic blood culture surveillance to detect non-typhoidal Salmonella. One grant from NIAID (R01 AI029471 to MML) supports the use of attenuated Salmonella to the immune system. A second grant from NIAID (U54 AI057168-06 to MML) supports the development of a vaccine to prevent invasive non-typhoidal Salmonella disease. These funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 47 TC 55 Z9 60 U1 2 U2 17 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1935-2727 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD MAR PY 2010 VL 4 IS 3 AR e621 DI 10.1371/journal.pntd.0000621 PG 9 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA 578RG UT WOS:000276312200022 PM 20231882 ER PT J AU Vinayak, S Alam, MT Mixson-Hayden, T McCollum, AM Sem, R Shah, NK Lim, P Muth, S Rogers, WO Fandeur, T Barnwell, JW Escalante, AA Wongsrichanalai, C Ariey, F Meshnick, SR Udhayakumar, V AF Vinayak, Sumiti Alam, Md Tauqeer Mixson-Hayden, Tonya McCollum, Andrea M. Sem, Rithy Shah, Naman K. Lim, Pharath Muth, Sinuon Rogers, William O. Fandeur, Thierry Barnwell, John W. Escalante, Ananias A. Wongsrichanalai, Chansuda Ariey, Frederick Meshnick, Steven R. Udhayakumar, Venkatachalam TI Origin and Evolution of Sulfadoxine Resistant Plasmodium falciparum SO PLOS PATHOGENS LA English DT Article ID HUMAN MALARIA PARASITE; CHLORPROGUANIL-DAPSONE TREATMENT; CAR NICOBAR ISLAND; PYRIMETHAMINE RESISTANCE; DRUG-RESISTANCE; DIHYDROPTEROATE SYNTHETASE; MOLECULAR MARKERS; ANTIMALARIAL RESISTANCE; DIHYDROFOLATE-REDUCTASE; POPULATION-STRUCTURE AB The Thailand-Cambodia border is the epicenter for drug-resistant falciparum malaria. Previous studies have shown that chloroquine (CQ) and pyrimethamine resistance originated in this region and eventually spread to other Asian countries and Africa. However, there is a dearth in understanding the origin and evolution of dhps alleles associated with sulfadoxine resistance. The present study was designed to reveal the origin(s) of sulfadoxine resistance in Cambodia and its evolutionary relationship to African and South American dhps alleles. We sequenced 234 Cambodian Plasmodium falciparum isolates for the dhps codons S436A/F, A437G, K540E, A581G and A613S/T implicated in sulfadoxine resistance. We also genotyped 10 microsatellite loci around dhps to determine the genetic backgrounds of various alleles and compared them with the backgrounds of alleles prevalent in Africa and South America. In addition to previously known highly-resistant triple mutant dhps alleles SGEGA and AGEAA (codons 436, 437, 540, 581, 613 are sequentially indicated), a large proportion of the isolates (19.3%) contained a 540N mutation in association with 437G/581G yielding a previously unreported triple mutant allele, SGNGA. Microsatellite data strongly suggest the strength of selection was greater on triple mutant dhps alleles followed by the double and single mutants. We provide evidence for at least three independent origins for the double mutants, one each for the SGKGA, AGKAA and SGEAA alleles. Our data suggest that the triple mutant allele SGEGA and the novel allele SGNGA have common origin on the SGKGA background, whereas the AGEAA triple mutant was derived from AGKAA on multiple, albeit limited, genetic backgrounds. The SGEAA did not share haplotypes with any of the triple mutants. Comparative analysis of the microsatellite haplotypes flanking dhps alleles from Cambodia, Kenya, Cameroon and Venezuela revealed an independent origin of sulfadoxine resistant alleles in each of these regions. C1 [Vinayak, Sumiti] Atlanta Res & Educ Fdn, Atlanta, GA USA. [Vinayak, Sumiti; Alam, Md Tauqeer; Mixson-Hayden, Tonya; McCollum, Andrea M.; Barnwell, John W.; Udhayakumar, Venkatachalam] Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis, Natl Ctr Zoonot Vector Borne & Enter Dis,Cooordin, Atlanta, GA USA. [Sem, Rithy; Muth, Sinuon] Natl Malaria Ctr, Phnom Penh, Cambodia. [Sem, Rithy; Rogers, William O.; Wongsrichanalai, Chansuda] USN, Med Res Unit 2, Jakarta, Indonesia. [Shah, Naman K.; Meshnick, Steven R.] UNC, Sch Publ Hlth, Dept Epidemiol, Chapel Hill, NC USA. [Lim, Pharath; Ariey, Frederick] Inst Pasteur, Phnom Penh, Cambodia. [Fandeur, Thierry] Inst Pasteur, Unite Immunol Mol Parasites, Paris, France. [Escalante, Ananias A.] Arizona State Univ, Sch Life Sci, Tempe, AZ USA. RP Vinayak, S (reprint author), Atlanta Res & Educ Fdn, Atlanta, GA USA. EM vxu0@cdc.gov RI Vinayak, Sumiti/F-9395-2013 FU Atlanta Research and Education Foundation; VA Medical Center; CDC Antimicrobial Resistance Working Group; US Navy Medical In-House Laboratory Independent Research Program at Naval Health Research Center/Naval Medical Research Center; Department of Defense Global Emerging Infections Systems (GEIS); NIH [5D43TW007402-02, R01GM084320] FX The financial support from the Atlanta Research and Education Foundation, VA Medical Center and the CDC Antimicrobial Resistance Working Group is acknowledged. Partial support from the US Navy Medical In-House Laboratory Independent Research Program at Naval Health Research Center/Naval Medical Research Center, Department of Defense Global Emerging Infections Systems (GEIS) and NIH grant 5D43TW007402-02 is also acknowledged. AAE is supported by grant R01GM084320 from the National Institutes of Health (NIH), USA. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 70 TC 50 Z9 50 U1 1 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1553-7366 J9 PLOS PATHOG JI PLoS Pathog. PD MAR PY 2010 VL 6 IS 3 AR e1000830 DI 10.1371/journal.ppat.1000830 PG 12 WC Microbiology; Parasitology; Virology SC Microbiology; Parasitology; Virology GA 596XY UT WOS:000277720400038 PM 20360965 ER PT J AU Slonim, A Wheeler, FC Quinlan, KM Smith, SM AF Slonim, Amy Wheeler, Fran C. Quinlan, Kathleen M. Smith, Suzanne M. TI Designing Competencies for Chronic Disease Practice SO PREVENTING CHRONIC DISEASE LA English DT Article AB Introduction Competencies are the cornerstone of effective public health practice, and practice specialties require competencies specific to their work. Although more than 30 specialty competency sets have been developed, a particular need remained to define competencies required of professionals who practice chronic disease prevention and control. To that end, the National Association of Chronic Disease Directors (NACDD) engaged a group of stakeholders in developing competencies for chronic disease practice. Methods Concept mapping was blended with document analysis of existing competencies in public health to develop a unique framework. Public health experts reviewed the results, providing extensive and richer understanding of the issues. Results The final product presents an integrated picture that highlights interrelationships among the specific skills and knowledge required for leading and managing state chronic disease programs. Those competencies fall into 7 clusters: 1) lead strategically, 2) manage people, 3) manage programs and resources, 4) design and evaluate programs, 5) use public health science, 6) influence policies and systems change, and 7) build support. Conclusion The project yielded a framework with a categorization scheme and language that reflects how chronic disease practitioners view their work, including integrating communications and cultural competency skills into relevant job functions. Influencing policies and systems change has distinct relevance to chronic disease practice. We suggest uses of the competencies in the field. C1 [Slonim, Amy] Michigan Publ Hlth Inst, Okemos, MI USA. [Slonim, Amy] Ctr Dis Control & Prevent, Washington, DC USA. [Wheeler, Fran C.] Natl Assoc Chron Dis Directors, Atlanta, GA USA. [Smith, Suzanne M.] Univ Massachusetts, Amherst, MA 01003 USA. [Quinlan, Kathleen M.] Concept Syst Inc, Ithaca, NY USA. RP Quinlan, KM (reprint author), Oxford Learning Inst, Littlegate House,16-17 St Ebbes St, Oxford OX1 1PT, England. EM kathleenm.quinlan@yahoo.com RI Quinlan, Kathleen M/A-4525-2017 OI Quinlan, Kathleen M/0000-0003-3606-4148 FU CDC with the National Association of Chronic Disease Directors [U58/CCU324336] FX This work was supported by CDC Cooperative Agreement no. U58/CCU324336 with the National Association of Chronic Disease Directors. The authors acknowledge the contributions of the Competencies Planning Group, which helped select the focus prompt, brainstormed, sorted, and contributed to the selection and refinement of the original competency. The planning group was composed of the authors and Ramona Schaeffer, Cynthia Boddie-Willis, Robert Smariga, Charles Gollmar, Paula Marmet, and Mary Kane. Brenda Pepe, and Heather Freeborn helped manage the concept-mapping process. The authors also acknowledge the contributions of the interviewees and the NACDD Professional Development Committee. NR 19 TC 5 Z9 5 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD MAR PY 2010 VL 7 IS 2 AR A44 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA V20SA UT WOS:000208158500018 PM 20158972 ER PT J AU Fan, AZ Mallawaarachchi, DSV Gilbertz, D Li, Y Mokdad, AH AF Fan, Amy Z. Mallawaarachchi, Dona Stephnie Virginie Gilbertz, David Li, Yan Mokdad, Ali H. TI Lifestyle behaviors and receipt of preventive health care services among hypertensive Americans aged 45 years or older in 2007 SO PREVENTIVE MEDICINE LA English DT Article DE Exercise; Fruits and vegetables; Hypertension; Lifestyle behaviors; Medication; Obesity ID HIGH BLOOD-PRESSURE; RANDOMIZED CONTROLLED-TRIALS; JOINT-NATIONAL-COMMITTEE; UNITED-STATES; ALCOHOL-CONSUMPTION; CLINICAL-TRIAL; 7TH REPORT; MEN; METAANALYSIS; PREVALENCE AB Objective. The aim of the study was to explore opportunities for more effective interventions on lifestyle modifications among hypertensives. Methods. Using 2007 data from the Behavioral Risk Factor Surveillance System from the United States, we assessed the prevalence of various lifestyle behaviors and receipt of preventive health care services among US adults aged 45 years or older based on hypertension and treatment status (n = 218,228). Results. Compared with nonhypertensives, hypertensives were significantly less likely to engage in recommended levels of physical activity and to be more obese regardless of treatment status. Compared to nonhypertensives, hypertensives on medical treatment were less likely to consume five or more servings of fruit and vegetables per day, be current smokers, and binge drinkers. Hypertensives not on medical treatment were more likely to be Current smokers, binge and heavy drinkers. Hypertensives on medical treatment were More likely to have routine health checkup, have blood cholesterol checkup within previous 5 years and have a flu shot within the previous year than hypertensives not on treatment. Conclusion. Different patterns of lifestyle behaviors and use of preventive health care services were found based on treatment status among hypertensives. Intervention programs should be tailored accordingly to achieve optimal Outcome on lifestyle modification. Published by Elsevier Inc. C1 [Fan, Amy Z.; Mallawaarachchi, Dona Stephnie Virginie; Gilbertz, David; Li, Yan] Ctr Dis Control & Prevent, Behav Surveillance Branch, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Adult & Community Hlth, Atlanta, GA 30341 USA. [Mokdad, Ali H.] Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USA. RP Fan, AZ (reprint author), Ctr Dis Control & Prevent, Behav Surveillance Branch, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Adult & Community Hlth, 4770 Buford Highway NE,MS K-66, Atlanta, GA 30341 USA. EM afan@cdc.gov NR 37 TC 7 Z9 7 U1 0 U2 2 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-7435 J9 PREV MED JI Prev. Med. PD MAR PY 2010 VL 50 IS 3 BP 138 EP 142 DI 10.1016/j.ypmed.2009.12.007 PG 5 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 560PB UT WOS:000274913500008 PM 20006640 ER PT J AU Gaffney, M Green, DR Gaffney, C AF Gaffney, Marcus Green, Denise R. Gaffney, Claudia TI Newborn Hearing Screening and Follow-up: Are Children Receiving Recommended Services? SO PUBLIC HEALTH REPORTS LA English DT Article AB Objectives. Newborn hearing screening programs have been implemented by all 50 states and most U.S. territories to detect hearing loss in infants and prevent delays in speech, language, and social and emotional development. To monitor progress toward national goals, the Centers for Disease Control and Prevention (CDC) collects data from state and territorial programs. This article summarizes findings from the CDC Early Hearing Detection and Intervention (EHDI) Hearing Screening and Follow-up Survey (HSFS) and provides a summary of recent efforts to identify infants with hearing loss in the U.S. Methods. The HSFS was sent to representatives of U.S. EHDI programs to gather aggregate screening, diagnostic, intervention, and demographic data for 2005 and 2006. We analyzed these data to evaluate progress toward national goals. Results. In 2005 and 2006, more than 90% of infants were screened for hearing loss. Of these infants, 2% in both years did not pass their final screening. Out of those not passing the final screening, approximately two-thirds were not documented as having a diagnostic finding. In both years, the reason reported for the majority of infants was loss to follow-up/loss to documentation (LFU/LTD). Although the majority of infants with permanent hearing loss were receiving intervention, more than 30% were classified as LFU/LTD and could not be documented as receiving intervention services. Conclusions. The HSFS enables the collection of more complete data that highlight the progress in screening infants for hearing loss. However, data indicate improvements are needed to reduce LFU/LTD and meet the national benchmarks. C1 [Gaffney, Marcus] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Green, Denise R.; Gaffney, Claudia] McKing Consulting Corp, Fairfax, VA USA. RP Gaffney, M (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, MS E-87,1600 Clifton Rd, Atlanta, GA 30333 USA. EM MGaffney@cdc.gov NR 14 TC 22 Z9 30 U1 0 U2 1 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1101 15TH ST NW, STE 910, WASHINGTON, DC 20005 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD MAR-APR PY 2010 VL 125 IS 2 BP 199 EP 207 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 556OG UT WOS:000274599900007 PM 20297746 ER PT J AU Pazol, K Kramer, MR Hogue, CJ AF Pazol, Karen Kramer, Michael R. Hogue, Carol J. TI Condoms for Dual Protection: Patterns of Use with Highly Effective Contraceptive Methods SO PUBLIC HEALTH REPORTS LA English DT Article ID UNITED-STATES; UNINTENDED PREGNANCY; ORAL-CONTRACEPTIVES; LEVONORGESTREL IMPLANTS; ADOLESCENT WOMEN; PERSPECTIVES; CONSISTENCY; ABORTIONS; BEHAVIOR; NORPLANT AB Objectives. U.S. women experience high rates of unplanned pregnancy and sexually transmitted infections (STIs), yet they seldom combine condoms with highly effective contraceptives for optimal protection. Because oral contraceptives (OCs) have been the predominant form of highly effective contraception in the U.S., it is unknown whether condom use is similarly low with increasingly promoted user-independent methods. Methods. We used weighted data from the National Survey of Family Growth to assess condom use odds among women relying on OCs vs. user-independent methods (i.e., injectibles, intrauterine devices, and implants). We also estimated the expected reduction in unplanned pregnancies and abortions if half or all of the women currently using a single highly effective method also used condoms. Results. Across every demographic subgroup based on age, partner status, race/ethnicity, household income, and education, condom use prevalence was lower for women relying on user-independent methods vs. OCs. Multivariable models for adult women also revealed a significant reduction within most demographic subgroups in the odds of condom use among women relying on user-independent methods vs. OCs. Population estimates suggested that if half of all women using highly effective methods alone also used condoms, approximately 40% of unplanned pregnancies and abortions among these women could be prevented, for an annual reduction of 393,000 unplanned pregnancies and nearly 76,000 abortions. If all highly effective method users also used condoms, approximately 80% of unplanned pregnancies and abortions among these women could be prevented, for an annual reduction of 786,000 unplanned pregnancies and nearly 152,000 abortions. Conclusions. Adding condoms to other methods should be considered seriously as the first line of defense against unplanned pregnancy and STIs. This analysis can serve to target interventions where dual-method promotion is needed most. C1 [Pazol, Karen] Emory Univ, Sch Med, Dept Med, Atlanta, GA USA. [Kramer, Michael R.; Hogue, Carol J.] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA. [Kramer, Michael R.; Hogue, Carol J.] Emory Univ, Rollins Sch Publ Hlth, Womens & Childrens Ctr, Atlanta, GA 30322 USA. RP Pazol, K (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, Maternal & Infant Hlth Branch, 477 Buford Hwy,MS-K21, Atlanta, GA 30341 USA. EM kpazol@cdc.gov RI Kramer, Michael/A-3195-2013; Hogue, Carol/H-5442-2012 NR 46 TC 25 Z9 25 U1 3 U2 18 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1101 15TH ST NW, STE 910, WASHINGTON, DC 20005 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD MAR-APR PY 2010 VL 125 IS 2 BP 208 EP 217 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 556OG UT WOS:000274599900008 PM 20297747 ER PT J AU Sekhobo, JP Edmunds, LS Reynolds, DK Dalenius, K Sharma, A AF Sekhobo, Jackson P. Edmunds, Lynn S. Reynolds, Daniel K. Dalenius, Karen Sharma, Andrea TI Trends in Prevalence of Obesity and Overweight Among Children Enrolled in the New York State WIC Program, 2002-2007 SO PUBLIC HEALTH REPORTS LA English DT Article ID EXPERT COMMITTEE RECOMMENDATIONS; BODY-MASS INDEX; QUALITY-OF-LIFE; US CHILDREN; CHILDHOOD OBESITY; ADOLESCENTS; PREVENTION; INCOME; INTERVENTIONS; ENVIRONMENT AB Objectives. We examined recent overweight and obesity trends in a multi-ethnic population of low-income preschool children. Methods. We defined overweight as sex-specific body mass index (BMI)-forage >= 85th and <95th percentile and obesity as sex-specific BMI-for-age >= 95th percentile, and calculated them using demographic data and randomly selected height and weight measurements that were recorded while 2- to <5-year-old children were enrolled in the New York State (NYS) Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) during 2002-2007. Results. Obesity prevalence peaked at 16.7% in 2003, declined from 2003 through 2005, and stabilized at 14.7% through 2007. Among both boys and girls, the downward trend in annual prevalence of obesity was evident only among Hispanic children (22.8% boys and 20.9% girls in 2002 vs. 19.3% boys and 17.5% girls in 2007) and non-Hispanic black children (15.6% boys and 14.2% girls in 2002 vs. 13.6% boys and 12.4% girls in 2007). In contrast, the annual prevalence estimate for overweight showed an increasing trend from 2002 through 2007. Conclusions. These results showed a slight decline in prevalence of childhood obesity and a continuing rise in prevalence of childhood overweight among children enrolled in the NYS WIC program during 2002-2007. Future research should investigate the extent to which the slight decline in childhood obesity prevalence may be attributable to population-based and high-risk obesity prevention efforts in NYS. C1 [Sekhobo, Jackson P.; Edmunds, Lynn S.] New York State Dept Hlth, Div Nutr, Bur Adm & Evaluat, Evaluat & Anal Unit, Albany, NY 12204 USA. [Reynolds, Daniel K.] SUNY Albany, Sch Publ Hlth, Dept Epidemiol & Biostat, Albany, NY USA. [Dalenius, Karen; Sharma, Andrea] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Nutr Phys Activ & Obes, Obes Prevent & Control Branch, Atlanta, GA USA. RP Sekhobo, JP (reprint author), New York State Dept Hlth, Div Nutr, Bur Adm & Evaluat, Evaluat & Anal Unit, 150 Broadway,Riverview Ctr,5th Fl E, Albany, NY 12204 USA. EM jps04@health.state.ny.us OI Sharma, Andrea/0000-0003-0385-0011 NR 40 TC 24 Z9 25 U1 2 U2 6 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1101 15TH ST NW, STE 910, WASHINGTON, DC 20005 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD MAR-APR PY 2010 VL 125 IS 2 BP 218 EP 224 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 556OG UT WOS:000274599900009 PM 20297748 ER PT J AU Wolbarst, AB Wiley, AL Nemhauser, JB Christensen, DM Hendee, WR AF Wolbarst, Anthony B. Wiley, Albert L., Jr. Nemhauser, Jeffrey B. Christensen, Doran M. Hendee, William R. TI Medical Response to a Major Radiologic Emergency: A Primer for Medical and Public Health Practitioners SO RADIOLOGY LA English DT Review ID NUCLEAR TERRORISM; SUPPORTIVE CARE; DOSE-RESPONSE; RADIATION; MANAGEMENT; TRIAGE; TRANSPLANTATION; RECOMMENDATIONS; PROTECTION; CASUALTIES AB There are several types of serious nuclear or radiologic emergencies that would require a specialized medical response. Four scenarios of great public health, economic, and psychologic impact are the detonation of a nuclear weapon, the meltdown of a nuclear reactor, the explosion of a large radiologic dispersal device ("dirty bomb"), or the surreptitious placement of a radiation exposure device in a public area of high population density. With any of these, medical facilities that remain functional may have to deal with large numbers of ill, wounded, and probably contaminated people. Special care and/or handling will be needed for those with trauma, blast injuries, or thermal burns as well as significant radiation exposures or contamination. In addition, radiologists, nuclear medicine specialists, and radiation oncologists will be called on to perform a number of diverse and critically important tasks, including advising political and public health leaders, interfacing with the media, managing essential resources, and, of course, providing medical care. This article describes the medical responses needed following a radiologic or nuclear incident, including the symptoms of and specific treatments for acute radiation syndrome and other early health effects. (C) RSNA, 2010). C1 [Wolbarst, Anthony B.] Univ Kentucky, Sch Med, Dept Radiol, Lexington, KY 40536 USA. [Wiley, Albert L., Jr.; Christensen, Doran M.] Radiat Emergency Assistance Ctr, Oak Ridge, TN USA. [Nemhauser, Jeffrey B.] Ctr Dis Control & Prevent, Radiat Studies Branch, Atlanta, GA USA. [Hendee, William R.] Med Coll Wisconsin, Milwaukee, WI 53226 USA. RP Wolbarst, AB (reprint author), Univ Kentucky, Sch Med, Dept Radiol, 900 S Limestone St,CTW Bldg,Room 209D, Lexington, KY 40536 USA. EM wolbarst.anthony@uky.edu NR 74 TC 22 Z9 27 U1 0 U2 5 PU RADIOLOGICAL SOC NORTH AMERICA PI OAK BROOK PA 820 JORIE BLVD, OAK BROOK, IL 60523 USA SN 0033-8419 J9 RADIOLOGY JI Radiology PD MAR PY 2010 VL 254 IS 3 BP 660 EP 677 DI 10.1148/radiol.09090330 PG 18 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 559CA UT WOS:000274796200007 PM 20177084 ER PT J AU Kesmodel, US Underbjerg, M Kilburn, TR Bakketeig, L Mortensen, EL Landro, NI Schendel, D Bertrand, J Grove, J Ebrahim, S Thorsen, P AF Kesmodel, Ulrik Schioler Underbjerg, Mette Kilburn, Tina Rondrup Bakketeig, Leiv Mortensen, Erik Lykke Landro, Nils Inge Schendel, Diana Bertrand, Jacquelyn Grove, Jakob Ebrahim, Shahul Thorsen, Poul TI Lifestyle during pregnancy: Neurodevelopmental effects at 5 years of age. The design and implementation of a prospective follow-up study SO SCANDINAVIAN JOURNAL OF PUBLIC HEALTH LA English DT Article DE Alcohol; binge drinking; cognition; intelligence; lifestyle during pregnancy; neurobehavioural development; pregnancy ID PRENATAL ALCOHOL EXPOSURE; SEYCHELLES CHILD-DEVELOPMENT; FETAL ALCOHOL; BINGE DRINKING; METHYLMERCURY EXPOSURE; MATERNAL DRINKING; PRETERM DELIVERY; REACTION-TIME; BIRTH-WEIGHT; SCHOOL-AGE AB Background: It has been suggested that even mild exposure to alcohol, caffeine, smoking, and poor diet may have adverse long-term neurodevelopmental effects. In addition, there is evidence that timing of high exposures (e. g. binge drinking) can have particularly negative effects. This paper describes the design and implementation of The Lifestyle During Pregnancy Study addressing major methodological challenges for studies in this field. The study examines the effects of lifestyle during pregnancy on offspring neurodevelopment. Methods: In 2003, we initiated a prospective follow-up of 1750 mother-child pairs, sampled on the basis of maternal alcohol drinking patterns from The Danish National Birth Cohort (DNBC), a study of 101,042 pregnancies enrolled 1997-2003. Data collection in the DNBC involved four prenatal and postnatal maternal interviews, providing detailed information on maternal alcohol drinking patterns before and during pregnancy, caffeine intake, smoking, diet, and other lifestyle, medical, and sociodemographic factors. Results: At the age of 5 years, the children and their mothers participated in a comprehensive assessment of neurobehavioural development focusing on global cognition, specific cognitive functions, and behaviour. Two new tests assessing attention and speed of information processing among children were developed, and data on important potential confounders such as maternal intelligence quotient, vision, and hearing abilities were collected. Efforts were made to standardise procedures and obtain high inter-rater reliability. Conclusions: We expect that the study will illuminate the significance or lack of significance of maternal lifestyle during pregnancy and contribute to better understanding the effects of alcohol drinking during pregnancy at low to moderate consumption levels. C1 [Kesmodel, Ulrik Schioler; Underbjerg, Mette; Kilburn, Tina Rondrup; Mortensen, Erik Lykke; Grove, Jakob; Thorsen, Poul] Univ Aarhus, Sch Publ Hlth, Dept Epidemiol, DK-8000 Aarhus C, Denmark. [Underbjerg, Mette] Vejlefjord Childrens Neuroctr, Stouby, Denmark. [Bakketeig, Leiv] Univ So Denmark, Inst Publ Hlth, Epidemiol Res Unit, Odense, Denmark. [Mortensen, Erik Lykke] Univ Copenhagen, Inst Publ Hlth, DK-1168 Copenhagen, Denmark. [Landro, Nils Inge] Univ Oslo, Ctr Study Human Cognit, Dept Psychol, N-0316 Oslo, Norway. [Schendel, Diana; Bertrand, Jacquelyn; Ebrahim, Shahul] Ctr Dis Control & Prevent, Atlanta, GA USA. [Thorsen, Poul] Emory Univ, Dept Epidemiol, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. RP Kesmodel, US (reprint author), Univ Aarhus, Sch Publ Hlth, Dept Epidemiol, Bartholins Alle 2, DK-8000 Aarhus C, Denmark. EM ukes@soci.au.dk OI Mortensen, Erik Lykke/0000-0002-6985-451X; Grove, Jakob/0000-0003-2284-5744 FU Danish National Board of Health; Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA; Lundbeck Foundation, Denmark; Pharmacy Foundation; Egmont Foundation; March of Dimes Birth Defects Foundation; Augustinus Foundation; Health Foundation FX This study was supported financially by the Danish National Board of Health, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA, and Lundbeck Foundation, Denmark. We gratefully acknowledge the participation and enthusiasm of the children and their parents in this study as well as the Danish National Birth Cohort.; The Danish National Research Foundation has established The Danish Epidemiology Science Centre that initiated and created the Danish National Birth Cohort. The cohort is furthermore a result of a major grant from this Foundation. Additional support for the Danish National Birth Cohort is obtained from the Pharmacy Foundation, the Egmont Foundation, the March of Dimes Birth Defects Foundation, the Augustinus Foundation, and the Health Foundation NR 74 TC 19 Z9 19 U1 2 U2 13 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1403-4948 J9 SCAND J PUBLIC HEALT JI Scand. J. Public Health PD MAR PY 2010 VL 38 IS 2 BP 208 EP 219 DI 10.1177/1403494809357093 PG 12 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 558YS UT WOS:000274785700014 PM 20064917 ER PT J AU Bohm, MK Newman, L Satterwhite, CL Tao, GY Weinstock, HS AF Bohm, Michele K. Newman, Lori Satterwhite, Catherine Lindsey Tao, Guoyu Weinstock, Hillard S. TI Pelvic Inflammatory Disease Among Privately Insured Women, United States, 2001-2005 SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID GENITAL CHLAMYDIAL INFECTION; PUBLIC-HEALTH SURVEILLANCE; COMPLICATIONS AB Background: We explored the utility of using insurance claims data for surveillance of pelvic inflammatory disease (PID). PID rates are an important indicator of population level trends in reproductive morbidity; however, data available to monitor PID trends are limited. National survey data are currently used to estimate PID rates in the United States, but a declining number of cases threaten their future usefulness. Methods: We performed a retrospective analysis of PID diagnosis rates using administrative claims data from 2001 to 2005. Diagnostic codes were used to identify women aged 15 to 44 in the study population that were diagnosed with acute PID as inpatients, in emergency departments, and in outpatient ambulatory settings. Results: Rates of PID diagnoses among privately insured women declined significantly from 2001 to 2005 among all age groups examined and within all geographic regions. Annual PID diagnosis rates decreased from 317.0 to 236.0 per 100,000 enrollees, representing a 25.5% decline over the study period. The highest rates of PID were among 25- to 29-year-olds (352.8 per 100,000 in 2005) and among those residing in the South (314.3 per 100,000 in 2005). Most women (70.1%) received PID care through physician offices and other outpatient facilities; of these women, approximately 40% were treated by an obstetrician/gynecologist. Conclusions: The decline in PID diagnoses corresponds with previous reports from national surveys. Claims data offer a much needed new data source that will allow for continued monitoring of PID among a broad population in both inpatient and outpatient clinical settings. C1 [Bohm, Michele K.; Newman, Lori; Satterwhite, Catherine Lindsey; Tao, Guoyu; Weinstock, Hillard S.] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div STD Prevent, Atlanta, GA 30329 USA. RP Bohm, MK (reprint author), Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div STD Prevent, 1600 Clifton Rd NE,MS D28, Atlanta, GA 30329 USA. EM mbohm@cdc.gov NR 24 TC 25 Z9 26 U1 0 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD MAR PY 2010 VL 37 IS 3 BP 131 EP 136 DI 10.1097/OLQ.0b013e3181bf576f PG 6 WC Infectious Diseases SC Infectious Diseases GA 565CC UT WOS:000275265600001 PM 20051931 ER PT J AU Freeman, AH Katz, KA Pandori, MW Rauch, LM Kohn, RP Liska, S Bernstein, KT Klausner, JD AF Freeman, Alexandra H. Katz, Kenneth A. Pandori, Mark W. Rauch, Leah M. Kohn, Robert P. Liska, Sally Bernstein, Kyle T. Klausner, Jeffrey D. TI Prevalence and Correlates of Trichomonas vaginalis Among Incarcerated Persons Assessed Using a Highly Sensitive Molecular Assay SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID SEXUALLY-TRANSMITTED-DISEASES; HUMAN-IMMUNODEFICIENCY-VIRUS; LOW-BIRTH-WEIGHT; NEW-YORK-CITY; RISK-FACTORS; LABORATORY DIAGNOSIS; CLINICAL-MANIFESTATIONS; UNITED-STATES; WOMEN; INFECTION AB We describe the epidemiology of Trichomonas vaginalis (TV) among San Francisco County Jail inmates using APTIMA TV analyte-specific reagents on remnant urine. We detected TV in 15/713 (2.1%) men and 95/297 (32.0%) women. Among women, increased age was significantly associated with TV. The benefits of TV screening should be determined. C1 [Freeman, Alexandra H.; Katz, Kenneth A.; Kohn, Robert P.; Bernstein, Kyle T.; Klausner, Jeffrey D.] San Francisco Dept Publ Hlth, STD Prevent & Control Serv, San Francisco, CA 94103 USA. [Katz, Kenneth A.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Pandori, Mark W.; Rauch, Leah M.; Liska, Sally] San Francisco Dept Publ Hlth, Publ Hlth Lab, San Francisco, CA 94103 USA. RP Freeman, AH (reprint author), San Francisco Dept Publ Hlth, STD Prevent & Control Serv, 1360 Mission St,Suite 401, San Francisco, CA 94103 USA. EM jana.h.freeman@gmail.com FU Gen-Probe Inc.; San Diego, California FX Supported financially and technically by the Gen-Probe Inc., San Diego, California. NR 41 TC 16 Z9 16 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD MAR PY 2010 VL 37 IS 3 BP 165 EP 168 DI 10.1097/OLQ.0b013e3181bcd3fc PG 4 WC Infectious Diseases SC Infectious Diseases GA 565CC UT WOS:000275265600007 PM 20023598 ER PT J AU Pickett, G Seagrave, J Boggs, S Polzin, G Richter, P Tesfaigzi, Y AF Pickett, Gavin Seagrave, JeanClare Boggs, Susan Polzin, Gregory Richter, Patricia Tesfaigzi, Yohannes TI Effects of 10 Cigarette Smoke Condensates on Primary Human Airway Epithelial Cells by Comparative Gene and Cytokine Expression Studies SO TOXICOLOGICAL SCIENCES LA English DT Article DE cigarette smoke condensates; primary human lung epithelial cells; gene expression; toxicity; cytokine ID TOBACCO-SPECIFIC NITROSAMINES; BONE MORPHOGENETIC PROTEIN-9; HEME OXYGENASE-1 GENE; IN-VITRO EXPOSURE; INDUCED EMPHYSEMA; MAINSTREAM SMOKE; COMMERCIAL CIGARETTES; PULMONARY-EMPHYSEMA; A/J MICE; APOPTOSIS AB Cigarettes vary in tobacco blend, filter ventilation, additives, and other physical and chemical properties, but little is known regarding potential differences in toxicity to a smoker's airway epithelia. We compared changes in gene expression and cytokine production in primary normal human bronchial epithelial cells following treatment for 18 h with cigarette smoke condensates (CSCs) prepared from five commercial and four research cigarettes, at doses of similar to 4 mu g/ml nicotine. Nine of the CSCs were produced under a standard International Organization for Standardization smoking machine regimen and one was produced by a more intense smoking machine regimen. Isolated messenger RNA (mRNA) was analyzed by microarray hybridization, and media was analyzed for secreted cytokines and chemokines. Twenty-one genes were differentially expressed by at least 9 of the 10 CSCs by more than twofold, including genes encoding detoxifying and antioxidant proteins. Cytochrome P450, family 1, subfamily A, polypeptide 1 (CYP1A1) and NAD(P)H dehydrogenase, quinone 1 (NQO-1) were selected for validation with quantitative real-time PCR (qRT-PCR) and Western blot analyses. NQO-1 expression determined with microarrays, qRT-PCR, and Western blotting differed among the CSC types, with good correlation among the different assays. CYP1A1 mRNA levels varied substantially, but there was little correlation with the protein levels. For each CSC, the three most induced and three most repressed genes were identified. These genes may be useful as markers of exposure to that particular cigarette type. Furthermore, differences in interleukin-8 secretion were observed. These studies lay the foundation for future investigations to analyze differences in the responses of in vivo systems to tobacco products marketed with claims of reduced exposure or reduced harm. C1 [Seagrave, JeanClare; Tesfaigzi, Yohannes] Lovelace Resp Res Inst, COPD Program, Albuquerque, NM 87108 USA. [Pickett, Gavin] Univ New Mexico, Sch Med, Ctr Canc, Keck UNM Genom Resource Facil, Albuquerque, NM 87131 USA. [Boggs, Susan] Sandia Natl Labs, Albuquerque, NM 87185 USA. [Polzin, Gregory] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. [Richter, Patricia] Ctr Dis Control & Prevent, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Seagrave, J (reprint author), Lovelace Resp Res Inst, COPD Program, 2425 Ridgecrest Dr SE, Albuquerque, NM 87108 USA. EM jseagrav@lrri.org FU U.S. Centers for Disease Control and Prevention; Flight Attendant Medical Research Institute [CIA_062442, 042281_CIA] FX U.S. Centers for Disease Control and Prevention and the Flight Attendant Medical Research Institute (#CIA_062442 and 042281_CIA). NR 40 TC 23 Z9 23 U1 2 U2 4 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1096-6080 J9 TOXICOL SCI JI Toxicol. Sci. PD MAR PY 2010 VL 114 IS 1 BP 79 EP 89 DI 10.1093/toxsci/kfp298 PG 11 WC Toxicology SC Toxicology GA 555HN UT WOS:000274499800009 PM 20015843 ER PT J AU Marienau, KJ Burgess, GW Cramer, E Averhoff, FM Buff, AM Russell, M Kim, C Neatherlin, JC Lipman, H AF Marienau, Karen J. Burgess, Gregory W. Cramer, Elaine Averhoff, Francisco M. Buff, Ann M. Russell, Michelle Kim, Curi Neatherlin, John C. Lipman, Harvey TI Tuberculosis investigations associated with air travel: U. S. Centers for Disease Control and Prevention, January 2007-June 2008 SO TRAVEL MEDICINE AND INFECTIOUS DISEASE LA English DT Article DE TB; Aircraft; Contact tracing; Disease transmission; Transmission risk ID MYCOBACTERIUM-TUBERCULOSIS; UNITED-STATES; TRANSMISSION; EXPOSURE; FLIGHTS; HEALTH AB Introduction: Contact investigations conducted in the United States of persons with tuberculosis (TB) who traveled by air while infectious have increased. However, data about transmission risks of Mycobacterium tuberculosis on aircraft are limited. Methods: We analyzed data on index TB cases and passenger contacts from contact investigations initiated by the U.S. Centers for Disease Control and Prevention from January 2007 through June 2008. Results: Contact investigations for 131 index cases met study inclusion criteria, including 4550 passenger contacts. U.S. health departments reported TB screening test results for 758 (22%) of assigned contacts; 182 (24%) had positive results. Of the 142 passenger contacts with positive TB test results with information about risk factors for prior TB infection, 130 (92%) had at least one risk factor and 12(8%) had no risk factors. Positive TB test results were significantly associated with risk factors for prior TB infection (OR 23; p<0.001). No cases of TB disease among passenger contacts were reported. Conclusion: The risks of M. tuberculosis transmission during air travel remain difficult to quantify. Definitive assessment of transmission risks during flights and determination of the effectiveness of contact-tracing efforts will require comprehensive cohort studies. Published by Elsevier Ltd. C1 [Marienau, Karen J.] Ctr Dis Control & Prevent, Natl Ctr Preparedness Detect & Control Infect Dis, Div Global Migrat & Quarantine, CDC Minneapolis Quarantine Stn,Quarantine & Borde, Minneapolis, MN 55450 USA. [Cramer, Elaine] SRA Int Inc, Global Hlth Sector, Atlanta, GA USA. [Buff, Ann M.] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div TB Eliminat, Atlanta, GA USA. RP Marienau, KJ (reprint author), Ctr Dis Control & Prevent, Natl Ctr Preparedness Detect & Control Infect Dis, Div Global Migrat & Quarantine, CDC Minneapolis Quarantine Stn,Quarantine & Borde, Ste 2168,7150 Humphrey Dr, Minneapolis, MN 55450 USA. EM kqm5@cdc.gov NR 25 TC 13 Z9 15 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1477-8939 J9 TRAVEL MED INFECT DI JI Travel Med. Infect. Dis. PD MAR PY 2010 VL 8 IS 2 SI SI BP 104 EP 112 DI 10.1016/j.tmaid.2010.02.003 PG 9 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 767WY UT WOS:000290890700009 PM 20478518 ER PT J AU Kornylo-Duong, K Kim, C Cramer, EH Buff, AM Rodriguez-Howell, D Doyle, J Higashi, J Fruthaler, CS Robertson, CL Marienau, KJ AF Kornylo-Duong, Krista Kim, Curi Cramer, Elaine H. Buff, Ann M. Rodriguez-Howell, Daniel Doyle, June Higashi, Julie Fruthaler, Carolyn S. Robertson, Carrie L. Marienau, Karen J. TI Three air travel-related contact investigations associated with infectious tuberculosis, 2007-2008 SO TRAVEL MEDICINE AND INFECTIOUS DISEASE LA English DT Article DE Multidrug-resistant TB; Contact tracing; Airplane; Disease transmission; WHO guidelines ID MULTIDRUG-RESISTANT TUBERCULOSIS; TRANSMISSION; FLIGHTS; CHILD AB Background: The potential for transmission of Mycobacterium tuberculosis during air travel has garnered considerable attention in the media and among public health authorities due to high-profile cases of international travelers with infectious tuberculosis (TB). Methods: During 2007 and 2008, state and local health officials were asked to locate and conduct diagnostic follow-up for airline passengers considered contacts of three travelers, two with multidrug-resistant (MDR) TB and one considered highly contagious, who undertook air travel while infectious with TB disease. Results: Public health departments in 21 states located and evaluated 79 (60%) of the 131 passenger contacts identified; 52 (40%) were lost to follow-up. Eight (10%) contacts had a history of TB disease or latent TB infection and were not retested. Sixteen (23%) of 71 contacts tested had positive TB test results suggesting latent TB infection, 15 of whom were from countries reporting estimated TB disease rates of greater than 200 cases/100,000 persons. Conclusions: Passenger contacts' positive test results may represent prior TB infection acquired in their countries of residence or may be a result of new TB infection resulting from exposure during air travel. Published by Elsevier Ltd. C1 [Kornylo-Duong, Krista] Ctr Dis Control & Prevent, Natl Ctr Preparedness Detect & Control Infect Dis, Div Global Migrat & Quarantine, CDC Angeles Quarantine Stn,Quarantine & Border Hl, Los Angeles, CA 90045 USA. [Buff, Ann M.] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div TB Eliminat, Atlanta, GA USA. [Doyle, June] Wisconsin Dept Hlth Serv, Bur Communicable Dis & Preparedness, Div Publ Hlth, Dept Hlth & Family Serv, Madison, WI USA. [Higashi, Julie] Santa Clara Publ Hlth Dept, TB Prevent & Control Program, San Jose, CA USA. [Fruthaler, Carolyn S.; Robertson, Carrie L.] Harris Cty Publ Hlth & Environm Serv, Div Dis Control & Clin Prevent, Dis Control & Med Epidemiol Sect, Houston, TX USA. RP Kornylo-Duong, K (reprint author), Ctr Dis Control & Prevent, Natl Ctr Preparedness Detect & Control Infect Dis, Div Global Migrat & Quarantine, CDC Angeles Quarantine Stn,Quarantine & Border Hl, 380 World Way,N-19, Los Angeles, CA 90045 USA. EM frl3@cdc.gov FU Applied Epidemiology Fellowship; Centers for Disease Control and Prevention (CDC) Cooperative Agreement [U60/CCU007277] FX This study was supported in part by the Applied Epidemiology Fellowship Program administered by the Council of State and Territorial Epidemiologists (CSTE) and funded by the Centers for Disease Control and Prevention (CDC) Cooperative Agreement U60/CCU007277. NR 26 TC 9 Z9 10 U1 1 U2 2 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1477-8939 J9 TRAVEL MED INFECT DI JI Travel Med. Infect. Dis. PD MAR PY 2010 VL 8 IS 2 SI SI BP 120 EP 128 DI 10.1016/j.tmaid.2009.08.001 PG 9 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 767WY UT WOS:000290890700011 PM 20478520 ER PT J AU Newton, PN Green, MD Fernandez, FM AF Newton, Paul N. Green, Michael D. Fernandez, Facundo M. TI Impact of poor-quality medicines in the 'developing' world SO TRENDS IN PHARMACOLOGICAL SCIENCES LA English DT Editorial Material ID DRUGS AB Since our ancestors began trading several millennia ago, counterfeit and substandard medicines have been a recurring problem, with history punctuated by crises in the supply of anti-microbials, such as fake cinchona bark in the 1600s and fake quinine in the 1800s. Unfortunately this problem persists, in particular afflicting unsuspecting patients in 'developing' countries. Poor-quality drugs are a vital (but neglected) public health problem. They contribute to a 'crevasse' between the enormous effort in therapeutic research and policy decisions and implementation of good-quality medicines. C1 [Newton, Paul N.] Mahosot Hosp, Microbiol Lab, Wellcome Trust Mahosot Hosp Oxford Trop Med Res C, Vientiane, Lao Pdr, Thailand. [Newton, Paul N.] Univ Oxford, Churchill Hosp, Ctr Clin Vaccinol & Trop Med, Oxford OX3 7LJ, England. [Green, Michael D.] Ctr Dis Control & Prevent, Div Parasit Dis, Atlanta, GA 30333 USA. [Fernandez, Facundo M.] Georgia Inst Technol, Sch Chem & Biochem, Atlanta, GA 30332 USA. RP Newton, PN (reprint author), Mahosot Hosp, Microbiol Lab, Wellcome Trust Mahosot Hosp Oxford Trop Med Res C, Vientiane, Lao Pdr, Thailand. EM paul@tropmedres.ac RI Fernandez, Facundo/B-7015-2008 FU Wellcome Trust of Great Britain; Bill and Melinda Gates Foundation through the ACT Consortium; US National Science Foundation FX PNN is supported by the Wellcome Trust of Great Britain. PNN, MDG and FMF thank the Bill and Melinda Gates Foundation through the ACT Consortium, and the US National Science Foundation for support. The authors thank many people for their help and for discussions, particularly NR 15 TC 56 Z9 57 U1 2 U2 24 PU ELSEVIER SCIENCE LONDON PI LONDON PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND SN 0165-6147 J9 TRENDS PHARMACOL SCI JI Trends Pharmacol. Sci. PD MAR PY 2010 VL 31 IS 3 BP 99 EP 101 DI 10.1016/j.tips.2009.11.005 PG 3 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 576IA UT WOS:000276136500001 PM 20117849 ER PT J AU Turmelle, AS Allen, LC Jackson, FR Kunz, TH Rupprecht, CE McCracken, GF AF Turmelle, Amy S. Allen, Louise C. Jackson, Felix R. Kunz, Thomas H. Rupprecht, Charles E. McCracken, Gary F. TI Ecology of Rabies Virus Exposure in Colonies of Brazilian Free-Tailed Bats (Tadarida brasiliensis) at Natural and Man-Made Roosts in Texas SO VECTOR-BORNE AND ZOONOTIC DISEASES LA English DT Article DE Brazilian free-tailed bat; Epizootiology; Rabies virus; Roost ecology ID SOUTHWESTERN UNITED-STATES; EPTESICUS-FUSCUS; ORAL VACCINATION; IMMUNE-RESPONSE; MYOTIS-MYOTIS; NEW-MEXICO; INFECTION; SEASONALITY; PREVALENCE; DYNAMICS AB Previous studies have investigated rabies virus (RABV) epizootiology in Brazilian free-tailed bats (Tadarida brasiliensis) in natural cave roosts. However, little is known about geographic variation in RABV exposure, or if the use of man-made roosts by this species affects enzootic RABV infection dynamics within colonies. We sampled rabies viral neutralizing antibodies in bats at three bridge and three cave roosts at multiple time points during the reproductive season to investigate temporal and roost variation in RABV exposure. We report seropositive bats in all age and sex classes with minimal geographic variation in RABV seroprevalence among Brazilian free-tailed bat colonies in south-central Texas. While roost type was not a significant predictor of RABV seroprevalence, it was significantly associated with seasonal fluctuations, suggesting patterns of exposure that differ between roosts. Temporal patterns suggest increased RABV seroprevalence after parturition in cave colonies, potentially related to an influx of susceptible young, in contrast to more uniform seroprevalence in bridge colonies. This study highlights the importance of life history and roost ecology in understanding patterns of RABV seroprevalence in colonies of the Brazilian free-tailed bat. C1 [Turmelle, Amy S.; McCracken, Gary F.] Univ Tennessee, Dept Ecol & Evolutionary Biol, Knoxville, TN 37996 USA. [Turmelle, Amy S.; Jackson, Felix R.; Rupprecht, Charles E.] Ctr Dis Control & Prevent, Div Viral & Rickettsial Dis, Atlanta, GA USA. [Allen, Louise C.; Kunz, Thomas H.] Boston Univ, Ctr Ecol & Conservat Biol, Boston, MA 02215 USA. RP Turmelle, AS (reprint author), Univ Tennessee, Dept Ecol & Evolutionary Biol, 569 Dabney Hall, Knoxville, TN 37996 USA. EM turmelle@utk.edu OI McCracken, Gary/0000-0002-2493-8103 FU National Science Foundation-National Institutes of Health Ecology [0430418]; U.S. Environmental Protection Agency; American Museum of Natural History; American Society of Mammalogists; Department of Ecology and Evolutionary Biology at the University of Tennessee FX Funding for this research included support from the National Science Foundation-National Institutes of Health Ecology of Infectious Disease Program (# 0430418 to G. F. M.). A. S. T. received support from a Science-To-Achieve-Results Fellowship from the U.S. Environmental Protection Agency. The research was also supported by a Theodore Roosevelt Memorial Fund Grant from the American Museum of Natural History, a Grant-in-Aid of Research from the American Society of Mammalogists, and a Summer Research Grant from the Department of Ecology and Evolutionary Biology at the University of Tennessee, to A. S. T. We express our thanks to members of the Rabies Program at the CDC (Centers for Disease Control) for invaluable advice and assistance, especially P. Yager, M. Niezgoda, and L. Orciari. We thank also S. Duncan, N. Hristov, J. Reichard, L. Borrelli, A. Frank, W. Reimer, and C. Schmaeman for their technical assistance in the field. We thank I. Marbach, D. Davis, and B. Cofer for allowing access to their property. Special thanks to P. Morton and M. Goodman (Texas Parks and Wildlife), M. Bloschock (Texas Department of Transportation), B. Walker (Hill Country Adventure Tours), and B. French (Bat Conservation International) for logistic and technical support in the field. Lastly, we thank A. Reed at the University of Tennessee for statistical advice and assistance. NR 65 TC 22 Z9 23 U1 2 U2 14 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-3667 J9 VECTOR-BORNE ZOONOT JI Vector-Borne Zoonotic Dis. PD MAR PY 2010 VL 10 IS 2 BP 165 EP 175 DI 10.1089/vbz.2008.0163 PG 11 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 575PS UT WOS:000276080100009 PM 19492942 ER PT J AU Whichard, JM Weigt, LA Borris, DJ Li, LL Zhang, Q Kapur, V Pierson, FW Lingohr, EJ She, YM Kropinski, AM Sriranganathan, N AF Whichard, Jean M. Weigt, Lee A. Borris, Douglas J. Li, Ling Ling Zhang, Qing Kapur, Vivek Pierson, F. William Lingohr, Erika J. She, Yi-Min Kropinski, Andrew M. Sriranganathan, Nammalwar TI Complete Genomic Sequence of Bacteriophage Felix O1 SO VIRUSES-BASEL LA English DT Article DE Salmonella; bacteriophage; Myoviridae; Felix O1; DNA sequence; bioinformatics ID ESCHERICHIA-COLI; RIBONUCLEOTIDE REDUCTASE; SMOOTH CHARACTER; T7 SUPERGROUP; 0-1 PHAGE; PHI-KMV; SALMONELLA; PROTEIN; IDENTIFICATION; MYOVIRIDAE AB Bacteriophage O1 is a Myoviridae A1 group member used historically for identifying Salmonella. Sequencing revealed a single, linear, 86,155-base-pair genome with 39% average G+C content, 131 open reading frames, and 22 tRNAs. Closest protein homologs occur in Erwinia amylovora phage phi Ea21-4 and Escherichia coli phage wV8. Proteomic analysis indentified structural proteins: Gp23, Gp36 (major tail protein), Gp49, Gp53, Gp54, Gp55, Gp57, Gp58 (major capsid protein), Gp59, Gp63, Gp64, Gp67, Gp68, Gp69, Gp73, Gp74 and Gp77 (tail fiber). Based on phage-host codon differences, 7 tRNAs could affect translation rate during infection. Introns, holin-lysin cassettes, bacterial toxin homologs and host RNA polymerase-modifying genes were absent. C1 [Sriranganathan, Nammalwar] Ctr Mol Med & Infect Dis, Blacksburg, VA 24061 USA. [Whichard, Jean M.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Weigt, Lee A.] Natl Museum Nat Hist, Smithsonian Natl Inst, MRC 534, Washington, DC 20560 USA. [Borris, Douglas J.] Abbot Point Care, Ottawa, ON K2H 8V4, Canada. [Li, Ling Ling] Penn State Univ, Dept Vet & Biomed Sci, Wartick Lab 204, University Pk, PA 16802 USA. [Zhang, Qing] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA. [Pierson, F. William] Virginia Polytech Inst & State Univ, VA MD Reg Coll Vet Med, Blacksburg, VA 24061 USA. [Lingohr, Erika J.; Kropinski, Andrew M.] Publ Hlth Agcy Canada, Lab Foodborne Zoonoses, Guelph, ON N1G 3W4, Canada. [She, Yi-Min] Hlth Canada, Biol Res Ctr, Ottawa, ON K1A 0K9, Canada. [Kropinski, Andrew M.] Univ Guelph, Dept Mol & Cellular Biol, Guelph, ON N1G 2W1, Canada. RP Sriranganathan, N (reprint author), Ctr Mol Med & Infect Dis, 1410 Prices Fork Rd, Blacksburg, VA 24061 USA. EM zyr3@cdc.gov; weigtl@si.edu; lul17@psu.edu; qing@fhcrc.org; vkapur@psu.edu; pierson@vt.edu; Erika_Lingohr@phac-aspc.gc.ca; yi-min.she@hc-sc.gc.ca; kropinsk@queensu.ca; nathans@vt.edu RI Kapur, Vivek/F-7610-2013; OI Kapur, Vivek/0000-0002-9648-0138; Kropinski, Andrew/0000-0002-6871-6799 FU Shady Brook Farms, Inc.; Wampler Foods, Inc.; Virginia-Maryland Regional College of Veterinary Medicine Food Safety Research Funding Unit; Natural Sciences and Engineering Research Council of Canada FX The authors wish to thank Dr. Hans-W. Ackermann of Universite Laval, Quebec for providing the Felix O1 bacteriophage and host strain for propagation. Dr. Dmitrij Frishman of the Munich Information Center for Protein Sequences helped with ORF analysis, and Dr. Dyanne Brewer (University of Guelph) carried out the preliminary mass spectral analyses. Funding for this research has been generously provided by Shady Brook Farms, Inc., Wampler Foods, Inc. and Virginia-Maryland Regional College of Veterinary Medicine Food Safety Research Funding Unit. A.K. is supported by a grant from the Natural Sciences and Engineering Research Council of Canada. NR 59 TC 25 Z9 27 U1 0 U2 4 PU MDPI AG PI BASEL PA POSTFACH, CH-4005 BASEL, SWITZERLAND SN 1999-4915 J9 VIRUSES-BASEL JI Viruses-Basel PD MAR PY 2010 VL 2 IS 3 BP 710 EP 730 DI 10.3390/v2030710 PG 21 WC Virology SC Virology GA 632HO UT WOS:000280413500002 PM 21994654 ER PT J AU Tulloch-Reid, MK Boyne, MS Smikle, MF Choo-Kang, EG Parkes, RH Wright-Pascoe, RA Barton, EN Wilks, RJ Williams, DE AF Tulloch-Reid, M. K. Boyne, M. S. Smikle, M. F. Choo-Kang, E. G. Parkes, R. H. Wright-Pascoe, R. A. Barton, E. N. Wilks, R. J. Williams, D. E. TI Clinical and Laboratory Features of Youth Onset Type 2 Diabetes in Jamaica SO WEST INDIAN MEDICAL JOURNAL LA English DT Article DE Adolescent; Caribbean; classification; diabetes mellitus; young adult ID CHILDREN; MELLITUS; ADOLESCENTS; PREVALENCE; SEARCH; POPULATION; AMERICAN; BURDEN; WHITE; UK AB Objectives: To assess the frequency of youth onset Type 2 diabetes mellitus (T2D) in Jamaica and the characteristics of youth with this form of diabetes. Methods: Patients from two major referral hospitals, diagnosed with diabetes before age 25 years and < 6 years prior to the study, were evaluated. Classification was based on the presence of GAD-65 and IA-2 diabetes autoantibodies (AB), fasting (FCP) and stimulated C-peptide (SCP) measurements, serum leptin and clinical phenotype as follows: (i) Type 1A diabetes - AB+, (ii) Type 1B diabetes - AB- and FCP < 230 pmol/l and/or SCP < 660pmol/l, (iii) Type 2 diabetes - AB- and FCP > 500pmol/L and or SCP >= 1160 pmol/l (iv) Untypeable diabetes - AB- and FCP 230-500 pmol/l and or SCP 660-1160 pmol/l and (v) Lipoatrophic diabetes - clinical phenotype and serum leptin. Results: Fifty-eight participants (21M, 37F, age 20 +/- 8 years, duration of diabetes 2.6 +/- 2 years) were enrolled in the study. Using the classification criteria, Type 1 diabetes was the most common form of diabetes: 18(31%) Type 1A, 18(31%) Type 1B. Overall 22% (13 patients) had T2D. Patients with T2D were more likely to be female, older at diagnosis, obese and have a higher blood pressure when compared to those with Type 1 diabetes. In logistic regression analysis, age of diabetes onset, gender, BMI, systolic and diastolic blood pressure were significantly associated with T2D. Obesity measured by BMI was the strongest predictor of T2D. Conclusions: While Type 1 diabetes was the predominant form of diabetes in this study, a significant proportion of Jamaicans with youth onset diabetes may have T2D. Obesity is the strongest clinical predictor of Type 2 diabetes in the young diabetic patient. C1 [Tulloch-Reid, M. K.] Univ W Indies, Epidemiol Res Unit, TMRI, Kingston 7, Jamaica. [Smikle, M. F.] Univ W Indies, Dept Microbiol, Mona, Jamaica. [Choo-Kang, E. G.] Univ W Indies, Dept Pathol, Kingston 7, Jamaica. [Parkes, R. H.] Kingston Publ Hosp, Dept Med, Kingston, Jamaica. [Wright-Pascoe, R. A.; Barton, E. N.] Univ W Indies, Dept Med, Kingston 7, Jamaica. [Williams, D. E.] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA. RP Tulloch-Reid, MK (reprint author), Univ W Indies, Epidemiol Res Unit, TMRI, Kingston 7, Jamaica. EM marshall.tullochreid@uwimona.edu.jm RI Tulloch-Reid, Marshall/E-4383-2012; Boyne, Michael/I-2242-2013 OI Boyne, Michael/0000-0002-5227-2492 FU Caribbean Health Research Council; University of the West Indies New Initiative Fund FX We wish to thank the participants, Margaret White, Donnahae Rhoden-Salmon, Stacey Chin and Dominique Turnquest for their contribution to this study. We also thank the SEARCH committee for making their protocol available. Funding for this project was provided by the Caribbean Health Research Council and The University of the West Indies New Initiative Fund. NR 32 TC 1 Z9 1 U1 0 U2 4 PU UNIV WEST INDIES FACULTY MEDICAL SCIENCES PI KINGSTON PA MONA CAMPUS, KINGSTON 7, JAMAICA SN 0043-3144 J9 W INDIAN MED J JI West Ind. Med. J. PD MAR PY 2010 VL 59 IS 2 BP 131 EP 138 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 680RM UT WOS:000284252100004 PM 21275116 ER PT J AU Schenker, N Raghunathan, TE Bondarenko, I AF Schenker, Nathaniel Raghunathan, Trivellore E. Bondarenko, Irina TI Improving on analyses of self-reported data in a large-scale health survey by using information from an examination-based survey SO STATISTICS IN MEDICINE LA English DT Article DE diabetes; hypertension; measurement error; missing data; multiple imputation; obesity; propensity score; two-phase sampling ID BODY-MASS INDEX; MULTIPLE-IMPUTATION; CARDIOVASCULAR-DISEASE; LOGISTIC-REGRESSION; MEASUREMENT-ERROR; PROPENSITY SCORE; RISK-FACTORS; VITAL-RATES; HYPERTENSION; SAMPLES AB Common data sources for assessing the health of a population of interest include large-scale surveys based on interviews that often pose questions requiring a self-report, such as, 'Has a doctor or other health professional ever told you that you have < health condition of interest >?' or 'What is your (height/weight)?' Answers to such questions might not always reflect the true prevalences of health conditions (for example, if a respondent misreports height/weight or does not have access to a doctor or other health professional). Such 'measurement error' in health data could affect inferences about measures of health and health disparities. Drawing on two surveys conducted by the National Center for Health Statistics, this paper describes an imputation-based strategy for using clinical information from an examination-based health survey to improve on analyses of self-reported data in a larger interview-based health survey. Models predicting clinical values from self-reported values and covariates are fitted to data from the National Health and Nutrition Examination Survey (NHANES), which asks self-report questions during an interview component and also obtains clinical measurements during a physical examination component. The fitted models are used to multiply impute clinical values for the National Health Interview Survey (NHIS), a larger survey that obtains data solely via interviews. Illustrations involving hypertension, diabetes, and obesity suggest that estimates of health measures based on the multiply imputed clinical values are different from those based on the NHIS self-reported data alone and have smaller estimated standard errors than those based solely on the NHANES clinical data. The paper discusses the relationship of the methods used in the study to two-phase/two-stage/valiclation sampling and estimation, along with limitations, practical considerations, and areas for future research. Published in 2009 by John Wiley & Sons, Ltd. C1 [Schenker, Nathaniel] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Raghunathan, Trivellore E.; Bondarenko, Irina] Univ Michigan, Sch Publ Hlth, Dept Biostat, Ann Arbor, MI 48109 USA. [Raghunathan, Trivellore E.] Univ Michigan, Inst Social Res, Ann Arbor, MI 48109 USA. RP Schenker, N (reprint author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, 3311 Toledo Rd,Room 3209, Hyattsville, MD 20782 USA. EM nschenker@cdc.gov NR 39 TC 24 Z9 24 U1 1 U2 13 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0277-6715 EI 1097-0258 J9 STAT MED JI Stat. Med. PD FEB 28 PY 2010 VL 29 IS 5 BP 533 EP 545 DI 10.1002/sim.3809 PG 13 WC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Medicine, Research & Experimental; Statistics & Probability SC Mathematical & Computational Biology; Public, Environmental & Occupational Health; Medical Informatics; Research & Experimental Medicine; Mathematics GA 569FZ UT WOS:000275583300002 PM 20029804 ER PT J AU Bayoh, MN Mathias, DK Odiere, MR Mutuku, FM Kamau, L Gimnig, JE Vulule, JM Hawley, WA Hamel, MJ Walker, ED AF Bayoh, M. Nabie Mathias, Derrick K. Odiere, Maurice R. Mutuku, Francis M. Kamau, Luna Gimnig, John E. Vulule, John M. Hawley, William A. Hamel, Mary J. Walker, Edward D. TI Anopheles gambiae: historical population decline associated with regional distribution of insecticide-treated bed nets in western Nyanza Province, Kenya SO MALARIA JOURNAL LA English DT Article ID PERENNIAL MALARIA TRANSMISSION; SPATIAL-DISTRIBUTION; OMS-43 FENITROTHION; YOUNG-CHILDREN; GILES COMPLEX; KISUMU AREA; SPECIES-A; CULICIDAE; DIPTERA; MOSQUITOS AB Background: High coverage of insecticide-treated bed nets in Asembo and low coverage in Seme, two adjacent communities in western Nyanza Province, Kenya; followed by expanded coverage of bed nets in Seme, as the Kenya national malaria programme rolled out; provided a natural experiment for quantification of changes in relative abundance of two primary malaria vectors in this holoendemic region. Both belong to the Anopheles gambiae sensu lato (s.l.) species complex, namely A. gambiae sensu stricto (s.s.) and Anopheles arabiensis. Historically, the former species was proportionately dominant in indoor resting collections of females. Methods: Data of the relative abundance of adult A. gambiae s.s. and A. arabiensis sampled from inside houses were obtained from the literature from 1970 to 2002 for sites west of Kisumu, Kenya, to the region of Asembo ca. 50 km from the city. A sampling transect was established from Asembo (where bed net use was high due to presence of a managed bed net distribution programme) eastward to Seme, where no bed net programme was in place. Adults of A. gambiae s.l. were sampled from inside houses along the transect from 2003 to 2009, as were larvae from nearby aquatic habitats, providing data over a nearly 40 year period of the relative abundance of the two species. Relative proportions of A. gambiae s.s. and A. arabiensis were determined for each stage by identifying species by the polymerase chain reaction method. Household bed net ownership was measured with surveys during mosquito collections. Data of blood host choice, parity rate, and infection rate for Plasmodium falciparum in A. gambiae s.s. and A. arabiensis were obtained for a sample from Asembo and Seme from 2005. Results: Anopheles gambiae s.s. adult females from indoor collections predominated from 1970 to 1998 (ca. 85%). Beginning in 1999, A. gambiae s.s decreased proportionately relative to A. arabiensis, then precipitously declined to rarity coincident with increased bed net ownership as national bed net distribution programmes commenced in 2004 and 2006. By 2009, A. gambiae s.s. comprised proportionately ca. 1% of indoor collections and A. arabiensis 99%. In Seme compared to Asembo in 2003, proportionately more larvae were A. gambiae s.s., larval density was higher, and more larval habitats were occupied. As bed net use rose in Seme, the proportion of A. gambiae larvae declined as well. These trends continued to 2009. Parity and malaria infection rates were lower in both species in Asembo (high bed net use) compared to Seme (low bed net use), but host choice did not vary within species in both communities (predominantly cattle for A. arabiensis, humans for A. gambiae s.s.). Conclusions: A marked decline of the A. gambiae s.s. population occurred as household ownership of bed nets rose in a region of western Kenya over a 10 year period. The increased bed net coverage likely caused a mass effect on the composition of the A. gambiae s.l. species complex, resulting in the observed proportionate increase in A. arabiensis compared to its closely related sibling species, A. gambiae s.s. These observations are important in evaluating the process of regional malaria elimination, which requires sustained vector control as a primary intervention. C1 [Mathias, Derrick K.; Walker, Edward D.] Michigan State Univ, Dept Microbiol & Mol Genet, E Lansing, MI 48824 USA. [Bayoh, M. Nabie; Mathias, Derrick K.; Odiere, Maurice R.; Mutuku, Francis M.; Vulule, John M.] Kenya Govt Med Res Ctr, Ctr Global Hlth Res, Kisumu, Kenya. [Bayoh, M. Nabie; Mathias, Derrick K.; Odiere, Maurice R.; Mutuku, Francis M.; Hamel, Mary J.] Ctr Dis Control & Prevent, Kisumu, Kenya. [Kamau, Luna] Kenya Govt Med Res Ctr, Ctr Biotechnol Res & Dev, Nairobi, Kenya. [Gimnig, John E.; Hawley, William A.; Hamel, Mary J.] Ctr Dis Control & Prevent, Div Parasit Dis, Atlanta, GA 30341 USA. RP Walker, ED (reprint author), Michigan State Univ, Dept Microbiol & Mol Genet, E Lansing, MI 48824 USA. EM walker@msu.edu FU NIAID NIH HHS [AI05842, AI50703] NR 48 TC 122 Z9 122 U1 2 U2 19 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1475-2875 J9 MALARIA J JI Malar. J. PD FEB 26 PY 2010 VL 9 AR 62 DI 10.1186/1475-2875-9-62 PG 12 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA 571EI UT WOS:000275733900001 PM 20187956 ER PT J AU Bansal, S Pourbohloul, B Hupert, N Grenfell, B Meyers, LA AF Bansal, Shweta Pourbohloul, Babak Hupert, Nathaniel Grenfell, Bryan Meyers, Lauren Ancel TI The Shifting Demographic Landscape of Pandemic Influenza SO PLOS ONE LA English DT Article ID HONG-KONG INFLUENZA; TRANSMISSION PARAMETERS; INFECTIOUS AGENTS; ASIAN INFLUENZA; EPIDEMIC; VIRUS; MORTALITY; SPREAD; IMMUNITY; VACCINE AB Background: As Pandemic (H1N1) 2009 influenza spreads around the globe, it strikes school-age children more often than adults. Although there is some evidence of pre-existing immunity among older adults, this alone may not explain the significant gap in age-specific infection rates. Methods and Findings: Based on a retrospective analysis of pandemic strains of influenza from the last century, we show that school-age children typically experience the highest attack rates in primarily naive populations, with the burden shifting to adults during the subsequent season. Using a parsimonious network-based mathematical model which incorporates the changing distribution of contacts in the susceptible population, we demonstrate that new pandemic strains of influenza are expected to shift the epidemiological landscape in exactly this way. Conclusions: Our analysis provides a simple demographic explanation for the age bias observed for H1N1/09 attack rates, and suggests that this bias may shift in coming months. These results have significant implications for the allocation of public health resources for H1N1/09 and future influenza pandemics. C1 [Bansal, Shweta] Penn State Univ, Ctr Infect Dis Dynam, University Pk, PA 16802 USA. [Bansal, Shweta; Grenfell, Bryan] NIH, Fogarty Int Ctr, Bethesda, MD 20892 USA. [Pourbohloul, Babak] British Columbia Ctr Dis Control, Div Math Modeling, Vancouver, BC, Canada. [Pourbohloul, Babak] Univ British Columbia, Fac Med, Sch Populat & Publ Hlth, Vancouver, BC, Canada. [Hupert, Nathaniel] Weill Cornell Med Coll, Dept Publ Hlth, New York, NY USA. [Hupert, Nathaniel] US Ctr Dis Control & Prevent, Preparedness Modeling Unit, Atlanta, GA USA. [Grenfell, Bryan] Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA. [Meyers, Lauren Ancel] Univ Texas Austin, Sect Integrat Biol, Austin, TX 78712 USA. [Meyers, Lauren Ancel] Santa Fe Inst, Santa Fe, NM 87501 USA. RP Bansal, S (reprint author), Penn State Univ, Ctr Infect Dis Dynam, University Pk, PA 16802 USA. EM shweta@sbansal.com OI Bansal, Shweta/0000-0002-1740-5421 FU Research and Policy for Infectious Disease Dynamics (RAPIDD) program of the Science and Technology Directorate; Department of Homeland Security; Fogarty International Center; National Institutes of Health (NIH); James F. McDonnell Foundation; National Science Foundation [DEB-0749097]; NIH Models of Infectious Disease Agent Study (MIDAS) [U01-GM087719-01]; Canadian Institutes of Health Research [PTL97125, PAP93425]; Michael Smith Foundation for Health Research FX This work was supported by the Research and Policy for Infectious Disease Dynamics (RAPIDD) program of the Science and Technology Directorate, Department of Homeland Security, and the Fogarty International Center, National Institutes of Health (NIH); grants from the James F. McDonnell Foundation, National Science Foundation (DEB-0749097), and NIH Models of Infectious Disease Agent Study (MIDAS) (U01-GM087719-01) to L. A. M.; and support from the Canadian Institutes of Health Research (PTL97125 and PAP93425) and the Michael Smith Foundation for Health Research to B. P. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 75 TC 37 Z9 38 U1 0 U2 7 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD FEB 26 PY 2010 VL 5 IS 2 AR e9360 DI 10.1371/journal.pone.0009360 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 561RS UT WOS:000274997000004 PM 20195468 ER PT J AU Cain, KP McCarthy, KD Heilig, CM Monkongdee, P Tasaneeyapan, T Kanara, N Kimerling, ME Chheng, P Thai, S Sar, B Phanuphak, P Teeratakulpisarn, N Phanuphak, N Nguyen, HD Hoang, TQ Le, HT Varma, JK AF Cain, Kevin P. McCarthy, Kimberly D. Heilig, Charles M. Monkongdee, Patama Tasaneeyapan, Theerawit Kanara, Nong Kimerling, Michael E. Chheng, Phalkun Thai, Sopheak Sar, Borann Phanuphak, Praphan Teeratakulpisarn, Nipat Phanuphak, Nittaya Nguyen Huy Dung Hoang Thi Quy Le Hung Thai Varma, Jay K. TI An Algorithm for Tuberculosis Screening and Diagnosis in People with HIV SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID RECONSTITUTION INFLAMMATORY SYNDROME; ISONIAZID PREVENTIVE THERAPY; IMMUNE RECONSTITUTION; ANTIRETROVIRAL THERAPY; INFECTED PERSONS; RISK-FACTORS; PULMONARY TUBERCULOSIS; SPUTUM SMEARS; PREVALENCE; SETTINGS AB BACKGROUND Tuberculosis screening is recommended for people with human immunodeficiency virus (HIV) infection to facilitate early diagnosis and safe initiation of antiretroviral therapy and isoniazid preventive therapy. No internationally accepted, evidence-based guideline addresses the optimal means of conducting such screening, although screening for chronic cough is common. METHODS We consecutively enrolled people with HIV infection from eight outpatient clinics in Cambodia, Thailand, and Vietnam. For each patient, three samples of sputum and one each of urine, stool, blood, and lymph-node aspirate (for patients with lymphadenopathy) were obtained for mycobacterial culture. We compared the characteristics of patients who received a diagnosis of tuberculosis (on the basis of having one or more specimens that were culture-positive) with those of patients who did not have tuberculosis to derive an algorithm for screening and diagnosis. RESULTS Tuberculosis was diagnosed in 267 (15%) of 1748 patients (median CD4+ T-lymphocyte count, 242 per cubic millimeter; interquartile range, 82 to 396). The presence of a cough for 2 or 3 weeks or more during the preceding 4 weeks had a sensitivity of 22 to 33% for detecting tuberculosis. The presence of cough of any duration, fever of any duration, or night sweats lasting 3 or more weeks in the preceding 4 weeks was 93% sensitive and 36% specific for tuberculosis. In the 1199 patients with any of these symptoms, a combination of two negative sputum smears, a normal chest radiograph, and a CD4+ cell count of 350 or more per cubic millimeter helped to rule out a diagnosis of tuberculosis, whereas a positive diagnosis could be made only for the 113 patients (9%) with one or more positive sputum smears; mycobacterial culture was required for most other patients. CONCLUSIONS In persons with HIV infection, screening for tuberculosis should include asking questions about a combination of symptoms rather than only about chronic cough. It is likely that antiretroviral therapy and isoniazid preventive therapy can be started safely in people whose screening for all three symptoms is negative, whereas diagnosis in most others will require mycobacterial culture. C1 [Cain, Kevin P.; McCarthy, Kimberly D.; Heilig, Charles M.; Varma, Jay K.] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA. [Monkongdee, Patama; Tasaneeyapan, Theerawit; Varma, Jay K.] Thailand Minist Publ Hlth CDC Collaborat, Nonthaburi, Thailand. [Phanuphak, Praphan; Teeratakulpisarn, Nipat; Phanuphak, Nittaya] Thai Red Cross AIDS Res Ctr, Bangkok, Thailand. [Kanara, Nong] US CDC, Global AIDS Program, Phnom Penh, Cambodia. [Thai, Sopheak] Sihanouk Hosp Ctr Hope, Phnom Penh, Cambodia. [Sar, Borann] Inst Pasteur Cambodia, Phnom Penh, Cambodia. [Kimerling, Michael E.; Chheng, Phalkun] Univ Alabama Birmingham, Birmingham, AL USA. [Nguyen Huy Dung; Hoang Thi Quy] Pham Ngoc Thach Hosp TB & Lung Dis, Ho Chi Minh City, Vietnam. [Le Hung Thai] US CDC, Global AIDS Program, Ho Chi Minh City, Vietnam. [Kimerling, Michael E.] Bill & Melinda Gates Fdn, Seattle, WA USA. RP Cain, KP (reprint author), CDC, 1600 Clifton Rd,MS-E-10, Atlanta, GA 30333 USA. EM kcain@cdc.gov RI Heilig, Charles/C-2753-2008 OI Heilig, Charles/0000-0003-1075-1310 FU U.S. Agency for International Development FX Supported by a grant from the U.S. Agency for International Development. NR 29 TC 132 Z9 135 U1 1 U2 9 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD FEB 25 PY 2010 VL 362 IS 8 BP 707 EP 716 DI 10.1056/NEJMoa0907488 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA 559SA UT WOS:000274845600009 PM 20181972 ER PT J AU Ramowski, SK Nystrom, RJ Chaumeton, NR Rosenberg, KD Gilchrist, J AF Ramowski, S. K. Nystrom, R. J. Chaumeton, N. R. Rosenberg, K. D. Gilchrist, J. TI "Choking Game" Awareness and Participation Among 8th Graders-Oregon, 2008 (Reprinted from MMWR, vol 59, pg 1-5, 2010) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Gilchrist, J.] CDC, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD FEB 24 PY 2010 VL 303 IS 8 BP 723 EP 725 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 559DD UT WOS:000274800000009 ER PT J AU Shepard, CW Gallagher, K Bodach, SD Kowalski, A Terzian, AS Begier, E Weisfuse, I Blank, S Branson, BM AF Shepard, C. W. Gallagher, K. Bodach, S. D. Kowalski, A. Terzian, A. S. Begier, E. Weisfuse, I. Blank, S. Branson, B. M. TI Acute HIV Infection-New York City, 2008 (Reprinted from MMWR, vol 58, pg 1296-1299, 2009) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint ID NORTH-CAROLINA; TRANSMISSION C1 [Shepard, C. W.; Gallagher, K.; Bodach, S. D.; Kowalski, A.; Terzian, A. S.; Begier, E.; Weisfuse, I.] New York City Dept Hlth & Mental Hyg, New York, NY USA. [Blank, S.] CDC, Div Sexually Transmitted Dis Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Branson, B. M.] CDC, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP Shepard, CW (reprint author), New York City Dept Hlth & Mental Hyg, New York, NY USA. NR 11 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD FEB 24 PY 2010 VL 303 IS 8 BP 725 EP 727 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 559DD UT WOS:000274800000010 ER PT J AU Trivers, KF Messer, LC Kaufman, JS AF Trivers, Katrina F. Messer, Lynne C. Kaufman, Jay S. TI Re: Racial Disparities in Cancer Survival Among Randomized Clinical Trials of the Southwest Oncology Group SO JOURNAL OF THE NATIONAL CANCER INSTITUTE LA English DT Letter ID BREAST-CANCER; EPIDEMIOLOGY; VARIABLES C1 [Trivers, Katrina F.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Messer, Lynne C.] Duke Global Hlth Inst, Ctr Hlth Policy, Hlth Inequal Program, Durham, NC USA. [Kaufman, Jay S.] McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ H3A 2T5, Canada. RP Trivers, KF (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway,NE MS K-55, Atlanta, GA 30341 USA. EM ktrivers@cdc.gov OI Kaufman, Jay/0000-0003-1606-401X FU NICHD NIH HHS [R24 HD050924] NR 6 TC 3 Z9 3 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0027-8874 J9 J NATL CANCER I JI J. Natl. Cancer Inst. PD FEB 24 PY 2010 VL 102 IS 4 BP 278 EP 279 DI 10.1093/jnci/djp508 PG 2 WC Oncology SC Oncology GA 561NM UT WOS:000274984500017 PM 20075364 ER PT J AU Jima, D Getachew, A Bilak, H Steketee, RW Emerson, PM Graves, PM Gebre, T Reithinger, R Hwang, J AF Jima, Daddi Getachew, Asefaw Bilak, Hana Steketee, Richard W. Emerson, Paul M. Graves, Patricia M. Gebre, Teshome Reithinger, Richard Hwang, Jimee CA Ethiopia Malaria Indicator Survey TI Malaria indicator survey 2007, Ethiopia: coverage and use of major malaria prevention and control interventions SO MALARIA JOURNAL LA English DT Article ID RISK-FACTORS; HOUSEHOLD; OROMIA; AMHARA; CHILDREN; REGIONS; NETS AB Background: In 2005, a nationwide survey estimated that 6.5% of households in Ethiopia owned an insecticide-treated net (ITN), 17% of households had been sprayed with insecticide, and 4% of children under five years of age with a fever were taking an anti-malarial drug. Similar to other sub-Saharan African countries scaling-up malaria interventions, the Government of Ethiopia set an ambitious national goal in 2005 to (i) provide 100% ITN coverage in malarious areas, with a mean of two ITNs per household; (ii) to scale-up indoor residual spraying of households with insecticide (IRS) to cover 30% of households targeted for IRS; and (iii) scale-up the provision of case management with rapid diagnostic tests (RDTs) and artemisinin-based combination therapy (ACT), particularly at the peripheral level. Methods: A nationally representative malaria indicator survey (MIS) was conducted in Ethiopia between September and December 2007 to determine parasite and anaemia prevalence in the population at risk and to assess coverage, use and access to scaled-up malaria prevention and control interventions. The survey used a two-stage random cluster sample of 7,621 households in 319 census enumeration areas. A total of 32,380 people participated in the survey. Data was collected using standardized Roll Back Malaria Monitoring and Evaluation Reference Group MIS household and women's questionnaires, which were adapted to the local context. Results: Data presented is for households in malarious areas, which according to the Ethiopian Federal Ministry of Health are defined as being located <2,000 m altitude. Of 5,083 surveyed households, 3,282 (65.6%) owned at least one ITN. In ITN-owning households, 53.2% of all persons had slept under an ITN the prior night, including 1,564/2,496 (60.1%) children <5 years of age, 1,891/3,009 (60.9%) of women 15 - 49 years of age, and 166/266 (65.7%) of pregnant women. Overall, 906 (20.0%) households reported to have had IRS in the past 12 months. Of 747 children with reported fever in the two weeks preceding the survey, 131 (16.3%) sought medical attention within 24 hours. Of those with fever, 86 (11.9%) took an anti-malarial drug and 41 (4.7%) took it within 24 hours of fever onset. Among 7,167 surveyed individuals of all ages, parasitaemia as estimated by microscopy was 1.0% (95% CI 0.5 - 1.5), with 0.7% and 0.3% due to Plasmodium falciparum and Plasmodium vivax, respectively. Moderate-severe anaemia (haemoglobin <8 g/dl) was observed in 239/3,366 (6.6%, 95% CI 4.9-8.3) children <5 years of age. Conclusions: Since mid-2005, the Ethiopian National Malaria Control Programme has considerably scaled-up its malaria prevention and control interventions, demonstrating the impact of strong political will and a committed partnership. The MIS showed, however, that besides sustaining and expanding malaria intervention coverage, efforts will have to be made to increase intervention access and use. With ongoing efforts to sustain and expand malaria intervention coverage, to increase intervention access and use, and with strong involvement of the community, Ethiopia expects to achieve its targets in terms of coverage and uptake of interventions in the coming years and move towards eliminating malaria. C1 [Reithinger, Richard] US Agcy Int Dev, Addis Ababa, Ethiopia. [Jima, Daddi] Fed Minist Hlth, Dis Prevent & Control Dept, Addis Ababa, Ethiopia. [Getachew, Asefaw] PATH, Addis Ababa, Ethiopia. [Bilak, Hana; Steketee, Richard W.] PATH, Ferney Voltaire, France. [Emerson, Paul M.; Graves, Patricia M.] Emory Univ, Carter Ctr, Atlanta, GA 30322 USA. [Gebre, Teshome] Carter Ctr, Addis Ababa, Ethiopia. [Hwang, Jimee] Ctr Dis Control & Prevent, Atlanta, GA USA. [Hwang, Jimee] UCSF Global Hlth Sci, Global Hlth Grp, San Francisco, CA USA. RP Reithinger, R (reprint author), US Agcy Int Dev, Addis Ababa, Ethiopia. EM rreithinger@yahoo.co.uk RI Graves, Patricia/J-8691-2014 OI Graves, Patricia/0000-0002-5215-3901 FU World Health Organization; United Nations International Children Emergency Fund; U.S. Agency for International Development; U.S. Centers for Disease Control and Prevention; Central Statistical Agency; Center for National Health Development in Ethiopia; Malaria Consortium; President's Emergency Plan for AIDS Relief [663-A-00-07-00418] FX The Malaria Indicator Survey was the result of joint efforts by multiple partners, including the Federal Ministry of Health of Ethiopia, The Carter Center, Malaria Control and Evaluation Partnership for Africa ( a programme at PATH), World Health Organization, United Nations International Children Emergency Fund, U.S. Agency for International Development, U.S. Centers for Disease Control and Prevention, the Central Statistical Agency, Center for National Health Development in Ethiopia, and Malaria Consortium. We thank Carlos C. ( Kent) Campbell for his comments on the manuscript and thank Behar Hussein, International Rescue Committee, for Figures 1, 2, 3, 4, which were generated under the U.S. Agency for International Development/Ethiopia's Geospatial Analysis for Public Health Programmes Cooperative Agreement (663-A-00-07-00418) funded by the President's Emergency Plan for AIDS Relief. NR 32 TC 66 Z9 66 U1 0 U2 6 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1475-2875 J9 MALARIA J JI Malar. J. PD FEB 24 PY 2010 VL 9 AR 58 DI 10.1186/1475-2875-9-58 PG 12 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA 571EE UT WOS:000275733500001 PM 20178654 ER PT J AU Jang, S Wheeler, L Carey, RB Jensen, B Crandall, CM Schrader, KN Jessup, D Colegrove, K Gulland, FMD AF Jang, Spencer Wheeler, Liz Carey, Roberta B. Jensen, Bette Crandall, Claudia M. Schrader, Kimmi N. Jessup, David Colegrove, Kathleen Gulland, Frances M. D. TI Pleuritis and suppurative pneumonia associated with a hypermucoviscosity phenotype of Klebsiella pneumoniae in California sea lions (Zalophus californianus) SO VETERINARY MICROBIOLOGY LA English DT Article DE Klebsiella pneumoniae; Hypermucoviscosity type; Pleuritis; Suppurative pneumonia; California sea lion ID PYOGENIC LIVER-ABSCESS; RMPA; MAGA; COMPLICATIONS; STRAINS; TAIWAN; ISLAND; GENES; COAST; K1 AB The aim of this study is to document the isolation of a hypermucoviscosity (HMV) phenotype of Klebsiella pneumoniae from 25 cases of suppurative pneumonia and pleuritis and two cases of abscesses in California sea lions (Zalophus californianus) from the central California coast, representing the first report of this zoonotic pathogen from the marine environment and only the second report in non-humans. Animals died 2 h to 4 days after first being observed sick on beaches. Clinical signs varied from dyspnoea to coma. Gross post-mortem examination of 25 cases revealed fibrinous pleuritis, copious pus in the pleural cavity and suppurative bronchopneumonia. K. pneumoniae isolates obtained from lung and pleural swabs and the hepatic and subcuticular abscesses were highly mucoid on blood agar culture media and were positive to the "string test". Twenty-one of the 27 isolates were examined by PCR and all were positive for rmpA and K2wyz and negative for K1magA genes. Although pneumonia and pleuritis have previously commonly been observed in marine mammals, their association with pure cultures of a zoonotic bacteria, K. pneumoniae HMV phenotype, has not. This report provides further evidence of the role marine mammals play as sentinels of health risks to humans from coastal waters. (C) 2009 Elsevier B.V. All rights reserved. C1 [Wheeler, Liz; Gulland, Frances M. D.] Marine Mammal Ctr, Sausalito, CA 94965 USA. [Jang, Spencer] William R Pritchard Vet Med Teaching Hosp, Sch Vet Med, Davis, CA 95616 USA. [Carey, Roberta B.; Jensen, Bette] CDC, Clin & Environm Microbiol Branch, Div Healthcare Qual Promot, Atlanta, GA 30333 USA. [Crandall, Claudia M.; Schrader, Kimmi N.] Calif Dept Publ Hlth, Ctr Infect Dis, Div Communicable Dis Control, Microbial Dis Lab, Richmond, CA 94804 USA. [Jessup, David] Marine Wildlife Vet Care & Res Ctr, Calif Dept Fish & Game, Santa Cruz, CA 95060 USA. [Colegrove, Kathleen] Univ Illinois LUMC, Zool Pathol Program, Maywood, IL 60153 USA. RP Gulland, FMD (reprint author), Marine Mammal Ctr, 2000 Bunker Rd, Sausalito, CA 94965 USA. EM gullandf@tmmc.org FU John H. Prescott Marine Mammal Rescue Assistance; National Marine Fisheries Service; NOAA; National Marine Fisheries Service's Northwest Fisheries Science Center FX This work was supported by the John H. Prescott Marine Mammal Rescue Assistance Grant Program, National Marine Fisheries Service, and the West Coast Center for Oceans and Human Health as part of the NOAA Oceans and Human Health Initiative: the WCCOHH is part of the National Marine Fisheries Service's Northwest Fisheries Science Center, Seattle, WA. We thank Denise Greig, Tenaya Norris and Carlos Rios and the staff and volunteers at The Marine Mammal Center for assistance with rescue, care and necropsy of the animals, JoAnn Yee at the VMTH for cultivation of specimens, and the Armed Forces Institute of Pathology for histological examination of tissues. NR 20 TC 9 Z9 9 U1 0 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0378-1135 J9 VET MICROBIOL JI Vet. Microbiol. PD FEB 24 PY 2010 VL 141 IS 1-2 BP 174 EP 177 DI 10.1016/j.vetmic.2009.07.032 PG 4 WC Microbiology; Veterinary Sciences SC Microbiology; Veterinary Sciences GA 569PO UT WOS:000275610200027 PM 19709820 ER PT J AU Xiang, NJ Shi, Y Wu, JB Zhang, SX Ye, M Peng, ZB Zhou, L Zhou, H Liao, QH Huai, Y Li, LL Yu, ZD Cheng, XW Su, WK Wu, XM Ma, HW Lu, JH McFarland, J Yu, HJ AF Xiang, Nijuan Shi, Ying Wu, Jiabing Zhang, Shunxiang Ye, Min Peng, Zhibin Zhou, Lei Zhou, Hang Liao, Qiaohong Huai, Yang Li, Leilei Yu, Zhangda Cheng, Xiaowen Su, Weike Wu, Xiaomin Ma, Hanwu Lu, Jianhua McFarland, Jeffrey Yu, Hongjie TI Knowledge, attitudes and practices (KAP) relating to avian influenza in urban and rural areas of China SO BMC INFECTIOUS DISEASES LA English DT Article ID H5N1 VIRUS-INFECTION; A H5N1; HONG-KONG; RISK-FACTORS; POULTRY; POPULATION; OUTBREAK; HUMANS AB Background: Studies have revealed that visiting poultry markets and direct contact with sick or dead poultry are significant risk factors for H5N1 infection, the practices of which could possibly be influenced by people's knowledge, attitudes and practices (KAPs) associated with avian influenza (AI). To determine the KAPs associated with AI among the Chinese general population, a cross-sectional survey was conducted in China. Methods: We used standardized, structured questionnaires distributed in both an urban area (Shenzhen, Guangdong Province; n = 1,826) and a rural area (Xiuning, Anhui Province; n = 2,572) using the probability proportional to size (PPS) sampling technique. Results: Approximately three-quarters of participants in both groups requested more information about AI. The preferred source of information for both groups was television. Almost three-quarters of all participants were aware of AI as an infectious disease; the urban group was more aware that it could be transmitted through poultry, that it could be prevented, and was more familiar with the relationship between AI and human infection. The villagers in Xiuning were more concerned than Shenzhen residents about human AI viral infection. Regarding preventative measures, a higher percentage of the urban group used soap for hand washing whereas the rural group preferred water only. Almost half of the participants in both groups had continued to eat poultry after being informed about the disease. Conclusions: Our study shows a high degree of awareness of human AI in both urban and rural populations, and could provide scientific support to assist the Chinese government in developing strategies and health-education campaigns to prevent AI infection among the general population. C1 [Xiang, Nijuan; Shi, Ying; Ye, Min; Peng, Zhibin; Zhou, Lei; Zhou, Hang; Liao, Qiaohong; Huai, Yang; Yu, Hongjie] Chinese Ctr Dis Control & Prevent, Off Dis Control & Emergency Response, Beijing, Peoples R China. [Shi, Ying] Chinese Ctr Dis Control & Prevent, Chinese Field Epidemiol Training Program, Beijing, Peoples R China. [Wu, Jiabing] Anhui Prov Ctr Dis Control & Prevent, Hefei, Peoples R China. [Zhang, Shunxiang; Cheng, Xiaowen; Wu, Xiaomin; Ma, Hanwu; Lu, Jianhua] Shenzhen Ctr Dis Control & Prevent, Shenzhen, Peoples R China. [Li, Leilei] Chongqing Med Univ, Chongqing, Peoples R China. [Yu, Zhangda] Huanshan Ctr Dis Control & Prevent, Huangshan, Peoples R China. [Su, Weike] Xiuning Ctr Dis Control & Prevent, Xiuning, Peoples R China. [McFarland, Jeffrey] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Yu, HJ (reprint author), Chinese Ctr Dis Control & Prevent, Off Dis Control & Emergency Response, Beijing, Peoples R China. EM yuhj@chinacdc.cn FU Ministry of Science and Technology of the People's Republic of China [2004BA519A17, 2004BA519A71, 2006BAD06A02] FX We thank the Health Bureaus of Shenzhen, Huang Shan and Xiuning for their assistance in coordinating the field investigations and provision of logistical support. This study was supported by grants from the China-U. S. Collaborative Program on Emerging and Re-emerging Infectious Diseases, and from the Ministry of Science and Technology of the People's Republic of China (2004BA519A17, 2004BA519A71 and 2006BAD06A02). The views expressed in this study are those of the authors and do not represent the policy of the Chinese Center for Disease Control and Prevention. NR 15 TC 18 Z9 23 U1 1 U2 9 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2334 J9 BMC INFECT DIS JI BMC Infect. Dis. PD FEB 21 PY 2010 VL 10 AR 34 DI 10.1186/1471-2334-10-34 PG 7 WC Infectious Diseases SC Infectious Diseases GA 569SW UT WOS:000275622500001 PM 20170542 ER PT J AU Hudelson, SE McConnell, MS Bagenda, D Piwowar-Manning, E Parsons, TL Nolan, ML Bakaki, PM Thigpen, MC Mubiru, M Fowler, MG Eshleman, SH AF Hudelson, Sarah E. McConnell, Michelle S. Bagenda, Danstan Piwowar-Manning, Estelle Parsons, Teresa L. Nolan, Monica L. Bakaki, Paul M. Thigpen, Michael C. Mubiru, Michael Fowler, Mary Glenn Eshleman, Susan H. TI Emergence and persistence of nevirapine resistance in breast milk after single-dose nevirapine administration SO AIDS LA English DT Article DE breast milk; HIV-1; nevirapine; nevirapine resistance; Uganda; vertical transmission ID HIV-1 SUBTYPE-C; VERTICAL TRANSMISSION; WOMEN; PLASMA; MUTATIONS; INFANTS; HIVNET-012; AGE; NVP AB Objective: Single-dose nevirapine (NVP) (sdNVP) can reduce the risk of HIV vertical transmission. We assessed risk factors for NVP resistance in plasma and breast milk from sdNVP-exposed Ugandan women. Methods: Samples were analyzed using the Roche AMPLICOR HIV-1 Monitor Test Kit, version 1.5, and the ViroSeq HIV-1 Genotyping System. NVP concentrations were determined by liquid chromatography with tandem mass spectroscopy. Results: HIV genotypes (plasma and breast milk) were obtained for 30 women 4 weeks after sdNVP (HIV subtypes: 15A, 1C, 12D, two recombinant). NVP resistance was detected in 12 (40%) of 30 breast milk samples. There was a nonsignificant trend between detection of NVP resistance in breast milk and plasma (P = 0.06). There was no association of HIV resistance in breast milk with median maternal pre-NVP viral load or CD4 cell count, median breast milk viral load at 4 weeks, breast milk sodium more than 10 mmol/l, HIV subtype, or concentration of NVP in breast milk or plasma. Conclusion: NVP resistance was frequently detected in breast milk 4 weeks after sdNVP exposure. In this study, we were unable to identify specific factors associated with breast milk NVP resistance. (C) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins C1 [Hudelson, Sarah E.; Piwowar-Manning, Estelle; Fowler, Mary Glenn; Eshleman, Susan H.] Johns Hopkins Univ, Dept Pathol, Sch Med, Baltimore, MD 21205 USA. [McConnell, Michelle S.; Thigpen, Michael C.] Ctr Dis Control & Prevent, Epidemiol Branch, Div HIV AIDS Prevent, Atlanta, GA USA. [Bagenda, Danstan] Makerere Univ, Sch Publ Hlth, Kampala, Uganda. [Bagenda, Danstan; Mubiru, Michael] Johns Hopkins Univ, Res Collaborat, Makerere Univ, Kampala, Uganda. [Parsons, Teresa L.] Johns Hopkins Univ, Sch Med, Dept Clin Pharmacol, Baltimore, MD USA. [Nolan, Monica L.] Mothers2mothers, Dept Strateg Informat, Cape Town, South Africa. [Bakaki, Paul M.] Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA. RP Eshleman, SH (reprint author), Johns Hopkins Univ, Dept Pathol, Sch Med, Ross Bldg 646,720 Rutland Ave, Baltimore, MD 21205 USA. EM seshlem@jhmi.edu FU National Institutes of Allergy and Infectious Diseases (NIAID); National Institutes of Child Health and Human Development (NICHD); National Institute on Drug Abuse, National Institute of Mental Health; Office of AIDS Research of the National Institutes of Health (NIH) [U01-AI-068613]; CDC subcontract to Johns Hopkins University [200-2004-M-09279]; International Maternal Pediatric Adolescent AIDS Clinical Trials Network [U01-AI-068632] FX The Pathophysiology of Breast Milk study was supported by the U.S. CDC. The resistance substudy was supported by the HIV Prevention Trials Network (HPTN) sponsored by the National Institutes of Allergy and Infectious Diseases (NIAID), National Institutes of Child Health and Human Development (NICHD), National Institute on Drug Abuse, National Institute of Mental Health, and Office of AIDS Research of the National Institutes of Health (NIH) (U01-AI-068613), CDC subcontract to Johns Hopkins University (200-2004-M-09279), and the International Maternal Pediatric Adolescent AIDS Clinical Trials Network (U01-AI-068632, NIAID, NICHD). NR 16 TC 11 Z9 12 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0269-9370 J9 AIDS JI Aids PD FEB 20 PY 2010 VL 24 IS 4 BP 557 EP 561 DI 10.1097/QAD.0b013e3283346e60 PG 5 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA 563QK UT WOS:000275148000008 PM 20057308 ER PT J AU Lo, LM Hu, SC Chen, DR Pui, DYH AF Lo, Li-Ming Hu, Shih-Cheng Chen, Da-Ren Pui, David Y. H. TI Numerical study of pleated fabric cartridges during pulse-jet cleaning SO POWDER TECHNOLOGY LA English DT Article DE Pleated filter cartridge; Pulse-jet cleaning; Computational fluid dynamics analysis; Area-weighted average overpressure ID CERAMIC FILTER; FILTRATION; PARAMETERS; SYSTEM; MEDIA AB We established a numerical model and used computational fluid dynamics (CFD) analysis to observe transient flow behavior across pleated filter cartridges in a dust collector during pulse-jet cleaning. The numerical results were in good agreement with the filter-testing data during important periods including during pressure ramp-Lip and valve opening. Larger errors for predicting overpressure occurred during the pressure ramp-down period likely due to the uniformity of the filters' permeability. This confirmed that the numerical model demonstrated the cleaning efficiency and the local cleaning quality of three different filter cartridges with different filter dimensions and pleat ratios. Data Calculated from the average static pressure on the filters' surfaces were more closely correlated to cleaning efficiency than overpressure. The surface static pressure distribution along all filter cartridges showed that the top area of the filter cartridge is difficult to clean because of the lower surface pressure generated by the pulse jet. Filter cartridges with higher pleat ratios were found to have greater instances of incomplete cleaning due to the large variation of static pressure distribution along the filter cartridges. Our results showed that although information such as average pressure and pressure distribution on the filter surface is difficult to obtain by physical measurement, this data is tractable using CFD analysis and is useful for filter design and system optimization. Published by Elsevier B.V. C1 [Lo, Li-Ming] NIOSH, US Dept HHS, Publ Hlth Serv, Ctr Dis Control & Prevent,Div Appl Res & Technol, Cincinnati, OH 45226 USA. [Hu, Shih-Cheng] Natl Taipei Univ Technol, Dept Energy & Refrigerating Air Conditioning, Taipei 106, Taiwan. [Chen, Da-Ren] Washington Univ, Dept Energy Environm & Chem Engn, St Louis, MO 63130 USA. [Pui, David Y. H.] Univ Minnesota, Dept Mech Engn, Particle Technol Lab, Minneapolis, MN 55455 USA. RP Lo, LM (reprint author), NIOSH, US Dept HHS, Publ Hlth Serv, Ctr Dis Control & Prevent,Div Appl Res & Technol, 4676 Columbia Pkwy,MS-R5, Cincinnati, OH 45226 USA. EM LLo@cdc.gov FU Center for Filtration Research: 3 M Corporation; Cummins Filtration Inc.; Donaldson Company, Inc.; E. I. du Pontde Nemours and Company; Entegris Inc.; Samsung Semiconductor Inc.; Shigematsu Works CO., LTD; TSI Inc.; W. L. Gore Associates; National Institute for Occupational Safety and Health (NIOSH) FX The authors thank the support of members of the Center for Filtration Research: 3 M Corporation, Cummins Filtration Inc., Donaldson Company, Inc., E. I. du Pontde Nemours and Company, Entegris Inc., Samsung Semiconductor Inc., Shigematsu Works CO., LTD, TSI Inc., and W. L. Gore & Associates and the affiliate member National Institute for Occupational Safety and Health (NIOSH). Special appreciation is given to W. L. Gore & Associates, Inc. and Donaldson Company, Inc. for their help in filter testing.; We also acknowledge NIOSH colleagues including Jennifer Toprniller, Scott Earnest, James Bennett, Benjamin Eimer, and Chaolong Qi for their critical review of the manuscript, and thank Douglas Platt for his useful editing. NR 22 TC 18 Z9 28 U1 4 U2 17 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0032-5910 EI 1873-328X J9 POWDER TECHNOL JI Powder Technol. PD FEB 20 PY 2010 VL 198 IS 1 BP 75 EP 81 DI 10.1016/j.powtec.2009.10.017 PG 7 WC Engineering, Chemical SC Engineering GA 552HY UT WOS:000274281400011 ER PT J AU High, P Handschur, EF Eze, OS Montana, B Robertson, C Tan, C Rosen, JB Cummings, KP Doll, MK Zucker, JR Zimmerman, CM Dolinsky, T Goodell, S Schulte, C Blog, D Leblanc, MA Li, YA Barskey, A Wallace, G Gallagher, K Armstrong, G Lowe, L McNall, R Rota, J Rota, P Hickman, C Bellini, WJ Apostolou, A AF High, P. Handschur, E. F. Eze, O. S. Montana, B. Robertson, C. Tan, C. Rosen, J. B. Cummings, K. P. Doll, M. K. Zucker, J. R. Zimmerman, C. M. Dolinsky, T. Goodell, S. Schulte, C. Blog, D. Leblanc, M. A. Li, Y. A. Barskey, A. Wallace, G. Gallagher, K. Armstrong, G. Lowe, L. McNall, R. Rota, J. Rota, P. Hickman, C. Bellini, W. J. Apostolou, A. TI Mumps Outbreak-NewYork, New Jersey, Quebec, 2009 (Reprinted from MMWR, vol 58, pg 1270-1274, 2009) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Rosen, J. B.; Cummings, K. P.; Doll, M. K.; Zucker, J. R.; Zimmerman, C. M.] New York City Dept Hlth & Mental Hyg, New York, NY USA. [Schulte, C.; Blog, D.] New York State Dept Hlth, Albany, NY 12237 USA. [Apostolou, A.] CDC, Atlanta, GA 30333 USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD FEB 17 PY 2010 VL 303 IS 7 BP 607 EP + PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 555NK UT WOS:000274518600010 ER PT J AU Palomaki, GE Melillo, S Bradley, LA AF Palomaki, Glenn E. Melillo, Stephanie Bradley, Linda A. TI Association Between 9p21 Genomic Markers and Heart Disease A Meta-analysis SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Review ID CORONARY-ARTERY-DISEASE; RANDOMIZED CONTROLLED-TRIAL; ABDOMINAL AORTIC-ANEURYSM; CHROMOSOME 9P21; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; GENETIC-VARIATION; 4 SNPS; SUSCEPTIBILITY LOCUS; SYSTEMATIC REVIEWS AB Context Associations between chromosome 9p21 single-nucleotide polymorphisms ( SNPs) and heart disease have been reported and replicated. If testing improves risk assessments using traditional factors, it may provide opportunities to improve public health. Objectives To perform a targeted systematic review of published literature for effect size, heterogeneity, publication bias, and strength of evidence and to consider whether testing might provide clinical utility. Data Sources Electronic search via HuGE Navigator through January 2009 and review of reference lists from included articles. Study Selection English-language articles that tested for 9p21 SNPs with coronary heart/artery disease or myocardial infarction as primary outcomes. Included articles also provided race, numbers of participants, and data to compute an odds ratio ( OR). Articles were excluded if reporting only intermediate outcomes (eg, atherosclerosis) or if all participants had existing disease. Twenty-five articles were initially identified and 16 were included. A follow-up search identified 6 additional articles. Data Extraction Independent extraction was performed by 2 reviewers and consensus was reached. Credibility of evidence was assessed using published Venice criteria. Data Synthesis Forty-seven distinct data sets from the 22 articles were analyzed, including 35 872 cases and 95 837 controls. The summary OR for heart disease among individuals with 2 vs 1 at-risk alleles was 1.25 (95% confidence interval [CI], 1.21-1.29), with low to moderate heterogeneity. Age at disease diagnosis was a significant covariate, with ORs of 1.35 (95% CI, 1.30-1.40) for age 55 years or younger and 1.21 (95% CI, 1.16-1.25) for age 75 years or younger. For a 65-year-old man, the 10-year heart disease risk for 2 vs 1 at-risk alleles would be 13.2% vs 11%. For a 40-year-old woman, the 10-year heart disease risk for 2 vs 1 at-risk alleles would be 2.4% vs 2.0%. Nearly identical but inverse results were found when comparing 1 vs 0 at-risk alleles. Three studies showed net reclassification indexes ranging from -0.1% to 4.8%. Conclusion We found a statistically significant association between 9p21 SNPs and heart disease that varied by age at disease onset, but the magnitude of the association was small. JAMA. 2010;303(7):648-656 www.jama.com C1 [Palomaki, Glenn E.] Brown Univ, Women & Infants Hosp, Alpert Med Sch, Providence, RI 02903 USA. [Melillo, Stephanie; Bradley, Linda A.] Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA USA. [Melillo, Stephanie] McKing Consulting Corp, Atlanta, GA USA. RP Palomaki, GE (reprint author), Brown Univ, Women & Infants Hosp, Alpert Med Sch, 70 Elm St,2nd Floor, Providence, RI 02903 USA. EM gpalomaki@ipmms.org RI Max, Mad/E-5238-2010 OI Max, Mad/0000-0001-6966-6829 FU OPHG, Centers for Disease Control and Prevention [200-2003-01396-0128] FX This study was funded by the OPHG, Centers for Disease Control and Prevention (contract 200-2003-01396-0128 to McKing Consulting Corp Inc). NR 74 TC 84 Z9 87 U1 0 U2 8 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD FEB 17 PY 2010 VL 303 IS 7 BP 648 EP 656 DI 10.1001/jama.2010.118 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 555NK UT WOS:000274518600023 PM 20159873 ER PT J AU Mangtani, P Mulholland, K Madhi, SA Edmond, K O'Loughlin, R Hajjeh, R AF Mangtani, Punam Mulholland, Kim Madhi, Shabir A. Edmond, Karen O'Loughlin, Rosalyn Hajjeh, Rana TI Haemophilus influenzae type b disease in HIV-infected children: A review of the disease epidemiology and effectiveness of Hib conjugate vaccines SO VACCINE LA English DT Review DE HIb vaccine; HIV; Low-income settings; Vaccine schedule ID HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; SOUTH-AFRICA; HIV-1-INFECTED CHILDREN; OROPHARYNGEAL CARRIAGE; POLYSACCHARIDE CAPSULE; ANTIBODY-RESPONSES; UNINFECTED INFANTS; IMMUNIZATION; VACCINATION AB The paper reviews the literature on the epidemiology of Hib disease and the effectiveness of Hib conjugate vaccine (HibCV) in HIV-infected children. The current three-dose primary Hib conjugate vaccine schedule in low-income settings has had a striking impact on the incidence of Hib disease. However, HIV-infected children have an almost 6-fold higher risk of Haemophilus influenzae type b (Hib) invasive disease than HIV-Uninfected children and HibCV effectiveness is lower in this population. HIV-related HibCV failures are difficult to detect without well functioning surveillance systems and HIV testing of cases. Breakthrough Hib cases have been noted in vaccinated HIV-infected children in South Africa. A HibCV booster dose in addition to the three-dose primary schedule is routine in many, but not all, high-income countries. In order to determine whether a booster dose should be given to HIV-infected children in developing countries, well-designed studies need to be conducted to better determine the persistence of protective antibody concentrations, response to booster doses of vaccine as well as timing of and risk factors for vaccine failure in HIV-infected children both treated and naive to antiretroviral drug therapy (ART). Meanwhile, physicians and public health personnel should be especially vigilant at ensuring that HIV-infected infants receive their primary doses of HibCV, ART and co-trimoxazole prophylaxis. Until more definitive evidence is available, physicians may also need to consider a booster dose for such children irrespective of ART status. In any updating of vaccine schedules, HIV-infected children need particular consideration. (C) 2009 Published by Elsevier Ltd. C1 [Mangtani, Punam] London Sch Hyg & Trop Med, Infect Dis Epidemiol Unit, Dept Epidemiol & Populat Hlth, London WC1 7HT, England. [Madhi, Shabir A.] Univ Witwatersrand, Dept Sci & Technol, Natl Res Fdn, Vaccine Preventable Dis & Resp & Meningeal Pathog, Johannesburg, South Africa. [Hajjeh, Rana] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Hajjeh, Rana] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA. RP Mangtani, P (reprint author), London Sch Hyg & Trop Med, Infect Dis Epidemiol Unit, Dept Epidemiol & Populat Hlth, Keppel St, London WC1 7HT, England. EM Punam.Mangtani@lshtm.ac.uk NR 55 TC 18 Z9 18 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD FEB 17 PY 2010 VL 28 IS 7 BP 1677 EP 1683 DI 10.1016/j.vaccine.2009.12.011 PG 7 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 563TX UT WOS:000275158500005 PM 20034606 ER PT J AU Brown, DS Johnson, FR Poulos, C Messonnier, ML AF Brown, Derek S. Johnson, F. Reed Poulos, Christine Messonnier, Mark L. TI Mothers' preferences and willingness to pay for vaccinating daughters against human papillomavirus SO VACCINE LA English DT Article DE Conjoint analysis; Human papillomavirus vaccine; Cost-benefit analysis; Preferences; Demand; Mothers; Adolescent girls; Discrete choice experiment ID TRANSMITTED INFECTION VACCINATION; HPV VACCINE; CONJOINT-ANALYSIS; PRIVATE DEMAND; UNITED-STATES; OLDER-ADULTS; HEALTH-CARE; ATTITUDES; COST; RECOMMENDATIONS AB A choice-format, conjoint-analysis survey was developed and fielded to estimate how features of human papillomavirus (HPV) vaccines affect mothers' perceived benefit and stated vaccine uptake for daughters. Data were collected from a national sample of 307 U.S. mothers of girls aged 13-17 years who had not yet received an HPV vaccine. Preferences for four features of HPV vaccines were evaluated: protection against cervical cancer, protection against genital warts, duration of protection, and cost. We estimate that mean maximum willingness-to-pay (WTP)-an economic measure of the total benefits to consumers-for current HPV vaccine technology ranges between $560 and $660. All vaccine features were statistically significant determinants of WTP and uptake. Mothers were willing to pay $238 more for a vaccine that provides 90% protection for genital warts relative to a vaccine that provides no protection against warts. WTP for lifetime protection vs. 10 years protection was $245. Mothers strongly valued greater cervical cancer efficacy, with 100% protection against cervical cancers the most desired feature overall. Adding a second HPV vaccine choice to U.S. consumers' alternatives is predicted to increase stated uptake by 16%. Several features were significantly associated with stated choices and uptake: age of mother, Face/ethnicity, household income, and concern about HPV risks. These findings provide new data on how HPV vaccines are viewed and valued by mothers, and how uptake may change in the context of evolving vaccine technology and as new data ate reported on duration and efficacy. (C) 2009 Elsevier Ltd. All rights reserved. C1 [Brown, Derek S.; Johnson, F. Reed; Poulos, Christine] RTI Int, Res Triangle Pk, NC 27709 USA. [Messonnier, Mark L.] Ctr Dis Control & Prevent, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30329 USA. RP Brown, DS (reprint author), RTI Int, 3040 Cornwallis Rd,POB 12194, Res Triangle Pk, NC 27709 USA. EM dsbrown@rti.org RI Brown, Derek/J-3035-2013 OI Brown, Derek/0000-0001-9908-9882 FU Centers for Disease Control and Prevention (CDC) [200-2002-00776TO43]; RTI International FX This study was supported by the Centers for Disease Control and Prevention (CDC) under contract # 200-2002-00776TO43 with RTI International. The findings and conclusions in the article are those of the authors and do not necessarily represent the views of CDC or RTI. The study was reviewed and approved by IRBs at RTI and CDC. Harrell Chesson and Lauri Markowitz of CDC provided valuable feedback several times. Juan Marcos Gonzalez, Thomas Hylands, Olga Khavjou, Ateesha Mohamed, Semra Ozdemir, and Jui-Chen Yang of RTI all assisted in the study. Arne Rise Hole of the University of Sheffield generously shared Stata code. We also benefited from feedback by participants in seminars at CDC, RTI International, Vaccine 2nd Global Congress, the American Society of Health Economists 2008 Meeting, and the 2009 Conjoint Analysis in Health Conference. NR 49 TC 29 Z9 29 U1 4 U2 7 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD FEB 17 PY 2010 VL 28 IS 7 BP 1702 EP 1708 DI 10.1016/j.vaccine.2009.12.024 PG 7 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 563TX UT WOS:000275158500007 PM 20044060 ER PT J AU Rodriguez, J Jiang, R Johnson, WC MacKenzie, BA Smith, LJ Barr, RG AF Rodriguez, Josanna Jiang, Rui Johnson, W. Craig MacKenzie, Barbara A. Smith, Lewis J. Barr, R. Graham TI The Association of Pipe and Cigar Use With Cotinine Levels, Lung Function, and Airflow Obstruction A Cross-sectional Study SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID RESPIRATORY SYMPTOMS; PULMONARY-DISEASE; REFERENCE VALUES; PASSIVE SMOKING; MORTALITY; CANCER; MEN; POPULATION; ADULTS; ATHEROSCLEROSIS AB Background: Cigarette smoking is the major cause of chronic obstructive pulmonary disease, but studies on the contribution of other smoking techniques are sparse. Objective: To determine whether pipe and cigar smoking was associated with elevated cotinine levels, decrements in lung function, and increased odds of airflow obstruction. Design: Cross-sectional study. Setting: Population-based sample from 6 U. S. communities. Participants: Men and women aged 48 to 90 years without clinical cardiovascular disease at enrollment who were part of MESA (Multi-Ethnic Study of Atherosclerosis). Measurements: The MESA Lung Study measured spirometry according to American Thoracic Society guidelines and urine cotinine levels by immunoassay on a subsample of MESA. Pipe-years and cigar-years were calculated as years from self-reported age of starting to age of quitting (or to current age in current users) multiplied by pipe-bowls or cigars per day. Results: Of 3528 participants, 9% reported pipe smoking (median, 15 pipe-years), 11% reported cigar smoking (median, 6 cigar-years), and 52% reported cigarette smoking (median, 18 pack-years). Self-reported current pipe and cigar smokers had elevated urine cotinine levels compared with never-smokers. Pipe-years were associated with decrements in FEV1, and cigar-years were associated with decrements in the FEV1-FVC ratio. Participants who smoked pipes or cigars had increased odds of airflow obstruction whether they had also smoked cigarettes (odds ratio, 3.43 [95% CI, 1.75 to 6.71]; P < 0.001) or not (odds ratio, 2.31 [CI, 1.04 to 5.11]; P = 0.039) compared with participants with no smoking history. Limitation: Cross-sectional design. Conclusion: Pipe and cigar smoking increased urine cotinine levels and was associated with decreased lung function and increased odds of airflow obstruction, even in participants who had never smoked cigarettes. C1 [Barr, R. Graham] Columbia Univ, Med Ctr, New York, NY 10032 USA. Univ Washington, Seattle, WA 98195 USA. NIOSH, Cincinnati, OH 45226 USA. Northwestern Univ, Chicago, IL 60611 USA. RP Barr, RG (reprint author), Columbia Univ, Med Ctr, 630 W 168th St,PH 9 E,Room 105, New York, NY 10032 USA. EM rgb9@columbia.edu OI Smith, Lewis J/0000-0002-4728-1562 FU National Heart, Lung, and Blood Institute, National Institutes of Health; National Institutes of Health [R01-HL077612, N01-HC95159, HC95169, R01-HL075476] FX National Heart, Lung, and Blood Institute, National Institutes of Health.; By the National Institutes of Health (R01-HL077612, N01-HC95159 to HC95169, R01-HL075476). NR 33 TC 42 Z9 42 U1 0 U2 5 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD FEB 16 PY 2010 VL 152 IS 4 BP 201 EP U17 DI 10.7326/0003-4819-152-4-201002160-00004 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA 560AF UT WOS:000274873300001 PM 20157134 ER PT J AU Wang, CY Haskell, WL Farrell, SW LaMonte, MJ Blair, SN Curtin, LR Hughes, JP Burt, VL AF Wang, Chia-Yih Haskell, William L. Farrell, Stephen W. LaMonte, Michael J. Blair, Steven N. Curtin, Lester R. Hughes, Jeffery P. Burt, Vicki L. TI Cardiorespiratory Fitness Levels Among US Adults 20-49 Years of Age: Findings From the 1999-2004 National Health and Nutrition Examination Survey SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Article DE body mass index; cardiovascular diseases; chronic disease; exercise; nutrition surveys; physical fitness; reference values ID ALL-CAUSE MORTALITY; CARDIOVASCULAR-DISEASE MORTALITY; LIPID RESEARCH CLINICS; PHYSICAL-FITNESS; EXERCISE CAPACITY; BODY-COMPOSITION; YOUNG-ADULTS; MEN; WOMEN; RISK AB Data from the 1999-2004 National Health and Nutrition Examination Survey were used to describe the distribution of cardiorespiratory fitness and its association with obesity and leisure-time physical activity (LTPA) for adults 20-49 years of age without physical limitations or indications of cardiovascular disease. A sample of 7,437 adults aged 20-49 years were examined at a mobile examination center. Of 4,860 eligible for a submaximal treadmill test, 3,250 completed the test and were included in the analysis. The mean maximal oxygen uptake ((V) over dotO(2)max) was estimated as 44.5, 42.8, and 42.2 mL/kg/minute for men 20-29, 30-39, and 40-49 years of age, respectively. For women, it was 36.5, 35.4, and 34.4 mL/kg/minute for the corresponding age groups. Non-Hispanic black women had lower fitness levels than did non-Hispanic white and Mexican-American women. Regardless of gender or race/ethnicity, people who were obese had a significantly lower estimated maximal oxygen uptake than did nonobese adults. Furthermore, a positive association between fitness level and LTPA participation was observed for both men and women. These results can be used to track future population assessments and to evaluate interventions. The differences in fitness status among population subgroups and by obesity status or LTPA can also be used to develop health policies and targeted educational campaigns. C1 [Wang, Chia-Yih] Ctr Dis Control & Prevent, Div Hlth & Nutr Examinat Surveys, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Haskell, William L.] Stanford Univ, Stanford Ctr Res Dis Prevent, Palo Alto, CA 94304 USA. [Farrell, Stephen W.] Cooper Inst, Dallas, TX USA. [LaMonte, Michael J.] SUNY Buffalo, Dept Social & Prevent Med, Buffalo, NY 14260 USA. [Blair, Steven N.] Univ S Carolina, Dept Exercise Sci, Arnold Sch Publ Hlth, Columbia, SC 29208 USA. [Blair, Steven N.] Univ S Carolina, Dept Epidemiol & Biostat, Arnold Sch Publ Hlth, Columbia, SC 29208 USA. RP Wang, CY (reprint author), Ctr Dis Control & Prevent, Div Hlth & Nutr Examinat Surveys, Natl Ctr Hlth Stat, 3311 Toledo Rd,Room 4328, Hyattsville, MD 20782 USA. EM cwang@cdc.gov NR 35 TC 79 Z9 80 U1 0 U2 10 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD FEB 15 PY 2010 VL 171 IS 4 BP 426 EP 435 DI 10.1093/aje/kwp412 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 553BY UT WOS:000274340900005 PM 20080809 ER PT J AU Miller, EA Rasmussen, SA Siega-Riz, AM Frias, JL Honein, MA AF Miller, Eric A. Rasmussen, Sonja A. Siega-Riz, Anna Maria Frias, Jaime L. Honein, Margaret A. CA Natl Birth Defects Prevention Stud TI Risk Factors for Non-Syndromic Holoprosencephaly in the National Birth Defects Prevention Study SO AMERICAN JOURNAL OF MEDICAL GENETICS PART C-SEMINARS IN MEDICAL GENETICS LA English DT Article DE holoprosencephaly; forebrain defect; epidemiology ID IN-VITRO FERTILIZATION; DIETARY-FOLATE INTAKE; POPULATION; SUPPLEMENTS; CALIFORNIA; ANOMALIES; CYCLOPIA; ASPIRIN; INFANTS; WOMEN AB Holoprosencephaly (HPE) is a complex structural brain anomaly that results from incomplete cleavage of the forebrain. The prevalence of HPE at birth is low, and risk factors have been difficult to identify. Using data from a large multi-state population-based case-control study, we examined risk factors for non-syndromic HPE. Data from maternal telephone interviews were available for 74 infants with HPE and 5871 controls born between 1997 and 2004. Several characteristics and exposures were examined, including pregnancy history, medical history, maternal diet and use of nutritional supplements, medications, tobacco, alcohol, and illegal substances. We used chi(2)-tests and logistic regression (excluding women with pre-existing diabetes) to examine associations with HPE. Except for diet (year before pregnancy) and sexually transmitted infections (STIs) (throughout pregnancy), most exposures were examined for the time period from the month before to the third month of pregnancy. HPE was found to be associated with pre-existing diabetes (chi(2) = 6.01 P = 0.01), aspirin use [adjusted odds ratio (aOR) = 3.4; 95% confidence interval (CI) 1.6-6.9], lower education level (aOR = 2.5; 95% CI 1.1-5.6), and use of assisted reproductive technologies (ART) (crude OR = 4.2; 95% CI 1.3-13.7). Consistent maternal folic acid use appeared to be protective (aOR = 0.4; 95% CI 0.2-1.0), but the association was of borderline statistical significance. While some of these findings support previous observations, other potential risk factors identified warrant further study. Published 2010 Wiley-Liss, Inc. C1 [Miller, Eric A.] Texas Dept State Hlth Serv, Canc Epidemiol & Surveillance Branch, Austin, TX 78714 USA. [Frias, Jaime L.] Univ S Florida, Tampa, FL USA. [Honein, Margaret A.] Ctr Dis Control & Prevent, Birth Defects Surveillance & Epidemiol Branch, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. RP Miller, EA (reprint author), Texas Dept State Hlth Serv, Canc Epidemiol & Surveillance Branch, MC 1928,POB 149347, Austin, TX 78714 USA. EM eric.miller@dshs.state.tx.us RI Publications, NBDPS/B-7692-2013 FU Centers for Disease Control and Prevention [U50/CCU613232] FX Grant sponsor: Centers for Disease Control and Prevention, Grant number: U50/CCU613232. NR 33 TC 17 Z9 17 U1 0 U2 2 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1552-4868 J9 AM J MED GENET C JI Am. J. Med. Genet. C PD FEB 15 PY 2010 VL 154C IS 1 BP 62 EP 72 DI 10.1002/ajmg.c.30244 PG 11 WC Genetics & Heredity SC Genetics & Heredity GA 554YE UT WOS:000274471700009 PM 20104597 ER PT J AU Johnson, CY Rasmussen, SA AF Johnson, Candice Y. Rasmussen, Sonja A. TI Non-Genetic Risk Factors for Holoprosencephaly SO AMERICAN JOURNAL OF MEDICAL GENETICS PART C-SEMINARS IN MEDICAL GENETICS LA English DT Article DE holoprosencephaly; risk factors; teratogens; diabetes; salicylates; cholesterol ID BIRTH-DEFECTS PREVENTION; CENTRAL-NERVOUS-SYSTEM; DIABETES-MELLITUS; RETINOIC ACID; EMBRYONIC-DEVELOPMENT; SONIC-HEDGEHOG; MOUSE EMBRYOS; CYCLOPIA; EPIDEMIOLOGY; PREGNANCY AB Holoprosencephaly (HPE) is a congenital defect of the brain characterized by incomplete cleavage of the embryonic forebrain into left and right hemispheres. Although a substantial proportion of cases of HPE can be attributed to genetic abnormalities, the etiology in many cases remains unknown, with non-genetic risk factors believed to be important contributors. Due to the low birth prevalence of this defect, it has proven difficult to conduct studies of sufficient size to identify risk factors with certainty, This article provides a summary of non-genetic risk factors for HPE that have been investigated in case reports and case series, animal studies, and epidemiologic studies, including maternal illnesses, therapeutic and non-therapeutic exposures, nutritional factors, and sociodemographic factors, The article also highlights challenges in study design and further areas for research to better understand the etiology of HPE. Published 2010 Wiley-Liss, Inc. C1 [Johnson, Candice Y.; Rasmussen, Sonja A.] CDC, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Johnson, Candice Y.] Emory Univ, Dept Epidemiol, Atlanta, GA 30322 USA. RP Rasmussen, SA (reprint author), CDC, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd,MS E-86, Atlanta, GA 30333 USA. EM skr9@cdc.gov NR 85 TC 20 Z9 20 U1 0 U2 7 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1552-4868 J9 AM J MED GENET C JI Am. J. Med. Genet. C PD FEB 15 PY 2010 VL 154C IS 1 BP 73 EP 85 DI 10.1002/ajmg.c.30242 PG 13 WC Genetics & Heredity SC Genetics & Heredity GA 554YE UT WOS:000274471700010 PM 20104598 ER PT J AU Kemper, AR Ouyang, LJ Grosse, SD AF Kemper, Alex R. Ouyang, Lijing Grosse, Scott D. TI Discontinuation of thyroid hormone treatment among children in the United States with congenital hypothyroidism: findings from health insurance claims data SO BMC PEDIATRICS LA English DT Article ID PUBLICLY INSURED CHILDREN; SICKLE-CELL-DISEASE; RISK-FACTORS; NEWBORN; PSYCHOMOTOR; DIAGNOSIS AB Background: Thyroid hormone treatment in children with congenital hypothyroidism can prevent intellectual disability. Guidelines recommend that children diagnosed with congenital hypothyroidism through newborn screening remain on treatment to at least 3 years of age, after which a trial off therapy can determine which children have transient hypothyroidism. The purpose of this study was to describe the rate at which children with congenital hypothyroidism in the United States discontinue thyroid hormone treatment in early childhood. Methods: Retrospective analysis of the 2002-2006 MarketScan (R) Commercial Claims and Encounters research databases and the 2001-2005 MarketScan Multi-State Medicaid databases. Children were classified as having congenital hypothyroidism based on billing codes and having filled a prescription for thyroid hormone treatment. Kaplan-Meier curve analysis was used to determine discontinuation rates. Results: There were a total of 412 Medicaid-enrolled children and 292 privately-insured children with presumed congenital hypothyroidism included in this study. The overall birth prevalence of congenital hypothyroidism across both datasets was about 1 per 2,300. By 36 months, the percentage who had discontinued thyroid replacement treatment was 38% (95% Confidence Interval: 32%-44%). Medicaid-enrolled children had a more rapid decline in the first 24 months of treatment compared to those with private insurance (P = 0.02). Conclusions: More than one-third of children treated for congenital hypothyroidism discontinued treatment within 36 months, which is inconsistent with current guidelines. It is not known how many of these children required continued treatment or experience adverse effects from discontinuation. These findings emphasize the critical need for follow-up systems to monitor the outcome of newborn screening. C1 [Kemper, Alex R.] Duke Univ, Med Ctr, Dept Pediat, Program Pediat Hlth Serv Res, Durham, NC 27710 USA. [Ouyang, Lijing; Grosse, Scott D.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. RP Kemper, AR (reprint author), Duke Univ, Med Ctr, Dept Pediat, Program Pediat Hlth Serv Res, Durham, NC 27710 USA. EM alex.kemper@duke.edu FU National Newborn Screening and Genetics Resource Center; Health Resources and Services Administration [U32 MC 00148] FX MarketScan is a registered trademark of Thomson Reuters Healthcare, Inc. Financial Support: Dr. Kemper received support funding through a contract with the National Newborn Screening and Genetics Resource Center as part of their funding from the Health Resources and Services Administration (Grant U32 MC 00148). NR 26 TC 22 Z9 22 U1 1 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2431 J9 BMC PEDIATR JI BMC Pediatr. PD FEB 15 PY 2010 VL 10 AR 9 DI 10.1186/1471-2431-10-9 PG 6 WC Pediatrics SC Pediatrics GA 566VB UT WOS:000275400200002 PM 20156344 ER PT J AU Shapiro, MR Fritz, CL Tait, K Paddock, CD Nicholson, WL Abramowicz, KF Karpathy, SE Dasch, GA Sumner, JW Adem, PV Scott, JJ Padgett, KA Zaki, SR Eremeeva, ME AF Shapiro, Marc R. Fritz, Curtis L. Tait, Karen Paddock, Christopher D. Nicholson, William L. Abramowicz, Kyle F. Karpathy, Sandor E. Dasch, Gregory A. Sumner, John W. Adem, Patricia V. Scott, Jamesina J. Padgett, Kerry A. Zaki, Sherif R. Eremeeva, Marina E. TI Rickettsia 364D: A Newly Recognized Cause of Eschar-Associated Illness in California SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID MOUNTAIN-SPOTTED-FEVER; RHIPICEPHALUS-SANGUINEUS TICKS; NORTHERN CALIFORNIA; SPOTLESS FEVER; IDENTIFICATION; FEATURES; ARIZONA; PARKERI; VECTOR; RISK AB Background. Four spotted fever group rickettsiae (SFGR) are known to infect humans in the United States. A member of the SFGR designated 364D and detected in Dermacentor occidentalis ticks has not previously been identified as a human pathogen. Methods. An 80-year-old man from a rural northern California community presented with an eschar on his forearm. A skin punch biopsy of the lesion was evaluated by immunohistochemistry and molecular analysis. Serum specimens obtained from the patient and 3 other area residents with similar illnesses were tested by immunofluorescence and Western immunoblot for antibodies to SFGR. Ticks were collected near the patient's residence and tested for SFGR. Results. Abundant intracellular rickettsiae and fragmented rickettsial antigens were observed in the mononuclear inflammatory infiltrates of the biopsy. Nucleotide sequences of DNA fragments amplified from the biopsy were identical to those of 364D. Convalescent sera from all four patients exhibited high immunoglobulin G titers to Rickettsia rickettsii, Rickettsia rhipicephali, and 364D antigens. Three adult D. occidentalis were positive for 364D, R. rhipicephali, and an unidentified Rickettsia species. Conclusions. This is the first confirmation of human disease associated with the SFGR 364D, which was likely transmitted by D. occidentalis. Although the patients described here presented with a single cutaneous eschar as the principal manifestation, the full spectrum of illness associated with 364D has yet to be determined. Possible infection with 364D or other SFGR should be confirmed through molecular techniques in patients who present with "spotless" Rocky Mountain spotted fever or have serum antibodies to R. rickettsii with group-specific assays. C1 [Shapiro, Marc R.] St Helena Hosp Clearlake, Clearlake, CA USA. [Fritz, Curtis L.; Padgett, Kerry A.] Calif Dept Publ Hlth, Div Communicable Dis Control, Sacramento, CA USA. [Tait, Karen] Lake Cty Hlth Serv Dept, Lakeport, CA USA. [Scott, Jamesina J.] Lake Cty Vector Control Dist, Lakeport, CA USA. [Paddock, Christopher D.; Nicholson, William L.; Abramowicz, Kyle F.; Karpathy, Sandor E.; Dasch, Gregory A.; Sumner, John W.; Adem, Patricia V.; Zaki, Sherif R.; Eremeeva, Marina E.] Ctr Dis Control & Prevent, Div Viral & Rickettsial Dis, Atlanta, GA USA. RP Shapiro, MR (reprint author), 3400 Emerson St,Ste A, Clearlake, CA 95422 USA. EM shapirmr@ah.org OI Dasch, Gregory/0000-0001-6090-1810 FU Robert Massung and Jennifer McQuiston (CDC) FX We thank the Sacramento County Public Health Laboratory for preliminary diagnostic assistance; James Gathany (CDC) for photography of ticks; Carol Glaser (California Department of Public Health) for helping to initiate focused surveillance for rickettsioses in California; Porter Anderson, Sandi Courcier, Brittany Mills, Bonnie Ryan, Terry Sanderson, and Dave Woodward (Lake County Vector Control District), Piper Kimball (Marin/ Sonoma Mosquito and Vector Control District), Denise Bonilla and Martin Castro (California Department of Public Health), and Lauren Robinson and Frankie White (CDC) for assistance with collection of ticks; and Robert Massung and Jennifer McQuiston (CDC) for their support in this investigation. Primers were synthesized by the CDC Biotechnology Core Facility Branch (Atlanta, GA). NR 34 TC 44 Z9 46 U1 0 U2 5 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD FEB 15 PY 2010 VL 50 IS 4 BP 541 EP 548 DI 10.1086/649926 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 546WX UT WOS:000273846400018 PM 20073993 ER PT J AU Harris, JR Neil, KP Behravesh, CB Sotir, MJ Angulo, FJ AF Harris, Julie R. Neil, Karen P. Behravesh, Casey Barton Sotir, Mark J. Angulo, Frederick J. TI Recent Multistate Outbreaks of Human Salmonella Infections Acquired from Turtles: A Continuing Public Health Challenge SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID REPTILE-ASSOCIATED SALMONELLOSIS; PSEUDEMYS-SCRIPTA-ELEGANS; UNITED-STATES; PET TURTLES; ARIZONA ORGANISMS; FOODNET; EPIDEMIOLOGY; HATCHLINGS; LOUISIANA; CHILDREN AB The federal ban in the United States on the sale of turtles with shell lengths < 4 inches that was established in 1975 has reduced the number of turtle-associated human Salmonella infections during subsequent years, especially among children. Although numerous sporadic turtle-associated Salmonella infections in humans have been reported since the ban went into effect, outbreaks were not reported until recently. Since 2006, 3 multistate outbreaks of turtle-associated Salmonella infections have been documented in the United States. This review examines the history of turtle-associated human Salmonella infections in the United States and discusses reasons why an increase in turtle-associated salmonellosis may be occurring and how challenges in enforcement of the ban affect disease control. Additional steps should be considered by the public health community, state governments, and enforcement agencies to prevent turtle-associated Salmonella infections in humans. C1 [Harris, Julie R.; Neil, Karen P.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Off Workforce & Career Dev, Atlanta, GA USA. [Harris, Julie R.; Neil, Karen P.; Behravesh, Casey Barton; Sotir, Mark J.; Angulo, Frederick J.] Ctr Dis Control & Prevent, Enter Dis Epidemiol Branch, Div Foodborne Bacterial & Mycot Dis, Natl Ctr Zoonot Vector Borne & Enter Dis, Atlanta, GA USA. RP Harris, JR (reprint author), 1600 Clifton Rd NE,MS C-09, Atlanta, GA 30309 USA. EM ggt5@cdc.gov NR 53 TC 38 Z9 40 U1 2 U2 5 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD FEB 15 PY 2010 VL 50 IS 4 BP 554 EP 559 DI 10.1086/649932 PG 6 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 546WX UT WOS:000273846400021 PM 20085463 ER PT J AU Dharan, NJ Gubareva, LV Klimov, AI Fiore, AE Bresee, JS Fry, AM AF Dharan, Nila J. Gubareva, Larisa V. Klimov, Alexander I. Fiore, Anthony E. Bresee, Joseph S. Fry, Alicia M. TI Antiviral Treatment of Patients with Oseltamivir-Resistant and Oseltamivir-Susceptible Seasonal Influenza A (H1N1) Infection during the 2007-2008 Influenza Season in the United States SO CLINICAL INFECTIOUS DISEASES LA English DT Letter C1 [Dharan, Nila J.; Gubareva, Larisa V.; Klimov, Alexander I.; Fiore, Anthony E.; Bresee, Joseph S.; Fry, Alicia M.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA. [Dharan, Nila J.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Off Workforce & Career Dev, Atlanta, GA 30333 USA. RP Fry, AM (reprint author), Ctr Dis Control & Prevent, Influenza Div, 1600 Clifton Rd MS A-20, Atlanta, GA 30333 USA. EM agf1@cdc.gov NR 3 TC 13 Z9 13 U1 0 U2 0 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD FEB 15 PY 2010 VL 50 IS 4 BP 621 EP 622 DI 10.1086/650178 PG 2 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 546WX UT WOS:000273846400033 PM 20095841 ER PT J AU Meeker, JD Calafat, AM Hauser, R AF Meeker, John D. Calafat, Antonia M. Hauser, Russ TI Urinary Bisphenol A Concentrations in Relation to Serum Thyroid and Reproductive Hormone Levels in Men from an Infertility Clinic SO ENVIRONMENTAL SCIENCE & TECHNOLOGY LA English DT Article ID IN-VITRO; INHIBIN-B; MICROARRAY ANALYSIS; HUMAN EXPOSURE; SERTOLI-CELLS; MICE; RATS; SPERMATOGENESIS; ANDROGEN; SPERM AB Human exposure to bisphenol A (BPA) is widespread. Animal studies have demonstrated that BPA can alter endocrine function, but human studies are limited. For the present study, we measured urinary BPA concentrations and serum thyroid and reproductive hormone levels in 167 men recruited through an infertility clinic. BPA was detected in 89% of urine samples with a median (range) of 1.3 (<0.4 - 36.4) ng/mL. In multivariable regression models adjusted for potential confounders, BPA concentrations in urine collected on the same day as a blood sample were inversely associated with serum levels of inhibin B and estradiol-testosterone ratio (E-2:T) and positively associated with follicle-stimulating hormone (FSH) and FSH:inhibin B ratio. Because BPA is metabolized quickly and multiple urine measures may better reflect exposure than a single measure, we also considered among a subset of the men the BPA concentrations in repeated urine samples collected weeks or months following serum sample collection. In these analyses, the effect estimates remained consistent for FSH and E-2:T but were somewhat weakened for inhibin B. In addition,we observed inverse relationships between urinary BPA concentrations and free androgen index (ratio of testosterone to sex hormone binding globulin), estradiol, and thyroid stimulating hormone. Our results suggest that urinary BPA concentrations may be associated with altered hormone levels in men, but these findings need to be substantiated through further research. C1 [Meeker, John D.] Univ Michigan, Dept Environm Hlth Sci, Ann Arbor, MI 48109 USA. [Calafat, Antonia M.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Hauser, Russ] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA. [Hauser, Russ] Massachusetts Gen Hosp, Vincent Mem Obstet & Gynecol Serv, Androl Lab, Boston, MA 02114 USA. [Hauser, Russ] Massachusetts Gen Hosp, Vitro Fertilizat Unit, Boston, MA 02114 USA. RP Meeker, JD (reprint author), Univ Michigan, Dept Environm Hlth Sci, Ann Arbor, MI 48109 USA. EM meekerj@umich.edu OI zaraat, javad/0000-0001-5341-7481; Meeker, John/0000-0001-8357-5085 FU National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health (NIH) [ES009718, ES00002] FX Work supported by grants ES009718 and ES00002 from the National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health (NIH). We gratefully acknowledge Xiaoyun Ye, Amber Bishop, Tao Jia, and Jack Reidy (CDC, Atlanta, GA) for measuring the urinary concentrations of BPA. We thank the study research nurses, Jennifer Ford and Myra Keller, and are especially appreciative of the willingness of study subjects to participate. Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 45 TC 96 Z9 101 U1 4 U2 26 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0013-936X EI 1520-5851 J9 ENVIRON SCI TECHNOL JI Environ. Sci. Technol. PD FEB 15 PY 2010 VL 44 IS 4 BP 1458 EP 1463 DI 10.1021/es9028292 PG 6 WC Engineering, Environmental; Environmental Sciences SC Engineering; Environmental Sciences & Ecology GA 553EC UT WOS:000274347800048 PM 20030380 ER PT J AU Aiello, AE Murray, GF Perez, V Coulborn, RM Davis, BM Uddin, M Shay, DK Waterman, SH Monto, AS AF Aiello, Allison E. Murray, Genevra F. Perez, Vanessa Coulborn, Rebecca M. Davis, Brian M. Uddin, Monica Shay, David K. Waterman, Stephen H. Monto, Arnold S. TI Mask Use, Hand Hygiene, and Seasonal Influenza-Like Illness among Young Adults: A Randomized Intervention Trial SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID NONPHARMACEUTICAL INTERVENTIONS; VIRUSES; WORKING; CLOSURE; RISK AB Background. During the influenza A(H1N1) pandemic, antiviral prescribing was limited, vaccines were not available early, and the effectiveness of nonpharmaceutical interventions (NPIs) was uncertain. Our study examined whether use of face masks and hand hygiene reduced the incidence of influenza-like illness (ILI). Methods. A randomized intervention trial involving 1437 young adults living in university residence halls during the 2006-2007 influenza season was designed. Residence halls were randomly assigned to 1 of 3 groups face mask use, face masks with hand hygiene, or control-for 6 weeks. Generalized models estimated rate ratios for clinically diagnosed or survey-reported ILI weekly and cumulatively. Results. We observed significant reductions in ILI during weeks 4-6 in the mask and hand hygiene group, compared with the control group, ranging from 35% (confidence interval [CI], 9%-53%) to 51% (CI, 13%-73%), after adjusting for vaccination and other covariates. Face mask use alone showed a similar reduction in ILI compared with the control group, but adjusted estimates were not statistically significant. Neither face mask use and hand hygiene nor face mask use alone was associated with a significant reduction in the rate of ILI cumulatively. Conclusions. These findings suggest that face masks and hand hygiene may reduce respiratory illnesses in shared living settings and mitigate the impact of the influenza A(H1N1) pandemic. C1 [Aiello, Allison E.; Perez, Vanessa; Coulborn, Rebecca M.; Davis, Brian M.; Uddin, Monica] Univ Michigan, Sch Publ Hlth, Ctr Social Epidemiol & Populat Hlth, Ann Arbor, MI 48109 USA. [Aiello, Allison E.; Perez, Vanessa; Coulborn, Rebecca M.; Davis, Brian M.; Uddin, Monica; Monto, Arnold S.] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA. [Murray, Genevra F.] Univ S Alabama, Dept Sociol Anthropol & Social Work, Mobile, AL 36688 USA. [Shay, David K.; Waterman, Stephen H.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Aiello, AE (reprint author), Univ Michigan, Sch Publ Hlth, Ctr Social Epidemiol & Populat Hlth, 1415 Washington Hts, Ann Arbor, MI 48109 USA. EM aielloa@umich.edu OI Shay, David/0000-0001-9619-4820 FU PHS HHS [U01C1000441] NR 26 TC 98 Z9 101 U1 0 U2 6 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD FEB 15 PY 2010 VL 201 IS 4 BP 491 EP 498 DI 10.1086/650396 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 546WF UT WOS:000273843900004 PM 20088690 ER PT J AU Manoff, SB Liss, C Caulfield, MJ Marchese, RD Silber, J Boslego, J Romero-Steiner, S Rajam, G Glass, NE Whitney, CG Carlone, GM AF Manoff, Susan B. Liss, Charles Caulfield, Michael J. Marchese, Rocio D. Silber, Jeffrey Boslego, John Romero-Steiner, Sandra Rajam, Gowrisankar Glass, Nina E. Whitney, Cynthia G. Carlone, George M. TI Revaccination with a 23-Valent Pneumococcal Polysaccharide Vaccine Induces Elevated and Persistent Functional Antibody Responses in Adults Aged >= 65 Years SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID LINKED-IMMUNOSORBENT-ASSAY; COMMUNITY-ACQUIRED PNEUMONIA; STREPTOCOCCUS-PNEUMONIAE; ELDERLY PERSONS; HOSPITALIZED ADULTS; IMMUNIZATION; INDIVIDUALS; PREVALENCE; EFFICACY; IMMUNITY AB Background. Older adults are at high risk of developing invasive pneumococcal disease, but the optimal timing and number of vaccine doses needed to prevent disease among this group are unknown. We compared revaccination with 23-valent pneumococcal polysaccharide vaccine (PN23) with primary vaccination for eliciting initial and persistent functional antibody responses. Methods. Subjects aged >= 65 years were enrolled. Functional (opsonic) and total immunoglobulin (Ig) G antibody levels were measured following either PN23 primary vaccination (n = 60) or revaccination 3-5 years after receiving a first PN23 vaccination (n = 60). Antibody against vaccine serotypes 4, 14, and 23F was measured at prevaccination (day 0), 30 days after vaccination, and 5 years after vaccination. Results. By day 30, both primary vaccination and revaccination induced significant increases in opsonic and IgG antibody levels. Day 30 levels following revaccination were slightly lower but not significantly different than those after primary vaccination. Year 5 levels were similar in both groups and remained significantly higher than prevaccination levels for primary vaccination subjects. There was good agreement between postvaccination opsonic and IgG antibody levels. Conclusions. Revaccination of older adults with PN23 was comparable to primary vaccination for inducing elevated and persistent functional and IgG antibody responses. C1 [Manoff, Susan B.; Liss, Charles; Caulfield, Michael J.; Marchese, Rocio D.; Silber, Jeffrey; Boslego, John] Merck Res Labs, N Wales, PA 19454 USA. [Romero-Steiner, Sandra; Rajam, Gowrisankar; Glass, Nina E.; Whitney, Cynthia G.; Carlone, George M.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Manoff, SB (reprint author), Merck Res Labs, UG3CD-28,POB 1000, N Wales, PA 19454 USA. EM susan_manoff@merck.com OI Romero-Steiner, Sandra/0000-0003-4128-7768 NR 37 TC 43 Z9 43 U1 0 U2 5 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD FEB 15 PY 2010 VL 201 IS 4 BP 525 EP 533 DI 10.1086/651131 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 546WF UT WOS:000273843900009 PM 20088694 ER PT J AU Kibuuka, H Kimutai, R Maboko, L Sawe, F Schunk, MS Kroidl, A Shaffer, D Eller, LA Kibaya, R Eller, MA Schindler, KB Schuetz, A Millard, M Kroll, J Dally, L Hoelscher, M Bailer, R Cox, JH Marovich, M Birx, DL Graham, BS Michael, NL de Souza, MS Robb, ML AF Kibuuka, Hannah Kimutai, Robert Maboko, Leonard Sawe, Fred Schunk, Mirjam S. Kroidl, Arne Shaffer, Douglas Eller, Leigh Anne Kibaya, Rukia Eller, Michael A. Schindler, Karin B. Schuetz, Alexandra Millard, Monica Kroll, Jason Dally, Len Hoelscher, Michael Bailer, Robert Cox, Josephine H. Marovich, Mary Birx, Deborah L. Graham, Barney S. Michael, Nelson L. de Souza, Mark S. Robb, Merlin L. TI A Phase 1/2 Study of a Multiclade HIV-1 DNA Plasmid Prime and Recombinant Adenovirus Serotype 5 Boost Vaccine in HIV-Uninfected East Africans (RV 172) SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID IMMUNODEFICIENCY VIRUS CHALLENGE; MEMORY T-CELLS; CANDIDATE VACCINE; AIDS VACCINE; DOUBLE-BLIND; INFECTION; TRIAL; SURVIVAL; IMMUNITY; MONKEYS AB Background. Human immunodeficiency virus (HIV) vaccine development remains a global priority. We describe the safety and immunogenicity of a multiclade DNA vaccine prime with a replication-defective recombinant adenovirus serotype 5 (rAd5) boost. Methods. The vaccine is a 6-plasmid mixture encoding HIV envelope (env) subtypes A, B, and C and subtype B gag, pol, and nef, and an rAd5 expressing identical genes, with the exception of nef. Three hundred and twenty-four participants were randomized to receive placebo (n = 138), a single dose of rAd5 at 10(10) (n = 24) or 10(11) particle units (n = 24), or DNA at 0, 1, and 2 months, followed by rAd5 at either 10(10) (n = 114) or 10(11) particle units (n = 24) boosting at 6 months. Participants were followed up for 24 weeks after the final vaccination. Results. The vaccine was safe and well tolerated. HIV-specific T cell responses were detected in 63% of vaccinees. Titers of preexisting Ad5 neutralizing antibody did not affect the frequency and magnitude of T cell responses in prime-boost recipients but did affect the response rates in participants that received rAd5 alone (P = .037). Conclusion. The DNA/rAd5 vaccination regimen was safe and induced HIV type 1 multi-clade T cell responses, which were not significantly affected by titers of preexisting rAd5 neutralizing antibody. C1 [Kibuuka, Hannah; Eller, Leigh Anne; Eller, Michael A.; Millard, Monica] Makerere Univ, Walter Reed Project, Kampala, Uganda. [Kimutai, Robert; Sawe, Fred; Shaffer, Douglas; Kibaya, Rukia] US Army Med Res Unit Kenya, Walter Reed Project, Kericho, Kenya. [Maboko, Leonard; Schunk, Mirjam S.; Kroidl, Arne; Schindler, Karin B.; Schuetz, Alexandra; Hoelscher, Michael] Mbeya Med Res Programme, Mbeya, Tanzania. [Schunk, Mirjam S.; Kroidl, Arne; Schindler, Karin B.; Schuetz, Alexandra; Hoelscher, Michael] Klinikum Ludwigs Maximilians Univ, Munich, Germany. [Eller, Leigh Anne; Eller, Michael A.; Marovich, Mary; Michael, Nelson L.; de Souza, Mark S.; Robb, Merlin L.] US Mil, HIV Res Program, Rockville, MD USA. [Kroll, Jason; Dally, Len] Emmes Corp, Rockville, MD USA. [Bailer, Robert; Graham, Barney S.] NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA. [Cox, Josephine H.] Int AIDS Vaccine Initiat, New York, NY USA. [Birx, Deborah L.] Ctr Dis Control & Prevent, Atlanta, GA USA. [de Souza, Mark S.] Armed Forces Res Inst Med Sci, Bangkok 10400, Thailand. RP Robb, ML (reprint author), 1600 Gude Dr, Rockville, MD 20850 USA. EM mrobb@hivresearch.org RI Hoelscher, Michael/D-3436-2012 FU NIAID NIH HHS [Y01 AI2642-12] NR 24 TC 70 Z9 71 U1 0 U2 3 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD FEB 15 PY 2010 VL 201 IS 4 BP 600 EP 607 DI 10.1086/650299 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 546WF UT WOS:000273843900017 PM 20078213 ER PT J AU Goodman, AG Zeng, H Proll, SC Peng, XX Cilloniz, C Carter, VS Korth, MJ Tumpey, TM Katze, MG AF Goodman, Alan G. Zeng, Hui Proll, Sean C. Peng, Xinxia Cilloniz, Cristian Carter, Victoria S. Korth, Marcus J. Tumpey, Terrence M. Katze, Michael G. TI The Alpha/Beta Interferon Receptor Provides Protection against Influenza Virus Replication but Is Dispensable for Inflammatory Response Signaling SO JOURNAL OF VIROLOGY LA English DT Article ID NF-KAPPA-B; DOUBLE-STRANDED-RNA; INNATE IMMUNE-RESPONSE; A VIRUS; GENE-EXPRESSION; PROTEIN-KINASE; ANTIVIRAL ACTIVITY; HOST-DEFENSE; IFN-LAMBDA; ACTIVATION AB The innate immune response provides the first line of defense against foreign pathogens by responding to molecules that are a signature of a pathogenic infection. Certain RNA viruses, such as influenza virus, produce double-stranded RNA as an intermediate during the replication life cycle, which activates pathogen recognition receptors capable of inducing interferon production. By engaging interferon receptors, interferon activates the JAK-STAT pathway and results in the positive feedback of interferon production, amplifying the response to viral infection. To examine how deficiencies in interferon signaling affect the cellular response to infection, we performed influenza virus infections of mouse embryonic fibroblasts lacking the alpha/beta interferon receptor, the gamma interferon receptor, or both. In the absence of the alpha/beta interferon receptor, we observed increased viral replication but decreased activation of PKR, Stat1, and NF-kappa B; the presence or absence of the gamma interferon receptor did not exhibit discernible differences in these readouts. Analysis of gene expression profiles showed that while cells lacking the alpha/beta interferon receptor exhibited decreased levels of transcription of antiviral genes, genes related to inflammatory and apoptotic responses were transcribed to levels similar to those of cells containing the receptor. These results indicate that while the alpha/beta interferon receptor is needed to curb viral replication, it is dispensable for the induction of certain inflammatory and apoptotic genes. We have identified potential pathways, via interferon regulatory factor 3 (IRF3) activation or Hoxa13, Polr2a, Nr4a1, or Ing1 induction, that contribute to this redundancy. This study illustrates another way in which the host has evolved to establish several overlapping mechanisms to respond to viral infections. C1 [Goodman, Alan G.; Proll, Sean C.; Peng, Xinxia; Cilloniz, Cristian; Carter, Victoria S.; Korth, Marcus J.; Katze, Michael G.] Univ Washington, Dept Microbiol, Seattle, WA 98195 USA. [Katze, Michael G.] Washington Natl Primate Res Ctr, Seattle, WA 98195 USA. [Zeng, Hui; Tumpey, Terrence M.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Katze, MG (reprint author), Univ Washington, Dept Microbiol, Box 358070, Seattle, WA 98195 USA. EM honey@u.washington.edu FU NIH [R01AI022646] FX This work was supported by NIH grant R01AI022646 (M. G. K.). NR 59 TC 25 Z9 25 U1 1 U2 4 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD FEB 15 PY 2010 VL 84 IS 4 BP 2027 EP 2037 DI 10.1128/JVI.01595-09 PG 11 WC Virology SC Virology GA 546ZB UT WOS:000273853200036 PM 19939913 ER PT J AU Gregg, EW AF Gregg, Edward W. TI Are Children the Future of Type 2 Diabetes Prevention? SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material ID BODY-MASS INDEX; US; PREVALENCE; RISK; MORTALITY; TRENDS C1 Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Gregg, EW (reprint author), Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. NR 14 TC 15 Z9 15 U1 0 U2 2 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD FEB 11 PY 2010 VL 362 IS 6 BP 548 EP 550 DI 10.1056/NEJMe0912192 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 553WJ UT WOS:000274397200015 PM 20147721 ER PT J AU Glass, RI Parashar, UD Estes, MK AF Glass, Roger I. Parashar, Umesh D. Estes, Mary K. TI Norovirus Gastroenteritis REPLY SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Letter ID INFLAMMATORY-BOWEL-DISEASE C1 [Glass, Roger I.] NIH, Bethesda, MD 20892 USA. [Parashar, Umesh D.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Estes, Mary K.] Baylor Coll Med, Houston, TX 77030 USA. RP Glass, RI (reprint author), NIH, Bldg 10, Bethesda, MD 20892 USA. NR 4 TC 0 Z9 0 U1 0 U2 9 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD FEB 11 PY 2010 VL 362 IS 6 BP 557 EP 558 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 553WJ UT WOS:000274397200023 ER PT J AU Hall, J Poulson, M Fawcett, L Cosgrove, S Lujan, K Torres, P Adams-Cameron, M Winpisinger, K Yeager, J Hudecek, P Hyytia-Trees, E Garrett, N Adams, J Ewald, G Le, B Hausman, L Behravesh, CB Williams, I Sodha, S Capewell, L Mettee, S AF Hall, J. Poulson, M. Fawcett, L. Cosgrove, S. Lujan, K. Torres, P. Adams-Cameron, M. Winpisinger, K. Yeager, J. Hudecek, P. Hyytia-Trees, E. Garrett, N. Adams, J. Ewald, G. Le, B. Hausman, L. Behravesh, C. Barton Williams, I. Sodha, S. Capewell, L. Mettee, S. TI Multistate Outbreak of Human Salmonella Typhimurium Infections Associated With Aquatic Frogs-United States, 2009 (Reprinted from MMWR, vol 58, pg 1433-1436, 2010) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint ID TURTLES C1 [Hall, J.; Poulson, M.] Utah Dept Hlth, Salt Lake City, UT 84116 USA. [Winpisinger, K.] Ohio Dept Hlth, Columbus, OH 43266 USA. [Capewell, L.; Mettee, S.] CDC, Atlanta, GA 30333 USA. RP Hall, J (reprint author), Utah Dept Hlth, Salt Lake City, UT 84116 USA. NR 9 TC 0 Z9 0 U1 3 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD FEB 10 PY 2010 VL 303 IS 6 BP 500 EP + PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 553PG UT WOS:000274378700010 ER PT J AU Brackney, M Baumbach, J Ewers, C Martinez, AL Hagan, J Czuchlewski, D Foucar, K Fekrazad, MH Seifert, SA Dimple, D Nolte, KB Buchanan, JA Lavonas Nelson, C Wood, RW Duchin, JS VanEenwyk, J Reuter, N Ta, ML Vagi, S AF Brackney, M. Baumbach, J. Ewers, C. Martinez, A. L. Hagan, J. Czuchlewski, D. Foucar, K. Fekrazad, M. H. Seifert, S. A. Dimple, D. Nolte, K. B. Buchanan, J. A. Lavonas Nelson, C. Wood, R. W. Duchin, J. S. VanEenwyk, J. Reuter, N. Ta, M. L. Vagi, S. TI Agranulocytosis Associated With Cocaine Use-Four States, March 2008-November 2009 (Reprinted from MMWR, vol 58, pg 1381-1385, 2009) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint ID LEVAMISOLE C1 [Czuchlewski, D.; Foucar, K.] Univ New Mexico, Hlth Sci Ctr, Albuquerque, NM 87131 USA. [Fekrazad, M. H.] Univ New Mexico, Canc Res & Treatment Ctr, Albuquerque, NM 87131 USA. [Dimple, D.] Univ New Mexico Hosp, Dept Emergency Med, Albuquerque, NM USA. [Nolte, K. B.] Univ New Mexico, Off Med Investigator, Albuquerque, NM 87131 USA. [VanEenwyk, J.] Washington State Dept Hlth, Washington, DC USA. [Ta, M. L.; Vagi, S.] CDC, Atlanta, GA 30333 USA. NR 10 TC 1 Z9 1 U1 1 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD FEB 10 PY 2010 VL 303 IS 6 BP 504 EP + PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 553PG UT WOS:000274378700011 ER PT J AU Jang, SW Liu, X Yepes, M Shepherd, KR Miller, GW Liu, Y Wilson, WD Xiao, G Blanchi, B Sun, YE Ye, KQ AF Jang, Sung-Wuk Liu, Xia Yepes, Manuel Shepherd, Kennie R. Miller, Gary W. Liu, Yang Wilson, W. David Xiao, Ge Blanchi, Bruno Sun, Yi E. Ye, Keqiang TI A selective TrkB agonist with potent neurotrophic activities by 7,8-dihydroxyflavone SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE BDNF; neuroprotection; small molecule; binding ID AMYOTROPHIC-LATERAL-SCLEROSIS; LIGAND-BINDING DOMAINS; NERVOUS-SYSTEM; BRAIN; RECEPTOR; ACTIVATION; NEURONS; AROMATASE; MIMETICS; MEMORY AB Brain-derived neurotrophic factor (BDNF), a cognate ligand for the tyrosine kinase receptor B (TrkB) receptor, mediates neuronal survival, differentiation, synaptic plasticity, and neurogenesis. However, BDNF has a poor pharmacokinetic profile that limits its therapeutic potential. Here we report the identification of 7,8-dihydroxyflavone as a bioactive high-affinity TrkB agonist that provokes receptor dimerization and autophosphorylation and activation of downstream signaling. 7,8-Dihydroxyflavone protected wild-type, but not TrkB-deficient, neurons from apoptosis. Administration of 7,8-dihydroxyflavone to mice activated TrkB in the brain, inhibited kainic acid-induced toxicity, decreased infarct volumes in stroke in a TrkB-dependent manner, and was neuroprotective in an animal model of Parkinson disease. Thus, 7,8-dihydroxyflavone imitates BDNF and acts as a robust TrkB agonist, providing a powerful therapeutic tool for the treatment of various neurological diseases. C1 [Jang, Sung-Wuk; Liu, Xia; Ye, Keqiang] Emory Univ, Dept Pathol & Lab Med, Sch Med, Atlanta, GA 30322 USA. [Yepes, Manuel] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA. [Shepherd, Kennie R.; Miller, Gary W.] Emory Univ, Rollins Publ Sch Hlth, Dept Environm & Occupat Hlth, Atlanta, GA 30322 USA. [Liu, Yang; Wilson, W. David] Georgia State Univ, Dept Chem, Atlanta, GA 30302 USA. [Xiao, Ge] Ctr Dis Control & Prevent, Atlanta, GA 30322 USA. [Blanchi, Bruno; Sun, Yi E.] Univ Calif Los Angeles, Med Retardat Res Ctr, Inst Neuropsychiat, Los Angeles, CA 90095 USA. RP Ye, KQ (reprint author), Emory Univ, Dept Pathol & Lab Med, Sch Med, Atlanta, GA 30322 USA. EM kye@emory.edu RI Yepes, Manuel/C-3576-2011; OI blanchi, bruno/0000-0002-0814-5525 FU Johns Hopkins University [TrkA F592A, TrkB F616A]; National Institute of Health [RO1 NS045627, P01 ES016731] FX The authors thank Dr. D. Ginty, Johns Hopkins University, for providing TrkA F592A and TrkB F616A knockin mice. This work was supported by National Institute of Health Grants RO1 NS045627 to K. Y. and P01 ES016731 to G. W. M. NR 25 TC 238 Z9 249 U1 6 U2 32 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD FEB 9 PY 2010 VL 107 IS 6 BP 2687 EP 2692 DI 10.1073/pnas.0913572107 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 554AO UT WOS:000274408100059 PM 20133810 ER PT J AU MacFarquhar, JK Broussard, DL Melstrom, P Hutchinson, R Wolkin, A Martin, C Burk, RF Dunn, JR Green, AL Hammond, R Schaffner, W Jones, TF AF MacFarquhar, Jennifer K. Broussard, Danielle L. Melstrom, Paul Hutchinson, Richard Wolkin, Amy Martin, Colleen Burk, Raymond F. Dunn, John R. Green, Alice L. Hammond, Roberta Schaffner, William Jones, Timothy F. TI Acute Selenium Toxicity Associated With a Dietary Supplement SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article ID NUTRITIONAL SUPPLEMENT; PLASMA; HEPATOTOXICITY; URINE; CHINA; SE AB Background: Selenium is an element necessary for normal cellular function, but it can have toxic effects at high doses. We investigated an outbreak of acute selenium poisoning. Methods: A case was defined as the onset of symptoms of selenium toxicity in a person within 2 weeks after ingesting a dietary supplement manufactured by "Company A," purchased after January 1, 2008. We conducted case finding, administered initial and 90-day follow-up questionnaires to affected persons, and obtained laboratory data where available. Results: The source of the outbreak was identified as a liquid dietary supplement that contained 200 times the labeled concentration of selenium. Of 201 cases identified in 10 states, 1 person was hospitalized. The median estimated dose of selenium consumed was 41749 mu g/d (recommended dietary allowance is 55 mu g/d). Frequently reported symptoms included diarrhea (78%), fatigue (75%), hair loss (72%), joint pain (70%), nail discoloration or brittleness (61%), and nausea (58%). Symptoms persisting 90 days or longer included fingernail discoloration and loss (52%), fatigue (35%), and hair loss (29%). The mean initial serum selenium concentration of 8 patients was 751 mu g/L (reference range, <= 125 mu g/L). The mean initial urine selenium concentration of 7 patients was 166 mu g/24h (reference range, <= 55 mu g/24 h). Conclusions: Toxic concentrations of selenium in a liquid dietary supplement resulted in a widespread outbreak. Had the manufacturers been held to standards used in the pharmaceutical industry, it may have been prevented. C1 [Jones, Timothy F.] Tennessee Dept Hlth, Communicable Serv, Nashville, TN 37247 USA. [MacFarquhar, Jennifer K.; Melstrom, Paul] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Wolkin, Amy; Martin, Colleen] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. [Broussard, Danielle L.; Hutchinson, Richard; Hammond, Roberta] Florida Dept Hlth, Tallahassee, FL USA. [Broussard, Danielle L.] Council State & Territorial Epidemiol, Atlanta, GA USA. [Melstrom, Paul] Georgia Div Publ Hlth, Atlanta, GA USA. [Schaffner, William; Jones, Timothy F.] Vanderbilt Univ, Sch Med, Dept Prevent Med, Nashville, TN 37212 USA. [Burk, Raymond F.; Schaffner, William] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37212 USA. [Burk, Raymond F.] Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37212 USA. [Jones, Timothy F.] Vanderbilt Univ, Sch Med, Dept Family Practice, Nashville, TN 37212 USA. RP Jones, TF (reprint author), Tennessee Dept Hlth, Communicable Serv, 1st Floor,Cordell Hull Bldg,425 5th Ave N, Nashville, TN 37247 USA. EM Tim.F.Jones@tn.gov FU National Institutes of Health [DK058763] FX Dr Burk is supported in part by National Institutes of Health grant DK058763. NR 25 TC 68 Z9 72 U1 3 U2 14 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD FEB 8 PY 2010 VL 170 IS 3 BP 256 EP 261 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA 552LF UT WOS:000274291100005 PM 20142570 ER PT J AU Fujita, N Miller, A Miller, G Gershman, K Gallagher, N Marano, N Hale, C Jentes, E AF Fujita, N. Miller, A. Miller, G. Gershman, K. Gallagher, N. Marano, N. Hale, C. Jentes, E. TI Imported Case of Marburg Hemorrhagic Fever-Colorado, 2008 (Reprinted from MMWR, vol 58, pg 1377-1381, 2009) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Fujita, N.] Western Infect Dis Consultants, Wheat Ridge, CO USA. [Miller, A.] Exempla Lutheran Med Ctr, Wheat Ridge, CO USA. [Miller, G.] Jefferson Cty Publ Hlth, Jefferson, AR USA. [Gershman, K.] Natl Ctr Zoon Vector Borne & Enter Dis, Div Viral & Rickettsial Dis, Colorado Dept Publ Hlth & Environm, Special Pathogens Br, Denver, CO USA. [Gallagher, N.; Marano, N.] Natl Ctr Prevent Detect & Control Infect Dis, Div Global Migrat & Quarantine, Denver, CO USA. [Hale, C.; Jentes, E.] CDC, Atlanta, GA 30333 USA. RP Fujita, N (reprint author), Western Infect Dis Consultants, Wheat Ridge, CO USA. NR 1 TC 1 Z9 1 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD FEB 3 PY 2010 VL 303 IS 5 BP 413 EP 415 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 550QR UT WOS:000274143600006 ER PT J AU Goldman, M Selke, HM Pardo, I Clare, SE Emerson, RE Howell, JF Shieh, WJ Zaki, S Sanchez, C Sinkowitz-Cochran, RL Srinivasan, A Jhung, M Chester, TJ Ritchey, M Jarquin, VG Meites, E AF Goldman, M. Selke, H. M. Pardo, I. Clare, S. E. Emerson, R. E. Howell, J. F. Shieh, W-J Zaki, S. Sanchez, C. Sinkowitz-Cochran, R. L. Srinivasan, A. Jhung, M. Chester, T. J. Ritchey, M. Jarquin, V. G. Meites, E. TI Idiopathic Granulomatous Mastitis in Hispanic Women-Indiana, 2006-2008 (Reprinted from MMWR, vol 58, pg 1317-1321, 2009) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint ID CLINICAL PRESENTATION; DISEASE; EXPERIENCE C1 [Goldman, M.; Selke, H. M.; Pardo, I.; Clare, S. E.; Emerson, R. E.] Indiana Univ, Sch Med, Bloomington, IN 47405 USA. [Howell, J. F.] Indiana State Dept Hlth, Indianapolis, IN 46202 USA. [Shieh, W-J; Zaki, S.] Natl Ctr Zoonot Vector Borne & Enter Dis, Div Viral & Rickettsial Dis, Denver, CO USA. [Sanchez, C.; Sinkowitz-Cochran, R. L.; Srinivasan, A.; Jhung, M.] Natl Ctr Preparedness Detect & Control Infect Dis, Div Healthcare Qual Promot, Denver, CO USA. [Ritchey, M.; Jarquin, V. G.; Meites, E.] CDC, Atlanta, GA 30333 USA. RP Goldman, M (reprint author), Indiana Univ, Sch Med, Bloomington, IN 47405 USA. NR 11 TC 0 Z9 0 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD FEB 3 PY 2010 VL 303 IS 5 BP 415 EP 417 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 550QR UT WOS:000274143600007 ER PT J AU Barr, IG McCauley, J Cox, N Daniels, R Engelhardt, OG Fukuda, K Grohmann, G Hay, A Kelso, A Klimov, A Odagiri, T Smith, D Russell, C Tashiro, M Webby, R Wood, J Ye, ZP Zhang, WQ AF Barr, Ian G. McCauley, John Cox, Nancy Daniels, Rod Engelhardt, Othmar G. Fukuda, Keiji Grohmann, Gary Hay, Alan Kelso, Anne Klimov, Alexander Odagiri, Takato Smith, Derek Russell, Colin Tashiro, Masato Webby, Richard Wood, John Ye, Zhiping Zhang, Wenqing CA World Hlth Org Consultation No Hem TI Epidemiological, antigenic and genetic characteristics of seasonal influenza A(H1N1), A(H3N2) and B influenza viruses: Basis for the WHO recommendation on the composition of influenza vaccines for use in the 2009-2010 Northern Hemisphere season SO VACCINE LA English DT Article DE Influenza; Vaccine; Human; Seasonal ID SOUTH EAST-ASIA; ADAMANTANE RESISTANCE; ISOLATED WORLDWIDE; AUSTRALIA; COUNTRIES; EMERGENCE AB Influenza vaccines form an important component of the global response against infections and subsequent illness caused in man by influenza viruses. Twice a year, in February and September, the World Health Organisation through its Global Influenza Surveillance Network (GISN), recommends appropriate influenza viruses to be included in the seasonal influenza vaccine for the upcoming Northern and Southern Hemisphere winters. This recommendation is based on the latest data generated from many sources and the availability of viruses that are suitable for vaccine manufacture. This article gives a summary of the data and background to the recommendations for the 2009-2010 Northern Hemisphere influenza vaccine formulation. (C) 2009 Elsevier Ltd. All rights reserved. C1 [Barr, Ian G.; Kelso, Anne] VIDRL, WHO Collaborating Ctr Reference & Res Influenza, Melbourne, Vic, Australia. [Cox, Nancy; Klimov, Alexander] CDC, WHO Collaborating Ctr Surveillance Epidemiol & Co, Atlanta, GA 30333 USA. [McCauley, John; Daniels, Rod; Hay, Alan] NIMR, WHO Collaborating Ctr Reference & Res Influenza, London, England. [Odagiri, Takato; Tashiro, Masato] NIID, WHO Collaborating Ctr Reference & Res Influenza, Tokyo, Japan. [Fukuda, Keiji; Zhang, Wenqing] WHO GIP, Geneva, Switzerland. [Engelhardt, Othmar G.; Wood, John] NIBSC, London, England. [Ye, Zhiping] CBER, Bethesda, MD USA. [Grohmann, Gary] TGA, Canberra, ACT, Australia. [Smith, Derek; Russell, Colin] NIH, Fogarty Int Ctr, Bethesda, MD 20892 USA. [Smith, Derek; Russell, Colin] Univ Cambridge, Cambridge CB2 1TN, England. [Webby, Richard] St Jude Childrens Hosp, WHO Collaborating Ctr Studies Ecol Influenza Anim, Memphis, TN 38105 USA. RP Barr, IG (reprint author), WHO Collaborating Ctr Reference & Res Influenza, VIDRL, 10 Wreckyn St, Melbourne, Vic 3051, Australia. EM Ian.Barr@influenzacentre.org; GISN@who.int OI Russell, Colin/0000-0002-2113-162X FU Medical Research Council [MC_U117585868, MC_U117512723] NR 18 TC 78 Z9 80 U1 2 U2 11 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD FEB 3 PY 2010 VL 28 IS 5 BP 1156 EP 1167 DI 10.1016/j.vaccine.2009.11.043 PG 12 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 563IN UT WOS:000275122200005 PM 20004635 ER PT J AU Davis, MM Butchart, AT Coleman, MS Singer, DC Wheeler, JRC Pok, A Freed, GL AF Davis, Matthew M. Butchart, Amy T. Coleman, Margaret S. Singer, Dianne C. Wheeler, John R. C. Pok, Angela Freed, Gary L. TI The expanding vaccine development pipeline, 1995-2008 SO VACCINE LA English DT Article DE Vaccine; Clinical trials; Industry ID INVASIVE PNEUMOCOCCAL DISEASE; UNITED-STATES; VARICELLA VACCINATION; CONJUGATE VACCINE; DRUG DEVELOPMENT; DECLINE; IMPACT; COSTS AB Successful launches of recently licensed vaccines contrast with pharmaceutical industry concerns about unfavorable market conditions, making the status and future of vaccine development uncertain. We assessed trends in private-sector vaccine research and development for the period 1995-2008, using a global pharmaceutical database to identify prophylactic vaccines in preclinical, Phase I, Phase II, or Phase III stages of development. We counted companies that research and/or manufacture vaccines ("vaccine originators") and their vaccine products in each year. The global number of vaccine originators doubled (to 136), as did the number of prophylactic vaccine products in development (to 354); the majority of this growth was in preclinical and early phase clinical research. Because rapid growth in earlier research phases has not yet led to growth in Phase III, it is not yet clear whether recent industry expansion will translate to an increase in the number of available vaccines in the near future. (C) 2009 Elsevier Ltd. All rights reserved. C1 [Davis, Matthew M.] Univ Michigan, Dept Pediat, Child Hlth Evaluat & Res Unit, Div Gen Pediat, Ann Arbor, MI 48109 USA. [Davis, Matthew M.] Univ Michigan, Div Gen Internal Med, Ann Arbor, MI 48109 USA. [Davis, Matthew M.] Univ Michigan, Gerald R Ford Sch Publ Policy, Ann Arbor, MI 48109 USA. [Wheeler, John R. C.; Freed, Gary L.] Univ Michigan, Dept Hlth Policy & Management, Sch Publ Hlth, Ann Arbor, MI 48109 USA. [Davis, Matthew M.; Coleman, Margaret S.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Immunizat Serv Div, Atlanta, GA USA. RP Davis, MM (reprint author), Univ Michigan, Dept Pediat, Child Hlth Evaluat & Res Unit, Div Gen Pediat, 300 NIB,6C23, Ann Arbor, MI 48109 USA. EM mattdav@med.umich.edu FU Centers for Disease Control and Prevention FX This study was funded by the Centers for Disease Control and Prevention. The authors had complete control of the study data and take full responsibility for the study analyses and presentation of findings. NR 17 TC 15 Z9 15 U1 3 U2 5 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD FEB 3 PY 2010 VL 28 IS 5 BP 1353 EP 1356 DI 10.1016/j.vaccine.2009.11.007 PG 4 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 563IN UT WOS:000275122200030 PM 19932670 ER PT J AU Jain, RB AF Jain, Ram B. TI Comparison of three weighting schemes in weighted regression analysis for use in a chemistry laboratory SO CLINICA CHIMICA ACTA LA English DT Article DE Accuracy; Precision; Weighted regression analysis; Heteroscedasticity ID PERFORMANCE LIQUID-CHROMATOGRAPHY; TANDEM MASS-SPECTROMETRY; LINEAR-REGRESSION; 2-COMPONENT MODEL; QUANTIFICATION; SERUM; METHOTREXATE; VALIDATION; NONSMOKERS; COTININE AB Background: To minimize the effect of heteroscedasticity in chemical and other data, weighted regression analysis is the preferred regression technique. In this work a regression weight that maximizes accuracy and precision was sought. Method: Using real and simulated data from a serum cotinine assay, performance of 3 weighting schemes, namely, 1/X, 1/X(2), and 1/s(2)(Y) to calibrate chemical data was evaluated. Two performance measures were used to evaluate the accuracy and precision of each scheme to estimate concentrations in unknown specimens. Results: The weight, 1/X-particularly for low concentrations-was not acceptable. The performance of both, 1/X(2) and 1/s(2)(Y) was close, 1/X(2) being slightly better in many cases. Overall, however, when the variance of instrument signal increased beyond certain limits, none of the weighting schemes performed acceptably. Conclusion: Because of its simplicity and ease of use, 1/X(2) is recommended for general application. If, however, instrument signal variance is too high to be managed by statistical techniques, the only solution is to control such variance through laboratory-based solutions. Published by Elsevier B.V. C1 [Jain, Ram B.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Chamblee, GA 30341 USA. RP Jain, RB (reprint author), Ctr Dis Control & Prevent, Mail Stop F-4, Atlanta, GA 30341 USA. EM RIJO@cdc.gov NR 14 TC 8 Z9 8 U1 2 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0009-8981 J9 CLIN CHIM ACTA JI Clin. Chim. Acta PD FEB 2 PY 2010 VL 411 IS 3-4 BP 270 EP 279 DI 10.1016/j.cca.2009.11.021 PG 10 WC Medical Laboratory Technology SC Medical Laboratory Technology GA 550BS UT WOS:000274102700027 PM 19945448 ER PT J AU Maeshiro, R Johnson, I Koo, D Parboosingh, J Carney, JK Gesundheit, N Ho, ET Butler-Jones, D Donovan, D Finkelstein, JA Bennett, NM Shore, B McCurdy, SA Novick, LF Velarde, LD Dent, MM Banchoff, A Cohen, L AF Maeshiro, Rika Johnson, Ian Koo, Denise Parboosingh, Jean Carney, Jan K. Gesundheit, Neil Ho, Evelyn T. Butler-Jones, David Donovan, Denise Finkelstein, Jonathan A. Bennett, Nancy M. Shore, Barbie McCurdy, Stephen A. Novick, Lloyd F. Velarde, Lily Dow Dent, M. Marie Banchoff, Ann Cohen, Laurence TI Medical Education for a Healthier Population: Reflections on the Flexner Report From a Public Health Perspective SO ACADEMIC MEDICINE LA English DT Article ID UNITED-STATES; CURRICULUM; PROJECT; SCHOOL; DEATH AB Abraham Flexner's 1910 report is credited with promoting critical reforms in medical education. Because Flexner advocated scientific rigor and standardization in medical education, his report has been perceived to place little emphasis on the importance of public health in clinical education and training. However, a review of the report reveals that Flexner presciently identified at least three public-health-oriented principles that contributed to his arguments for medical education reform: (1) The training, quality, and quantity of physicians should meet the health needs of the public, (2) physicians have societal obligations to prevent disease and promote health, and medical training should include the breadth of knowledge necessary to meet these obligations, and (3) collaborations between the academic medicine and public health communities result in benefits to both parties. In this article, commemorating the Flexner Centenary, the authors review the progress of U.S. and Canadian medical schools in addressing these principles in the context of contemporary societal health needs, provide an update on recent efforts to address what has long been perceived as a deficit in medical education (inadequate grounding of medical students in public health), and provide new recommendations on how to create important linkages between medical education and public health. Contemporary health challenges that require a public health approach in addition to one-on-one clinical skills include containing epidemics of preventable chronic diseases, reforming the health care system to provide equitable high-quality care to populations, and responding to potential disasters in an increasingly interconnected world. The quantitative skills and contextual knowledge that will prepare physicians to address these and other population health problems constitute the basics of public health and should be included throughout the continuum of medical education. C1 [Maeshiro, Rika] Assoc Amer Med Coll, Publ Hlth Project, Washington, DC 20037 USA. [Maeshiro, Rika] Assoc Amer Med Coll, Prevent Project, Washington, DC 20037 USA. [Johnson, Ian] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada. [Koo, Denise] US Ctr Dis Control & Prevent, Off Workforce & Career Dev, Atlanta, GA USA. [Shore, Barbie] Assoc Fac Med Canada, Publ Hlth Project, Ottawa, ON, Canada. [Carney, Jan K.] Univ Vermont, Coll Med, Burlington, VT USA. [Ho, Evelyn T.] Stanford Univ, Sch Med, Off Community Hlth, Cardinal Free Clin, Stanford, CA 94305 USA. [Ho, Evelyn T.] Stanford Univ, Sch Med, Off Community Hlth, Educ Programs, Stanford, CA 94305 USA. [Butler-Jones, David] Publ Hlth Agcy Canada, Ottawa, ON, Canada. [Donovan, Denise] Univ Sherbrooke, Fac Med & Hlth Sci, Sherbrooke, PQ J1K 2R1, Canada. [Finkelstein, Jonathan A.] Harvard Univ, Sch Med, Boston, MA USA. [Finkelstein, Jonathan A.] Harvard Pilgrim Hlth Care Inst, Boston, MA USA. [Bennett, Nancy M.] Univ Rochester, Med Ctr, Ctr Community Hlth, Rochester, NY 14642 USA. [Bennett, Nancy M.] Monroe Cty Dept Publ Hlth, Rochester, NY USA. [Shore, Barbie] Assoc Fac Med Canada, Indigenous Hlth Project, Ottawa, ON, Canada. [McCurdy, Stephen A.] Univ Calif Davis, Davis Sch Med, MPH Program, Davis, CA 95616 USA. [McCurdy, Stephen A.] Univ Calif Davis, Davis Sch Med, Dept Publ Hlth Sci, Davis, CA 95616 USA. [Novick, Lloyd F.] E Carolina Univ, Dept Publ Hlth, Brody Sch Med, Greenville, NC USA. [Velarde, Lily Dow] Univ New Mexico, Dept Family & Community Med, Hlth Sci Ctr, Albuquerque, NM 87131 USA. [Dent, M. Marie] Mercer Univ, Sch Med, Community Med Programs, Macon, GA 31207 USA. [Cohen, Laurence] Ctr Dis Control & Prevent, Student Programs, Career Dev Div, Off Workforce & Career Dev, Atlanta, GA USA. RP Maeshiro, R (reprint author), Assoc Amer Med Coll, Publ Hlth Project, 2450 N St,NW, Washington, DC 20037 USA. EM rmaeshiro@aamc.org FU Strengthen Collaboration Between the Disciplines of Academic Medicine and Public Health [5U36CD319276-08]; Public Health Agency of Canada's; AFMC for Enhancing the Health of the Population: Strengthening the Role of Canadian Faculties of Medicine [6266-15-2006/8660005] FX Funding/ Support: Dr. Maeshiro's work on this article was supported by the AAMC's cooperative agreement with the CDC, a partnership to Strengthen Collaboration Between the Disciplines of Academic Medicine and Public Health, grant number 5U36CD319276-08. Ms. Shore's work on this article was supported by the Public Health Agency of Canada's contribution agreement with the AFMC for Enhancing the Health of the Population: Strengthening the Role of Canadian Faculties of Medicine, contribution agreement number 6266-15-2006/8660005. NR 44 TC 46 Z9 46 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1040-2446 J9 ACAD MED JI Acad. Med. PD FEB PY 2010 VL 85 IS 2 BP 211 EP 219 DI 10.1097/ACM.0b013e3181c885d8 PG 9 WC Education, Scientific Disciplines; Health Care Sciences & Services SC Education & Educational Research; Health Care Sciences & Services GA 576GF UT WOS:000276131700017 PM 20107345 ER PT J AU Stout, JE Kosinski, AS Hamilton, CD Goodman, PC Mosher, A Menzies, D Schluger, N Khan, A Johnson, JL AF Stout, Jason E. Kosinski, Andrzej S. Hamilton, Carol Dukes Goodman, Philip C. Mosher, Ann Menzies, Dick Schluger, Neil Khan, Awal Johnson, John L. CA TB Trials Consortium TI Effect of Improving the Quality of Radiographic Interpretation on the Ability to Predict Pulmonary Tuberculosis Relapse SO ACADEMIC RADIOLOGY LA English DT Article DE Tuberculosis; radiography; thoracic; reliability and validity ID CHEST RADIOGRAPH; DISEASE; ERROR; RISK AB Rationale and Objectives: Chest radiographic findings are important for diagnosis and management of tuberculosis. The reliability of these findings is therefore of interest. We sought to describe interobserver reliability of chest radiographic findings in pulmonary tuberculosis, and to understand how the reliability of these findings might affect the utility of radiographic findings in predicting tuberculosis relapse. Materials and Methods: Three blinded readers independently reviewed chest radiographs from a randomly selected group of 10% of HIV-seronegative subjects participating in a tuberculosis treatment trial. The three readers then arrived at a fourth, consensus radiographic interpretation. Results: A total of 241 films obtained from 99 patients were reviewed. Agreement among the independent readers was very good for the findings of bilateral disease (kappa = 0.71-0.86 among readers) and cavitation (kappa = 0.66-0.73). The original interpretation was reasonably sensitive and specific (compared to the consensus interpretation) for bilateral disease, but the sensitivity for cavity decreased from 81% for the 2-month film to 47% at end of treatment (P = 0.013). Substituting the consensus interpretation for the original interpretation increased the odds ratio for the association between cavitation on early chest radiograph and subsequent tuberculosis relapse from 4.97 to 8,97. Conclusion: Radiographic findings were reasonably reliable between independent reviewers and the original interpretations. The original investigators, who knew the patient's clinical course, were less likely to identify cavitation on the end of treatment chest radiograph. Improving the reliability of these findings could improve the utility of chest radiographs for predicting tuberculosis relapse. C1 [Stout, Jason E.; Hamilton, Carol Dukes; Mosher, Ann] 3306 Duke Univ, Med Ctr, Div Infect Dis & Int Hlth, Dept Med, Durham, NC 27710 USA. [Kosinski, Andrzej S.] 3306 Duke Univ, Med Ctr, Dept Biostat & Bioinformat, Durham, NC 27710 USA. [Goodman, Philip C.] 3306 Duke Univ, Med Ctr, Div Thorac Imaging, Dept Radiol, Durham, NC 27710 USA. [Menzies, Dick] McGill Univ, Montreal Chest Inst, Montreal, PQ, Canada. [Schluger, Neil] Columbia Univ Coll Phys & Surg, Div Pulm Allergy & Crit Care Med, New York, NY 10032 USA. [Khan, Awal] Ctr Dis Control & Prevent, Atlanta, GA USA. [Johnson, John L.] Case Western Reserve Univ, Div Infect Dis, Cleveland, OH 44106 USA. RP Stout, JE (reprint author), 3306 Duke Univ, Med Ctr, Div Infect Dis & Int Hlth, Dept Med, Durham, NC 27710 USA. EM stout002@mc.duke.edu OI Stout, Jason/0000-0002-6698-8176 FU United States Centers for Disease Control and Prevention; CDC, Washington, D.C.; National Institutes of Health [K23AI051409, K24AI001833] FX USPHS/TB Trials Consortium Study 22 was sponsored by the United States Centers for Disease Control and Prevention and was funded in part through a Memorandum of Understanding between the CDC and the Washington, D.C. Veterans Affairs Medical Center. Hoechst Marion Roussel, the manufacturer of rifapentine, provided rifapentine and contributed to the cost of 3 investigator meetings, but did not participate in original or secondary analysis study design, data collection, data analysis, data interpretation, or writing of the report. Dr. Stout received salary support from the National Institutes of Health (K23AI051409). Dr. Hamilton also received salary support from the National Institutes of Health (K24AI001833). NR 25 TC 3 Z9 3 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1076-6332 J9 ACAD RADIOL JI Acad. Radiol. PD FEB PY 2010 VL 17 IS 2 BP 157 EP 162 DI 10.1016/j.acra.2009.08.013 PG 6 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA 546TF UT WOS:000273834100005 PM 19910216 ER PT J AU Guo, Q Unger, JB Azen, SP Li, CY Spruijt-Metz, D Palmer, PH Chou, CP Lee, LM Sun, P Johnson, CA AF Guo, Qian Unger, Jennifer B. Azen, Stanley P. Li, Chaoyang Spruijt-Metz, Donna Palmer, Paula H. Chou, Chih-Ping Lee, Liming Sun, Ping Johnson, C. Anderson TI Cognitive attributions for smoking among adolescents in China SO ADDICTIVE BEHAVIORS LA English DT Article DE Attributions; Smoking; Attribution theory; Adolescents; China ID CIGARETTE-SMOKING; COLLEGE STUDENTS; TOBACCO SMOKING; SCHOOL-STUDENTS; SOCIAL IMAGE; NON-SMOKERS; REASONS; BEHAVIOR; NONSMOKERS; INITIATION AB To design more effective health communication messages for smoking cessation and prevention. it is important to understand people's own perceptions of the factors that influence their decisions to smoke. Studies have examined cognitive attributions for smoking in Western countries but not in the Chinese cultural context. In a study of 14,434 Chinese adolescents, exploratory factor analysis grouped 17 cognitive attributions into 8 factors: curiosity, coping, social image, social belonging, engagement, autonomy, mental enhancement, and weight control. The factors were ranked based on the participants' self-reports of importance and by the strength of their associations with smoking behavior. Among all smokers, curiosity was the most frequently-ranked attribution factor at the early stages of smoking but not for daily smoking. Coping was highly-ranked across smoking stages. Social image and social belonging were more highly-ranked at earlier stages, whereas engagement and mental enhancement were ranked more highly at later stages of smoking. More attributions were associated with smoking among males than among females. This information could be useful for the development of evidence-based anti-smoking programs in China. Published by Elsevier Ltd. C1 [Guo, Qian] Alcohol & Drug Program Adm, Dept Publ Hlth, Alhambra, CA 91803 USA. [Unger, Jennifer B.; Johnson, C. Anderson] Claremont Grad Univ, Sch Community & Global Hlth, Claremont, CA USA. [Azen, Stanley P.; Spruijt-Metz, Donna; Palmer, Paula H.; Chou, Chih-Ping; Sun, Ping] Univ So Calif, Keck Sch Med, Los Angeles, CA 90089 USA. [Li, Chaoyang] Ctr Dis Control & Prevent, Div Adult & Community Hlth, Atlanta, GA USA. [Lee, Liming] Peking Univ, Hlth Sci Ctr, Beijing, Peoples R China. RP Guo, Q (reprint author), Alcohol & Drug Program Adm, Dept Publ Hlth, 1000 S Fremont Ave,Bldg A9 E,3rd Floor, Alhambra, CA 91803 USA. EM qguo8@yahoo.com OI Unger, Jennifer/0000-0001-9064-6603 FU Chinese Center for Disease Control and Prevention; Peking University School of Public Health; Health Bureau, and Education Committee FX We also thank the principals, physicians, and teachers in the participating schools for their cooperation. Finally, we express our gratitude to the national Chinese Center for Disease Control and Prevention, Peking University School of Public Health, and the municipal government. Health Bureau, and Education Committee in each participating city for their support. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the U.S. Centers for Disease Control and Prevention. NR 46 TC 13 Z9 14 U1 5 U2 10 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4603 J9 ADDICT BEHAV JI Addict. Behav. PD FEB PY 2010 VL 35 IS 2 BP 95 EP 101 DI 10.1016/j.addbeh.2009.09.008 PG 7 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA 532QD UT WOS:000272763600004 PM 19800741 ER PT J AU Mizuno, Y Purcell, DW Latka, MH Metsch, LR Ding, H Gomez, CA Knowlton, AR AF Mizuno, Yuko Purcell, David W. Latka, Mary H. Metsch, Lisa R. Ding, Helen Gomez, Cynthia A. Knowlton, Amy R. TI Is Sexual Serosorting Occurring Among HIV-Positive Injection Drug Users? Comparison Between Those with HIV-Positive Partners Only, HIV-Negative Partners Only, and Those with any Partners of Unknown Status SO AIDS AND BEHAVIOR LA English DT Article DE HIV-positive IDUs; Partner HIV status; Serosorting; Partner selection ID TRANSMISSION RISK BEHAVIOR; UNPROTECTED SEX; UNITED-STATES; MEN; SEROSTATUS; RESPONSIBILITY; PREVENTION; INTERVENTION; CALIFORNIA; REDUCTION AB Using baseline data from a multi-site, randomized controlled study (INSPIRE), we categorized 999 HIV-positive IDUs into three groups based on serostatus of their sex partners. Our data provide some evidence for serosorting occurring in our sample; about 40% of the sample had sex exclusively with HIV-positive partners, and about half of them reported having unprotected sex with these partners. Twenty per cent had sex exclusively with HIV-negative partners; their sexual behaviors tended to be least risky with about two-thirds reporting their sex was protected. However, we also found that another 40% had at least one partner of unknown HIV status and sexual and drug risk was the highest among them. They were also least empowered, showing attributes that may undermine HIV prevention. Some of these findings are consistent with findings from MSM studies, suggesting that partner selection practices are similar between primarily heterosexual IDUs and MSM. C1 [Mizuno, Yuko; Purcell, David W.; Ding, Helen] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Latka, Mary H.] New York Acad Med, Ctr Urban Epidemiol Studies, New York, NY USA. [Metsch, Lisa R.] Univ Miami, Dept Epidemiol & Publ Hlth, Leonard M Miller Sch Med, Miami, FL USA. [Gomez, Cynthia A.] Univ Calif San Francisco, Dept Med, Ctr AIDS Prevent Studies, San Francisco, CA USA. [Knowlton, Amy R.] Johns Hopkins Univ, Dept Hlth Behav & Soc, Bloomberg Sch Publ Hlth, Baltimore, MD USA. RP Mizuno, Y (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd NE,Mail Stop E37, Atlanta, GA 30333 USA. EM ymizuno@cdc.gov OI Purcell, David/0000-0001-8125-5168 NR 38 TC 7 Z9 7 U1 0 U2 3 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 J9 AIDS BEHAV JI AIDS behav. PD FEB PY 2010 VL 14 IS 1 BP 92 EP 102 DI 10.1007/s10461-009-9548-8 PG 11 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA 550DD UT WOS:000274107600013 PM 19308717 ER PT J AU Hageman, KM Dube, HMB Mugurungi, O Gavin, LE Hader, SL St Louis, ME AF Hageman, Kathy M. Dube, Hazel M. B. Mugurungi, Owen Gavin, Loretta E. Hader, Shannon L. St Louis, Michael E. TI Beyond Monogamy: Opportunities to Further Reduce Risk for HIV Infection Among Married Zimbabwean Women with only One Lifetime Partner SO AIDS AND BEHAVIOR LA English DT Article DE HIV testing; Monogamy; Sexual behavior; Africa; Serostatus knowledge; Women; Risk factors ID CONSISTENT CONDOM USE; IMMUNODEFICIENCY-VIRUS-INFECTION; CHILDBEARING WOMEN; DISCORDANT COUPLES; SEXUAL-BEHAVIOR; AFRICA; AIDS; TRANSMISSION; PREVALENCE; PREVENTION AB The main objective of this paper was to identify HIV risk factors at the individual, partner, and partnership levels among married, lifetime monogamous women in a nationally representative sample of Zimbabweans aged 15-29 years. Cross-sectional data were collected through individual survey interviews among 1,286 women who provided blood for HIV testing. The HIV prevalence among these women was high (21.8%). HIV risk increased with female age, within-couple age difference of more than 5 years, the husband having children with other women, and the respondent being 'extremely likely' to discuss monogamy in the next 3 months with her husband. The latter suggests that women were attempting to communicate their concerns while unaware that they were already HIV positive. HIV risk largely appears related to the partner's past and present sexual behavior, resulting in limited ability for married women to protect themselves from infection. Overall, lifetime monogamy offers insufficient protection for women. C1 [Hageman, Kathy M.] Emory Univ, Dept Behav Sci & Hlth Educ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Dube, Hazel M. B.] Zimbabwe Natl Family Planning Council, Harare, Zimbabwe. [Mugurungi, Owen] Minist Hlth & Child Welf, Harare, Zimbabwe. [Gavin, Loretta E.; Hader, Shannon L.; St Louis, Michael E.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Hageman, KM (reprint author), Emory Univ, Dept Behav Sci & Hlth Educ, Rollins Sch Publ Hlth, 1518 Clifton Rd, Atlanta, GA 30322 USA. EM khagema@emory.edu FU NIMH NIH HHS [F31 MH082634] NR 42 TC 4 Z9 4 U1 1 U2 3 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 J9 AIDS BEHAV JI AIDS behav. PD FEB PY 2010 VL 14 IS 1 BP 113 EP 124 DI 10.1007/s10461-009-9603-5 PG 12 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA 550DD UT WOS:000274107600015 PM 19685181 ER PT J AU Tate, J Singh, K Ndubani, P Kamwanga, J Buckner, B AF Tate, Jackie Singh, Kavita Ndubani, Phillimon Kamwanga, Jolly Buckner, Bates TI Measurement of HIV Prevention Indicators: A Comparison of the PLACE Method and a Household Survey in Zambia SO AIDS AND BEHAVIOR LA English DT Article DE HIV prevention; Sexual behavior; Measurement; Zambia ID SEXUAL-BEHAVIOR AB Reaching populations at greatest risk for acquiring HIV is essential for efforts to combat the epidemic. This paper presents, the Priorities for Local AIDS Control Efforts (PLACE) method which focuses on understanding the venues where people are meeting new sexual partners and behaviors which put people at risk. A comparison of data from two PLACE studies in Zambia with a national household survey, the Zambia Sexual Behavior Survey 2005, indicated that the PLACE population was at greater risk of acquiring HIV. Respondents in the two PLACE studies were significantly more likely to report 1+ new partners in the past 4 weeks, 2+ partners in the past 12 months, 1+ new partner in the past 12 months and transactional sex. Data from the PLACE method is important for targeting interventions for those most likely to acquire and transmit HIV. C1 [Singh, Kavita; Buckner, Bates] Univ N Carolina, MEASURE Evaluat, Chapel Hill, NC 27516 USA. [Tate, Jackie] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA USA. [Ndubani, Phillimon; Kamwanga, Jolly] Frontiers Dev & Res Grp, Lusaka, Zambia. RP Singh, K (reprint author), Univ N Carolina, MEASURE Evaluat, CB 8120, Chapel Hill, NC 27516 USA. EM kavita_singh@unc.edu FU NICHD NIH HHS [R24 HD050924] NR 15 TC 5 Z9 5 U1 0 U2 0 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 J9 AIDS BEHAV JI AIDS behav. PD FEB PY 2010 VL 14 IS 1 BP 209 EP 217 DI 10.1007/s10461-008-9505-y PG 9 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA 550DD UT WOS:000274107600026 PM 19089607 ER PT J AU Courtenay-Quirk, C Horvath, KJ Ding, H Fisher, H McFarlane, M Kachur, R O'Leary, A Rosser, BRS Harwood, E AF Courtenay-Quirk, Cari Horvath, Keith J. Ding, Helen Fisher, Holly McFarlane, Mary Kachur, Rachel O'Leary, Ann Rosser, B. R. Simon Harwood, Eileen TI Perceptions of HIV-Related Websites Among Persons Recently Diagnosed with HIV SO AIDS PATIENT CARE AND STDS LA English DT Article ID INTERNET USE; TRANSGENDER PERSONS; HEALTH INFORMATION; NEEDS-ASSESSMENT; DIGITAL DIVIDE; UNITED-STATES; SEXUAL RISK; HIV/AIDS; PEOPLE; MEN AB Many HIV-positive persons use the Internet to address at least some of their needs for HIV-specific information and support. The aim of this multimethod study was to understand how a diverse sample of persons who were recently diagnosed with HIV (PRDH) used the Internet after an HIV diagnosis and their perceptions of online HIV-related information and resources. HIV-positive persons (N = 63) who had been diagnosed since the year 2000 were recruited primarily through HIV-related websites and HIV medical clinics. One third of participants (33%, n = 21) were gay or bisexual men, 25% (n = 16) were heterosexual men, 32% (n = 20) were heterosexual women, and 10% (n = 6) were transgender women (male to female). Semistructured interviews and brief postinterview surveys were used to collect qualitative and quantitative data. Qualitative findings suggested that the most appealing websites to PRDH included those that: (1) provided usable information on topics of immediate concern; (2) used accessible formats that were easy to navigate; (3) were perceived as trustworthy, and (4) provided access to diverse perspectives of persons living with HIV/AIDS. Topics that PRDH found most useful included various medical treatment-related issues, tools for coping with depression and fear, and learning how others cope with HIV. Incorporating the perspectives of HIV-positive persons into the design and content of HIV-related websites is important to enhance their appeal for this diverse and growing population. C1 [Courtenay-Quirk, Cari; Ding, Helen; Fisher, Holly; O'Leary, Ann] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. [Horvath, Keith J.; Rosser, B. R. Simon; Harwood, Eileen] Univ Minnesota, Dept Epidemiol & Community Hlth, Minneapolis, MN USA. [McFarlane, Mary; Kachur, Rachel] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA 30333 USA. RP Courtenay-Quirk, C (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, 1600 Clifton Rd,MS E-37, Atlanta, GA 30333 USA. EM afv2@cdc.gov FU CDC Cooperative [5UR6PS000341] FX This study was funded by the CDC Cooperative agreement #5UR6PS000341. The findings and conclusions in this report are those of the authors and do not necessarily reflect the views of the CDC. NR 39 TC 15 Z9 15 U1 2 U2 3 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1087-2914 J9 AIDS PATIENT CARE ST JI Aids Patient Care STDS PD FEB PY 2010 VL 24 IS 2 BP 105 EP 115 DI 10.1089/apc.2009.0228 PG 11 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 555QB UT WOS:000274527200006 PM 20064028 ER PT J AU Baron, S Cone, J Markowitz, SB Souza, K AF Baron, Sherry Cone, James Markowitz, Steven B. Souza, Kerry TI Introduction to a Special Issue: Occupational Health Disparities SO AMERICAN JOURNAL OF INDUSTRIAL MEDICINE LA English DT Editorial Material C1 [Baron, Sherry; Souza, Kerry] NIOSH, Cincinnati, OH 45226 USA. [Cone, James] New York City Dept Hlth & Mental Hyg, New York, NY USA. [Markowitz, Steven B.] Queens Coll, Ctr Biol Nat Syst, Queens, NY USA. RP Baron, S (reprint author), 4676 Columbia Pkwy, Cincinnati, OH 45226 USA. EM sbaron@cdc.gov NR 8 TC 1 Z9 1 U1 1 U2 3 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0271-3586 J9 AM J IND MED JI Am. J. Ind. Med. PD FEB PY 2010 VL 53 IS 2 SI SI BP 82 EP 83 DI 10.1002/ajim.20776 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 549SV UT WOS:000274075500002 PM 20094987 ER PT J AU Souza, K Steege, AL Baron, SL AF Souza, Kerry Steege, Andrea L. Baron, Sherry L. TI Surveillance of Occupational Health Disparities: Challenges and Opportunities SO AMERICAN JOURNAL OF INDUSTRIAL MEDICINE LA English DT Editorial Material DE surveillance; disparities; occupational health; immigrant workers; socioeconomic status ID SOCIOECONOMIC-STATUS; MUSCULOSKELETAL INJURIES; INTERVIEW SURVEY; UNITED-STATES; US WORKERS; MORTALITY; EXPOSURE; ILLNESS; SYSTEM; SAFETY AB Increasingly, the occupational health community is turning its attention to the effects of work on previously underserved populations, and researchers have identified many examples of disparities in occupational health outcomes. However, the occupational health status of some underserved worker populations is not described due to limitations in existing surveillance systems. As such, the occupational health. community has identified the need to enhance and improve occupational health surveillance to describe the nature and extent of disparities in occupational illnesses and injuries (including fatalities), identify priorities for research and intervention, and evaluate trends. This report summarizes the data sources and methods discussed at an April 2008 workshop organized by NIOSH on the topic of improving surveillance for occupational health disparities. We discuss the capability of existing occupational health surveillance systems to document occupational health disparities and to provide surveillance data on minority and other underserved communities. Use of administrative data, secondary data analysis, and the development of targeted surveillance systems for occupational health surveillance are also discussed. Identifying and reducing occupational health disparities is one of NIOSH's priority areas under the National Occupational Research Agenda (NORA). Am. J. Ind. Med. 5 3:84-94 2010. Published 2010 Wiley-Liss, Inc.(dagger) C1 [Souza, Kerry] US Ctr Dis Control & Prevent CDC, DSHEFS, NIOSH, Washington, DC USA. [Steege, Andrea L.; Baron, Sherry L.] US Ctr Dis Control & Prevent CDC, DSHEFS, NIOSH, Cincinnati, OH USA. RP Souza, K (reprint author), 395 E St SW,Patriots Plaza,Suite 9257, Washington, DC 20201 USA. EM ksouza@cdc.gov RI Steege, Andrea/H-8900-2016 OI Steege, Andrea/0000-0001-5665-2559 NR 81 TC 21 Z9 21 U1 5 U2 10 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0271-3586 J9 AM J IND MED JI Am. J. Ind. Med. PD FEB PY 2010 VL 53 IS 2 SI SI BP 84 EP 94 DI 10.1002/ajim.20777 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 549SV UT WOS:000274075500003 PM 20094988 ER PT J AU Calvert, GM Higgins, SA AF Calvert, Geoffrey M. Higgins, Sheila A. TI Using Surveillance Data to Promote Occupational Health and Safety Policies and Practice at the State Level: A Case Study SO AMERICAN JOURNAL OF INDUSTRIAL MEDICINE LA English DT Editorial Material DE congenital abnormalities; farmworkers; insecticides; pesticides; prevention and control; surveillance ID ILLNESSES AB Background Following the investigation of a birth defects cluster involving migrant farmworkers employed in North Carolina and Florida, it became clear that greater efforts were needed to protect agricultural workers from pesticide exposure. Methods Documentation is drawn from peer-reviewed published articles, government reports and news accounts. Results The birth defects cluster was identified and investigated by state and federal pesticide poisoning surveillance system staff. Following the investigation, efforts were initiated to highlight pesticides as an important public health issue needing more attention. A series of subsequent events led to the creation and passage of important legislation recently enacted in North Carolina. The legislation resulted in funding to promote various activities to prevent harm form pesticides including strengthening surveillance, improving the quality of pesticide compliance inspections, and increasing and improving pesticide safety training. The legislation also broadened the coverage of anti-retaliation rules to include agricultural workers, and increased recordkeeping requirements pertaining to pesticide applications. Conclusion The important and positive impacts that can occur through surveillance activities are highlighted. As such, it is important to continue to support and improve occupational illness and injury surveillance programs. Am. J. Ind. Med. 53: 188-193 2010. Published 2009 Wiley-Liss, Inc.(dagger) C1 [Calvert, Geoffrey M.] Ctr Dis Control & Prevent, Div Surveillance Hazard Evaluat & Field Studies, NIOSH, Cincinnati, OH 45226 USA. [Higgins, Sheila A.] N Carolina Dept Hlth & Human Serv, Raleigh, NC USA. RP Calvert, GM (reprint author), Ctr Dis Control & Prevent, Div Surveillance Hazard Evaluat & Field Studies, NIOSH, 4676 Columbia Pkwy,R-17, Cincinnati, OH 45226 USA. EM jac6@cdc.gov NR 24 TC 3 Z9 3 U1 2 U2 6 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0271-3586 J9 AM J IND MED JI Am. J. Ind. Med. PD FEB PY 2010 VL 53 IS 2 SI SI BP 188 EP 193 DI 10.1002/ajim.20707 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 549SV UT WOS:000274075500014 PM 19479875 ER PT J AU Fujishiro, K Gong, F Baron, S Jacobson, CJ DeLaney, S Flynn, M Eggerth, DE AF Fujishiro, Kaori Gong, Fang Baron, Sherry Jacobson, C. Jeffery, Jr. DeLaney, Sheli Flynn, Michael Eggerth, Donald E. TI Translating Questionnaire Items for a Multi-Lingual Worker Population: The Iterative Process of Translation and Cognitive Interviews With English-, Spanish-, and Chinese-Speaking Workers SO AMERICAN JOURNAL OF INDUSTRIAL MEDICINE LA English DT Article DE immigrant workers; homecare; cognitive interview; translation; questionnaire development; qualitative analysis ID IMMIGRANT; INJURIES; HEALTH; RISKS AB Background The increasing ethnic diversity of the US workforce has created a need for research tools that can be used with multi-lingual worker populations. Developing multi-language questionnaire items is a complex process; however; very little has been documented in the literature. Methods Commonly used English items from the Job Content Questionnaire and Quality of Work Life Questionnaire were translated by two interdisciplinary bilingual teams and cognitively tested in interviews with English-, Spanish-, and Chinese-speaking workers. Results Common problems across languages mainly concerned response format. Language-specific problems required more conceptual than literal translations. Some items were better understood by non-English speakers than by English Speakers. De-centering (i.e., modifying the English original to correspond with translation) produced better understanding for one item. Conclusions Translating questionnaire items and achieving equivalence across languages require various kinds of expertise. Backward translation itself is not sufficient. More research efforts should be concentrated on qualitative approaches to developing useful research tools. Am. J. Ind. Med. 53: 194-203 2010. Published 2009 Wiley-Liss, Inc.(dagger) C1 [Fujishiro, Kaori; Gong, Fang; Baron, Sherry] NIOSH, DSHEFS, Cincinnati, OH 45226 USA. [Gong, Fang] Ball State Univ, Dept Sociol, Muncie, IN 47306 USA. [Jacobson, C. Jeffery, Jr.] Univ Cincinnati, Dept Anthropol & Family Med, Cincinnati, OH USA. [DeLaney, Sheli; Flynn, Michael; Eggerth, Donald E.] NIOSH, Educ & Informat Div, Cincinnati, OH 45226 USA. RP Fujishiro, K (reprint author), NIOSH, DSHEFS, 4676 Columbia Pkwy,R-15, Cincinnati, OH 45226 USA. EM kfujishiro@cdc.gov OI Jacobson Jr., C. Jeffrey/0000-0001-7072-5777 FU National Institute for Occupational Safety and Health [NORA FY05 DSHEFS12.3] FX Contract grant sponsor: National Institute for Occupational Safety and Health; Contract grant number: NORA FY05 DSHEFS12.3.; This study was funded by the National Institute for Occupational Safety and Health (NORA FY05 DSHEFS 12.3). The authors wish to thank the 30 respondents and 2 interviewers, Heather Lloyd and Jimmy Zhang Ming. We also thank SEIU Long Term Care Workers Union and Linda Ayala from Public Authority for In-Home Supportive Services in Alameda County for providing access to the respondents. Dan La Botz, Carlos Aristeguieta, Ken Wong, Kai Lui, and Xu Zhang assisted with translation. Laura Stock and the Labor Occupational Health Program at University of California, Berkeley, provided technical assistance. NR 31 TC 5 Z9 5 U1 1 U2 2 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0271-3586 J9 AM J IND MED JI Am. J. Ind. Med. PD FEB PY 2010 VL 53 IS 2 SI SI BP 194 EP 203 DI 10.1002/ajim.20733 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 549SV UT WOS:000274075500015 PM 19650081 ER PT J AU Allen-Bridson, K Horan, T AF Allen-Bridson, Katherine Horan, Teresa TI Recent changes in the NHSN Definition for UTI: For better AND worse Response SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Letter ID STAPHYLOCOCCUS-AUREUS; BACTERIURIA; ASSOCIATION; BACTEREMIA C1 [Allen-Bridson, Katherine; Horan, Teresa] Ctr Dis Control & Prevent CDC, Atlanta, GA 30333 USA. RP Allen-Bridson, K (reprint author), Ctr Dis Control & Prevent CDC, Atlanta, GA 30333 USA. EM NHSN@cdc.gov NR 6 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD FEB PY 2010 VL 38 IS 1 BP 82 EP 83 DI 10.1016/j.ajic.2009.08.002 PG 3 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 559WQ UT WOS:000274859400019 ER PT J AU Sanchez-Lara, PA Carmichael, SL Graham, JM Lammer, EJ Shaw, GM Ma, C Rasmussen, SA AF Sanchez-Lara, Pedro A. Carmichael, Suzan L. Graham, John M., Jr. Lammer, Edward J. Shaw, Gary M. Ma, Chen Rasmussen, Sonja A. CA Natl Birth Defects Prevention Stud TI Fetal Constraint as a Potential Risk Factor for Craniosynostosis SO AMERICAN JOURNAL OF MEDICAL GENETICS PART A LA English DT Article DE craniosynostosis; fetal constraint; plurality; twinning; macrosomia; prolonged gestation; low birth weight; calvarial morphogenesis; skull deformation; sagittal synostosis; metopic synostosls ID BIRTH-DEFECTS PREVENTION; HEAD CONSTRAINT; GROWTH; CRANIOSTENOSIS; TWINS; FERTILITY; WEIGHT; EXPRESSION; MACROSOMIA; NOGGIN AB Non-syndromic craniosynostosis is multifactorial, and fetal head constraint has been hypothesized as one factor thought to play a role. Data from the National Birth Defects Prevention Study (NBDPS), a large multi-site case-control study of birth defects, were used to evaluate associations between four selected factors related to fetal constraint and craniosynostosis: plurality (twins or higher), macrosomia (birth weight >4,000 g), post-term gestational age (>= 42 weeks), and nulliparity (no previous live births). Case infants (n = 675) had craniosynostosis documented either by radiographic evidence or by surgical intervention. Infants with a recognized or strongly suspected single-gene conditions or chromosomal abnormalities were excluded. Control infants (n = 5,958) had no major birth defects and were randomly selected from the same population as case infants. Logistic regression was used to estimate odds ratios for the association between these four factors and craniosynostosis, while adjusting for several covariates. We found that plurality and nulliparity were associated with a twofold increased risk for metopic craniosynostosis, and macrosomia had almost twice the risk of developing coronal craniosynostosis. Contrary to our hypothesis, prematurity and low birth weight were also associated with craniosynostosis. In conclusion, these four constraint-related factors were not found to be associated with craniosynostosis when all suture types were combined, though some types of craniosynostosis were associated with individual constraint-related factors. (C) 2010 Wiley-Liss, Inc. C1 [Sanchez-Lara, Pedro A.] Univ So Calif, Childrens Hosp Los Angeles, Keck Sch Med, Los Angeles, CA 90027 USA. [Carmichael, Suzan L.; Shaw, Gary M.; Ma, Chen] March Dimes Fdn, Calif Res Div, Oakland, CA USA. [Graham, John M., Jr.] Univ Calif Los Angeles, David Geffen Sch Med, Cedars Sinai Med Ctr, Inst Med Genet, Los Angeles, CA 90095 USA. [Lammer, Edward J.] Childrens Hosp Oakland, Res Inst, Oakland, CA 94609 USA. [Shaw, Gary M.] Stanford Univ, Sch Med, Stanford, CA 94305 USA. [Rasmussen, Sonja A.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Sanchez-Lara, PA (reprint author), Univ So Calif, Childrens Hosp Los Angeles, Keck Sch Med, 4650 Sunset Blvd,MS-90, Los Angeles, CA 90027 USA. EM pedro.sanchez@usc.edu RI Sanchez-Lara, Pedro/F-6352-2012; Publications, NBDPS/B-7692-2013 OI Sanchez-Lara, Pedro/0000-0002-8027-177X; FU Centers for Disease Control and Prevention Centers of Excellence Award [U50/CCU925286]; Harold Amos Faculty Development Program through the Robert Wood Johnson Foundation; CHLA-USC Child Health Research Career Development Program [NIH K12-HD05954]; SHARE's Childhood Disability Center; Steven Spielberg Pediatric Research Center; NIH/NICHD [HD22657]; Medical Genetics NIH/NIGMS [5-T32-GM08243] FX The authors are grateful to all of the participating families which made this research possible. We would also like to thank the staff, abstractors, and study investigators from each site for the invaluable contributions. This work was made possible by funding from the Centers for Disease Control and Prevention Centers of Excellence Award No. U50/CCU925286. PAS is supported by the Harold Amos Faculty Development Program through the Robert Wood Johnson Foundation and the CHLA-USC Child Health Research Career Development Program (NIH K12-HD05954). JMG is supported by SHARE's Childhood Disability Center, the Steven Spielberg Pediatric Research Center, the NIH/NICHD Program Project Grant (HD22657), and the Medical Genetics NIH/NIGMS Training Program Grant (5-T32-GM08243). We thank the California Department of Public Health, Maternal Child and Adolescent Health Division for providing surveillance data from California for this study. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention, the National Institute of Child Health and Human Development, the National Institutes of Health, or the California Department of Public Health. NR 43 TC 25 Z9 25 U1 0 U2 11 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 1552-4825 J9 AM J MED GENET A JI Am. J. Med. Genet. A PD FEB PY 2010 VL 152A IS 2 BP 394 EP 400 DI 10.1002/ajmg.a.33246 PG 7 WC Genetics & Heredity SC Genetics & Heredity GA 555KA UT WOS:000274508300019 PM 20101684 ER PT J AU Zhao, Z Luman, ET AF Zhao, Zhen Luman, Elizabeth T. TI Progress Toward Eliminating Disparities in Vaccination Coverage Among US Children, 2000-2008 SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID NATIONAL IMMUNIZATION SURVEY; ODDS RATIOS MISLEAD; UNITED-STATES; RACIAL/ETHNIC DISPARITIES; CHILDHOOD VACCINATION; ETHNIC DISPARITIES; YOUNG-CHILDREN; OUTCOMES; IMPACT AB Background: The goal year for the Healthy People 2010 initiative is approaching. Purpose: This article aims to assess progress toward reaching the overarching goal of eliminating disparities in vaccination coverage among young children in the U.S. Methods: Coverage for the 4:3.1.3-3:1 vaccine series (at least four doses of diphtheria-tetanus-pertussis, three poliovirus, one measles-mumps-rubella, three hepatitis B, three Haemophilus influenzae type B, and one varicella vaccine) was assessed among 185,516 children in the 2000-2008 National Immunization Surveys. Observed and adjusted disparities in coverage were evaluated for various sociodemographic groups previously associated with vaccination coverage. Linear trends ill disparities were assessed. Results: In 2000, disparities among population segments were significant (p<0.05) for all sociodemographic factors assessed except provider participation in the Vaccines for Children program. By 2008, most disparities were smaller than those in 2000, and racial and urban/suburban/rural differences were reduced to levels below significance. Disparities between children living in suburban versus rural localities narrowed approximately 0.5% per year. Vaccination covet-age increased substantially among children in all sociodemographic groups, although children without siblings were the only group to reach the 8096 tat-get by 2008 Conclusions: Progress has been made toward eliminating vaccination coverage disparities among children in various sociodemographic groups in the U.S. As the end of the Healthy People 2010 goal period approaches, maintaining and advancing these reductions will require innovative strategies to reach Underserved groups. (Am J Prev Med 2010,38(2).127-137) Published by Elsevier Inc on behalf of American Journal of Preventive Medicine C1 [Zhao, Zhen] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, CDC, Atlanta, GA 30333 USA. RP Zhao, Z (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, CDC, 1600 Clifton Rd NE,MS E62, Atlanta, GA 30333 USA. FU CDC, USDHHS FX This research and the National Immunization Survey were conducted through funding and approval by the CDC, USDHHS. NR 29 TC 16 Z9 17 U1 2 U2 9 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD FEB PY 2010 VL 38 IS 2 BP 127 EP 137 DI 10.1016/j.amepre.2009.10.035 PG 11 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 554EZ UT WOS:000274419600002 PM 20117568 ER PT J AU Naimi, TS Nelson, DE Brewer, RD AF Naimi, Timothy S. Nelson, David E. Brewer, Robert D. TI The Intensity of Binge Alcohol Consumption Among US Adults SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID OBVIOUSLY INTOXICATED PATRONS; DRINKING; STATES; RISK; ESTABLISHMENTS; SALES AB Background: Binge drinking (consuming five or more drinks during, a drinking occasion) is responsible for more than half of the 79,000 annual deaths due to excessive drinking in the U.S. Although studies show a strong close-response relationship between the intensity of binge drinking (i.e., the number of drinks consumed per binge episode) and adverse outcomes, there are no population-based Studies assessing this measure. Purpose: This study aims to analyze population-based data from a module of questions on binge drinking among U.S. adults to assess the number of drinks consumed by binge drinkers and the associated independent risk factors for consuming more drinks Methods: Data were analyzed from 14,143 adult binge drinkers who responded to the Behavioral Risk Factor Surveillance System binge drinking module in 2003 and 2004 Total drinks were calculated by summing the total number of beer, wine, and liquor-containing drinks consumed during a respondents' most recent binge drinking episode Results: Binge drinkers consumed an average of 8.0 drinks (median 6) during their most recent binge drinking episode, 70.0% of binge drinkers consumed six or more drinks, and 38.4% consumed eight or more drinks. Men consumed more drinks during their last binge episode than women (M =8.3 vs 7.0, median=7 vs 6), and those aged 18-34 years consumed more drinks than those aged >34 years for both men and women. Independent risk factors for consuming eight or more drinks included being male, being aged <35 years; being other than white race/ethnicity; having less education, not being married, binge drinking three or more times in the past 30 days; and drinking mostly beer Conclusions: Most adult binge drinkers drink in excess of the five-drink threshold defining this risky behavior. The intensity of binge drinking should be monitored regularly by health agencies to improve surveillance and to better assess the impact of interventions designed to reduce binge drinking and its consequences. (Am J Prev Med 2010,38(2) 201-207) Published by Elsevier Inc on behalf of American Journal of Preventive Medicine C1 [Naimi, Timothy S.; Nelson, David E.; Brewer, Robert D.] CDC, Alcohol Team, Emerging Invest & Analyt Methods Branch, Div Adult & Community Hlth,Natl Ctr Chron Dis Pre, Atlanta, GA 30333 USA. RP Naimi, TS (reprint author), GIM, Boston Med Ctr, 801 Massachusetts Ave,Crosstown Bldg,2nd Floor, Boston, MA 02118 USA. NR 25 TC 44 Z9 46 U1 2 U2 16 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD FEB PY 2010 VL 38 IS 2 BP 201 EP 207 DI 10.1016/j.amepre.2009.09.039 PG 7 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 554EZ UT WOS:000274419600011 PM 20117577 ER PT J AU Elder, RW Lawrence, B Ferguson, A Naimi, TS Brewer, RD Chattopadhyay, SK Toomey, TL Fielding, JE AF Elder, Randy W. Lawrence, Briana Ferguson, Aneeqah Naimi, Timothy S. Brewer, Robert D. Chattopadhyay, Sajal K. Toomey, Traci L. Fielding, Jonathan E. CA Task Force Community Preventive TI The Effectiveness of Tax Policy Interventions for Reducing Excessive Alcohol Consumption and Related Harms SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Review ID MOTOR-VEHICLE FATALITIES; TIME-SERIES ANALYSIS; UNITED-STATES; BEVERAGE PRICES; BEER TAXES; ECONOMIC-DETERMINANTS; TRAFFIC FATALITIES; EMPIRICAL-ANALYSIS; HEAVY DRINKING; LIQUOR DEMAND AB A systematic review of the literature to assess the effectiveness of alcohol tax policy Interventions for reducing excessive alcohol consumption and related harms was conducted for the Guide to Community Preventive Services (Community Guide) Seventy-two papers or technical reports, which were published prior to July 2005, met specified quality criteria, and included evaluation outcomes relevant to Public health (e.g, binge drinking, alcohol-related crash fatalities), were Included in the final review. Nearly all studies, including those with different Study designs, found that there was all inverse relationship between the tax or price of alcohol and indices of excessive drinking or alcohol-related health outcomes Among Studies restricted to underage populations, most found that increased taxes were also significantly associated with reduced consumption and alcohol-related harms. According to Community Guide rules of evidence, these results Constitute strong evidence that raising alcohol excise taxes is all effective strategy for reducing excessive alcohol consumption and related harms. The impact of a potential tax increase is expected to be proportional to its Magnitude and to be modified by such factors as disposable income and the demand elasticity for alcohol among various population groups. (Am J Prev Med 2010,38(2).217-229) Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Elder, Randy W.; Lawrence, Briana; Ferguson, Aneeqah; Chattopadhyay, Sajal K.] CDC, Natl Ctr Hlth Mkt, Atlanta, GA 30333 USA. [Naimi, Timothy S.; Brewer, Robert D.] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Toomey, Traci L.] Univ Minnesota, Sch Publ Hlth, Minneapolis, MN USA. [Fielding, Jonathan E.] Los Angeles Cty Dept Publ Hlth, Los Angeles, CA USA. RP Elder, RW (reprint author), Guide Community Prevent Serv, 1600 Clifton Rd,Mailstop E-69, Atlanta, GA 30333 USA. RI Stockwell, Tim/B-6662-2012 FU Oak Ridge Institute for Scientific Education (ORISE) FX The work of Briana Lawrence and Aneeqah Ferguson Was Supported with funds from the Oak Ridge Institute for Scientific Education (ORISE) NR 110 TC 116 Z9 118 U1 5 U2 33 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD FEB PY 2010 VL 38 IS 2 BP 217 EP 229 DI 10.1016/j.amepre.2009.11.005 PG 13 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 554EZ UT WOS:000274419600013 PM 20117579 ER PT J AU Hopkins, DP Razi, S Leeks, KD Kalra, GP Chattopadhyay, SK Soler, RE AF Hopkins, David P. Razi, Sima Leeks, Kimberly D. Kalra, Geetika Priya Chattopadhyay, Sajal K. Soler, Robin E. CA Task Force Community Preventive Se TI Smokefree Policies to Reduce Tobacco Use A Systematic Review SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Review ID WORKPLACE SMOKING RESTRICTIONS; SHORT-TERM IMPACT; EMPLOYEE SMOKING; SECONDHAND SMOKE; CIGARETTE CONSUMPTION; NATIONAL-SURVEY; PASSIVE SMOKING; MEDICAL-CENTER; TOTAL BAN; BEHAVIOR AB In 2001, a systematic review for the Guide to Community Preventive Services identified strong evidence of effectiveness of smoking bans and restrictions in reducing exposure to environmental (secondhand) tobacco smoke. As follow-up to that earlier review, the focus here was on the evidence on effectiveness of smokefree policies in reducing tobacco use. Smokefree policies implemented by worksites or communities prohibit smoking in workplaces and designated public areas. The conceptual approach was modified for this review; an updated search for evidence was conducted; and the available evidence was evaluated. Published articles that met quality criteria and evaluated changes in tobacco-use prevalence or cessation were included in the review. A total of 57 studies were identified in the period 1976 through June 2005 that met criteria to be candidates for review; of these, 37 met study design and quality of execution criteria to qualify for final assessment. Twenty-one studies measured absolute differences in tobacco-use prevalence with a median effect of -3.4 percentage points (interquartile interval: -6.3 to -1.4 percentage points). Eleven studies measured differences in tobacco-use cessation among tobacco users exposed to a smokefree policy compared with tobacco users not exposed to a smokefree policy. The median absolute change was an increase in cessation of 6.4 percentage points (interquartile interval: 1.3 to 7.9 percentage points). The qualifying studies provided sufficient evidence that smokefree policies reduce tobacco use among workers when implemented in worksites or by communities. Finally, a systematic economic review identified four studies that, overall, demonstrated economic benefits from a smokefree workplace policy. Additional research is needed to more fully evaluate the total economic effects of these policies. (Am J Prev Med 2010;38(2S):S275-S289) Published by Elsevier Inc. on behalf of American journal of Preventive Medicine C1 [Hopkins, David P.; Razi, Sima; Leeks, Kimberly D.; Kalra, Geetika Priya; Chattopadhyay, Sajal K.; Soler, Robin E.; Task Force Community Preventive Se] CDC, Guide Community Prevent Serv, Natl Ctr Hlth Mkt, Atlanta, GA 30333 USA. RP Hopkins, DP (reprint author), Ctr Dis Control & Prevent, Community Guide Branch, 1600 Clifton Rd,MS-E69, Atlanta, GA 30333 USA. EM DHopkins@cdc.gov NR 120 TC 73 Z9 74 U1 8 U2 22 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD FEB PY 2010 VL 38 IS 2 SU 2 BP S275 EP S289 DI 10.1016/j.amepre.2009.10.029 PG 15 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 554FA UT WOS:000274419700007 PM 20117612 ER PT J AU Leeks, KD Hopkins, DP Soler, RE Aten, A Chattopadhyay, SK AF Leeks, Kimberly D. Hopkins, David P. Soler, Robin E. Aten, Adam Chattopadhyay, Sajal K. CA Task Force Community Preventive Se TI Worksite-Based Incentives and Competitions to Reduce Tobacco Use A Systematic Review SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Review ID SMOKING-CESSATION PROGRAM; SELF-HELP; CHEMICAL EMPLOYEES; QUIT RATES; INTERVENTION; HEALTH; IMPACT; PARTICIPATION; TRIAL; METAANALYSIS AB The Guide to Community Preventive Service (Community Guide) methods for systematic reviews were used to evaluate the evidence of effectiveness of worksite-based incentives and competitions to reduce tobacco use among workers. These interventions offer a reward to individuals or to teams of individuals on the basis of participation or success in a specified smoking behavior change (such as abstaining from tobacco use for a period of time). The review team identified a total of 26 published studies, 14 of which met study design and quality of execution criteria for inclusion in the final assessment. Only one study, which did not qualify for review, evaluated the use of incentives when implemented alone. All of the 14 qualifying studies evaluated incentives and competitions when implemented in combination with a variety of additional interventions, such as client education, smoking cessation groups, and telephone cessation support. Of the qualifying studies, 13 evaluated differences in tobacco-use cessation among intervention participants, with a median follow-up period of 12 months. The median change in self-reported tobacco-use cessation was an increase of 4.4 percentage points (a median relative percentage improvement of 67%). The present evidence is insufficient to determine the effectiveness of incentives or competitions, when implemented alone, to reduce tobacco use. However, the qualifying studies provide strong evidence, according to Community Guide rules, that worksite-based incentives and competitions in combination with additional interventions are effective in increasing the number of workers who quit using tobacco. In addition, these multicomponent interventions have the potential to generate positive economic returns over investment when the averted costs of tobacco-associated illnesses are considered. A concurrent systematic review identified four studies with economic evidence. Two of these studies provided evidence of net cost savings to employers when program costs are adjusted for averted healthcare expenses and productivity losses, based on referenced secondary estimates. (Am J Prev Med 2010;38(2S):S263-S274) Published by Elsevier Inc. on behalf of American journal of Preventive Medicine C1 [Soler, Robin E.] Ctr Dis Control & Prevent, Community Guide Branch, Div Hlth Commun & Mkt Strategy, Natl Ctr Hlth Mkt,CDC, Atlanta, GA 30333 USA. RP Soler, RE (reprint author), Ctr Dis Control & Prevent, Community Guide Branch, Div Hlth Commun & Mkt Strategy, Natl Ctr Hlth Mkt,CDC, 1600 Clifton Rd,MS-E69, Atlanta, GA 30333 USA. EM RSoler@cdc.gov NR 55 TC 21 Z9 21 U1 2 U2 17 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD FEB PY 2010 VL 38 IS 2 SU 2 BP S263 EP S274 DI 10.1016/j.amepre.2009.10.034 PG 12 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 554FA UT WOS:000274419700006 PM 20117611 ER PT J AU Pearson-Clarke, T AF Pearson-Clarke, Tony CA Task Force Community Preventive TI Recommendations for Worksite-Based Interventions to Improve Workers' Health SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID PROMOTION C1 [Pearson-Clarke, Tony; Task Force Community Preventive] CDC, Community Guide Branch, Div Hlth Commun & Mkt Strategy, Natl Ctr Hlth Mkt,Century Ctr 2500, Atlanta, GA 30333 USA. RP Pearson-Clarke, T (reprint author), CDC, Community Guide Branch, Div Hlth Commun & Mkt Strategy, Natl Ctr Hlth Mkt,Century Ctr 2500, 1600 Clifton Rd,MS E-69,Room 4100-10, Atlanta, GA 30333 USA. EM TPearsonClarke@cdc.gov NR 13 TC 0 Z9 0 U1 3 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD FEB PY 2010 VL 38 IS 2 SU 2 BP S232 EP S236 DI 10.1016/j.amepre.2009.10.033 PG 5 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 554FA UT WOS:000274419700004 ER PT J AU Soler, RE Leeks, KD Buchanan, LR Brownson, RC Heath, GW Hopkins, DH AF Soler, Robin E. Leeks, Kimberly D. Buchanan, Leigh Ramsey Brownson, Ross C. Heath, Gregory W. Hopkins, David H. CA Task Force Community Preventive Se TI Point-of-Decision Prompts to Increase Stair Use A Systematic Review Update SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Review ID HEALTH-PROMOTION; POSTERS; EXERCISE; WORKSITE; PEOPLE; IMPACT; SIGNS AB In 2000, the Guide to Community Preventive Services (Community Guide) completed a systematic review of the effectiveness of various approaches to increasing physical activity including informational, behavioral and social, and environmental and policy approaches. Among these approaches was the use of signs placed by elevators and escalators to encourage stair use. This approach was found to be effective based on sufficient evidence. Over the past 5 years the body of evidence of this intervention has increased substantially, warranting an updated review. This update was conducted on 16 peer-reviewed studies (including the six studies in the previous systematic review), which met specified quality criteria and included evaluation outcomes of interest. These studies evaluated two interventions: point-of-decision prompts to increase stair use and enhancements to stairs or stairwells (e.g., painting walls, laying carpet, adding artwork, playing music) when combined with point-of-decision prompts to increase stair use. This latter intervention was not included in the original systematic review. According to the Community Guide rules of evidence, there is strong evidence that point-of-decision prompts are effective in increasing the use of stairs. There is insufficient evidence, due to an inadequate number of studies, to determine whether or not enhancements to stairs or stairwells are an effective addition to point-of-decision prompts. This article describes the rationale for these systematic reviews, along with information about the review process and the resulting conclusions. Additional information about applicability, other effects, and barriers to implementation is also provided. (Am J Prev Med 2010;38(2S):S292-S300) Published by Elsevier Inc. on behalf of American journal of Preventive Medicine C1 [Soler, Robin E.] Ctr Dis Control & Prevent, Community Guide Branch, Div Hlth Commun & Mkt Strategy, Natl Ctr Hlth Mkt,CDC, Atlanta, GA 30333 USA. [Buchanan, Leigh Ramsey] CDC, Chron Dis Nutr Branch, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Brownson, Ross C.] St Louis Univ, Sch Publ Hlth, St Louis, MO 63103 USA. [Heath, Gregory W.] Univ Tennessee, Dept Hlth & Human Performance, Chattanooga, TN USA. RP Soler, RE (reprint author), Ctr Dis Control & Prevent, Community Guide Branch, Div Hlth Commun & Mkt Strategy, Natl Ctr Hlth Mkt,CDC, 1600 Clifton Rd,MS-E69, Atlanta, GA 30333 USA. EM RSoler@cdc.gov NR 31 TC 52 Z9 52 U1 3 U2 24 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD FEB PY 2010 VL 38 IS 2 SU 2 BP S292 EP S300 DI 10.1016/j.amepre.2009.10.028 PG 9 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 554FA UT WOS:000274419700009 PM 20117614 ER PT J AU Soler, RE Leeks, KD Razi, S Hopkins, DP Griffith, M Aten, A Chattopadhyay, SK Smith, SC Habarta, N Goetzel, RZ Pronk, NP Richling, DE Bauer, DR Buchanan, LR Florence, CS Koonin, L MacLean, D Rosenthal, A Koffman, DM Grizzell, JV Walker, AM AF Soler, Robin E. Leeks, Kimberly D. Razi, Sima Hopkins, David P. Griffith, Matt Aten, Adam Chattopadhyay, Sajal K. Smith, Susan C. Habarta, Nancy Goetzel, Ron Z. Pronk, Nicolaas P. Richling, Dennis E. Bauer, Deborah R. Buchanan, Leigh Ramsey Florence, Curtis S. Koonin, Lisa MacLean, Debbie Rosenthal, Abby Koffman, Dyann Matson Grizzell, James V. Walker, Andrew M. CA Task Force Community Preventive Se TI A Systematic Review of Selected Interventions for Worksite Health Promotion The Assessment of Health Risks with Feedback SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Review ID CORONARY-HEART-DISEASE; WORKING WELL TRIAL; RANDOMIZED CONTROLLED-TRIAL; LONG-TERM IMPACT; EMPLOYEE HEALTH; BEHAVIOR-CHANGE; CANCER PREVENTION; AUTO WORKERS; STEP TRIAL; MULTIFACTORIAL PREVENTION AB Background: Many health behaviors and physiologic indicators can be used to estimate one's likelihood of illness or premature death. Methods have been developed to assess this risk, most notably the use of a health-risk assessment or biometric screening tool. This report provides recommendations on the effectiveness of interventions that use an Assessment of Health Risks with Feedback (AHRF) when used alone or as part of a broader worksite health promotion program to improve the health of employees. Evidence acquisition: The Guide to Community Preventive Services' methods for systematic reviews were used to evaluate the effectiveness of AHRF when used alone and when used in combination with other intervention components. Effectiveness was assessed on the basis of changes in health behaviors and physiologic estimates, but was also informed by changes in risk estimates, healthcare service use, and worker productivity. Evidence synthesis: The review team identified strong evidence of effectiveness of AHRF when used with health education with or without other intervention components for five outcomes. There is sufficient evidence of effectiveness for four additional outcomes assessed. There is insufficient evidence to determine effectiveness for others such as changes in body composition and fruit and vegetable intake. The team also found insufficient evidence to determine the effectiveness of AHRF when implemented alone. Conclusions: The results of these reviews indicate that AHRF is useful as a gateway intervention to a broader worksite health promotion program that includes health education lasting I hour or repeating multiple times during I year, and that may include an array of health promotion activities. These reviews form the basis of the recommendations by the Task Force on Community Preventive Services presented elsewhere in this supplement. (Am J Prev Med 2010;38(2S):S237-S262) Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Soler, Robin E.] Ctr Dis Control & Prevent, Community Guide Branch, Div Hlth Commun & Mkt, Natl Ctr Hlth Mkt,CDC, Atlanta, GA 30333 USA. [Koonin, Lisa] CDC, Coordinating Ctr Infect Dis, Atlanta, GA 30333 USA. [Smith, Susan C.] CDC, Informat Ctr, Atlanta, GA 30333 USA. [Buchanan, Leigh Ramsey; Rosenthal, Abby; Koffman, Dyann Matson] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Nutr Phys Act & Obes, Atlanta, GA 30333 USA. [Goetzel, Ron Z.] Thomson Reuters Healthcare, Washington, DC USA. [Goetzel, Ron Z.] Emory Univ, Rollins Sch Publ Hlth, Inst Hlth & Prod Studies, Washington, DC USA. [Pronk, Nicolaas P.] HealthPartners Res Fdn, Bloomington, MN USA. [Richling, Dennis E.] CorSolutions, Chicago, IL USA. [Bauer, Deborah R.] McKing Consulting, Olympia, WA USA. [Florence, Curtis S.] Emory Univ, Sch Publ Hlth, Atlanta, GA USA. [MacLean, Debbie] Coca Cola Co, Atlanta, GA USA. [Grizzell, James V.] Cal Poly Pomona & George Washington Univ, Pomona, CA USA. RP Soler, RE (reprint author), Ctr Dis Control & Prevent, Community Guide Branch, Div Hlth Commun & Mkt, Natl Ctr Hlth Mkt,CDC, 1600 Clifton Rd,MS E-69, Atlanta, GA 30333 USA. EM RSoler@cdc.gov NR 147 TC 111 Z9 111 U1 11 U2 55 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD FEB PY 2010 VL 38 IS 2 SU 2 BP S237 EP S262 DI 10.1016/j.amepre.2009.10.030 PG 26 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 554FA UT WOS:000274419700005 PM 20117610 ER PT J AU Soler, RE AF Soler, Robin E. CA Task Force Community Preventive TI Recommendation for Use of Point-of-Decision Prompts to Increase Stair Use in Communities SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Editorial Material C1 [Soler, Robin E.] Ctr Dis Control & Prevent, Community Guide Branch, Div Hlth Commun & Mkt Strategy, Natl Ctr Hlth Mkt,CDC, Atlanta, GA 30333 USA. RP Soler, RE (reprint author), Ctr Dis Control & Prevent, Community Guide Branch, Div Hlth Commun & Mkt Strategy, Natl Ctr Hlth Mkt,CDC, 1600 Clifton Rd,MS E-69, Atlanta, GA 30333 USA. EM RSoler@cdc.gov NR 8 TC 0 Z9 0 U1 1 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD FEB PY 2010 VL 38 IS 2 SU 2 BP S290 EP S291 DI 10.1016/j.amepre.2009.10.031 PG 2 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 554FA UT WOS:000274419700008 ER PT J AU Coury-Doniger, P Wilton, L Herbst, JH Painter, TM AF Coury-Doniger, Patricia Wilton, Leo Herbst, Jeffrey H. Painter, Thomas M. TI HIV PREVENTION INTERVENTIONS FOR BLACK MSM SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Letter ID MEN; SEX C1 [Coury-Doniger, Patricia] Univ Rochester, Ctr Hlth & Behav Training, Sch Med & Dent, Dept Med, Rochester, NY 14611 USA. [Wilton, Leo] SUNY Binghamton, Dept Human Dev, Coll Community & Publ Affairs, Binghamton, NY USA. [Herbst, Jeffrey H.; Painter, Thomas M.] Ctr Dis Control & Prevent, Prevent Res Branch, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. RP Coury-Doniger, P (reprint author), Univ Rochester, Ctr Hlth & Behav Training, Sch Med & Dent, Dept Med, 855 W Main St, Rochester, NY 14611 USA. EM pcoury-doniger@monroecounty.gov FU PHS HHS [U65/CCU223830, U65/CCU224517] NR 6 TC 2 Z9 2 U1 1 U2 2 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD FEB PY 2010 VL 100 IS 2 BP 198 EP 198 DI 10.2105/AJPH.2009.182485 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 554DF UT WOS:000274415000004 PM 20019294 ER PT J AU Grillet, ME Barrera, R Martinez, JE Berti, J Fortin, MJ AF Grillet, Maria-Eugenia Barrera, Roberto Martinez, Juan-Eudes Berti, Jesus Fortin, Marie-Josee TI Disentangling the Effect of Local and Global Spatial Variation on a Mosquito-Borne Infection in a Neotropical Heterogeneous Environment SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID LINEAR MIXED MODELS; 2 MALARIOUS AREAS; SUCRE STATE; NORTHEASTERN VENEZUELA; ANOPHELES-AQUASALIS; EPIDEMIOLOGY; DISEASES; AUTOCORRELATION; TRANSMISSION; STATISTICS AB Mosquito-borne pathogen transmission exhibits spatial-temporal variability caused by ecological interactions acting at different scales. We used local spatial statistics and geographically weighted regression (GWR) to determine the spatial pattern of malaria incidence and persistence in northeastern Venezuela. Seven to 11 hot spots of malaria transmission were detected by Using local spatial statistics, although disease persistence was explained only for four Of those hot spots. The GWR models greatly improved predictions of malaria risk compared with ordinary least squares, (OLS) regression models. Malaria incidence vas largely explained by the proximity to and number of Anopheles aquasalis habitats nearby (1-3 km). and low-elevation terrains. Disease persistence was associated with greater human population density, lower elevations, and proximity to aquatic habitats. However. there was significant local spatial variation in the relationship between malaria and environmental variables. Spatial modeling improves the understanding of the causal factors operating at several scales in the transmission of malaria. C1 [Grillet, Maria-Eugenia; Martinez, Juan-Eudes] Cent Univ Venezuela, Lab Biol Vectores, Inst Zool Trop, Fac Ciencias, Caracas 1041A, Venezuela. [Barrera, Roberto] Ctr Dis Control & Prevent, Dengue Branch, Div Vector Borne & Infect Dis, Natl Ctr Infect Dis, San Juan, PR USA. [Fortin, Marie-Josee] Univ Toronto, Dept Ecol & Evolutionary Biol, Toronto, ON, Canada. RP Grillet, ME (reprint author), Cent Univ Venezuela, Lab Biol Vectores, Inst Zool Trop, Fac Ciencias, Ave Ilustres,Apartado Postal 47072, Caracas 1041A, Venezuela. EM maria.grillet@ciens.ucv.ve; rbarrera@cdc.gov; jbertimoser@yahoo.com; mariejosee.fortin@utoronto.ca OI Grillet, Maria Eugenia/0000-0003-2922-6751 FU Venezuelan Fondo Nacional de Investigaciones Cientificas [PG-2000001541, UC-2008000911-3]; Council for Sciences and Humanities Development [PI-030064412006]; Invensys Systems Latin America Corporation [2007-2009]; CDCH-UCV FX This study was supported by Venezuelan Fondo Nacional de Investigaciones Cientificas (FONACIT, PG-2000001541 and UC-2008000911-3), the Council for Sciences and Humanities Development (CDCH-UCV, PI-030064412006), and Invensys Systems Latin America Corporation (LOCTI Grant 2007-2009). MEG especially thanks CDCH-UCV for a visitor scholar/sabbatical fellowship. NR 43 TC 24 Z9 24 U1 0 U2 9 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD FEB PY 2010 VL 82 IS 2 BP 194 EP 201 DI 10.4269/ajtmh.2010.09-0040 PG 8 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 552CC UT WOS:000274263300005 PM 20133991 ER PT J AU Hossain, MJ Gurley, ES Montgomery, S Petersen, L Sejvar, J Fischer, M Panella, A Powers, AM Nahar, N Uddin, AKMR Rahman, ME Ekram, ARMS Luby, SP Breiman, RF AF Hossain, M. Jahangir Gurley, Emily S. Montgomery, Susan Petersen, Lyle Sejvar, James Fischer, Marc Panella, Amanda Powers, Ann M. Nahar, Nazmun Uddin, A. K. M. Rafique Rahman, M. Ekhlasur Ekram, A. R. M. Saifuddin Luby, Stephen P. Breiman, Robert F. TI Hospital-Based Surveillance for Japanese Encephalitis at Four Sites in Bangladesh, 2003-2005 SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID IMMUNIZATION; FLAVIVIRUSES; INDONESIA; VACCINES; INDIA; NEPAL; BALI AB We investigated the epidemiology and etiology of encephalitis at four tertiary hospitals in Bangladesh during 2003-2005. Patients who met a clinical case definition for acute encephalitis and had cerebrospinal fluid (CSF) pleocytosis were eligible for enrollment: a standardized sampling pattern was used to enroll eligible patients. Recent Japanese encephalitis virus (JEV) infection was defined by presence of IgM antibodies against JEV in CSF or serum. Twenty (4%) of 492 cases had laboratory evidence of recent JEV infection; two died. All JE cases occurred during May-December, and cases were identified among all age groups. All cases resided in rural areas. Fifteen patients were re-assessed 4-6 weeks after hospitalizations 5 (33%) patients had physical disabilities and 7 (47%) reported cognitive difficulties. Infection with JEV is clearly an etiology of encephalitis in Bangladesh. Population-based studies to quantity burden of disease could assess options for targeted immunization programs. C1 [Hossain, M. Jahangir] Int Ctr Diarrhoeal Dis Res, Div Clin Sci, Dhaka 1212, Bangladesh. [Montgomery, Susan; Petersen, Lyle; Sejvar, James; Fischer, Marc; Panella, Amanda; Powers, Ann M.; Luby, Stephen P.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Nahar, Nazmun; Uddin, A. K. M. Rafique] Dhaka Med Coll Hosp, Dhaka, Bangladesh. [Rahman, M. Ekhlasur] Mymensingh Med Coll Hosp, Mymemsingh, Bangladesh. Mymensingh Med Coll Hosp, Mymensingh, Bangladesh. [Rahman, M. Ekhlasur] MAG Osmani Med Coll Hosp, Sylhet, Bangladesh. [Ekram, A. R. M. Saifuddin] Rajshahi Med Coll Hosp, Rajshahi, Bangladesh. RP Hossain, MJ (reprint author), Int Ctr Diarrhoeal Dis Res, Div Clin Sci, 68 Shaheed Tajuddin, Dhaka 1212, Bangladesh. EM jhossain@icddrb.org; egurley@icddrb.org; zqu6@cdc.gov; lxp2@cdc.gov; zea3@cdc.gov; mxf2@cdc.gov; ahf6@cdc.gov; akp7@cdc.gov; nahar@dab-bd.org; rudduin-bsm@yahoo.com; pediatrics_03@yahoo.com; armsekram@yahoo.com; sluby@icddrb.org; rbreiman@ke.cdc.gov RI Gurley, Emily/B-7903-2010 OI Gurley, Emily/0000-0002-8648-9403 FU Centers for Disease Control and Prevention FX This study was supported by the Centers for Disease Control and Prevention. NR 32 TC 11 Z9 11 U1 0 U2 4 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD FEB PY 2010 VL 82 IS 2 BP 344 EP 349 DI 10.4269/ajtmh.2010.09-0125 PG 6 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 552CC UT WOS:000274263300028 PM 20134015 ER PT J AU Rowe, AK AF Rowe, Alexander K. TI Continuous Surveys and Quality Management in Low-Income Countries: A Good Idea Response SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Letter ID LUMEFANTRINE TREATMENT POLICY; MALARIA TREATMENT PRACTICES; ARTEMETHER-LUMEFANTRINE; PEDIATRIC MALARIA; ZAMBIA; KENYA C1 Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis, Atlanta, GA 30341 USA. RP Rowe, AK (reprint author), Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis, Atlanta, GA 30341 USA. EM axr9@cdc.gov NR 10 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD FEB PY 2010 VL 82 IS 2 BP 361 EP 362 DI 10.4269/ajtmh.2010.09-0581b PG 2 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 552CC UT WOS:000274263300032 ER PT J AU Li, Z Pittman, EN Trinidad, DA Romanoff, LC Mulholland, J Sjodin, A AF Li, Zheng Pittman, Erin N. Trinidad, Debra A. Romanoff, Lovisa C. Mulholland, James Sjodin, Andreas TI Determination of 43 polycyclic aromatic hydrocarbons in air particulate matter by use of direct elution and isotope dilution gas chromatography/mass spectrometry SO ANALYTICAL AND BIOANALYTICAL CHEMISTRY LA English DT Article DE Polycyclic aromatic hydrocarbon; PAH; PM; Method; GC/MS ID PERFORMANCE LIQUID-CHROMATOGRAPHY; AMBIENT AIR; SOLVENT-EXTRACTION; ASSISTED EXTRACTION; MASS-SPECTROMETRY; ORGANIC-COMPOUNDS; WOOD COMBUSTION; RISK-ASSESSMENT; URBAN DUST; GC-MS AB We are reporting a method for measuring 43 polycyclic aromatic hydrocarbons (PAH) and their methylated derivatives (Me-PAHs) in air particulate matter (PM) samples using isotope dilution gas chromatography/high-resolution mass spectrometry (GC/HRMS). In this method, PM samples were spiked with internal standards, loaded into solid phase extraction cartridges, and eluted by dichloromethane. The extracts were concentrated, spiked with a recovery standard, and analyzed by GC/HRMS at 10,000 resolution. Sixteen (13)C-labeled PAHs and two deuterated Me-PAHs were used as internal standards to account for instrument variability and losses during sample preparation. Recovery of labeled internal standards was in the range of 86-115%. The proposed method is less time-consuming than commonly used extraction methods, such as sonication and accelerated solvent extraction (ASE), and it eliminates the need for a filtration step required after the sonication extraction method. Limits of detection ranged from 41 to 332 pg/sample for the 43 analytes. This method was used to analyze reference materials from the National Institute of Standards and Technology. The results were consistent with those from ASE and sonication extraction, and these results were also in good agreement with the certified or reference concentrations. The proposed method was then used to measure PAHs on PM(2.5) samples collected at three sites (urban, suburban, and rural) in Atlanta, GA. The results showed distinct seasonal and spatial variation and were consistent with an earlier study measuring PM(2.5) samples using an ASE method, further demonstrating the compatibility of this method and the commonly used ASE method. C1 [Li, Zheng; Pittman, Erin N.; Trinidad, Debra A.; Romanoff, Lovisa C.; Sjodin, Andreas] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. [Mulholland, James] Georgia Inst Technol, Sch Environm & Civil Engn, Atlanta, GA 30332 USA. RP Li, Z (reprint author), Ctr Dis Control & Prevent, 4770 Buford Highway F-53, Atlanta, GA 30341 USA. EM ZJLi@cdc.gov RI Sjodin, Andreas/F-2464-2010 NR 44 TC 6 Z9 7 U1 3 U2 29 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 1618-2642 J9 ANAL BIOANAL CHEM JI Anal. Bioanal. Chem. PD FEB PY 2010 VL 396 IS 3 BP 1321 EP 1330 DI 10.1007/s00216-009-3297-4 PG 10 WC Biochemical Research Methods; Chemistry, Analytical SC Biochemistry & Molecular Biology; Chemistry GA 546WN UT WOS:000273845200037 PM 19936717 ER PT J AU Burt, RD Hagan, H Sabin, K Thiede, H AF Burt, Richard D. Hagan, Holly Sabin, Keith Thiede, Hanne TI Evaluating Respondent-Driven Sampling in a Major Metropolitan Area: Comparing Injection Drug Users in the 2005 Seattle Area National HIV Behavioral Surveillance System Survey with Participants in the RAVEN and Kiwi Studies SO ANNALS OF EPIDEMIOLOGY LA English DT Article DE Respondent-Driven Sampling; Injection Drug Users; HIV; Hepatitis C ID SEXUAL RISK BEHAVIOR; NEW-YORK-CITY; HIDDEN POPULATIONS; INTERNATIONAL SETTINGS; HEPATITIS-B; LATINO GAY; MEN; INFECTION; METHODOLOGY; PREVALENCE AB PURPOSE: To empirically evaluate respondent-driven sampling (RDS) recruitment methods, which. have been proposed as an advantageous means of surveying hidden populations. METHODS: The National HIV Behavioral Surveillance system used RDS to recruit 370 injection drug users (IDU) in the Seattle area in 2005 (NHBS-IDU1). We compared the NHBS-IDU1 estimates of participants' area of residence, age, race, sex, and drug most frequently injected to corresponding data from two previous surveys, the RAVEN and Kiwi Studies, and to persons newly diagnosed with HIV/AIDS and reported from 2001 through 2005. RESULTS: The NHBS-IDU1 population was estimated to be more likely to reside in downtown Seattle (52%) than participants in the other data sources (22%-25%), be older than 50 years of age (29% vs. 5% -10%), and report multiple races (12% vs. 3%-5%). The NHBS-IDU1 population resembled persons using the downtown needle exchange in age and race distribution. An examination of cross-group recruitment frequencies in NHBS-IDU1 suggested barriers to recruitment across different areas of residence, races, and drugs most frequently injected. CONCLUSIONS: The substantial differences in age and area of residence between NHBS-IDU1 and the other data sources suggest that RDS may not have accessed the full universe of Seattle area injection networks. Further empirical data are needed to guide the evaluation of RDS-generated samples. Ann Epidemiol 2010;20:159-167. (C) 2010 Elsevier Inc. All rights reserved. C1 [Burt, Richard D.; Hagan, Holly; Thiede, Hanne] Publ Hlth Seattle & King Cty, Seattle, WA 98104 USA. [Sabin, Keith] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. RP Burt, RD (reprint author), Publ Hlth Seattle & King Cty, 400 Yesler Way, Seattle, WA 98104 USA. EM richard.burt@kingcounty.gov OI Sabin, Keith/0000-0002-2290-8621 FU NIDA NIH HHS [1R01DA08023, R01 DA008023-08, R01 DA008023-07]; PHS HHS [U62/CCU006260] NR 40 TC 37 Z9 37 U1 2 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1047-2797 J9 ANN EPIDEMIOL JI Ann. Epidemiol. PD FEB PY 2010 VL 20 IS 2 BP 159 EP 167 DI 10.1016/j.annepidem.2009.10.002 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 574NT UT WOS:000275997700010 PM 20123167 ER PT J AU Sheu, TG Deyde, VM Garten, RJ Klimov, AI Gubareva, LV AF Sheu, Tiffany G. Deyde, Varough M. Garten, Rebecca J. Klimov, Alexander I. Gubareva, Larisa V. TI Detection of antiviral resistance and genetic lineage markers in influenza B virus neuraminidase using pyrosequencing SO ANTIVIRAL RESEARCH LA English DT Article DE Influenza B; Neuraminidase; Resistance; Genetic analysis; Evolution ID A VIRUSES; ADAMANTANE RESISTANCE; INHIBITOR-RESISTANT; ISOLATED WORLDWIDE; MOLECULAR MARKERS; A(H1N1) VIRUSES; UNITED-STATES; SURVEILLANCE; OSELTAMIVIR; AMANTADINE AB We report here the design of a pyrosequencing approach for the detection of molecular markers of resistance to the neuraminidase inhibitors zanamivir and oseltamivir in influenza viruses of type B. Primers were designed to analyze the sequences at eight amino acid positions E119, R152, D198. 1222, S250, H274, R371, and G402 (universal A/N2 numbering) in the neuraminidase (NA) which have been previously found to be associated with resistance or reduced susceptibility to oseltamivir and/or zanamivir in the NA inhibition assay. In addition, the designed primers could be utilized to the distinguish between the NAs of influenza B viruses from the two major lineages (Victoria and Yamagata) that have co-circulated globally in recent years, thus providing a valuable tool for virus strain surveillance. Published by Elsevier B.V. C1 [Sheu, Tiffany G.; Deyde, Varough M.; Garten, Rebecca J.; Klimov, Alexander I.; Gubareva, Larisa V.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Gubareva, LV (reprint author), Mail Stop G-16,1600 Clifton Rd, Atlanta, GA 30333 USA. EM lgubareva@cdc.gov FU Oak Ridge Institute for Science and Education, Oak Ridge, TN (ORISE) FX We thank the entire influenza Division for their contributions to this project, especially Michael Shaw for his editorial assistance. We are also grateful to Dr. Yan Li from the Public Health Agency of Canada for providing the B/Canada/88/2007 D198N virus as well as the State Laboratories, National Influenza Centers in many countries, and WHO Collaborating Centers for submitting their specimens for testing.; T.G.S. received financial support for this work from the Oak Ridge Institute for Science and Education, Oak Ridge, TN (ORISE). NR 36 TC 21 Z9 25 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0166-3542 J9 ANTIVIR RES JI Antiviral Res. PD FEB PY 2010 VL 85 IS 2 BP 354 EP 360 DI 10.1016/j.antiviral.2009.10.022 PG 7 WC Pharmacology & Pharmacy; Virology SC Pharmacology & Pharmacy; Virology GA 558MY UT WOS:000274748900004 PM 19887086 ER PT J AU Okomo-Adhiambo, M Nguyen, HT Sleeman, K Sheu, TG Deyde, VM Garten, RJ Xu, XY Shaw, MW Klimov, AI Gubareva, LV AF Okomo-Adhiambo, Margaret Nguyen, Ha T. Sleeman, Katrina Sheu, Tiffany G. Deyde, Varough M. Garten, Rebecca J. Xu, Xiyan Shaw, Michael W. Klimov, Alexander I. Gubareva, Larisa V. TI Host cell selection of influenza neuraminidase variants: Implications for drug resistance monitoring in A(H1N1) viruses SO ANTIVIRAL RESEARCH LA English DT Article DE Cell culture; Antiviral resistance; Tamiflu; Relenza; Peramivir; A-315675 ID RANDOMIZED CONTROLLED-TRIAL; A H3N2 VIRUSES; B VIRUSES; IN-VITRO; INHIBITOR 4-GUANIDINO-NEU5AC2EN; OSELTAMIVIR RESISTANCE; REDUCED SENSITIVITY; ISOLATED WORLDWIDE; MEDIATED VARIATION; UNITED-STATES AB The neuraminidase inhibitors (NAIs), oseltamivir and zanamivir, are essential for treatment and prevention of influenza A and B infections. Oseltamivir resistance among influenza A (H1N1) viruses rapidly emerged and spread globally during the 2007-2008 and 2008-2009 influenza seasons. Approximately 20% and 90% of viruses tested for NAI susceptibility at CDC during these seasons, respectively, were resistant to oseltamivir (IC(50) similar to 100-3000 time > those of sensitive viruses), based on the chemiluminescent NA inhibition assay. Pyrosequencing analysis confirmed H274Y mutation (H275Y in NI numbering) in the neuraminidase (NA) gene of oseltamivir-resistant viruses. Full NA sequence analysis of a subset of oseltamivir-resistant and sensitive virus isolates from both seasons (n = 725) showed that 53 (7.3%) had mutations at residue D151 (D -> E/C/N), while 9 (1.2%) had mutations at Q1 36 (Q -> K) and 2 (0.3%) had mutations at both residues. Viruses with very high IC(50) for oseltamivir and peramivir, and elevated IC(50) for zanamivir, had H274Y in addition to mutations at D151 and/or Q136, residues which can potentially confer NAI resistance based on recent N1 NA crystal structure data. Mutations at D151 without H274Y, did not elevate IC(50) for any tested NAI, however, Q136K alone significantly reduced susceptibility to zanamivir (36-fold), peramivir (80-fold) and A-315675 (114-fold) but not oseltamivir. Mutations at D151 and Q136 were present only in MDCK grown viruses but not in matching original clinical specimens (n = 33) which were available for testing, suggesting that these variants were the result of cell culture selection or they were present in very low proportions. Our findings provide evidence that propagation of influenza virus outside its natural host may lead to selection of virus variants with mutations in the NA that affect sensitivity to NAIs and thus poses implications for drug resistance monitoring and diagnostics. Published by Elsevier B.V. C1 [Okomo-Adhiambo, Margaret; Nguyen, Ha T.; Sleeman, Katrina; Sheu, Tiffany G.; Deyde, Varough M.; Garten, Rebecca J.; Xu, Xiyan; Shaw, Michael W.; Klimov, Alexander I.; Gubareva, Larisa V.] Ctr Dis Control & Prevent, Virus Surveillance & Diag Branch, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Gubareva, LV (reprint author), Ctr Dis Control & Prevent, Virus Surveillance & Diag Branch, Influenza Div, Natl Ctr Immunizat & Resp Dis, Mail Stop G-16,1600 Clifton Rd, Atlanta, GA 30333 USA. EM lgubareva@cdc.gov FU Atlanta Research and Education Foundation (AREF) FX M.O-A. and HTN received financial support for this work from the Atlanta Research and Education Foundation (AREF).; We wish to thank our collaborators in the WHO Global Influenza Surveillance Network and United States public health laboratories for the submission of virus isolates and clinical specimens. We also thank members of the Virus Reference Team and members of the Sequencing Group, Influenza Division, CDC for technical assistance on this project. NR 66 TC 57 Z9 58 U1 0 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0166-3542 J9 ANTIVIR RES JI Antiviral Res. PD FEB PY 2010 VL 85 IS 2 BP 381 EP 388 DI 10.1016/j.antiviral.2009.11.005 PG 8 WC Pharmacology & Pharmacy; Virology SC Pharmacology & Pharmacy; Virology GA 558MY UT WOS:000274748900008 PM 19917319 ER PT J AU Cromeans, TL Kahler, AM Hill, VR AF Cromeans, Theresa L. Kahler, Amy M. Hill, Vincent R. TI Inactivation of Adenoviruses, Enteroviruses, and Murine Norovirus in Water by Free Chlorine and Monochloramine SO APPLIED AND ENVIRONMENTAL MICROBIOLOGY LA English DT Article ID HEPATITIS-A VIRUS; FELINE CALICIVIRUS; UNITED-STATES; RECREATIONAL WATER; COXSACKIE-VIRUSES; ENTERIC VIRUSES; DRINKING-WATER; POLIOVIRUS; DISINFECTION; MODEL AB Inactivation of infectious viruses during drinking water treatment is usually achieved with free chlorine. Many drinking water utilities in the United States now use monochloramine as a secondary disinfectant to minimize disinfectant by-product formation and biofilm growth. The inactivation of human adenoviruses 2, 40, and 41 (HAdV2, HAdV40, and HAdV41), coxsackieviruses B3 and B5 (CVB3 and CVB5), echoviruses 1 and 11 (E1 and E11), and murine norovirus (MNV) are compared in this study. Experiments were performed with 0.2 mg of free chlorine or 1 mg of monochloramine/liter at pH 7 and 8 in buffered reagent-grade water at 5 degrees C. CT values (disinfectant concentration x time) for 2- to 4-log(10) (99 to 99.99%) reductions in virus titers were calculated by using the efficiency factor Hom model. The enteroviruses required the longest times for chlorine inactivation and MNV the least time. CVB5 required the longest exposure time, with CT values of 7.4 and 10 mg . min/liter (pH 7 and 8) for 4-log(10) inactivation. Monochloramine disinfection was most effective for E1 (CT values ranged from 8 to 18 mg . min/liter for 2- and 3-log(10) reductions, respectively). E11 and HAdV2 were the least susceptible to monochloramine disinfection (CT values of 1,300 and 1,600 mg-min/liter for 3-log(10) reductions, respectively). Monochloramine inactivation was most successful for the adenoviruses, CVB5, and E1 at pH 7. A greater variation in inactivation rates between viruses was observed during monochloramine disinfection than during chlorine disinfection. These data will be useful in drinking water risk assessment studies and disinfection system planning. C1 [Cromeans, Theresa L.; Kahler, Amy M.; Hill, Vincent R.] Ctr Dis Control & Prevent, Natl Ctr Zoonot Vector Borne & Enter Dis, Div Parasit Dis, Atlanta, GA 30341 USA. [Cromeans, Theresa L.; Kahler, Amy M.; Hill, Vincent R.] Atlanta Res & Educ Fdn, Atlanta, GA 30341 USA. RP Hill, VR (reprint author), Ctr Dis Control & Prevent, Natl Ctr Zoonot Vector Borne & Enter Dis, Div Parasit Dis, 4770 Buford Highway,Mail Stop F-36, Atlanta, GA 30341 USA. EM vhill@cdc.gov RI Hill, Vincent/G-1789-2012 OI Hill, Vincent/0000-0001-7069-7737 FU Water Research Foundation [3134]; CDC; Atlanta Research and Education Foundation FX Funding for this project was provided by the Water Research Foundation (Project #3134, Contaminant Candidate List Viruses: Evaluation of Disinfection Efficacy), the CDC, and the Atlanta Research and Education Foundation. NR 44 TC 52 Z9 53 U1 3 U2 32 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0099-2240 J9 APPL ENVIRON MICROB JI Appl. Environ. Microbiol. PD FEB PY 2010 VL 76 IS 4 BP 1028 EP 1033 DI 10.1128/AEM.01342-09 PG 6 WC Biotechnology & Applied Microbiology; Microbiology SC Biotechnology & Applied Microbiology; Microbiology GA 552XS UT WOS:000274328900007 PM 20023080 ER PT J AU Nelson, AE Braga, L Renner, JB Atashili, J Woodard, J Hochberg, MC Helmick, CG Jordan, JM AF Nelson, Amanda E. Braga, Larissa Renner, Jordan B. Atashili, Julius Woodard, Janice Hochberg, Marc C. Helmick, Charles G. Jordan, Joanne M. TI Characterization of Individual Radiographic Features of Hip Osteoarthritis in African American and White Women and Men: The Johnston County Osteoarthritis Project SO ARTHRITIS CARE & RESEARCH LA English DT Article ID BONE-MINERAL DENSITY; UNITED-STATES; PREVALENCE; ARTHRITIS; KNEE; COXARTHROSIS; REPLACEMENT; POPULATION; CAUCASIANS; SYMPTOMS AB Objective. To describe differences in radiographic features of hip osteoarthritis (OA) between African American and white men and women. Methods. We conducted a cross-sectional analysis of radiographic hip OA using baseline data from the Johnston County Osteoarthritis Project, using Kellgren/Lawrence (K/L) grade, and the presence, location, and severity of 4 individual radiographic features (joint space narrowing [JSN], subchondral cysts, sclerosis, and osteophytes). Sex-specific logistic regression was used to evaluate associations between race and individual radiographic features, adjusting for age, body mass index, education, and prior hip injury. Robust variance estimators via generalized estimating equations were used to account for correlation between hips from the same individual. Results. The sample (n = 2,739) comprised 57% women and 31% African American participants. Among women, African Americans and whites had a similar prevalence of hip OA, defined as K/L grade >= 2 (23% versus 22%), but African American women were significantly more likely to have superior or medial JSN, moderate or severe axial JSN, medial or lateral osteophytes, and subchondral cysts. Among men, 21% of African Americans and 17% of whites had hip OA; African American men were more likely to have superior or medial JSN and lateral osteophytes, but were less likely to have axial JSN. Conclusion. Individual radiographic features and patterns of hip OA differed by race among women and men, suggesting the possibility of anatomic and/or developmental variation in the hip joint. African Americans have an increased frequency of features that have been predictive of hip replacement in other populations, a finding worthy of further study. C1 [Nelson, Amanda E.] Univ N Carolina, Thurston Arthrit Res Ctr, Chapel Hill, NC 27599 USA. [Braga, Larissa] Univ Nebraska, Omaha, NE 68182 USA. [Hochberg, Marc C.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. [Helmick, Charles G.] CDC, Atlanta, GA 30333 USA. RP Nelson, AE (reprint author), Univ N Carolina, Thurston Arthrit Res Ctr, 3300 Thurston Bldg CB 7280, Chapel Hill, NC 27599 USA. EM AENelson@med.unc.edu FU Association of Schools of Public Health; CDC [S043, S1733, S3486]; National Institute of Arthritis and Musculoskeletal and Skin Diseases [P60-AR30701, P60-AR49465, T32-AR007416]; John A. Hartford Foundation FX Supported in part by the Association of Schools of Public Health and the CDC (S043, S1733, and S3486); by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (P60-AR30701 and P60-AR49465); by an Arthritis and Immunology Training grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant T32-AR007416); and by a John A. Hartford Foundation Centers of Excellence in Geriatric Medicine fellowship grant. NR 26 TC 18 Z9 18 U1 0 U2 1 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 2151-464X J9 ARTHRIT CARE RES JI Arthritis Care Res. PD FEB PY 2010 VL 62 IS 2 BP 190 EP 197 DI 10.1002/acr.20067 PG 8 WC Rheumatology SC Rheumatology GA 639MM UT WOS:000280978900007 PM 20191517 ER PT J AU Maziarz, RT Sridharan, P Slater, S Meyers, G Post, M Erdman, DD Peret, TCT Taplitz, RA AF Maziarz, Richard T. Sridharan, Praseeda Slater, Susan Meyers, Gabrielle Post, Mary Erdman, Dean D. Peret, Teresa C. -T. Taplitz, Randy A. TI Control of an Outbreak of Human Parainfluenza Virus 3 in Hematopoietic Stem Cell Transplant Recipients SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Article DE Parainfluenza; Stem cell transplant; Infection control ID RESPIRATORY SYNCYTIAL VIRUS; VIRAL-INFECTIONS; HEMATOLOGY UNIT; RIBAVIRIN; THERAPY; TYPE-3; DISEASE; RISK AB Human parainfluenza virus 3 (HPIV3) infection can cause significant morbidity and mortality in patients undergoing hematopoietic stem cell transplantation (HSCT). There are no standard guidelines for the prevention and control of HPIV3 in the outpatient setting. After 2 HSCT inpatients diagnosed with HPIV3 were noted to have had multiple recent HSCT outpatient clinic (OPC) visits, an investigation of policy and procedures in the HSCT OPC was undertaken, and active surveillance for respiratory viral illness was instituted in the at-risk HSCT population. Between July 19 and August 30, 2005, 13 patients were diagnosed with HPIV3 infection. Morbidity in affected patients was significant, and mortality was high (38.5%) and not affected by antiviral therapy. Molecular typing identified several genetically distinct groups of the hemagglutinin-neuraminidase gene of the II available isolates. Based on sequence relatedness among the isolates and the demographic and exposure history of the patients, in many of these cases HPIV3 infection likely was acquired in the HSCT OPC. The major infection control interventions were introduced between August 20 and August 24. An epidemic curve revealed that HPIV3 infection frequency peaked between August 17 and August 26, with no cases identified after August 30. Prompt attention and focus on infection control interventions were associated with a rapid decrease in the number of incident cases. Policies and procedures regarding patients with respiratory viral illnesses in HSCT OPC populations should be formulated and universally reinforced with HSCT clinic staff to prevent the spread of these infections. Biol Blood Marrow Transplant 16: 192-198 (2010) (C) 2010 Elsevier Inc. All rights reserved. C1 [Taplitz, Randy A.] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA. [Maziarz, Richard T.; Sridharan, Praseeda; Slater, Susan; Meyers, Gabrielle; Post, Mary] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA. [Erdman, Dean D.; Peret, Teresa C. -T.] Ctr Dis Control & Prevent, Gastrointestinal & Resp Viruses Lab Branch, Div Viral Dis, Atlanta, GA USA. RP Taplitz, RA (reprint author), Univ Calif San Diego, Moores Canc Ctr, 3855 Hlth Sci Dr,0960, La Jolla, CA 92093 USA. EM rtaplitz@ucsd.edu NR 23 TC 19 Z9 20 U1 2 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD FEB PY 2010 VL 16 IS 2 BP 192 EP 198 DI 10.1016/j.bbmt.2009.09.014 PG 7 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA 584DN UT WOS:000276730700005 PM 19781656 ER PT J AU Capewell, S Ford, ES Croft, JB Critchley, JA Greenlund, KJ Labarthe, DR AF Capewell, Simon Ford, Earl S. Croft, Janet B. Critchley, Julia A. Greenlund, Kurt J. Labarthe, Darwin R. TI Cardiovascular risk factor trends and potential for reducing coronary heart disease mortality in the United States of America SO BULLETIN OF THE WORLD HEALTH ORGANIZATION LA English DT Article ID BLOOD-PRESSURE; PHYSICAL-ACTIVITY; WALES; POPULATION; DECLINE; ENGLAND; DEATHS; ADULTS; PROGRAM; FINLAND AB Objective To examine the potential for reducing cardiovascular risk factors in the United States of America enough to cause age-adjusted coronary heart disease (CHID) mortality rates to drop by 20% (from 2000 baseline figures) by 2010, as targeted under the Healthy People 2010 initiative. Methods Using a previously validated, comprehensive CHD mortality model known as IMPACT that integrates trends in all the major cardiovascular risk factors, stratified by age and sex, we calculated how much CHID mortality would drop between 2000 and 2010 in the projected population of the United States aged 25-84 years (198 million). We did this for three assumed scenarios: (i) if recent risk factor trends were to continue to 2010; (ii) success in reaching all the Healthy People 2010 risk factor targets, and (iii) further drops in risk factors, to the levels already seen in the low-risk stratum. Findings If age-adjusted CHD mortality rates observed in 2000 remained unchanged, some 388 000 CHD deaths would occur in 2010. First scenario: if recent risk factor trends continued to 2010, there would be approximately 19 000 fewer deaths than in 2000. Although improved total cholesterol, lowered blood pressure in men, decreased smoking and increased physical activity would account for some 51 000 fewer deaths, these would be offset by approximately 32 000 additional deaths from adverse trends in obesity and diabetes and in blood pressure in women. Second scenario: If Healthy People 2010 cardiovascular risk factor targets were reached, approximately 188 000 CHD deaths would be prevented. Scenario three: If the cardiovascular risk levels of the low-risk stratum were reached, approximately 372 000 CHD deaths would be prevented. Conclusion Achievement of the Healthy People 2010 cardiovascular risk factor targets would almost halve the predicted CHD death rates. Additional reductions in major risk factors could prevent or postpone substantially more deaths from CHD. C1 [Capewell, Simon] Univ Liverpool, Div Publ Hlth, Liverpool L69 3GB, Merseyside, England. [Ford, Earl S.] Ctr Dis Control & Prevent, Div Adult & Community Hlth, Atlanta, GA USA. [Croft, Janet B.; Greenlund, Kurt J.; Labarthe, Darwin R.] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Atlanta, GA USA. [Critchley, Julia A.] Newcastle Univ, Inst Hlth & Soc, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England. RP Capewell, S (reprint author), Univ Liverpool, Div Publ Hlth, Liverpool L69 3GB, Merseyside, England. EM capewell@liverpool.ac.uk FU Higher Education Funding Council for England; United States Centers for Disease Control and Prevention FX This Study was Supported by investigator salaries only - Higher Education Funding Council for England (SC, JAC). and United States Centers for Disease Control and Prevention (ESF, JBC, KJG, DRL). NR 51 TC 82 Z9 88 U1 3 U2 17 PU WORLD HEALTH ORGANIZATION PI GENEVA 27 PA MARKETING AND DISSEMINATION, CH-1211 GENEVA 27, SWITZERLAND SN 0042-9686 J9 B WORLD HEALTH ORGAN JI Bull. World Health Organ. PD FEB PY 2010 VL 88 IS 2 BP 120 EP 130 DI 10.2471/BLT.08.057885 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 561HH UT WOS:000274966200011 PM 20428369 ER PT J AU Edwards, BK Ward, E Kohler, BA Eheman, C Zauber, AG Anderson, RN Jemal, A Schymura, MJ Lansdorp-Vogelaar, I Seeff, LC van Ballegooijen, M Goede, SL Ries, LAG AF Edwards, Brenda K. Ward, Elizabeth Kohler, Betsy A. Eheman, Christie Zauber, Ann G. Anderson, Robert N. Jemal, Ahmedin Schymura, Maria J. Lansdorp-Vogelaar, Iris Seeff, Laura C. van Ballegooijen, Marjolein Goede, S. Luuk Ries, Lynn A. G. TI Annual Report to the Nation on the Status of Cancer, 1975-2006, Featuring Colorectal Cancer Trends and Impact of Interventions (Risk Factors, Screening, and Treatment) to Reduce Future Rates SO CANCER LA English DT Editorial Material DE cancer; incidence; mortality; Surveillance; Epidemiology, and End Results; North American Association of Central Cancer Registries; National Program of Cancer Registries; United States; Cancer Intervention and Surveillance Modeling Network colon models; microsimulation models; colorectal cancer ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; FLUOROURACIL PLUS LEVAMISOLE; HEALTH INTERVIEW SURVEY; SERVICES TASK-FORCE; FECAL OCCULT-BLOOD; B2 COLON-CANCER; UNITED-STATES; PHYSICAL-ACTIVITY; ADJUVANT THERAPY; CIGARETTE-SMOKING AB BACKGROUND. The American Cancer Society, the Centers for Disease Control and Prevention (CDC), the National Cancer Institute (NCI), and the North American Association of Central Cancer Registries (NAACCR) collaborate annually to provide updated information regarding cancer occurrence and trends in the United States. This year's report includes trends in colorectal cancer (CRC) incidence and death rates and highlights the use of microsimulation modeling as a tool for interpreting past trends and projecting future trends to assist in cancer control planning and policy decisions. METHODS. Information regarding invasive cancers was obtained from the NCI, CDC, and NAACCR; and information on deaths was obtained from the CDC's National Center for Health Statistics. Annual percentage changes in the age-standardized incidence and death rates (based on the year 2000 US population standard) for all cancers combined and for the top 15 cancers were estimated by joinpoint analysis of long-term trends (1975-2006) and for short-term fixed-interval trends (1997-2006). All statistical tests were 2-sided. RESULTS. Both incidence and death rates from all cancers combined significantly declined (P <.05) in the most recent time period for men and women overall and for most racial and ethnic populations. These decreases were driven largely by declines in both incidence and death rates for the 3 most common cancers in men (ie, lung and prostate cancers and CRQ and for 2 of the 3 leading cancers in women (ie, breast cancer and CRC). The long-term trends for lung cancer mortality in women had smaller and smaller increases until 2003, when there was a change to a nonsignificant decline. Microsimulation modeling demonstrates that declines in CRC death rates are consistent with a relatively large contribution from screening and with a smaller but demonstrable impact of risk factor reductions and improved treatments. These declines are projected to continue if risk factor modification, screening, and treatment remain at current rates, but they could be accelerated further with favorable trends in risk factors and higher utilization of screening and optimal treatment. CONCLUSIONS. Although the decrease in overall cancer incidence and death rates is encouraging, rising incidence and mortality for some cancers are of concern. Cancer 2010;116:544-73.(C) 2009 American Cancer Society. C1 [Edwards, Brenda K.] NCI, Surveillance Res Program, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA. [Ward, Elizabeth; Jemal, Ahmedin] Amer Canc Soc, Surveillance & Hlth Policy Res Dept, Atlanta, GA 30329 USA. [Kohler, Betsy A.; Schymura, Maria J.] N Amer Assoc Cent Canc Registries, Springfield, IL USA. [Eheman, Christie; Seeff, Laura C.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Canc Prevent & Control, Atlanta, GA USA. [Zauber, Ann G.] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA. [Anderson, Robert N.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Div Vital Stat, Hyattsville, MD 20782 USA. [Schymura, Maria J.] New York State Canc Registry, Menands, NY USA. [Lansdorp-Vogelaar, Iris; van Ballegooijen, Marjolein; Goede, S. Luuk] Univ Med Ctr Rotterdam, Erasmus Med Ctr, Dept Publ Hlth, Rotterdam, Netherlands. RP Edwards, BK (reprint author), NCI, Surveillance Res Program, Div Canc Control & Populat Sci, 6116 Execut Blvd, Bethesda, MD 20892 USA. EM edwardsb@mail.nih.gov FU Intramural NIH HHS [Z99 CA999999]; NCI NIH HHS [P30 CA008748] NR 168 TC 741 Z9 778 U1 7 U2 67 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0008-543X EI 1097-0142 J9 CANCER-AM CANCER SOC JI Cancer PD FEB 1 PY 2010 VL 116 IS 3 BP 544 EP 573 DI 10.1002/cncr.24760 PG 30 WC Oncology SC Oncology GA 550YA UT WOS:000274169200001 PM 19998273 ER PT J AU Horsburgh, CR Goldberg, S Bethel, J Chen, S Colson, PW Hirsch-Moverman, Y Hughes, S Shrestha-Kuwahara, R Sterling, TR Wall, K Weinfurter, P AF Horsburgh, C. Robert, Jr. Goldberg, Stefan Bethel, James Chen, Shande Colson, Paul W. Hirsch-Moverman, Yael Hughes, Stephen Shrestha-Kuwahara, Robin Sterling, Timothy R. Wall, Kirsten Weinfurter, Paul CA TB Epidemiologic Studies Consortiu TI Latent TB Infection Treatment Acceptance and Completion in the United States and Canada SO CHEST LA English DT Article ID TUBERCULOSIS INFECTION; CONTACT INVESTIGATIONS; RIFAMPIN; POPULATION; HEALTH; TRIAL; PYRAZINAMIDE; IMMIGRANTS; COHORT AB Background: Treatment of latent TB infection (LTBI) is essential for preventing TB in North America, but acceptance and completion of this treatment have not been systematically assessed. Methods: We performed a retrospective, randomized two-stage cross-sectional survey of treatment and completion of LTBI at public and private clinics in 19 regions of the United States and Canada in 2002. Results: At 32 clinics that both performed tuberculin skin testing and offered treatment, 123 (17.1%; 95% CI, 14.5%-20.0%) of 720 subjects tested and offered treatment declined. Employees at health-care facilities were more likely to decline (odds ratio [OR], 4.74; 95% CI, 1.75-12.9; P = .003), whereas those in contact with a patient with TB were less likely to decline (OR, 0.19; 95% CI, 0.07-0.50; P = .001). At 68 clinics starting treatment regardless of where skin testing was performed, 1,045 (52.7%; 95% CI, 48.5%-56.8%) of 1,994 people starting treatment failed to complete the recommended course. Risk factors for failure to complete included starting the 9-month isoniazid regimen (OR, 2.08; 95% CI, 1.23-3.57), residence in a congregate setting (nursing home, shelter, or jail; OR, 2.94; 95% CI, 1.58-5.56), injection drug use (OR, 2.13; 95% CI, 1.04-4.35), age >= 15 years (OR, 1.49; 95% CI, 1.14-1.94), and employment at a health-care facility (1.37; 95% CI, 1.00-1.85). Conclusions: Fewer than half of the people starting treatment of LTBI completed therapy. Shorter regimens and interventions targeting residents of congregate settings, injection drug users, and employees of health-care facilities are needed to increase completion. CHEST 2010,137(2):401-409 C1 [Horsburgh, C. Robert, Jr.] Boston Univ, Dept Epidemiol, Sch Publ Hlth, Boston, MA 02118 USA. [Goldberg, Stefan; Shrestha-Kuwahara, Robin; Weinfurter, Paul] Ctr Dis Control & Prevent, Atlanta, GA USA. [Bethel, James] WESTAT Corp, Rockville, MD 20850 USA. [Chen, Shande] Univ N Texas, Hlth Sci Ctr, Dept Biostat, Ft Worth, TX USA. [Colson, Paul W.; Hirsch-Moverman, Yael] Columbia Univ, New York, NY USA. [Hughes, Stephen] New York State Dept Hlth, Albany, NY USA. [Sterling, Timothy R.] Vanderbilt Univ, Sch Med, Div Infect Dis, Nashville, TN 37212 USA. [Wall, Kirsten] Denver Hlth & Hosp Author, Denver, CO USA. RP Horsburgh, CR (reprint author), Boston Univ, Dept Epidemiol, Sch Publ Hlth, 715 Albany St,T3E, Boston, MA 02118 USA. EM rhorsbu@bu.edu OI Horsburgh, C./0000-0001-6838-7895; Tamhane, Ashutosh/0000-0002-4475-2760 FU Centers for Disease Control and Prevention [200-2001-00082] FX This study wits supported by the Centers for Disease Control and Prevention, Contract Number 200-2001-00082. NR 30 TC 96 Z9 96 U1 0 U2 8 PU AMER COLL CHEST PHYSICIANS PI NORTHBROOK PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA SN 0012-3692 J9 CHEST JI Chest PD FEB PY 2010 VL 137 IS 2 BP 401 EP 409 DI 10.1378/chest.09-0394 PG 9 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 556SQ UT WOS:000274612600024 PM 19793865 ER PT J AU Janssens, ACJW Khoury, MJ AF Janssens, A. Cecile J. W. Khoury, Muin J. TI Assessment of Improved Prediction Beyond Traditional Risk Factors When Does a Difference Make a Difference? SO CIRCULATION-CARDIOVASCULAR GENETICS LA English DT Editorial Material DE editorial; prediction; family history; risk assessment; cardiovascular disease; area under receiver operating characteristic curve; reclassification ID FAMILY-HISTORY; PUBLIC-HEALTH; RECLASSIFICATION; PERFORMANCE; BIOMARKERS; DISEASE; MODELS; CURVE; TOOL C1 [Janssens, A. Cecile J. W.] Erasmus Univ, Dept Epidemiol, Med Ctr, NL-3000 CA Rotterdam, Netherlands. [Khoury, Muin J.] Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA USA. RP Janssens, ACJW (reprint author), Erasmus Univ, Dept Epidemiol, Med Ctr, POB 2040, NL-3000 CA Rotterdam, Netherlands. EM a.janssens@erasmusmc.nl RI janssens, cecile/L-1075-2015; OI Janssens, A Cecile/0000-0002-6153-4976 NR 21 TC 22 Z9 22 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1942-325X J9 CIRC-CARDIOVASC GENE JI Circ.-Cardiovasc. Genet. PD FEB PY 2010 VL 3 IS 1 BP 3 EP 5 DI 10.1161/CIRCGENETICS.110.938092 PG 3 WC Cardiac & Cardiovascular Systems; Genetics & Heredity SC Cardiovascular System & Cardiology; Genetics & Heredity GA 574HJ UT WOS:000275979700002 PM 20160189 ER PT J AU Ko, CW Riffle, S Michaels, L Morris, C Holub, J Shapiro, JA Ciol, MA Kimmey, MB Seeff, LC Lieberman, D AF Ko, Cynthia W. Riffle, Stacy Michaels, Leann Morris, Cynthia Holub, Jennifer Shapiro, Jean A. Ciol, Marcia A. Kimmey, Michael B. Seeff, Laura C. Lieberman, David TI Serious Complications Within 30 Days of Screening and Surveillance Colonoscopy Are Uncommon SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Article ID COLORECTAL-CANCER; OUTPATIENT COLONOSCOPY; ASYMPTOMATIC ADULTS; AMERICAN-COLLEGE; TASK-FORCE; PERFORATION; RISK; POPULATION; MANAGEMENT; OUTCOMES AB BACKGROUND & AIMS: The risk of serious complications after colonoscopy has important implications for the overall benefits of colorectal cancer screening programs. We evaluated the incidence of serious complications within 30 days after screening or surveillance colonoscopies in diverse clinical settings and sought to identify potential risk factors for complications. METHODS: Patients age 40 and over undergoing colonoscopy for screening, surveillance, or evaluation based an abnormal result from another screening test were enrolled through the National Endoscopic Database (CORI). Patients completed a standardized telephone interview approximately 7 and 30 days after their colonoscopy. We estimated the incidence of serious complications within 30 days of colonoscopy and identified risk factors associated with complications using logistic regression analyses. RESULTS: We enrolled 21,375 patients. Gastrointestinal bleeding requiring hospitalization occurred in 34 patients (incidence 1.59/1000 exams; 95% confidence interval [CI], 1.10-2.22). Perforations occurred in 4 patients (0.19/1000 exams; 95% CI, 0.05-0.48), diverticulitis requiring hospitalization in 5 patients (0.23/1000 exams; 95% CI, 0.08-0.54), and postpolypectomy syndrome in 2 patients (0.09/1000 exams; 95% CI, 0.02-0.30). The overall incidence of complications directly related to colonoscopy was 2.01 per 1000 exams (95% CI, 1.46-2.71). Two of the 4 perforations occurred without biopsy or polypectomy. The risk of complications increased with preprocedure warfarin use and performance of polypectomy with cautery. CONCLUSIONS: Complications after screening or surveillance colonoscopy are uncommon. Risk factors for complications include warfarin use and polypectomy with cautery. C1 [Ko, Cynthia W.] Univ Washington, Div Gastroenterol, Seattle, WA 98195 USA. [Michaels, Leann; Morris, Cynthia; Holub, Jennifer; Lieberman, David] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Shapiro, Jean A.; Seeff, Laura C.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Ko, CW (reprint author), Univ Washington, Div Gastroenterol, Box 356424, Seattle, WA 98195 USA. EM cwko@u.washington.edu FU University of Washington Health Promotion Research Center [U48/CCU009654, 1-U48-DP-000050]; National Institutes of Health grant [U01 DK057132] FX This work was supported by the Centers for Disease Control and Prevention, Prevention Research Program, through the University of Washington Health Promotion Research Center, cooperative agreement numbers U48/CCU009654 and 1-U48-DP-000050, and by the National Institutes of Health grant (U01 DK057132) to Oregon Health and Sciences University. NR 23 TC 82 Z9 83 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD FEB PY 2010 VL 8 IS 2 BP 166 EP 173 DI 10.1016/j.cgh.2009.10.007 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 592ZP UT WOS:000277421000017 PM 19850154 ER PT J AU Sedmak, G Nix, WA Jentzen, J Haupt, TE Davis, JP Bhattacharyya, S Pallansch, MA Oberste, MS AF Sedmak, Gerald Nix, W. Allan Jentzen, Jeffrey Haupt, Thomas E. Davis, Jeffrey P. Bhattacharyya, Sanjib Pallansch, Mark A. Oberste, M. Steven TI Infant Deaths Associated with Human Parechovirus Infection in Wisconsin SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID REAL-TIME PCR; STOOL SAMPLES; IDENTIFICATION; EPIDEMIOLOGY; PREVALENCE; CHILDREN; SEROTYPE; TYPE-22 AB Background. From December 1987 through August 2004, lung tissue, nasopharyngeal swabs, and colon swab specimens obtained during 1263 autopsies of infants and young children were examined to assess the role of viruses in deaths of children aged < 2 years. Methods. Multiple cell cultures were used to isolate viruses. With 4 exceptions, virus isolates were identified by neutralization, immunofluorescence assay, or enzyme immunoassay. RNA extracted from these 4 isolates and associated autopsy specimens was tested using parechovirus-specific real-time polymerase chain reaction (RT-PCR) and sequencing assays. Results. Specimens from 426 (34%) autopsies were positive for at least 1 virus; enteroviruses and adenoviruses were the most commonly identified. Human parechoviruses (HPeVs) were identified antigenically in isolates from 18 decedents (all HPeV type 1) and by RT-PCR in isolates and multiple autopsy specimens from 4 decedents with untypeable virus isolates. Sequencing of the VP1 region identified these 4 HPeVs as HPeV type 3 (n = 3) and HPeV type 6 (n = 1). Despite the detection of HPeV, the deaths of decedents 3 and 4 were determined to have been from noninfectious causes. Conclusions. These are the first confirmed HPeV type 3 and HPeV type 6 detections in the United States. This is also the initial report of fatal cases with associated HPeV type 3 infection. These results support prior findings associating HPeVs with serious disease in young children. Clinical testing for HPeVs and routine HPeV surveillance by public health laboratories will help determine the burden of disease caused by HPeVs. C1 [Sedmak, Gerald; Bhattacharyya, Sanjib] Virol & Mol Sci Lab, City Milwaukee Hlth Dept, Milwaukee, WI USA. [Jentzen, Jeffrey] Milwaukee Cty Med Examiners Off, Milwaukee, WI USA. [Haupt, Thomas E.; Davis, Jeffrey P.] Bur Communicable Dis, Wisconsin Div Publ Hlth, Madison, WI USA. [Nix, W. Allan; Pallansch, Mark A.] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA USA. RP Oberste, MS (reprint author), 1600 Clifton Rd NE,Mailstop G-17, Atlanta, GA 30333 USA. EM soberste@cdc.gov NR 35 TC 48 Z9 52 U1 0 U2 0 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD FEB 1 PY 2010 VL 50 IS 3 BP 357 EP 361 DI 10.1086/649863 PG 5 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 542NG UT WOS:000273500300008 PM 20047496 ER PT J AU Brown, DW Croft, JB Greenlund, KJ Giles, WH AF Brown, David W. Croft, Janet B. Greenlund, Kurt J. Giles, Wayne H. TI Trends in Hospitalization with Chronic Obstructive Pulmonary Disease-United States, 1990-2005 SO COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE LA English DT Article DE Pulmonary disease; Chronic obstructive Hospitalization; Epidemiology ID EPIDEMIOLOGY; EXPOSURE AB Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death in the United States and a major cause of morbidity and disability. To update national estimates and examine trends for hospitalization with COPD between 1990 and 2005, we analyzed data from the National Hospital Discharge Survey (NHDS). The results indicated that an estimated 715,000 hospitalizations with COPD, or 23.6 per 10,000 population, occurred during 2005, an increase in the number and the rate of COPD hospitalizations since 1990 (370,000 hospitalizations; rate = 15.9 per 10,000 population). To reverse increases in the number of COPD hospitalizations and decrease the burden of COPD, public health programs should continue focused efforts to reduce total personal exposure to tobacco smoke, including passive smoke exposure; to occupational dusts and chemicals; and to other indoor and outdoor air pollutants linked to COPD. C1 [Brown, David W.] Ctr Dis Control & Prevent, Div Adult & Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Brown, DW (reprint author), Ctr Dis Control & Prevent, Div Adult & Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway NE MS K67, Atlanta, GA 30341 USA. EM dbrown6@cdc.gov; jbc0@cdc.gov; keg9@cdc.gov; hwg0@cdc.gov NR 12 TC 27 Z9 27 U1 0 U2 3 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 1541-2555 J9 COPD JI COPD-J. Chronic Obstr. Pulm. Dis. PD FEB PY 2010 VL 7 IS 1 BP 59 EP 62 DI 10.3109/15412550903499548 PG 4 WC Respiratory System SC Respiratory System GA 604KE UT WOS:000278277100009 PM 20214464 ER PT J AU Templeton, DJ Millett, GA Grulich, AE AF Templeton, David J. Millett, Gregorio A. Grulich, Andrew E. TI Male circumcision to reduce the risk of HIV and sexually transmitted infections among men who have sex with men SO CURRENT OPINION IN INFECTIOUS DISEASES LA English DT Review DE circumcision; HIV; homosexuality; male; sexually transmitted diseases ID NEGATIVE HOMOSEXUAL-MEN; VIRUS TYPE-2 INFECTION; NEW-YORK-CITY; UNITED-STATES; PROSPECTIVE COHORT; LATINO MEN; PREVENTION; DISEASES; HEALTH; PREVALENCE AB Purpose of review The success of male circumcision in reducing HIV acquisition among African heterosexuals has led to renewed interest in this biological intervention for HIV/sexually transmissible infection (STI) prevention in men who have sex with men (MSM). This review summarizes the available data on the association of circumcision and HIV/STI among MSM populations. Recent findings Results of observational studies indicate that circumcision has limited impact on HIV/STI acquisition among MSM populations overall. Longitudinal data suggest that circumcision may reduce the risk of incident syphilis, but there is little evidence of a protective effect for other STIs. The subgroup of MSM who predominantly practise the insertive role in anal intercourse may be at lower risk of HIV, although the relative inefficiency of HIV acquisition for insertive compared with receptive partners has resulted in imprecise estimates of effect. Summary The evidence that circumcision reduces HIV and other STIs among MSM is weak and inconsistent. However, recent studies have found that circumcised MSM who predominantly take the insertive role in anal intercourse may be at a lower risk of HIV infection. Although MSM may be willing to undergo adult circumcision, should it be proven to reduce HIV acquisition risk, there is substantial potential that behavioural disinhibition could offset any benefits achieved by a circumcision intervention. C1 [Templeton, David J.; Grulich, Andrew E.] Univ New S Wales, Natl Ctr HIV Epidemiol & Clin Res, Sydney, NSW 2010, Australia. [Templeton, David J.] Royal Prince Alfred Hosp, RPA Sexual Hlth, Sydney, NSW, Australia. [Millett, Gregorio A.] US Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. RP Templeton, DJ (reprint author), Univ New S Wales, Natl Ctr HIV Epidemiol & Clin Res, Level 2,376 Victoria St, Sydney, NSW 2010, Australia. EM dtempleton@nchecr.unsw.edu.au RI Paparello, Joel/F-7521-2011; OI Templeton, David/0000-0003-2157-9587 FU Australian Government Department of Health and Ageing FX The National Centre in HIV Epidemiology and Clinical Research is funded by the Australian Government Department of Health and Ageing. NR 68 TC 34 Z9 34 U1 1 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0951-7375 J9 CURR OPIN INFECT DIS JI Curr. Opin. Infect. Dis. PD FEB PY 2010 VL 23 IS 1 BP 45 EP 52 DI 10.1097/QCO.0b013e328334e54d PG 8 WC Infectious Diseases SC Infectious Diseases GA 597YZ UT WOS:000277799900008 PM 19935420 ER PT J AU Lewinsohn, DA Lobato, MN Jereb, JA AF Lewinsohn, Deborah A. Lobato, Mark N. Jereb, John A. TI Interferon-gamma release assays: new diagnostic tests for Mycobacterium tuberculosis infection, and their use in children SO CURRENT OPINION IN PEDIATRICS LA English DT Review DE child; diagnosis; infant; Mycobacterium tuberculosis; tuberculosis ID QUANTIFERON-TB-GOLD; LATENT TUBERCULOSIS; SKIN-TEST; ACTIVE TUBERCULOSIS; BLOOD-TESTS; HIGH-RISK; PERFORMANCE; DISEASE; SENSITIVITY; PREVALENCE AB Purpose of review The testing and treatment of children at risk for Mycobacterium tuberculosis infection represents an important public health priority in the United States. Until recently, diagnosis has relied upon the tuberculin skin test (TST). New interferon-gamma release assays (IGRAs) offer improvements over TST, but these tests have not been studied in children until recently. Recent findings Evidence regarding IGRA performance in children is accumulating rapidly. Overall, the findings demonstrate performance of IGRAs equivalent or superior to that of the TST. However, IGRAs have biological limitations similar to TST and some technical problems of their own, and critical gaps in our knowledge remain. Summary Current evidence supports usage of IGRAs in children aged 5 years or older. IGRAs are preferred over TST when specificity is paramount or wherein patients might fail to return for TST reading. Evidence for use in children aged less than 5 years is insufficient at this time: the sensitivity is poorly defined, and TST is preferred for testing these children. Future IGRA research should focus on children aged less than 5 years for informing expanded usage in this vulnerable population. C1 [Lewinsohn, Deborah A.] Oregon Hlth & Sci Univ, Dept Pediat, Div Infect Dis, CDRCP, Portland, OR 97239 USA. [Lobato, Mark N.; Jereb, John A.] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA. RP Lewinsohn, DA (reprint author), Oregon Hlth & Sci Univ, Dept Pediat, Div Infect Dis, CDRCP, 707 SW Gaines Rd, Portland, OR 97239 USA. EM lewinsde@ohsu.edu NR 50 TC 32 Z9 33 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1040-8703 J9 CURR OPIN PEDIATR JI CURR. OPIN. PEDIATR. PD FEB PY 2010 VL 22 IS 1 BP 71 EP 76 DI 10.1097/MOP.0b013e3283350301 PG 6 WC Pediatrics SC Pediatrics GA 549GS UT WOS:000274036000012 PM 19952926 ER PT J AU Wharton, M AF Wharton, Melinda TI Vaccine safety: current systems and recent findings SO CURRENT OPINION IN PEDIATRICS LA English DT Review DE immunization; pharmacoepidemiology; postlicensure surveillance; vaccine safety; vaccines ID EVENT REPORTING SYSTEM; UNITED-STATES; ADVERSE EVENTS; SMALLPOX VACCINATION; ROTAVIRUS VACCINE; SURVEILLANCE; IMMUNIZATION; SYNCOPE; INTUSSUSCEPTION; IMMUNOGENETICS AB Purpose of review An understanding of vaccine safety is important for all immunization providers, who have responsibilities to identify, report, and prevent adverse events. Recent findings New analytic methods can provide more rapid information on adverse events compared with traditional observational studies. Some adverse events following vaccination are preventable. Syncope is increasingly recognized postvaccination and may be associated with severe injury or death. Both human and system factors should be addressed to prevent vaccine administration errors. Ongoing basic science and clinical research is critical to improved understanding of vaccine safety. A recent study suggests that many cases of encephalopathy following whole-cell pertussis vaccine were due to severe myoclonic epilepsy of infancy, a severe seizure disorder associated with mutations of the sodium channel gene SCN1A. Summary Vaccine safety requires prelicensure evaluation, postlicensure surveillance and investigation, addressing preventable adverse events, reconsideration of vaccine policy as understanding of risks and benefits changes, and ongoing research to better understand the response to vaccination and the pathogenesis of adverse events. C1 Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Wharton, M (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd,Mailstop E05, Atlanta, GA 30333 USA. EM mew2@cdc.gov NR 48 TC 12 Z9 12 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1040-8703 J9 CURR OPIN PEDIATR JI CURR. OPIN. PEDIATR. PD FEB PY 2010 VL 22 IS 1 BP 88 EP 93 DI 10.1097/MOP.0b013e3283350425 PG 6 WC Pediatrics SC Pediatrics GA 549GS UT WOS:000274036000015 PM 19952750 ER PT J AU Zhao, GX Ford, ES Li, CY AF Zhao, Guixiang Ford, Earl S. Li, Chaoyang TI Associations of Serum Concentrations of 25-Hydroxyvitamin D and Parathyroid Hormone With Surrogate Markers of Insulin Resistance Among US Adults Without Physician-Diagnosed Diabetes: NHANES, 2003-2006 SO DIABETES CARE LA English DT Article ID VITAMIN-D; METABOLIC SYNDROME; SENSITIVITY; POPULATION; WOMEN AB OBJECTIVE - To examine whether concentrations of serum 25-hydroxyvitamin D (25[OH]D) and parathyroid hormone (PTH) are associated with surrogate markers of insulin resistance (IR) in U.S. adults without physician-diagnosed diabetes. RESEARCH DESIGN AND METHODS - Cross-sectional data (n = 3,206) from the National Health and Nutrition Examination Survey (NHANES) 2003-2006 were analyzed. RESULTS - The age-adjusted prevalence of hyperinsulinemia, high homeostasis model assessment-IR, high GHb, and fasting and 2-h hyperglycemia decreased linearly across quintiles of 25(OH)D but increased linearly across quintiles of PTH (except for a quadratic trend for fasting hyperglycemia). After extensive adjustment for Potential confounders, the relationships between 25(OH)D and the markers of IR and 2-h hyperglycemia persisted. Only hyperinsulinemia was positively associated with PTH (P < 0.05). CONCLUSIONS - Among U.S. adults without physician-diagnosed diabetes, low concentrations of serum 25(OH)D were associated with markers of IR. The role of PTH in IR deserves further investigation. C1 [Zhao, Guixiang; Ford, Earl S.; Li, Chaoyang] Ctr Dis Control & Prevent, Div Adult & Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Zhao, GX (reprint author), Ctr Dis Control & Prevent, Div Adult & Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM gzhao@cdc.gov NR 15 TC 50 Z9 56 U1 0 U2 2 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 J9 DIABETES CARE JI Diabetes Care PD FEB PY 2010 VL 33 IS 2 BP 344 EP 347 DI 10.2337/dc09-0924 PG 4 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA 563PA UT WOS:000275143700026 PM 19846799 ER PT J AU Ross, DS Visser, SN Holstrum, WJ Qin, TL Kenneson, A AF Ross, Danielle S. Visser, Susanna N. Holstrum, W. June Qin, Tielin Kenneson, Aileen TI Highly Variable Population-Based Prevalence Rates of Unilateral Hearing Loss After the Application of Common Case Definitions SO EAR AND HEARING LA English DT Article ID NUTRITION EXAMINATION SURVEY; 3RD NATIONAL-HEALTH; CHILDREN 6; AGE AB Objectives: This study shows how population-based estimates of the prevalence of unilateral hearing loss (UHL) in children aged 6 to 19 yrs can differ considerably with various applications of commonly accepted case definitions. It also examines demographic variables and risk factors related to UHL. Design: The Third National Health and Nutrition Examination Survey, conducted from 1988 to 1994, is a national population-based, cross-sectional survey. This study examined results of audiometric testing at 0.5 to 8 kHz and demographic data from in-person examination interviews. Three definitions of UHL were used: (1) 0.5, 1, and 2 kHz >= 15 dB pure-tone average (PTA); (2) 0.5, 1, 2, and 4 kHz >= 15 dB PTA; and (3) 0.5, 1, and 2 kHz >= 20 dB or PTA >25 dB at two or more frequencies above 2 kHz (3, 4, 6, and 8 kHz). Case definitions 2 and 3 are not merely subsets of case definition 1. Some overlap exists between the groups, but each case definition classifies a proportion of children who fall uniquely under that case definition. Inclusion of participants based on tympanometry results (test of middle ear function) was also examined as were demographic characteristics and risk factors associated with UHL. Results: Overall, the weighted proportion of children with UHL using case definition 1 was 6.3% (approximately 3,213,000 children nationally); using case definition 2, it was 5.8% (approximately 2,958,000 nationally); using case definition 3, it was 3.0% (approximately 1,530,000 nationally). For all three case definitions, children who failed tympanometry were at higher risk for UHL than children who passed. For case definition 2, children from rural areas were at higher risk for UHL than were children from urban areas. Conclusions: This study demonstrates that different applications of well-accepted case definitions of UHL can influence population-based prevalence estimates, in this study by as much as a factor of 2. These findings highlight the importance of controlling for tympanometry status as a risk factor in such estimates. Which demographic characteristics and risk factors are significantly associated with hearing loss seem to vary depending on the case definition. These findings have implications for the interpretation of prevalence rates and risk factors in the literature on hearing loss in general. Prevalence rate estimates require careful consideration of the case definition of hearing loss, tympanometry status, and demographic characteristics. C1 [Ross, Danielle S.; Visser, Susanna N.; Qin, Tielin] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Div Human Dev & Disabil, Atlanta, GA USA. [Holstrum, W. June; Kenneson, Aileen] McKing Consulting Corp, Atlanta, GA USA. RP Ross, DS (reprint author), CDC, NCBDDD, 1600 Clifton Rd NE,MS E88, Atlanta, GA 30333 USA. EM dross3@cdc.gov NR 21 TC 9 Z9 11 U1 2 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0196-0202 J9 EAR HEARING JI Ear Hear. PD FEB PY 2010 VL 31 IS 1 BP 126 EP 133 DI 10.1097/AUD.0b013e3181bb69db PG 8 WC Audiology & Speech-Language Pathology; Otorhinolaryngology SC Audiology & Speech-Language Pathology; Otorhinolaryngology GA 618PH UT WOS:000279367600015 PM 19816180 ER PT J AU Kutty, PK Woods, CW Sena, AC Benoit, SR Naggie, S Frederick, J Evans, S Engel, J McDonald, LC AF Kutty, Preeta K. Woods, Christopher W. Sena, Arlene C. Benoit, Stephen R. Naggie, Susanna Frederick, Joyce Evans, Sharon Engel, Jeffery McDonald, L. Clifford TI Risk Factors for and Estimated Incidence of Community-associated Clostridium difficile Infection, North Carolina, USA SO EMERGING INFECTIOUS DISEASES LA English DT Article ID INFLAMMATORY-BOWEL-DISEASE; NOSOCOMIAL DIARRHEA; EPIDEMIOLOGY; MORTALITY; STRAIN C1 [Kutty, Preeta K.; Benoit, Stephen R.; McDonald, L. Clifford] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Woods, Christopher W.; Naggie, Susanna; Frederick, Joyce] Dept Vet Affairs Med Ctr, Durham, NC USA. [Woods, Christopher W.; Naggie, Susanna; Evans, Sharon] Duke Univ, Med Ctr, Durham, NC USA. [Sena, Arlene C.] Durham Cty Hlth Dept, Durham, NC USA. [Sena, Arlene C.] Univ N Carolina, Chapel Hill, NC USA. [Engel, Jeffery] N Carolina Dept Hlth & Human Serv, Raleigh, NC USA. RP McDonald, LC (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop A31, Atlanta, GA 30333 USA. EM cmcdonald1@cdc.gov NR 32 TC 91 Z9 92 U1 0 U2 4 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD FEB PY 2010 VL 16 IS 2 BP 197 EP 204 DI 10.3201/eid1602.090953 PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 553XO UT WOS:000274400300003 PM 20113547 ER PT J AU Effler, PV Carcione, D Giele, C Dowse, GK Goggin, L Mak, DB AF Effler, Paul V. Carcione, Dale Giele, Carolien Dowse, Gary K. Goggin, Leigh Mak, Donna B. TI Household Responses to Pandemic (H1N1) 2009-related School Closures, Perth, Western Australia SO EMERGING INFECTIOUS DISEASES LA English DT Article ID PUBLIC-HEALTH; INFLUENZA; TRANSMISSION AB School closure is often purported to reduce influenza transmission, but little is known about its effect on families. We surveyed families affected by pandemic (H1N1) 2009-related school closures in Perth, Western Australia, Australia. Surveys were returned for 233 (58%) of 402 students. School closure was deemed appropriate by 110 parents (47%); however, 91 (45%) parents of 202 asymptomatic students reported taking >= 1 day off work to care for their child, and 71 (35%) had to make childcare arrangements because of the class closures. During the week, 172 (74%) students participated in activities outside the home on >= 1 occasion, resulting in an average of 3.7 out-of-home activities for each student. In our survey, activities outside the home were commonly reported by students affected by school closure, the effect on families was substantial, and parental opinion regarding school closures as a means to mitigate the outbreak of pandemic (H1N1) 2009 was divided. C1 [Effler, Paul V.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Effler, Paul V.; Carcione, Dale; Giele, Carolien; Dowse, Gary K.; Goggin, Leigh; Mak, Donna B.] Dept Hlth, Perth, WA, Australia. RP Effler, PV (reprint author), Perth Business Ctr, POB 8172, Perth, WA 6849, Australia. EM paul.effler@health.wa.gov.au NR 21 TC 27 Z9 30 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD FEB PY 2010 VL 16 IS 2 BP 205 EP 211 DI 10.3201/eid1602.091372 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 553XO UT WOS:000274400300004 PM 20113548 ER PT J AU Lossifova, Y Bailey, R Wood, J Kreiss, K AF Lossifova, Yulia Bailey, Rachel Wood, John Kreiss, Kathleen TI Concurrent Silicosis and Pulmonary Mycosis at Death SO EMERGING INFECTIOUS DISEASES LA English DT Article ID PNEUMOCONIOSIS; ASPERGILLOSIS AB To examine risk for mycosis among persons with silicosis, we examined US mortality data for 1979-2004. Persons with silicosis were more likely to die with pulmonary mycosis than were those without pneumoconiosis or those with more common pneumoconioses. Health professionals should consider enhanced risk for mycosis for silica-exposed patients. C1 [Lossifova, Yulia; Bailey, Rachel; Wood, John; Kreiss, Kathleen] Ctr Dis Control & Prevent, Morgantown, WV USA. RP Kreiss, K (reprint author), NIOSH, CDC, 1095 Willowdale Rd,Mailstop H2800, Morgantown, WV 26505 USA. EM kkreiss@cdc.gov NR 10 TC 3 Z9 3 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD FEB PY 2010 VL 16 IS 2 BP 318 EP 320 DI 10.3201/eid1602.090824 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 553XO UT WOS:000274400300025 ER PT J AU Asnis, DS Muana, O Kim, DG Garcia, M Rollin, PE Slavinski, S AF Asnis, Deborah S. Muana, Owen Kim, Do Gyun Garcia, Minerva Rollin, Pierre E. Slavinski, Sally TI Lymphocytic Choriomeningitis Virus Meningitis, New York, NY, USA, 2009 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID INFECTION AB We describe a case of lymphocytic choriomeningitis virus (LCMV) meningitis in a New York, NY, resident who had no apparent risk factors. Clues leading to the diagnosis included aseptic meningitis during winter and the finding of hypoglycorrachia and lymphocytosis in the cerebrospinal fluid. LCMV continues to be an underdiagnosed zoonotic disease. C1 [Asnis, Deborah S.; Muana, Owen; Kim, Do Gyun; Garcia, Minerva] Flushing Hosp & Med Ctr, Med Ctr, Flushing, NY 11355 USA. [Rollin, Pierre E.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Slavinski, Sally] New York City Dept Hlth & Mental Hyg Communicable, New York, NY USA. RP Asnis, DS (reprint author), Flushing Hosp & Med Ctr, Med Ctr, 4500 Parsons Blvd, Flushing, NY 11355 USA. EM iddoc@erols.com NR 9 TC 6 Z9 7 U1 0 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD FEB PY 2010 VL 16 IS 2 BP 328 EP 330 DI 10.3201/eid1602.091347 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 553XO UT WOS:000274400300028 PM 20113573 ER PT J AU Sak, B Kucerova, Z Kvac, M Kvetonova, D Rost, M Secor, EW AF Sak, Bohumil Kucerova, Zuzana Kvac, Martin Kvetonova, Dana Rost, Michael Secor, Evan W. TI Seropositivity for Enterocytozoon bieneusi, Czech Republic SO EMERGING INFECTIOUS DISEASES LA English DT Article ID VIRUS-INFECTED PATIENTS; INTESTINAL MICROSPORIDIOSIS; IMMUNOCOMPETENT SUBJECTS; PREVALENCE; DIARRHEA; SEROPREVALENCE; ANTIBODIES; CUNICULI AB To determine seropositivity for Enterocytozoon bieneusi in the Czech Republic, we tested 115 serum samples from various groups. We found that 20% from HIV-positive persons, 33% from persons with occupational exposure to animals, and 10% from healthy persons were positive by indirect immunofluorescence assay. Proteins of 32 kDa were detected in serum samples from seropositive persons. C1 [Sak, Bohumil; Kvac, Martin; Kvetonova, Dana] Acad Sci Czech Republic, Ctr Biol, Ceske Budejovice, Czech Republic. [Kucerova, Zuzana; Secor, Evan W.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Kvac, Martin; Rost, Michael] Univ S Bohemia, Ceske Budejovice, Czech Republic. RP Kvac, M (reprint author), Acad Sci Czech Republic, Ctr Biol, Branisovska 31, Ceske Budejovice, Czech Republic. EM kvac@paru.cas.cz RI Kvac, Martin/G-7299-2014 OI Kvac, Martin/0000-0003-0013-6090 FU Academy of Sciences of the Czech Republic [KJB500960701]; Grant Agency of the Czech Republic [523/07/P117]; Institute of Parasitology, Academy of Sciences of the Czech Republic [Z60220518]; National Institute of Allergy and Infectious Diseases [R13AI078718] FX This study was funded by a grant of the Academy of Sciences of the Czech Republic (KJB500960701), the Grant Agency of the Czech Republic (project No. 523/07/P117), research project of the Institute of Parasitology, Academy of Sciences of the Czech Republic (Z60220518), and in part by National Institutes of Health grant R13AI078718 from the National Institute of Allergy and Infectious Diseases. NR 15 TC 9 Z9 9 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD FEB PY 2010 VL 16 IS 2 BP 335 EP 337 DI 10.3201/eid1602.090964 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 553XO UT WOS:000274400300030 PM 20113575 ER PT J AU Kuzmin, IV Niezgoda, M Franka, R Agwanda, B Markotter, W Breiman, RF Shieh, WJ Zaki, SR Rupprecht, CE AF Kuzmin, Ivan V. Niezgoda, Michael Franka, Richard Agwanda, Bernard Markotter, Wanda Breiman, Robert F. Shieh, Wun-Ju Zaki, Sherif R. Rupprecht, Charles E. TI Marburg Virus in Fruit Bat, Kenya SO EMERGING INFECTIOUS DISEASES LA English DT Letter ID DISEASE C1 [Kuzmin, Ivan V.; Niezgoda, Michael; Franka, Richard; Shieh, Wun-Ju; Zaki, Sherif R.; Rupprecht, Charles E.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Agwanda, Bernard] Natl Museums Kenya, Nairobi, Kenya. [Markotter, Wanda] Univ Pretoria, ZA-0002 Pretoria, South Africa. [Breiman, Robert F.] Ctr Dis Control & Prevent Kenya, Nairobi, Kenya. RP Kuzmin, IV (reprint author), Ctr Dis Control & Prevent, 1600 Cliflon Rd NE,Mailstop G33, Atlanta, GA 30333 USA. EM ikuzmin@cdc.gov OI Markotter, Wanda/0000-0002-7550-0080 NR 10 TC 21 Z9 22 U1 1 U2 20 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD FEB PY 2010 VL 16 IS 2 BP 352 EP 354 DI 10.3201/eid1602.091269 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 553XO UT WOS:000274400300039 PM 20113584 ER PT J AU Potter, P AF Potter, Polyxeni TI Bird's Eye View of Emerging Zoonoses SO EMERGING INFECTIOUS DISEASES LA English DT Editorial Material C1 Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Potter, P (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop D61, Atlanta, GA 30333 USA. EM PMP1@cdc.gov NR 5 TC 0 Z9 0 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD FEB PY 2010 VL 16 IS 2 BP 369 EP 370 DI 10.3201/eid1602.000000 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 553XO UT WOS:000274400300050 PM 20113594 ER PT J AU Aylward, LL Morgan, MK Arbuckle, TE Barr, DB Burns, CJ Alexander, BH Hays, SM AF Aylward, Lesa L. Morgan, Marsha K. Arbuckle, Tye E. Barr, Dana B. Burns, Carol J. Alexander, Bruce H. Hays, Sean M. TI Biomonitoring Data for 2,4-Dichlorophenoxyacetic Acid in the United States and Canada: Interpretation in a Public Health Risk Assessment Context Using Biomonitoring Equivalents SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Review DE 2,4-dichlorophenoxyacetic acid; biomonitoring; exposure biomarkers; exposure monitoring; risk assessment ID NON-HODGKINS-LYMPHOMA; SOFT-TISSUE SARCOMA; HERBICIDE EXPOSURE; CHILDRENS EXPOSURE; EXPERT WORKSHOP; ONTARIO FARMS; 2,4-D; URINARY; GUIDELINES; FAMILIES AB BACKGROUND: Several extensive studies of exposure to 2,4-dichlorophenoxyacetic acid (2,4-D) using urinary concentrations in samples front the general population, farm applicators, and farm family members are now available. Reference doses (RfDs) exist for 2,4-D, and Biomonitoring Equivalents (BEs; concentrations in urine or plasma that are consistent with those RfDs) for 2,4-D have recently been derived and published. OBJECTIVE: We reviewed the available biomonitoring data for 2,4-D from the United States and Canada and compared them with BE values to draw conclusions regarding the margin of safety for 2,4-D exposures within each population group. DATA SOURCES: Data on urinary 2,4-D excretion in general and target populations from recent published Studies are tabulated and the derivation of BE values for 2,4-D summarized. DATA SYNTHESIS: The biomonitoring data indicate margins of safety (ratio of BE value to biomarker concentration) of approximately 200 at the central tendency, and 50 at the extremes in the general Population. Median exposures for applicators and their family members during periods of use appear to be well within acute exposure guidance values. CONCLUSIONS: Biomonitoring data from these studies indicate that current exposures to, 2,4-D are below applicable exposure guidance values. This review demonstrates the value of biomonitoring data in assessing population exposures in the context of existing risk assessments using the BE approach. Risk managers can use this approach to integrate the available biomonitoring data into an overall assessment of current risk management practices for 2,4-D. C1 [Aylward, Lesa L.] Summit Toxicol LLP, Falls Church, VA 22044 USA. [Morgan, Marsha K.] US EPA, Res Triangle Pk, NC 27711 USA. [Arbuckle, Tye E.] Hlth Canada, Environm Hlth Sci & Res Bur, Ottawa, ON K1A 0L2, Canada. [Barr, Dana B.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. [Burns, Carol J.] Dow Chem Co USA, Midland, MI 48674 USA. [Alexander, Bruce H.] Univ Minnesota, Sch Publ Hlth, Div Environm Hlth Sci, Minneapolis, MN USA. [Hays, Sean M.] Summit Toxicol LLP, Lyons, CO USA. RP Aylward, LL (reprint author), Summit Toxicol LLP, 6343 Carolyn Dr, Falls Church, VA 22044 USA. EM laylward@summittoxicology.com RI Barr, Dana/E-6369-2011; Barr, Dana/E-2276-2013; OI Aylward, Lesa/0000-0003-3191-8175 FU U.S. Environmental Protection Agency (EPA) through its Office of Research and Development; Industry Task Force II on 2,4-D Research Data; Dow Chemical Company FX The U.S. Environmental Protection Agency (EPA) through its Office of Research and Development Funded and managed some of the research described here.; L.L.A. and S.M.H. received funding to support preparation of this review from the Industry Task Force II on 2,4-D Research Data. C.J.B. is employed by the Dow Chemical Company, which manufactures 2,4-dichlorophenoxyacetic acid. B.H.A. was a researcher oil the Farm Family Exposure Study, which was funded in part by the Dow Chemical Company. NR 40 TC 18 Z9 18 U1 0 U2 5 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 EI 1552-9924 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD FEB PY 2010 VL 118 IS 2 BP 177 EP 181 DI 10.1289/ehp.0900970 PG 5 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 555BQ UT WOS:000274482400015 PM 20123603 ER PT J AU Hansen, C Luben, TJ Sacks, JD Olshan, A Jeffay, S Strader, L Perreault, SD AF Hansen, Craig Luben, Thomas J. Sacks, Jason D. Olshan, Andrew Jeffay, Susan Strader, Lillian Perreault, Sally D. TI The Effect of Ambient Air Pollution on Sperm Quality SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article DE air pollution; male reproductive system; O(3); ozone; particulate matter; sperm quality ID SEMEN QUALITY; DIESEL EXHAUST; EPIDEMIOLOGIC EVIDENCE; REPRODUCTIVE HEALTH; DNA FRAGMENTATION; MALE-INFERTILITY; EXPOSURE; MEN; PREGNANCY; OUTCOMES AB BACKGROUND: Research has suggested an association with ambient air Pollution and sperm quality. OBJECTIVES: We investigated the effect of exposure to ozone (O(3)) and particulate matter < 2.5 mu m in aerodynamic diameter (PM(2.5)) on sperm quality. METHODS: We reexamined a previous cohort study of water disinfection by-products to evaluate sperm quality in 228 presumed fertile men with different air pollution profiles. Outcomes included sperm concentration, total sperm per ejaculate (count), and morphology, as well as DNA integrity and chromatin maturity. Exposures to O(3) and PM(2.5) were evaluated for the 90-day period before sampling. We used multivariable linear regression, which included different levels of adjustment (i.e., without and with season and temperature) to assess the relationship between exposure to air pollutants during key periods of sperm development and adverse sperm outcomes. RESULTS: Sperm concentration and count were not associated with exposure to PM(2.5), but there was evidence of an association (but not statistically significant) with O(3) concentration and decreased sperm concentration and count. Additionally, a significant increase in the percentage of sperm cells with cytoplasmic drop [beta = 2.64; 95% confidence interval (CI), 0.21-5.06] and abnormal head (beta = 0.47; 95% CI, 0.03-0.92) was associated with PM(2.5) concentration in the base model. However, these associations, along with all other sperm Outcomes, were not significantly associated with either pollutant after controlling for season and temperature. Overall, although we found both protective and adverse effects, there was generally no consistent pattern of increased abnormal sperm quality with elevated exposure to O(3) or PM(2.5). CONCLUSIONS: Exposures to O(3) or PM2.5 at levels below the current National Ambient Air Quality Standards were not associated with statistically significant decrements in sperm outcomes in this cohort of fertile men. However, some results suggested effects on sperm concentration, count, and morphology. C1 [Hansen, Craig; Luben, Thomas J.; Sacks, Jason D.] US EPA, Natl Ctr Environm Assessment, Off Res & Dev, Res Triangle Pk, NC 27711 USA. [Olshan, Andrew] Univ N Carolina, Sch Publ Hlth, Dept Epidemiol, Chapel Hill, NC USA. [Jeffay, Susan; Strader, Lillian; Perreault, Sally D.] US EPA, Off Assistant Administrator, Off Res & Dev, Res Triangle Pk, NC 27711 USA. RP Hansen, C (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Mail Stop E86,1600 Clifton Rd, Atlanta, GA 30333 USA. EM hya2@cdc.gov RI Hansen, Craig /C-7543-2014 OI Hansen, Craig /0000-0002-5227-0155 FU U.S. EPA [R-82932701]; National Institute of Environmental Health Sciences [P30ES10126, T32ES007018] FX C.H.'s participation was supported by his appointment to the Postgraduate Research Program administered by Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and the U.S. Environmental Protection Agency (EPA). This research was supported in part by grants from the U.S. EPA (R-82932701) and National Institute of Environmental Health Sciences (P30ES10126, T32ES007018). NR 42 TC 29 Z9 31 U1 1 U2 21 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD FEB PY 2010 VL 118 IS 2 BP 203 EP 209 DI 10.1289/ehp.0901022 PG 7 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 555BQ UT WOS:000274482400019 PM 20123611 ER PT J AU Bartell, SM Calafat, AM Lyu, C Kato, K Ryan, PB Steenland, K AF Bartell, Scott M. Calafat, Antonia M. Lyu, Christopher Kato, Kayoko Ryan, P. Barry Steenland, Kyle TI Rate of Decline in Serum PFOA Concentrations after Granular Activated Carbon Filtration at Two Public Water Systems in Ohio and West Virginia SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article DE exposure; half-life; intervention; perfluorooctanoic acid ID PERFLUOROOCTANOATE; ELIMINATION; MONKEYS; PLASMA; ACIDS AB BACKGROUND: Drinking water in multiple water districts in the Mid-Ohio Valley has been contaminated with perfluorooctanoic acid (PFOA), which was released by a nearby DuPont chemical plant. Two highly contaminated water districts began granular activated carbon filtration in 2007. OBJECTIVES: To determine the rate of decline in serum PFOA, and its corresponding half-life, during the first year after filtration. METHODS: Up to six blood samples were collected from each of 200 participants from May 2007 until August 2008. The primary Source of drinking water varied over time for some participants; Our analyses were grouped according to water source at baseline in May-June 2007. RESULTS: For Lubeck Public Service District customers, the average decrease in serum PFOA concentrations between May-June 2007 and May-August 2008 was 32 ng/mL (26%) for those primarily consuming public water at home (n = 130), and 16 ng/mL (28%) for those primarily consuming bottled water at home (n = 17). For Little Hocking Water Association customers, the average decrease in serum PFOA concentrations between November-December 2007 and May-June 2008 was 39 ng/mL (11%) for consumers of public water (n = 39) and 28 ng/mL (20%) for consumers of bottled water (n = 11). The covariate-adjusted average rate of decrease in serum PFOA concentration after water filtration was 26% per year (95% confidence interval, 25-28% per year). CONCLUSIONS: The observed data are consistent with first-order elimination and a median serum PFOA half-life of 2.3 years. Ongoing follow-up will lead to improved half-life estimation. C1 [Bartell, Scott M.] Univ Calif Irvine, Program Publ Hlth, Irvine, CA 92697 USA. [Bartell, Scott M.; Ryan, P. Barry; Steenland, Kyle] Emory Univ, Dept Environm & Occupat Hlth, Atlanta, GA 30322 USA. [Calafat, Antonia M.; Kato, Kayoko] Ctr Dis Control & Prevent, Atlanta, GA USA. [Lyu, Christopher] Battelle Ctr Publ Hlth Res & Evaluat, Durham, NC USA. RP Bartell, SM (reprint author), Univ Calif Irvine, Program Publ Hlth, 2241 Bren Hall, Irvine, CA 92697 USA. EM sbartell@uci.edu RI Bartell, Scott/M-8919-2013 OI Bartell, Scott/0000-0001-7797-2906 FU Circuit Court of Wood County, WV FX This research is funded by the C8 Class Action Settlement Agreement (Circuit Court of Wood County, WV) between DuPont and plaintiffs, which resulted Front releases of PFOA (or CS) into drinking water. NR 21 TC 123 Z9 123 U1 2 U2 33 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD FEB PY 2010 VL 118 IS 2 BP 222 EP 228 DI 10.1289/ehp.0901252 PG 7 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 555BQ UT WOS:000274482400022 PM 20123620 ER PT J AU Scinicariello, F Yesupriya, A Chang, MH Fowler, BA AF Scinicariello, Franco Yesupriya, Ajay Chang, Man-huei Fowler, Bruce A. CA Natl Canc Inst TI Modification by ALAD of the Association between Blood Lead and Blood Pressure in the US Population: Results from the Third National Health and Nutrition Examination Survey SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article DE ALAD polymorphism; blood pressure; hypertension; lead; NHANES ID ACID DEHYDRATASE GENOTYPE; UNITED-STATES; NITRIC-OXIDE; CARDIOVASCULAR-DISEASE; NHANES-III; HYPERTENSION; EXPOSURE; POLYMORPHISM; GENE; METAANALYSIS AB BACKGROUND: Environmental lead exposure has been found to be associated with an increased risk of hypertension. Individuals vary greatly in susceptibility to lead toxicity, and genetic susceptibility has often been cited as the probable cause for such variation. OBJECTIVE: The main objective is to determine the role of the aminolevulinic acid dehydratase (ALAD) gene, which encodes the main carrier protein of lead in blood, in the association between lead exposure and blood pressure (BP) and hypertension in the U.S. population. METHODS: We analyzed data from individuals >= 17 years of age who participated in the Third National Health and Nutrition Examination Survey for whom DNA was available (n = 6,016). Multivariable logistic and linear regressions stratified by race/ethnicity were used to examine whether hypertension and BP were associated with ALAD and blood lead levels (BLL). RESULTS: BLL was associated with systolic BP in non-Hispanic whites and with hypertension and systolic and diastolic BP in non-Hispanic blacks. BLL was not associated with BP outcomes in Mexican Americans. Non-Hispanic white ALAD2 carriers in the highest BLL quartile (3.8-52.9 mu g/dL) had a significantly higher adjusted prevalence odds ratio for hypertension compared with ALAD1 homozygous individuals. We also found a significant interaction between lead concentration and the ALAD2 allele in non-Hispanic whites and non-Hispanic blacks in relation to systolic BP. CONCLUSIONS: BLL may be an important risk factor for hypertension and increased systolic and diastolic FIR These associations may be modified by A LAD genotype. C1 [Scinicariello, Franco] Ctr Dis Control & Prevent, Div Toxicol & Environm Med, Agcy Tox Subst & Dis Registry, Atlanta, GA 30341 USA. [Yesupriya, Ajay; Chang, Man-huei] Ctr Dis Control & Prevent, Off Publ Hlth Genom, Coordinating Ctr Hlth Promot, Atlanta, GA 30341 USA. RP Scinicariello, F (reprint author), Ctr Dis Control & Prevent, Div Toxicol & Environm Med, Agcy Tox Subst & Dis Registry, MS F-32,4770 Buford Hwy, Atlanta, GA 30341 USA. EM fes6@cdc.gov NR 45 TC 21 Z9 21 U1 0 U2 6 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD FEB PY 2010 VL 118 IS 2 BP 259 EP 264 DI 10.1289/ehp.0900866 PG 6 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 555BQ UT WOS:000274482400028 PM 20123609 ER PT J AU Vesper, HW Caudill, SP Osterloh, JD Meyers, T Scott, D Myers, GL AF Vesper, Hubert W. Caudill, Samuel P. Osterloh, John D. Meyers, Tunde Scott, Deanna Myers, Gary L. TI Exposure of the US Population to Acrylamide in the National Health and Nutrition Examination Survey 2003-2004 SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article DE acrylamide; biomonitoring; glycidamide; human exposure; hemoglobin adducts; NHANES; US population ID HEMOGLOBIN ADDUCTS; OCCUPATIONAL-EXPOSURE; GENETIC-POLYMORPHISM; DIETARY-INTAKE; GENERAL-POPULATION; MAILLARD REACTION; GLYCIDAMIDE; BIOMARKERS; CANCER; MICE AB BACKGROUND: The lifelong exposure of the population to acrylamide has raised concerns about the possible health effects of the chemical. Data on the extent of exposure to acrylamide and its primary metabolite, glycidamide, arc needed to aid in the assessment of potential health effects. OBJECTIVES: The aim of this study was to assess human exposure to acrylamide and glycidamide in the general U.S. population through the measurement of hemoglobin adducts of acrylamide (HbAA) and glycidamide (HbGA). METHODS: HbAA and HbGA were measured in 7,166 subjects front the National Health and Nutrition Examination Survey. Stratified HbAA and HbGA data were reported by sex, age groups, race/ethnicity (Mexican American, non-Hispanic black, non-Hispanic white), and smoking status based on serum cotinine levels. Covariate-adjusted geometric means for each demographic group were calculated using multiple regression analysis. RESULTS: HbAA and HbGA levels ranged from 3 to 910 and from 4 to 756 pmol/g hemoglobin, respectively, with smokers having the highest levels overall. Tobacco smoke exposure in nonsmokers had a small but significant effect on HbAA and HbGA levels. Adjusted geometric mean levels for children 3-11 years of age were higher than for adults >= 60 years of age [mean (95% confidence interval): HbAA, 54.5 (49.1-51-5) and HbGA, 73.9 (71.3-76.6) vs. HbAA, 46.2 (44.3-48.2) and HbGA, 41.8 (38.7-45.2)]. Levels were highest in Mexican Americans [HbAA: 54.8 (51.9-57.8), HbGA: 57.9 (53.7-62.5)], whereas non-Hispanic blacks had the lowest HbGA levels [43.5 (41.1-45.9)]. CONCLUSIONS: U.S. population levels of acrylamide and glycidamide adducts are described. The high variability among individuals but modest differences between population subgroups suggest that sex, age, and race/ethnicity do not strongly affect acrylamide exposure. Adduct concentration data can be used to estimate relative exposure and to validate intake estimates. C1 [Vesper, Hubert W.; Caudill, Samuel P.; Osterloh, John D.; Meyers, Tunde; Scott, Deanna; Myers, Gary L.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA USA. RP Vesper, HW (reprint author), 4770 Buford Hwy NE,MS F25, Atlanta, GA 30341 USA. EM HVesper@cdc.gov NR 55 TC 19 Z9 19 U1 0 U2 6 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD FEB PY 2010 VL 118 IS 2 BP 278 EP 283 DI 10.1289/ehp.0901021 PG 6 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 555BQ UT WOS:000274482400031 PM 20123601 ER PT J AU Adibi, JJ Whyatt, RM Hauser, R Bhat, HK Davis, BJ Calafat, AM Hoepner, LA Perera, FP Tang, D Williams, PL AF Adibi, Jennifer J. Whyatt, Robin M. Hauser, Russ Bhat, Hari K. Davis, Barbara J. Calafat, Antonia M. Hoepner, Lori A. Perera, Frederica P. Tang, Deliang Williams, Paige L. TI Transcriptional Biomarkers of Steroidogenesis and Trophoblast Differentiation in the Placenta in Relation to Prenatal Phthalate Exposure SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article DE epidemiology; gene expression; phthalates; placenta; pregnancy; prenatal; steroidogenesis; trophoblast differentiation ID HUMAN CHORIONIC-GONADOTROPIN; NONMONOTONIC DOSE-RESPONSE; RAT GRANULOSA-CELLS; IN-UTERO EXPOSURE; GENE-EXPRESSION; MONO-(2-ETHYLHEXYL) PHTHALATE; DI(N-BUTYL) PHTHALATE; PPAR-GAMMA; FETAL-RAT; DI-(2-ETHYLHEXYL) PHTHALATE AB BACKGROUND: Phthalates can alter steroidogenesis and peroxisome proliferator-activated receptor gamma (PPAR gamma)-mediated transcription in rodent tissues. The placenta offers a rich source of biomarkers to study these relationships in humans. OBJECTIVE: We evaluated whether gestational phthalate exposures in humans were associated with altered human placental steroidogenesis and trophoblast differentiation as measured by markers of mRNA transcription. METHODS: We measured seven target genes in placentas collected from 54 Dominican and African-American women at delivery in New York City using quantitative real-time polymerase chain reaction (qPCR), normalized to 18S rRNA. qPCR results for the target genes were log-transformed, converted to Z-scores, and grouped into two functional pathways: steroidogenesis (aromatase, cholesterol side chain cleavage enzyme, 17 beta-hydroxysteroid dehydrogenase type 1, and cytochrome P450 1B1) and trophoblast differentiation (PPAR gamma, aryl hydrocarbon receptor, and human chorionic gonadotropin). Repeated measures models were used to evaluate the association of phthalate metabolites measured in third-trimester urine samples with each group of target genes, accounting for correlation among the genes within a pathway. RESULTS: Higher urinary concentrations of five phthalate metabolites were associated with lower expression of the target genes reflecting trophoblast differentiation. Results were less consistent for genes in the steroidogenesis pathway and suggested a nonlinear dose-response pattern for some phthalate metabolites. CONCLUSIONS: We observed a significant association between prenatal exposure to phthalates and placental gene expression within two pathways. Further studies are warranted to understand the significance of this association with respect to fetal development and placental function. C1 [Adibi, Jennifer J.; Hauser, Russ] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA. [Whyatt, Robin M.; Bhat, Hari K.; Hoepner, Lori A.; Perera, Frederica P.; Tang, Deliang] Mailman Sch Publ Hlth, Columbia Ctr Childrens Environm Hlth, New York, NY USA. [Davis, Barbara J.] Millennium Pharmaceut Inc, Cambridge, MA USA. [Calafat, Antonia M.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. [Williams, Paige L.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. RP Adibi, JJ (reprint author), Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, 513 Parnassus Ave,Box 0556, San Francisco, CA 94143 USA. EM adibij@obgyn.ucsf.edu RI Adibi, Jennifer/I-8077-2016; OI Adibi, Jennifer/0000-0001-6562-8315; Hoepner, Lori/0000-0002-4404-8140 FU National Institute of Environniental Health [P50 LS09600, R01 ES013543, R01 ES08977, R01 ES11158]; U.S. Environmental Protection Agency [R827027, R8286090] FX This work was supported by National Institute of Environniental Health Sciences grants P50 LS09600, R01 ES013543, R01 ES08977, and R01 ES11158 and by U.S. Environmental Protection Agency grants R827027 and R8286090 NR 55 TC 18 Z9 18 U1 0 U2 10 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD FEB PY 2010 VL 118 IS 2 BP 291 EP 296 DI 10.1289/ehp.0900788 PG 6 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA 555BQ UT WOS:000274482400033 PM 20123604 ER PT J AU Blair, PJ Wierzba, TF Touch, S Vonthanak, S Xu, X Garten, RJ Okomo-Adhiambo, MA Klimov, AI Kasper, MR Putnam, SD AF Blair, P. J. Wierzba, T. F. Touch, S. Vonthanak, S. Xu, X. Garten, R. J. Okomo-Adhiambo, M. A. Klimov, A. I. Kasper, M. R. Putnam, S. D. TI Influenza epidemiology and characterization of influenza viruses in patients seeking treatment for acute fever in Cambodia SO EPIDEMIOLOGY AND INFECTION LA English DT Article DE Avian flu; Cambodia; epidemiology; influenza ID A H3N2 VIRUSES; ISOLATED WORLDWIDE; SOUTHEAST-ASIA; B VIRUSES; SURVEILLANCE; RESISTANCE; EVOLUTION; INFECTIONS; PATTERNS; HISTORY AB The epidemiology, symptomology, and viral aetiology of endemic influenza remain largely uncharacterized in Cambodia. In December 2006, we established passive hospital-based surveillance to identify the causes of acute undifferentiated fever in patients seeking healthcare. Fever was defined as tympanic membrane temperature >38 degrees C. From December 2006 to December 2008, 4233 patients were screened for influenza virus by real-time reverse-transcriptase polymerase chain reaction (rRT-PCR). Of these patients, 1151 (27.2%) were positive for influenza. Cough (68.8% vs. 50.5%, P<0.0001) and sore throat (55.0% vs. 41.9%, P<0.0001) were more often associated with laboratory-confirmed influenza-infected patients compared to influenza-negative enrollees. A clear influenza season was evident between July and December with a peak during the rainy season. Influenza A and B viruses were identified in 768 (66.3%) and 388 (33.7%) of the influenza-positive population (n = 1153), respectively. In December 2008, passive surveillance identified infection of the avian influenza virus H5N1 in a 19-year-old farmer from Kandal province who subsequently recovered. From a subset of diagnostic samples submitted in 2007, 15 A(H1N1), seven A(H3N2) and seven B viruses were isolated. The predominant subtype tested was influenza A(H1N1), with the majority antigenically related to the A/Solomon Island/03/2006 vaccine strain. The influenza A(H3N2) isolates and influenza B viruses analysed were closely related to A/Brisbane/10/2007 or B/Ohio/01/2005 (B/Victoria/2/87-lineage) vaccine strains, respectively. Phylogenetic analysis of the HA1 region of the HA gene of influenza A(H1N1) viruses demonstrated that the Cambodian isolates belonged to clade 2C along with representative H1N1 viruses circulating in SE Asia at the time. These viruses remained sensitive to oseltamivir. In total, our data suggest that viral influenza infections contribute to nearly one-fifth of acute febrile illnesses and demonstrate the importance of influenza surveillance in Cambodia. C1 [Blair, P. J.; Kasper, M. R.; Putnam, S. D.] US Naval Med Res Unit 2, Jakarta, Indonesia. [Wierzba, T. F.] US Naval Med Res Unit 2, Phnom Penh, Cambodia. [Touch, S.] Kingdom Cambodia Minist Hlth, Dept Communicable Dis Control, Phnom Penh, Cambodia. [Vonthanak, S.] Kingdom Cambodia Minist Hlth, Natl Inst Publ Hlth, Phnom Penh, Cambodia. [Xu, X.; Garten, R. J.; Okomo-Adhiambo, M. A.; Klimov, A. I.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. RP Putnam, SD (reprint author), JMI Labs, 345 Beaver Kreek Ctr, N Liberty, IA 52240 USA. EM shan8299@hotmail.com RI Valle, Ruben/A-7512-2013 FU Influenza Division of the U.S. CDC; U.S. Department of Defenses' Global Emerging Infection Systems (DoD-GEIS) FX This work was funded in part by grants from the Influenza Division of the U.S. CDC and the U.S. Department of Defenses' Global Emerging Infection Systems (DoD-GEIS). The authors are grateful to the clinicians and staff at the field sites in Cambodia for their assistance in enrolling and sampling patients. We thank the laboratories at NAMRU2-Phnom Penh and the CDC for the conduct of the work. The views expressed herein are those of the authors and do not represent those of the U.S. Department of Health and Human Services, Department of Defense or Department of the Navy. NR 46 TC 23 Z9 24 U1 0 U2 7 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0950-2688 J9 EPIDEMIOL INFECT JI Epidemiol. Infect. PD FEB PY 2010 VL 138 IS 2 BP 199 EP 209 DI 10.1017/S095026880999063X PG 11 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 546VT UT WOS:000273842600006 PM 19698213 ER PT J AU Zafar, SN Luby, SP Mendoza, C AF Zafar, S. N. Luby, S. P. Mendoza, C. TI Recall errors in a weekly survey of diarrhoea in Guatemala: determining the optimal length of recall SO EPIDEMIOLOGY AND INFECTION LA English DT Article DE Bias; diarrhoea; recall; survey ID HEALTH INTERVIEW SURVEYS; DEVELOPING-COUNTRIES; ACCURACY; DISEASES; WATER AB We measured the recall error, optimal recall length and factors associated with diarrhoea in a weekly survey. Data was taken from a year-long randomized controlled trial in which characteristics of diarrhoeal episodes were recorded weekly. We labelled the recall period as days 1-6; day I being the day before the visit. Recall error was the percentage difference between the number of episodes reported to begin on a particular day and the mean for days I and 2. Generalized estimating equations were used to determine associations. Recall error was 37% on day 3 and 51% on day 5. The error was less in younger children (by 10%), severe episodes (by 29%) and when blood was present in the stool (by 18%). Diarrhoea was underreported when the recall period extended beyond 2 days. Surveys that use longer recall periods risk underestimating diarrhoea incidence and selectively capturing more severe episodes. C1 [Zafar, S. N.] Aga Khan Univ, Karachi, Pakistan. [Zafar, S. N.] Jinnah Postgrad Med Ctr, Karachi, Pakistan. [Luby, S. P.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Mendoza, C.] Univ Valle Guatemala, Med Entomol Res & Training Unit, Guatemala City, Guatemala. RP Zafar, SN (reprint author), M-79 Khayaban e Ittehad Phase 7 DHA, Karachi, Pakistan. EM zafar.nabeel@gmail.com FU Centers for Disease Control and Prevention; Procter Gamble Company FX We thank Rudinio Acevedo for assistance with data management, our team of field-workers for careful collection of data, and Sergio Ordonez and Edwin Ortega for their supervision of the field work. Funding for the original study was supported by a cooperative research and development agreement between the Centers for Disease Control and Prevention and the Procter & Gamble Company. This study itself was not funded. NR 19 TC 14 Z9 14 U1 0 U2 4 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0950-2688 J9 EPIDEMIOL INFECT JI Epidemiol. Infect. PD FEB PY 2010 VL 138 IS 2 BP 264 EP 269 DI 10.1017/S0950268809990422 PG 6 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 546VT UT WOS:000273842600013 PM 19653923 ER PT J AU Pinkerton, SD Galletly, CL McAuliffe, TL DiFranceisco, W Raymond, HF Chesson, HW AF Pinkerton, Steven D. Galletly, Carol L. McAuliffe, Timothy L. DiFranceisco, Wayne Raymond, H. Fisher Chesson, Harrell W. TI Aggregate Versus Individual-Level Sexual Behavior Assessment: How Much Detail Is Needed to Accurately Estimate HIV/STI Risk? SO EVALUATION REVIEW LA English DT Article DE HIV/STI prevention; sexual behavior; assessment; risk ID HIV PREVENTION INTERVENTIONS; TRANSMISSION; REDUCTION; CONDOMS; PEOPLE; MODEL AB The sexual behaviors of HIV/sexually transmitted infection (STI) prevention intervention participants can be assessed on a partner-by-partner basis: in aggregate (i.e., total numbers of sex acts, collapsed across partners) or using a combination of these two methods (e. g., assessing five partners in detail and any remaining partners in aggregate). There is a natural trade-off between the level of sexual behavior detail and the precision of HIV/STI acquisition risk estimates. The results of this study indicate that relatively simple aggregate data collection techniques suffice to adequately estimate HIV risk. For highly infectious STIs, in contrast, accurate STI risk assessment requires more intensive partner-by-partner methods. C1 [Pinkerton, Steven D.; Galletly, Carol L.; McAuliffe, Timothy L.; DiFranceisco, Wayne] Med Coll Wisconsin, Ctr AIDS Intervent Res, Dept Psychiat & Behav Med, Milwaukee, WI 53202 USA. [Raymond, H. Fisher] San Francisco Dept Publ Hlth, HIV Epidemiol Sect, San Francisco, CA USA. [Chesson, Harrell W.] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. RP Pinkerton, SD (reprint author), Med Coll Wisconsin, Ctr AIDS Intervent Res, Dept Psychiat & Behav Med, 2071 N Summit Ave, Milwaukee, WI 53202 USA. EM pinkrton@mcw.edu FU NIMH NIH HHS [P30-MH52776, P30 MH052776, R01 MH062961, R01 MH072474, R01-MH62961, R01-MH72474] NR 21 TC 8 Z9 8 U1 1 U2 1 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0193-841X J9 EVALUATION REV JI Eval. Rev. PD FEB PY 2010 VL 34 IS 1 BP 19 EP 34 DI 10.1177/0193841X09353534 PG 16 WC Social Sciences, Interdisciplinary SC Social Sciences - Other Topics GA 551QS UT WOS:000274224700002 PM 20130234 ER PT J AU Chandra, A Stephen, EH AF Chandra, Anjani Stephen, Elizabeth Hervey TI Infertility service use among US women: 1995 and 2002 SO FERTILITY AND STERILITY LA English DT Article; Proceedings Paper CT Annual Meeting of the Population-Association-of-America CY MAR 30-APR 01, 2006 CL Los Angeles, CA SP Populat Assoc Amer DE Infertility services; infertility treatment; socioeconomic differentials; infertility; impaired fecundity ID ASSISTED REPRODUCTIVE TECHNOLOGY; UNITED-STATES; SINGLETONS; HEALTH AB Objective: To examine trends in use Of Medical services for infertility, by individual characteristics of women. Design: Pooled data from two cycles (1995 and 2002) of the National Survey of Family Growth, a periodically conducted, nationally representative, cross-sectional survey of women 15-44 years of age. Participant(s): The analysis sample was composed of 2,005 women 22-44 years of age with Current fertility problems. Intervention(s): None. Main Outcome Measure(s): Ever having used infertility services, and highest level of services used. Result(S): Between 1995 and 2002, ever-use of infertility services by fertility-impaired women age 22-44 years continued to be closely associated with older age, nulliparity, formal marital status, and higher socioeconomic stains (education, household income, and private health insurance). Net of these factors, race and Hispanic origin, showed no significant association with either the use of services overall or the highest level of services used. After controlling for compositional changes in these individual characteristics, a slight decline was seen in ever-use of services overall from 1995 to 2002. No effect of Survey year was noted in the highest level of services. Conclusion(s): Infertility service use among fertility-impaired women remains closely tied with socioeconomic factors. The "threshold effect" of these factors has shifted upward to the receipt of more costly services such as assisted reproductive technologies. These higher level services remain a relatively small fraction of the services reported in a general Population sample of fertility-impaired women. (Fertil Steril (R) 20 10:93:725-36, (C)2010 by American Society for Reproductive Medicine.) C1 [Chandra, Anjani] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Stephen, Elizabeth Hervey] Georgetown Univ, Sch Foreign Serv, Washington, DC 20057 USA. RP Chandra, A (reprint author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, 3311 Toledo Rd, Hyattsville, MD 20782 USA. EM achandra@cdc.gov NR 27 TC 41 Z9 43 U1 0 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0015-0282 J9 FERTIL STERIL JI Fertil. Steril. PD FEB PY 2010 VL 93 IS 3 BP 725 EP 736 DI 10.1016/j.fertnstert.2008.10.049 PG 12 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA 561EA UT WOS:000274957300008 PM 19100531 ER PT J AU Carley-Baxter, LR Peytchev, A Black, MC AF Carley-Baxter, Lisa R. Peytchev, Andy Black, Michele C. TI Comparison of Cell Phone and Landline Surveys: A Design Perspective SO FIELD METHODS LA English DT Article DE cell phone survey; nonresponse; cell phone use ID TELEPHONE SURVEY; NONRESPONSE; SERVICE; NUMBERS; US AB Rapidly decreasing coverage of landline surveys is increasing the need to implement dual-frame surveys for inference to the adult U.S. population. Vast differences between the way cell phones and landlines are used, and the populations using them, require separate data collection designs. Yet research comparing cell phone surveys to landline telephone surveys is scarce with respect to operational outcomes. The authors test hypothesized differences between cell phone and landline interviewing through experiments on survey topic and length and find that these factors may not have the same impact in cell phone surveys. To help optimize calling cell phone numbers in future studies, the authors present self-reported cell phone use patterns and other factors affecting the probability of contact and sampling design. To inform the inclusion of adults with both a cell and landline phone, they compare cell phone use among cell phone only and cell with landline cases. The authors found notable differences between the cell only and cell with landline respondents in terms of cell phone use. Implications and directions for future work are discussed. C1 [Carley-Baxter, Lisa R.; Peytchev, Andy] RTI Int, Res Triangle Pk, NC 27709 USA. [Black, Michele C.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Carley-Baxter, LR (reprint author), RTI Int, 3040 Cornwallis Rd, Res Triangle Pk, NC 27709 USA. EM lcbaxter@rti.org NR 19 TC 7 Z9 7 U1 1 U2 7 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1525-822X J9 FIELD METHOD JI Field Methods PD FEB PY 2010 VL 22 IS 1 BP 3 EP 15 DI 10.1177/1525822X09360310 PG 13 WC Anthropology; Social Sciences, Interdisciplinary SC Anthropology; Social Sciences - Other Topics GA 564RC UT WOS:000275232900001 ER PT J AU Hu, SS Link, MW Mokdad, AH AF Hu, S. Sean Link, Michael W. Mokdad, Ali H. TI Reaching Linguistically Isolated People: Findings from a Telephone Survey Using Real-time Interpreters SO FIELD METHODS LA English DT Article DE BRFSS; RDD; language barrier; minority; interpreter AB We can no longer ignore nonresponse rates in telephone surveys because of a language barrier (i.e., people who could not speak either English or Spanish) and the corresponding potential for bias in estimates from surveys that involve only English- or Spanish-speaking respondents. Building on a few published studies focusing on this problem, a pilot study was conducted in California as part of the Behavioral Risk Factor Surveillance System (BRFSS), the world's largest ongoing public health telephone survey. The aim of this follow-up study is to evaluate the effectiveness of conducting BRFSS interviews of non-English- and non-Spanish-speaking respondents via real-time interpreters. One hundred and ninety-five people identified as having a language barrier in the 2006 California BRFSS were interviewed with the assistance of on-phone interpreters. The use of real-time interpreters increased the number of completed interviews among Asian respondents in the California BRFSS from 262 to 400 and allowed a more reliable examination of key health conditions and behavioral risk factors among Asian Americans. In addition, the study reached persons with demographic profiles different from those typically interviewed in English or Spanish. The methodology used in this study might be an effective tool for telephone survey researchers to consider using to reach linguistically isolated respondents. C1 [Hu, S. Sean] Ctr Dis Control & Prevent, Div Adult & Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Link, Michael W.] Nielsen Co, Alpharetta, GA USA. [Mokdad, Ali H.] Univ Washington, IHME, Seattle, WA 98195 USA. RP Hu, SS (reprint author), Ctr Dis Control & Prevent, Div Adult & Community Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. EM shu@cdc.gov NR 11 TC 1 Z9 1 U1 1 U2 1 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1525-822X J9 FIELD METHOD JI Field Methods PD FEB PY 2010 VL 22 IS 1 BP 39 EP 56 DI 10.1177/1525822X09349924 PG 18 WC Anthropology; Social Sciences, Interdisciplinary SC Anthropology; Social Sciences - Other Topics GA 564RC UT WOS:000275232900003 ER PT J AU Hyytia-Trees, E Lafon, P Vauterin, P Ribot, EM AF Hyytia-Trees, Eija Lafon, Patricia Vauterin, Paul Ribot, Efrain M. TI Multilaboratory Validation Study of Standardized Multiple-Locus Variable-Number Tandem Repeat Analysis Protocol for Shiga Toxin-Producing Escherichia coli O157: A Novel Approach to Normalize Fragment Size Data Between Capillary Electrophoresis Platforms SO FOODBORNE PATHOGENS AND DISEASE LA English DT Article ID FIELD GEL-ELECTROPHORESIS; LISTERIA-MONOCYTOGENES; DNA; PULSENET; ENTERITIDIS; COLLECTION; SUBTYPE; STRAINS; GENOMES; ASSAY AB The PulseNet USA subtyping network recently established a standardized protocol for multiple-locus variable-number tandem repeat analysis (MLVA) to characterize Shiga toxin-producing Escherichia coli O157. To enable data comparisons from different laboratories in the same database, reproducibility and high quality of the data must be ensured. The aim of this study was to test the robustness and reproducibility of the proposed standardized protocol by subjecting it to a multilaboratory validation process and to address any discrepancies that may have arisen from the study. A set of 50 strains was tested in 10 PulseNet participating laboratories that used capillary electrophoresis instruments from two manufacturers. Six out of the 10 laboratories were able to generate correct MLVA types for 46 (92%) or more strains. The discrepancies in MLVA type assignment were caused mainly by difficulties in optimizing polymerase chain reactions that were attributed to technical inexperience of the staff and suboptimal quality of reagents and instrumentation. It was concluded that proper training of staff must be an integral part of technology transfer. The interlaboratory reproducibility of fragment sizing was excellent when the same capillary electrophoresis platform was used. However, sizing discrepancies of up to six base pairs for the same fragment were detected between the two platforms. These discrepancies were attributed to different dye and polymer chemistries employed by the manufacturers. A novel software script was developed to assign alleles based on two platform-specific (Beckman Coulter CEQ(TM)8000 and Applied Biosystems Genetic Analyzer 3130xl) look-up tables containing fragment size ranges for all alleles. The new allele assignment method was validated at the PulseNet central laboratory using a diverse set of 502 Shiga toxin-producing Escherichia coli O157 isolates. The validation confirmed that the script reliably assigned the same allele for the same fragment regardless of the platform used to size the fragment. C1 [Hyytia-Trees, Eija; Lafon, Patricia; Ribot, Efrain M.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Vauterin, Paul] Appl Maths, Kortrijk, Belgium. RP Hyytia-Trees, E (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,Mail Stop CO3, Atlanta, GA 30333 USA. EM ehyytia-trees@cdc.gov NR 21 TC 31 Z9 32 U1 1 U2 7 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1535-3141 J9 FOODBORNE PATHOG DIS JI Foodborne Pathog. Dis. PD FEB PY 2010 VL 7 IS 2 BP 129 EP 136 DI 10.1089/fpd.2009.0371 PG 8 WC Food Science & Technology SC Food Science & Technology GA 547CD UT WOS:000273862200003 PM 19785535 ER PT J AU Folster, JP Pecic, G Bolcen, S Theobald, L Hise, K Carattoli, A Zhao, SH McDermott, PF Whichard, JM AF Folster, Jason P. Pecic, Gary Bolcen, Shanna Theobald, Lisa Hise, Kelley Carattoli, Alessandra Zhao, Shaohua McDermott, Patrick F. Whichard, Jean M. TI Characterization of Extended-Spectrum Cephalosporin-Resistant Salmonella enterica Serovar Heidelberg Isolated from Humans in the United States SO FOODBORNE PATHOGENS AND DISEASE LA English DT Article ID AMPC BETA-LACTAMASE; ESCHERICHIA-COLI; RETAIL MEATS; PLASMID; INFECTIONS; POULTRY; OUTBREAKS; ANIMALS; FRANCE; STRAIN AB During the past decade, extended-spectrum cephalosporin resistance has increased among human isolates of Salmonella enterica serovar Heidelberg, the fourth most common serotype in the United States. We therefore characterized 54 Heidelberg isolates with decreased susceptibility (minimum inhibitory concentrations >= 2 mg/L) to ceftriaxone or ceftiofur; 49 (90.7%) contained the CMY-type beta-lactamase (bla(CMY)) gene. The 49 bla(CMY)-positive human Heidelberg isolates demonstrated a high degree of relatedness; 4 clusters (25 isolates total) had indistinguishable XbaI and BlnI patterns by pulsed-field gel electrophoresis and were indistinguishable from 42 retail meat Heidelberg isolates. Further characterization of 15 of these isolates demonstrated that all of the bla genes were bla(CMY-2) and plasmid-encoded, and most (11/15) of the plasmids were approximately 100 kb in size and belong to the incompatibility group I1 (IncI1). All five IncI1 plasmids tested by plasmid multilocus sequence typing analysis were ST12. This report suggests that extended-spectrum cephalosporin resistance among human Heidelberg isolates is mediated by the spread of a common IncI1 bla(CMY-2) plasmid, which may have a preference for a particular genetic background. C1 [Folster, Jason P.] Ctr Dis Control & Prevent, CCID, NCZVED, DFBMD,EDLB, Atlanta, GA 30329 USA. [Folster, Jason P.; Pecic, Gary] Atlanta Res & Educ Fdn, Decatur, GA USA. [Carattoli, Alessandra] Ist Super Sanita, Dept Infect Parasit & Immune Mediated Dis, I-00161 Rome, Italy. [Zhao, Shaohua; McDermott, Patrick F.] US FDA, Div Anim & Food Microbiol, Res Off, Ctr Vet Med, Laurel, MD USA. RP Folster, JP (reprint author), Ctr Dis Control & Prevent, CCID, NCZVED, DFBMD,EDLB, 1600 Clifton Rd, Atlanta, GA 30329 USA. EM gux8@cdc.gov OI Carattoli, Alessandra/0000-0002-6120-6526 FU CDC; FDA-CVM FX We thank the NARMS-participating public health laboratories for submitting the isolates, Anne Whitney for DNA sequencing, and Maria Karlsson for her critical review. This work was supported by an interagency agreement between CDC and the FDA-CVM. NR 31 TC 29 Z9 29 U1 1 U2 8 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1535-3141 J9 FOODBORNE PATHOG DIS JI Foodborne Pathog. Dis. PD FEB PY 2010 VL 7 IS 2 BP 181 EP 187 DI 10.1089/fpd.2009.0376 PG 7 WC Food Science & Technology SC Food Science & Technology GA 547CD UT WOS:000273862200010 PM 19785533 ER PT J AU Mvundura, M Grosse, SD Hampel, H Palomaki, GE AF Mvundura, Mercy Grosse, Scott D. Hampel, Heather Palomaki, Glenn E. TI The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer SO GENETICS IN MEDICINE LA English DT Article DE cost-effectiveness analysis; genetic testing; Lynch syndrome; HNPCC; cancer; genomics; economic evaluation ID QUALITY-OF-LIFE; NONPOLYPOSIS COLON-CANCER; MICROSATELLITE INSTABILITY; ECONOMIC EVALUATIONS; PREVENTIVE SERVICES; UNITED-STATES; HNPCC; SURVEILLANCE; COLONOSCOPY; MUTATIONS AB Purpose: To estimate the cost-effectiveness of genetic testing strategies to identify Lynch syndrome among newly diagnosed patients with colorectal cancer and to offer targeted testing to relatives of patients with Lynch syndrome. Methods: We calculated incremental costs per life-year saved for universal testing relative to no testing and age-targeted testing for strategies that use preliminary genetic tests (immunohistochemistry or microsatellite instability) of tumors followed by sequencing of mismatch repair genes. We also calculated incremental cost-effectiveness ratios for pairs of testing strategies. Results: Strategies to test for Lynch syndrome in newly diagnosed colorectal tumors using preliminary tests before gene sequencing have incremental cost-effectiveness ratios of <=$45,000 per life-year saved compared with no testing and <=$75,000 per life-year saved compared with testing restricted to patients younger than 50 years. The lowest cost testing strategies, using immunohistochemistry as a preliminary test, cost <=$25,000 per life-year saved relative to no testing and <=$40,000 per life-year saved relative to testing only patients younger than 50 years. Other testing strategies have incremental cost-effectiveness ratios <=$700,000 per life-year saved relative to the lowest cost strategies. Increasing the number of relatives tested would improve cost-effectiveness. Conclusion: Laboratory-based strategies using preliminary tests seem cost-effective from the US health care system perspective. Universal testing detects nearly twice as many cases of Lynch syndrome as targeting younger patients and has an incremental cost-effectiveness ratio comparable with other preventive services. This finding provides support for a recent US recommendation to offer testing for Lynch syndrome to all newly diagnosed patients with colorectal cancer. Genet Med 2010:12(2):93-104. C1 [Mvundura, Mercy] Ctr Dis Control & Prevent, Off Publ Hlth Genom, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Grosse, Scott D.] Ctr Dis Control & Prevent, Div Blood Disorders, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Hampel, Heather] Ohio State Univ, Dept Internal Med, Arthur G James Canc Hosp, Columbus, OH 43210 USA. [Hampel, Heather] Richard J Solove Res Inst, Columbus, OH USA. [Palomaki, Glenn E.] Brown Univ, Dept Pathol, Women & Infants Hosp, Providence, RI 02912 USA. [Palomaki, Glenn E.] Brown Univ, Lab Med, Warren Alpert Med Sch, Providence, RI 02912 USA. RP Grosse, SD (reprint author), 1600 Clifton Rd NE,MS E-64, Atlanta, GA 30333 USA. EM sgrosse@cdc.gov OI Mvundura, Mercy/0000-0002-7711-9558 FU Centers for Disease Control and Prevention through McKing Consulting Corporation FX Disclosure: Drs. Mvundura, Grosse, and Palomaki declare no conflict of interest. Dr. Palomaki is partially supported as a consultant to the EGAPP Initiative, funded by the Centers for Disease Control and Prevention through a contract with McKing Consulting Corporation. Ms. Hampel has two potential conflicts to disclose. She has received honoraria From Myriad Genetic Laboratories, Inc. for Advisory Group work and from Falco Biosystems for giving a lecture. NR 51 TC 133 Z9 135 U1 0 U2 6 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1098-3600 J9 GENET MED JI Genet. Med. PD FEB PY 2010 VL 12 IS 2 BP 93 EP 104 DI 10.1097/GIM.0b013e3181cd666c PG 12 WC Genetics & Heredity SC Genetics & Heredity GA 565BX UT WOS:000275265100005 PM 20084010 ER PT J AU Kirkpatrick, B Pierce, R Cheng, YS Henry, MS Blum, P Osborn, S Nierenberg, K Pederson, BA Fleming, LE Reich, A Naar, J Kirkpatrick, G Backer, LC Baden, D AF Kirkpatrick, Barbara Pierce, Richard Cheng, Yung Sung Henry, Michael S. Blum, Patricia Osborn, Shannon Nierenberg, Kate Pederson, Bradley A. Fleming, Lora E. Reich, Andrew Naar, Jerome Kirkpatrick, Gary Backer, Lorraine C. Baden, Daniel TI Inland transport of aerosolized Florida red tide toxins SO HARMFUL ALGAE LA English DT Article DE Brevetoxins; Harmful algal blooms (HABs); Red tides; Karenia brevis; Asthma; Air monitoring ID MARINE AEROSOL; HUMAN EXPOSURE; BREVETOXINS; ASTHMA AB Florida red tides, an annual event off the west coast of Florida, are caused by the toxic dinoflagellate, Karenia brevis. K. brevis produces a suite of potent neurotoxins, brevetoxins, which kill fish, sea birds, and marine mammals, as well as sickening humans who consume contaminated shellfish. These toxins become part of the marine aerosol, and can also be inhaled by humans and other animals. Recent studies have demonstrated a significant increase in symptoms and decrease in lung function in asthmatics after only one hour of beach exposure during an onshore Florida red tide bloom. This study constructed a transect line placing high volume air samplers to measure brevetoxins at sites beginning at the beach, moving approximately 6.4 km inland. One non-exposure and 2 exposure studies, each of 5 days duration, were conducted. No toxins were measured in the air during the non-exposure period. During the 2 exposure periods, the amount of brevetoxins varied considerably by site and by date. Nevertheless, brevetoxins were measured at least 4.2 km from the beach and/or 1.6 km from the coastal shoreline. Therefore, populations sensitive to brevetoxins (such as asthmatics) need to know that leaving the beach may not discontinue their environmental exposure to brevetoxin aerosols. (C) 2009 Elsevier B.V. All rights reserved. C1 [Kirkpatrick, Barbara; Pierce, Richard; Henry, Michael S.; Blum, Patricia; Osborn, Shannon; Nierenberg, Kate; Pederson, Bradley A.; Kirkpatrick, Gary] Mote Marine Lab, Sarasota, FL 34236 USA. [Cheng, Yung Sung] Lovelace Resp Res Inst, Albuquerque, NM 87108 USA. [Fleming, Lora E.] Univ Miami, Rosenstiel Sch Marine & Atmospher Sci, NSF NIEHS Oceans & Human Hlth Ctr, Miami, FL 33149 USA. [Naar, Jerome; Baden, Daniel] Univ N Carolina, Marine Sci Res Ctr, Wilmington, NC 28409 USA. [Backer, Lorraine C.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. RP Fleming, LE (reprint author), Univ Miami, Sch Med, Dept Epidemiol & Publ Hlth, 1120 NW 14th Ave,Clin Res Bldg,Room 1049 R 669, Miami, FL 33136 USA. EM lfleming@med.miami.edu FU Centers for Disease Control and Prevention; Florida Department of Health [U50/CCU423360-02]; National Institute of Environmental Health Sciences [P01 ES 10594] FX This research was supported by the Centers for Disease Control and Prevention and the Florida Department of Health (Cooperative Agreement: U50/CCU423360-02) as well as by the P01 ES 10594 from the National Institute of Environmental Health Sciences. The authors thank the Tropical Breeze Motel (Siesta Key, FL) and the Sarasota residents for allowing air samplers to be placed on their property, and their support of our studies.[SS] NR 17 TC 7 Z9 7 U1 0 U2 12 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1568-9883 J9 HARMFUL ALGAE JI Harmful Algae PD FEB PY 2010 VL 9 IS 2 BP 186 EP 189 DI 10.1016/j.hal.2009.09.003 PG 4 WC Marine & Freshwater Biology SC Marine & Freshwater Biology GA 549ZB UT WOS:000274093500008 PM 20161504 ER PT J AU Rein, DB Lesesne, SB O'Fallon, A Weinbaum, CM AF Rein, David B. Lesesne, Sarah B. O'Fallon, Ann Weinbaum, Cindy M. TI Prevalence of Hepatitis B Surface Antigen Among Refugees Entering the United States Between 2006 and 2008 SO HEPATOLOGY LA English DT Article ID INFECTION AB The Centers for Disease Control and Prevention recommends hepatitis B surface antigen (HBsAg) testing to identify chronic hepatitis B virus infection for foreign-born persons from countries or regions with HBsAg prevalence of >= 2%. However, limited data exist to indicate which countries meet this definition. To address this data gap, we estimated the HBsAg prevalence among refugees entering the United States between 2006 and 2008. We contacted state refugee health coordinators and asked them to report the number of refugees, country of origin, and HBsAg prevalence among refugees screened in their jurisdiction during the most recently available 12-month period prior to August 2008. We pooled data across jurisdictions and calculated the prevalence for any country with more than 30 refugees entering the United States, and where this level of data was not available by country, continents were considered. Of the 47 jurisdictions contacted, we received basic information from 3 1, with nine jurisdictions reporting HBsAg prevalence by country of origin applicable to 31,980 refugees (approximately 42% of refugees entering the United States during the observation period). We estimated an HBsAg prevalence of 2.8% (95% confidence interval 2.6%-3.0%) for refugees overall. Of the 37 countries with 30 or more refugees entering the United States, 25 had a prevalence of >= 2%. Prevalence was highest among refugees from Africa and Southeast Asia, and lowest among refugees from the Middle East and South/Central America. In the eight countries for which we had comparison data, six had lower HBsAg prevalence than in 1991. (HEPATOLOGY 2010;51:431-434.) C1 [Rein, David B.; Lesesne, Sarah B.] RTI Int, Atlanta, GA 30341 USA. [O'Fallon, Ann] Assoc Refugee Hlth Coordinators, Minnesota Dept Hlth, St Paul, MN USA. [Weinbaum, Cindy M.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA USA. RP Rein, DB (reprint author), RTI Int, 2951 Flowers Rd,Suite 119, Atlanta, GA 30341 USA. EM drein@rti.org FU Centers for Disease Control and Prevention Division of Viral Hepatitis [200-2003-02489] FX Supported by the Centers for Disease Control and Prevention Division of Viral Hepatitis (contract number 200-2003-02489, Task Order 7). NR 13 TC 13 Z9 13 U1 0 U2 1 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0270-9139 J9 HEPATOLOGY JI Hepatology PD FEB PY 2010 VL 51 IS 2 BP 431 EP 434 DI 10.1002/hep.23353 PG 4 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA 550ME UT WOS:000274131200012 PM 19902482 ER PT J AU Pandey, A Singh, N Sambhara, S Mittal, SK AF Pandey, Aseem Singh, Neetu Sambhara, Suryaprakash Mittal, Suresh K. TI Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses SO HUMAN VACCINES LA English DT Review DE H5N1 influenza; cell-derived vaccine; egg-independent; pandemic influenza; viral-vector ID VESICULAR STOMATITIS-VIRUS; NEWCASTLE-DISEASE VIRUS; PROTECTIVE IMMUNE-RESPONSES; LIVE ATTENUATED VACCINE; CELL-MEDIATED-IMMUNITY; AVIAN INFLUENZA; PANDEMIC INFLUENZA; LETHAL CHALLENGE; RECOMBINANT HEMAGGLUTININ; ADENOVIRUS VECTOR AB The emergence of a highly pathogenic H5N1 influenza virus in Hong Kong in 1997 and the subsequent appearance of other H5N1 strains and their spread to several countries in Southeast Asia, Africa, the Middle East and Europe has evoked fear of a global influenza pandemic. Vaccines offer the best hope to combat the threat of an influenza pandemic. However, the global demand for a pandemic vaccine cannot be fulfilled by the current egg-based vaccine manufacturing strategies, thus creating a need to explore alternative technologies for vaccine production and delivery. Several egg-independent vaccine approaches such as cell culture-derived whole virus or subvirion vaccines, recombinant protein-based vaccines, virus-like particle (VLP) vaccines, DNA vaccines and viral vector-based vaccines are currently being investigated and appear promising both in preclinical and clinical studies. The present review will highlight the various egg-independent alternative vaccine approaches for pandemic influenza. C1 [Pandey, Aseem; Singh, Neetu; Mittal, Suresh K.] Purdue Univ, Dept Comparat Pathobiol, Sch Vet Med, W Lafayette, IN 47907 USA. [Pandey, Aseem; Singh, Neetu; Mittal, Suresh K.] Purdue Univ, Bindley Biosci Ctr, W Lafayette, IN 47907 USA. [Sambhara, Suryaprakash] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. RP Mittal, SK (reprint author), Purdue Univ, Dept Comparat Pathobiol, Sch Vet Med, W Lafayette, IN 47907 USA. EM mittal@purdue.edu FU National Institute of Allergy and Infectious Diseases [AI059374]; NVPO FX This work was supported by Public Health Service grant AI059374 from the National Institute of Allergy and Infectious Diseases to S. K. M. and an NVPO grant to S. S. We are thankful to Jane Kovach for her secretarial assistance. NR 148 TC 16 Z9 19 U1 0 U2 5 PU LANDES BIOSCIENCE PI AUSTIN PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA SN 1554-8600 J9 HUM VACCINES JI Hum. Vaccines PD FEB PY 2010 VL 6 IS 2 BP 178 EP 188 PG 11 WC Biotechnology & Applied Microbiology; Immunology SC Biotechnology & Applied Microbiology; Immunology GA 591FH UT WOS:000277284400011 PM 19875936 ER PT J AU Manivannan, B Rawson, P Jordan, TW Secor, WE La Flamme, AC AF Manivannan, B. Rawson, P. Jordan, T. W. Secor, W. E. La Flamme, A. C. TI Differential Patterns of Liver Proteins in Experimental Murine Hepatosplenic Schistosomiasis SO INFECTION AND IMMUNITY LA English DT Article ID MAJOR HISTOCOMPATIBILITY COMPLEX; HEPATOCELLULAR-CARCINOMA; PROTEOME ANALYSIS; EXPRESSION ANALYSIS; GC-GLOBULIN; EGG ANTIGEN; MANSONI; DISEASE; RAT; PROHIBITIN AB Schistosoma mansoni eggs produced by adult worms in the mesenteric vasculature become trapped in the liver, where they induce granulomatous lesions and strong immune responses. Infected individuals suffer from intestinal schistosomiasis (INT) in 90% of cases, whereas the remaining 10% present with severe hepatosplenic schistosomiasis (HS). The CBA/J mouse model mimics human disease, with 20% of infected mice developing hypersplenomegaly syndrome (HSS) that resembles HS and 80% developing moderate splenomegaly syndrome (MSS) similar to INT. We studied differential patterns of protein expression in livers of 20-week-infected CBA/J mice with MSS or HSS to understand the molecular changes that underlie these two disease forms. Using differential in-gel electrophoresis to identify differentially expressed protein spots, we found 80 protein spots significantly changed with infection and 35 changes specific to severe disease. In particular, the abundances of prohibitin 2, transferrin isoforms, and major urinary protein isoforms were significantly altered in HSS mice. Furthermore, annexin 5, glutathione S-transferase pi class, and S. mansoni phosphoenolpyruvate carboxykinase expression levels changed significantly with schistosome infection. Additionally, levels of major urinary protein decreased and levels of transferrin increased significantly in the sera of HSS mice compared to levels in sera of MSS or control mice, and these differences correlated to the degree of splenomegaly. These findings indicate that the liver protein abundances differ between MSS and HSS mice and may be used for the development of diagnostic markers for the early detection of hepatosplenic schistosomiasis. C1 [Manivannan, B.; Rawson, P.; Jordan, T. W.; La Flamme, A. C.] Victoria Univ Wellington, Sch Biol Sci, Wellington, New Zealand. [Manivannan, B.; Rawson, P.; Jordan, T. W.; La Flamme, A. C.] Victoria Univ Wellington, Ctr Biodiscovery, Wellington, New Zealand. [Secor, W. E.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP La Flamme, AC (reprint author), Victoria Univ Wellington, Sch Biol Sci, POB 600, Wellington, New Zealand. EM anne.laflamme@vuw.ac.nz FU University Research Fund; Wellington Medical Research Foundation FX This work was supported by funds from the University Research Fund and Wellington Medical Research Foundation. NR 67 TC 5 Z9 5 U1 0 U2 2 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0019-9567 J9 INFECT IMMUN JI Infect. Immun. PD FEB PY 2010 VL 78 IS 2 BP 618 EP 628 DI 10.1128/IAI.00647-09 PG 11 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 546ZY UT WOS:000273855600007 PM 19933830 ER PT J AU Tsan, L Langberg, R Gibert, C Davis, C Hojlo, C Pierce, J Phillips, Y Gaynes, R Montgomery, O Danko, L Roselle, G AF Tsan, Linda Langberg, Robert Gibert, Cynthia Davis, Chester Hojlo, Christa Pierce, John Phillips, Yancy Gaynes, Robert Montgomery, Ona Danko, Linda Roselle, Gary TI Influenza Vaccination Rates among Healthcare Workers in the Department of Veterans Affairs Community Living Centers SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article C1 [Tsan, Linda; Langberg, Robert; Davis, Chester; Hojlo, Christa; Pierce, John; Phillips, Yancy; Danko, Linda; Roselle, Gary] Dept Vet Affairs Cent Off, Washington, DC USA. [Gibert, Cynthia] Vet Affairs Med Ctr, Washington, DC 20422 USA. [Gaynes, Robert] Vet Affairs Med Ctr, Atlanta, GA 30033 USA. [Gaynes, Robert] Ctr Dis Control & Prevent, Atlanta, GA USA. [Montgomery, Ona] Vet Affairs Med Ctr, Amarillo, TX USA. [Danko, Linda; Roselle, Gary] Vet Affairs Med Ctr, Cincinnati, OH 45267 USA. RP Tsan, L (reprint author), Off Med Inspector 10MI, Dept Vet Affairs, 810 Vermont Ave NW, Washington, DC 20420 USA. EM linda.tsan@va.gov FU Department of Veterans Affairs FX Financial support. Department of Veterans Affairs. NR 5 TC 0 Z9 0 U1 0 U2 0 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0899-823X J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD FEB PY 2010 VL 31 IS 2 BP 191 EP 192 DI 10.1086/650376 PG 2 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 541FC UT WOS:000273399100014 PM 20017634 ER PT J AU Damon, SA Naylor, R Therriault, S AF Damon, Scott A. Naylor, Roger Therriault, Shannon TI Public communication in unplanned biomass burning events SO INHALATION TOXICOLOGY LA English DT Article; Proceedings Paper CT Conference on International Biomass Smoke and Health Effects CY AUG 21-22, 2007 CL Missoula, MT SP Ctr Dis Control Prevent, Univ Montana, Ctr Environm Health Sci DE Emergency; public notification; response; unplanned burn AB Public communication related to emergency, unplanned, or "wildfire" biomass burning is best understood as a function of the audience for that communication. Two enduring communication models, the Health Belief Model and the Stages of Change or Transtheoretical Model, are instructive in analyzing and preparing differing communication response strategies that are indicated for communities with varying degrees of experience in responding to unplanned biomass burning smoke events. C1 [Damon, Scott A.] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. [Naylor, Roger] Georgia Dept Human Resources SE Hlth Dist, Waycross, GA USA. [Therriault, Shannon] City Cty Hlth Dept, Missoula, MT USA. RP Damon, SA (reprint author), Ctr Dis Control & Prevent, MS F58 4770 Buford Highway, Atlanta, GA 30341 USA. EM scd3@cdc.gov NR 4 TC 3 Z9 3 U1 0 U2 1 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 0895-8378 J9 INHAL TOXICOL JI Inhal. Toxicol. PD FEB PY 2010 VL 22 IS 2 BP 113 EP 116 DI 10.3109/08958370903008896 PG 4 WC Toxicology SC Toxicology GA 544GU UT WOS:000273643300006 PM 20041806 ER PT J AU Boal, W Leiss, J Ratcliffe, J Sousa, S Lyden, J Li, J Jagger, J AF Boal, Winifred L. Leiss, Jack K. Ratcliffe, Jennifer M. Sousa, Sara Lyden, Jennifer T. Li, Jia Jagger, Janine TI The national study to prevent blood exposure in paramedics: rates of exposure to blood SO INTERNATIONAL ARCHIVES OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH LA English DT Article DE Paramedics; Needlestick; Blood exposure; Survey; Incidence; Occupational health ID HEALTH-CARE WORKERS; B VIRUS-INFECTION; PERCUTANEOUS INJURIES; NEEDLESTICK INJURIES; RISK; IMMUNIZATION; PRECAUTIONS; PREVALENCE; DEVICES; SYSTEM AB The purpose of this analysis is to present incidence rates of exposure to blood among paramedics in the United States by selected variables and to compare all percutaneous exposure rates among different types of healthcare workers. A survey on blood exposure was mailed in 2002-2003 to a national sample of paramedics. Results for California paramedics were analyzed with the national sample and also separately. The incidence rate for needlestick/lancet injuries was 100/1,000 employee-years [95% confidence interval (CI), 40-159] among the national sample and 26/1,000 employee-years (95% CI, 15-38) for the California sample. The highest exposure rate was for non-intact skin, 230/1,000 employee-years (95% CI, 130-329). The rate for all exposures was 465/1,000 employee-years (95% CI, 293-637). California needlestick/lancet rates, but not national, were substantially lower than rates in earlier studies of paramedics. Rates for all percutaneous injuries among paramedics were similar to the mid to high range of rates reported for most hospital-based healthcare workers. Paramedics in the United States are experiencing percutaneous injury rates at least as high as, and possibly substantially higher than, most hospital-based healthcare workers, as well as substantially higher rates of exposure to blood on non-intact skin. C1 [Boal, Winifred L.] NIOSH, Cincinnati, OH 45226 USA. [Leiss, Jack K.] Cedar Grove Inst Sustainable Communities, Mebane, NC USA. [Ratcliffe, Jennifer M.; Sousa, Sara] Constella Grp, Durham, NC USA. [Lyden, Jennifer T.] Adv Hlth Solut, La Jolla, CA USA. [Jagger, Janine] Univ Virginia, Charlottesville, VA USA. RP Boal, W (reprint author), NIOSH, Cincinnati, OH 45226 USA. EM wboal@cdc.gov FU National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention [U01 OH04266-01] FX This study was supported by cooperative agreement number U01 OH04266-01 from the National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention. The authors declare that they have no conflict of interest. NR 33 TC 7 Z9 8 U1 0 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0340-0131 J9 INT ARCH OCC ENV HEA JI Int. Arch. Occup. Environ. Health PD FEB PY 2010 VL 83 IS 2 BP 191 EP 199 DI 10.1007/s00420-009-0421-x PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 543PR UT WOS:000273591100008 PM 19437031 ER PT J AU Day, GE Lanier, AP Bulkow, L Kelly, JJ Murphy, N AF Day, Gretchen Ehrsam Lanier, Anne P. Bulkow, Lisa Kelly, Janet J. Murphy, Neil TI CANCERS OF THE BREAST, UTERUS, OVARY AND CERVIX AMONG ALASKA NATIVE WOMEN, 1974-2003 SO INTERNATIONAL JOURNAL OF CIRCUMPOLAR HEALTH LA English DT Article DE neoplasm; Alaska Native; breast cancer; uterus cancer; ovarian cancer; cervix cancer; cancer incidence; cancer trends; period effect; birth cohort ID ORAL-CONTRACEPTIVES; ENDOMETRIAL CANCER; BODY-SIZE; STATISTICS; RISK; TRENDS; AGE AB Objectives. Alaska Native (AN) women have exhibited some of the highest incidence rates of cancer overall, and different patterns of site-specific incidence compared to other U.S. populations. This study compares incidence rates between AN and U.S. white women (USW) for cancers of the breast, uterus, ovary and cervix, and examines effects of time period and birth cohort as determinants of incidence trends among AN women. Study design. Observational, population-based study. Methods. Cancer incidence data from the Alaska Native Tumor Registry and SEERStat, 1974-2003. Age-adjusted World Standard Population rates were calculated for a current 5-year period and over time (30 years), and compared to other populations using rate ratios with 95% confidence intervals. Log-linear regression models used to assess impact on trend of age, time period and birth cohort. Results. Compared to U.S. white women, current cancer rates among AN women are not significantly different for cancer of the breast and cervix, and significantly lower for cancers of the ovary and uterus. Trends over time over a 30-year time period also differ for these cancer sites. There were significant increases in breast and uterine cancer, and in contrast, a marked decline in cervical cancer. There was no significant change for cancer of the ovary. Changes appear to be due largely to period, not birth cohort effects. Conclusions. Increases in breast cancer may be due to a combination of modifiable behaviours: increased BMI and a shift to a non-traditional diet. Increases in uterine cancer could be associated with increased BMI and diabetes. Cervical cancer rates have declined to USW levels. The marked decline is likely due to enhanced screening and control efforts within the Alaska Native Tribal Health System (formerly Alaska Area USPHS, Indian Health Service utilizing resources available from the Centers for Disease Control tribal and state Breast and Cervical Cancer Early Detection Programs). C1 [Day, Gretchen Ehrsam; Lanier, Anne P.; Kelly, Janet J.] Alaska Native Tribal Hlth Consortium, Div Community Hlth Serv, Off Alaska Native Hlth Res, Anchorage, AK USA. [Bulkow, Lisa] CDC, Arct Invest Program, Anchorage, AK USA. [Murphy, Neil] S Cent Fdn, Anchorage, AK USA. RP Lanier, AP (reprint author), 4000 Ambassador Dr, Anchorage, AK 99508 USA. EM aplanier@anmc.org NR 36 TC 8 Z9 10 U1 3 U2 3 PU INT ASSOC CIRCUMPOLAR HEALTH PUBL PI OULU PA AAPISTIE1, OULU, FIN-90220, FINLAND SN 1239-9736 J9 INT J CIRCUMPOL HEAL JI Int. J. Circumpolar Health PD FEB PY 2010 VL 69 IS 1 BP 72 EP 86 PG 15 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 572NN UT WOS:000275839800008 PM 20167158 ER PT J AU Parkinson, AJ AF Parkinson, Alan J. TI SUSTAINABLE DEVELOPMENT, CLIMATE CHANGE AND HUMAN HEALTH IN THE ARCTIC SO INTERNATIONAL JOURNAL OF CIRCUMPOLAR HEALTH LA English DT Article C1 [Parkinson, Alan J.] US Ctr Dis Control & Prevent, Arct Invest Program, Anchorage, AK USA. RP Parkinson, AJ (reprint author), Ctr Dis Control & Prevent, Arct Invest Program, 4055 Tudor Ctr Dr, Anchorage, AK 99508 USA. EM ajp1@CDC.GOV NR 9 TC 4 Z9 4 U1 2 U2 6 PU INT ASSOC CIRCUMPOLAR HEALTH PUBL PI OULU PA AAPISTIE1, OULU, FIN-90220, FINLAND SN 1239-9736 J9 INT J CIRCUMPOL HEAL JI Int. J. Circumpolar Health PD FEB PY 2010 VL 69 IS 1 BP 99 EP 105 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 572NN UT WOS:000275839800010 PM 20167160 ER PT J AU Shaman, J Day, JF Komar, N AF Shaman, Jeffrey Day, Jonathan F. Komar, Nicholas TI Hydrologic Conditions Describe West Nile Virus Risk in Colorado SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH LA English DT Article DE West Nile Virus; hydrology; transmission; amplification; spatial autocorrelation; Culex mosquitoes ID DROUGHT-INDUCED AMPLIFICATION; MOSQUITOS DIPTERA; VECTOR COMPETENCE; TRANSMISSION; CALIFORNIA; CULICIDAE; FLORIDA; CULEX AB We examine the relationship between hydrologic variability and the incidence of human disease associated with West Nile virus (WNV; family Flaviviridae, genus Flavivirus) infection (hereafter termed "human WN cases") in Colorado from 2002 to 2007. We find that local hydrologic conditions, as simulated by the Mosaic hydrology model, are associated with differences in human WN cases. In Colorado's eastern plains, wetter spring conditions and drier summer conditions predict human WN cases. In Colorado's western mountains, drier spring and summer conditions weakly predict human WN cases. These findings support two working hypotheses: (1) wet spring conditions increase the abundance of Culex tarsalis vectors in the plains, and (2) dry summer conditions, and respondent irrigational practices during such droughts, favor Cx. pipiens and Cx. tarsalis abundance throughout Colorado. Both of these processes potentially increase the local vector-to-host ratio, favoring WNV amplification among competent avian hosts and bridging to humans. C1 [Shaman, Jeffrey] Oregon State Univ, Coll Ocean & Atmospher Sci, Corvallis, OR 97330 USA. [Day, Jonathan F.] Univ Florida, Inst Food & Agr Sci, Florida Med Entomol Lab, Vero Beach, FL 32962 USA. [Komar, Nicholas] Ctr Dis Control & Prevent, Arbovirus Dis Branch, Ft Collins, CO 80521 USA. RP Shaman, J (reprint author), Oregon State Univ, Coll Ocean & Atmospher Sci, 104 COAS Adm Bldg, Corvallis, OR 97330 USA. EM jshaman@coas.oregonstate.edu; jfda@ufl.edu; nck6@cdc.gov NR 25 TC 20 Z9 20 U1 0 U2 10 PU MOLECULAR DIVERSITY PRESERVATION INTERNATIONAL-MDPI PI BASEL PA KANDERERSTRASSE 25, CH-4057 BASEL, SWITZERLAND SN 1660-4601 J9 INT J ENV RES PUB HE JI Int. J. Environ. Res. Public Health PD FEB PY 2010 VL 7 IS 2 BP 494 EP 508 DI 10.3390/ijerph7020494 PG 15 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA 561JK UT WOS:000274972000011 PM 20616987 ER PT J AU Biedron, C Pagano, M Hedt, BL Kilian, A Ratcliffe, A Mabunda, S Valadez, JJ AF Biedron, Caitlin Pagano, Marcello Hedt, Bethany L. Kilian, Albert Ratcliffe, Amy Mabunda, Samuel Valadez, Joseph J. TI An assessment of Lot Quality Assurance Sampling to evaluate malaria outcome indicators: extending malaria indicator surveys SO INTERNATIONAL JOURNAL OF EPIDEMIOLOGY LA English DT Article ID BURDEN; AREAS AB Methods The Mozambique Ministry of Health conducted a Malaria Indicator Survey (MIS) in June and July 2007. We applied LQAS classification rules to the 345 sampled enumeration areas to demonstrate identifying high- and low-performing areas with respect to two malaria program indicators-'household possession of any bednet' and 'household possession of any insecticide-treated bednet (ITN)'. Results As shown by the MIS, no province in Mozambique achieved the 70% coverage target for household possession of bednets or ITNs. By applying LQAS classification rules to the data, we identify 266 of the 345 enumeration areas as having bednet coverage severely below the 70% target. An additional 73 were identified with low ITN coverage. Conclusions This article demonstrates the feasibility of integrating LQAS into multistage cluster sampling surveys and using these results to support a comprehensive national, regional and local programme M&E system. Furthermore, in the recommendations we outlined how to integrate the Large Country-LQAS design into macro-surveys while still obtaining results available through current sampling practices. C1 [Biedron, Caitlin] Harvard Univ, Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA 02115 USA. [Pagano, Marcello; Hedt, Bethany L.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Kilian, Albert] Malaria Consortium, London, England. [Ratcliffe, Amy] Ctr Dis Control & Prevent, Malaria Branch, Atlanta, GA USA. [Mabunda, Samuel] Minist Hlth, Natl Malaria Control Program, Maputo, Mozambique. [Valadez, Joseph J.] Univ Liverpool, Liverpool Sch Trop Med, Int Hlth Grp, Liverpool L3 5QA, Merseyside, England. RP Pagano, M (reprint author), Harvard Univ, Sch Publ Hlth, Dept Global Hlth & Populat, 665 Huntington Ave, Boston, MA 02115 USA. EM pagano@hsph.harvard.edu FU National Institutes of Health [T32 AI007358, R01 EB006195] FX The Mozambique MIS was funded by the President's Malaria Initiative. National Institutes of Health Grants T32 AI007358 and R01 EB006195 to M. P. and B. H.; and ExxonMobil to the Malaria Implementation Resource Team of the World Bank, which supported J. V. NR 28 TC 17 Z9 17 U1 0 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0300-5771 J9 INT J EPIDEMIOL JI Int. J. Epidemiol. PD FEB PY 2010 VL 39 IS 1 BP 72 EP 79 DI 10.1093/ije/dyp363 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 555EO UT WOS:000274491000015 PM 20139435 ER PT J AU Lonnroth, K Williams, BG Cegielski, P Dye, C AF Loennroth, Knut Williams, Brian G. Cegielski, Peter Dye, Christopher TI A consistent log-linear relationship between tuberculosis incidence and body mass index SO INTERNATIONAL JOURNAL OF EPIDEMIOLOGY LA English DT Article DE Tuberculosis; nutrition; body mass index; review ID CAUSE-SPECIFIC MORTALITY; RISK; ASSOCIATION; OBESITY; DISEASE; BUILD AB Methods A systematic literature review was carried out to identify cohort studies that collected data on weight and height at baseline and that used a diagnosis of active TB as the study outcome. Weight-for-height measures used in the original studies were transformed into body mass index (BMI). Exponential trend lines were fitted to each data set. Results Six studies were included. In all of them, there was a log-linear inverse relationship between TB incidence and BMI, within the BMI range 18.5-30 kg/m(2). The average slope gave a reduction in TB incidence of 13.8% [95% confidence interval 13.4-14.2] per unit increase in BMI. The dose-response relationship was less certain at BMI < 18.5 and > 30 kg/m(2). Conclusion There is a strong and consistent log-linear relationship between TB incidence and BMI across a variety of settings with different levels of TB burden. More research is required to test the relationship at very low and very high BMI levels, to establish the biological mechanism linking BMI with risk of TB and to establish the potential impact on the global TB epidemic of changing nutritional status of populations. C1 [Loennroth, Knut; Williams, Brian G.; Dye, Christopher] WHO, Stop TB Dept, CH-1211 Geneva, Switzerland. [Cegielski, Peter] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA. RP Lonnroth, K (reprint author), WHO, Stop TB Dept, 20 Ave Appia, CH-1211 Geneva, Switzerland. EM lonnrothk@who.int RI Lonnroth, Knut/L-2339-2014 OI Lonnroth, Knut/0000-0001-5054-8240 NR 26 TC 85 Z9 88 U1 0 U2 6 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0300-5771 J9 INT J EPIDEMIOL JI Int. J. Epidemiol. PD FEB PY 2010 VL 39 IS 1 BP 149 EP 155 DI 10.1093/ije/dyp308 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 555EO UT WOS:000274491000025 PM 19820104 ER PT J AU Wilfley, DE Haymond, M Anderson, B Gunn, S Holden, H Jones, M Hwu, K McGirk, S Mckay, S Schreiner, B Cuttler, L Abrams, E Casey, T Dahms, W Drotar, D Huestis, S Levers-Landis, C McGuigan, P Sundararajan, S Geffner, M Chang, N Dreimane, D Halvorson, M Hernandez, S Kaufman, F Mansilla, V Ortiz, R Ward, A Wexler, K Yasuda, P Katz, LL Berkowitz, R Boyd, S Carchidi, C Kaplan, J Keating, C Kneeshaw-Price, S Lassiter, C Lipman, T Magge, S McGinley, G Schwartzman, B Willi, S Arslanian, S Bacha, F Foster, S Galvin, B Hannon, T Kriska, A Libman, I Marcus, M Porter, K Songer, T Venditti, E Goland, R Cain, R Fennoy, I Gallagher, D Kringas, P Leibel, N Motaghedi, R Ng, D Ovalles, M Pellizzari, M Rapaport, R Robbins, K Seidman, D Siegel-Czarkowski, L Speiser, P Laffel, L Goebel-Fabbri, A Higgins, L Malloy, M Milaszewski, K Orkin, L Rodriguez-Ventura, A Nathan, D Bissett, L Blumenthal, K Delahanty, L Goldman, V Goseco, A Larkin, M Levitsky, L McEachern, R Milaszewski, K Norman, D Nwosu, B Park-Bennett, S Richards, D Sherry, N Steiner, B Tollefsen, S Carnes, S Dempsher, D Flomo, D Kociela, V Whelan, T Wolff, B Weinstock, R Bowerman, D Duncan, K Franklin, R Hartsig, J Izquierdo, R Kanaley, J Kearns, J Meyer, S Saletsky, R Trief, P Zeitler, P Bradhurst, A Celona-Jacobs, N Glazner, J Higgins, J Hoe, F Klingensmith, G Nadeau, K Strike, H Walders, N Witten, T Copeland, K Brown, R Chadwick, J Chalmers, L Macha, C Nordyke, A Poulsen, T Pratt, L Preske, J Schanuel, J Smith, J Sternlof, S Swisher, R Hale, D Amodei, N Barajas, R Cody, C Haffner, S Hernandez, J Lynch, J Morales, E Rivera, S Rupert, G Wauters, A White, N Arbelaez, A Jones, J Jones, T Sadler, M Tanner, M Welch, R Caprio, S Grey, M Guandalini, C Lavietes, S Rose, P Syme, A Tamborlane, W Hirst, K Coombs, L Edelstein, S Grover, N Long, C Pyle, L Linder, B Marcovina, S Chmielewski, J Ramirez, M Strylewicz, G Shepherd, J Fan, B Marquez, L Sherman, M Wang, J Mayer-Davis, E Liu, Y Nichols, M Aldrich-Rasche, D Franklin, K Massmann, C O'Brien, D Patterson, J Tibbs, T Van Buren, D Zhang, P Palmert, M Epstein, L Silverstein, J AF Wilfley, D. E. Haymond, M. Anderson, B. Gunn, S. Holden, H. Jones, M. Hwu, K. McGirk, S. Mckay, S. Schreiner, B. Cuttler, L. Abrams, E. Casey, T. Dahms, W. Drotar, D. Huestis, S. Levers-Landis, C. McGuigan, P. Sundararajan, S. Geffner, M. Chang, N. Dreimane, D. Halvorson, M. Hernandez, S. Kaufman, F. Mansilla, V. Ortiz, R. Ward, A. Wexler, K. Yasuda, P. Katz, L. Levitt Berkowitz, R. Boyd, S. Carchidi, C. Kaplan, J. Keating, C. Kneeshaw-Price, S. Lassiter, C. Lipman, T. Magge, S. McGinley, G. Schwartzman, B. Willi, S. Arslanian, S. Bacha, F. Foster, S. Galvin, B. Hannon, T. Kriska, A. Libman, I. Marcus, M. Porter, K. Songer, T. Venditti, E. Goland, R. Cain, R. Fennoy, I. Gallagher, D. Kringas, P. Leibel, N. Motaghedi, R. Ng, D. Ovalles, M. Pellizzari, M. Rapaport, R. Robbins, K. Seidman, D. Siegel-Czarkowski, L. Speiser, P. Laffel, L. Goebel-Fabbri, A. Higgins, L. Malloy, M. Milaszewski, K. Orkin, L. Rodriguez-Ventura, A. Nathan, D. Bissett, L. Blumenthal, K. Delahanty, L. Goldman, V. Goseco, A. Larkin, M. Levitsky, L. McEachern, R. Milaszewski, K. Norman, D. Nwosu, B. Park-Bennett, S. Richards, D. Sherry, N. Steiner, B. Tollefsen, S. Carnes, S. Dempsher, D. Flomo, D. Kociela, V. Whelan, T. Wolff, B. Weinstock, R. Bowerman, D. Duncan, K. Franklin, R. Hartsig, J. Izquierdo, R. Kanaley, J. Kearns, J. Meyer, S. Saletsky, R. Trief, P. Zeitler, P. Bradhurst, A. Celona-Jacobs, N. Glazner, J. Higgins, J. Hoe, F. Klingensmith, G. Nadeau, K. Strike, H. Walders, N. Witten, T. Copeland, K. Brown, R. Chadwick, J. Chalmers, L. Macha, C. Nordyke, A. Poulsen, T. Pratt, L. Preske, J. Schanuel, J. Smith, J. Sternlof, S. Swisher, R. Hale, D. Amodei, N. Barajas, R. Cody, C. Haffner, S. Hernandez, J. Lynch, J. Morales, E. Rivera, S. Rupert, G. Wauters, A. White, N. Arbelaez, A. Jones, J. Jones, T. Sadler, M. Tanner, M. Welch, R. Caprio, S. Grey, M. Guandalini, C. Lavietes, S. Rose, P. Syme, A. Tamborlane, W. Hirst, K. Coombs, L. Edelstein, S. Grover, N. Long, C. Pyle, L. Linder, B. Marcovina, S. Chmielewski, J. Ramirez, M. Strylewicz, G. Shepherd, J. Fan, B. Marquez, L. Sherman, M. Wang, J. Mayer-Davis, E. Liu, Y. Nichols, M. Aldrich-Rasche, D. Franklin, K. Massmann, C. O'Brien, D. Patterson, J. Tibbs, T. Van Buren, D. Zhang, P. Palmert, M. Epstein, L. Silverstein, J. CA Today Study Grp TI Design of a family-based lifestyle intervention for youth with type 2 diabetes: the TODAY study The TODAY Study Group SO INTERNATIONAL JOURNAL OF OBESITY LA English DT Review DE pediatric; chronic illness; childhood obesity; adolescents ID IMPAIRED GLUCOSE-TOLERANCE; LONG-TERM MANAGEMENT; PEDIATRIC OBESITY; WEIGHT-LOSS; ADOLESCENT OVERWEIGHT; PHYSICAL-ACTIVITY; RANDOMIZED-TRIAL; BEHAVIOR-MODIFICATION; CHILDHOOD OVERWEIGHT; COST-EFFECTIVENESS AB Type 2 diabetes is associated with obesity and is increasing at an alarming rate in youth. Although weight loss through lifestyle change is one of the primary treatment recommendations for adults with type 2 diabetes, the efficacy of this approach has not been tested with youth. This paper provides a summary of the reviews and meta-analyses of pediatric weight-loss interventions that informed the design and implementation of an intensive, family-based lifestyle weight management program for adolescents with type 2 diabetes and their families developed for the Treatment Options for type 2 Diabetes in Adolescents and Youth ( TODAY) study. A total of 1092 youth have been screened, and 704 families have been randomized for inclusion in this 15-center clinical trial sponsored by the National Institutes of Health. The TODAY study is designed to test three approaches ( metformin, metformin plus rosiglitazone and metformin plus an intensive lifestyle intervention) to the treatment of a diverse cohort of youth, 10-17 years of age, within 2 years of their diagnosis. The principal goal of the TODAY Lifestyle Program (TLP) is to decrease baseline weight of youth by 7-10% ( or the equivalent for children who are growing in height) through changes in eating and physical activity habits, and to sustain these changes through ongoing treatment contact. The TLP is implemented by interventionists called Personal Activity and Nutrition Leaders (PALs) and delivered to youth with type 2 diabetes, and at least one family support person. The TLP provides a model for taking a comprehensive, continuous care approach to the treatment of severe overweight in youth with comorbid medical conditions such as type 2 diabetes. International Journal of Obesity (2010) 34, 217-226; doi: 10.1038/ijo.2009.195; published online 13 October 2009 C1 [Haymond, M.; Anderson, B.; Gunn, S.; Holden, H.; Jones, M.; Hwu, K.; McGirk, S.; Mckay, S.; Schreiner, B.] Baylor Coll Med, Ctr Clin, Houston, TX 77030 USA. [Cuttler, L.; Abrams, E.; Casey, T.; Dahms, W.; Drotar, D.; Huestis, S.; Levers-Landis, C.; McGuigan, P.; Sundararajan, S.] Case Western Reserve Univ, Cleveland, OH 44106 USA. [Geffner, M.; Chang, N.; Dreimane, D.; Halvorson, M.; Hernandez, S.; Kaufman, F.; Mansilla, V.; Ortiz, R.; Ward, A.; Wexler, K.; Yasuda, P.] Childrens Hosp Los Angeles, Los Angeles, CA USA. [Katz, L. Levitt; Berkowitz, R.; Boyd, S.; Carchidi, C.; Kaplan, J.; Keating, C.; Kneeshaw-Price, S.; Lassiter, C.; Lipman, T.; Magge, S.; McGinley, G.; Schwartzman, B.; Willi, S.] Childrens Hosp Philadelphia, Philadelphia, PA USA. [Arslanian, S.; Bacha, F.; Foster, S.; Galvin, B.; Hannon, T.; Kriska, A.; Libman, I.; Marcus, M.; Porter, K.; Songer, T.; Venditti, E.] Childrens Hosp Pittsburgh, Pittsburgh, PA USA. [Goland, R.; Cain, R.; Fennoy, I.; Gallagher, D.; Kringas, P.; Leibel, N.; Motaghedi, R.; Ng, D.; Ovalles, M.; Pellizzari, M.; Rapaport, R.; Robbins, K.; Seidman, D.; Siegel-Czarkowski, L.; Speiser, P.] Columbia Univ, Med Ctr, New York, NY 10027 USA. [Milaszewski, K.; Nathan, D.; Bissett, L.; Blumenthal, K.; Delahanty, L.; Goldman, V.; Goseco, A.; Larkin, M.; Levitsky, L.; McEachern, R.; Norman, D.; Nwosu, B.; Park-Bennett, S.; Richards, D.; Sherry, N.; Steiner, B.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Tollefsen, S.; Carnes, S.; Dempsher, D.; Flomo, D.; Kociela, V.; Whelan, T.; Wolff, B.] St Louis Univ, St Louis, MO 63103 USA. [Weinstock, R.; Bowerman, D.; Duncan, K.; Franklin, R.; Hartsig, J.; Izquierdo, R.; Kanaley, J.; Kearns, J.; Meyer, S.; Saletsky, R.; Trief, P.] SUNY Upstate Med Univ, Syracuse, NY USA. [Zeitler, P.; Bradhurst, A.; Celona-Jacobs, N.; Glazner, J.; Higgins, J.; Hoe, F.; Klingensmith, G.; Nadeau, K.; Strike, H.; Walders, N.; Witten, T.] Univ Colorado, Hlth Sci Ctr, Boulder, CO 80309 USA. [Copeland, K.; Brown, R.; Chadwick, J.; Chalmers, L.; Macha, C.; Nordyke, A.; Poulsen, T.; Pratt, L.; Preske, J.; Schanuel, J.; Smith, J.; Sternlof, S.; Swisher, R.] Univ Oklahoma, Hlth Sci Ctr, Norman, OK 73019 USA. [Hale, D.; Amodei, N.; Barajas, R.; Cody, C.; Haffner, S.; Hernandez, J.; Lynch, J.; Morales, E.; Rivera, S.; Rupert, G.; Wauters, A.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX USA. [White, N.; Arbelaez, A.; Jones, J.; Jones, T.; Sadler, M.; Tanner, M.; Welch, R.] Washington Univ, Sch Med, St Louis, MO 63130 USA. [Caprio, S.; Grey, M.; Guandalini, C.; Lavietes, S.; Rose, P.; Syme, A.; Tamborlane, W.] Yale Univ, New Haven, CT 06520 USA. [Hirst, K.; Coombs, L.; Edelstein, S.; Grover, N.; Long, C.; Pyle, L.] Washington Univ, Ctr Biostat, Coordinating Ctr George, St Louis, MO 63130 USA. [Linder, B.] NIDDK, Project Off, Bethesda, MD 20892 USA. [Marcovina, S.; Chmielewski, J.; Ramirez, M.; Strylewicz, G.] Univ Washington, NW Lipid Res Labs, Cent Units Cent Blood Lab, Seattle, WA 98195 USA. [Shepherd, J.; Fan, B.; Marquez, L.; Sherman, M.; Wang, J.] Univ Calif San Francisco, DEXA Reading Ctr, San Francisco, CA 94143 USA. [Mayer-Davis, E.; Liu, Y.; Nichols, M.] Univ S Carolina, Diet Assessment Ctr, Columbia, SC 29208 USA. [Wilfley, D. E.; Patterson, J.; Tibbs, T.; Van Buren, D.] Washington Univ, Lifestyle Program Core, St Louis, MO 63130 USA. [Zhang, P.] Ctr Dis Control, Atlanta, GA 30333 USA. [Palmert, M.] Hosp Sick Children, Toronto, ON M5G 1X8, Canada. [Epstein, L.] SUNY Buffalo, Buffalo, NY 14260 USA. [Silverstein, J.] Univ Florida, Gainesville, FL 32611 USA. RP Wilfley, DE (reprint author), WUSM, Campus Box 8134,660 S Euclid, St Louis, MO 63110 USA. EM wilfleyd@psychiatry.wustl.edu FU NIDDK/NIH [U01-DK61212, U01-DK61230, U01-DK61239, U01-DK61242, U01-DK61254]; NIMH [1K24MH070446-01]; National Center for Research Resources General Clinical Research Centers Program; Washington University School of Medicine [M01-RR00036]; Children's Hospital Los Angeles [M01-RR00043-45]; University of Colorado Health Sciences Center [M01-RR00069]; Children's Hospital of Pittsburgh [M01-RR00084]; Massachusetts General Hospital [M01-RR01066]; Yale University [M01-RR00125]; University of Oklahoma Health Sciences Center [M01-RR14467] FX This work was completed with funding from NIDDK/NIH grant numbers U01-DK61212, U01-DK61230, U01-DK61239, U01-DK61242, U01-DK61254, from NIMH grant number 1K24MH070446-01 (Dr Wilfley) and from the National Center for Research Resources General Clinical Research Centers Program grant numbers M01-RR00036 (Washington University School of Medicine), M01-RR00043-45 (Children's Hospital Los Angeles), M01-RR00069 (University of Colorado Health Sciences Center), M01-RR00084 (Children's Hospital of Pittsburgh), M01-RR01066 (Massachusetts General Hospital), M01-RR00125 (Yale University) and M01-RR14467 (University of Oklahoma Health Sciences Center). Members of the writing group were D Wilfley (chair), B Berkowitz, L Epstein, K Hirst, A Kriska, L Laffel, M Marcus, T Tibbs and D Van Buren. NR 66 TC 12 Z9 12 U1 4 U2 17 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 0307-0565 J9 INT J OBESITY JI Int. J. Obes. PD FEB PY 2010 VL 34 IS 2 BP 217 EP 226 DI 10.1038/ijo.2009.195 PG 10 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA 555JZ UT WOS:000274508100001 ER PT J AU Castro, KG Bell, BP Schuchat, A AF Castro, Kenneth G. Bell, Beth P. Schuchat, Anne TI Preventing complications from 2009 influenza A (H1N1) in persons with underlying lung diseases: a formidable challenge for 2010 Year of the Lung SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE LA English DT Editorial Material ID PANDEMIC INFLUENZA; UNITED-STATES; CALIFORNIA; INFECTION; A(H1N1) C1 [Castro, Kenneth G.; Bell, Beth P.; Schuchat, Anne] Ctr Dis Control & Prevent, US Dept Hlth & Human Serv, Atlanta, GA 30333 USA. RP Castro, KG (reprint author), Ctr Dis Control & Prevent, US Dept Hlth & Human Serv, Atlanta, GA 30333 USA. EM kgc1@cdc.gov NR 22 TC 0 Z9 0 U1 0 U2 1 PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) PI PARIS PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE SN 1027-3719 J9 INT J TUBERC LUNG D JI Int. J. Tuberc. Lung Dis. PD FEB PY 2010 VL 14 IS 2 BP 127 EP 129 PG 3 WC Infectious Diseases; Respiratory System SC Infectious Diseases; Respiratory System GA 549FV UT WOS:000274033300001 PM 20074400 ER PT J AU van Griensven, F Varangrat, A Wimonsate, W Tanpradech, S Kladsawad, K Chemnasiri, T Suksripanich, O Phanuphak, P Mock, P Kanggarnrua, K McNicholl, J Plipat, T AF van Griensven, Frits Varangrat, Anchalee Wimonsate, Wipas Tanpradech, Suvimon Kladsawad, Keratikarn Chemnasiri, Tareerat Suksripanich, Orapin Phanuphak, Praphan Mock, Philip Kanggarnrua, Kamolset McNicholl, Janet Plipat, Tanarak TI Trends in HIV Prevalence, Estimated HIV Incidence, and Risk Behavior Among Men Who Have Sex With Men in Bangkok, Thailand, 2003-2007 SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE epidemiology; HIV; men who have sex with men; Thailand ID INFECTION; EPIDEMIC; HEALTH AB Background: Men who have sex with men (MSM) continue to be at high risk for HIV infection. Here we evaluate trends in HIV prevalence, estimated HIV incidence, and risk behavior among MSM in Bangkok, Thailand. Methods: Between 2003 and 2007, 3 biennial cross-sectional HIV prevalence assessments were conducted among MSM in Bangkok, Thailand, using venue-day-time sampling. Oral fluid was tested for HIV infection; demographic and behavioral data were self-collected using hand-held computers. Estimates of annual HIV incidence in young MSM were derived as follows: (number of HIV infections/sum of [current age-age at start of anal intercourse]) X 100). Logistic and Poisson regression was used to evaluate trends in HIV prevalence, estimated HIV incidence, and risk behavior. Findings: The overall HIV prevalence increased from 17.3% in 2003 to 28.3% in 2005 to 30.8% in 2007 (P < 0.001 for trend). The estimated HIV incidence among young MSM increased from 4.1% in 2003 to 6.4% in 2005, to 7.7% in 2007 (P < 0.02 for trend). The increase in HIV prevalence from 2005 to 2007 was not statistically significant. The proportion of men reporting anal sex and casual or steady male sex partners in the past 3 months significantly decreased, whereas the proportion reporting drug use and drug use during sex significantly increased. No increase was observed in the proportion of men reporting consistent condom use. Interpretation: Our data suggest that after a strong increase from 2003 to 2005, the HIV prevalence among MSM in Bangkok may have begun to stabilize. Given the continuing high levels of risk behavior and the estimated high HIV incidence in young MSM, additional HIV preventive interventions are necessary. C1 [van Griensven, Frits] US Ctr Dis Control & Prevent Collaborat, Thailand Minist Publ Hlth, Minist Publ Hlth, Nonthaburi 11000, Thailand. [van Griensven, Frits; McNicholl, Janet] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Kladsawad, Keratikarn; Plipat, Tanarak] Minist Publ Hlth, Bur Epidemiol, Nonthaburi, Thailand. [Phanuphak, Praphan] AIDS Res Ctr, Thai Red Cross Soc, Bangkok, Thailand. [Kanggarnrua, Kamolset] Rainbow Sky Assoc Thailand, Bangkok, Thailand. RP van Griensven, F (reprint author), US Ctr Dis Control & Prevent Collaborat, Thailand Minist Publ Hlth, Minist Publ Hlth, Nonthaburi 11000, Thailand. EM fav1@cdc.gov RI van Griensven, Frits/G-4719-2013 OI van Griensven, Frits/0000-0002-0971-2843 FU Division of HIV/AIDS Prevention and the Global AIDS Program of the US Centers for Disease Control and Prevention; Ministry of Public Health of Thailand FX This work was Supported by the Division of HIV/AIDS Prevention and the Global AIDS Program of the US Centers for Disease Control and Prevention and by the Ministry of Public Health of Thailand. NR 20 TC 54 Z9 54 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1525-4135 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD FEB 1 PY 2010 VL 53 IS 2 BP 234 EP 239 PG 6 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA 549EQ UT WOS:000274029000012 PM 19901844 ER PT J AU Liddon, N Hood, J Wynn, BA Markowitz, LE AF Liddon, Nicole Hood, Julia Wynn, Bridget A. Markowitz, Lauri E. TI Acceptability of Human Papillomavirus Vaccine for Males: A Review of the Literature SO JOURNAL OF ADOLESCENT HEALTH LA English DT Review DE HPV vaccine; Vaccine acceptability; Males ID HPV VACCINE; CERVICAL-CANCER; PEDIATRICIANS INTENTION; PARENTAL ACCEPTANCE; UNITED-STATES; ATTITUDES; MEN; KNOWLEDGE; WOMEN; PREVALENCE AB The quadrivalent human papillomavirus virus vaccine was recently licensed for use in males in the United States. This study reviews available published literature on acceptability among parents, health care providers, and young males. Among 23 published articles, half were conducted in the United States. The majority (87%) used quantitative survey methodology, and 13% used more explorative qualitative techniques. Convenience samples were used in most cases (74%) and 26% relied on nationally representative samples. Acceptability of a human papillomavirus virus (HPV) vaccine that protects against cervical cancer and genital warts was high in studies conducted among male college students (74%-78%) but lower in a community sample of males (33%). Among mothers of sons, support of HPV vaccination varied widely from 12% to 100%, depending on the mother's ethnicity and type of vaccine, but was generally high for a vaccine that would protect against both genital warts and cervical cancer. Health providers' intention to recommend HPV vaccine to male patients varied by patient age but was high (82%-92%) for older adolescent patients. A preference to vaccinate females over males was reported in a majority of studies among parents and health care providers. Messages about cervical cancer prevention for female partners did not resonate among adult males or parents. Future acceptability studies might incorporate more recent data on HPV-related disease, HPV vaccines, and cost-effectiveness data to provide more current information on vaccine acceptability. Published by Elsevier Inc. C1 [Liddon, Nicole; Hood, Julia; Wynn, Bridget A.; Markowitz, Lauri E.] Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV Hepatitis STD & TB Prevent, Atlanta, GA USA. RP Liddon, N (reprint author), 1600 Clifton Rd,MS E-44, Atlanta, GA 30333 USA. EM nliddon@cdc.gov NR 35 TC 85 Z9 85 U1 3 U2 15 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD FEB PY 2010 VL 46 IS 2 BP 113 EP 123 DI 10.1016/j.jadohealth.2009.11.199 PG 11 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA 548RH UT WOS:000273983400004 PM 20113917 ER PT J AU Fournier, M Quinlisk, P Garvey, A Goddard, J Lyss, S AF Fournier, Mary Quinlisk, Patricia Garvey, Ann Goddard, Judy Lyss, Sheryl TI PERCEIVED FAMILY SUPPORT ASSOCIATED WITH DECREASED ALCOHOL USE AMONG IOWA YOUTH SO JOURNAL OF ADOLESCENT HEALTH LA English DT Meeting Abstract C1 [Fournier, Mary; Lyss, Sheryl] Ctr Dis Control & Prevent, US Publ Hlth Serv, Atlanta, GA USA. [Quinlisk, Patricia; Garvey, Ann; Goddard, Judy] Iowa Dept Publ Hlth, Des Moines, IA 50319 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD FEB PY 2010 VL 46 IS 2 SU 1 BP S60 EP S60 PG 1 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA 550BL UT WOS:000274101600129 ER PT J AU McRee, AL Brewer, N Reiter, P Smith, J Gottlieb, S AF McRee, Annie-Laurie Brewer, Noel Reiter, Paul Smith, Jennifer Gottlieb, Sami TI HPV VACCINE: WHAT ARE MOTHERS SAYING TO THEIR ADOLESCENT DAUGHTERS? SO JOURNAL OF ADOLESCENT HEALTH LA English DT Meeting Abstract C1 [Gottlieb, Sami] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD FEB PY 2010 VL 46 IS 2 SU 1 BP S69 EP S69 PG 1 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA 550BL UT WOS:000274101600149 ER PT J AU Skiles, M English, A Cai, JW Agans, R Koumans, E Stokley, S Markowitz, L Ford, C AF Skiles, Martha English, Abigail Cai, Jianwen Agans, Robert Koumans, Emilia Stokley, Shannon Markowitz, Lauri Ford, Carol TI MINOR CONSENTAND DELIVERY OF ADOLESCENT VACCINES SO JOURNAL OF ADOLESCENT HEALTH LA English DT Meeting Abstract C1 [Koumans, Emilia; Stokley, Shannon; Markowitz, Lauri] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Skiles, Martha; Cai, Jianwen; Agans, Robert; Ford, Carol] Univ N Carolina, Chapel Hill, NC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD FEB PY 2010 VL 46 IS 2 SU 1 BP S71 EP S71 PG 1 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA 550BL UT WOS:000274101600154 ER PT J AU Skiles, M English, A Cai, JW Agans, R Koumans, E Stokley, S Markowitz, L Ford, C AF Skiles, Martha English, Abigail Cai, Jianwen Agans, Robert Koumans, Emilia Stokley, Shannon Markowitz, Lauri Ford, Carol TI ADOLESCENT VACCINE-RELATED ATTITUDES AND BELIEFS AMONG KEY PROFESSIONAL STAKEHOLDERS AND OPINION LEADERS ACROSS THE UNITED STATES SO JOURNAL OF ADOLESCENT HEALTH LA English DT Meeting Abstract C1 [Koumans, Emilia; Stokley, Shannon; Markowitz, Lauri] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Skiles, Martha; Cai, Jianwen; Agans, Robert; Ford, Carol] Univ N Carolina, Chapel Hill, NC USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD FEB PY 2010 VL 46 IS 2 SU 1 BP S71 EP S72 PG 2 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA 550BL UT WOS:000274101600155 ER PT J AU Green, BJ Cummings, KJ Gaughan, DM Blachere, FM Bledsoe, TA Hettick, JM Siegel, PD Kullman, GJ Kreiss, K Cox-Ganser, J Beezhold, DH AF Green, B. J. Cummings, K. J. Gaughan, D. M. Blachere, F. M. Bledsoe, T. A. Hettick, J. M. Siegel, P. D. Kullman, G. J. Kreiss, K. Cox-Ganser, J. Beezhold, D. H. TI Sensitization to Soy Antigens in Workers at a Soy Plant SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT 66th Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology CY FEB 26-MAR 02, 2010 CL New Orleans, LA SP Amer Acad Allergy, Asthma & Immunol C1 [Green, B. J.; Cummings, K. J.; Gaughan, D. M.; Blachere, F. M.; Bledsoe, T. A.; Hettick, J. M.; Siegel, P. D.; Kullman, G. J.; Kreiss, K.; Cox-Ganser, J.; Beezhold, D. H.] NIOSH, Ctr Dis Control & Prevent, Morgantown, WV USA. RI Hettick, Justin/E-9955-2010 NR 0 TC 0 Z9 0 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD FEB PY 2010 VL 125 IS 2 SU 1 BP AB83 EP AB83 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA 629MS UT WOS:000280204100326 ER PT J AU Gupta, RS Zhang, X Springston, EE Weiss, KB Holl, J AF Gupta, R. S. Zhang, X. Springston, E. E. Weiss, K. B. Holl, J. TI The Impact of Violence and Stress on Childhood Asthma Severity SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT 66th Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology CY FEB 26-MAR 02, 2010 CL New Orleans, LA SP Amer Acad Allergy, Asthma & Immunol C1 [Gupta, R. S.; Springston, E. E.; Holl, J.] Childrens Mem Hosp, Chicago, IL 60614 USA. [Gupta, R. S.; Weiss, K. B.; Holl, J.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Zhang, X.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Weiss, K. B.] Amer Board Med Specialties, Chicago, IL USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD FEB PY 2010 VL 125 IS 2 SU 1 BP AB121 EP AB121 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA 629MS UT WOS:000280204100480 ER PT J AU Morrison, T Zhang, X Holt, JB Callahan, D AF Morrison, T. Zhang, X. Holt, J. B. Callahan, D. TI Asthma Prevalence: A State-by-State Trend Analysis-United States, 2000-2008 SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT 66th Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology CY FEB 26-MAR 02, 2010 CL New Orleans, LA SP Amer Acad Allergy, Asthma & Immunol C1 [Morrison, T.; Zhang, X.; Holt, J. B.; Callahan, D.] CDC, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD FEB PY 2010 VL 125 IS 2 SU 1 BP AB232 EP AB232 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA 629MS UT WOS:000280204100906 ER PT J AU Schwartz, G Gupta, RS Springston, E Zhang, X Grammer, LC AF Schwartz, G. Gupta, R. S. Springston, E. Zhang, X. Grammer, L. C. TI The Association between Crime and Adult Asthma Severity SO JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY LA English DT Meeting Abstract CT 66th Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology CY FEB 26-MAR 02, 2010 CL New Orleans, LA SP Amer Acad Allergy, Asthma & Immunol C1 [Schwartz, G.; Gupta, R. S.; Grammer, L. C.] Northwestern Univ, Chicago, IL 60611 USA. [Springston, E.] Childrens Mem Hosp, Chicago, IL 60614 USA. [Zhang, X.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0091-6749 J9 J ALLERGY CLIN IMMUN JI J. Allergy Clin. Immunol. PD FEB PY 2010 VL 125 IS 2 SU 1 BP AB32 EP AB32 PG 1 WC Allergy; Immunology SC Allergy; Immunology GA 629MS UT WOS:000280204100126 ER PT J AU Rosenfeld, L Rudd, R Chew, GL Emmons, K Acevedo-Garcia, D AF Rosenfeld, Lindsay Rudd, Rima Chew, Ginger L. Emmons, Karen Acevedo-Garcia, Dolores TI Are Neighborhood-Level Characteristics Associated with Indoor Allergens in the Household? SO JOURNAL OF ASTHMA LA English DT Article DE indoor allergens; dust mite; cat; cockroach; mouse; asthma; neighborhoods; community districts; housing code violations; policy; New York City; Puerto Rican ID INNER-CITY CHILDREN; NEW-YORK-CITY; ENVIRONMENTAL RISK-FACTORS; HEALTH IMPACT ASSESSMENT; PUERTO-RICAN CHILDREN; 1ST NATIONAL-SURVEY; COCKROACH ALLERGEN; AIR-POLLUTION; CHILDHOOD ASTHMA; LOW-INCOME AB Background: Individual home characteristics have been associated with indoor allergen exposure, however, the influence of neighborhood-level characteristics has not been well studied. We defined neighborhoods as community districts determined by the New York City Department of City Planning. Objective: We examined the relationship between neighborhood-level characteristics and the presence of dust mite (Der f 1), cat (Fel d 1). cockroach (Bla g 2), and mouse (MUP) allergens in the household. Methods: Using data from the Puerto Rican Asthma Project, a birth cohort of Puerto Rican children at risk of allergic sensitization (n = 261), we examined associations between neighborhood characteristics (percent tree canopy, asthma hospitalizations per 1,000 children, roadway length within 100 meters of buildings, serious housing code violations per 1000 rental units, poverty rates, and felony crime rates), and the presence of indoor allergens. Allergen cutpoints were used for categorical analyses and defined as follows: dust mite: >0.25 mu g/g; cat: > 1 mu g/g; cockroach: > 1 U/g; mouse: > 1.6 mu g/g. Results: Serious housing code violations were statistically significantly positively associated with dust mite, cat, and mouse allergens (continuous variables), adjusting for mother's income and education, and all neighborhood-level characteristics. In multivariable logistic regression analyses, medium levels of housing code violations were associated with higher dust mite and cat allergens (1.81, 95%CI: 1.08. 3.03 and 3.10, 95%CI: 1.22, 7.92, respectively). A high level of serious housing code violations was associated with higher mouse allergen (2.04, 95%CI: 1.15, 3.62). A medium level of housing code violations was associated with higher cockroach allergen (3.30. 95%CI: 1.11, 9.78). Conclusions: Neighborhood-level characteristics, specifically housing code violations, appear to be related to indoor allergens, which may have implications for future research explorations and policy decisions. C1 [Rosenfeld, Lindsay; Rudd, Rima; Acevedo-Garcia, Dolores] Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Boston, MA 02130 USA. [Rosenfeld, Lindsay; Acevedo-Garcia, Dolores] Northeastern Univ, Inst Urban Hlth Res, Bouve Coll Hlth Sci, Boston, MA 02115 USA. [Emmons, Karen] Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Boston, MA 02115 USA. [Chew, Ginger L.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. RP Rosenfeld, L (reprint author), Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, 677 Huntington Ave,Kresge 7th Floor, Boston, MA 02130 USA. EM lrosenfe@hsph.harvard.edu FU NIEHS [R01 ES 10922, P30 ES 009089] FX The authors thank the Puerto Rican Asthma Project research participants and staff for their time and effort, especially Dr. Luis Acosta and Marianne Turner. They also thank Jeff Blossom for creating variables and maps in ArcGIS 9.2, and Amy Cohen for her SAS programming expertise. This work was supported by NIEHS grants R01 ES 10922 and P30 ES 009089. NR 113 TC 17 Z9 18 U1 5 U2 8 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 0277-0903 J9 J ASTHMA JI J. Asthma PD FEB PY 2010 VL 47 IS 1 BP 66 EP 75 DI 10.3109/02770900903362676 PG 10 WC Allergy; Respiratory System SC Allergy; Respiratory System GA 565EL UT WOS:000275271900012 PM 20100024 ER PT J AU Lauritsen, MB Jorgensen, M Madsen, KM Lemcke, S Toft, S Grove, J Schendel, DE Thorsen, P AF Lauritsen, Marlene B. Jorgensen, Meta Madsen, Kreesten M. Lemcke, Sanne Toft, Susanne Grove, Jakob Schendel, Diana E. Thorsen, Poul TI Validity of Childhood Autism in the Danish Psychiatric Central Register: Findings from a Cohort Sample Born 1990-1999 SO JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS LA English DT Article DE Quality; Validity; Autism; Diagnosis; Population register ID PERVASIVE DEVELOPMENTAL DISORDERS; INFANTILE-AUTISM; MENTAL-RETARDATION; RISK-FACTORS; SPECTRUM DISORDERS; INDIVIDUALS; ASSOCIATION; PREVALENCE; VALIDATION; DIAGNOSES AB The purpose of this study was to assess the validity of the diagnosis of childhood autism in the Danish Psychiatric Central Register (DPCR) by reviewing medical records from 499 of 504 total children with childhood autism born 1990-1999. Based on review of abstracted behaviors recorded in case records from child psychiatric hospitals, case status determination was performed using a standardized coding scheme. In 499 children diagnosed with childhood autism in the DPCR, the diagnosis could be confirmed in 469 children (94%). Of the 30 non-confirmed cases, five were classified by the reviewers as non-autistic cases and the remaining 25 cases were either classified with another ASD diagnosis or the specific diagnosis was not possible to determine. C1 [Lauritsen, Marlene B.; Jorgensen, Meta; Toft, Susanne] Aarhus Univ Hosp, Reg Ctr Child & Adolescent Psychiat, Risskov, Denmark. [Lauritsen, Marlene B.; Lemcke, Sanne; Toft, Susanne; Grove, Jakob; Thorsen, Poul] Univ Aarhus, Inst Publ Hlth, Dept Epidemiol & Social Med, NANEA, Aarhus, Denmark. [Schendel, Diana E.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Lauritsen, MB (reprint author), Aarhus Univ Hosp, Reg Ctr Child & Adolescent Psychiat, Risskov, Denmark. EM mbl@dadlnet.dk OI Lemcke, Sanne/0000-0002-0542-713X; Grove, Jakob/0000-0003-2284-5744 NR 32 TC 87 Z9 87 U1 2 U2 4 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0162-3257 J9 J AUTISM DEV DISORD JI J. Autism Dev. Disord. PD FEB PY 2010 VL 40 IS 2 BP 139 EP 148 DI 10.1007/s10803-009-0818-0 PG 10 WC Psychology, Developmental SC Psychology GA 553NN UT WOS:000274374200001 PM 19728067 ER PT J AU Kozak, NA Buss, M Lucas, CE Frace, M Govil, D Travis, T Olsen-Rasmussen, M Benson, RF Fields, BS AF Kozak, Natalia A. Buss, Meghan Lucas, Claressa E. Frace, Michael Govil, Dhwani Travis, Tatiana Olsen-Rasmussen, Melissa Benson, Robert F. Fields, Barry S. TI Virulence Factors Encoded by Legionella longbeachae Identified on the Basis of the Genome Sequence Analysis of Clinical Isolate D-4968 SO JOURNAL OF BACTERIOLOGY LA English DT Article ID II PROTEIN SECRETION; INTRACELLULAR MULTIPLICATION; LEGIONNAIRES-DISEASE; HUMAN MACROPHAGES; POTTING SOILS; IV PILI; PNEUMOPHILA; SYSTEM; GENE; INFECTION AB Legionella longbeachae causes most cases of legionellosis in Australia and may be underreported worldwide due to the lack of L. longbeachae-specific diagnostic tests. L. longbeachae displays distinctive differences in intracellular trafficking, caspase 1 activation, and infection in mouse models compared to Legionella pneumophila, yet these two species have indistinguishable clinical presentations in humans. Unlike other legionellae, which inhabit freshwater systems, L. longbeachae is found predominantly in moist soil. In this study, we sequenced and annotated the genome of an L. longbeachae clinical isolate from Oregon, isolate D-4968, and compared it to the previously published genomes of L. pneumophila. The results revealed that the D-4968 genome is larger than the L. pneumophila genome and has a gene order that is different from that of the L. pneumophila genome. Genes encoding structural components of type II, type IV Lvh, and type IV Icm/Dot secretion systems are conserved. In contrast, only 42/140 homologs of genes encoding L. pneumophila Icm/Dot substrates have been found in the D-4968 genome. L. longbeachae encodes numerous proteins with eukaryotic motifs and eukaryote-like proteins unique to this species, including 16 ankyrin repeat-containing proteins and a novel U-box protein. We predict that these proteins are secreted by the L. longbeachae Icm/Dot secretion system. In contrast to the L. pneumophila genome, the L. longbeachae D-4968 genome does not contain flagellar biosynthesis genes, yet it contains a chemotaxis operon. The lack of a flagellum explains the failure of L. longbeachae to activate caspase 1 and trigger pyroptosis in murine macrophages. These unique features of L. longbeachae may reflect adaptation of this species to life in soil. C1 [Kozak, Natalia A.; Buss, Meghan; Lucas, Claressa E.; Travis, Tatiana; Benson, Robert F.; Fields, Barry S.] Ctr Dis Control & Prevent, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Coordinating Ctr Infect Dis, Atlanta, GA 30333 USA. [Frace, Michael; Govil, Dhwani; Olsen-Rasmussen, Melissa] Ctr Dis Control & Prevent, Biotechnol Core Facil Branch, Div Sci Resources, Natl Ctr Preparedness Detect & Control Infect Dis, Atlanta, GA 30333 USA. RP Kozak, NA (reprint author), Ctr Dis Control & Prevent, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Coordinating Ctr Infect Dis, 1600 Clifton Rd NE,Mailstop G03, Atlanta, GA 30333 USA. EM htv2@cdc.gov NR 94 TC 41 Z9 41 U1 1 U2 6 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0021-9193 J9 J BACTERIOL JI J. Bacteriol. PD FEB PY 2010 VL 192 IS 4 BP 1030 EP 1044 DI 10.1128/JB.01272-09 PG 15 WC Microbiology SC Microbiology GA 549DF UT WOS:000274021900014 PM 20008069 ER PT J AU Fang, J Keenan, NL Ayala, C AF Fang, Jing Keenan, Nora L. Ayala, Carma TI Health Care Services Provided During Physician Office Visits for Hypertension: Differences by Specialty SO JOURNAL OF CLINICAL HYPERTENSION LA English DT Article ID CONGESTIVE-HEART-FAILURE; JOINT NATIONAL COMMITTEE; HIGH BLOOD-PRESSURE; UNITED-STATES; MYOCARDIAL-INFARCTION; ELDERLY-PATIENTS; 7TH REPORT; PREVENTION; METAANALYSIS; PREVALENCE AB The changing health care system has reduced patients' access to specialty care. Often, patients with hypertension visit noncardiologists. The objective of this study is to compare differences by physician specialty in the provision of health care services during office visits for hypertension. The authors examined office visits for US physicians by using data from the National Ambulatory Medical Care Survey for 2003 to 2005. Of more than 274 million hypertension visits, 35.5%, 43.9%, 8.5%, and 12.1% visits were made to general practitioners/family physicians, internists, cardiologists, and other specialties, respectively. Visitors to cardiologists were more likely to have coronary heart disease and heart failure than visitors to other physicians. While prescriptions for antihypertensive drugs overall were similar by specialty, cardiologists were more likely to prescribe lipid-lowering drugs (odds ratio [OR], 1.60; 95% confidence interval [CI], 1.14-2.24) and aspirin (OR, 2.76; 95% CI, 1.81-4.20), calcium channel blockers (OR, 1.48; 95% CI, 1.12-1.96), beta-blockers (OR, 1.83; 95% CI, 1.35-2.48), and alpha-blockers (OR, 2.10; 95% CI, 1.46-2.95) than general practitioners/family physicians after adjusting for relevant risk factors. There was no difference by specialty in providing/making a referral for nutrition/exercise counseling among physicians. Among hypertension office visits in the United States, cardiologists were more likely to provide lipid-lowering drugs, aspirin, calcium channel blocker, beta-blockers, and alpha-blockers than other physicians. J Clin Hypertens (Greenwich). 2010;12:89-95. (C)2009 Wiley Periodicals, Inc. C1 [Fang, Jing; Keenan, Nora L.; Ayala, Carma] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Fang, J (reprint author), Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway NE,MS K-47, Atlanta, GA 30341 USA. EM jfang@cdc.gov NR 36 TC 7 Z9 7 U1 0 U2 0 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1524-6175 J9 J CLIN HYPERTENS JI J. Clin. Hypertens. PD FEB PY 2010 VL 12 IS 2 BP 89 EP 95 DI 10.1111/j.1751-7176.2009.00219.x PG 7 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 547MZ UT WOS:000273895000004 PM 20167031 ER PT J AU Iqbal, N DeBess, EE Wohrle, R Sun, B Nett, RJ Ahlquist, AM Chiller, T Lockhart, SR AF Iqbal, Naureen DeBess, Emilio E. Wohrle, Ron Sun, Ben Nett, Randall J. Ahlquist, Angela M. Chiller, Tom Lockhart, Shawn R. CA Cryptococcus Gattii Publ Hlth Work TI Correlation of Genotype and In Vitro Susceptibilities of Cryptococcus gattii Strains from the Pacific Northwest of the United States SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID BRITISH-COLUMBIA; VANCOUVER-ISLAND; ANTIFUNGAL SUSCEPTIBILITY; 2 VARIETIES; NEOFORMANS; EPIDEMIOLOGY; INFECTION; CANADA; OUTBREAK; FLUCONAZOLE AB Cryptococcus gattii emerged in North America in 1999 as a human and veterinary pathogen on Vancouver Island, British Columbia. The emergent subtype, VGIIa, and the closely related subtype VGIIb can now be found in the United States in Washington, Oregon, and California. We performed multilocus sequence typing and antifungal susceptibility testing on 43 isolates of C. gattii from human patients in Oregon, Washington, California, and Idaho. In contrast to Vancouver Island, VGIIa was the most frequent but not the predominant subtype in the northwest United States. Antifungal susceptibility testing showed statistically significant differences in MICs between the subtypes. This is the first study to apply antifungal susceptibility testing to C. gattii isolates from the Pacific Northwest and the first to make direct comparisons between subtypes. C1 [Nett, Randall J.; Lockhart, Shawn R.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Off Workforce & Career Dev, Atlanta, GA 30333 USA. [Wohrle, Ron] Washington State Dept Hlth, Tumwater, WA USA. [DeBess, Emilio E.] Oregon Dept Human Serv, Portland, OR USA. [Sun, Ben] Calif Dept Publ Hlth, Sacramento, CA USA. [Nett, Randall J.] Idaho Dept Hlth & Welf, Boise, ID USA. RP Lockhart, SR (reprint author), Ctr Dis Control & Prevent, Epidem Intelligence Serv, Off Workforce & Career Dev, 1600 Clifton Rd,Mailstop G-11, Atlanta, GA 30333 USA. EM gyi2@cdc.gov NR 31 TC 57 Z9 57 U1 0 U2 5 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD FEB PY 2010 VL 48 IS 2 BP 539 EP 544 DI 10.1128/JCM.01505-09 PG 6 WC Microbiology SC Microbiology GA 550TB UT WOS:000274151700028 PM 20007380 ER PT J AU Winchell, JM Schwartz, SB AF Winchell, Jonas M. Schwartz, Stephanie B. TI Identification and Classification of P1 Variants of Mycoplasma pneumoniae Reply SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Letter C1 [Winchell, Jonas M.; Schwartz, Stephanie B.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Div Bacterial Dis, Resp Dis Branch, Atlanta, GA 30333 USA. RP Winchell, JM (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Div Bacterial Dis, Resp Dis Branch, 1600 Clifton Rd,NE Mail Stop G-03, Atlanta, GA 30333 USA. EM jwinchell@cdc.gov NR 3 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD FEB PY 2010 VL 48 IS 2 BP 680 EP 680 PG 1 WC Microbiology SC Microbiology GA 550TB UT WOS:000274151700068 ER PT J AU Brown, DW AF Brown, David W. TI Smoking Prevalence among US Veterans SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE smoking; veterans; prevalence; Behavioral Risk Factor Surveillance System ID POSTTRAUMATIC-STRESS-DISORDER; UNITED-STATES; MORTALITY; CESSATION AB BACKGROUND/OBJECTIVE: Cigarette smoking is a significant health problem within the US military. Data from the 2003-2007 Behavioral Risk Factor Surveillance System (BRFSS) were used to estimate and compare the prevalence of smoking among US veterans with that of adults who did not serve in the US armed forces. METHODS: Data from the BRFSS, a state-based random-digit dialed telephone survey supported by the Centers for Disease Control and Prevention, were used to estimate the prevalence of current smoking among adults (aged >= 18 years) who reported ever serving on active duty in the United States Armed Forces. We compared, by birth cohort, age-adjusted smoking prevalence among veterans with that of adults who did not serve in the military. RESULTS: A total of 224,169 US veterans participated during 2003-2007. The age-adjusted prevalence of smoking during the period was 27.0% (standard error, 0.36) among veterans and 21% (0.12) among non-veterans. For both groups, the prevalence decreased across years from 29% (0.79) in 2003 to 25% (0.82) in 2007 among veterans and from 23% (0.29) in 2003 to 20% (0.26) in 2007 among non-veterans. Among veterans, smoking prevalence was highest among men born between 1975-1984 (36%; 90%CI=33.7-37.5) and those born between 1985-1989 (37%; 90%CI=31.7-48.2) with lower prevalences among men born between 1945-1954 (26%; 90%CI=25.1-26.3), 1955-1964 (33%; 90%CI= 32.3-34.3), and 1965-1974 (27%; 90%CI=26.0-28.1). The prevalence of smoking was 43% (90%CI=39.0-47.6) among veterans with self-reported coronary heart disease (CHD), greater than that for non-veterans with CHD (31%; 90%CI=28.6-33.1). CONCLUSIONS: Although the prevalence of smoking has declined among US adults, there are opportunities to further reduce smoking among US veterans, particularly young veterans for whom the prevalence of smoking is similar to that of the US adult population during the late 1960s/early 1970s. Continued work is necessary to target the high smoking prevalence among veterans with CHD, a group for which smoking cessation is especially important. C1 Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. RP Brown, DW (reprint author), Ctr Dis Control & Prevent, 4770 Buford Highway NE,MS K67, Atlanta, GA 30341 USA. EM dbrown6@cdc.gov NR 19 TC 50 Z9 50 U1 3 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD FEB PY 2010 VL 25 IS 2 BP 147 EP 149 DI 10.1007/s11606-009-1160-0 PG 3 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA 558LV UT WOS:000274744800011 PM 19894079 ER PT J AU Fair, AM Wujcik, D Lin, JMS Zheng, W Egan, KM Grau, AM Champion, VL Wallston, KA AF Fair, Alecia Malin Wujcik, Debra Lin, Jin-Mann Sally Zheng, Wei Egan, Kathleen M. Grau, Ana M. Champion, Victoria L. Wallston, Kenneth A. TI Psychosocial Determinants of Mammography Follow-up after Receipt of Abnormal Mammography Results in Medically Underserved Women SO JOURNAL OF HEALTH CARE FOR THE POOR AND UNDERSERVED LA English DT Article DE Medically underinsured; health beliefs; mammography; follow-up studies ID AFRICAN-AMERICAN WOMEN; HEALTH BELIEF MODEL; BREAST-CANCER KNOWLEDGE; LOW-INCOME WOMEN; SCREENING MAMMOGRAPHY; RACIAL-DIFFERENCES; EDUCATIONAL-DIFFERENCES; PATIENT NAVIGATION; REPEAT MAMMOGRAPHY; ETHNIC-DIFFERENCES AB This article targets the relationship between psychosocial determinants and abnormal screening mammography follow-up in a medically underserved population. Health belief scales were modified to refer to diagnostic follow-up versus annual screening. A retrospective cohort study design was used. Statistical analyses were performed examining relationships among sociodemographic factors, psychosocial determinants, and abnormal mammography follow-up. Women with lower mean internal health locus of control scores (3.14) were two times more likely than women with higher mean internal health locus of control scores (3.98) to have inadequate follow-up (OR=2.53, 95% CI = 1.12-5.36). Women with less than a high school education had lower cancer fatalism scores than women who had completed high school (47.5 vs. 55.2, p-value=.02) and lower mean external health locus of control scores (3.0 vs. 5.3) (p-value<.01). These constructs have implications for understanding mammography follow-up among minority and medically underserved women. Further comprehensive study of these concepts is warranted. C1 [Fair, Alecia Malin] Meharry Med Coll, Dept Surg, Nashville, TN 37208 USA. [Wujcik, Debra] Nashville Gen Hosp, Meharry Vanderbilt Canc Partnership, Clin Trials Off, Nashville, TN USA. [Lin, Jin-Mann Sally] Ctr Dis Control & Prevent, Chron Viral Dis Branch, Natl Ctr Zoonot Vector Borne & Enter Dis, Atlanta, GA USA. [Zheng, Wei] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Dept Med,Vanderbilt Epidemiol Ctr, Nashville, TN USA. [Egan, Kathleen M.] Univ S Florida, H Lee Moffitt Canc Ctr, Risk Assessment Detect & Intervent Program, Tampa, FL 33682 USA. [Grau, Ana M.] Vanderbilt Univ, Div Surg Oncol, Nashville, TN USA. [Champion, Victoria L.] Indiana Univ, Sch Nursing, Indianapolis, IN 46204 USA. [Wallston, Kenneth A.] Vanderbilt Sch Nursing, Nashville, TN USA. RP Fair, AM (reprint author), Meharry Med Coll, Dept Surg, 1005 Dr DB Todd Blvd, Nashville, TN 37208 USA. EM afair@mmc.edu FU NCI NIH HHS [U54 CA091408, U54 CA091408-06A1, U54 CA091408-07, U54 CA091408-08, U54 CA091408-09, U54 CA915408-04, U54 CA915408-06]; NCRR NIH HHS [P20 RR011792, P20RR011792] NR 98 TC 14 Z9 14 U1 6 U2 9 PU JOHNS HOPKINS UNIV PRESS PI BALTIMORE PA JOURNALS PUBLISHING DIVISION, 2715 NORTH CHARLES ST, BALTIMORE, MD 21218-4363 USA SN 1049-2089 J9 J HEALTH CARE POOR U JI J. Health Care Poor Underserved PD FEB PY 2010 VL 21 IS 1 SU S BP 71 EP 94 PG 24 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA 557WP UT WOS:000274701100008 PM 20173286 ER PT J AU Ake, JA Massung, RF Whitman, TJ Gleeson, TD AF Ake, Julie A. Massung, Robert F. Whitman, Timothy J. Gleeson, Todd D. TI Difficulties in the diagnosis and management of a US servicemember presenting with possible chronic Q fever SO JOURNAL OF INFECTION LA English DT Article DE Q fever; Endocarditis; Mitral regurgitation; Coxiella burnetii ID FOLLOW-UP; ENDOCARDITIS; MILITARY; FATIGUE; IRAQ AB A 34 year old corpsman developed acute Q fever upon return from Iraq. Subsequent testing demonstrated trace mitral regurgitation and widely discrepant serologic testing results between commercial and reference laboratories. We discuss the dilemma of isolated minor echocardiographic abnormalities and propose caution in the interpretation of Q fever serologic tests. Published by Elsevier Ltd on behalf of The British Infection Society. C1 [Ake, Julie A.] Walter Reed Army Med Ctr, Infect Dis Serv, Washington, DC 20307 USA. [Massung, Robert F.] Ctr Dis Control & Prevent, Rickettsial Zoonoses Branch, Div Viral & Rickettsial Dis, Natl Ctr Zoonot Vector Borne & Enter Dis, Atlanta, GA 30333 USA. [Whitman, Timothy J.; Gleeson, Todd D.] Natl Naval Med Ctr, Div Infect Dis, Bethesda, MD 20889 USA. RP Ake, JA (reprint author), Walter Reed Army Med Ctr, Infect Dis Serv, 6900 Georgia Ave, Washington, DC 20307 USA. EM julie.ake@amedd.army.mil NR 13 TC 11 Z9 11 U1 0 U2 0 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 0163-4453 J9 J INFECTION JI J. Infect. PD FEB PY 2010 VL 60 IS 2 BP 175 EP 177 DI 10.1016/j.jinf.2009.09.010 PG 3 WC Infectious Diseases SC Infectious Diseases GA 552IH UT WOS:000274282400013 PM 19766138 ER PT J AU Correia, JB Patel, MM Nakagomi, O Montenegro, FMU Germano, EM Correia, NB Cuevas, LE Parashar, UD Cunliffe, NA Nakagomi, T AF Correia, Jailson B. Patel, Manish M. Nakagomi, Osamu Montenegro, Fernanda M. U. Germano, Eliane M. Correia, Nancy B. Cuevas, Luis E. Parashar, Umesh D. Cunliffe, Nigel A. Nakagomi, Toyoko TI Effectiveness of Monovalent Rotavirus Vaccine (Rotarix) against Severe Diarrhea Caused by Serotypically Unrelated G2P[4] Strains in Brazil SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID 1ST 2 YEARS; RHESUS-HUMAN; DOUBLE-BLIND; EFFICACY; REASSORTANT; SAFETY; CHILDREN; GASTROENTERITIS; POPULATION; INFANTS AB Background. In a Latin American trial, a monovalent G1P[8] rotavirus vaccine showed high efficacy against severe rotavirus diarrhea. Protection was lower against serotypically unrelated G2P[4] strains, which circulated infrequently. This case-control study was undertaken to assess the effectiveness of this monovalent G1P[8] rotavirus vaccine against G2P[4] strains in Brazil. Methods. Case patients were children with severe G2P[4] rotavirus diarrhea who presented at a hospital in Recife, Brazil, from March 2006 through September 2008. Vaccination rates among case patients were compared with rates among 2 groups of control participants-children with rotavirus-negative diarrhea and children admitted for acute respiratory tract infection (ARI)-to calculate vaccine effectiveness, after controlling for the birth month and year. Results. We enrolled 70 G2P[4] rotavirus-positive case patients with severe diarrhea, 484 rotavirus-negative control participants with diarrhea, and 416 control participants with ARI, aged >= 6 months. Among children aged 6-11 months, the effectiveness of the vaccine against G2P[4] diarrhea was 77% (95% confidence interval [CI], 42%-91%) and 77% (95% CI, 43%-90%) among the rotavirus-negative control participants with diarrhea and control participants with ARI, respectively. Vaccine effectiveness in children aged >= 12 months decreased to -24% (95% CI, -190% to 47%) and 15% (95% CI, -101 to 64) among the rotavirus-negative control groups with diarrhea and ARI, respectively. Conclusions. This monovalent G1P[8] rotavirus vaccine was effective against severe G2P[4] rotavirus diarrhea among children aged 6-11 months. Effectiveness declined among children aged >= 12 months, which suggests waning immunity. C1 [Nakagomi, Toyoko] Nagasaki Univ, Dept Mol Microbiol & Immunol, Grad Sch Biomed Sci, Nagasaki 8528523, Japan. [Nakagomi, Osamu; Nakagomi, Toyoko] Nagasaki Univ, Global Ctr Excellence, Nagasaki 8528523, Japan. [Correia, Jailson B.; Montenegro, Fernanda M. U.; Germano, Eliane M.; Correia, Nancy B.] Inst Med Integral Prof Fernando Figueira, Recife, PE, Brazil. [Patel, Manish M.; Parashar, Umesh D.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Nakagomi, Osamu; Cunliffe, Nigel A.; Nakagomi, Toyoko] Univ Liverpool, Dept Med Microbiol, Liverpool L69 3BX, Merseyside, England. [Cuevas, Luis E.] Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England. RP Nakagomi, T (reprint author), Nagasaki Univ, Dept Mol Microbiol & Immunol, Grad Sch Biomed Sci, 1-12-4 Sakamoto, Nagasaki 8528523, Japan. EM tnakagom@nagasaki-u.ac.jp OI Cunliffe, Nigel/0000-0002-5449-4988; Cuevas, Luis E./0000-0002-6581-0587 FU Program for Appropriate Technology in Health; Global Alliance for Vaccines and Immunization; Global Centre of Excellence, Nagasaki University; Japan Society for the Promotion of Science; Japan Anti-Tuberculosis Association; National Council for Scientific and Technological Development of Brazil FX Financial support: The Program for Appropriate Technology in Health, the Global Alliance for Vaccines and Immunization, the Global Centre of Excellence, Nagasaki University, Japan Society for the Promotion of Science, Japan Anti-Tuberculosis Association, and National Council for Scientific and Technological Development of Brazil. The funding sources had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 28 TC 117 Z9 120 U1 0 U2 4 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD FEB 1 PY 2010 VL 201 IS 3 BP 363 EP 369 DI 10.1086/649843 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 541SO UT WOS:000273441000008 PM 20047501 ER PT J AU Hagan, H Pouget, ER Williams, IT Garfein, RL Strathdee, SA Hudson, SM Latka, MH Ouellet, LJ AF Hagan, Holly Pouget, Enrique R. Williams, Ian T. Garfein, Richard L. Strathdee, Steffanie A. Hudson, Sharon M. Latka, Mary H. Ouellet, Lawrence J. TI Attribution of Hepatitis C Virus Seroconversion Risk in Young Injection Drug Users in 5 US Cities SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article ID AUDIO COMPUTER; PREVALENCE; COHORT; INFECTION; HIV; PREVENTION; AUSTRALIA; EQUIPMENT; INTERVENTION; TRANSMISSION AB Background. In studies of hepatitis C virus (HCV) seroconversion in injection drug users (IDUs), some have questioned whether underreporting of syringe sharing, a stigmatized behavior, has led to misattribution of HCV risk to other injection-related behaviors. Methods. IDUs aged 15-30 years who were seronegative for human immunodeficiency virus and HCV antibodies were recruited into a prospective study in 5 US cities. Behavioral data were collected via computer-assisted self-interviewing to reduce socially desirable reporting. Hazard ratios (HRs) were estimated to assess associations between behavior and HCV seroconversion. Because the shared use of cookers, cottons, and rinse water was highly correlated, a summary variable was created to represent drug preparation equipment sharing. Results. Among 483 IDUs who injected during the period covered by the follow-up assessments, the incidence of HCV infection was 17.2 cases per 100 person years; no HIV seroconversions occurred. Adjusting for confounders, the shared use of drug preparation equipment was significantly associated with HCV seroconversion (adjusted HR, 2.66; 95% confidence interval, 1.03-23.92), but syringe sharing was not (adjusted HR, 0.91). We estimated that 37% of HCV seroconversions in IDUs were due to the sharing of drug preparation equipment. Conclusions. Associations between sharing drug preparation equipment and HCV seroconversion are not attributable to underascertainment of syringe sharing. Avoiding HCV infection will require substantial reductions in exposure to all sources of contaminated blood. C1 [Hagan, Holly] NYU, Coll Nursing, New York, NY 10003 USA. [Pouget, Enrique R.] Natl Dev & Res Inst, New York, NY USA. [Williams, Ian T.; Garfein, Richard L.] Ctr Dis Control & Prevent, Natl Ctr Zoonot Vector Borne & Enter Dis, Atlanta, GA USA. [Williams, Ian T.; Garfein, Richard L.] Ctr Dis Control & Prevent, Natl Ctr HIV Hepatitis STD & TB Prevent, Atlanta, GA USA. [Garfein, Richard L.; Strathdee, Steffanie A.] Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA. [Hudson, Sharon M.] Hlth Res Assoc, Los Angeles, CA USA. [Ouellet, Lawrence J.] Univ Illinois, Sch Publ Hlth, Chicago, IL USA. [Latka, Mary H.] Aurum Inst Hlth Res, Johannesburg, South Africa. RP Hagan, H (reprint author), NYU, Coll Nursing, 246 Greene St,Rm 409W, New York, NY 10003 USA. EM hh50@nyu.edu FU Division of HIV/AIDS Prevention; Division of Viral Hepatitis; Centers for Disease Control and Prevention [U64/CCU317662, U64/CCU517656, U64/CCU917655, U64/CCU217659, U64/CCU017615] FX Financial support: Division of HIV/AIDS Prevention and Division of Viral Hepatitis, Centers for Disease Control and Prevention (grants U64/CCU317662, U64/CCU517656, U64/CCU917655, U64/CCU217659, and U64/CCU017615). NR 34 TC 62 Z9 62 U1 0 U2 2 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 0022-1899 J9 J INFECT DIS JI J. Infect. Dis. PD FEB 1 PY 2010 VL 201 IS 3 BP 378 EP 385 DI 10.1086/649783 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 541SO UT WOS:000273441000010 PM 20053137 ER PT J AU Sejvar, JJ Davis, LE Szabados, E Jackson, AC AF Sejvar, James J. Davis, Larry E. Szabados, Erica Jackson, Alan C. TI Delayed-onset and recurrent limb weakness associated with West Nile virus infection SO JOURNAL OF NEUROVIROLOGY LA English DT Article DE myelitis; neuroinvasive disease; poliomyelitis; West Nile virus ID GUILLAIN-BARRE-SYNDROME; ACUTE FLACCID PARALYSIS; SPINAL-CORD; POLIOMYELITIS; EXCITOTOXICITY; DEATH; POLYNEUROPATHY; SPECTRUM; CRITERIA; NEURONS AB Human neurologic illness following infection with West Nile virus (WNV) may include meningitis, encephalitis, and acute flaccid paralysis (AFP). Most WNV-associated AFP is due to involvement of the spinal motor neurons producing an anterior (polio)myelitis. WNV poliomyelitis is typically characterized by acute and rapidly progressing limb weakness occurring early in the course of illness, which is followed by death or clinical plateauing with subsequent improvement to varying degrees. We describe four cases of WNV poliomyelitis in which the limb weakness was characterized by an atypical temporal pattern, including one case with onset several weeks after illness onset, and three cases developing relapsing or recurrent limb weakness following a period of clinical plateauing or improvement. Delayed onset or recurrent features may be due to persistence of viral infection or delayed neuroinvasion with delayed injury by excitotoxic or other mechanisms, by immune-mediated mechanisms, or a combination thereof. Further clinical and pathogenesis studies are needed to better understand the mechanisms for these phenomena. Clinicians should be aware of these clinical patterns in patients with WNV poliomyelitis. C1 [Sejvar, James J.] Ctr Dis Control & Prevent, Div Viral & Rickettsial Dis, Div Vector Borne Infect Dis, Natl Ctr Zoonot Vectorborne & Enter Dis, Atlanta, GA 30333 USA. [Davis, Larry E.] New Mexico VA Hlth Care Syst, Neurol Serv, Albuquerque, NM USA. [Davis, Larry E.] Univ New Mexico, Sch Med, Dept Neurol, Albuquerque, NM 87131 USA. [Szabados, Erica] Brown Univ, Warren Alpert Med Sch, Dept Clin Neurosci Neurol Clin, Providence, RI 02912 USA. [Jackson, Alan C.] Univ Manitoba, Dept Internal Med Neurol, Winnipeg, MB, Canada. [Jackson, Alan C.] Univ Manitoba, Dept Med Microbiol, Winnipeg, MB, Canada. RP Sejvar, JJ (reprint author), Ctr Dis Control & Prevent, Div Viral & Rickettsial Dis, Div Vector Borne Infect Dis, Natl Ctr Zoonot Vectorborne & Enter Dis, 1600 Clifton Rd,Mailstop A-39, Atlanta, GA 30333 USA. EM zea3@cdc.gov OI Jackson, Alan/0000-0003-0413-4236 NR 37 TC 9 Z9 9 U1 2 U2 3 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 1355-0284 J9 J NEUROVIROL JI J. Neurovirol. PD FEB PY 2010 VL 16 IS 1 BP 93 EP 100 DI 10.3109/13550280903586378 PG 8 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA 563EM UT WOS:000275110700011 PM 20166837 ER PT J AU Thomas, GA Delaney, LJ Mueller, C Page, E AF Thomas, Gregory A. Delaney, Lisa J. Mueller, Charles Page, Elena TI Evaluation of Coumaphos Exposure Among Tick Eradication Workers SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article AB Objective: To evaluate both the cholinesterase monitoring program and newer field methods of determining coumaphos exposure among tick eradication workers. Methods: Measured blood cholinesterase by the Ellman and field testing methods and tested urine for chlorferon pre- and postshift; conducted personal air sampling, patch sampling of clothing, and wipe sampling of hands for coumaphos. Results: Fifteen workers had normal plasma cholinesterase and acetylcholinesterase levels. No significant changes occurred pre- to postshift. High correlation was found between plasma cholinesterase and acetylcholinesterase levels by field testing and Ellman methods (r = 0.91. P < 0.01 and r = 0.63, P < 0.01. respectively). Chlorferon levels rose 4 to 6 hours after use (P < 0.01). Airborne coumaphos was detected in only one sample, in a trace amount. The majority of patch and hand wipe samples detected coumaphos. Conclusions: Dermal exposure to coumaphos resulted in significant increases in urinary metabolites of coumaphos. C1 [Page, Elena] NIOSH, CDC, Div Surveillance Hazard Evaluat & Field Studies, Cincinnati, OH 45226 USA. RP Page, E (reprint author), NIOSH, CDC, Div Surveillance Hazard Evaluat & Field Studies, 4676 Columbia Pkwy,Mailstop R-10, Cincinnati, OH 45226 USA. EM epage@cdc.gov NR 11 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1076-2752 J9 J OCCUP ENVIRON MED JI J. Occup. Environ. Med. PD FEB PY 2010 VL 52 IS 2 BP 131 EP 136 DI 10.1097/JOM.0b013e3181cd7e80 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 555ET UT WOS:000274491600003 PM 20134347 ER PT J AU Dang, B Chen, LL Mueller, C Dunn, KH Almaguer, D Roberts, JL Otto, CS AF Dang, Bich Chen, Lilia Mueller, Charles Dunn, Kevin H. Almaguer, Daniel Roberts, Jennifer L. Otto, Charles S. TI Ocular and Respiratory Symptoms Among Lifeguards at a Hotel Indoor Waterpark Resort SO JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE LA English DT Article ID SWIMMING-POOL; NITROGEN TRICHLORIDE; EXPOSURE; CHLORAMINES; CHLORINE AB Objectives: To determine the cause of eye and respiratory irritation symptoms among lifeguards at an indoor waterpark. Methods: Investigators 1) performed environmental sampling for chloramine, endotoxin, and microbials; 2) administered symptom questionnaires; 3) reviewed ventilation system designs: and 4) reviewed water chemistry. Results: Airborne trichloramine concentrations were found at levels reported to cause irritation symptoms in other studies. Some endotoxin concentrations were found at levels associated with cough and fever in previous studies. Exposed lifeguards were significantly more likely to report work-related irritation symptoms than unexposed individuals. The ventilation system may not have provided sufficient air movement and distribution to adequately capture and remove air contaminants at deck level. No water microbes were detected, and water chemistry met state standards. Conclusions: Indoor waterparks need to control water chemistry and ensure adequate air movement and distribution to control air contaminants and reduce health symptoms. C1 [Chen, Lilia] NIOSH, Ctr Dis Control & Prevent, CDC, Div Surveillance Hazard Evaluat & Field Studies, Cincinnati, OH 45226 USA. [Dunn, Kevin H.; Almaguer, Daniel; Roberts, Jennifer L.] Natl Ctr Environm Hlth, CDC, Div Appl Res & Technol, Atlanta, GA USA. [Otto, Charles S.] Natl Ctr Environm Hlth, CDC, Div Emergency & Environm Hlth Serv, Atlanta, GA USA. RP Chen, LL (reprint author), NIOSH, Ctr Dis Control & Prevent, CDC, Div Surveillance Hazard Evaluat & Field Studies, 4676 Columbia Pkwy,MS-R11, Cincinnati, OH 45226 USA. EM Lchen4@cdc.gov RI Dunn, Kevin/I-2195-2012 NR 26 TC 12 Z9 14 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 1076-2752 J9 J OCCUP ENVIRON MED JI J. Occup. Environ. Med. PD FEB PY 2010 VL 52 IS 2 BP 207 EP 213 DI 10.1097/JOM.0b013e3181cf00d5 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 555ET UT WOS:000274491600013 PM 20134344 ER PT J AU Kodadkova, A Kvac, M Ditrich, O Sak, B Xiao, L AF Kodadkova, A. Kvac, M. Ditrich, Oleg Sak, B. Xiao, L. TI Cryptosporidium muris in a Reticulated Giraffe (Giraffa camelopardalis reticulata) SO JOURNAL OF PARASITOLOGY LA English DT Article ID BARCELONA ZOO; MOLECULAR CHARACTERIZATION; LISBON-ZOO; NEW-YORK; GENOTYPES; RUMINANTS; GIARDIA; MAMMALS; SPP.; ANIMALS AB Cryptosporidium spp. infection in captive exotic mammals was investigated using staining and molecular biological methods. A total of 323 fecal samples from 100 mammalian species (62 Artiodactyla, 33 Rodentia, 3 Perissodactyla, and 2 Paenungultata) in 4 zoological gardens in the Czech Republic was examined. Only in a reticulated giraffe (Giraffa camelopardalis reticulata) sample was Cryptosporidium sp. infection detected. The partial small subunit rRNA sequence obtained from the isolate was identical to sequences of Cryptosporidium muris in rock hyrax (Procavia capensis) and Bactrian camel (Camelus bactrianus). Neonatal BALB/c mice inoculated with 1 x 10(3) fresh oocysts of the C. minis giraffe isolate did not produce a detectable infection. C1 [Kodadkova, A.] Univ S Bohemia, Fac Sci, Ceske Budejovice 37005, Czech Republic. [Kvac, M.] Univ S Bohemia, Fac Agr, Ceske Budejovice 37005, Czech Republic. [Ditrich, Oleg; Sak, B.] Acad Sci Czech Republic, Ctr Biol, Inst Parasitol, Ceske Budejovice 37005, Czech Republic. [Xiao, L.] Ctr Dis Control & Prevent, Div Parasit Dis, Natl Ctr Zoonot Vector Borne & Enter Dis, Dept Hlth & Human Serv, Atlanta, GA 30341 USA. RP Kodadkova, A (reprint author), Univ S Bohemia, Fac Sci, Branisovska 31, Ceske Budejovice 37005, Czech Republic. EM casio@paru.cas.cz RI Xiao, Lihua/B-1704-2013; Kvac, Martin/G-7299-2014; Sak, Bohumil/G-9262-2014; Kodadkova, Alena/L-9740-2015 OI Xiao, Lihua/0000-0001-8532-2727; Kvac, Martin/0000-0003-0013-6090; FU Czech Science Foundation [524/05/0992, 523/07/P117]; Institute of Parasitology, Czechs Academy of Sciences [Z60220518] FX We thank the staff of the zoological gardens participated in the study for assistance its animal sampling, especially Ludek Culik., Pavel Brandl. Svatopluk Jerab, Pavel Moucha, Tomas Pes, and Jaroslav Simek. The study was supported in part by a grant from the Czech Science Foundation (524/05/0992 and 523/07/P117) and by the Institute of Parasitology, Czechs Academy of Sciences (Z60220518). The findings and conclusions in this publication are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. NR 26 TC 8 Z9 9 U1 1 U2 8 PU AMER SOC PARASITOLOGISTS PI LAWRENCE PA 810 EAST 10TH STREET, LAWRENCE, KS 66044 USA SN 0022-3395 J9 J PARASITOL JI J. Parasitol. PD FEB PY 2010 VL 96 IS 1 BP 211 EP 212 DI 10.1645/GE-2212.1 PG 2 WC Parasitology SC Parasitology GA 579ZZ UT WOS:000276417400033 PM 19685941 ER PT J AU McHenry, AM Barnwell, JW Adams, JH AF McHenry, A. M. Barnwell, J. W. Adams, J. H. TI Plasmodium vivax DBP Binding to Aotus nancymaae Erythrocytes Is Duffy Antigen Dependent SO JOURNAL OF PARASITOLOGY LA English DT Article ID MEROZOITE SURFACE PROTEIN-1; BLOOD-GROUP; MALARIA MEROZOITES; CELL INVASION; FALCIPARUM; MONKEYS; PARASITES; KNOWLESI; IDENTIFICATION; SPECIFICITY AB Plasmodium vivax is the second leading cause of malaria worldwide. Invasion of human erythrocytes by P. vivax merozoites is dependent upon the interaction between the parasite Duffy binding protein (PvDBP) and the erythrocyte Duffy antigen receptor. Therefore. disruption of this vital interaction is an attractive target for therapeutic intervention. Although Aotus nancymaae is a commonly used primate model for human P. vivax infections, it has not been confirmed that the interaction between Ao. nancymaae erythrocytes and P. vivax is Duffy antigen dependent. Our results indicate that normal Ao. nancymaae. erythrocytes readily bind to PvDBPII and that this binding is completely abolished with chymotrypsin treatment of the erythrocytes. Furthermore, the results of our inhibition assays show a dose-dependent decrease in binding with increasing amounts of anti-PvDBPII polyclonal rabbit sera or anti-Fy6 monoclonal antibody. These data indicate that the interaction between Ao, nancymaae erythrocytes and P. vivax DBPII is Duffy antigen dependent, validating this model system for in vivo studies of anti-PvDBP inhibition. C1 [Adams, J. H.] Univ S Florida, Global Hlth Infect Dis Res Program, Tampa, FL 33612 USA. [McHenry, A. M.] Univ Notre Dame, Dept Biol Sci, Notre Dame, IN 46556 USA. [Barnwell, J. W.] Ctr Dis Control & Prevent, Div Parasit Dis, Atlanta, GA 30333 USA. RP Adams, JH (reprint author), Univ S Florida, Global Hlth Infect Dis Res Program, Tampa, FL 33612 USA. EM jadams3@usf.health.edu RI Adams, John/G-1800-2015 OI Adams, John/0000-0003-3707-7979 FU National Institutes of Health [R01 AI064478]; Arthur J. Schmitt Presidential Fellowship FX We would like to thank Christopher L. King of Case Western Reserve University, Cleveland. Ohio, for providing the anti-PvDBPII rabbit sera. This work was funded. in part, by a National Institutes of Health grant (R01 AI064478) to J.H.A. and an Arthur J. Schmitt Presidential Fellowship to A.M.M. NR 28 TC 3 Z9 3 U1 1 U2 2 PU AMER SOC PARASITOLOGISTS PI LAWRENCE PA 810 EAST 10TH STREET, LAWRENCE, KS 66044 USA SN 0022-3395 J9 J PARASITOL JI J. Parasitol. PD FEB PY 2010 VL 96 IS 1 BP 225 EP 227 DI 10.1645/GE-2281.1 PG 3 WC Parasitology SC Parasitology GA 579ZZ UT WOS:000276417400038 PM 19799492 ER PT J AU Lomenick, JP Calafat, AM Castro, MSM Mier, R Stenger, P Foster, MB Wintergerst, KA AF Lomenick, Jefferson P. Calafat, Antonia M. Castro, Maria S. Melguizo Mier, Richard Stenger, Peggy Foster, Michael B. Wintergerst, Kupper A. TI Phthalate Exposure and Precocious Puberty in Females SO JOURNAL OF PEDIATRICS LA English DT Article ID IN-VITRO; ESTROGENIC ACTIVITY; HUMAN URINE; US GIRLS; AGE; MENARCHE; METABOLITES; ESTERS; RACE; PHYTOESTROGENS AB Objective To determine whether phthalate exposure is associated with precocious puberty in girls. Study design This was a multicenter cross-sectional study in which 28 girls with central precocious puberty (CPP) and 28 age- and race-matched prepubertal females were enrolled. Nine phthalate metabolites and creatinine were measured in spot urine samples from these 56 children. Results Levels of 8 of the 9 phthalate metabolites were above the limit of detection (LOD) in all 56 subjects. Mono (2-ethylhexyl) phthalate (MEHP) was below the LOD in 25/56 samples (14 subjects with precocious puberty and 11 controls). No significant differences between the children with CPP and the controls in either absolute or creatinine-normalized concentrations of any of the 9 phthalate metabolites were measured. Conclusions Although phthalates may be associated with certain other toxicities in humans, our study suggests that their exposure is not associated with precocious puberty in female children. (J Pediatr 2010;156:221-5). C1 [Lomenick, Jefferson P.; Castro, Maria S. Melguizo; Mier, Richard] Univ Kentucky, Coll Med, Dept Pediat, Lexington, KY USA. [Lomenick, Jefferson P.] Univ Kentucky, Coll Med, Div Endocrinol, Lexington, KY USA. [Calafat, Antonia M.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Stenger, Peggy] Cincinnati Childrens Hosp Med Ctr, Div Pediat Endocrinol, Cincinnati, OH USA. [Foster, Michael B.; Wintergerst, Kupper A.] Univ Louisville, Sch Med, Div Pediat Endocrinol, Louisville, KY 40292 USA. RP Lomenick, JP (reprint author), Vanderbilt Univ, Div Endocrinol, Sch Med, 11136 Doctors Off Tower,2200 Childrens Way, Nashville, TN 37232 USA. EM jefferson.lomenick@vanderbilt.edu NR 33 TC 34 Z9 35 U1 4 U2 16 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-3476 J9 J PEDIATR-US JI J. Pediatr. PD FEB PY 2010 VL 156 IS 2 BP 221 EP 225 DI 10.1016/j.jpeds.2009.09.047 PG 5 WC Pediatrics SC Pediatrics GA 549LW UT WOS:000274051500014 PM 19892364 ER PT J AU Stevens, JA Teh, SL Haileyesus, T AF Stevens, Judy A. Teh, S. L. Haileyesus, Tadesse TI Dogs and cats as environmental fall hazards SO JOURNAL OF SAFETY RESEARCH LA English DT Article DE Cats; Dogs; Falls; Injury; Pets AB Problem Falls are the leading cause of non-fatal injuries in the United States This study assessed the prevalence of fall injuries associated with cats and dogs in the United States and describes the types of injuries sustained, the location. activity. and circumstances under which they occurred Methods Data were from a nationally representative sample of emergency department visits from January 1, 2001 to December 31, 2006, available through the National Electronic Injury Surveillance System All Injury Program (NEISS-AIP). Results: Based on 7.456 cases, an estimated 86,629 fall injuries each year were associated with cats and dogs, for an injury rate of 297 there were 75 times as many injuries involving dogs as cats and females were 2 1 times more likely to be injured than males. Injury rates were highest among people aged >= 75, but pets were a fall hazard for all ages Fractures and contusions or abrasions were the most common injuries, the highest rates were for injuries to the extremities About 66 4% of falls associated with cats and 31 3 % of falls associated with dogs were caused by falling or tripping over the pet An additional 21 2% of falls related to clogs were caused by being pushed or pulled Summary Although pets were associated with fall injuries, this risk can be reduced by increasing public awareness about situations that can lead to falls, such as dog-walking and chasing pets, and by calling attention to the importance of obedience training for dogs to minimize hazardous behaviors such as pulling and pushing Impact On industry Fall injuries represent a burden to individuals. our society and our health care system Increasing public awareness and implementing basic prevention strategies can help people of all ages enjoy then pets, reduce their chances of experiencing pet-related falls, and lessen the impact of fall injuries on our health care system National Safety Council and Elsevier Ltd All rights reserved C1 [Stevens, Judy A.; Teh, S. L.; Haileyesus, Tadesse] Natl Ctr Injury Prevent & Control, Div Unintent Injury Prevent, Atlanta, GA 30341 USA. RP Stevens, JA (reprint author), Natl Ctr Injury Prevent & Control, Div Unintent Injury Prevent, 4770 Buford Highway NE,MS F-62, Atlanta, GA 30341 USA. NR 9 TC 4 Z9 4 U1 0 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-4375 J9 J SAFETY RES JI J. Saf. Res. PD FEB PY 2010 VL 41 IS 1 BP 69 EP 73 DI 10.1016/j.jsr.2010.01.001 PG 5 WC Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation SC Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation GA 588UN UT WOS:000277099700011 PM 20226954 ER PT J AU Bugarski, AD Cauda, EG Janisko, SJ Hummer, JA Patts, LD AF Bugarski, Aleksandar D. Cauda, Emanuele G. Janisko, Samuel J. Hummer, Jon A. Patts, Larry D. TI Aerosols Emitted in Underground Mine Air by Diesel Engine Fueled with Biodiesel SO JOURNAL OF THE AIR & WASTE MANAGEMENT ASSOCIATION LA English DT Article ID SIZE DISTRIBUTION; EMISSIONS; INJECTION; EXHAUST; HEALTH; IMPACT AB Using biodiesel in place of petroleum diesel is considered by several underground metal and nonmetal mine operators to be a viable strategy for reducing the exposure of miners to diesel particulate matter. This study was conducted in an underground experimental mine to evaluate the effects of soy methyl ester biodiesel on the concentrations and size distributions of diesel aerosols and nitric oxides in mine air. The objective was to compare the effects of neat and blended biodiesel fuels with those of ultralow sulfur petroleum diesel. The evaluation was performed using a mechanically controlled, naturally aspirated diesel engine equipped with a muffler and a diesel oxidation catalyst. The effects of biodiesel fuels on size distributions and number and total aerosol mass concentrations were found to be strongly dependent on engine operating conditions. When fueled with biodiesel fuels, the engine contributed less to elemental carbon concentrations for all engine operating modes and exhaust configurations. The substantial increases in number concentrations and fraction of organic carbon (OC) in total carbon over the baseline were observed when the engine was fueled with biodiesel fuels and operated at light-load operating conditions. Size distributions for all test conditions were found to be single modal and strongly affected by engine operating conditions, fuel type, and exhaust configuration. The peak and total number concentrations as well as median diameter decreased with an increase in the fraction of biodiesel in the fuels, particularly for high-load operating conditions. The effects of the diesel oxidation catalyst, commonly deployed to counteract the potential increase in OC emissions due to use of biodiesel, were found to vary depending upon fuel formulation and engine operating conditions. The catalyst was relatively effective in reducing aerosol number and mass concentrations, particularly at light-load conditions, but also showed the potential for an increase in nitrogen dioxide concentrations at high-load modes. C1 [Bugarski, Aleksandar D.; Cauda, Emanuele G.; Janisko, Samuel J.; Hummer, Jon A.; Patts, Larry D.] NIOSH, US Dept HHS, Publ Hlth Serv, Ctr Dis Control & Prevent,Pittsburgh Res Lab, Pittsburgh, PA USA. RP Bugarski, AD (reprint author), 626 Cochrans Mill Rd,POB 18070, Pittsburgh, PA 15236 USA. EM abugarski@cdc.gov NR 24 TC 12 Z9 13 U1 0 U2 8 PU AIR & WASTE MANAGEMENT ASSOC PI PITTSBURGH PA ONE GATEWAY CENTER, THIRD FL, PITTSBURGH, PA 15222 USA SN 1047-3289 J9 J AIR WASTE MANAGE JI J. Air Waste Manage. Assoc. PD FEB PY 2010 VL 60 IS 2 BP 237 EP 244 DI 10.3155/1047-3289.60.2.237 PG 8 WC Engineering, Environmental; Environmental Sciences; Meteorology & Atmospheric Sciences SC Engineering; Environmental Sciences & Ecology; Meteorology & Atmospheric Sciences GA 552RA UT WOS:000274309900014 PM 20222537 ER PT J AU Counard, CA Perz, JF Linchangco, PC Christiansen, D Ganova-Raeva, L Xia, GL Jones, S Vernon, MO AF Counard, Catherine A. Perz, Joseph F. Linchangco, Purisima C. Christiansen, Demian Ganova-Raeva, Lilia Xia, Guoliang Jones, Steven Vernon, Michael O. TI Acute Hepatitis B Outbreaks Related to Fingerstick Blood Glucose Monitoring in Two Assisted Living Facilities SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE Hepatitis B virus; disease outbreaks; diabetes; elderly; assisted living facility ID VIRUS-INFECTION; TRANSMISSION AB OBJECTIVES: To establish the etiology for outbreaks of hepatitis B virus (HBV) infections at two assisted living facilities (ALFs) and devise appropriate control measures. DESIGN: Multisite outbreak investigations, retrospective cohort. SETTING: Two ALFs in Illinois. PARTICIPANTS: Facility A residents (n = 120) and Facility B residents (n = 105) and nursing staff (n = 6). MEASUREMENTS: For Facility A, a retrospective cohort study to identify risk factors for HBV infection through serological testing of all residents and a medical record extraction. For Facility A and B, investigation of fingerstick blood glucose monitoring techniques. For Facility B, serological HBV testing of nurses and residents receiving fingerstick blood glucose monitoring. RESULTS: At Facility A, five confirmed acute, two probable acute, and one probable chronic HBV infections were identified in the 109 residents tested. All of the eight identified residents with HBV infection had diabetes mellitus. HBV deoxyribonucleic acid (DNA) sequences from the chronic and acute cases were identical. Transmission of HBV was associated with fingerstick blood glucose monitoring (relative risk (RR) = 28.5, 95% confidence interval (CI) = 1.6-498; P < .001) and insulin injections (RR = 7.4, 95% CI = 1.3-40.8; P = .03). At Facility B, seven of 21 residents (33.3%) receiving fingerstick blood glucose monitoring had evidence of recent HBV infection. CONCLUSION: Nurses probably transmitted HBV infection from resident to resident during fingerstick blood glucose monitoring in two separate ALFs, causing outbreaks. Awareness of the high risk for HBV transmission during procedures for the care of diabetes mellitus was limited. Following established infection control measures is critical to prevent spread of this highly contagious virus. J Am Geriatr Soc 58:306-311, 2010. C1 [Counard, Catherine A.; Linchangco, Purisima C.; Christiansen, Demian; Jones, Steven; Vernon, Michael O.] Cook Cty Dept Publ Hlth, Communicable Dis Control Unit, Oak Pk, IL USA. [Perz, Joseph F.] Natl Ctr Preparedness Detect & Control Infect Dis, Div Healthcare Qual Promot, Atlanta, GA USA. [Ganova-Raeva, Lilia; Xia, Guoliang] Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. RP Counard, CA (reprint author), Skokie Hlth Dept, 5127 Oakton St, Skokie, IL 60077 USA. EM catherine.counard@skokie.org NR 17 TC 14 Z9 14 U1 0 U2 2 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 0002-8614 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD FEB PY 2010 VL 58 IS 2 BP 306 EP 311 DI 10.1111/j.1532-5415.2009.02669.x PG 6 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA 551CQ UT WOS:000274183800012 PM 20070418 ER PT J AU Parekh, BS Anyanwu, J Patel, H Downer, M Kalou, M Gichimu, C Keipkerich, BS Clement, N Omondi, M Mayer, O Ou, CY Nkengasong, JN AF Parekh, Bharat S. Anyanwu, Juliana Patel, Hetal Downer, Marie Kalou, Mireille Gichimu, Catherine Keipkerich, Bera Steven Clement, Nelly Omondi, Michael Mayer, Oren Ou, Chin-Yih Nkengasong, John N. TI Dried tube specimens: A simple and cost-effective method for preparation of HIV proficiency testing panels and quality control materials for use in resource-limited settings SO JOURNAL OF VIROLOGICAL METHODS LA English DT Article DE HIV; Proficiency testing; External quality assessment; Quality assurance; Dried tube specimens (DTS) ID CLINICAL-TRIALS GROUP; ASSURANCE PROGRAM; IMMUNODEFICIENCY; PERFORMANCE; ASSAYS; PCR AB HIV testing has rapidly expanded worldwide, but proficiency testing (PT) programs to monitor and improve the quality of testing are often lacking in resource-limited settings (RLS). Traditional PT programs and quality control reagents use serum or plasma specimens requiring stringent conditions for storage and transportation. A novel, simple and easy to use approach, based on dried tube specimens (DTS), was developed that can help monitor the quality of HIV antibody testing in RLS. DTS were prepared by drying 20 mu 1 of specimen overnight at room temperature. The addition of a green dye (0.1 %) made the DTS pellets visible without affecting the test results. Before testing, the DTS were rehydrated with 200 mu 1 of PBS-Tween buffer. A panel of 303 DTS samples (135 HIV positive and 168 HIV negative) was evaluated with two rapid tests. Sensitivity and specificity with the Determine HIV-1/2 test were 99.3% and 99.4%, respectively, and with OraQuick were 98.5% and 100%, respectively. Stability studies showed that HIV-specific antibodies in the DTS specimens were stable at 4 degrees C and 25 degrees C for 4 weeks, with only marginal decline at 37 degrees C and 45 degrees C over 4 weeks. The DTS-based PT program was piloted successfully in 24 testing sites in Kenya. Results demonstrate that the DTS is a simple to use, practical method to prepare and distribute PT panels and quality control specimens to monitor HIV testing practices in RLS. Published by Elsevier B.V. C1 [Parekh, Bharat S.; Anyanwu, Juliana; Patel, Hetal; Downer, Marie; Kalou, Mireille; Omondi, Michael; Mayer, Oren; Ou, Chin-Yih; Nkengasong, John N.] Ctr Dis Control & Prevent, Int Lab Branch, Div Global AIDS, Atlanta, GA 30345 USA. [Gichimu, Catherine; Keipkerich, Bera Steven; Clement, Nelly] Natl Publ Hlth Lab, Nairobi, Kenya. [Downer, Marie] CDC Cambodia, Sangkat Wat Phnom, Cambodia. RP Parekh, BS (reprint author), Ctr Dis Control & Prevent, Int Lab Branch, Div Global AIDS, 1600 Clifton Rd,MS-G19,Bldg 15,Room 2611, Atlanta, GA 30345 USA. EM bparekh@cdc.gov NR 22 TC 20 Z9 20 U1 1 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0166-0934 EI 1879-0984 J9 J VIROL METHODS JI J. Virol. Methods PD FEB PY 2010 VL 163 IS 2 BP 295 EP 300 DI 10.1016/j.jviromet.2009.10.013 PG 6 WC Biochemical Research Methods; Biotechnology & Applied Microbiology; Virology SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Virology GA 562SJ UT WOS:000275074500021 PM 19878697 ER PT J AU Chen, J Lau, YF Lamirande, EW Paddock, CD Bartlett, JH Zaki, SR Subbarao, K AF Chen, Jun Lau, Yuk Fai Lamirande, Elaine W. Paddock, Christopher D. Bartlett, Jeanine H. Zaki, Sherif R. Subbarao, Kanta TI Cellular Immune Responses to Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) Infection in Senescent BALB/c Mice: CD4(+) T Cells Are Important in Control of SARS-CoV Infection SO JOURNAL OF VIROLOGY LA English DT Article ID INFLUENZA-VIRUS INFECTION; CYTOKINE/CHEMOKINE PROFILES; PULMONARY INFECTION; INTERFERON-GAMMA; MOUSE MODEL; IN-VITRO; B-CELLS; A VIRUS; PATHOGENESIS; CLEARANCE AB We characterized the cellular immune response to severe acute respiratory syndrome coronavirus (SARS-CoV) infection in 12- to 14-month-old BALB/c mice, a model that mimics features of the human disease. Following intranasal administration, the virus replicated in the lungs, with peak titers on day 2 postinfection. Enhanced production of cytokines (tumor necrosis factor alpha [TNF-alpha] and interleukin-6 [IL-6]) and chemokines (CXCL10, CCL2, CCL3, and CCL5) correlated with migration of NK cells, macrophages, and plasmacytoid dendritic cells (pDC) into the lungs. By day 7, histopathologic evidence of pneumonitis was seen in the lungs when viral clearance occurred. At this time, a second wave of enhanced production of cytokines (TNF-alpha, IL-6, gamma interferon [IFN-gamma], IL-2, and IL-5), chemokines (CXCL9, CXCL10, CCL2, CCL3, and CCL5), and receptors (CXCR3, CCR2, and CCR5), was detected in the lungs, associated with an influx of T lymphocytes. Depletion of CD8(+) T cells at the time of infection did not affect viral replication or clearance. However, depletion of CD4(+) T cells resulted in an enhanced immune-mediated interstitial pneumonitis and delayed clearance of SARS-CoV from the lungs, which was associated with reduced neutralizing antibody and cytokine production and reduced pulmonary recruitment of lymphocytes. Innate defense mechanisms are able to control SARS-CoV infection in the absence of CD4(+) and CD8(+) T cells and antibodies. Our findings provide new insights into the pathogenesis of SARS, demonstrating the important role of CD4(+) but not CD8(+) T cells in primary SARS-CoV infection in this model. C1 [Chen, Jun; Lau, Yuk Fai; Lamirande, Elaine W.; Subbarao, Kanta] NIAID, Infect Dis Lab, NIH, Bethesda, MD 20892 USA. [Paddock, Christopher D.; Bartlett, Jeanine H.; Zaki, Sherif R.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Subbarao, K (reprint author), NIAID, Infect Dis Lab, NIH, Bldg 33,Room 3E13C1,33 North Dr, Bethesda, MD 20892 USA. EM KSUBBARAO@niaid.nih.gov FU NIAID, NIH FX This research was supported by the Intramural Research Program of NIAID, NIH. NR 59 TC 27 Z9 28 U1 0 U2 2 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD FEB PY 2010 VL 84 IS 3 BP 1289 EP 1301 DI 10.1128/JVI.01281-09 PG 13 WC Virology SC Virology GA 542XC UT WOS:000273531600008 PM 19906920 ER PT J AU Bansil, P Kuklina, EV Meikle, SF Posner, SF Kourtis, AP Ellington, SR Jamieson, DJ AF Bansil, Pooja Kuklina, Elena V. Meikle, Susan F. Posner, Samuel F. Kourtis, Athena P. Ellington, Sascha R. Jamieson, Denise J. TI Maternal and Fetal Outcomes Among Women with Depression SO JOURNAL OF WOMENS HEALTH LA English DT Article ID SEROTONIN-REUPTAKE INHIBITORS; SUBSTANCE USE DISORDERS; LOW-BIRTH-WEIGHT; POSTPARTUM DEPRESSION; PREGNANCY; RISK; SYMPTOMS; PREVALENCE; DIAGNOSES; DELIVERY AB Objective: To compare maternal and fetal outcomes among women with and without diagnosed depression at the time of delivery. Methods: Hospital discharge data from the 1998-2005 Nationwide Inpatient Sample (NIS) were used to examine delivery-related hospitalizations for select maternal and fetal outcomes by depression diagnosis. Results: The rate of depression per 1000 deliveries increased significantly from 2.73 in 1998 to 14.1 in 2005 (p<0.001). Women diagnosed with depression were significantly more likely to have cesarean delivery, preterm labor, anemia, diabetes, and preeclampsia or hypertension compared with women without depression. Fetal outcomes significantly associated with maternal depression were fetal growth restriction, fetal abnormalities, fetal distress, and fetal death. Conclusions: These findings suggest that depression is associated with adverse maternal and fetal outcomes. Our results provide additional impetus to screen for depression among women of reproductive age, especially those who plan to become pregnant. C1 [Bansil, Pooja] CONRAD, Atlanta, GA 30341 USA. [Kuklina, Elena V.] Quantell Inc, Mchenry, MD USA. [Meikle, Susan F.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Bethesda, MD USA. [Posner, Samuel F.; Kourtis, Athena P.; Jamieson, Denise J.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA. [Ellington, Sascha R.] Sci Applicat Int Corp, Atlanta, GA USA. RP Bansil, P (reprint author), CONRAD, 4770 Buford Highway NE,MS-K34, Atlanta, GA 30341 USA. EM pbansil@cdc.gov OI Posner, Samuel/0000-0003-1574-585X NR 33 TC 36 Z9 37 U1 0 U2 11 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 J9 J WOMENS HEALTH JI J. Womens Health PD FEB PY 2010 VL 19 IS 2 BP 329 EP 334 DI 10.1089/jwh.2009.1387 PG 6 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA 557JF UT WOS:000274664700020 PM 20095906 ER PT J AU Hale, MJ Zaki, SR Paddock, CD Shieh, WJ Paweska, JT Swanepoel, R AF Hale, M. J. Zaki, S. R. Paddock, C. D. Shieh, W-J. Paweska, J. T. Swanepoel, R. TI The Pivotal Role of Histopathology In the Diagnosis of a Novel Old World Arenavirus Viral Haemorrhagic Fever Outbreak In Southern Africa SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 99th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 20-26, 2010 CL Washington, DC SP US & Canadian Acac Pathol C1 Univ Witwatersrand, Johannesburg, South Africa. Natl Hlth Lab Serv, Johannesburg, South Africa. Ctr Dis Control & Prevent, Atlanta, GA USA. Natl Inst Communicable Dis, Johannesburg, South Africa. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2010 VL 90 SU 1 MA 1487 BP 333A EP 333A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 553AR UT WOS:000274337302001 ER PT J AU Shieh, WJ Blau, DM Adem, P Liu, L Schmitz, A Denison, AM Bhatnagar, J Deleon-Carnes, M Sumner, J Jost, HA Grecr, P Smith, C Batten, B Jones, T Seales, C White, L Montagne, J Bartlett, J Goldsmith, C Rollin, D Patel, M Zaki, SR AF Shieh, W. J. Blau, D. M. Adem, P. Liu, L. Schmitz, A. Denison, A. M. Bhatnagar, J. Deleon-Carnes, M. Sumner, J. Jost, H. A. Grecr, P. Smith, C. Batten, B. Jones, T. Seales, C. White, L. Montagne, J. Bartlett, J. Goldsmith, C. Rollin, D. Patel, M. Zaki, S. R. TI Pathologic Studies of Fatal 2009 Pandemic Influenza A (H1N1) Virus Infection in the US SO LABORATORY INVESTIGATION LA English DT Meeting Abstract CT 99th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 20-26, 2010 CL Washington, DC SP US & Canadian Acac Pathol C1 [Shieh, W. J.; Blau, D. M.; Adem, P.; Liu, L.; Schmitz, A.; Denison, A. M.; Bhatnagar, J.; Deleon-Carnes, M.; Sumner, J.; Jost, H. A.; Grecr, P.; Smith, C.; Batten, B.; Jones, T.; Seales, C.; White, L.; Montagne, J.; Bartlett, J.; Goldsmith, C.; Rollin, D.; Patel, M.; Zaki, S. R.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0023-6837 J9 LAB INVEST JI Lab. Invest. PD FEB PY 2010 VL 90 SU 1 MA 1493 BP 334A EP 334A PG 1 WC Medicine, Research & Experimental; Pathology SC Research & Experimental Medicine; Pathology GA 553AR UT WOS:000274337301508 ER PT J AU Bushby, K Finkel, R Birnkrant, DJ Case, LE Clemens, PR Cripe, L Kaul, A Kinnett, K McDonald, C Pandya, S Poysky, J Shapiro, F Tomezsko, J Constantin, C AF Bushby, Katharine Finkel, Richard Birnkrant, David J. Case, Laura E. Clemens, Paula R. Cripe, Linda Kaul, Ajay Kinnett, Kathi McDonald, Craig Pandya, Shree Poysky, James Shapiro, Frederic Tomezsko, Jean Constantin, Carolyn CA DMD Care Considerations TI Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care SO LANCET NEUROLOGY LA English DT Review ID MECHANICAL INSUFFLATION-EXSUFFLATION; VENTRICULAR SYSTOLIC DYSFUNCTION; HOME NOCTURNAL VENTILATION; ANKLE-FOOT ORTHOSES; LOWER-LIMB TENOTOMY; PEAK COUGH FLOW; NEUROMUSCULAR DISEASE; NONINVASIVE VENTILATION; DILATED CARDIOMYOPATHY; VERTEBRAL COMPRESSION AB Optimum management of Duchenne muscular dystrophy (DMD) requires a multidisciplinary approach that focuses on anticipatory and preventive measures as well as active interventions to address the primary and secondary aspects of the disorder. Implementing comprehensive management strategies can favourably alter the natural history of the disease and improve function, quality of life, and longevity. Standardised care can also facilitate planning for multicentre trials and help with the identification of areas in which care can be improved. Here, we present a comprehensive set of DMD care recommendations for management of rehabilitation, orthopaedic, respiratory, cardiovascular, gastroenterology/nutrition, and pain issues, as well as general surgical and emergency-room precautions. Together with part 1 of this Review, which focuses on diagnosis, pharmacological treatment, and psychosocial care, these recommendations allow diagnosis and management to occur in a coordinated multidisciplinary fashion. C1 [Bushby, Katharine] Newcastle Univ, Inst Human Genet, Int Ctr Life, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England. [Finkel, Richard] Childrens Hosp Philadelphia, Div Neurol, Philadelphia, PA 19104 USA. [Tomezsko, Jean] Childrens Hosp Philadelphia, Div Pulm Med, Philadelphia, PA 19104 USA. [Tomezsko, Jean] Childrens Hosp Philadelphia, Div Gastroenterol, Philadelphia, PA 19104 USA. [Tomezsko, Jean] Childrens Hosp Philadelphia, Div Hepatol, Philadelphia, PA 19104 USA. [Tomezsko, Jean] Childrens Hosp Philadelphia, Div Nutr, Philadelphia, PA 19104 USA. [Birnkrant, David J.] Case Western Reserve Univ, Div Pediat Pulm Med, Metrohlth Med Ctr, Cleveland, OH 44106 USA. [Case, Laura E.] Duke Univ, Div Phys Therapy, Dept Community & Family Med, Durham, NC USA. [Clemens, Paula R.] Univ Pittsburgh, Dept Neurol Mol Genet & Biochem, Pittsburgh, PA USA. [Clemens, Paula R.] Dept Vet Affairs Med Ctr, Pittsburgh, PA USA. [Cripe, Linda; Kinnett, Kathi] Cincinnati Childrens Hosp, Med Ctr, Div Cardiol, Cincinnati, OH USA. [Kaul, Ajay] Cincinnati Childrens Hosp, Med Ctr, Div Pediat Gastroenterol Hepatol & Nutr, Cincinnati, OH USA. [McDonald, Craig] Univ Calif Davis, Dept Phys Med & Rehabil, Davis, CA 95616 USA. [Pandya, Shree] Univ Rochester, Dept Neurol, Rochester, NY USA. [Poysky, James] Baylor Coll Med, Sch Allied Hlth Sci, Houston, TX 77030 USA. [Shapiro, Frederic] Childrens Hosp, Dept Orthopaed Surg, Boston, MA 02115 USA. [Constantin, Carolyn] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. RP Bushby, K (reprint author), Newcastle Univ, Inst Human Genet, Int Ctr Life, Ctr Pkwy, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England. EM kate.bushby@newcastle.ac.uk OI Case, Laura/0000-0002-2941-2186; McDonald, Craig/0000-0002-8779-3220 FU Genzyme Corporation; PTC Therapeutics; Leal Foundation; Families of Spinal Muscular Atrophy; National Skeletal Muscle Research Center FX KB is a consultant for Acceleron, AVI, Debiopharm, Prosensa, and Santhera. LEC has received honoraria from Genzyme Corporation, has participated in research supported by Genzyme Corporation, PTC Therapeutics, the Leal Foundation, and Families of Spinal Muscular Atrophy, has been awarded grant support from the National Skeletal Muscle Research Center, and is a member of the Pompe Registry Board of Advisors. All other authors have no conflicts of interest. NR 158 TC 323 Z9 338 U1 6 U2 66 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1474-4422 EI 1474-4465 J9 LANCET NEUROL JI Lancet Neurol. PD FEB PY 2010 VL 9 IS 2 BP 177 EP 189 DI 10.1016/S1474-4422(09)70272-8 PG 13 WC Clinical Neurology SC Neurosciences & Neurology GA 547XB UT WOS:000273922000015 PM 19945914 ER PT J AU Hale, MJ Zaki, SR Paddock, CD Shieh, WJ Paweska, JT Swanepoel, R AF Hale, M. J. Zaki, S. R. Paddock, C. D. Shieh, W-J Paweska, J. T. Swanepoel, R. TI The Pivotal Role of Histopathology in the Diagnosis of a Novel Old World Arenavirus Viral Haemorrhagic Fever Outbreak in Southern Africa SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 99th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 20-26, 2010 CL Washington, DC SP US & Canadian Acac Pathol C1 Univ Witwatersrand, Johannesburg, South Africa. Natl Hlth Lab Serv, Johannesburg, South Africa. Ctr Dis Control & Prevent, Atlanta, GA USA. Natl Inst Communicable Dis, Johannesburg, South Africa. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2010 VL 23 SU 1 MA 1487 BP 333A EP 333A PG 1 WC Pathology SC Pathology GA 556HX UT WOS:000274582502168 ER PT J AU Shieh, WJ Blau, DM Adem, P Liu, L Schmitz, A Denison, AM Bhatnagar, J Deleon-Carnes, M Sumner, J Jost, HA Greer, P Smith, C Batten, B Jones, T Seales, C White, L Montague, J Bartlett, J Goldsmith, C Rollin, D Patel, M Zaki, SR AF Shieh, W. J. Blau, D. M. Adem, P. Liu, L. Schmitz, A. Denison, A. M. Bhatnagar, J. Deleon-Carnes, M. Sumner, J. Jost, H. A. Greer, P. Smith, C. Batten, B. Jones, T. Seales, C. White, L. Montague, J. Bartlett, J. Goldsmith, C. Rollin, D. Patel, M. Zaki, S. R. TI Pathologic Studies of Fatal 2009 Pandemic Influenza A (H1N1) Virus Infection in the US SO MODERN PATHOLOGY LA English DT Meeting Abstract CT 99th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology CY MAR 20-26, 2010 CL Washington, DC SP US & Canadian Acac Pathol C1 [Shieh, W. J.; Blau, D. M.; Adem, P.; Liu, L.; Schmitz, A.; Denison, A. M.; Bhatnagar, J.; Deleon-Carnes, M.; Sumner, J.; Jost, H. A.; Greer, P.; Smith, C.; Batten, B.; Jones, T.; Seales, C.; White, L.; Montague, J.; Bartlett, J.; Goldsmith, C.; Rollin, D.; Patel, M.; Zaki, S. R.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0893-3952 J9 MODERN PATHOL JI Mod. Pathol. PD FEB PY 2010 VL 23 SU 1 MA 1493 BP 334A EP 334A PG 1 WC Pathology SC Pathology GA 556HX UT WOS:000274582502174 ER PT J AU Zhou, H De Jesus, V Vogt, R Hannon, WH AF Zhou, Hui De Jesus, Victor Vogt, Robert Hannon, W. Harry TI Update on laboratory support at the Centers for Disease Control and Prevention for newborn bloodspot screening to detect lysosomal storage disorders SO MOLECULAR GENETICS AND METABOLISM LA English DT Meeting Abstract CT 6th Annual World Symposium of the Lysosomal-Disease-Network CY FEB 10-12, 2010 CL Miami, FL SP Lysosomal Dis Network C1 [Zhou, Hui; De Jesus, Victor; Vogt, Robert; Hannon, W. Harry] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 1096-7192 J9 MOL GENET METAB JI Mol. Genet. Metab. PD FEB PY 2010 VL 99 IS 2 MA 155 BP S40 EP S40 DI 10.1016/j.ymgme.2009.10.172 PG 1 WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research & Experimental SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental Medicine GA 548XV UT WOS:000274004300168 ER PT J AU Pouliot, SH Xiong, X Harville, E Paz-Soldan, V Tomashek, KM Breart, G Buekens, P AF Pouliot, Sawyer H. Xiong, Xu Harville, Emily Paz-Soldan, Valerie Tomashek, Kay M. Breart, Gerard Buekens, Pierre TI Maternal Dengue and Pregnancy Outcomes A Systematic Review SO OBSTETRICAL & GYNECOLOGICAL SURVEY LA English DT Article ID VERTICAL TRANSMISSION; HEMORRHAGIC-FEVER; VIRUS-INFECTION; ANTIBODIES; MANAGEMENT; SEVERITY; INFANTS; VIREMIA; DISEASE AB To assess the impact of dengue infection during pregnancy on birth outcomes, we conducted a systematic review of 30 published studies (19 case reports, 9 case series, and 2 comparison studies). Studies were identified by searching computerized databases using dengue and dengue hemorrhagic fever, cross-referenced with pregnancy, preterm birth or delivery, low birth weight, small-for-gestational age, spontaneous abortion, pre-eclampsia, eclampsia, or fetal death as search-terms. The case reports examined showed high rates of cesarean deliveries (44.0%) and pre-eclampsia (12.0%) among women with dengue infection during pregnancy, while the case series showed elevated rates of preterm birth (16.1%) and cesarean delivery (20.4%). One comparative study found an increase in low birth weight among infants born to women with dengue infections during pregnancy, compared with infants born to noninfected women. Vertical transmission was described in 64.0% and 12.6% of women in case reports and case series (respectively), as well as in one comparative study. The authors conclude that there is a risk of vertical transmission, but whether maternal dengue infection is a significant risk factor for adverse pregnancy outcomes is inconclusive. More comparative studies are needed. Target Audience: Obstetricians & Gynecologists, Family Physicians. Learning Objectives: After completion of this educational activity, the participant should be better able to assess symptoms of dengue fever and locations where dengue fever occurs, describe possible perinatal complications of maternal dengue fever, and identify the limitations of available literature describing dengue fever in pregnancy. C1 [Pouliot, Sawyer H.; Paz-Soldan, Valerie] Tulane Univ, Sch Publ Hlth & Trop Med, Dept Int Hlth & Dev, New Orleans, LA 70112 USA. [Tomashek, Kay M.] Ctr Dis Control & Prevent, Div Vector Borne Infect Dis, San Juan, PR USA. [Breart, Gerard] Hosp Tenon, UPMC, Epidemiol Res Unit Perinatal Hlth & Womens & Chil, INSERM,URMS 953, Paris, France. [Buekens, Pierre] Tulane Univ, Sch Publ Hlth & Trop Med, Dept Epidemiol, New Orleans, LA 70112 USA. RP Pouliot, SH (reprint author), Tulane Univ, Sch Publ Hlth & Trop Med, Dept Int Hlth & Dev, 1440 Canal St,Suite 2200, New Orleans, LA 70112 USA. EM spouliot@tulane.edu FU Embassy of France in Washington, DC; Consulate General of France in New Orleans, Louisiana FX The authors thank the Embassy of France in Washington, DC, and the Consulate General of France in New Orleans, Louisiana, for their support. NR 40 TC 50 Z9 55 U1 1 U2 7 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0029-7828 J9 OBSTET GYNECOL SURV JI Obstet. Gynecol. Surv. PD FEB PY 2010 VL 65 IS 2 BP 107 EP 118 PG 12 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 552SZ UT WOS:000274315100021 PM 20100360 ER PT J AU Liu, LL Lawrence, JM Davis, C Liese, AD Pettitt, DJ Pihoker, C Dabelea, D Hamman, R Waitzfelder, B Kahn, HS AF Liu, Lenna L. Lawrence, Jean M. Davis, Cralen Liese, Angela D. Pettitt, David J. Pihoker, Catherine Dabelea, Dana Hamman, Richard Waitzfelder, Beth Kahn, Henry S. CA SEARCH Diabet Youth Study Grp TI Prevalence of overweight and obesity in youth with diabetes in USA: the SEARCH for Diabetes in Youth Study SO PEDIATRIC DIABETES LA English DT Article DE adolescents; children; diabetes; obesity; overweight ID ETHNIC-GROUP DIFFERENCES; BODY-MASS INDEX; ACCELERATOR HYPOTHESIS; UNITED-STATES; CHILDREN; MELLITUS; ADOLESCENTS; DIAGNOSIS; AGE; WEIGHT AB Objective: Obesity's association with type 2 diabetes (T2DM) is well established, but is less clear with type 1 diabetes (T1DM). We calculated the prevalence of overweight and obesity among diabetic youth in the USA from a six-center, population-based study of racially and ethnically diverse youth with diabetes, and we compared these rates with estimates among nondiabetic youth. Design/setting: Diabetic participants were examined in 2001-2004 for the SEARCH for Diabetes in Youth study (SEARCH) and nondiabetic participants were examined during the same years of the National Health and Nutrition Examination Survey (NHANES). Participants: 3953 diabetic youth and 7666 nondiabetic youth aged 3-19 yr. Main outcome measures: Overweight was defined as body mass index (BMI) from the 85th to <95th percentile for age and sex and obesity defined as >= 95th percentile. Diabetes type was categorized as T1DM or T2DM based on physician diagnosis. Results: Among youth with T2DM, the prevalence of overweight was 10.4% and obesity was 79.4%. Among youth with T1DM, 22.1% were overweight. The prevalence of overweight among youth with T1DM was higher than among those without diabetes overall (22.1% vs. 16.1%) (P <.05). The obesity rate for T1DM was 12.6% overall (range Non-Hispanic White 10.7%-African-American 20.1%). Conclusions: As expected, most of the youth with T2DM were obese. Youth with T1DM had a higher prevalence of overweight, but not of obesity, than nondiabetic youth. Future studies of obesity among youth with diabetes of all types will further our understanding of the impact of obesity on diabetes both as a risk factor and a comorbidity. C1 [Liu, Lenna L.] Seattle Childrens Hosp, Ctr Child Hlth Behav & Dev, Res Inst, Seattle, WA 98101 USA. [Lawrence, Jean M.] Kaiser Permanente So Calif, Res & Evaluat, Pasadena, CA 91101 USA. [Davis, Cralen] Wake Forest Univ Hlth Sci, Dept Publ Hlth Sci, Winston Salem, NC 27109 USA. [Liese, Angela D.] Univ S Carolina, Dept Epidemiol & Biostat, Arnold Sch Publ Hlth, Columbia, SC 29208 USA. [Liese, Angela D.] Univ S Carolina, Ctr Res Nutr & Hlth Dispar, Arnold Sch Publ Hlth, Columbia, SC 29208 USA. [Pettitt, David J.] Sansum Diabet Res Inst, Santa Barbara, CA 93105 USA. [Pihoker, Catherine] Seattle Childrens Hosp, Div Pediat Endocrinol, Seattle, WA 98105 USA. [Dabelea, Dana; Hamman, Richard] Univ Colorado, Dept Epidemiol, Colorado Sch Publ Hlth, Denver, CO 80262 USA. [Waitzfelder, Beth] Pacific Hlth Res Inst, Honolulu, HI 96813 USA. [Liu, Lenna L.; Lawrence, Jean M.; Davis, Cralen; Liese, Angela D.; Pettitt, David J.; Pihoker, Catherine; Dabelea, Dana; Hamman, Richard; Waitzfelder, Beth; Kahn, Henry S.] Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Liu, LL (reprint author), Seattle Childrens Hosp, Ctr Child Hlth Behav & Dev, Res Inst, Metropolitan Pk W,8th Floor 1100 Olive Way,Suite, Seattle, WA 98101 USA. EM lennall@u.washington.edu OI Kahn, Henry/0000-0003-2533-1562 FU Centers for Disease Control and Prevention [PA 00097, DP-05-069]; National Institute of Diabetes and Digestive and Kidney Diseases; Kaiser Permanente Southern California [U01 DP000246]; University of Colorado Health Sciences Center [U01 DP000247]; Pacific Health Research Institute [U01 DP000245]; Children's Hospital Medical Center (Cincinnati) [U01 DP000248]; University of North Carolina at Chapel Hill [U01 DP000254]; University of Washington School of Medicine [U01 DP000244, M01RR00037, M01RR001271]; Wake Forest University School of Medicine [U01 DP000250]; Medical University of South Carolina [M01 RR01070]; Cincinnati Children's Hospital [M01 RR08084]; Children's Hospital and Regional Medical Center; Colorado Pediatric General Clinical Research Center [M01 RR00069] FX SEARCH for Diabetes in Youth is funded by the Centers for Disease Control and Prevention (PA number 00097 and DP-05-069) and supported by the National Institute of Diabetes and Digestive and Kidney Diseases. Site Contract Numbers: Kaiser Permanente Southern California (U01 DP000246), University of Colorado Health Sciences Center (U01 DP000247), Pacific Health Research Institute (U01 DP000245), Children's Hospital Medical Center (Cincinnati) (U01 DP000248), University of North Carolina at Chapel Hill (U01 DP000254), University of Washington School of Medicine (U01 DP000244), Wake Forest University School of Medicine (U01 DP000250). The authors wish to acknowledge the involvement of General Clinical Research Centers (GCRC) at the following institutions in the SEARCH for Diabetes in Youth Study: Medical University of South Carolina (Grant Number M01 RR01070); Cincinnati Children's Hospital (Grant Number M01 RR08084); Children's Hospital and Regional Medical Center and the University of Washington School of Medicine (Grant Number M01RR00037 and M01RR001271); Colorado Pediatric General Clinical Research Center (Grant Number M01 RR00069). The contents of this paper are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention. The SEARCH for Diabetes in Youth study is indebted to the many youth and their families, and their health care providers, whose participation made this study possible. Lenna Liu had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Preliminary results of this analysis were presented at the American Diabetes Association Annual Meeting, 10 - 14 June 2005, in San Diego, CA. NR 40 TC 90 Z9 91 U1 0 U2 12 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1399-543X J9 PEDIATR DIABETES JI Pediatr. Diabetes PD FEB PY 2010 VL 11 IS 1 BP 4 EP 11 DI 10.1111/j.1399-5448.2009.00519.x PG 8 WC Endocrinology & Metabolism; Pediatrics SC Endocrinology & Metabolism; Pediatrics GA 551EK UT WOS:000274188900003 PM 19473302 ER PT J AU Bruce, M Singleton, R Lem, M Zulz, T Wenger, J Hennessy, T AF Bruce, Michael Singleton, Rosalyn Lem, Marcus Zulz, Tammy Wenger, Jay Hennessy, Thomas TI Haemophilus Disease in Alaskan and Canadian Children SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Letter ID VACCINE C1 [Bruce, Michael; Zulz, Tammy; Wenger, Jay; Hennessy, Thomas] Ctr Dis Control & Prevent, Anchorage, AK USA. [Singleton, Rosalyn] Alaska Native Med Ctr, Anchorage, AK USA. [Lem, Marcus] First Nations & Inunit Hlth, Vancouver, BC, Canada. RP Bruce, M (reprint author), Ctr Dis Control & Prevent, Anchorage, AK USA. NR 6 TC 4 Z9 4 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0891-3668 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD FEB PY 2010 VL 29 IS 2 BP 186 EP 186 PG 1 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA 549EV UT WOS:000274029600025 PM 20118746 ER PT J AU Tongren, JE Sites, A Zwicker, K Pelletier, A AF Tongren, Jon Eric Sites, Anne Zwicker, Katharyn Pelletier, Andrew TI Injury-Prevention Practices as Depicted in G- and PG-Rated Movies, 2003-2007 SO PEDIATRICS LA English DT Article DE movie; children; injury ID CONSEQUENCES; PROGRAMS AB OBJECTIVE: Our goal was to determine if the depiction of injury-prevention practices in children's movies is different from what was reported from 2 earlier studies, which showed infrequent depiction of characters practicing recommended safety behaviors. METHODS: The top-grossing 25 domestic G-rated (general audience) and PG-rated (parental guidance suggested) movies per year for 2003-2007 were included in this study. Movies or scenes were excluded if they were animated, not set in the present day, fantasy, documentary, or not in English. Injury-prevention practices involving motor vehicles, pedestrians, boaters, and bicyclists were recorded for characters with speaking roles. RESULTS: Sixty-seven (54%) of 125 movies met the inclusion criteria for this study. A total of 958 person-scenes were examined: 524 (55%) depicted children and 434 (45%) adults. Twenty-two person-scenes involved crashes or falls, resulting in 3 injuries and no deaths. Overall, 311 (56%) of 555 motor-vehicle passengers were belted; 73 (35%) of 211 pedestrians used crosswalks; 60 (75%) of 80 boaters wore personal flotation devices; and 8 (25%) of 32 bicyclists wore helmets. In comparison with previous studies, usage of safety belts, crosswalks, personal flotation devices, and bicycle helmets increased significantly. CONCLUSIONS: The entertainment industry has improved the depiction of selected safety practices in G- and PG-rated movies. However, approximately one half of scenes still depict unsafe practices, and the consequences of these behaviors are rarely shown. The industry should continue to improve how it depicts safety practices in children's movies. Parents should highlight the depiction of unsafe behaviors and educate children in following safe practices. Pediatrics 2010; 125: 290-294 C1 [Tongren, Jon Eric] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Off Workforce & Career Dev, Atlanta, GA USA. [Pelletier, Andrew] Ctr Dis Control & Prevent, Coordinating Off Terrorism Preparedness & Emergen, Atlanta, GA USA. [Tongren, Jon Eric; Sites, Anne; Zwicker, Katharyn; Pelletier, Andrew] Maine Ctr Dis Control & Prevent, Augusta, ME USA. RP Tongren, JE (reprint author), US Agcy Int Dev, PMI, GH HIDN 3-7-105,1300 Penn Ave NW, Washington, DC 20523 USA. EM jjt9@cdc.gov NR 27 TC 4 Z9 5 U1 0 U2 1 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 J9 PEDIATRICS JI Pediatrics PD FEB PY 2010 VL 125 IS 2 BP 290 EP 294 DI 10.1542/peds.2009-1282 PG 5 WC Pediatrics SC Pediatrics GA 573VH UT WOS:000275942900013 PM 20064866 ER PT J AU Boom, JA Tate, JE Sahni, LC Rench, MA Hull, JJ Gentsch, JR Patel, MM Baker, CJ Parashar, UD AF Boom, Julie A. Tate, Jacqueline E. Sahni, Leila C. Rench, Marcia A. Hull, Jennifer J. Gentsch, Jon R. Patel, Manish M. Baker, Carol J. Parashar, Umesh D. TI Effectiveness of Pentavalent Rotavirus Vaccine in a Large Urban Population in the United States SO PEDIATRICS LA English DT Article DE diarrhea; rotavirus; rotavirus vaccine; vaccine effectiveness ID POLYMERASE CHAIN-REACTION; EMERGENCY-DEPARTMENT; HOSPITALIZATIONS; CHILDREN; SURVEILLANCE; DIARRHEA; GASTROENTERITIS; IDENTIFICATION; REASSORTANT; EFFICACY AB OBJECTIVE: The goal was to assess the effectiveness of complete (3-dose) or partial (1- or 2-dose) immunization with pentavalent rotavirus vaccine (RV5) against rotavirus acute gastroenteritis (AGE) in US clinical practice. METHODS: A case-control evaluation was conducted in February through June 2008 at an emergency department in Houston, Texas. Case patients with rotavirus AGE (N = 90) were identified through testing for rotavirus in fecal specimens obtained from 205 children 15 days through 23 months of age presenting with AGE. Control groups included rotavirus-negative AGE patients (N = 115), concurrently enrolled patients with acute respiratory infection (ARI) (N = 228), and up to 10 age- and zip code-matched children sampled from the Houston-Harris County Immunization Registry (HHCIR) for each case patient >8 months of age. Immunization data were obtained from parent records, health care providers, and/or the HHCIR. Vaccine effectiveness was calculated as 1 minus odds of RV5 vaccination for case patients versus control patients, after adjustment for age at presentation and birth date. RESULTS: The vaccine effectiveness of a complete RV5 series was 89% (95% confidence interval [CI]: 70%-96%) and 85% (95% CI: 55%-95%) with rotavirus-negative AGE and ARI control patients, respectively. Immunization data were available for 44% of case patients (n = 40) from the HHCIR; the estimated 3- dose vaccine effectiveness with these HHCIR control patients was 82% (95% CI: 19%-96%). A complete RV5 series conferred 100% protection (95% CI: 71%-100%) against severe rotavirus disease requiring hospitalization and 96% protection (95% CI: 72%-99%) against disease requiring intravenous hydration. Vaccine effectiveness of 1 and 2 doses against hospitalization and emergency department visits was 69% (95% CI: 13%-89%) and 81% (95% CI: 13%-96%), respectively, using rotavirus-negative AGE and ARI control groups combined. CONCLUSIONS: In this setting, a complete series of RV5 was highly effective against severe rotavirus AGE. Partial immunization also conferred substantial protection. Pediatrics 2010; 125: e199-e207 C1 [Boom, Julie A.; Sahni, Leila C.; Rench, Marcia A.; Baker, Carol J.] Texas Childrens Hosp, Baylor Coll Med, Ctr Vaccine Awareness & Res, Houston, TX 77030 USA. [Boom, Julie A.; Sahni, Leila C.] Texas Childrens Hosp, Immunizat Project, Houston, TX 77030 USA. [Boom, Julie A.; Rench, Marcia A.; Baker, Carol J.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA. [Baker, Carol J.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA. [Tate, Jacqueline E.; Sahni, Leila C.; Hull, Jennifer J.; Gentsch, Jon R.; Patel, Manish M.; Parashar, Umesh D.] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Boom, JA (reprint author), Texas Childrens Hosp, Baylor Coll Med, Ctr Vaccine Awareness & Res, 6701 Fannin St,CC1540, Houston, TX 77030 USA. EM jboom@bcm.edu FU Centers for Disease Control and Prevention FX This work was funded by a sole-source grant from the Centers for Disease Control and Prevention that was awarded to the Houston Department of Health and Human Services and then to Texas Children's Hospital. The Centers for Disease Control and Prevention were involved in securing of funding and all aspects of study design, conduct of the study, analysis and interpretation of the data, and preparation and review of the manuscript. NR 21 TC 120 Z9 122 U1 0 U2 9 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 J9 PEDIATRICS JI Pediatrics PD FEB PY 2010 VL 125 IS 2 BP E199 EP E207 DI 10.1542/peds.2009-1021 PG 9 WC Pediatrics SC Pediatrics GA 573VH UT WOS:000275942900032 PM 20083525 ER PT J AU Ghandour, RM Kogan, MD Blumberg, SJ Perry, DF AF Ghandour, Reem M. Kogan, Michael D. Blumberg, Stephen J. Perry, Deborah F. TI Prevalence and Correlates of Internalizing Mental Health Symptoms Among CSHCN SO PEDIATRICS LA English DT Article DE special health care needs; child; adolescent; affective symptoms ID MAJOR DEPRESSIVE DISORDER; COMORBIDITY SURVEY REPLICATION; OPPOSITIONAL DEFIANT DISORDER; HIGH-SCHOOL-STUDENTS; ADOLESCENT DEPRESSION; GENDER-DIFFERENCES; CARE NEEDS; PSYCHIATRIC-DISORDERS; ANXIETY DISORDERS; OLDER ADOLESCENTS AB OBJECTIVES: This study provides nationally representative prevalence estimates of internalizing mental health symptoms among children with special health care needs (CSHCN) and identifies significant co-variates of these symptoms by using multivariate regression. Internalizing symptoms include feeling anxious and depressed. METHODS: Data were obtained from the 2005-2006 National Survey of Children with Special Health Care Needs, a nationally representative, parent-reported, cross-sectional survey of 40 465 CSHCN. The presence of internalizing mental health symptoms was assessed by using 2 binary items capturing whether a child had or experienced difficulty with depression, anxiety, disordered eating, or other emotional problems. The odds of experiencing internalizing symptoms were assessed by using multivariate regression, controlling for sociodemographic, health-related, and burden-related covariates. RESULTS: A total of 31.9% of CSHCN 3 to 17 years of age experienced internalizing mental health symptoms. Multivariate logistic regression showed internalizing symptoms to be strongly associated with female gender, older age, and frequent activity limitations, as well as externalizing mental health symptoms and conditions with behavioral components. Children with behavior problems had 6 times the odds of internalizing symptoms ( adjusted odds ratio [aOR]: 5.95 [95% confidence interval [CI]: 5.30-6.69]), whereas children with autism spectrum disorder had 3 times the odds (aOR: 3.00 [95% CI: 2.39-3.77]). Increased odds of symptoms also were associated with frequent headaches ( aOR: 1.76 [95% CI: 1.45-2.13]) and chronic pain (aOR: 1.46 [95% CI: 1.221.75]). Odds of symptoms were greater for children living in households that experienced employment changes or financial burdens resulting from the children's needs. CONCLUSIONS: Internalizing mental health symptoms are common among CSHCN. Findings may help caregivers focus screening and prevention efforts for high-risk groups in this heterogeneous population. Pediatrics 2010; 125:e269-e277 C1 [Ghandour, Reem M.; Kogan, Michael D.] Maternal & Child Hlth Bur, Off Data & Program Dev, US Hlth Resources & Serv Adm, Rockville, MD 20857 USA. [Blumberg, Stephen J.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Perry, Deborah F.] Georgetown Univ, Ctr Child & Human Dev, Washington, DC USA. RP Ghandour, RM (reprint author), Maternal & Child Hlth Bur, Off Data & Program Dev, US Hlth Resources & Serv Adm, Parklawn Bldg,5600 Fishers Lane,Room 18-41, Rockville, MD 20857 USA. EM rghandour@hrsa.gov NR 68 TC 12 Z9 12 U1 5 U2 11 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 J9 PEDIATRICS JI Pediatrics PD FEB PY 2010 VL 125 IS 2 BP E269 EP E277 DI 10.1542/peds.2009-0622 PG 9 WC Pediatrics SC Pediatrics GA 573VH UT WOS:000275942900040 PM 20083529 ER PT J AU Payne, DC Edwards, KM Bowen, MD Keckley, E Peters, J Esona, MD Teel, EN Kent, D Parashar, UD Gentsch, JR AF Payne, Daniel C. Edwards, Kathryn M. Bowen, Michael D. Keckley, Erin Peters, Jody Esona, Mathew D. Teel, Elizabeth N. Kent, Diane Parashar, Umesh D. Gentsch, Jon R. TI Sibling Transmission of Vaccine-Derived Rotavirus (RotaTeq) Associated With Rotavirus Gastroenteritis SO PEDIATRICS LA English DT Article DE rotavirus; acute gastroenteritis; RotaTeq; rotavirus vaccine; WC3; sibling transmission; horizontal transmission; shedding; reassortant; New Vaccine Surveillance Network; NVSN ID IMMUNIZATION PRACTICES ACIP; UNITED-STATES; ADVISORY-COMMITTEE; HEALTHY INFANTS; EFFICACY; SAFETY; IMMUNOGENICITY; PREVENTION; CHILDREN; RECOMMENDATIONS AB Although rotavirus vaccines are known to be shed in stools, transmission of vaccine-derived virus to unvaccinated contacts resulting in symptomatic rotavirus gastroenteritis has not been reported to our knowledge. We document here the occurrence of vaccine-derived rotavirus (RotaTeq [Merck and Co, Whitehouse Station, NJ]) transmission from a vaccinated infant to an older, unvaccinated sibling, resulting in symptomatic rotavirus gastroenteritis that required emergency department care. Results of our investigation suggest that reassortment between vaccine component strains of genotypes P7[5] G1 and P1A[8] G6 occurred during replication either in the vaccinated infant or in the older sibling, raising the possibility that this reassortment may have increased the virulence of the vaccine-derived virus. Both children remain healthy 11 months after this event and are without underlying medical conditions. Pediatrics 2010;125:e438-e441 C1 [Payne, Daniel C.; Parashar, Umesh D.] Ctr Dis Control & Prevent, Epidemiol Branch, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Bowen, Michael D.; Esona, Mathew D.; Teel, Elizabeth N.; Gentsch, Jon R.] Ctr Dis Control & Prevent, Gastroenteritis & Resp Viruses Lab Branch, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Edwards, Kathryn M.; Keckley, Erin; Peters, Jody; Kent, Diane] Vanderbilt Univ, Med Ctr, Dept Pediat, Div Infect Dis, Nashville, TN 37232 USA. RP Payne, DC (reprint author), Ctr Dis Control & Prevent, Epidemiol Branch, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE,MS-A47, Atlanta, GA 30333 USA. EM dvp6@cdc.gov NR 29 TC 43 Z9 43 U1 0 U2 4 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 J9 PEDIATRICS JI Pediatrics PD FEB PY 2010 VL 125 IS 2 BP E438 EP E441 DI 10.1542/peds.2009-1901 PG 4 WC Pediatrics SC Pediatrics GA 573VH UT WOS:000275942900060 PM 20100758 ER PT J AU Haldar, J de Cienfuegos, LA Tumpey, TM Gubareva, LV Chen, JZ Klibanov, AM AF Haldar, Jayanta de Cienfuegos, Luis Alvarez Tumpey, Terrence M. Gubareva, Larisa V. Chen, Jianzhu Klibanov, Alexander M. TI Bifunctional Polymeric Inhibitors of Human Influenza A Viruses SO PHARMACEUTICAL RESEARCH LA English DT Article DE drug-resistant mutant; influenza virus; polymeric antiviral agents; sialic acid; zanamivir ID BEARING 4-GUANIDINO-NEU5AC2EN DERIVATIVES; SIALIDASE INHIBITORS; STRONGLY INHIBIT; ANTIINFLUENZA EVALUATION; RESISTANT; COATINGS; AGGLUTINATION; ERYTHROCYTES; OSELTAMIVIR; INACTIVATE AB New antiviral agents were prepared by attaching derivatives of sialic acid (1) and of the drug zanamivir (2) to poly(isobutylene-alt-maleic anhydride) (poly-(1 + 2)) or by mixing poly-1 and poly-2, followed by assaying them against wild-type and drug-resistant influenza A Wuhan viruses. Individually or together, 1 and 2 were covalently bonded to the polymer. The antiviral potencies of the resultant poly-1, poly-2, poly-(1 + 2), and poly-1 + poly-2, as well as 1 and 2, were assessed using plaque reduction assay. Attaching 1 to the polymer improved at best millimolar IC(50) values over three orders of magnitude. While 2 exhibited micromolar IC(50) values, poly-2 was > 100-fold even more potent. The IC(50) of poly-(1 + 2) against the wild-type strain was > 300-fold and similar to 17-fold better than of poly-1 and poly-2, respectively. In contrast, the potency of poly-(1 + 2) vs. poly-2 against the mutant strain merely doubled. The mixture of poly-1 + poly-2 inhibited both viral strains similarly to poly-2. The bifunctional poly-(1 + 2) acts synergistically against the wild-type influenza virus, but not against its drug-resistant mutant, as compared to a physical mixture of the monofunctional poly-1 and poly-2. C1 [Chen, Jianzhu] MIT, Dept Biol, Cambridge, MA 02139 USA. [Haldar, Jayanta; de Cienfuegos, Luis Alvarez; Klibanov, Alexander M.] MIT, Dept Chem, Cambridge, MA 02139 USA. [Tumpey, Terrence M.; Gubareva, Larisa V.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Chen, Jianzhu] MIT, David H Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA. [Klibanov, Alexander M.] MIT, Dept Biol Engn, Cambridge, MA 02139 USA. RP Chen, JZ (reprint author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA. EM jchen@mit.edu; klibanov@mit.edu RI Alvarez de Cienfuegos, Luis/K-2391-2014; OI Alvarez de Cienfuegos, Luis/0000-0001-8910-4241; zaraat, javad/0000-0001-5341-7481 FU NIH [U01-AI074443]; Fundacion Ramon Areces of Spain FX This work was financially supported by NIH grant U01-AI074443. L.A.d.C. is grateful to Fundacion Ramon Areces of Spain for a postdoctoral fellowship. NR 20 TC 12 Z9 12 U1 1 U2 16 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0724-8741 J9 PHARM RES-DORD JI Pharm. Res. PD FEB PY 2010 VL 27 IS 2 BP 259 EP 263 DI 10.1007/s11095-009-0013-1 PG 5 WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy SC Chemistry; Pharmacology & Pharmacy GA 549IM UT WOS:000274041400005 PM 20013036 ER PT J AU Stringer, JSA McConnell, MS Kiarie, J Bolu, O Anekthananon, T Jariyasethpong, T Potter, D Mutsotso, W Borkowf, CB Mbori-Ngacha, D Muiruri, P Ong'ech, JO Zulu, I Njobvu, L Jetsawang, B Pathak, S Bulterys, M Shaffer, N Weidle, PJ AF Stringer, Jeffrey S. A. McConnell, Michelle S. Kiarie, James Bolu, Omotayo Anekthananon, Thanomsak Jariyasethpong, Tavatchai Potter, Dara Mutsotso, Winnie Borkowf, Craig B. Mbori-Ngacha, Dorothy Muiruri, Peter Ong'ech, John Odero Zulu, Isaac Njobvu, Lungowe Jetsawang, Bongkoch Pathak, Sonal Bulterys, Marc Shaffer, Nathan Weidle, Paul J. TI Effectiveness of Non-nucleoside Reverse-Transcriptase Inhibitor-Based Antiretroviral Therapy in Women Previously Exposed to a Single Intrapartum Dose of Nevirapine: A Multi-country, Prospective Cohort Study SO PLOS MEDICINE LA English DT Article ID TO-CHILD TRANSMISSION; HIV TRANSMISSION; RANDOMIZED-TRIAL; PREVENTION; ZIDOVUDINE; K103N; HIVNET-012; RESISTANCE; EXPERIENCE; PROGRAM AB Background: Intrapartum and neonatal single-dose nevirapine (NVP) reduces the risk of mother-to-child HIV transmission but also induces viral resistance to non-nucleoside reverse transcriptase inhibitor (NNRTI) drugs. This drug resistance largely fades over time. We hypothesized that women with a prior single-dose NVP exposure would have no more than a 10% higher cumulative prevalence of failure of their NNRTI-containing antiretroviral therapy (ART) over the first 48 wk of therapy than would women without a prior exposure. Methods and Findings: We enrolled 355 NVP-exposed and 523 NVP-unexposed women at two sites in Zambia, one site in Kenya, and two sites in Thailand into a prospective, non-inferiority cohort study and followed them for 48 wk on ART. Those who died, discontinued NNRTI-containing ART, or had a plasma viral load >= 400 copies/ml at either the 24 wk or 48 wk study visits and confirmed on repeat testing were characterized as having failed therapy. Overall, 114 of 355 NVP-exposed women (32.1%) and 132 of 523 NVP-unexposed women (25.2%) met criteria for treatment failure. The difference in failure rates between the exposure groups was 6.9% (95% confidence interval [CI] 0.8%-13.0%). The failure rates of women stratified by our predefined exposure interval categories were as follows: 47 of 116 women in whom less than 6 mo elapsed between exposure and starting ART failed therapy (40%; p<0.001 compared to unexposed women); 25 of 67 women in whom 7-12 mo elapsed between exposure and starting ART failed therapy (37%; p = 0.04 compared to unexposed women); and 42 of 172 women in whom more than 12 mo elapsed between exposure and starting ART failed therapy (24%; p = 0.82 compared to unexposed women). Locally weighted regression analysis also indicated a clear inverse relationship between virologic failure and the exposure interval. Conclusions: Prior exposure to single-dose NVP was associated with an increased risk of treatment failure; however, this risk seems largely confined to women with a more recent exposure. Women requiring ART within 12 mo of NVP exposure should not be prescribed an NNRTI-containing regimen as first-line therapy. C1 [Stringer, Jeffrey S. A.; Potter, Dara; Njobvu, Lungowe] Univ Alabama, Birmingham Ctr Infect Dis Res Zambia, Lusaka, Zambia. [McConnell, Michelle S.; Jetsawang, Bongkoch] US Ctr Dis Control & Prevent CDC Collaborat, Thailand Minist Publ Health, Nonthaburi, Thailand. [McConnell, Michelle S.; Bolu, Omotayo; Shaffer, Nathan] CDC, Global AIDS Program, Atlanta, GA 30333 USA. [Kiarie, James; Muiruri, Peter; Ong'ech, John Odero] Kenyatta Natl Hosp, Nairobi, Kenya. [Kiarie, James; Mbori-Ngacha, Dorothy; Ong'ech, John Odero] Univ Nairobi, Nairobi, Kenya. [Anekthananon, Thanomsak] Mahidol Univ, Siriraj Hosp, Bangkok 10700, Thailand. [Jariyasethpong, Tavatchai] Rajavithi Hosp, Bangkok, Thailand. [Potter, Dara; Zulu, Isaac; Bulterys, Marc] CDC Zambia, Global AIDS Program, Lusaka, Zambia. [Mutsotso, Winnie; Mbori-Ngacha, Dorothy] CDC Kenya, Global AIDS Program, Nairobi, Kenya. [Borkowf, Craig B.; Pathak, Sonal] CDC, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. [Zulu, Isaac] Univ Teaching Hosp, Lusaka, Zambia. [Pathak, Sonal] Northrup Grumman Corp, Atlanta, GA USA. RP Stringer, JSA (reprint author), Univ Alabama, Birmingham Ctr Infect Dis Res Zambia, Lusaka, Zambia. EM stringer@cidrz.org FU US Centers for Disease Control and Prevention (CDC) [U62/CCU12354, U62/CCU024526, Bangkok-07-M-0424, Bangkok-07-M-0425]; University of Alabama at Birmingham (UAB) FX The Zambia work was supported by grant U62/CCU12354 from the US Centers for Disease Control and Prevention (CDC), with complementary funding from the University of Alabama at Birmingham (UAB). The Kenya work was supported by cooperative agreement U62/CCU024526 from the US CDC. The Thailand work was supported by the US CDC through purchase orders # Bangkok-07-M-0424 to the Department of Pediatrics, Faculty of Medicine, Siriraj Hospital, Mahidol University and # Bangkok-07-M-0425 to Rajavithi Hospital. US CDC employees were involved in the planning, design, conduct, and interpretation of this manuscript, and in the decision to submit it for publication. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the US CDC. NR 35 TC 39 Z9 39 U1 0 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1549-1277 J9 PLOS MED JI PLos Med. PD FEB PY 2010 VL 7 IS 2 AR e1000233 DI 10.1371/journal.pmed.1000233 PG 13 WC Medicine, General & Internal SC General & Internal Medicine GA 565LW UT WOS:000275295600009 PM 20169113 ER PT J AU Bern, C Courtenay, O Alvar, J AF Bern, Caryn Courtenay, Orin Alvar, Jorge TI Of Cattle, Sand Flies and Men: A Systematic Review of Risk Factor Analyses for South Asian Visceral Leishmaniasis and Implications for Elimination SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID AZAR DERMAL LEISHMANIASIS; INDIAN KALA-AZAR; DELTAMETHRIN-IMPREGNATED BEDNETS; PHLEBOTOMUS-ARGENTIPES DIPTERA; INSECTICIDE-TREATED BEDNETS; HIV-INFECTED PATIENTS; LUTZOMYIA-LONGIPALPIS; CUTANEOUS LEISHMANIASIS; WEST-BENGAL; DONOVANI INFECTION AB Background: Studies performed over the past decade have identified fairly consistent epidemiological patterns of risk factors for visceral leishmaniasis (VL) in the Indian subcontinent. Methods and Principal Findings: To inform the current regional VL elimination effort and identify key gaps in knowledge, we performed a systematic review of the literature, with a special emphasis on data regarding the role of cattle because primary risk factor studies have yielded apparently contradictory results. Because humans form the sole infection reservoir, clustering of kala-azar cases is a prominent epidemiological feature, both at the household level and on a larger scale. Subclinical infection also tends to show clustering around kala-azar cases. Within villages, areas become saturated over a period of several years; kala-azar incidence then decreases while neighboring areas see increases. More recently, post kalaazar dermal leishmaniasis (PKDL) cases have followed kala-azar peaks. Mud walls, palpable dampness in houses, and peridomestic vegetation may increase infection risk through enhanced density and prolonged survival of the sand fly vector. Bed net use, sleeping on a cot and indoor residual spraying are generally associated with decreased risk. Poor micronutrient status increases the risk of progression to kala-azar. The presence of cattle is associated with increased risk in some studies and decreased risk in others, reflecting the complexity of the effect of bovines on sand fly abundance, aggregation, feeding behavior and leishmanial infection rates. Poverty is an overarching theme, interacting with individual risk factors on multiple levels. Conclusions: Carefully designed demonstration projects, taking into account the complex web of interconnected risk factors, are needed to provide direct proof of principle for elimination and to identify the most effective maintenance activities to prevent a rapid resurgence when interventions are scaled back. More effective, short-course treatment regimens for PKDL are urgently needed to enable the elimination initiative to succeed. C1 [Bern, Caryn] Ctr Dis Control & Prevent, Div Parasit Dis, Atlanta, GA 30333 USA. [Courtenay, Orin] Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England. [Alvar, Jorge] World Hlth Org, Leishmaniasis Control Program, Dept Control Neglected Trop Dis HTM NTD IDM, Geneva, Switzerland. RP Bern, C (reprint author), Ctr Dis Control & Prevent, Div Parasit Dis, Atlanta, GA 30333 USA. EM CBern@cdc.gov NR 96 TC 48 Z9 50 U1 0 U2 18 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD FEB PY 2010 VL 4 IS 2 AR e599 DI 10.1371/journal.pntd.0000599 PG 9 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA 565MC UT WOS:000275296200010 PM 20161727 ER PT J AU Yiin, JH Anderson, JL Daniels, RD AF Yiin, James H. Anderson, Jeri L. Daniels, Robert D. TI The US Nuclear Regulatory Commission Radiation Exposure Information Reporting System (REIRS) Response SO RADIATION RESEARCH LA English DT Letter ID WORKERS C1 [Yiin, James H.; Anderson, Jeri L.; Daniels, Robert D.] NIOSH, DSHEFS, Cincinnati, OH 45226 USA. RP Yiin, JH (reprint author), NIOSH, DSHEFS, 4676 Columbia Pkwy,MS R-15, Cincinnati, OH 45226 USA. EM JYiin@cdc.gov NR 3 TC 0 Z9 0 U1 0 U2 0 PU RADIATION RESEARCH SOC PI LAWRENCE PA 810 E TENTH STREET, LAWRENCE, KS 66044 USA SN 0033-7587 J9 RADIAT RES JI Radiat. Res. PD FEB PY 2010 VL 173 IS 2 BP 255 EP 255 DI 10.1667/RR1958.1.R PG 1 WC Biology; Biophysics; Radiology, Nuclear Medicine & Medical Imaging SC Life Sciences & Biomedicine - Other Topics; Biophysics; Radiology, Nuclear Medicine & Medical Imaging GA 552EH UT WOS:000274270200015 ER PT J AU Naeher, LP Tulve, NS Egeghy, PP Barr, DB Adetona, O Fortmann, RC Needham, LL Bozeman, E Hilliard, A Sheldon, LS AF Naeher, Luke P. Tulve, Nicolle S. Egeghy, Peter P. Barr, Dana B. Adetona, Olorunfemi Fortmann, Roy C. Needham, Larry L. Bozeman, Elizabeth Hilliard, Aaron Sheldon, Linda S. TI Organophosphorus and pyrethroid insecticide urinary metabolite concentrations in young children living in a southeastern United States city SO SCIENCE OF THE TOTAL ENVIRONMENT LA English DT Article DE Pediatric; Pesticide; Organophosphate; Pyrethroid; Biomarker; Urinary metabolites ID DIALKYL PHOSPHATE METABOLITES; TANDEM MASS-SPECTROMETRY; 1990/1992 GERES II; PESTICIDE EXPOSURE; CREATININE EXCRETION; PRESCHOOL-CHILDREN; CARE-CENTERS; POPULATION; SPECIMENS; URBAN AB Pesticide metabolites are routinely measured in the urine of children in the United States. Although the sources of these metabolites are believed to include residues in food from agricultural applications and residues from applications in everyday environments (e.g., homes), few studies have been able to demonstrate an association between indoor residential pesticide applications and pesticide metabolite concentrations. To better quantify the effects of potential risk factors related to demographics, household characteristics, occupation, and pesticide use practices on urinary biomarker levels, we performed a study in a city (Jacksonville, Florida) previously determined to have elevated rates of pesticide use. We enrolled a convenience sample of 203 children ranging in age from 4 to 6 years: their caregivers completed a questionnaire and the children provided a urine sample, which was analyzed for a series of organophosphorus and pyrethroid insecticide metabolites. The questionnaire responses substantiated much higher pesticide use for the study participants as compared to other studies. Urinary metabolite concentrations were approximately an order of magnitude higher than concentrations reported for young children in other studies. Few statistically significant differences (at the p<0.05 level) were observed, however, several trends are worth noting. In general, mean urinary pesticide metabolite concentrations were higher for males, Caucasians, and those children living in homes with an indoor pesticide application occurring within the past four weeks. Comparing the urinary pesticide metabolite concentrations in this study to those reported in the NHANES and GerES studies showed that the children living in Jacksonville had substantially higher pyrethroid pesticide exposures than the general populations of the United States and Germany. Further research is needed in communities where routine pesticide use has been documented to obtain information on the most important routes and pathways of exposure and to develop the most effective strategies for reducing pesticide exposures for children. Published by Elsevier B.V. C1 [Tulve, Nicolle S.; Egeghy, Peter P.; Fortmann, Roy C.; Sheldon, Linda S.] US EPA, Natl Exposure Res Lab, Off Res & Dev, Res Triangle Pk, NC 27711 USA. [Tulve, Nicolle S.; Egeghy, Peter P.; Fortmann, Roy C.; Sheldon, Linda S.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Environm Hazards & Hlth Effects, Atlanta, GA USA. [Barr, Dana B.; Needham, Larry L.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, Atlanta, GA USA. [Adetona, Olorunfemi] Univ Georgia, Coll Publ Hlth, Dept Environm Hlth Sci, Athens, GA USA. [Bozeman, Elizabeth; Hilliard, Aaron] Duval Cty Hlth Dept, Div Environm Hlth & Engn, Jacksonville, FL USA. RP Tulve, NS (reprint author), US EPA, Natl Exposure Res Lab, Off Res & Dev, 109 TW Alexander Dr,MD-E205-G4, Res Triangle Pk, NC 27711 USA. EM tulve.nicolle@epa.gov RI Needham, Larry/E-4930-2011; Barr, Dana/E-6369-2011; Barr, Dana/E-2276-2013 FU United States Environmental Protection Agency FX The United States Environmental Protection Agency through its Office of Research and Development partially funded and collaborated in the research described here. It has been subjected to Agency peer and administrative review and approved for publication. Mention of trade names or commercial products does not constitute endorsement or recommendation for use.; Although reviewed and approved by Agency representatives, this manuscript reflects the views of the authors and does not necessarily represent the official views of the Centers for Disease Control and Prevention or the United States Environmental Protection Agency. We thank Stephen L Rathbun and Jinae Lee from the University of Georgia for statistical consultations, Carol Rubin, Adrianne Holmes, Roberto Bravo, Sam Baker, Anders Cisson, Pam Olive, Lee-Yang Wong, and Stephanie M. Kieszak-Holloway from the CDC for valuable contributions to the study, Hazel Brown and David Jones from the DCHD for valuable contributions to the study, Carry Croghan from the EPA for valuable contributions to the demographic analyses, Jeff Evans from the EPA for help with Table 1, and the children and their caregivers for participating in this study. NR 31 TC 47 Z9 50 U1 1 U2 18 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0048-9697 EI 1879-1026 J9 SCI TOTAL ENVIRON JI Sci. Total Environ. PD FEB 1 PY 2010 VL 408 IS 5 BP 1145 EP 1153 DI 10.1016/j.scitotenv.2009.10.022 PG 9 WC Environmental Sciences SC Environmental Sciences & Ecology GA 553KH UT WOS:000274365000018 PM 19896164 ER PT J AU Satterwhite, CL Tian, LH Braxton, J Weinstock, H AF Satterwhite, Catherine Lindsey Tian, Lin H. Braxton, Jimmy Weinstock, Hillard TI Chlamydia Prevalence Among Women and Men Entering the National Job Training Program: United States, 2003-2007 SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID SEXUALLY-TRANSMITTED-DISEASES; PUBLIC-HEALTH LABORATORIES; TRACHOMATIS INFECTIONS; TESTS; TRENDS AB Objective: To analyze 5-year prevalence trends in Chlamydia trachomatis infections among high-risk young men and women aged 16 to 24 years entering the National Job Training Program, where universal screening is required. Methods: Entrance exams conducted in over 100 National Job Training Program centers from 2003 to 2007 were considered. Women provided cervical specimens tested using either a DNA hybridization probe (PACE 2, Gen-Probe, San Diego, CA) or a strand displacement amplification test (SDA, BD ProbeTec ET, Becton-Dickinson, Sparks, MD). In the absence of a pelvic exam, urine specimens were tested using SDA. PACE 2 testing was performed predominately from 2002 to 2005; from 2005 to 2007, SDA was used. All mate testing was conducted using SDA on urine specimens. Chlamydia prevalence trends were assessed for women and men, using logistic regression models. Adjusted odds ratios (AOR), 95% confidence intervals (CI), and P-values were calculated. Results: Approximately 15,000 women and 30,000 men were screened annually for chlamydia. Among both sexes, adjusted prevalence declined significantly from 2003 to 2007. In 2003, crude prevalence among women was 9.9%; in 2007, prevalence was 13.7%. However, after controlling for covariates, including increasingly sensitive tests, the model indicated a significant declining prevalence trend (AOR: 0.95, CI: 0.93-0.97, 4.6% decrease in odds per year). Among men, crude prevalence in 2003 was 8.4%; in 2007, prevalence was 8.3%; after controlling for possible confounding, a significant decline in prevalence was also detected (AOR: 0.98, CI: 0.96-0.99, 1.9% decrease in odds per year). Conclusions: In a relatively stable, high-risk population of young women and trien, adjusted chlamydia prevalence declined from 2003 to 2007. Test technology plays I critical role in interpreting rates and should be considered whenever chlamydia rates are examined. C1 [Satterwhite, Catherine Lindsey; Tian, Lin H.; Braxton, Jimmy; Weinstock, Hillard] CDC, Div STD Prevent, Atlanta, GA 30333 USA. RP Satterwhite, CL (reprint author), CDC, Div STD Prevent, 1600 Clifton Rd,Mailstop E-02, Atlanta, GA 30333 USA. EM clindsey@cdc.gov NR 25 TC 25 Z9 27 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD FEB PY 2010 VL 37 IS 2 BP 63 EP 67 DI 10.1097/OLQ.0b013e3181bc097a PG 5 WC Infectious Diseases SC Infectious Diseases GA 549RG UT WOS:000274070900001 PM 19801962 ER PT J AU Javanbakht, M Gorbach, PM Amani, B Walker, S Cranston, RD Datta, SD Kerndt, PR AF Javanbakht, Marjan Gorbach, Pamina M. Amani, Bita Walker, Susan Cranston, Ross D. Datta, S. Deblina Kerndt, Peter R. TI Concurrency, Sex Partner Risk, and High-Risk Human Papillomavirus Infection Among African American, Asian, and Hispanic Women SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID SEXUALLY-TRANSMITTED INFECTIONS; CERVICAL-CANCER; UNITED-STATES; YOUNG-WOMEN; NATURAL-HISTORY; COMMON OUTCOMES; MIXING PATTERNS; POPULATION; SPREAD; HIV AB Background: Although the role of concurrent sexual partnerships (i.e., having sexual activity with another partner after a current partnership has been established) has been most strongly associated with the transmission of bacterial sexually transmitted infections, its role in the transmission of viral sexually transmitted infections, specifically human papillomavirus (HPV) is less clear. Methods: Analysis of risk behavior data collected from 812 women screened for HPV as part of a sentinel surveillance project conducted in a family planning clinic, a primary care clinic, and 2 sexually transmitted disease clinics in Los Angeles, CA. Results: The mean age of participants was 34.2 years (range: 1865), with 31.8% identifying as African American 32.8% as Asian, and 28.4% as Hispanic. The overall prevalence of high-risk HPV (HR-HPV) was 21.7% and was higher among women who reported a concurrent partnership (25.7%) as compared to those who reported no concurrency (17.1%; P = 0.004). In multivariate analysis, concurrency was associated with HR-HPV and this relationship varied by race/ethnicity. Among Hispanic women those reporting a concurrent partnership were nearly twice as likely to have HR-HPV as compared to those who did not report concurrency (adjusted odds ration [AOR] = 1.71; 95% confidence interval [CI]: 1.13-2.58). However. among African American women those who reported a concurrent partnership were less likely to be diagnosed with HR-HPV (AOR = 0.60; 95% CI: 0.37-0.98). Conclusions: This study demonstrates that concurrency is associated with HR-HPV and that there may be differences by race/ethnicity in the individual or partnership characteristics of those who report concurrency. C1 [Javanbakht, Marjan; Gorbach, Pamina M.; Amani, Bita] Univ Calif Los Angeles, Dept Epidemiol, Los Angeles, CA 90095 USA. [Walker, Susan; Kerndt, Peter R.] Los Angeles Cty Dept Publ Hlth, Sexually Transmitted Dis Program, Los Angeles, CA USA. [Cranston, Ross D.] Univ Pittsburgh, Med Ctr, Div Infect Dis, Pittsburgh, PA USA. [Datta, S. Deblina] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. RP Javanbakht, M (reprint author), Univ Calif Los Angeles, Dept Epidemiol, Box 957353,10880 Wilshire Blvd,Suite 540, Los Angeles, CA 90095 USA. EM javan@ucla.edu OI Cranston, Ross/0000-0002-2687-6217 FU Centers for Disease Control and Prevention FX Supported by the Centers for Disease Control and Prevention. NR 41 TC 14 Z9 14 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD FEB PY 2010 VL 37 IS 2 BP 68 EP 74 DI 10.1097/OLQ.0b013e3181bcd3e7 PG 7 WC Infectious Diseases SC Infectious Diseases GA 549RG UT WOS:000274070900002 PM 19823110 ER PT J AU Marcus, JL Katz, MH Katz, KA Bernstein, KT Wolf, W Klausner, JD AF Marcus, Julia L. Katz, Mitchell H. Katz, Kenneth A. Bernstein, Kyle T. Wolf, Wendy Klausner, Jeffrey D. TI Prediction Model to Maximize Impact of Syphilis Partner Notification-San Francisco, 2004-2008 SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID INFECTION; CHLAMYDIA; CRITERIA; WOMEN; RULE AB Background: Syphilis cases increased 55% in San Francisco from 2007 (n = 354) to 2008 (n = 548). The San Francisco Department of Public Health interviews syphilis patients to identify sex partners needing treatment, but interviewing resources are limited. We developed and validated a model to prioritize interviews likely to result in treated partners. Methods: We included data from interviews conducted from July 2004 through June 2008. We used multivariate analysis to model the number of treated partners per interview in a random half of the data set. We applied the model to the other half, calculating predicted and observed proportions of partners successfully treated and interviews conducted if limiting interviews by syphilis patient characteristics. Results: In 1340 patient interviews, 1665 partners were named; of those, 827 (49.7%) were treated. Ratios of treated partners were significantly higher among patients aged <50 years, compared with >= 50 years (ratio 1.4; 95% confidence interval [CI], 1.0-1.9); patients with primary/secondary syphilis, compared with early latent (ratio 1.4; 95% CI: 1.1-1.8); and patients diagnosed at the municipal sexually transmitted disease clinic, compared with elsewhere (ratio 1.7; 95% CI: 1.4-2.1). Limiting interviews to patients aged <50 years would reduce interviews by 14% and identify 92% of partners needing treatment. Limiting interviews to primary/secondary syphilis patients would reduce interviews by 35% and identify 68% of partners needing treatment. Conclusions: Our model can provide modest efficiencies in allocating resources for syphilis partner notification. Health departments should consider developing tools to maximize impact of syphilis prevention and control activities. C1 [Marcus, Julia L.] San Francisco Dept Publ Hlth, STD Prevent Serv, San Francisco, CA 94103 USA. [Katz, Kenneth A.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. RP Marcus, JL (reprint author), San Francisco Dept Publ Hlth, STD Prevent Serv, 1360 Mission St,Ste 401, San Francisco, CA 94103 USA. EM julia.marcus@sfdph.org FU comprehensive STD Prevention [1H25PS001354-01]; Centers for Disease Control and Prevention FX Supported by comprehensive STD Prevention Projects (1H25PS001354-01), and Centers for Disease Control and Prevention. NR 26 TC 5 Z9 5 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD FEB PY 2010 VL 37 IS 2 BP 109 EP 114 DI 10.1097/OLQ.0b013e3181bbf985 PG 6 WC Infectious Diseases SC Infectious Diseases GA 549RG UT WOS:000274070900009 PM 19823113 ER PT J AU Tanner, AE Muvva, R Miazad, R Johnson, S Burnett, P Olthoff, G Jackson, S Freeman, D Ellen, JM AF Tanner, Amanda E. Muvva, Ravikiran Miazad, Rafiq Johnson, Sheridan Burnett, Phyllis Olthoff, Glen Jackson, Sherell Freeman, Denise Ellen, Jonathan M. TI Integration of HIV Testing and Linkage to Care by the Baltimore City Health Department SO SEXUALLY TRANSMITTED DISEASES LA English DT Letter C1 [Tanner, Amanda E.] Univ N Carolina, Dept Publ Hlth Sci, Charlotte, NC 28223 USA. [Muvva, Ravikiran; Miazad, Rafiq; Johnson, Sheridan; Burnett, Phyllis; Olthoff, Glen; Jackson, Sherell] Baltimore City Dept Hlth, Bur STD & HIV Prevent, Baltimore, MD USA. [Freeman, Denise] Ctr Dis Control & Prevent, Div STD Prevent, Atlanta, GA USA. [Ellen, Jonathan M.] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA. RP Tanner, AE (reprint author), Univ N Carolina, Dept Publ Hlth Sci, Charlotte, NC 28223 USA. NR 8 TC 2 Z9 2 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0148-5717 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD FEB PY 2010 VL 37 IS 2 BP 129 EP 130 PG 2 WC Infectious Diseases SC Infectious Diseases GA 549RG UT WOS:000274070900015 PM 20038866 ER PT J AU Fenton, KA AF Fenton, Kevin A. TI Prevention with HIV-positive men who have sex with men: regaining lost ground SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Editorial Material ID UNITED-STATES; WESTERN-EUROPE; PARTNERSHIPS; PREVALENCE; HEALTH C1 Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP Fenton, KA (reprint author), Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd,Mailstop E07, Atlanta, GA 30333 USA. EM kfenton@cdc.gov NR 18 TC 7 Z9 7 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD FEB PY 2010 VL 86 IS 1 BP 2 EP 4 DI 10.1136/sti.2009.038935 PG 3 WC Infectious Diseases SC Infectious Diseases GA 555PO UT WOS:000274525800001 PM 20157175 ER PT J AU Laga, M Galavotti, C Sundaramon, S Moodie, R AF Laga, Marie Galavotti, Christine Sundaramon, Sundar Moodie, Rob TI The importance of sex-worker interventions: the case of Avahan in India SO SEXUALLY TRANSMITTED INFECTIONS LA English DT Editorial Material ID SEXUALLY-TRANSMITTED DISEASES; HIV PREVENTION; DECLINE C1 [Laga, Marie] Inst Trop Med, B-2000 Antwerp, Belgium. [Galavotti, Christine] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Moodie, Rob] Victoria Hlth Promot Fdn, Melbourne, Vic, Australia. RP Laga, M (reprint author), Inst Trop Med, Natl Str 155, B-2000 Antwerp, Belgium. EM mlaga@itg.be OI Moodie, Alan/0000-0002-8425-7975 NR 13 TC 14 Z9 14 U1 0 U2 1 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1368-4973 J9 SEX TRANSM INFECT JI Sex. Transm. Infect. PD FEB PY 2010 VL 86 SU 1 BP I6 EP I7 DI 10.1136/sti.2009.039255 PG 2 WC Infectious Diseases SC Infectious Diseases GA 557GW UT WOS:000274658600004 PM 20167733 ER PT J AU Luckhaupt, SE Tak, S Calvert, GM AF Luckhaupt, Sara E. Tak, SangWoo Calvert, Geoffrey M. TI The Prevalence of Short Sleep Duration by Industry and Occupation in the National Health Interview Survey SO SLEEP LA English DT Article DE Sleep duration; occupational groups; work ID LARGE US SAMPLE; UNNECESSARY ADJUSTMENT; GENERAL-POPULATION; RISK-FACTOR; JOB STRESS; WORK HOURS; INSOMNIA; ADULTS; OVERADJUSTMENT; HYPERTENSION AB Study Objectives: To explore whether employment in industries likely to have non-standard work schedules (e.g., manufacturing and service) and occupations with long work-weeks (e.g., managerial/professional, sales, and transportation) is associated with an increased risk of short sleep duration. Design: Cross-sectional epidemiologic survey. Setting: Household-based face-to-face survey of civilian, non-institutionalized US residents. Participants: Sample adults interviewed for the National Health Interview Survey in 1985 or 1990 (N = 74,734) or between 2004 and 2007 (N = 110,422). Most analyses focused on civilian employed workers interviewed between 2004 and 2007 (N = 66,099). Interventions: N/A Measurements and Results: The weighted prevalence of self-reported short sleep duration, defined as <= 6 h per day, among civilian employed workers from 2004-2007 was 29.9%. Among industry categories, the prevalence of short sleep duration was greatest for management of companies and enterprises (40.5%), followed by transportation/warehousing (37.1%) and manufacturing (34.8%). Occupational categories with the highest prevalence included production occupations in the transportation/warehousing industry, and installation, maintenance, and repair occupations in both the transportation/warehousing industry and the manufacturing industry. In the combined sample from 1985 and 1990, 24.2% of workers reported short sleep duration; the prevalence of short sleep duration was significantly lower during this earlier time period compared to 2004-2007 for 7 of 8 industrial sectors. Conclusions: Self-reported short sleep duration among US workers varies by industry and occupation, and has increased over the past two decades. These findings suggest the need for further exploration of the relationship between work and sleep, and development of targeted interventions for specific industry/occupation groups. C1 [Luckhaupt, Sara E.; Tak, SangWoo; Calvert, Geoffrey M.] NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. RP Luckhaupt, SE (reprint author), 4676 Columbia Pkwy,MS R-17, Cincinnati, OH 45226 USA. EM SLuckhaupt@cdc.gov NR 53 TC 71 Z9 73 U1 2 U2 11 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 J9 SLEEP JI Sleep PD FEB 1 PY 2010 VL 33 IS 2 BP 149 EP 159 PG 11 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA 553KD UT WOS:000274364500005 PM 20175398 ER PT J AU Garcia-Lerma, JG Paxton, L Kilmarx, PH Heneine, W AF Garcia-Lerma, J. Gerardo Paxton, Lynn Kilmarx, Peter H. Heneine, Walid TI Oral pre-exposure prophylaxis for HIV prevention SO TRENDS IN PHARMACOLOGICAL SCIENCES LA English DT Review ID SIMIAN IMMUNODEFICIENCY VIRUS; TENOFOVIR DISOPROXIL FUMARATE; PROTECT NEWBORN MACAQUES; GENITAL-TRACT; HIV-1-INFECTED MEN; INTRAVAGINAL INOCULATION; POSTEXPOSURE PROPHYLAXIS; VAGINAL TRANSMISSION; SEXUAL TRANSMISSION; INFANT MACAQUES AB In the absence of an effective vaccine, HIV continues to spread worldwide, emphasizing the need for new biomedical interventions to limit its transmission. Appreciation of the challenges that HIV has to face to initiate an infection mucosally has spurred interest in evaluating the use of antiretroviral drugs to prevent infection. Recent animal studies using macaques or humanized mice models of mucosall transmission of SIV or HIV have shown that daily or intermittent pre-exposure prophylaxis (PrEP) with tenofovir disoproxill fumarate (TDF) and erntricitabine (FTC) can exploit early virus vulnerabilities and effectively prevent establishment of infection. These preclinical findings have fueled interest in evaluating the safety and efficacy of PrEP in humans. We provide an overview of the rationale behind PrEP and discuss the next steps in PrEP research, including the need to better define the ability of current drugs to reach and accumulate in mucosal tissues and protect cells that are primary targets during early HIV infection. C1 [Garcia-Lerma, J. Gerardo; Paxton, Lynn; Kilmarx, Peter H.; Heneine, Walid] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV Hepatitis STD & Prevent, Atlanta, GA 30329 USA. RP Garcia-Lerma, JG (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV Hepatitis STD & Prevent, 1600 Clifton Rd, Atlanta, GA 30329 USA. EM GGarcia-Lerma@cdc.gov OI Kilmarx, Peter/0000-0001-6464-3345 NR 56 TC 41 Z9 48 U1 0 U2 6 PU ELSEVIER SCIENCE LONDON PI LONDON PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND SN 0165-6147 J9 TRENDS PHARMACOL SCI JI Trends Pharmacol. Sci. PD FEB PY 2010 VL 31 IS 2 BP 74 EP 81 DI 10.1016/j.tips.2009.10.009 PG 8 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA 559OO UT WOS:000274835300004 PM 19963288 ER PT J AU Cantey, PT Rao, G Rout, J Fox, LM AF Cantey, P. T. Rao, G. Rout, J. Fox, L. M. TI Predictors of compliance with a mass drug administration programme for lymphatic filariasis in Orissa State, India 2008 SO TROPICAL MEDICINE & INTERNATIONAL HEALTH LA English DT Article DE lymphatic filariasis; India; prevention; mass drug administration ID BANCROFTIAN FILARIASIS; TAMIL-NADU; COVERAGE; PREVALENCE; LEOGANE; HAITI; ELIMINATION; STRATEGIES; IMPACT; COSTS AB OBJECTIVES To assess the performance of an educational campaign to increase adherence to a mass-administered DEC regimen against lymphatic filariasis (LF) in Orissa, and to identify factors that could enhance future campaigns. METHOD Randomized cluster survey, comparing areas that did and did not receive the educational campaign, using a household coverage survey and knowledge, attitudes and practices (KAP) survey. RESULTS LF MDA coverage for the entire population (n = 3449) was 56% (95% CI: 50.0-61.9). There was no statistical difference between the areas that did and did not receive the educational campaign. The most common barriers to adherence were fear of medication side effects (47.4%) and lack of recognition of one's risk for LF (15.8%). Modifiable, statistically significant, multivariable predictors of adherence were knowing that DEC prevents LF (aOR = 2.6, 95% CI: 1.4-5.1), knowing that mosquitoes transmit LF (aOR = 1.9, 95% CI: 1.1-3.2), and knowing both about the mass drug administration (MDA) in advance and that mosquitoes transmit LF (aOR = 5.4, 95% CI: 2.8-10.4). CONCLUSION India needs to increase compliance with MDA programmes to reach its goal of interrupting LF transmission. Promoting a simple public health message before MDA distribution, which takes into account barriers to and predictors of adherence, could raise compliance with the LF MDA programme. C1 [Cantey, P. T.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Off Workforce & Career Dev, Atlanta, GA USA. [Cantey, P. T.; Fox, L. M.] Ctr Dis Control & Prevent, Div Parasit Dis, Natl Ctr Zoonot Vector Borne & Enter Dis, Atlanta, GA USA. [Rao, G.; Rout, J.] Churchs Auxiliary Social Act, Bhubaneswar, Orissa, India. RP Cantey, PT (reprint author), Natl Ctr Preparedness Detect & Control Infect Dis, Div Global Migrat & Quarantine, 1600 Clifton Rd NE,MS E-03, Atlanta, GA 30333 USA. EM gdn9@cdc.gov FU USAID [GHA-G-00-03-0005-00]; CDC [IAA GHH99-006] FX We acknowledge the contributions of the CASA team in Orissa, including task force volunteers and Mr Soumendra Dhir; the MDA surveyors; Mr Sushant Agrawal, CASA Director; Mr Aloke Micharyi, Public Relations Officer CASA; the Orissa Ministry of Health and Family Welfare; Drs Els Mathieu, Michael Deming, and John Williamson in the Division of Parasitic Diseases, CDC; our partners at IMA World Health, including Erika Pearl, Program Officer, Dr Sarla Chand, Vice President, and Mr Paul Derstine, President; and Dr K. D. Ramaiah for contributing to the coverage survey protocol. Disclaimer: the findings and conclusions in this report are those of the authors and do not necessarily represent the views of the CDC. Funding: funding for this work was provided by USAID (GHA-G-00-03-0005-00) to IMA World Health and by CDC (IAA GHH99-006). NR 25 TC 15 Z9 16 U1 0 U2 2 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1360-2276 J9 TROP MED INT HEALTH JI Trop. Med. Int. Health PD FEB PY 2010 VL 15 IS 2 BP 224 EP 231 DI 10.1111/j.1365-3156.2009.02443.x PG 8 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 543SS UT WOS:000273599400011 PM 20002615 ER PT J AU Biggins, DE Godbey, JL Gage, KL Carter, LG Montenieri, JA AF Biggins, Dean E. Godbey, Jerry L. Gage, Kenneth L. Carter, Leon G. Montenieri, John A. TI Vector Control Improves Survival of Three Species of Prairie Dogs (Cynomys) in Areas Considered Enzootic for Plague SO VECTOR-BORNE AND ZOONOTIC DISEASES LA English DT Article DE Conservation; Cynomys; Deltamethrin; Enzootic; Epizootic; Flea control; Oropsylla; Plague; Prairie dog; Pulex; Survival; Yersinia pestis ID VIRULENT YERSINIA-PESTIS; NATURAL CONDITIONS; OROPSYLLA-HIRSUTA; MARKED ANIMALS; UNITED-STATES; FLEAS; CLIMATE; COLONIES; ECOLOGY; ECTOPARASITES AB Plague causes periodic epizootics that decimate populations of prairie dogs (PDs) (Cynomys), but the means by which the causative bacterium ( Yersinia pestis) persists between epizootics are poorly understood. Plague epizootics in PDs might arise as the result of introductions of Y. pestis from sources outside PD colonies. However, it remains possible that plague persists in PDs during interepizootic periods and is transmitted at low rates among highly susceptible individuals within and between their colonies. If this is true, application of vector control to reduce flea numbers might reduce mortality among PDs. To test whether vector control enhances PD survival in the absence of obvious plague epizootics, we reduced the numbers of fleas ( vectors for Y. pestis) 96-98% ( 1 month posttreatment) on 15 areas involving three species of PDs ( Cynomys leucurus, Cynomys parvidens in Utah, and Cynomys ludovicianus in Montana) during 2000-2004 using deltamethrin dust delivered into burrows as a pulicide. Even during years without epizootic plague, PD survival rates at dusted sites were 31-45% higher for adults and 2-34% higher for juveniles compared to survival rates at nondusted sites. Y. pestis was cultured from 49 of the 851 flea pools tested ( 6882 total fleas) and antibodies against Y. pestis were identified in serum samples from 40 of 2631 PDs. Although other explanations are possible, including transmission of other potentially fatal pathogens by fleas, ticks, or other ectoparasites, our results suggest that plague might be maintained indefinitely in PD populations in the absence of free epizootics and widespread mortality among these animals. If PDs and their fleas support enzootic cycles of plague transmission, there would be important implications for the conservation of these animals and other species. C1 [Biggins, Dean E.] US Geol Survey, BRD, Ft Collins Sci Ctr, Ft Collins, CO 80526 USA. [Gage, Kenneth L.; Carter, Leon G.; Montenieri, John A.] Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Div Vector Borne Infect Dis, Ft Collins, CO USA. RP Biggins, DE (reprint author), US Geol Survey, BRD, Ft Collins Sci Ctr, 2150 Ctr Ave,Bldg C, Ft Collins, CO 80526 USA. EM dean_biggins@usgs.gov FU Fish and Wildlife Service; Geological Survey; Bureau of Land Management; Utah Division of Wildlife Resources; Utah Department of Natural Resources Endangered Species Mitigation Fund; Bryce Canyon National Park; Dixie National Forest; Bureau of Land Management offices in Utah (Vernal, Cedar City, Richfield, and Torrey); Colorado (Meeker); Montana (Malta) FX We appreciate assistance from the Centers for Disease Control and Prevention for flea identification and for testing of flea pools, blood samples, and carcasses. We are deeply indebted to our many crew leaders and technicians who assisted them (n = 70). R. Reading and B. Miller of the Denver Zoological Foundation arranged logistical support for the study. Funding was provided by several federal agencies, including the Fish and Wildlife Service, the Geological Survey, and the Bureau of Land Management, supplemented by additional funds from the Utah Division of Wildlife Resources and the Utah Department of Natural Resources Endangered Species Mitigation Fund. Additional in kind support was provided by the Bryce Canyon National Park, Dixie National Forest, and Bureau of Land Management offices in Utah (Vernal, Cedar City, Richfield, and Torrey), Colorado (Meeker), and Montana (Malta). We appreciate constructive reviews of this paper by R. Matchett, D. Eads, P. Stevens, and L. Ellison. Any use of trade, product, or firm names is for descriptive purposes only and does not imply endorsement by the U.S. Government. NR 61 TC 37 Z9 38 U1 5 U2 37 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-3667 J9 VECTOR-BORNE ZOONOT JI Vector-Borne Zoonotic Dis. PD FEB PY 2010 VL 10 IS 1 SI SI BP 17 EP 26 DI 10.1089/vbz.2009.0049 PG 10 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 555PS UT WOS:000274526200004 PM 20158328 ER PT J AU Brinkerhoff, RJ Collinge, SK Ray, C Gage, KL AF Brinkerhoff, Robert Jory Collinge, Sharon K. Ray, Chris Gage, Ken L. TI Rodent and Flea Abundance Fail to Predict a Plague Epizootic in Black-Tailed Prairie Dogs SO VECTOR-BORNE AND ZOONOTIC DISEASES LA English DT Article DE Boulder County; Colorado; Cynomys ludovicianus; Disease ecology; Pathogen dispersal; Yersinia pestis ID YERSINIA-PESTIS; CYNOMYS-LUDOVICIANUS; TRANSMISSION; COLONIES; PERSISTENCE; PREVALENCE; GRASSLANDS; OUTBREAKS; PATTERNS; SOIL AB Small rodents are purported to be enzootic hosts of Yersinia pestis and may serve as sources of infection to prairie dogs or other epizootic hosts by direct or flea-mediated transmission. Recent research has shown that small rodent species composition and small rodent flea assemblages are influenced by the presence of prairie dogs, with higher relative abundance of both small rodents and fleas at prairie dog colony sites compared to grass-lands without prairie dogs. However, it is unclear if increased rodent or flea abundance predisposes prairie dogs to infection with Y. pestis. We tracked rodent and flea occurrence for 3 years at a number of prairie dog colony sites in Boulder County, Colorado, before, during, and after a local plague epizootic to see if high rodent or flea abundance was associated with plague-affected colonies when compared to colonies that escaped infection. We found no difference in preepizootic rodent abundance or flea prevalence or abundance between plague-positive and plague-negative colonies. Further, we saw no significant before-plague/after-plague change in these metrics at either plague-positive or plague-negative sites. We did, however, find that small rodent species assemblages changed in the year following prairie dog die-offs at plague-affected colonies when compared to unaffected colonies. In light of previous research from this system that has shown that landscape features and proximity to recently plagued colonies are significant predictors of plague occurrence in prairie dogs, we suggest that landscape context is more important to local plague occurrence than are characteristics of rodent or flea species assemblages. C1 [Brinkerhoff, Robert Jory; Collinge, Sharon K.; Ray, Chris] Univ Colorado, Dept Ecol & Evolutionary Biol, Boulder, CO 80309 USA. [Collinge, Sharon K.] Univ Colorado, Environm Studies Program, Boulder, CO 80309 USA. [Gage, Ken L.] Ctr Dis Control & Prevent, Bacterial Zoonoses Branch, Div Vector Borne Infect Dis, Ft Collins, CO USA. RP Brinkerhoff, RJ (reprint author), Univ Colorado, Dept Ecol & Evolutionary Biol, Box 334, Boulder, CO 80309 USA. EM robert.brinkerhoff@yale.edu RI Brinkerhoff, Jory/I-9364-2012; OI RAY, CHRIS/0000-0002-7963-9637 FU NSF/NIH [DEB-0224328]; National Center for Environmental Research (NCER) [82909101-0] FX This research was funded by the NSF/NIH joint program in Ecology of Infectious Diseases (DEB-0224328) and the National Center for Environmental Research (NCER) STAR program of the US-EPA (R-82909101-0). We would like to thank both Boulder City Open Space and Boulder County Parks and Open Space departments for allowing us to conduct this study on their properties. We would also like to acknowledge the data collection efforts of graduate students D. Conlin and A. Markeson and a large number of field technicians. This manuscript benefited from the comments of two anonymous reviewers. NR 27 TC 6 Z9 7 U1 0 U2 11 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-3667 J9 VECTOR-BORNE ZOONOT JI Vector-Borne Zoonotic Dis. PD FEB PY 2010 VL 10 IS 1 SI SI BP 47 EP 52 DI 10.1089/vbz.2009.0044 PG 6 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 555PS UT WOS:000274526200007 PM 20158331 ER PT J AU Bearden, SW Brubaker, RR AF Bearden, Scott W. Brubaker, Robert R. TI Recent Findings Regarding Maintenance of Enzootic Variants of Yersinia pestis in Sylvatic Reservoirs and Their Significance in the Evolution of Epidemic Plague SO VECTOR-BORNE AND ZOONOTIC DISEASES LA English DT Article DE Aspartase; Glucose 6-phosphate dehydrogenase; Intermediary metabolism; Pestoides ID COMPLETE GENOME SEQUENCE; LOW-CALCIUM RESPONSE; PASTEURELLA-PESTIS; MURINE TOXIN; NUTRITIONAL REQUIREMENTS; PLASMINOGEN-ACTIVATOR; ASPARTASE DEFICIENCY; ESCHERICHIA-COLI; CAUSATIVE AGENT; O-ANTIGEN AB Despite the widespread presence of bubonic plague in sylvatic reservoirs throughout the world, the causative agent ( Yersinia pestis) evolved in its present form within the last 20,000 years from enteropathogenic Yersinia pseudotuberculosis. Comparison of the genomes from the two species revealed that Y. pestis possesses only a few unique plasmid-encoded genes that contribute to acute disease, whereas this organism has lost about 13% of the chromosomal genes that remain active in Y. pseudotuberculosis. These losses reflect readily detectable additions, deletions, transpositions, inversions, and acquisition of about 70 insertion sequence ( IS) inserts, none of which are likely to promote increased virulence. In contrast, major enzymes of intermediary metabolism, including glucose 6-phosphate dehydrogenase (Zwf) and aspartase, are present but not catalytically functional due to the presence of missense mutations. The latter are generally not detectable by the technology of bioinformatics and, in the case of Y. pestis, result in radical changes in the metabolic flow of carbon. As an important consequence, plague bacilli exhibit a stringent low-calcium response characterized by conversion of L-glutamate ( and metabolically related amino acids) to L-aspartate with secretion of the latter into supernatant fluid at 37 degrees C in culture media containing Na(+) but lacking added Ca(2+). This phenomenon also occurs in vivo and likely adversely affects the bioenergetics of host amino acid pools. Curiously, aspartase is functional in all tested enzootic (pestoides) strains of Y. pestis. These isolates are typically restricted to the ancient plague reservoirs of Central Asia and Africa and are fully virulent in members of the rodent Superfamily Muroidea but avirulent in guinea pigs and man. The implications of these findings for the distribution and ecology of Y. pestis could be significant. C1 [Bearden, Scott W.] Ctr Dis Control & Prevent, Div Vector Borne Infect Dis, Bacterial Dis Branch, Ft Collins, CO 80521 USA. [Brubaker, Robert R.] Univ Chicago, Dept Microbiol, Chicago, IL 60637 USA. RP Bearden, SW (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Infect Dis, Bacterial Dis Branch, 3150 Rampart Rd, Ft Collins, CO 80521 USA. EM zyv3@cdc.gov FU NIH/NIAID; Regional Center of Excellence for Biodefense and Emerging Infectious Diseases Research (RCE); Region V "Great Lakes'' RCE [1-U54-AI-057153] FX This work was sponsored by the NIH/NIAID ( National Institutes of Health/National Institute of Allergy and Infectious Diseases) Regional Center of Excellence for Biodefense and Emerging Infectious Diseases Research (RCE) Program. R. R. B wishes to acknowledge membership within and support from the Region V "Great Lakes'' RCE (NIH Award 1-U54-AI-057153). NR 79 TC 7 Z9 7 U1 1 U2 14 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-3667 J9 VECTOR-BORNE ZOONOT JI Vector-Borne Zoonotic Dis. PD FEB PY 2010 VL 10 IS 1 SI SI BP 85 EP 92 DI 10.1089/vbz.2009.0043 PG 8 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 555PS UT WOS:000274526200012 PM 20158336 ER PT J AU Antolin, MF Gage, KL Lowell, J AF Antolin, Michael F. Gage, Kenneth L. Lowell, Jennifer TI WHAT IS A PLAGUE FOCUS? SO VECTOR-BORNE AND ZOONOTIC DISEASES LA English DT Meeting Abstract C1 [Antolin, Michael F.] Colorado State Univ, Dept Biol, Ft Collins, CO 80523 USA. [Gage, Kenneth L.] Ctr Dis Control & Prevent, Bacterial Zoonoses Branch, Div Vector Borne Infect Dis, Natl Ctr Infect Dis, Ft Collins, CO USA. [Lowell, Jennifer] Univ Montana, Div Biol Sci, Microbial Ecol Program, Missoula, MT 59812 USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-3667 J9 VECTOR-BORNE ZOONOT JI Vector-Borne Zoonotic Dis. PD FEB PY 2010 VL 10 IS 1 SI SI BP 94 EP 94 PG 1 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 555PS UT WOS:000274526200015 ER PT J AU Ben Ari, T Gershunov, A Rouyer, T Cazelles, B Gage, K Stenseth, NC AF Ben Ari, Tamara Gershunov, Alexander Rouyer, Tristan Cazelles, Bernard Gage, Kenneth Stenseth, Nils Chr TI REGIONAL CLIMATE AND THE DYNAMICS OF HUMAN PLAGUE IN WESTERN US SO VECTOR-BORNE AND ZOONOTIC DISEASES LA English DT Meeting Abstract C1 [Ben Ari, Tamara; Rouyer, Tristan; Stenseth, Nils Chr] Univ Oslo, CEES, Oslo, Norway. [Gershunov, Alexander] Univ Calif San Diego, Scripps Inst Oceanog, Div Climate Res, La Jolla, CA 92093 USA. [Rouyer, Tristan] IFREMER Ctr Rech Halieut Mediterraneen & Trop, F-34203 Sete, France. [Cazelles, Bernard] Ecole Normale Super, CNRS, UMR 7625, F-75230 Paris, France. [Gage, Kenneth] Ctr Dis Control & Prevent, Bacterial Zoonoses Branch, Div Vector Borne Infect Dis, Natl Ctr Infect Dis, Ft Collins, CO USA. RI Cazelles, Bernard/B-1572-2013 OI Cazelles, Bernard/0000-0002-7972-361X NR 2 TC 0 Z9 0 U1 0 U2 7 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-3667 J9 VECTOR-BORNE ZOONOT JI Vector-Borne Zoonotic Dis. PD FEB PY 2010 VL 10 IS 1 SI SI BP 94 EP 94 PG 1 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 555PS UT WOS:000274526200017 ER PT J AU Castle, KT Cornish, T Tate, C Monson, S Nash, DF Enscore, RE Drew, M Wild, MA AF Castle, Kevin T. Cornish, Todd Tate, Cynthia Monson, Scott Nash, David F. Enscore, Russell E. Drew, Mark Wild, Margaret A. TI PATHOLOGY AND SEROPREVALENCE OF PLAGUE IN WILD FELIDS SO VECTOR-BORNE AND ZOONOTIC DISEASES LA English DT Meeting Abstract C1 [Castle, Kevin T.; Wild, Margaret A.] Natl Pk Serv, Nat Resource Program Ctr, Biol Resource Management Div, Ft Collins, CO USA. [Cornish, Todd] Univ Wyoming, Wyoming State Vet Lab, Laramie, WY 82071 USA. [Tate, Cynthia] Wyoming Game & Fish Dept, Laramie, WY USA. [Monson, Scott] Washoe Cty Dist Hlth Dept, Environm Hlth Serv Div, Reno, NV USA. [Nash, David F.] Washington Dept Hlth, Zoonot Dis Program, Olympia, WA USA. [Enscore, Russell E.] Ctr Dis Control & Prevent, Ft Collins, CO USA. [Drew, Mark] Idaho Wildlife Hlth Lab, Caldwell, NJ USA. NR 0 TC 0 Z9 0 U1 1 U2 2 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-3667 J9 VECTOR-BORNE ZOONOT JI Vector-Borne Zoonotic Dis. PD FEB PY 2010 VL 10 IS 1 SI SI BP 95 EP 95 PG 1 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 555PS UT WOS:000274526200018 ER PT J AU Davis, RM Borchert, JN Poche, RM Bruening, JJ AF Davis, Richard M. Borchert, Jeff N. Poche, Richard M. Bruening, J. Joshua TI DECREASING THE RISKS OF PLAGUE TO WILDLIFE AND HUMANS USING EASILY APPLIED GROUND SQUIRREL BAITS SO VECTOR-BORNE AND ZOONOTIC DISEASES LA English DT Meeting Abstract C1 [Davis, Richard M.] Calif Dept Publ Hlth, Vector Borne Dis Sect, Nipomo, CA USA. [Borchert, Jeff N.] Ctr Dis Control & Prevent, Div Vector Borne Infect Dis, Ft Collins, CO USA. [Poche, Richard M.; Bruening, J. Joshua] Genesis Labs, Wellington, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 3 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-3667 J9 VECTOR-BORNE ZOONOT JI Vector-Borne Zoonotic Dis. PD FEB PY 2010 VL 10 IS 1 SI SI BP 95 EP 95 PG 1 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 555PS UT WOS:000274526200019 ER PT J AU Kosoy, M Reynolds, P Powers, N Sheff, K Morway, C Van Wyk, K Bai, Y Montenieri, J Ettestad, P Gage, K AF Kosoy, Michael Reynolds, Pamela Powers, Nelson Sheff, Kelly Morway, Christina Van Wyk, Kristen Bai, Ying Montenieri, John Ettestad, Paul Gage, Kenneth TI LONGITUDINAL STUDY OF PLAGUE IN NEW MEXICO: SPATIAL AND TEMPORAL PATTERNS IN EPIZOOTIC DYNAMICS SO VECTOR-BORNE AND ZOONOTIC DISEASES LA English DT Meeting Abstract C1 Ctr Dis Control & Prevent, Div Vector Borne Infect Dis, Ft Collins, CO USA. New Mexico Dept Hlth, Santa Fe, NM USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-3667 J9 VECTOR-BORNE ZOONOT JI Vector-Borne Zoonotic Dis. PD FEB PY 2010 VL 10 IS 1 SI SI BP 96 EP 96 PG 1 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 555PS UT WOS:000274526200025 ER PT J AU Lowell, JL Andersen, GL Stowkowski, RP Antolin, MF Gage, KL AF Lowell, J. L. Andersen, G. L. Stowkowski, R. P. Antolin, M. F. Gage, K. L. TI SINGLE NUCLEOTIDE POLYMORPHISM DISCOVERY TO DETERMINE YERSINIA PESTIS POPULATION STRUCTURE IN THE WESTERN UNITED STATES SO VECTOR-BORNE AND ZOONOTIC DISEASES LA English DT Meeting Abstract C1 [Lowell, J. L.] Univ Montana, Div Biol Sci, Microbial Ecol Program, Missoula, MT 59812 USA. [Andersen, G. L.] Lawrence Berkeley Natl Lab, Ctr Environm Biotechnol, Berkeley, CA USA. [Stowkowski, R. P.] Perlegen Sci, Mountain View, CA USA. [Antolin, M. F.] Colorado State Univ, Dept Biol, Ft Collins, CO 80523 USA. [Gage, K. L.] Ctr Dis Control & Prevent, Bacterial Zoonoses Branch, Div Vector Borne Infect Dis, Natl Ctr Infect Dis, Ft Collins, CO USA. RI Andersen, Gary/G-2792-2015 OI Andersen, Gary/0000-0002-1618-9827 NR 2 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-3667 J9 VECTOR-BORNE ZOONOT JI Vector-Borne Zoonotic Dis. PD FEB PY 2010 VL 10 IS 1 SI SI BP 97 EP 97 PG 1 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 555PS UT WOS:000274526200027 ER PT J AU Stapp, P Salkeld, DJ Antolin, MF Gage, KL AF Stapp, Paul Salkeld, Daniel J. Antolin, Michael F. Gage, Kenneth L. TI THE ROLE OF ALTERNATIVE RODENT HOSTS IN THE DYNAMICS OF PLAGUE IN BLACK-TAILED PRAIRIE DOG COLONIES SO VECTOR-BORNE AND ZOONOTIC DISEASES LA English DT Meeting Abstract C1 [Stapp, Paul; Salkeld, Daniel J.] Calif State Univ Fullerton, Dept Sci Biol, Fullerton, CA 92634 USA. [Salkeld, Daniel J.] IUCN World Conservat Union, Washington, DC USA. [Antolin, Michael F.] Colorado State Univ, Dept Biol, Ft Collins, CO 80523 USA. [Gage, Kenneth L.] Ctr Dis Control & Prevent, Div Vector Borne Infect Dis, Natl Ctr Infect Dis, Ft Collins, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 5 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-3667 J9 VECTOR-BORNE ZOONOT JI Vector-Borne Zoonotic Dis. PD FEB PY 2010 VL 10 IS 1 SI SI BP 98 EP 98 PG 1 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 555PS UT WOS:000274526200031 ER PT J AU Schotthoefer, AM Eisen, RJ Reynolds, PJ Ettestad, P Brown, T Enscore, RE Biggerstaff, BJ Cheek, J Bueno, R Targhetta, J Montenieri, JA Gage, KL AF Schotthoefer, Anna M. Eisen, Rebecca J. Reynolds, Pamela J. Ettestad, Paul Brown, Ted Enscore, Russell E. Biggerstaff, Brad J. Cheek, James Bueno, Rudy Targhetta, Joseph Montenieri, John A. Gage, Kenneth L. TI SOCIO-ECONOMIC RISK FACTORS ASSOCIATED WITH HUMAN PLAGUE CASES IN NEW MEXICO SO VECTOR-BORNE AND ZOONOTIC DISEASES LA English DT Meeting Abstract C1 [Schotthoefer, Anna M.; Eisen, Rebecca J.; Enscore, Russell E.; Biggerstaff, Brad J.; Montenieri, John A.; Gage, Kenneth L.] Ctr Dis Control & Prevent, Bacterial Zoonoses Branch, Div Vector Borne Infect Dis, Natl Ctr Infect Dis, Ft Collins, CO USA. [Reynolds, Pamela J.; Ettestad, Paul] New Mexico Dept Hlth, Zoonoses Program, Santa Fe, NM USA. [Brown, Ted] New Mexico Environm Dept, Vector Control Program, Santa Fe, NM USA. [Cheek, James] Indian Hlth Serv, Div Epidemiol & Dis Prevent, Albuquerque, NM USA. [Bueno, Rudy; Targhetta, Joseph] City Albuquerque Div Environm Hlth, Albuquerque, NM USA. NR 1 TC 0 Z9 0 U1 0 U2 3 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-3667 J9 VECTOR-BORNE ZOONOT JI Vector-Borne Zoonotic Dis. PD FEB PY 2010 VL 10 IS 1 SI SI BP 102 EP 102 PG 1 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 555PS UT WOS:000274526200046 ER PT J AU Thiagarajan, B Cully, JF Gage, KL AF Thiagarajan, Bala Cully, Jack F., Jr. Gage, Kenneth L. TI ECOLOGY OF RODENTS AND FLEAS ASSOCIATED WITH BLACK-TAILED PRAIRIE DOGS IN AREAS WITH PLAGUE SO VECTOR-BORNE AND ZOONOTIC DISEASES LA English DT Meeting Abstract C1 [Thiagarajan, Bala] Univ Wisconsin, Dept Biol, Oshkosh, WI 54901 USA. [Cully, Jack F., Jr.] Kansas State Univ, Kansas Cooperat Fish & Wildlife Res Unit, USGS, Manhattan, KS 66506 USA. [Gage, Kenneth L.] Ctr Dis Control & Prevent, Vector Ecol Lab, Ft Collins, CO USA. NR 2 TC 0 Z9 0 U1 1 U2 4 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-3667 J9 VECTOR-BORNE ZOONOT JI Vector-Borne Zoonotic Dis. PD FEB PY 2010 VL 10 IS 1 SI SI BP 103 EP 103 PG 1 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 555PS UT WOS:000274526200048 ER PT J AU Tripp, DW Gage, KL Montenieri, JA Antolin, MF AF Tripp, Daniel W. Gage, Kenneth L. Montenieri, John A. Antolin, Michael F. TI FLEA LOADS ON BLACK-TAILED PRAIRIE DOGS (CYNOMYS LUDOVICIANUS) DURING PLAGUE EPIZOOTICS IN COLORADO SO VECTOR-BORNE AND ZOONOTIC DISEASES LA English DT Meeting Abstract C1 [Tripp, Daniel W.; Antolin, Michael F.] Colorado State Univ, Dept Biol, Ft Collins, CO 80523 USA. [Tripp, Daniel W.; Antolin, Michael F.] Colorado State Univ, Short Grass Steppe Long Term Ecol Res Project, Ft Collins, CO 80523 USA. [Gage, Kenneth L.; Montenieri, John A.] Ctr Dis Control & Prevent, Bacterial Zoonoses Branch, Div Vector Borne Infect Dis, Natl Ctr Infect Dis, Ft Collins, CO USA. NR 0 TC 0 Z9 0 U1 3 U2 5 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1530-3667 J9 VECTOR-BORNE ZOONOT JI Vector-Borne Zoonotic Dis. PD FEB PY 2010 VL 10 IS 1 SI SI BP 103 EP 103 PG 1 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA 555PS UT WOS:000274526200049 ER PT J AU Munoz-Jordan, JL Fredericksen, BL AF Munoz-Jordan, Jorge L. Fredericksen, Brenda L. TI How Flaviviruses Activate and Suppress the Interferon Response SO VIRUSES-BASEL LA English DT Review DE flavivirus; dengue; West Nile; interferon ID WEST-NILE-VIRUS; TOLL-LIKE RECEPTOR-3; ANTIVIRAL IMMUNE-RESPONSES; DENGUE HEMORRHAGIC-FEVER; INDUCIBLE GENE-I; NF-KAPPA-B; RIG-I; ALPHA/BETA-INTERFERON; REGULATORY FACTOR-3; DENDRITIC CELL AB The flavivirus genus includes viruses with a remarkable ability to produce disease on a large scale. The expansion and increased endemicity of dengue and West Nile viruses in the Americas exemplifies their medical and epidemiological importance. The rapid detection of viral infection and induction of the innate antiviral response are crucial to determining the outcome of infection. The intracellular pathogen receptors RIG-I and MDA5 play a central role in detecting flavivirus infections and initiating a robust antiviral response. Yet, these viruses are still capable of producing acute illness in humans. It is now clear that flaviviruses utilize a variety of mechanisms to modulate the interferon response. The non-structural proteins of the various flaviviruses reduce expression of interferon dependent genes by blocking phosphorylation, enhancing degradation or down-regulating expression of major components of the JAK/STAT pathway. Recent studies indicate that interferon modulation is an important factor in the development of severe flaviviral illness. This suggests that an increased understanding of viral-host interactions will facilitate the development of novel therapeutics to treat these viral infections and improved biological models to study flavivirus pathogenesis. C1 [Munoz-Jordan, Jorge L.] Ctr Dis Control & Prevent, Mol Diagnost & Res Lab, Div Vector Borne Infect Dis, Dengue Branch, San Juan, PR 00920 USA. [Fredericksen, Brenda L.] Univ Maryland, Dept Cell Biol & Mol Genet, College Pk, MD 20742 USA. [Fredericksen, Brenda L.] Univ Maryland, Maryland Pathogen Res Inst, College Pk, MD 20742 USA. RP Munoz-Jordan, JL (reprint author), Ctr Dis Control & Prevent, Mol Diagnost & Res Lab, Div Vector Borne Infect Dis, Dengue Branch, 1324 Calle Canada, San Juan, PR 00920 USA. EM ckq2@cdc.gov; bfreder@umd.edu FU CDC; NIAID [R01AI083397] FX J.L.M.-J. was supported by the CDC. B.L.F. was supported by a grant from NIAID (R01AI083397). NR 73 TC 16 Z9 16 U1 1 U2 5 PU MDPI AG PI BASEL PA KANDERERSTRASSE 25, CH-4057 BASEL, SWITZERLAND SN 1999-4915 J9 VIRUSES-BASEL JI Viruses-Basel PD FEB PY 2010 VL 2 IS 2 BP 676 EP 691 DI 10.3390/v2020676 PG 16 WC Virology SC Virology GA 632HN UT WOS:000280413400016 PM 21994652 ER PT J AU Jones, JL Krueger, A Schulkin, J Schantz, PM AF Jones, J. L. Krueger, A. Schulkin, J. Schantz, P. M. TI Toxoplasmosis Prevention and Testing in Pregnancy, Survey of Obstetrician-Gynaecologists SO ZOONOSES AND PUBLIC HEALTH LA English DT Article DE Toxoplasmosis; Toxoplasma gondii; survey; prevention; serological testing ID CONGENITAL TOXOPLASMOSIS; FELINE TOXOPLASMOSIS; RISK-FACTORS; GONDII INFECTION; CAT FECES; OOCYSTS; DIAGNOSIS; SURVIVAL; DURATION; IMMUNITY AB P>Toxoplasmosis in pregnant women can lead to congenital disease with severe neurological and ocular complications in the foetus. In 2006, we surveyed US obstetrician-gynaecologists to determine their knowledge and practices about toxoplasmosis prevention and testing. Questionnaires were mailed (four mailings) to a random sample of 1200 of the 33 354 members of the American College of Obstetricians and Gynecologists (ACOG). Of the 1200 surveyed, 502 (42%) responded. The respondents were similar to all ACOG members by gender, region of the country and practice type (P > 0.5), and age (respondents were slightly younger, mean 46 years versus 47 years). To prevent toxoplasmosis, most respondents indicated that they counsel pregnant women about cat litter (99.6%), but fewer counselled about eating undercooked meat (77.6%), handling raw meat (67.4%), gardening (65.4%) or washing fruits and vegetables (34.2%). Many (73.2%) respondents were not aware that some Toxoplasma IgM tests have had a high false positive rate, and most (91.2%) had not heard of the avidity test, which can help determine the timing of Toxoplasma gondii infection in relation to pregnancy. There is a need for more education about T. gondii serological testing, particularly the Toxoplasma avidity test. US obstetrician-gynaecologists are providing beneficial counselling to their patients, but could provide more information about undercooked meat and soil risks. C1 [Jones, J. L.; Krueger, A.; Schantz, P. M.] Ctr Dis Control & Prevent, Div Parasit Dis, NCZVED, CCID, Atlanta, GA 30341 USA. [Schulkin, J.] Amer Coll Obstetricians & Gynecologists, Dept Res, Washington, DC 20024 USA. RP Jones, JL (reprint author), Ctr Dis Control & Prevent, Div Parasit Dis, NCZVED, CCID, Mailstop F-22,4770 Buford Highway NE, Atlanta, GA 30341 USA. EM jlj1@cdc.gov FU Maternal and Child Health Bureau [R60 MC 05674]; Health Resources and Services Administration, Department of Health and Human Services FX This work was supported in part by Grant R60 MC 05674 from Maternal and Child Health Bureau (Title V, Social Security Act), Health Resources and Services Administration, Department of Health and Human Services. NR 41 TC 17 Z9 19 U1 1 U2 8 PU WILEY-BLACKWELL PUBLISHING, INC PI MALDEN PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA SN 1863-1959 J9 ZOONOSES PUBLIC HLTH JI Zoonoses Public Health PD FEB PY 2010 VL 57 IS 1 BP 27 EP 33 DI 10.1111/j.1863-2378.2009.01277.x PG 7 WC Public, Environmental & Occupational Health; Infectious Diseases; Veterinary Sciences SC Public, Environmental & Occupational Health; Infectious Diseases; Veterinary Sciences GA 540EW UT WOS:000273315000004 PM 19744302 ER PT J AU Busby-Hjerpe, AL Campbell, JA Smith, JN Lee, S Poet, TS Barr, DB Timchalk, C AF Busby-Hjerpe, Andrea L. Campbell, James A. Smith, Jordan Ned Lee, Sookwang Poet, Torka S. Barr, Dana B. Timchalk, Charles TI Comparative pharmacokinetics of chlorpyrifos versus its major metabolites following oral administration in the rat SO TOXICOLOGY LA English DT Article DE Chlorpyrifos; Diethylthiophosphate; Trichloropyridinol; Pharmacokinetics ID ORGANOPHOSPHORUS PESTICIDE EXPOSURE; INSECTICIDE CHLORPYRIFOS; AGRICULTURAL-WORKERS; PRESCHOOL-CHILDREN; LIVER-MICROSOMES; BIRTH OUTCOMES; PHARMACOKINETIC/PHARMACODYNAMIC MODEL; PHOSPHORYLATED ACETYLCHOLINESTERASE; URINARY ALKYLPHOSPHATES; BIOMONITORING DATA AB Chlorpyrifos (CPF) is a commonly used diethylphosphorothionate organophosphorus (OP) insecticide. Diethyl phosphate (DEP), diethylthiophosphate (DETP) and 3,5,6-trichloro-2-pyridinol (TCPy) are products of both in vivo metabolism and environmental degradation of CPF and are routinely measured in urine as biomarkers of exposure. Hence, urinary biomonitoring of TCPy, DEP and DETP may be reflective of an individual's contact with both the parent pesticide and exposure to these metabolites in the environment. In the current study, simultaneous dosing of C-13- or H-2-isotopically labeled CPF (C-13-labeled CPF, 5 C-13 on the TCPy ring; or H-2-labeled CPF, diethyl-D10 (deuterium labeled) on the side chain) were exploited to directly compare the pharmacokinetics and metabolism of CPF with TCPy, and DETP. The key objective in the current study was to quantitatively evaluate the pharmacokinetics of the individual metabolites relative to their formation following a dose of CPF. Individual metabolites were co-administered (oral gavage) with the parent compound at equal molar doses (14 mu mol/kg: similar to 5 mg/kg CPF). Major differences in the pharmacokinetics between CPF and metabolite doses were observed within the first 3 h of exposure, due to the required metabolism of CPF to initially form TCPy and DETP. Nonetheless, once a substantial amount of CPF has been metabolized <= 3 h post-dosing) pharmacokinetics for both treatment groups and metabolites were very comparable. Urinary excretion rates for orally administered TCPy and DETP relative to C-13-CPF or H-2-CPF derived C-13-TCPy and H-2-DETP were consistent with blood pharmacokinetics, and the urinary clearance of metabolite dosed groups were comparable with the results for the C-13- and 2H-CPF groups. Since the pharmacokinetics of the individual metabolites were not modified by co-exposure to CPF; it suggests that environmental exposure to low dose mixtures of pesticides and metabolites will not impact their pharmacokinetics. (C) 2009 Elsevier Ireland Ltd. All rights reserved. C1 [Busby-Hjerpe, Andrea L.; Campbell, James A.; Smith, Jordan Ned; Lee, Sookwang; Poet, Torka S.; Timchalk, Charles] Pacific NW Div, Richland, WA 99354 USA. [Barr, Dana B.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. RP Timchalk, C (reprint author), Pacific NW Div, Richland, WA 99354 USA. EM charles.timchalk@pnl.gov RI Barr, Dana/E-6369-2011; Barr, Dana/E-2276-2013 FU Centers for Disease Control and Prevention/National Institute for Occupational Safety and Health (CDC/NIOSH) [R01 OH008173, R01 OH003629, GR05FED40077.02] FX This publication was supported by funding from Centers for Disease Control and Prevention/National Institute for Occupational Safety and Health (CDC/NIOSH) grants R01 OH008173, R01 OH003629 and GR05FED40077.02. Findings in this study were those of the authors and do not necessarily reflect the official opinion of the CDC/NIOSH. NR 57 TC 16 Z9 17 U1 1 U2 14 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0300-483X J9 TOXICOLOGY JI Toxicology PD JAN 31 PY 2010 VL 268 IS 1-2 BP 55 EP 63 DI 10.1016/j.tox.2009.11.022 PG 9 WC Pharmacology & Pharmacy; Toxicology SC Pharmacology & Pharmacy; Toxicology GA 570VG UT WOS:000275705800008 PM 19963030 ER PT J AU Lidstrom, J Li, Q Hoover, DR Kafulafula, G Mofenson, LM Fowler, MG Thigpen, MC Kumwenda, N Taha, TE Eshleman, SH AF Lidstrom, Jessica Li, Qing Hoover, Donald R. Kafulafula, George Mofenson, Lynne M. Fowler, Mary G. Thigpen, Michael C. Kumwenda, Newton Taha, Taha E. Eshleman, Susan H. TI Addition of extended zidovudine to extended nevirapine prophylaxis reduces nevirapine resistance in infants who were HIV-infected in utero SO AIDS LA English DT Article DE HIV-1; infants; Malawi; nevirapine; resistance ID SINGLE-DOSE NEVIRAPINE; IMMUNODEFICIENCY-VIRUS TYPE-1; ANTIRETROVIRAL THERAPY; UGANDAN INFANTS; TRANSMISSION; AGE AB Background: In the Post-Exposure Prophylaxis of infants (PEPI)-Malawi trial, most women received single-dose nevirapine (NVP) at delivery, and infants in the extended study arms received single-dose NVP along with 1 week of daily zidovudine (ZDV), followed by either extended daily NVP or extended daily NVP and ZDV up to 14 weeks of age. Although extended NVP prophylaxis reduces the risk of postnatal HIV transmission, it may increase the risk of NVP resistance among infants who are HIV-infected despite prophylaxis. Methods: We analyzed 88 infants in the PEPI-Malawi trial who were HIV-infected in utero and who received prophylaxis for a median of 6 weeks prior to HIV diagnosis. HIV genotyping was performed using the ViroSeq HIV Genotyping System. Results: At 14 weeks of age, the proportion of infants with NVP resistance was lower in the extended NVP and ZDV arm than in the extended NVP arm (28/45, 62.2% vs. 37/43, 86.0%; P = 0.015). None of the infants had ZDV resistance. Addition of extended ZDV to extended NVP was associated with reduced risk of NVP resistance at 14 weeks if prophylaxis was stopped by 6 weeks (54.5 vs. 85.7%, P = 0.007) but not if prophylaxis was continued beyond 6 weeks (83.3 vs. 87.5%, P= 1.00). Conclusion: Addition of extended ZDV to extended NVP prophylaxis significantly reduced the risk of NVP resistance at 14 weeks in infants who were HIV-infected in utero, provided that HIV infection was diagnosed and the prophylaxis was stopped by 6 weeks of age. (C) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins C1 [Lidstrom, Jessica] Johns Hopkins Univ, Dept Pathol, Sch Med, Johns Hopkins Med Inst, Baltimore, MD 21205 USA. [Li, Qing; Kumwenda, Newton; Taha, Taha E.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA. [Hoover, Donald R.] Rutgers State Univ, Dept Stat & Biostat, Piscataway, NJ USA. [Hoover, Donald R.] Rutgers State Univ, Inst Hlth Healthcare Policy & Aging Res, Piscataway, NJ USA. [Kafulafula, George] Univ Malawi, Malawi Coll Med, Blantyre, Malawi. [Mofenson, Lynne M.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Pediat Adolescent & Maternal AIDS Branch, NIH, Rockville, MD USA. [Fowler, Mary G.; Thigpen, Michael C.] Ctr Dis Control & Prevent, Epidemiol Branch, Div HIV AIDS Prevent, Atlanta, GA USA. RP Eshleman, SH (reprint author), Johns Hopkins Univ, Dept Pathol, Sch Med, Johns Hopkins Med Inst, Ross Bldg 646,720 Rutland Ave, Baltimore, MD 21205 USA. EM seshlem@jhmi.edu OI Mofenson, Lynne/0000-0002-2818-9808 FU National Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy Shriver National Institutes of Child Health and Human Development (NICHD) [R03HD061299]; National Institute on Drug Abuse; National Institute of Mental Health; National Institutes of Health (NIH); Department of Health and Human Services (DHHS) [U01AI068613]; International Maternal Pediatric and Adolescent AIDS Clinical Trials (IMPAACT) Network [U01AI068633]; Centers for Disease Control and Prevention (CDC) Cooperative Agreement [U50/CCU022061] FX This work was supported by the HIV Prevention Trials Network (HPTN) sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institutes of Child Health and Human Development (NICHD), National Institute on Drug Abuse, National Institute of Mental Health, and Office of AIDS Research of the National Institutes of Health (NIH), Department of Health and Human Services (DHHS) (U01AI068613), the International Maternal Pediatric and Adolescent AIDS Clinical Trials (IMPAACT) Network (U01AI068633), NIHCHD R03HD061299, and Centers for Disease Control and Prevention (CDC) Cooperative Agreement U50/CCU022061. NR 15 TC 11 Z9 12 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0269-9370 J9 AIDS JI Aids PD JAN 28 PY 2010 VL 24 IS 3 BP 381 EP 386 DI 10.1097/QAD.0b013e3283352ef1 PG 6 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA 553NU UT WOS:000274374900009 PM 19996936 ER PT J AU Megazzini, KM Sinkala, M Vermund, SH Redden, DT Krebs, DW Acosta, EP Mwanza, J Goldenberg, RL Chintu, N Bulterys, M Stringer, JSA AF Megazzini, Karen M. Sinkala, Moses Vermund, Sten H. Redden, David T. Krebs, Daniel W. Acosta, Edward P. Mwanza, Joyce Goldenberg, Robert L. Chintu, Namwinga Bulterys, Marc Stringer, Jeffrey S. A. TI A cluster-randomized trial of enhanced labor ward-based PMTCT services to increase nevirapine coverage in Lusaka, Zambia SO AIDS LA English DT Article DE antiretroviral prophylaxis; coverage; HIV; labor ward; nevirapine; prevention of mother-to-child transmission; rapid HIV testing ID TO-CHILD TRANSMISSION; PERINATAL HIV TRANSMISSION; SINGLE-DOSE NEVIRAPINE; RESOURCE-POOR SETTINGS; HIGH-PREVALENCE; PREGNANT-WOMEN; COST-EFFECTIVENESS; SCALING-UP; RAPID HIV; INTRAPARTUM AB Objective: Determine whether enhanced labor ward-based services for prevention of mother-to-child transmission of HIV (PMTCT) would improve nevirapine (NVP) coverage. Design: Cluster-randomized trial at 12 public-sector delivery centers in Lusaka, Zambia. Methods: Following a baseline surveillance period, 12 labor wards were randomized, six to offer opt-in HIV testing to women of unknown serostatus (with NVP administration as indicated) and to assess NVP adherence among known HIV-infected women. The six control labor wards provided the standard of care. The NVP coverage endpoint was defined as the proportion of HIV-infected/exposed women/infant pairs with confirmed NVP ingestion. We used generalized estimating equations (GEE) to determine the odds of coverage associated with the intervention and ultimately used the parameters for the estimated GEE model to estimate relative risk. Results: Between October 2005 and January 2006, 7664 women gave birth at participating clinics. We collected anonymous-linked blood from 7592 (99%) umbilical cords; tested 7438 (97%) for HIV, 1618 (22%) were seropositive, and of these, 1279 (79%) were tested for NVP. At baseline (preintervention), the probability of HIV-infected/exposed women/infant pairs receiving NVP in treatment clinics (42%) was 0.89 times the probability of being covered in control clinics (53%) whereas during the intervention period the probability of treatment clinic coverage (52%) was 1.22 the probability control clinic coverage (43%), representing a multiplicative effect of 1.37 upon the RR at baseline (ratio of relative risks 1.37, bootstrapped 95% CI, 1.04-1.77). Conclusion: Labor ward-based PMTCT programs are feasible and can have a significant, positive impact on NVP coverage. (C) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins C1 [Megazzini, Karen M.; Redden, David T.; Acosta, Edward P.; Stringer, Jeffrey S. A.] Univ Alabama, Sch Publ Hlth, Birmingham, AL 35294 USA. [Megazzini, Karen M.; Redden, David T.; Acosta, Edward P.; Stringer, Jeffrey S. A.] Univ Alabama, Sch Med, Birmingham, AL USA. [Megazzini, Karen M.; Sinkala, Moses; Vermund, Sten H.; Krebs, Daniel W.; Mwanza, Joyce; Chintu, Namwinga; Stringer, Jeffrey S. A.] Ctr Infect Dis Res Zambia, Lusaka, Zambia. [Sinkala, Moses] Catholic Med Miss Board, Lusaka, Zambia. [Vermund, Sten H.] Vanderbilt Univ, Sch Med, Inst Global Hlth, Nashville, TN 37212 USA. [Goldenberg, Robert L.] Drexel Univ, Coll Med, Philadelphia, PA 19104 USA. [Bulterys, Marc] Ctr Dis Control & Prevent, Global AIDS Program, Atlanta, GA USA. [Stringer, Jeffrey S. A.] Univ Zambia, Sch Med, Lusaka, Zambia. RP Megazzini, KM (reprint author), PAC Westat, 1650 Res Blvd,WB2, Rockville, MD 20850 USA. EM KMegazzini@gmail.com OI Vermund, Sten/0000-0001-7289-8698 FU United States Centers for Disease Control and Prevention [U62/CCU12354]; University of Alabama at Birmingham; Elizabeth Glaser Pediatric AIDS Foundation [EGSA 19-02] FX Support for the programmatic work reported herein was supported by a multi-country grant to the Elizabeth Glaser Pediatric AIDS Foundation from the United States Centers for Disease Control and Prevention (U62/CCU12354) through the President's Emergency Plan for AIDS Relief (PEPFAR). Support for the intervention and evaluation components was provided by the University of Alabama at Birmingham and the Elizabeth Glaser Pediatric AIDS Foundation (EGSA 19-02). NR 29 TC 15 Z9 15 U1 0 U2 8 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA SN 0269-9370 J9 AIDS JI Aids PD JAN 28 PY 2010 VL 24 IS 3 BP 447 EP 455 DI 10.1097/QAD.0b013e328334b285 PG 9 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA 553NU UT WOS:000274374900017 PM 19926959 ER PT J AU Richardson, V Hernandez-Pichardo, J Quintanar-Solares, M Esparza-Aguilar, M Johnson, B Gomez-Altamirano, CM Parashar, U Patel, M AF Richardson, Vesta Hernandez-Pichardo, Joselito Quintanar-Solares, Manjari Esparza-Aguilar, Marcelino Johnson, Brian Misael Gomez-Altamirano, Cesar Parashar, Umesh Patel, Manish TI Effect of Rotavirus Vaccination on Death from Childhood Diarrhea in Mexico SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID 1ST 2 YEARS; DOUBLE-BLIND; EFFICACY; CHILDREN; GASTROENTERITIS; SAFETY; MORTALITY; VACCINES; INFANTS; LIFE AB BACKGROUND A phased introduction of a monovalent rotavirus vaccine occurred in Mexico from February 2006 through May 2007. We assessed the effect of vaccination on deaths from diarrhea in Mexican children in 2008 and 2009. METHODS We obtained data on deaths from diarrhea, regardless of cause, from January 2003 through May 2009 in Mexican children under 5 years of age. We compared diarrhea-related mortality in 2008 and during the 2008 and 2009 rotavirus seasons with the mortality at baseline (2003-2006), before the introduction of the rotavirus vaccine. Vaccine coverage was estimated from administrative data. RESULTS By December 2007, an estimated 74% of children who were 11 months of age or younger had received one dose of rotavirus vaccine. In 2008, there were 1118 diarrhea-related deaths among children younger than 5 years of age, a reduction of 675 from the annual median of 1793 deaths during the 2003-2006 period. Diarrhea-related mortality fell from an annual median of 18.1 deaths per 100,000 children at baseline to 11.8 per 100,000 children in 2008 (rate reduction, 35%; 95% confidence interval [CI], 29 to 39; P<0.001). Among infants who were 11 months of age or younger, diarrhea-related mortality fell from 61.5 deaths per 100,000 children at baseline to 36.0 per 100,000 children in 2008 (rate reduction, 41%; 95% CI, 36 to 47; P<0.001). As compared with baseline, diarrhea-related mortality was 29% lower for children between the ages of 12 and 23 months, few of whom were age-eligible for vaccination. Mortality among unvaccinated children between the ages of 24 and 59 months was not significantly reduced. The reduction in the number of diarrhea-related deaths persisted through two full rotavirus seasons (2008 and 2009). CONCLUSIONS After the introduction of a rotavirus vaccine, a significant decline in diarrhea-related deaths among Mexican children was observed, suggesting a potential benefit from rotavirus vaccination. C1 [Johnson, Brian; Parashar, Umesh; Patel, Manish] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Richardson, Vesta; Hernandez-Pichardo, Joselito; Quintanar-Solares, Manjari; Esparza-Aguilar, Marcelino; Misael Gomez-Altamirano, Cesar] Minist Hlth, Natl Ctr Child & Adolescent Hlth, Mexico City, DF, Mexico. RP Patel, M (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd,MS A-47, Atlanta, GA 30333 USA. EM mpatel@cdc.gov NR 18 TC 193 Z9 201 U1 0 U2 11 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD JAN 28 PY 2010 VL 362 IS 4 BP 299 EP 305 DI 10.1056/NEJMoa0905211 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 548OT UT WOS:000273975000005 PM 20107215 ER PT J AU Tiller, RV Gee, JE Lonsway, DR Gribble, S Bell, SC Jennison, AV Bates, J Coulter, C Hoffmaster, AR De, BK AF Tiller, Rebekah V. Gee, Jay E. Lonsway, David R. Gribble, Sonali Bell, Scott C. Jennison, Amy V. Bates, John Coulter, Chris Hoffmaster, Alex R. De, Barun K. TI Identification of an unusual Brucella strain (BO2) from a lung biopsy in a 52 year-old patient with chronic destructive pneumonia SO BMC MICROBIOLOGY LA English DT Article ID PULMONARY INVOLVEMENT; OCHROBACTRUM-ANTHROPI; COMPARATIVE SEQUENCE; GENETIC DIVERSITY; MARINE MAMMALS; MELITENSIS; RECA; DNA; MISIDENTIFICATION; POLYMORPHISM AB Background: Brucellosis is primarily a zoonotic disease caused by Brucella species. There are currently ten Brucella spp. including the recently identified novel B. inopinata sp. isolated from a wound associated with a breast implant infection. In this study we report on the identification of an unusual Brucella-like strain (BO2) isolated from a lung biopsy in a 52-year-old patient in Australia with a clinical history of chronic destructive pneumonia. Results: Standard biochemical profiles confirmed that the unusual strain was a member of the Brucella genus and the full-length 16S rRNA gene sequence was 100% identical to the recently identified B. inopinata sp. nov. (type strain BO1(T)). Additional sequence analysis of the recA, omp2a and 2b genes; and multiple locus sequence analysis (MLSA) demonstrated that strain BO2 exhibited significant similarity to the B. inopinata sp. compared to any of the other Brucella or Ochrobactrum species. Genotyping based on multiple-locus variable-number tandem repeat analysis (MLVA) established that the BO2 and BO1(T)strains form a distinct phylogenetic cluster separate from the other Brucella spp. Conclusion: Based on these molecular and microbiological characterizations, we propose that the BO2 strain is a novel lineage of the newly described B. inopinata species. C1 [Tiller, Rebekah V.; Gee, Jay E.; Lonsway, David R.; Hoffmaster, Alex R.; De, Barun K.] Ctr Dis Control & Prevent, Div Foodborne Bacterial & Mycot Dis, Atlanta, GA 30333 USA. [Tiller, Rebekah V.; Gee, Jay E.; Lonsway, David R.; Hoffmaster, Alex R.; De, Barun K.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30333 USA. [Gribble, Sonali; Bell, Scott C.; Coulter, Chris] Prince Charles Hosp, Chermside, Qld 4032, Australia. [Gribble, Sonali; Coulter, Chris] Royal Brisbane & Womens Hosp, Pathol Queensland Cent Lab, Brisbane, Qld 4029, Australia. [Jennison, Amy V.; Bates, John] Queensland Hlth, Clin & Statewide Serv Div, Coopers Plains, Qld 4108, Australia. RP De, BK (reprint author), Ctr Dis Control & Prevent, Div Foodborne Bacterial & Mycot Dis, 1600 Clifton Rd, Atlanta, GA 30333 USA. EM bkd1@cdc.gov RI Bell, Scott/A-7241-2011; Coulter, Sonali/K-8914-2013; Coulter, Christopher/K-8922-2013; OI Bell, Scott/0000-0001-8651-7139; Jennison, Amy/0000-0002-5599-7480 NR 49 TC 46 Z9 49 U1 0 U2 7 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2180 J9 BMC MICROBIOL JI BMC Microbiol. PD JAN 27 PY 2010 VL 10 AR 23 DI 10.1186/1471-2180-10-23 PG 11 WC Microbiology SC Microbiology GA 557QC UT WOS:000274683300002 PM 20105296 ER PT J AU Castrodale, L McLaughlin, J Imholte, S Komatsu, K Wells, E Landen, M Selvage, D Sewell, M Smelser, C Thompson, D Bradley, K McDonald, C Leman, R Powell, M Miller, T Vander-Busch, L Kightlinger, L Boulton, R Lofy, K Marfin, AA McClinton, R Hoopes, M Kim, T Hayes, JM Mahal, Z Chao, E Weiser, T Cheek, JE Redd, JT Bryan, R Jhung, M Morrison, M O'Leary, D Nichols, M AF Castrodale, L. McLaughlin, J. Imholte, S. Komatsu, K. Wells, E. Landen, M. Selvage, D. Sewell, M. Smelser, C. Thompson, D. Bradley, K. McDonald, C. Leman, R. Powell, M. Miller, T. Vander-Busch, L. Kightlinger, L. Boulton, R. Lofy, K. Marfin, A. A. McClinton, R. Hoopes, M. Kim, T. Hayes, J. M. Mahal, Z. Chao, E. Weiser, T. Cheek, J. E. Redd, J. T. Bryan, R. Jhung, M. Morrison, M. O'Leary, D. Nichols, M. TI Deaths Related to 2009 Pandemic Influenza A (H1N1) Among American Indian/Alaska Natives-12 States, 2009 (Reprinted from MMWR, vol 58, pg 1341-1344, 2009) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Bradley, K.; McDonald, C.] Oklahoma Dept Hlth, Oklahoma City, OK 73117 USA. [Boulton, R.] Utah Dept Hlth, Salt Lake City, UT 84116 USA. [Nichols, M.] CDC, Atlanta, GA 30333 USA. NR 1 TC 0 Z9 0 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JAN 27 PY 2010 VL 303 IS 4 BP 323 EP 324 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 548IC UT WOS:000273952800009 ER PT J AU Hopkins, DR Ruiz-Tiben, E Eberhard, ML Roy, S AF Hopkins, D. R. Ruiz-Tiben, E. Eberhard, M. L. Roy, S. TI Progress Toward Global Eradication of Dracunculiasis, January 2008-June 2009 (Reprinted from MMWR, vol 58, pg 1123-1125, 2009) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Hopkins, D. R.; Ruiz-Tiben, E.] Emory Univ, Carter Ctr, Atlanta, GA 30322 USA. [Eberhard, M. L.; Roy, S.] CDC, Div Parasit Dis, Natl Ctr Zoonot Vector Borne & Enter Dis, Atlanta, GA 30333 USA. RP Hopkins, DR (reprint author), Emory Univ, Carter Ctr, Atlanta, GA 30322 USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JAN 27 PY 2010 VL 303 IS 4 BP 325 EP 326 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 548IC UT WOS:000273952800010 ER PT J AU Hutson, CL Abel, JA Carroll, DS Olson, VA Braden, ZH Hughes, CM Dillon, M Hopkins, C Karem, KL Damon, IK Osorio, JE AF Hutson, Christina L. Abel, Jason A. Carroll, Darin S. Olson, Victoria A. Braden, Zachary H. Hughes, Christine M. Dillon, Michael Hopkins, Consuelo Karem, Kevin L. Damon, Inger K. Osorio, Jorge E. TI Comparison of West African and Congo Basin Monkeypox Viruses in BALB/c and C57BL/6 Mice SO PLOS ONE LA English DT Article ID EXPERIMENTAL-INFECTION; SQUIRRELS AB Although monkeypox virus (MPXV) studies in wild rodents and non-human primates have generated important knowledge regarding MPXV pathogenesis and inferences about disease transmission, it might be easier to dissect the importance of virulence factors and correlates of protection to MPXV in an inbred mouse model. Herein, we compared the two clades of MPXV via two routes of infection in the BALB/c and C57BL/6 inbred mice strains. Our studies show that similar to previous animal studies, the Congo Basin strain of MPXV was more virulent than West African MPXV in both mouse strains as evidenced by clinical signs. Although animals did not develop lesions as seen in human MPX infections, localized signs were apparent with the foot pad route of inoculation, primarily in the form of edema at the site of inoculation; while the Congo Basin intranasal route of infection led to generalized symptoms, primarily weight loss. We have determined that future studies with MPXV and laboratory mice would be very beneficial in understanding the pathogenesis of MPXV, in particular if used in in vivo imaging studies. Although this mouse model may not suffice as a model of human MPX disease, with an appropriate inbred mouse model, we can unravel many unknown aspects of MPX pathogenesis, including virulence factors, disease progression in rodent hosts, and viral shedding from infected animals. In addition, such a model can be utilized to test antivirals and the next generation of orthopoxvirus vaccines for their ability to alter the course of disease. C1 [Hutson, Christina L.; Abel, Jason A.; Carroll, Darin S.; Olson, Victoria A.; Braden, Zachary H.; Hughes, Christine M.; Dillon, Michael; Hopkins, Consuelo; Karem, Kevin L.; Damon, Inger K.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Osorio, Jorge E.] Univ Wisconsin, Sch Vet Med, Dept Pathobiol Sci, Madison, WI 53706 USA. RP Hutson, CL (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. EM zuu6@cdc.gov FU NIH [1-U54-AI-057153] FX The authors wish to acknowledge membership within and support from the Region V 'Great Lakes' RCE (NIH award 1-U54-AI-057153). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 20 TC 11 Z9 11 U1 1 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JAN 27 PY 2010 VL 5 IS 1 AR e8912 DI 10.1371/journal.pone.0008912 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 550FX UT WOS:000274114800015 PM 20111702 ER PT J AU Casper, M Nwaise, I Croft, JB Hong, YL Fang, J Greer, S AF Casper, Michele Nwaise, Isaac Croft, Janet B. Hong, Yuling Fang, Jing Greer, Sophia TI Geographic Disparities in Heart Failure Hospitalization Rates Among Medicare Beneficiaries SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article DE geographic disparities; heart failure; hospitalizations; Medicare beneficiaries ID QUALITY-OF-CARE; CARDIOLOGY AB Objectives This study was designed to document local-level geographic disparities in heart failure (HF) hospitalization rates among Medicare beneficiaries. Background Although the burden of HF is well documented at the national level, little is known about the geographic disparities in HF. Methods The study population consisted of fee-for-service Medicare beneficiaries >= 65 years of age who resided in the U.S., Puerto Rico, or the U.S. Virgin Islands during the years 2000 to 2006. Using hospital claims data for Medicare beneficiaries, we calculated spatially smoothed and age-adjusted average annual county-level HF hospitalization rates per 1,000 Medicare beneficiaries for the total population and by racial/ethnic group (blacks, Hispanics, and whites) for the years 2000 to 2006. A HF hospitalization was defined as a short-stay hospital claim with a principal (first-listed) discharge diagnosis of HF using the International Classification of Diseases-9th Revision-Clinical Modification code 428. Results The average annual age-adjusted HF hospitalization rate per 1,000 Medicare beneficiaries was 21.5 per 1,000, and ranged from 7 to 61 per 1,000 among counties in the U.S. For the total study population, a clear East-West gradient was evident, with the highest rates located primarily along the lower Mississippi River Valley and the Ohio River Valley, including the Appalachian region. Similar patterns were observed for blacks and whites, although the pattern for Hispanics differed. Conclusions The evidence of substantial geographic disparities in HF hospitalizations among Medicare beneficiaries is important information for health professionals to incorporate as they design prevention and treatment policies and programs tailored to the needs of their communities. (J Am Coll Cardiol 2010; 55: 294-9) (C) 2010 by the American College of Cardiology Foundation C1 [Casper, Michele] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Croft, Janet B.] Ctr Dis Control & Prevent, Div Adult & Community Hlth, Atlanta, GA 30341 USA. RP Casper, M (reprint author), Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway NE,Mailstop K-47, Atlanta, GA 30341 USA. EM mcasper@cdc.gov NR 18 TC 12 Z9 12 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD JAN 26 PY 2010 VL 55 IS 4 BP 294 EP 299 DI 10.1016/j.jacc.2009.10.021 PG 6 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA 546HP UT WOS:000273802200003 PM 20117432 ER PT J AU Gamboa, D Ho, MF Bendezu, J Torres, K Chiodini, PL Barnwell, JW Incardona, S Perkins, M Bell, D McCarthy, J Cheng, Q AF Gamboa, Dionicia Ho, Mei-Fong Bendezu, Jorge Torres, Katherine Chiodini, Peter L. Barnwell, John W. Incardona, Sandra Perkins, Mark Bell, David McCarthy, James Cheng, Qin TI A Large Proportion of P. falciparum Isolates in the Amazon Region of Peru Lack pfhrp2 and pfhrp3: Implications for Malaria Rapid Diagnostic Tests SO PLOS ONE LA English DT Article ID HISTIDINE-RICH PROTEIN-2; PLASMODIUM-FALCIPARUM; EXPERT MICROSCOPY; PERFORMANCE; COMMUNITY; PARASITES; ANTIGEN; ASSAYS; INSTRUCTIONS; INFECTION AB Background: Malaria rapid diagnostic tests (RDTs) offer significant potential to improve the diagnosis of malaria, and are playing an increasing role in malaria case management, control and elimination. Peru, along with other South American countries, is moving to introduce malaria RDTs as components of malaria control programmes supported by the Global Fund for AIDS, TB and malaria. The selection of the most suitable malaria RDTs is critical to the success of the programmes. Methods: Eight of nine microscopy positive P. falciparum samples collected in Iquitos, Peru tested negative or weak positive using HRP2-detecting RDTs. These samples were tested for the presence of pfhrp2 and pfhrp3 and their flanking genes by PCR, as well as the presence of HRP proteins by ELISA. To investigate for geographic extent of HRP-deleted parasites and their temporal occurrence a retrospective study was undertaken on 148 microscopy positive P. falciparum samples collected in different areas of the Amazon region of Peru. Findings: Eight of the nine isolates lacked the pfhrp2 and/or pfhrp3 genes and one or both flanking genes, and the absence of HRP was confirmed by ELISA. The retrospective study showed that 61 (41%) and 103 (70%) of the 148 samples lacked the pfhrp2 or pfhrp3 genes respectively, with 32 (21.6%) samples lacking both hrp genes. Conclusions: This is the first documentation of P. falciparum field isolates lacking pfhrp2 and/or pfhrp3. The high frequency and wide distribution of different parasites lacking pfhrp2 and/or pfhrp3 in widely dispersed areas in the Peruvian Amazon implies that malaria RDTs targeting HRP2 will fail to detect a high proportion of P. falciparum in malaria-endemic areas of Peru and should not be used. RDTs detecting parasite LDH or aldolase and quality microscopy should be use for malaria diagnosis in this region. There is an urgent need for investigation of the abundance and geographic distribution of these parasites in Peru and neighbouring countries. C1 [Gamboa, Dionicia; Bendezu, Jorge; Torres, Katherine] Univ Peruana Cayetano Heredia, Inst Med Trop Alexander von Humboldt, Lima, Peru. [Gamboa, Dionicia] Univ Peruana Cayetano Heredia, Fac Ciencias, Dept Bioquim Biol Mol & Farmacol, Lima, Peru. [Ho, Mei-Fong; McCarthy, James; Cheng, Qin] Queensland Inst Med Res, Brisbane, Qld 4006, Australia. [Chiodini, Peter L.] Hosp Trop Dis, London NW1 0PE, England. [Barnwell, John W.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Incardona, Sandra; Perkins, Mark; Bell, David] FIND, Geneva, Switzerland. [Bell, David] WHO, Reg Off Western Pacific, Manila, Philippines. [McCarthy, James] Univ Queensland, Sch Med, Brisbane, Qld, Australia. [Ho, Mei-Fong; Cheng, Qin] Australian Army Malaria Inst, Brisbane, Qld, Australia. RP Gamboa, D (reprint author), Univ Peruana Cayetano Heredia, Inst Med Trop Alexander von Humboldt, Lima, Peru. EM qin.cheng@defence.gov.au RI McCarthy, James/C-1681-2009; OI Chiodini, Peter/0000-0003-0317-7090; Incardona, Sandra/0000-0003-4994-1736 FU AusAID; World Health Organisation (WHO)-Western Pacific Regional Office; WHO/TDR; Foundation for Innovative New Diagnostics (FIND); Directorate General for Development Cooperation (DGCD) of the Belgian Government [95501]; NIH/NIAID [RO1 AI067727-03]; UCL Hospitals Comprehensive Biomedical Research Centre Infection Theme; NHMRC, Australia FX The work is partially funded by the AusAID, the World Health Organisation (WHO)-Western Pacific Regional Office, WHO/TDR and Foundation for Innovative New Diagnostics (FIND). The retrospective sample collection was financed by the Directorate General for Development Cooperation (DGCD) of the Belgian Government (framework agreement 02, 2003-2007), project 95501. DG is supported by DGCD and NIH/NIAID (RO1 AI067727-03). PLC is supported by the UCL Hospitals Comprehensive Biomedical Research Centre Infection Theme and JMC is supported by the NHMRC, Australia. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript, with the exception of WHO and FIND facilitating the sample collection and approving the publication of the findings. NR 42 TC 108 Z9 111 U1 0 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JAN 25 PY 2010 VL 5 IS 1 AR e8091 DI 10.1371/journal.pone.0008091 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 547NM UT WOS:000273896300001 PM 20111602 ER PT J AU Lo, LM Chen, DR Pui, DYH AF Lo, Li-Ming Chen, Da-Ren Pui, David Y. H. TI Experimental study of pleated fabric cartridges in a pulse-jet cleaned dust collector SO POWDER TECHNOLOGY LA English DT Article DE Pleated fabric filter; Pulse-jet cleaning; Dust collector; Baghouse; Clean-on-demand; Clean-on-time ID HIGH FILTRATION VELOCITY; FILTER; PARAMETERS; PERFORMANCE; OPERATION AB Six pleated filter cartridges with different base media and geometrical dimensions were tested in a full-size dust collector periodically cleaned by a short burst of pulse-jet. The evaluation was performed under two different cleaning modes called clean-on-demand (to clean the filter once the pressure drop reaches a preset value) and clean-on-time (to clean the filter at a fixed time interval). The filter performance was evaluated by the effective residual pressure drop and downstream particle concentration. The results showed that the pleat ratio, defined as the ratio of pleat height to pleat pitch, had a great influence on the preferred operating mode for cleaning the filter. Clean-on-time mode demonstrated better performance for filters with a high pleat ratio (>4.0), while clean-on-demand mode performed better for filters with a low pleat ratio (<4.0). The test results also showed the tank pressure was critical for cleaning the pleated filter cartridges, whereas the pulse duration only had a small effect on the cleaning efficiency. With the same base media, cartridges with surface treatment such as fine fiber were superior to those without surface treatment. Pulse-jet cleaning could also promote particle penetration through filter media. The downstream particle concentration during cleaning was at least twice of that during filtration process for all pleated filter cartridges tested. Further, the downstream particle concentration was independent of the applied cleaning mode and the cleaning intensity in this study. Published by Elsevier B.V. C1 [Lo, Li-Ming] NIOSH, US Dept Hlth & Human Serv, Publ Hlth Serv, Ctr Dis Control & Prevent,Div Appl Res & Technol, Cincinnati, OH 45226 USA. [Chen, Da-Ren] Washington Univ, Dept Energy Environm &Chem Engn, St Louis, MO 63130 USA. [Pui, David Y. H.] Univ Minnesota, Dept Mech Engn, Particle Technol Lab, Minneapolis, MN 55455 USA. RP Lo, LM (reprint author), NIOSH, US Dept Hlth & Human Serv, Publ Hlth Serv, Ctr Dis Control & Prevent,Div Appl Res & Technol, 4676 Columbia Pkwy,MS R5, Cincinnati, OH 45226 USA. EM LLo@cdc.gov NR 20 TC 26 Z9 28 U1 0 U2 16 PU ELSEVIER SCIENCE SA PI LAUSANNE PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND SN 0032-5910 J9 POWDER TECHNOL JI Powder Technol. PD JAN 25 PY 2010 VL 197 IS 3 BP 141 EP 149 DI 10.1016/j.powtec.2009.09.007 PG 9 WC Engineering, Chemical SC Engineering GA 538AH UT WOS:000273155500001 ER PT J AU Whiteman, MC Li, L Wicker, JA Kinney, RM Huang, C Beasley, DWC Chung, KM Diamond, MS Solomon, T Barrett, ADT AF Whiteman, Melissa C. Li, Li Wicker, Jason A. Kinney, Richard M. Huang, Claire Beasley, David W. C. Chung, Kyung Min Diamond, Michael S. Solomon, Tom Barrett, Alan D. T. TI Development and characterization of non-glycosylated E and NS1 mutant viruses as a potential candidate vaccine for West Nile virus SO VACCINE LA English DT Article DE West Nile virus; Attenuation; Glycosylation ID VALLEY ENCEPHALITIS-VIRUS; NONSTRUCTURAL PROTEIN NS1; TICK-BORNE ENCEPHALITIS; N-LINKED GLYCOSYLATION; DENGUE VIRUS; ENVELOPE PROTEIN; YELLOW-FEVER; NUCLEOTIDE-SEQUENCE; UNITED-STATES; DOMAIN-III AB West Nile Virus is an arthropod-borne flavivirus that has caused substantial morbidity and mortality to animals as well as humans since its introduction in to the New York area in 1999 Given that there are no antiviral drugs available for treatment of the disease. vaccines provide an efficacious alternative to control this disease Herein we describe an attenuated WNV strain developed by the ablation of the glycosylation sites in the envelope (E) and non-structural 1 (NS1) proteins This E-154S/NS1(130A/175A/207A) strain showed modest reduction in multiplication kinetics in cell Culture and small plaque phenotype compared to the parental NY99 strain yet displayed greater than a 200,000-fold attenuation for mouse neuroinvasiveness compared to the parental strain Mice infected with 1000 PFU of E-154S/NS1(130A/175A/207A) showed undectable viremia at either two or three days post infection, nonetheless, high titer neutralizing antibodies were detected in mice inoculated with low doses of this virus and protected against lethal challenge with a 50% protective dose of 50 PFU (C) 2009 Elsevier Ltd All rights reserved. C1 [Barrett, Alan D. T.] Univ Texas Galveston, Med Branch, Dept Pathol, Galveston, TX 77555 USA. [Whiteman, Melissa C.; Li, Li; Wicker, Jason A.; Barrett, Alan D. T.] Inst Human Infect, Ctr Biodef & Emerging Infect Dis, Sealy Ctr Vaccine Dev, Galveston, TX 77555 USA. [Beasley, David W. C.] Univ Texas Galveston, Dept Microbiol & Immunol, Galveston, TX 77555 USA. [Kinney, Richard M.; Huang, Claire] Ctr Dis Control & Prevent, Div Vector Borne Infect Dis, Publ Hlth Serv, US Dept Hlth & Human Serv, Ft Collins, CO 80521 USA. [Chung, Kyung Min; Diamond, Michael S.] Washington Univ, Dept Med, St Louis, MO 63110 USA. [Diamond, Michael S.] Washington Univ, Dept Mol Microbiol, St Louis, MO 63110 USA. [Diamond, Michael S.] Washington Univ, Dept Pathol & Immunol, St Louis, MO 63110 USA. [Whiteman, Melissa C.; Solomon, Tom] Univ Liverpool, Dept Neurol Sci, Liverpool L69 3BX, Merseyside, England. RP Barrett, ADT (reprint author), Univ Texas Galveston, Med Branch, Dept Pathol, 301 Univ Blvd, Galveston, TX 77555 USA. OI Solomon, Tom/0000-0001-7266-6547 FU Clayton Foundation for Research FX We would like to thank Nivia S. Radzieski for technical assistance and the UTMB Protein Chemistry Core for sequencing. This work Was Supported in part by the Clayton Foundation for Research. NR 52 TC 26 Z9 28 U1 1 U2 7 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD JAN 22 PY 2010 VL 28 IS 4 BP 1075 EP 1083 DI 10.1016/j.vaccine.2009.10.112 PG 9 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 560ZB UT WOS:000274943300034 PM 19896447 ER PT J AU Dabbagh, A Gacic-Dobo, M Simons, E Featherstone, D Strebel, P Okwo-Bele, JM Hoekstra, E Chopra, M Uzicanin, A Cochi, S AF Dabbagh, A. Gacic-Dobo, M. Simons, E. Featherstone, D. Strebel, P. Okwo-Bele, J. M. Hoekstra, E. Chopra, M. Uzicanin, A. Cochi, S. TI Global Measles Mortality, 2000-2008 (Reprinted from MMWR, vol 58, pg 1321-1326, 2009) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Dabbagh, A.; Gacic-Dobo, M.; Simons, E.; Featherstone, D.; Strebel, P.; Okwo-Bele, J. M.] WHO, Dept Immunizat Vaccines & Biol, CH-1211 Geneva, Switzerland. [Hoekstra, E.; Chopra, M.] United Nations Childrens Fund, New York, NY USA. [Uzicanin, A.; Cochi, S.] CDC, Global Immunizat Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Dabbagh, A (reprint author), WHO, Dept Immunizat Vaccines & Biol, CH-1211 Geneva, Switzerland. NR 1 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JAN 20 PY 2010 VL 303 IS 3 BP 216 EP 224 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 544WM UT WOS:000273690600008 ER PT J AU Hampson, N Dunn, S Bronstein, A Fife, C Villanacci, J Zane, D Forrester, M Hellsten, J Beal, R Beasley, C Clower, J Yip, F Iqbal, S Martin, C Cooper, C Wolkin, A Podgornik, M Tokars, J Benoit, S AF Hampson, N. Dunn, S. Bronstein, A. Fife, C. Villanacci, J. Zane, D. Forrester, M. Hellsten, J. Beal, R. Beasley, C. Clower, J. Yip, F. Iqbal, S. Martin, C. Cooper, C. Wolkin, A. Podgornik, M. Tokars, J. Benoit, S. TI Carbon Monoxide Exposures After Hurricane Ike-Texas, September 2008 (Reprinted from MMWR, vol 58, pg 845-849, 2009) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Hampson, N.; Dunn, S.] Virginia Mason Med Ctr, Ctr Hyperbar Med, Seattle, WA 98101 USA. [Bronstein, A.] Amer Assoc Poison Control Ctr, Alexandria, VA USA. [Fife, C.] Mem Hermann Texas Med Ctr, Houston, TX USA. [Villanacci, J.; Zane, D.; Forrester, M.; Hellsten, J.; Beal, R.; Beasley, C.] CDC, Texas Dept State Hlth Svcs, Atlanta, GA 30333 USA. [Clower, J.; Yip, F.; Iqbal, S.; Martin, C.; Cooper, C.; Wolkin, A.] CDC, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. [Podgornik, M.; Tokars, J.; Benoit, S.] CDC, Div Emergency Preparedness & Response, Natl Ctr Publ Hlth Informat, Atlanta, GA 30333 USA. RP Hampson, N (reprint author), Virginia Mason Med Ctr, Ctr Hyperbar Med, Seattle, WA 98101 USA. NR 1 TC 0 Z9 0 U1 1 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JAN 20 PY 2010 VL 303 IS 3 BP 224 EP 226 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 544WM UT WOS:000273690600009 ER PT J AU Flegal, KM Carroll, MD Ogden, CL Curtin, LR AF Flegal, Katherine M. Carroll, Margaret D. Ogden, Cynthia L. Curtin, Lester R. TI Prevalence and Trends in Obesity Among US Adults, 1999-2008 SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID BODY-MASS INDEX; UNITED-STATES; ETHNIC-GROUPS; OVERWEIGHT; MORTALITY; WOMEN; WHITE; COMMUNITIES; POPULATION; STRATEGIES AB Context The prevalence of obesity increased in the United States between 19761980 and 1988-1994 and again between 1988-1994 and 1999-2000. Objective To examine trends in obesity from 1999 through 2008 and the current prevalence of obesity and overweight for 2007-2008. Design, Setting, and Participants Analysis of height and weight measurements from 5555 adult men and women aged 20 years or older obtained in 2007-2008 as part of the National Health and Nutrition Examination Survey (NHANES), a nationally representative sample of the US population. Data from the NHANES obtained in 20072008 were compared with results obtained from 1999 through 2006. Main Outcome Measure Estimates of the prevalence of overweight and obesity in adults. Overweight was defined as a body mass index (BMI) of 25.0 to 29.9. Obesity was defined as a BMI of 30.0 or higher. Results In 2007-2008, the age-adjusted prevalence of obesity was 33.8% (95% confidence interval [CI], 31.6%-36.0%) overall, 32.2% (95% CI, 29.5%-35.0%) among men, and 35.5% (95% CI, 33.2%-37.7%) among women. The corresponding prevalence estimates for overweight and obesity combined (BMI >= 25) were 68.0% (95% CI, 66.3%-69.8%), 72.3% (95% CI, 70.4%-74.1%), and 64.1% (95% CI, 61.3%-66.9%). Obesity prevalence varied by age group and by racial and ethnic group for both men and women. Over the 10-year period, obesity showed no significant trend among women (adjusted odds ratio [AOR] for 2007-2008 vs 1999-2000, 1.12 [95% CI, 0.89-1.32]). For men, there was a significant linear trend (AOR for 2007-2008 vs 1999-2000, 1.32 [95% CI, 1.12-1.58]); however, the 3 most recent data points did not differ significantly from each other. Conclusions In 2007-2008, the prevalence of obesity was 32.2% among adult men and 35.5% among adult women. The increases in the prevalence of obesity previously observed do not appear to be continuing at the same rate over the past 10 years, particularly for women and possibly for men. JAMA. 2010;303(3):235-241 C1 [Flegal, Katherine M.; Carroll, Margaret D.; Ogden, Cynthia L.; Curtin, Lester R.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. RP Flegal, KM (reprint author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, 3311 Toledo Rd,Room 4315, Hyattsville, MD 20782 USA. EM kmf2@cdc.gov RI Flegal, Katherine/A-4608-2013; OI Flegal, Katherine/0000-0002-0838-469X NR 37 TC 1439 Z9 1472 U1 9 U2 172 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JAN 20 PY 2010 VL 303 IS 3 BP 235 EP 241 DI 10.1001/jama.2009.2014 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA 544WM UT WOS:000273690600019 ER PT J AU Ogden, CL Carroll, MD Curtin, LR Lamb, MM Flegal, KM AF Ogden, Cynthia L. Carroll, Margaret D. Curtin, Lester R. Lamb, Molly M. Flegal, Katherine M. TI Prevalence of High Body Mass Index in US Children and Adolescents, 2007-2008 SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID EXPERT COMMITTEE; UNITED-STATES; OVERWEIGHT; OBESITY; RECOMMENDATIONS; ADULTS AB Context The prevalence of high body mass index (BMI) among children and adolescents in the United States appeared to plateau between 1999 and 2006. Objectives To provide the most recent estimates of high BMI among children and adolescents and high weight for recumbent length among infants and toddlers and to analyze trends in prevalence between 1999 and 2008. Design, Setting, and Participants The National Health and Nutrition Examination Survey 2007-2008, a representative sample of the US population with measured heights and weights on 3281 children and adolescents (2 through 19 years of age) and 719 infants and toddlers (birth to 2 years of age). Main Outcome Measures Prevalence of high weight for recumbent length (>= 95th percentile of the Centers for Disease Control and Prevention growth charts) among infants and toddlers. Prevalence of high BMI among children and adolescents defined at 3 levels: BMI for age at or above the 97th percentile, at or above the 95th percentile, and at or above the 85th percentile of the BMI-for-age growth charts. Analyses of trends by age, sex, and race/ethnicity from 1999-2000 to 2007-2008. Results In 2007-2008, 9.5% of infants and toddlers (95% confidence interval [CI], 7.3%-11.7%) were at or above the 95th percentile of the weight-for-recumbent-length growth charts. Among children and adolescents aged 2 through 19 years, 11.9% (95% CI, 9.8%-13.9%) were at or above the 97th percentile of the BMI-for-age growth charts; 16.9% (95% CI, 14.1%-19.6%) were at or above the 95th percentile; and 31.7% (95% CI, 29.2%-34.1%) were at or above the 85th percentile of BMI for age. Prevalence estimates differed by age and by race/ethnic group. Trend analyses indicate no significant trend between 1999-2000 and 2007-2008 except at the highest BMI cut point (BMI for age >= 97th percentile) among all 6-through 19-year-old boys (odds ratio [OR], 1.52; 95% CI, 1.17-2.01) and among non-Hispanic white boys of the same age (OR, 1.87; 95% CI, 1.22-2.94). Conclusion No statistically significant linear trends in high weight for recumbent length or high BMI were found over the time periods 1999-2000, 2001-2002, 2003-2004, 2005-2006, and 2007-2008 among girls and boys except among the very heaviest 6-through 19-year-old boys. JAMA. 2010;303(3):242-249 C1 [Ogden, Cynthia L.; Carroll, Margaret D.; Curtin, Lester R.; Lamb, Molly M.; Flegal, Katherine M.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. RP Ogden, CL (reprint author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, 3311 Toledo Rd,Room 4414, Hyattsville, MD 20782 USA. EM cogden@cdc.gov RI Fruyt, Sofie/F-6843-2011; Flegal, Katherine/A-4608-2013; OI Flegal, Katherine/0000-0002-0838-469X NR 25 TC 1674 Z9 1695 U1 4 U2 118 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JAN 20 PY 2010 VL 303 IS 3 BP 242 EP 249 DI 10.1001/jama.2009.2012 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 544WM UT WOS:000273690600020 PM 20071470 ER PT J AU Huang, CYH Butrapet, S Moss, KJ Childers, T Erb, SM Calvert, AE Silengo, SJ Kinney, RM Blair, CD Roehrig, JT AF Huang, Claire Y. -H. Butrapet, Siritorn Moss, Kelly J. Childers, Thomas Erb, Steven M. Calvert, Amanda E. Silengo, Shawn J. Kinney, Richard M. Blair, Carol D. Roehrig, John T. TI The dengue virus type 2 envelope protein fusion peptide is essential for membrane fusion SO VIROLOGY LA English DT Article DE Dengue; Flavivirus; Fusion; Envelope; Virus-endosome membrane fusion; Virus uncoating; Mutagenesis ID BORNE ENCEPHALITIS-VIRUS; WEST-NILE-VIRUS; CROSS-REACTIVE EPITOPES; MOSQUITO C6/36 CELLS; ENDOCYTIC PATHWAY; E-GLYCOPROTEIN; FLAVIVIRUS FUSION; INFECTIOUS ENTRY; PDK-53 VIRUS; IN-VITRO AB The flaviviral envelope (E) protein directs virus-mediated membrane fusion. To investigate membrane fusion as a requirement for virus growth, we introduced 27 unique mutations into the fusion peptide of an infectious cDNA clone of dengue 2 virus and recovered seven stable mutant Viruses. The fusion efficiency of the mutants was impaired, demonstrating for the first time the requirement for specific FP AAs in optimal fusion. Mutant viruses exhibited different growth kinetics and/or genetic stabilities in different cell types and adult mosquitoes. Virus particles could be recovered following RNA transfection of cells with four lethal mutants; however, recovered viruses could not re-infect cells. These viruses Could enter cells, but internalized virus appeared to be retained in endosomal compartments of infected cells, thus suggesting a fusion blockade. Mutations of the FP also resulted in reduced virus reactivity with flavivirus group-reactive antibodies, confirming earlier reports using virus-like particles. Published by Elsevier Inc. C1 [Huang, Claire Y. -H.; Butrapet, Siritorn; Moss, Kelly J.; Childers, Thomas; Calvert, Amanda E.; Silengo, Shawn J.; Kinney, Richard M.; Roehrig, John T.] Ctr Dis Control & Prevent, Div Vector Borne Infect Dis, Publ Hlth Serv, US Dept HHS, Ft Collins, CO 80521 USA. [Erb, Steven M.; Blair, Carol D.] Colorado State Univ, Arthropod Borne & Infect Dis Lab, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA. RP Huang, CYH (reprint author), DVBID CDC, 3150 Rampart Rd, Ft Collins, CO 80521 USA. EM CHuang1@cdc.gov OI Roehrig, John/0000-0001-7581-0479 FU Centers for Disease Control and Prevention; Pediatric Dengue Vaccine Initiative (PDVI) [TR-159A]; College of Veterinary Medicine and Biomedical Sciences Research Council FX We would like to acknowledge Rich Tsuchiya, Betty Luy, Karen Boroughs, and Janae Stovall for their assistance in mutant viral genome sequencing and virus production. We also greatly appreciate Dr. Brad Biggerstaff and Mark Delorey for their expert consultations in statistical analysis. This study was supported by the Centers for Disease Control and Prevention, and grants from the Pediatric Dengue Vaccine Initiative (PDVI TR-159A) and the College of Veterinary Medicine and Biomedical Sciences Research Council. NR 58 TC 22 Z9 22 U1 1 U2 6 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0042-6822 J9 VIROLOGY JI Virology PD JAN 20 PY 2010 VL 396 IS 2 BP 305 EP 315 DI 10.1016/j.virol.2009.10.027 PG 11 WC Virology SC Virology GA 542OS UT WOS:000273504600015 PM 19913272 ER PT J AU Brown, DW Anda, RF Felitti, VJ Edwards, VJ Malarcher, AM Croft, JB Giles, WH AF Brown, David W. Anda, Robert F. Felitti, Vincent J. Edwards, Valerie J. Malarcher, Ann Marie Croft, Janet B. Giles, Wayne H. TI Adverse childhood experiences are associated with the risk of lung cancer: a prospective cohort study SO BMC PUBLIC HEALTH LA English DT Article ID NATIONAL DEATH INDEX; SEXUAL-ABUSE; HOUSEHOLD DYSFUNCTION; SMOKING; MORTALITY; ADULTHOOD; WOMEN; INFLAMMATION; PREVALENCE; DISEASE AB Background: Strong relationships between exposure to childhood traumatic stressors and smoking behaviours inspire the question whether these adverse childhood experiences (ACEs) are associated with an increased risk of lung cancer during adulthood. Methods: Baseline survey data on health behaviours, health status and exposure to adverse childhood experiences (ACEs) were collected from 17,337 adults during 1995-1997. ACEs included abuse (emotional, physical, sexual), witnessing domestic violence, parental separation or divorce, or growing up in a household where members with mentally ill, substance abusers, or sent to prison. We used the ACE score (an integer count of the 8 categories of ACEs) as a measure of cumulative exposure to traumatic stress during childhood. Two methods of case ascertainment were used to identify incident lung cancer through 2005 follow-up: 1) hospital discharge records and 2) mortality records obtained from the National Death Index. Results: The ACE score showed a graded relationship to smoking behaviors. We identified 64 cases of lung cancer through hospital discharge records (age-standardized risk = 201 x 100,000(-1) population) and 111 cases of lung cancer through mortality records (age-standardized mortality rate = 31.1 x 100,000(-1) person-years). The ACE score also showed a graded relationship to the incidence of lung cancer for cases identified through hospital discharge (P = 0.0004), mortality (P = 0.025), and both methods combined (P = 0.001). Compared to persons without ACEs, the risk of lung cancer for those with >= 6 ACEs was increased approximately 3-fold (hospital records: RR = 3.18, 95% CI = 0.71-14.15; mortality records: RR = 3.55, 95% CI = 1.25-10.09; hospital or mortality records: RR = 2.70, 95% CI = 0.94-7.72). After a priori consideration of a causal pathway (i.e., ACEs --> smoking --> lung cancer), risk ratios were attenuated toward the null, although not completely. For lung cancer identified through hospital or mortality records, persons with >= 6 ACEs were roughly 13 years younger on average at presentation than those without ACEs. Conclusions: Adverse childhood experiences may be associated with an increased risk of lung cancer, particularly premature death from lung cancer. The increase in risk may only be partly explained by smoking suggesting other possible mechanisms by which ACEs may contribute to the occurrence of lung cancer. C1 [Brown, David W.; Anda, Robert F.; Edwards, Valerie J.; Malarcher, Ann Marie; Croft, Janet B.; Giles, Wayne H.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Brown, David W.] Erasmus Univ, Med Ctr, Netherlands Inst Hlth Sci, Rotterdam, Netherlands. [Felitti, Vincent J.] Kaiser Permanente, So Calif Permanente Grp, San Diego, CA USA. RP Brown, DW (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. EM dbrown6@cdc.gov NR 50 TC 68 Z9 70 U1 0 U2 17 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2458 J9 BMC PUBLIC HEALTH JI BMC Public Health PD JAN 19 PY 2010 VL 10 AR 20 DI 10.1186/1471-2458-10-20 PG 12 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 566WV UT WOS:000275405100001 PM 20085623 ER PT J AU Notari, S Moleres, FJ Hunter, SB Belay, ED Schonberger, LB Cali, I Parchi, P Shieh, WJ Brown, P Zaki, S Zou, WQ Gambetti, P AF Notari, Silvio Moleres, Francisco J. Hunter, Stephen B. Belay, Ermias D. Schonberger, Lawrence B. Cali, Ignazio Parchi, Piero Shieh, Wun-Ju Brown, Paul Zaki, Sherif Zou, Wen-Quan Gambetti, Pierluigi TI Multiorgan Detection and Characterization of Protease-Resistant Prion Protein in a Case of Variant CJD Examined in the United States SO PLOS ONE LA English DT Article ID CREUTZFELDT-JAKOB-DISEASE; SPONGIFORM ENCEPHALOPATHY PRIONS; CLINICAL-FEATURES; TRUNCATED FORMS; URINE; TRANSMISSION; ACCUMULATION; PRPSC; BSE; LOCALIZATION AB Background: Variant Creutzfeldt-Jakob disease (vCJD) is a prion disease thought to be acquired by the consumption of prion-contaminated beef products. To date, over 200 cases have been identified around the world, but mainly in the United Kingdom. Three cases have been identified in the United States; however, these subjects were likely exposed to prion infection elsewhere. Here we report on the first of these subjects. Methodology/Principal Findings: Neuropathological and genetic examinations were carried out using standard procedures. We assessed the presence and characteristics of protease-resistant prion protein (PrP(res)) in brain and 23 other organs and tissues using immunoblots performed directly on total homogenate or following sodium phosphotungstate precipitation to increase PrP(res) detectability. The brain showed a lack of typical spongiform degeneration and had large plaques, likely stemming from the extensive neuronal loss caused by the long duration (32 months) of the disease. The PrP(res) found in the brain had the typical characteristics of the PrP(res) present in vCJD. In addition to the brain and other organs known to be prion positive in vCJD, such as the lymphoreticular system, pituitary and adrenal glands, and gastrointestinal tract, PrP(res) was also detected for the first time in the dura mater, liver, pancreas, kidney, ovary, uterus, and skin. Conclusions/Significance: Our results indicate that the number of organs affected in vCJD is greater than previously realized and further underscore the risk of iatrogenic transmission in vCJD. C1 [Notari, Silvio; Moleres, Francisco J.; Cali, Ignazio; Zou, Wen-Quan; Gambetti, Pierluigi] Case Western Reserve Univ, Inst Pathol, Cleveland, OH 44106 USA. [Hunter, Stephen B.] Emory Univ Hosp, Dept Pathol & Lab Med, Atlanta, GA 30322 USA. [Belay, Ermias D.; Schonberger, Lawrence B.; Shieh, Wun-Ju; Zaki, Sherif] Ctr Dis Control & Prevent, Natl Ctr Zoonot Vector Borne & Enter Dis, Atlanta, GA USA. [Parchi, Piero] Univ Bologna, Dipartimento Sci Neurol, I-40126 Bologna, Italy. [Brown, Paul] SEPIA, iMETI, DSV, CEA, Paris, France. RP Notari, S (reprint author), Case Western Reserve Univ, Inst Pathol, 2085 Adelbert Rd, Cleveland, OH 44106 USA. EM pxg13@case.edu RI Belay, Ermias/A-8829-2013; Parchi, Piero/L-9833-2015; OI Parchi, Piero/0000-0002-9444-9524; cali, ignazio/0000-0001-5770-3848 FU National Institutes of Health [AG14359]; Centers for Disease Control and Prevention ( [CCU515004]; Charles S. Britton Fund; NIH [R01 NS062787]; Creutzfeldt-Jakob Disease Foundation FX The study was supported by National Institutes of Health grant AG14359, Centers for Disease Control and Prevention (CCU515004), and the Charles S. Britton Fund to PG; grant NIH R01 NS062787 and the Creutzfeldt-Jakob Disease Foundation to WQZ, as for cost of supplies and salaries. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 54 TC 27 Z9 27 U1 1 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JAN 19 PY 2010 VL 5 IS 1 AR e8765 DI 10.1371/journal.pone.0008765 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 546AH UT WOS:000273778900009 PM 20098730 ER PT J AU Sansom, SL Prabhu, VS Hutchinson, AB An, Q Hall, HI Shrestha, RK Lasry, A Taylor, AW AF Sansom, Stephanie L. Prabhu, Vimalanand S. Hutchinson, Angela B. An, Qian Hall, H. Irene Shrestha, Ram K. Lasry, Arielle Taylor, Allan W. TI Cost-Effectiveness of Newborn Circumcision in Reducing Lifetime HIV Risk among US Males SO PLOS ONE LA English DT Article ID UNITED-STATES; NEONATAL CIRCUMCISION; UTILITY ANALYSIS; INFECTION; MEN; METAANALYSIS; PREVENTION; HERPES; TRIAL; SEX AB Background: HIV incidence was substantially lower among circumcised versus uncircumcised heterosexual African men in three clinical trials. Based on those findings, we modeled the potential effect of newborn male circumcision on a U. S. male's lifetime risk of HIV, including associated costs and quality-adjusted life-years saved. Methodology/Principal Findings: Given published estimates of U. S. males' lifetime HIV risk, we calculated the fraction of lifetime risk attributable to heterosexual behavior from 2005-2006 HIV surveillance data. We assumed 60% efficacy of circumcision in reducing heterosexually-acquired HIV over a lifetime, and varied efficacy in sensitivity analyses. We calculated differences in lifetime HIV risk, expected HIV treatment costs and quality-adjusted life years (QALYs) among circumcised versus uncircumcised males. The main outcome measure was cost per HIV-related QALY saved. Circumcision reduced the lifetime HIV risk among all males by 15.7% in the base case analysis, ranging from 7.9% for white males to 20.9% for black males. Newborn circumcision was a cost-saving HIV prevention intervention for all, black and Hispanic males. The net cost of newborn circumcision per QALY saved was $87,792 for white males. Results were most sensitive to the discount rate, and circumcision efficacy and cost. Conclusions/Significance: Newborn circumcision resulted in lower expected HIV-related treatment costs and a slight increase in QALYs. It reduced the 1.87% lifetime risk of HIV among all males by about 16%. The effect varied substantially by race and ethnicity. Racial and ethnic groups who could benefit the most from circumcision may have least access to it due to insurance coverage and state Medicaid policies, and these financial barriers should be addressed. More data on the long-term protective C1 [Sansom, Stephanie L.; Prabhu, Vimalanand S.; Hutchinson, Angela B.; An, Qian; Hall, H. Irene; Shrestha, Ram K.; Lasry, Arielle; Taylor, Allan W.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP Sansom, SL (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. EM sos9@cdc.gov NR 50 TC 38 Z9 40 U1 1 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JAN 18 PY 2010 VL 5 IS 1 AR e8723 DI 10.1371/journal.pone.0008723 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 545EJ UT WOS:000273715000003 PM 20090910 ER PT J AU Baker, MC Mathieu, E Fleming, FM Deming, M King, JD Garba, A Koroma, JB Bockarie, M Kabore, A Sankara, DP Molyneux, DH AF Baker, M. C. Mathieu, E. Fleming, F. M. Deming, M. King, J. D. Garba, A. Koroma, J. B. Bockarie, M. Kabore, A. Sankara, D. P. Molyneux, D. H. TI Neglected Tropical Diseases 3 Mapping, monitoring, and surveillance of neglected tropical diseases: towards a policy framework SO LANCET LA English DT Article ID CIRCULATING CATHODIC ANTIGEN; SUB-SAHARAN AFRICA; LOA-LOA INFECTION; LYMPHATIC FILARIASIS; BANCROFTIAN FILARIASIS; RAPID ASSESSMENT; URINARY SCHISTOSOMIASIS; ONCHOCERCIASIS CONTROL; COST-EFFECTIVENESS; SPATIAL-ANALYSIS AB As national programmes respond to the new opportunities presented for scaling up preventive chemotherapy programmes for the coadministration of drugs to target lymphatic filariasis, onchocerciasis, schistosomiasis, soil-transmitted helminthiasis, and trachoma, possible synergies between existing disease-specific policies and protocols need to be examined. In this report we compare present policies for mapping, monitoring, and surveillance for these diseases, drawing attention to both the challenges and opportunities for integration. Although full integration of all elements of mapping, monitoring, and surveillance strategies might not be feasible for the diseases targeted through the preventive chemotherapy approach, there are opportunities for integration, and we present examples of integrated strategies. Finally, if advantage is to be taken of scaled up interventions to address neglected tropical diseases, efforts to develop rapid, inexpensive, and easy-to-use methods, whether disease-specific or integrated, should be increased. We present a framework for development of an integrated monitoring and evaluation system that combines both integrated and disease-specific strategies. C1 [Baker, M. C.] RTI Int, Ctr Int Hlth, Washington, DC 20005 USA. [Mathieu, E.; Deming, M.] Ctr Dis Control & Prevent, Div Parasit Dis, Parasit Dis Branch, Atlanta, GA USA. [Fleming, F. M.] Univ London Imperial Coll Sci Technol & Med, Schistosomiasis Control Initiat, London, England. [King, J. D.] Emory Univ, Carter Ctr, Atlanta, GA 30322 USA. [Garba, A.] RISEAL, NTD Control Program, Niamey, Niger. [Koroma, J. B.] Minist Hlth & Sanitat, Natl Onchocerciasis Neglected Trop Dis Control Pr, Freetown, Sierra Leone. [Bockarie, M.; Molyneux, D. H.] Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England. [Kabore, A.] Liverpool Associates Hlth, Liverpool, Merseyside, England. RP Baker, MC (reprint author), RTI Int, Ctr Int Hlth, 805 15th St NW,Suite 601, Washington, DC 20005 USA. EM mcb93@georgetown.edu FU USAID FX We thank Annie Baridjord for her administrative supporting in preparing this report. The views of the authors are their own and do not necessarily represent those of the US Centers for Disease Control and Prevention. This study is made possible by the generous support of the American people through USAID. The contents are the responsibility of the authors and do not necessarily reflect the views of USAID or the US Government. NR 82 TC 37 Z9 38 U1 0 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0140-6736 J9 LANCET JI Lancet PD JAN 16 PY 2010 VL 375 IS 9710 BP 231 EP 238 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA 546ZH UT WOS:000273853800033 PM 20109924 ER PT J AU Biernath, KR Montero, DP Mehl, A Toomey, KE AF Biernath, Krista R. Montero, Daniel P. Mehl, Albert Toomey, Kathleen E. TI Universal Newborn Hearing Screening and Beyond SO AMERICAN FAMILY PHYSICIAN LA English DT Editorial Material ID STATEMENT; CHILDREN C1 [Biernath, Krista R.] Ctr Dis Control & Prevent, Natl Birth Defects Ctr & Dev Disabil, Atlanta, GA 30333 USA. [Montero, Daniel P.] Mayo Clin, Jacksonville, FL 32224 USA. [Mehl, Albert] Amer Acad Pediat Task Force Improving Newborn Hea, Boulder, CO USA. [Toomey, Kathleen E.] Ctr Dis Control & Prevent BOTUSA, Gaborone, Botswana. RP Biernath, KR (reprint author), Ctr Dis Control & Prevent, Natl Birth Defects Ctr & Dev Disabil, Atlanta, GA 30333 USA. EM kbiernath@cdc.gov NR 10 TC 2 Z9 2 U1 0 U2 0 PU AMER ACAD FAMILY PHYSICIANS PI KANSAS CITY PA 8880 WARD PARKWAY, KANSAS CITY, MO 64114-2797 USA SN 0002-838X J9 AM FAM PHYSICIAN JI Am. Fam. Physician PD JAN 15 PY 2010 VL 81 IS 2 BP 124 EP 125 PG 2 WC Primary Health Care; Medicine, General & Internal SC General & Internal Medicine GA 546TC UT WOS:000273833800003 PM 20082506 ER PT J AU Greene, SK Kulldorff, M Lewis, EM Li, R Yin, RH Weintraub, ES Fireman, BH Lieu, TA Nordin, JD Glanz, JM Baxter, R Jacobsen, SJ Broder, KR Lee, GM AF Greene, Sharon K. Kulldorff, Martin Lewis, Edwin M. Li, Rong Yin, Ruihua Weintraub, Eric S. Fireman, Bruce H. Lieu, Tracy A. Nordin, James D. Glanz, Jason M. Baxter, Roger Jacobsen, Steven J. Broder, Karen R. Lee, Grace M. TI Near Real-Time Surveillance for Influenza Vaccine Safety: Proof-of-Concept in the Vaccine Safety Datalink Project SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Article DE cohort studies; influenza; human; influenza vaccines; managed care programs; population surveillance; safety; vaccines ID IMMUNIZATION PRACTICES ACIP; GUILLAIN-BARRE-SYNDROME; PLACEBO-CONTROLLED TRIAL; EVENT REPORTING SYSTEM; ADVERSE EVENTS; ADVISORY-COMMITTEE; UNITED-STATES; ELDERLY-PEOPLE; BELLS-PALSY; CASE SERIES AB The emergence of pandemic H1N1 influenza in 2009 has prompted public health responses, including production and licensure of new influenza A (H1N1) 2009 monovalent vaccines. Safety monitoring is a critical component of vaccination programs. As proof-of-concept, the authors mimicked near real-time prospective surveillance for prespecified neurologic and allergic adverse events among enrollees in 8 medical care organizations (the Vaccine Safety Datalink Project) who received seasonal trivalent inactivated influenza vaccine during the 2005/06-2007/08 influenza seasons. In self-controlled case series analysis, the risk of adverse events in a prespecified exposure period following vaccination was compared with the risk in 1 control period for the same individual either before or after vaccination. In difference-in-difference analysis, the relative risk in exposed versus control periods each season was compared with the relative risk in previous seasons since 2000/01. The authors used Poisson-based analysis to compare the risk of Guillian-Barre syndrome following vaccination in each season with that in previous seasons. Maximized sequential probability ratio tests were used to adjust for repeated analyses on weekly data. With administration of 1,195,552 doses to children under age 18 years and 4,773,956 doses to adults, no elevated risk of adverse events was identified. Near real-time surveillance for selected adverse events can be implemented prospectively to rapidly assess seasonal and pandemic influenza vaccine safety. C1 [Greene, Sharon K.; Kulldorff, Martin; Li, Rong; Yin, Ruihua; Lieu, Tracy A.; Lee, Grace M.] Harvard Univ, Sch Med, Dept Populat Med, Boston, MA 02215 USA. [Greene, Sharon K.; Kulldorff, Martin; Li, Rong; Yin, Ruihua; Lieu, Tracy A.; Lee, Grace M.] Harvard Pilgrim Hlth Care Inst, Boston, MA USA. [Lewis, Edwin M.; Fireman, Bruce H.; Baxter, Roger] Kaiser Permanente, Vaccine Study Ctr, Oakland, CA USA. [Weintraub, Eric S.; Broder, Karen R.] Ctr Dis Control & Prevent, Immunizat Safety Off, Atlanta, GA USA. [Nordin, James D.] HealthPartners Res Fdn, Minneapolis, MN USA. [Glanz, Jason M.] Kaiser Permanente, Denver, CO USA. [Jacobsen, Steven J.] Kaiser Permanente So Calif, Dept Res & Evaluat, Pasadena, CA USA. [Lee, Grace M.] Childrens Hosp, Div Infect Dis, Dept Med, Boston, MA 02115 USA. [Lee, Grace M.] Childrens Hosp, Dept Lab Med, Boston, MA 02115 USA. RP Greene, SK (reprint author), Harvard Univ, Sch Med, Dept Populat Med, 133 Brookline Ave,6th Floor, Boston, MA 02215 USA. EM sharon_greene@harvardpilgrim.org RI Kulldorff, Martin/H-4282-2011; OI Kulldorff, Martin/0000-0002-5284-2993; Jacobsen, Steven/0000-0002-8174-8533 FU Sanofi Pasteur; Chiron; MedImmune; Merck; Wyeth; Novartis; GSK FX The findings and conclusions in this report are those of the authors and do not necessarily represent the views or policies of the Centers for Disease Control and Prevention. Edwin M. Lewis reports having received grant support from Sanofi Pasteur, Chiron, MedImmune, Merck, and Wyeth. Dr. James D. Nordin reports having received grant support from Sanofi Pasteur. Dr. Roger Baxter reports having received grant support from Sanofi Pasteur, Novartis, GSK, and MedImmune. No other authors have any potential or real conflicts of interest to declare. NR 67 TC 71 Z9 74 U1 1 U2 8 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD JAN 15 PY 2010 VL 171 IS 2 BP 177 EP 188 DI 10.1093/aje/kwp345 PG 12 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 539AD UT WOS:000273224700005 PM 19965887 ER PT J AU Cain, KP Varma, JK AF Cain, Kevin P. Varma, Jay K. TI Does Finding M. Tuberculosis in Sputum Always Equal Tuberculosis Disease? SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Letter ID HIV-INFECTION; MORTALITY; PATHOLOGY; DEATH C1 [Cain, Kevin P.; Varma, Jay K.] US Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Varma, Jay K.] US Ctr Dis Control & Prevent, Beijing, Peoples R China. RP Cain, KP (reprint author), US Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. NR 6 TC 0 Z9 0 U1 0 U2 1 PU AMER THORACIC SOC PI NEW YORK PA 1740 BROADWAY, NEW YORK, NY 10019-4374 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD JAN 15 PY 2010 VL 181 IS 2 BP 196 EP 197 PG 2 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 542ZY UT WOS:000273539800019 ER PT J AU Fan, AZ Yesupriya, A Chang, MH House, M Fang, J Ned, R Hayes, D Dowling, NF Mokdad, AH AF Fan, Amy Z. Yesupriya, Ajay Chang, Man-huei House, Meaghan Fang, Jing Ned, Renee Hayes, Donald Dowling, Nicole F. Mokdad, Ali H. TI Gene polymorphisms in association with emerging cardiovascular risk markers in adult women SO BMC MEDICAL GENETICS LA English DT Article ID C-REACTIVE PROTEIN; CORONARY-HEART-DISEASE; GENOME-WIDE ASSOCIATION; SERUM URIC-ACID; VASCULAR-DISEASE; BLOOD-PRESSURE; ENDOTHELIAL DYSFUNCTION; CRP GENE; INFLAMMATION; HOMOCYSTEINE AB Background: Evidence on the associations of emerging cardiovascular disease risk factors/markers with genes may help identify intermediate pathways of disease susceptibility in the general population. This population-based study is aimed to determine the presence of associations between a wide array of genetic variants and emerging cardiovascular risk markers among adult US women. Methods: The current analysis was performed among the National Health and Nutrition Examination Survey (NHANES) III phase 2 samples of adult women aged 17 years and older (sample size n = 3409). Fourteen candidate genes within ADRB2, ADRB3, CAT, CRP, F2, F5, FGB, ITGB3, MTHFR, NOS3, PON1, PPARG, TLR4, and TNF were examined for associations with emerging cardiovascular risk markers such as serum C-reactive protein, homocysteine, uric acid, and plasma fibrinogen. Linear regression models were performed using SAS-callable SUDAAN 9.0. The covariates included age, race/ethnicity, education, menopausal status, female hormone use, aspirin use, and lifestyle factors. Results: In covariate-adjusted models, serum C-reactive protein concentrations were significantly (P value controlling for false-discovery rate <= 0.05) associated with polymorphisms in CRP (rs3093058, rs1205), MTHFR (rs1801131), and ADRB3 (rs4994). Serum homocysteine levels were significantly associated with MTHFR (rs1801133). Conclusion: The significant associations between certain gene variants with concentration variations in serum C-reactive protein and homocysteine among adult women need to be confirmed in further genetic association studies. C1 [Fan, Amy Z.; Yesupriya, Ajay; Chang, Man-huei; Fang, Jing; Ned, Renee; Hayes, Donald; Dowling, Nicole F.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [House, Meaghan] Emory Univ, Sch Publ Hlth, Atlanta, GA 30329 USA. [Mokdad, Ali H.] Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98121 USA. RP Fan, AZ (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, 1600 Clifton Rd, Atlanta, GA 30333 USA. EM afan@cdc.gov RI Ned, Renee/D-3746-2009 FU CDC/NCI NHANES III FX The findings and conclusions in this article are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.; This project was completed in partnership with the CDC/NCI NHANES III Genomics Working Group. NR 63 TC 8 Z9 8 U1 0 U2 0 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2350 J9 BMC MED GENET JI BMC Med. Genet. PD JAN 15 PY 2010 VL 11 AR 6 DI 10.1186/1471-2350-11-6 PG 8 WC Genetics & Heredity SC Genetics & Heredity GA 565ZY UT WOS:000275340300001 PM 20078877 ER PT J AU Ma, HY Wang, YP Sullivan-Halley, J Weiss, L Marchbanks, PA Spirtas, R Ursin, G Burkman, RT Simon, MS Malone, KE Strom, BL McDonald, JA Press, MF Bernstein, L AF Ma, Huiyan Wang, Yaping Sullivan-Halley, Jane Weiss, Linda Marchbanks, Polly A. Spirtas, Robert Ursin, Giske Burkman, Ronald T. Simon, Michael S. Malone, Kathleen E. Strom, Brian L. McDonald, Jill A. Press, Michael F. Bernstein, Leslie TI Use of Four Biomarkers to Evaluate the Risk of Breast Cancer Subtypes in the Women's Contraceptive and Reproductive Experiences Study SO CANCER RESEARCH LA English DT Article ID AFRICAN-AMERICAN WOMEN; ESTROGEN-RECEPTOR; PROGESTERONE-RECEPTOR; HORMONE-RECEPTOR; PROTEIN OVEREXPRESSION; MONOCLONAL-ANTIBODIES; P53 EXPRESSION; HER-2/NEU GENE; MUTATIONS; CARCINOMA AB Epidemiologic studies suggest that some hormone-related risk factors in breast cancer differentially influence risk for disease subtypes classified by the status of the estrogen and progesterone receptors (ER/PR). However, it remains unclear whether human epidermal growth factor receptor 2 (HER2) or p53 expression status further differentiates these exposure-risk group associations. We evaluated the associations of oral contraceptive (OC) use and reproductive factors with incident invasive breast cancer subtypes among 1,197 population-based cases and 2,015 controls from the Los Angeles County or Detroit components of the Women's Contraceptive and Reproductive Experiences Study. Case-control comparisons by ER/PR/HER2/p53 status were conducted by multivariable polychotomous unconditional logistic regression methods. We found that OC use was not associated with any breast cancer subtype as defined by ER/PR/HER2/p53 status, except for a 2.9-fold increased risk of so-called triple-negative tumors (ER(-)/PR(-)/HER2(-)) among women of 45 to 64 years of age who started OC use before age 18. Parity was associated with a decreased risk of luminal A (ER(+) or PR(+), HER2(-)), luminal B (ER(+) or PR(+)/HER2(+)), and ER(-)/PR(-)/HER2(+) tumors. Age at first full-term pregnancy was positively associated with luminal A tumors among older women. Neither of these reproductive factors was associated with triple-negative tumors. Long duration of breast-feeding lowered the risk of triple-negative and luminal A tumors. p53 status did not define further differential risk patterns. Our findings offer evidence of differences in the hormone-related risk factors between triple-negative cancers and other ER/PR/HER2-defined subtypes of breast cancer. Cancer Res; 70(2); 575-87. (C)2010 AACR. C1 [Ma, Huiyan; Sullivan-Halley, Jane; Bernstein, Leslie] City Hope Med Ctr, Dept Populat Sci, Div Canc Etiol, Duarte, CA USA. [Wang, Yaping; Ursin, Giske; Bernstein, Leslie] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA. [Press, Michael F.] Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA. [Weiss, Linda] NCI, Canc Ctr Branch, Bethesda, MD 20892 USA. [Spirtas, Robert] NICHHD, Contracept & Reprod Hlth Branch, Populat Res Ctr, Bethesda, MD 20892 USA. [Marchbanks, Polly A.; McDonald, Jill A.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA. [Ursin, Giske] Univ Oslo, Dept Nutr, Oslo, Norway. [Burkman, Ronald T.] Baystate Med Ctr, Dept Obstet & Gynecol, Springfield, MA USA. [Simon, Michael S.] Wayne State Univ, Karmanos Canc Inst, Div Hematol Oncol, Detroit, MI USA. [Malone, Kathleen E.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA. [Strom, Brian L.] Univ Penn, Sch Med, Ctr Educ & Res Therapeut, Dept Biostat & Epidemiol,Ctr Clin Epidemiol & Bio, Philadelphia, PA 19104 USA. RP Bernstein, L (reprint author), City Hope Natl Med Ctr, Dept Populat Sci, Div Canc Etiol, 1500 E Duarte Rd, Duarte, CA 91010 USA. EM LBernstein@coh.org FU National Institute for Child Health and Human Development [NO1-HD-3-3175]; National Cancer Institute [CA48780]; National Institute of Child Health and Human Development and National Cancer Institute, NIH, through Emory University [N01-HD-3-3168]; Fred Hutchinson Cancer Research Center [N01-HD-2-3166]; Karmanos Cancer Institute at Wayne State University [N01-HD-3-3174]; University of Pennsylvania [NO1-HD-3-3276]; University of Southern California [N01-HD-3-3175]; Interagency Agreement with Centers for Disease Control and Prevention [Y01-HD-7022]; California Department of Health Services [103885]; [N01-PC-67006 (Atlanta)]; [N01-CN-65064 (Detroit)]; [N01-PC-67010 (LA)]; [N01-CN-0532 (Seattle)] FX Grant Support; National Institute for Child Health and Human Development grant NO1-HD-3-3175 and National Cancer Institute grant CA48780. Data collection for the Women's CARE Study was supported by the National Institute of Child Health and Human Development and National Cancer Institute, NIH, through contracts with Emory University (N01-HD-3-3168), Fred Hutchinson Cancer Research Center (N01-HD-2-3166), Karmanos Cancer Institute at Wayne State University (N01-HD-3-3174), University of Pennsylvania (NO1-HD-3-3276), and University of Southern California (N01-HD-3-3175) and Interagency Agreement with Centers for Disease Control and Prevention (Y01-HD-7022). Collection of cancer incidence data in LA County by University of Southern California was supported by California Department of Health Services as part of statewide cancer reporting program mandated by California Health and Safety Code, Section 103885. Support for use of SEER cancer registries through contracts N01-PC-67006 (Atlanta), N01-CN-65064 (Detroit), N01-PC-67010 (LA), and N01-CN-0532 (Seattle). NR 50 TC 50 Z9 50 U1 0 U2 5 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 0008-5472 J9 CANCER RES JI Cancer Res. PD JAN 15 PY 2010 VL 70 IS 2 BP 575 EP 587 DI 10.1158/0008-5472.CAN-09-3460 PG 13 WC Oncology SC Oncology GA 607FW UT WOS:000278485500018 PM 20068186 ER PT J AU Walter, ND Taylor, TH Shay, DK Thompson, WW Brammer, L Dowell, SF Moore, MR AF Walter, Nicholas D. Taylor, Thomas H., Jr. Shay, David K. Thompson, William W. Brammer, Lynnette Dowell, Scott F. Moore, Matthew R. CA Active Bacterial Core Surveillance TI Influenza Circulation and the Burden of Invasive Pneumococcal Pneumonia during a Non-pandemic Period in the United States SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID SECONDARY BACTERIAL PNEUMONIA; STREPTOCOCCUS-PNEUMONIAE; RESPIRATORY VIRUSES; DISEASE; NEURAMINIDASE; MORTALITY; PREPAREDNESS; ASSOCIATION; INFECTIONS; CHILDREN AB Background. Animal models and data from influenza pandemics suggest that influenza infection predisposes individuals to pneumococcal pneumonia. Influenza may contribute to high winter rates of pneumococcal pneumonia during non-pandemic periods, but the magnitude of this effect is unknown. With use of United States surveillance data during 1995-2006, we estimated the association between influenza circulation and invasive pneumococcal pneumonia rates. Methods. Weekly invasive pneumococcal pneumonia incidence, defined by isolation of pneumococci from normally sterile sites in persons with clinical or radiographic pneumonia, was estimated from active population-based surveillance in 3 regions of the United States. We used influenza virus data collected by World Health Organization collaborating laboratories in the same 3 regions in seasonally adjusted negative binomial regression models to estimate the influenza-associated fraction of pneumococcal pneumonia. Results. During similar to 185 million person-years of surveillance, we observed 21,239 episodes of invasive pneumococcal pneumonia; 485,691 specimens were tested for influenza. Influenza circulation was associated with 11%-14% of pneumococcal pneumonia during periods of influenza circulation and 5%-6% overall. In 2 of 3 regions, the association was strongest when influenza circulation data were lagged by 1 week. Conclusions. During recent seasonal influenza epidemics in the United States, a modest but potentially preventable fraction of invasive pneumococcal pneumonia was associated with influenza circulation. C1 [Walter, Nicholas D.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Off Workforce & Career Dev, Atlanta, GA USA. [Walter, Nicholas D.; Moore, Matthew R.] Ctr Dis Control & Prevent, Resp Dis Branch, Atlanta, GA USA. [Taylor, Thomas H., Jr.] Ctr Dis Control & Prevent, Div Bacterial Dis, Atlanta, GA USA. [Shay, David K.; Thompson, William W.; Brammer, Lynnette] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [Dowell, Scott F.] Ctr Dis Control & Prevent, Coordinating Off Global Hlth, Atlanta, GA USA. RP Walter, ND (reprint author), Univ Colorado Denver, Div Pulm Sci & Crit Care Med, Anschutz Med Campus Res,Box C272,9th Floor,127 E, Aurora, CO 80045 USA. EM Nicholas.Walter@ucdenver.edu OI Shay, David/0000-0001-9619-4820 FU Centers for Disease Control and Prevention Emerging Infections Program; National Center for Immunization and Respiratory Diseases FX Centers for Disease Control and Prevention Emerging Infections Program and the National Center for Immunization and Respiratory Diseases. NR 36 TC 50 Z9 52 U1 0 U2 6 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JAN 15 PY 2010 VL 50 IS 2 BP 175 EP 183 DI 10.1086/649208 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 536UK UT WOS:000273069100004 PM 20014948 ER PT J AU Cohn, AC MacNeil, JR Harrison, LH Hatcher, C Theodore, J Schmidt, M Pondo, T Arnold, KE Baumbach, J Bennett, N Craig, AS Farley, M Gershman, K Petit, S Lynfield, R Reingold, A Schaffner, W Shutt, KA Zell, ER Mayer, LW Clark, T Stephens, D Messonnier, NE AF Cohn, Amanda C. MacNeil, Jessica R. Harrison, Lee H. Hatcher, Cynthia Theodore, Jordan Schmidt, Mark Pondo, Tracy Arnold, Kathryn E. Baumbach, Joan Bennett, Nancy Craig, Allen S. Farley, Monica Gershman, Ken Petit, Susan Lynfield, Ruth Reingold, Arthur Schaffner, William Shutt, Kathleen A. Zell, Elizabeth R. Mayer, Leonard W. Clark, Thomas Stephens, David Messonnier, Nancy E. TI Changes in Neisseria meningitidis Disease Epidemiology in the United States, 1998-2007: Implications for Prevention of Meningococcal Disease SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID NASOPHARYNGEAL CARRIAGE; VACCINE; IDENTIFICATION; INFANTS AB Background. In January 2005, a quadrivalent (serogroups A, C, Y, and W-135) meningococcal conjugate vaccine was licensed for use in adolescents. This report describes the epidemiologic features of meningococcal disease in the United States from January 1998 through December 2007, before and during implementation of adolescent quadrivalent meningococcal conjugate vaccination. Methods. Data were collected from active surveillance for invasive Neisseria meningitidis conducted through the Active Bacterial Core surveillance (ABCs) sites during 1998-2007. Isolates from cases were serogrouped at the ABCs site and confirmed at the Centers for Disease Control and Prevention. Estimates of the incidence and number of cases in the 50 states were calculated, standardizing for race and age group. Results. In the period 1998-2007, a total of 2262 cases of meningococcal disease were reported from ABCs sites; 11.3% of these cases were fatal. The estimated United States average annual incidence of meningococcal disease was 0.53 cases per 100,000 population (95% confidence interval, 0.51-0.55), and an estimated 1525 ( 95% confidence interval, 1470-1598) cases occurred annually. The annual incidence decreased 64.1%, from 0.92 cases per 100,000 population in 1998 to 0.33 cases per 100,000 population in 2007. Infants aged ! 1 year have the highest incidence of meningococcal disease (5.38 cases per 100,000 population). After introduction of the quadrivalent meningococcal conjugate vaccine, no significant decrease in serogroup C or Y meningococcal disease was seen among those aged 11-19 years in 2006-2007, compared with 2004-2005. Conclusions. Before the introduction of the quadrivalent meningococcal conjugate vaccine, the incidence of meningococcal disease in the United States decreased to a historic low. However, meningococcal disease still causes a substantial burden of disease among all age groups. Future vaccination strategies may include targeting infants and preventing serogroup B meningococcal disease. C1 [Cohn, Amanda C.; MacNeil, Jessica R.; Hatcher, Cynthia; Theodore, Jordan; Pondo, Tracy; Zell, Elizabeth R.; Mayer, Leonard W.; Clark, Thomas; Messonnier, Nancy E.] Ctr Dis Control & Prevent, Meningitis & Vaccine Preventable Dis Branch, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Arnold, Kathryn E.; Stephens, David] Georgia Dept Human Resources, Div Publ Hlth, Atlanta, GA USA. [Farley, Monica] Emory Univ, Dept Med, Sch Med, Atlanta, GA 30322 USA. [Farley, Monica] Atlanta VA Med Ctr, Atlanta, GA USA. [Harrison, Lee H.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA. [Schmidt, Mark] Oregon Dept Human Serv, Portland, OR USA. [Baumbach, Joan] New Mexico Dept Hlth, Santa Fe, NM USA. [Bennett, Nancy] New York State Dept Hlth, Albany, NY 12237 USA. [Craig, Allen S.] Tennessee Dept Hlth, Nashville, TN USA. [Schaffner, William] Vanderbilt Univ, Sch Med, Dept Prevent Med, Nashville, TN 37212 USA. [Gershman, Ken] Colorado Dept Publ Hlth & Environm, Denver, CO USA. [Petit, Susan] Connecticut Dept Publ Hlth, Hartford, CT USA. [Lynfield, Ruth] Minnesota Dept Hlth, St Paul, MN USA. [Reingold, Arthur] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA. [Shutt, Kathleen A.] Univ Pittsburgh, Infect Dis Epidemiol, Res Unit, Pittsburgh, PA USA. RP Cohn, AC (reprint author), Ctr Dis Control & Prevent, Meningitis & Vaccine Preventable Dis Branch, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd,MS C-09, Atlanta, GA 30333 USA. EM acohn@cdc.gov RI Stephens, David/A-8788-2012; OI Shutt, Kathleen/0000-0003-3376-6152 FU CDC Emerging Infections Program [CI05 026] FX The ABCs sites received funding from the CDC Emerging Infections Program cooperative agreement CI05 026. NR 29 TC 187 Z9 194 U1 2 U2 11 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JAN 15 PY 2010 VL 50 IS 2 BP 184 EP 191 DI 10.1086/649209 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 536UK UT WOS:000273069100005 PM 20001736 ER PT J AU Campo, M Phung, MK Ahmed, R Cantey, P Bishop, H Bell, TK Gardiner, C Arias, CA AF Campo, Marcela Phung, Man K. Ahmed, Rehan Cantey, Paul Bishop, Henry Bell, Tanvir K. Gardiner, Carolyn Arias, Cesar A. TI A Woman with HIV Infection, Brain Abscesses, and Eosinophilia Trypanosoma cruzi reactivation in the central nervous system (CNS) SO CLINICAL INFECTIOUS DISEASES LA English DT Editorial Material ID CHAGAS-DISEASE C1 [Campo, Marcela; Bell, Tanvir K.; Arias, Cesar A.] Univ Texas Houston, Sch Med, Div Infect Dis, Houston, TX 77030 USA. [Campo, Marcela; Phung, Man K.; Ahmed, Rehan; Bell, Tanvir K.; Gardiner, Carolyn; Arias, Cesar A.] Univ Texas Houston, Sch Med, Dept Internal Med, Houston, TX 77030 USA. [Cantey, Paul; Bishop, Henry] Ctr Dis Control & Prevent, Div Parasit Dis, Natl Ctr Zoonot Vector Borne & Enter Dis, Atlanta, GA USA. [Cantey, Paul] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Off Workforce & Career Dev, Atlanta, GA USA. RP Arias, CA (reprint author), Univ Texas Houston, Sch Med, Div Infect Dis, 6431 Fannin St,MSB 2-112, Houston, TX 77030 USA. EM cesar.arias@uth.tmc.edu FU NIAID NIH HHS [K99 AI072961-01A2, K99 AI072961] NR 7 TC 2 Z9 2 U1 0 U2 0 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JAN 15 PY 2010 VL 50 IS 2 BP 239 EP + DI 10.1086/649538 PG 4 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 536UK UT WOS:000273069100013 PM 20034346 ER PT J AU Crump, JA Mintz, ED AF Crump, John A. Mintz, Eric D. TI Global Trends in Typhoid and Paratyphoid Fever SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID ENTERICA SEROTYPE TYPHI; RESISTANT SALMONELLA-TYPHI; ANTIMICROBIAL RESISTANCE; MULTIDRUG-RESISTANT; UNITED-STATES; DEVELOPING-COUNTRIES; SEROVARS PARATYPHI; ASIAN COUNTRIES; VACCINE; SURVEILLANCE AB Typhoid and paratyphoid fever continue to be important causes of illness and death, particularly among children and adolescents in south-central and Southeast Asia, where enteric fever is associated with poor sanitation and unsafe food and water. High-quality incidence data from Asia are underpinning efforts to expand access to typhoid vaccines. Efforts are underway to develop vaccines that are immunogenic in infants after a single dose and that can be produced locally in countries of endemicity. The growing importance of Salmonella enterica serotype Paratyphi A in Asia is concerning. Antimicrobial resistance has sequentially emerged to traditional first-line drugs, fluoroquinolones, and third-generation cephalosporins, posing patient treatment challenges. Azithromycin has proven to be an effective alternative for treatment of uncomplicated typhoid fever. The availability of full genome sequences for S. enterica serotype Typhi and S. enterica serotype Paratyphi A confirms their place as monomorphic, human-adapted pathogens vulnerable to control measures if international efforts can be redoubled. C1 [Crump, John A.; Mintz, Eric D.] Ctr Dis Control & Prevent, Enter Dis Epidemiol Branch, Natl Ctr Zoonot Vectorborne & Enter Dis, Atlanta, GA 30333 USA. [Crump, John A.] Duke Univ, Med Ctr, Div Infect Dis & Int Hlth, Durham, NC USA. [Crump, John A.] Duke Univ, Duke Global Hlth Inst, Durham, NC USA. [Crump, John A.] Tumaini Univ, Kilimanjaro Christian Med Ctr, Moshi, Tanzania. [Crump, John A.] Tumaini Univ, Kilimanjaro Christian Med Coll, Moshi, Tanzania. RP Crump, JA (reprint author), Ctr Dis Control & Prevent, Enter Dis Epidemiol Branch, Natl Ctr Zoonot Vectorborne & Enter Dis, 1600 Clifton Rd,MS A-38, Atlanta, GA 30333 USA. EM jcrump@cdc.gov FU US National Institutes of Health awards AIDS International Training and Research Program, Fogarty International Center [D43 PA-03-018]; International Studies of AIDS-Associated Coinfections [AI062563]; Duke University Center for AIDS Research [AI64518]; Duke Clinical Trials Unit and Clinical Research Sites [AI069484-01]; US Centers for Disease Control and Prevention FX US National Institutes of Health awards AIDS International Training and Research Program, Fogarty International Center (D43 PA-03-018 to J.A.C.); International Studies of AIDS-Associated Coinfections (AI062563 to J.A.C.); Duke University Center for AIDS Research (AI64518 to J.A.C.); Duke Clinical Trials Unit and Clinical Research Sites (AI069484-01 to J.A.C.); Intergovernmental Personnel Agreement from the US Centers for Disease Control and Prevention (to J.A.C.); and US Centers for Disease Control and Prevention (to E.D.M.). NR 55 TC 276 Z9 290 U1 5 U2 29 PU UNIV CHICAGO PRESS PI CHICAGO PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA SN 1058-4838 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JAN 15 PY 2010 VL 50 IS 2 BP 241 EP 246 DI 10.1086/649541 PG 6 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA 536UK UT WOS:000273069100014 PM 20014951 ER PT J AU Go, YM Park, H Koval, M Orr, M Reed, M Liang, YL Smith, D Pohl, J Jones, DP AF Go, Young-Mi Park, Heonyong Koval, Michael Orr, Michael Reed, Matthew Liang, Yongliang Smith, Debra Pohl, Jan Jones, Dean P. TI A key role for mitochondria in endothelial signaling by plasma cysteine/cystine redox potential SO FREE RADICAL BIOLOGY AND MEDICINE LA English DT Article DE Actin; Cytoskeleton; Endothelial cells; Extracellular redox state; Mitochondrial thioredoxin 2; Proinflammatory signaling; Redox proteomics; Redox ICAT; Free radicals ID OXIDANT-INDUCED APOPTOSIS; OXIDATIVE STRESS; ANGIOTENSIN-II; HEALTHY-ADULTS; CELLS; STATE; GLUTATHIONE; IDENTIFICATION; THIOREDOXIN; DYSFUNCTION AB The redox potential of the plasma cysteine/cystine couple (E(h)CySS) is oxidized in association with risk factors for cardiovascular disease (CVD), including age, smoking, type 2 diabetes, obesity, and alcohol abuse. Previous in vitro findings support a cause-effect relationship for extracellular E(h)CySS in cell signaling pathways associated with CVD, including those controlling monocyte adhesion to endothelial cells. In this study, we provide evidence that mitochondria are a major source of reactive oxygen species (ROS) in the signaling response to a more oxidized extracellular E(h)CySS. This increase in ROS was blocked by overexpression of mitochondrial thioredoxin-2 (Trx2) in endothelial cells from Trx2-transgenic mice, suggesting that mitochondrial thiol antioxidant status plays a key role in this redox signaling mechanism. Mass spectrometry-based redox proteomics showed that several classes of plasma membrane and cytoskeletal proteins involved in inflammation responded to this redox switch, including vascular cell adhesion molecule, integrins, actin, and several Ras family GTPases. Together, the data show that the proinflammatory effects of oxidized plasma E(h)CySS are due to a mitochondrial signaling pathway that is mediated through redox control of downstream effector proteins. (C) 2009 Elsevier Inc. All rights reserved. C1 [Go, Young-Mi; Koval, Michael; Orr, Michael; Liang, Yongliang; Smith, Debra; Jones, Dean P.] Emory Univ, Div Pulm Med, Atlanta, GA 30322 USA. [Park, Heonyong] Dankook Univ, Dept Mol Biol, Yongin, South Korea. [Reed, Matthew; Pohl, Jan] Emory Univ, Microchem & Prote Facil, Dept Med, Atlanta, GA 30322 USA. [Reed, Matthew; Pohl, Jan] Ctr Dis Control & Prevent, Biotechnol Core Facil, DSR, Atlanta, GA 30333 USA. RP Go, YM (reprint author), Emory Univ, Div Pulm Med, Atlanta, GA 30322 USA. EM ygo@emory.edu; dpjones@emory.edu RI Koval, Michael/C-6366-2015 OI Koval, Michael/0000-0002-5422-5614 FU NIH [ES011195, ES009047, HL083120] FX This work was supported by NIH Grants ES011195, ES009047, and HL083120. NR 36 TC 55 Z9 55 U1 2 U2 12 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0891-5849 J9 FREE RADICAL BIO MED JI Free Radic. Biol. Med. PD JAN 15 PY 2010 VL 48 IS 2 BP 275 EP 283 DI 10.1016/j.freeradbiomed.2009.10.050 PG 9 WC Biochemistry & Molecular Biology; Endocrinology & Metabolism SC Biochemistry & Molecular Biology; Endocrinology & Metabolism GA 547JQ UT WOS:000273883800011 PM 19879942 ER PT J AU Freundt, EC Yu, L Goldsmith, CS Welsh, S Cheng, A Yount, B Liu, W Frieman, MB Buchholz, UJ Screaton, GR Lippincott-Schwartz, J Zaki, SR Xu, XN Baric, RS Subbarao, K Lenardo, MJ AF Freundt, Eric C. Yu, Li Goldsmith, Cynthia S. Welsh, Sarah Cheng, Aaron Yount, Boyd Liu, Wei Frieman, Matthew B. Buchholz, Ursula J. Screaton, Gavin R. Lippincott-Schwartz, Jennifer Zaki, Sherif R. Xu, Xiao-Ning Baric, Ralph S. Subbarao, Kanta Lenardo, Michael J. TI The Open Reading Frame 3a Protein of Severe Acute Respiratory Syndrome-Associated Coronavirus Promotes Membrane Rearrangement and Cell Death SO JOURNAL OF VIROLOGY LA English DT Article ID SARS-ASSOCIATED CORONAVIRUS; VERO E6 CELLS; LINKED-IMMUNOSORBENT-ASSAY; TRANS-GOLGI NETWORK; ENDOPLASMIC-RETICULUM; REPLICATION COMPLEX; VIRUS-REPLICATION; BREFELDIN-A; POLIOVIRUS INFECTION; ORGANELLE STRUCTURE AB The genome of the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) contains eight open reading frames (ORFs) that encode novel proteins. These accessory proteins are dispensable for in vitro and in vivo replication and thus may be important for other aspects of virus-host interactions. We investigated the functions of the largest of the accessory proteins, the ORF 3a protein, using a 3a-deficient strain of SARS-CoV. Cell death of Vero cells after infection with SARS-CoV was reduced upon deletion of ORF 3a. Electron microscopy of infected cells revealed a role for ORF 3a in SARS-CoV induced vesicle formation, a prominent feature of cells from SARS patients. In addition, we report that ORF 3a is both necessary and sufficient for SARS-CoV-induced Golgi fragmentation and that the 3a protein accumulates and localizes to vesicles containing markers for late endosomes. Finally, overexpression of ADP-ribosylation factor 1 (Arf1), a small GTPase essential for the maintenance of the Golgi apparatus, restored Golgi morphology during infection. These results establish an important role for ORF 3a in SARS-CoV-induced cell death, Golgi fragmentation, and the accumulation of intracellular vesicles. C1 [Freundt, Eric C.; Yu, Li; Welsh, Sarah; Lenardo, Michael J.] NIAID, Immunol Lab, NIH, Bethesda, MD 20892 USA. [Cheng, Aaron; Buchholz, Ursula J.; Zaki, Sherif R.; Subbarao, Kanta] NIAID, Infect Dis Lab, NIH, Bethesda, MD 20892 USA. [Goldsmith, Cynthia S.] Ctr Dis Control & Prevent, Infect Dis Pathol Branch, Div Viral & Rickettsial Dis, Atlanta, GA 30333 USA. [Yount, Boyd; Frieman, Matthew B.; Baric, Ralph S.] Univ N Carolina, Sch Publ Hlth, Dept Epidemiol, Chapel Hill, NC 27599 USA. [Liu, Wei; Lippincott-Schwartz, Jennifer] NICHHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA. [Screaton, Gavin R.] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, London W12 0NN, England. [Freundt, Eric C.; Xu, Xiao-Ning] Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Med Res Council,Human Immunol Unit, Oxford OX3 9DS, England. RP Yu, L (reprint author), Tsinghua Univ, Dept Biol Sci & Biotechnol, Beijing 100084, Peoples R China. EM liyulab@mail.tsinghua.edu.cn OI Screaton, Gavin/0000-0002-3549-4309 FU National Institutes of Health-University of Oxford; National Institutes of Allergy and Infectious Diseases; National Institutes of Health; NIH AID [AI059136] FX The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the funding agency. NR 69 TC 12 Z9 14 U1 1 U2 9 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD JAN 15 PY 2010 VL 84 IS 2 BP 1097 EP 1109 DI 10.1128/JVI.01662-09 PG 13 WC Virology SC Virology GA 535TN UT WOS:000272994300040 PM 19889773 ER PT J AU Zhang, WL Choi, YJ Haynes, LM Harcourt, JL Anderson, LJ Jones, LP Tripp, RA AF Zhang, Wenliang Choi, Youngjoo Haynes, Lia M. Harcourt, Jennifer L. Anderson, Larry J. Jones, Les P. Tripp, Ralph A. TI Vaccination To Induce Antibodies Blocking the CX3C-CX3CR1 Interaction of Respiratory Syncytial Virus G Protein Reduces Pulmonary Inflammation and Virus Replication in Mice SO JOURNAL OF VIROLOGY LA English DT Article ID PURIFIED F PROTEIN; G FUSION PROTEIN; RSV G-PROTEIN; G-GLYCOPROTEIN; BALB/C MICE; SUBUNIT VACCINE; PROTECTIVE IMMUNITY; ENHANCED DISEASE; FIELD EVALUATION; BBG2NA VACCINE AB Respiratory syncytial virus (RSV) infection causes substantial morbidity and some deaths in the young and elderly worldwide. There is no safe and effective vaccine available, although it is possible to reduce the hospitalization rate for high-risk children by anti-RSV antibody prophylaxis. RSV has been shown to modify the immune response to infection, a feature linked in part to RSV G protein CX3C chemokine mimicry. This study determined if vaccination with G protein polypeptides or peptides spanning the central conserved region of the G protein could induce antibodies that blocked G protein CX3C-CX3CR1 interaction and disease pathogenesis mediated by RSV infection. The results show that mice vaccinated with G protein peptides or polypeptides containing the CX3C motif generate antibodies that inhibit G protein CX3C-CX3CR1 binding and chemotaxis, reduce lung virus titers, and prevent body weight loss and pulmonary inflammation. The results suggest that RSV vaccines that induce antibodies that block G protein CX3C-CX3CR1 interaction may offer a new, safe, and efficacious RSV vaccine strategy. C1 [Tripp, Ralph A.] Univ Georgia, Anim Hlth Res Ctr, Coll Vet Med, Dept Infect Dis, Athens, GA 30602 USA. [Haynes, Lia M.; Harcourt, Jennifer L.; Anderson, Larry J.] Ctr Dis Control & Prevent CDC, Natl Ctr Immunizat & Resp Dis, Div Viral Dis, Gastroenteritis & Resp Viruses Lab Branch, Atlanta, GA 30333 USA. RP Tripp, RA (reprint author), Univ Georgia, Anim Hlth Res Ctr, Coll Vet Med, Dept Infect Dis, 111 Carlton St, Athens, GA 30602 USA. EM ratripp@uga.edu RI Zhang, Wenliang/A-1071-2010; OI Tripp, Ralph/0000-0002-2924-9956 FU National Institutes of Health [5RO1AI06275-03] FX We thank Yi Kuang for her assistance with hematoxylin and eosin staining of lung samples, Jamie Barber for his discussions on flow cytometry, and Joseph Rimando and Jenna Dare for their technical support. NR 61 TC 41 Z9 43 U1 0 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X J9 J VIROL JI J. Virol. PD JAN 15 PY 2010 VL 84 IS 2 BP 1148 EP 1157 DI 10.1128/JVI.01755-09 PG 10 WC Virology SC Virology GA 535TN UT WOS:000272994300044 PM 19864390 ER PT J AU Barr, DB Ananth, CV Yan, XY Lashley, S Smulian, JC Ledoux, TA Hore, P Robson, MG AF Barr, Dana Boyd Ananth, Cande V. Yan, Xiaoyong Lashley, Susan Smulian, John C. Ledoux, Thomas A. Hore, Paromita Robson, Mark G. TI Pesticide concentrations in maternal and umbilical cord sera and their relation to birth outcomes in a population of pregnant women and newborns in New Jersey SO SCIENCE OF THE TOTAL ENVIRONMENT LA English DT Article DE Pesticides; Chlorpyrifos; Cord blood; Maternal blood; Pregnant women; New Jersey; Birth outcome; Birth weight ID URINARY METABOLITE LEVELS; ORGANOPHOSPHORUS PESTICIDES; EXPOSURE; CHLORPYRIFOS; ASSOCIATION; CHILDREN; DELIVERY; LENGTH; COHORT AB We evaluated in utero exposures to pesticides by measuring maternal and cord serum biomarkers in a New Jersey cohort of pregnant women and the birth outcomes of their neonates. The study was based on 150 women that underwent an elective cesarean delivery at term in a hospital in central New Jersey. We evaluated the following pesticide compounds in both maternal and umbilical cord sera: chlorpyrifos, diazinon, carbofuran, chlorothalonil, dacthal, metolachlor, trifluralin and diethyl-m-toluamide (DEET). Of these compounds, chlorpyrifos, carbofuran, chlorothalonil, trifluralin, metolachlor and DEET were the pesticides most frequently detected in the serum samples. We found high (>= 75th percentile) metolachlor concentrations in cord blood that were related to birth weight (3605 g in upper quartile vs 3399 g; p = 0.05). We also observed an increase in abdominal circumference with increasing cord dichloran concentrations (p = 0.031). These observations suggest that in utero exposures to certain pesticides may alter birth outcomes. (C) 2009 Elsevier B.V. All rights reserved. C1 [Robson, Mark G.] Rutgers State Univ, Dept Entomol, Sch Environm & Biol Sci, New Brunswick, NJ 08901 USA. [Barr, Dana Boyd] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA USA. [Ananth, Cande V.] UMDNJ Robert Wood Johnson Med Sch, Dept Obstet Gynecol & Reprod Sci, Div Epidemiol & Biostat, New Brunswick, NJ USA. [Yan, Xiaoyong; Hore, Paromita; Robson, Mark G.] Rutgers State Univ, UMDNJ, Joint Grad Program Toxicol, Piscataway, NJ USA. [Lashley, Susan] Univ Virginia, Dept Obstet Gynecol & Reprod Sci, Charlottesville, VA USA. [Smulian, John C.] Lehigh Valley Hosp, Dept Obstet & Gynecol, Div Maternal Fetal Med, Allentown, PA USA. [Ledoux, Thomas A.] New Jersey Dept Environm Protect, Div Sci Res & Technol, Risk Assessment & Toxicol Sect, Trenton, NJ USA. [Hore, Paromita; Robson, Mark G.] UMDNJ Sch Publ Hlth, Dept Environm & Occupat Hlth, Piscataway, NJ USA. RP Robson, MG (reprint author), Rutgers State Univ, Dept Entomol, Sch Environm & Biol Sci, 93 Lipman Dr, New Brunswick, NJ 08901 USA. EM robson@aesop.rutgers.edu RI Barr, Dana/E-6369-2011; Barr, Dana/E-2276-2013 FU New Jersey Department of Environmental Protection [DEP SR04-058, SR05-042]; NIEHS [P30ES005022, T32 007148] FX We thank members of the Pesticide Laboratory in the National Center for Environmental Health, Centers for Disease Control and Prevention (Atlanta, Georgia) for their guidance and help in the analytical pesticide analyses, especially Roberto Bravo and Jose Perez. We also thank Kenneth Reuhl in the Department of Pharmacology and Toxicology, Rutgers University/UMDNJ (Piscataway, NJ) for his assistance. This work was supported by grants from the New Jersey Department of Environmental Protection (DEP SR04-058 and SR05-042) and the NIEHS Center P30ES005022 and NIEHS Training Grant T32 007148. NR 28 TC 38 Z9 38 U1 3 U2 22 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0048-9697 J9 SCI TOTAL ENVIRON JI Sci. Total Environ. PD JAN 15 PY 2010 VL 408 IS 4 BP 790 EP 795 DI 10.1016/j.scitotenv.2009.10.007 PG 6 WC Environmental Sciences SC Environmental Sciences & Ecology GA 547ZI UT WOS:000273928000013 PM 19900697 ER PT J AU Weber, JT Nicoll, A Bridges, CB Ciancio, BC AF Weber, J. Todd Nicoll, Angus Bridges, Carolyn B. Ciancio, Bruno C. TI The truth about Tamiflu? Neuraminidase inhibitors in pandemic A/H1N1 flu SO BRITISH MEDICAL JOURNAL LA English DT Letter ID INFLUENZA C1 [Weber, J. Todd; Nicoll, Angus; Ciancio, Bruno C.] European Ctr Dis Prevent & Control, Influenza Programme, S-17183 Stockholm, Sweden. [Bridges, Carolyn B.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. RP Weber, JT (reprint author), European Ctr Dis Prevent & Control, Influenza Programme, S-17183 Stockholm, Sweden. EM jtodd.weber@ecdc.europa.eu NR 6 TC 2 Z9 2 U1 0 U2 0 PU B M J PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0959-535X J9 BRIT MED J JI Br. Med. J. PD JAN 13 PY 2010 VL 340 AR c130 DI 10.1136/bmj.c130 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 545DA UT WOS:000273711500004 PM 20071425 ER PT J AU Grigoryan, A Shouse, RL Durant, T Mastro, TD Espinoza, L Chen, M Kajese, T Wei, X Hall, HI AF Grigoryan, A. Shouse, R. L. Durant, T. Mastro, T. D. Espinoza, L. Chen, M. Kajese, T. Wei, X. Hall, H. I. TI HIV Infection Among Injection-Drug Users-34 States, 2004-2007 (Reprinted from MMWR, vol 58, pg 1291-1295, 2009) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Grigoryan, A.; Shouse, R. L.; Durant, T.; Mastro, T. D.; Espinoza, L.; Chen, M.; Kajese, T.; Wei, X.; Hall, H. I.] CDC, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. RP Grigoryan, A (reprint author), CDC, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. NR 1 TC 7 Z9 7 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JAN 13 PY 2010 VL 303 IS 2 BP 126 EP 128 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 542UI UT WOS:000273522600010 ER PT J AU Molinari, NA Darling, N McCauley, M AF Molinari, N. A. Darling, N. McCauley, M. TI National, State, and Local Area Vaccination Coverage Among Children Aged 19-35 Months-United States, 2008 (Reprinted from MMWR, vol 58, pg 921-926, 2009) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Molinari, N. A.; Darling, N.; McCauley, M.] CDC, Natl Ctr Immunizat & Resp, Atlanta, GA 30333 USA. RP Molinari, NA (reprint author), CDC, Natl Ctr Immunizat & Resp, Atlanta, GA 30333 USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JAN 13 PY 2010 VL 303 IS 2 BP 128 EP 129 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 542UI UT WOS:000273522600011 ER PT J AU Garcia-Lerma, JG Cong, ME Mitchell, J Youngpairoj, AS Zheng, Q Masciotra, S Martin, A Kuklenyik, Z Holder, A Lipscomb, J Pau, CP Barr, JR Hanson, DL Otten, R Paxton, L Folks, TM Heneine, W AF Garcia-Lerma, J. Gerardo Cong, Mian-er Mitchell, James Youngpairoj, Ae S. Zheng, Qi Masciotra, Silvina Martin, Amy Kuklenyik, Zsuzsanna Holder, Angela Lipscomb, Jonathan Pau, Chou-Pong Barr, John R. Hanson, Debra L. Otten, Ron Paxton, Lynn Folks, Thomas M. Heneine, Walid TI Intermittent Prophylaxis with Oral Truvada Protects Macaques from Rectal SHIV Infection SO SCIENCE TRANSLATIONAL MEDICINE LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; TENOFOVIR DISOPROXIL FUMARATE; HIV-1 INFECTION; REVERSE-TRANSCRIPTASE; SEXUAL TRANSMISSION; RHESUS MACAQUES; VIRAL LOAD; CHALLENGES; PREVENT; SIV AB HIV continues to spread globally, mainly through sexual contact. Despite advances in treatment and care, preventing transmission with vaccines or microbicides has proven difficult. A promising strategy to avoid transmission is prophylactic treatment with antiretroviral drugs before exposure to HIV. Clinical trials evaluating the efficacy of daily treatment with the reverse transcriptase inhibitors tenofovir disoproxil fumarate (TDF) or Truvada (TDF plus emtricitabine) are under way. We hypothesized that intermittent prophylactic treatment with long-acting antiviral drugs would be as effective as daily dosing in blocking the earliest stages of viral replication and preventing mucosal transmission. We tested this hypothesis by intermittently giving prophylactic Truvada to macaque monkeys and then exposing them rectally to simian-human immunodeficiency virus (SHIV) once a week for 14 weeks. A simple regimen with an oral dose of Truvada given 1, 3, or 7 days before exposure followed by a second dose 2 hours after exposure was as protective as daily drug administration, possibly because of the long intracellular persistence of the drugs. In addition, a two-dose regimen initiated 2 hours before or after virus exposure was effective, and full protection was obtained by doubling the Truvada concentration in both doses. We saw no protection if the first dose was delayed until 24 hours after exposure, underscoring the importance of blocking initial replication in the mucosa. Our results show that intermittent prophylactic treatment with an antiviral drug can be highly effective in preventing SHIV infection, with a wide window of protection. They strengthen the possibility of developing feasible, cost-effective strategies to prevent HIV transmission in humans. C1 [Garcia-Lerma, J. Gerardo; Cong, Mian-er; Mitchell, James; Youngpairoj, Ae S.; Zheng, Qi; Masciotra, Silvina; Martin, Amy; Holder, Angela; Lipscomb, Jonathan; Pau, Chou-Pong; Hanson, Debra L.; Otten, Ron; Paxton, Lynn; Folks, Thomas M.; Heneine, Walid] Ctr Dis Control & Prevent, Div HIVAIDS Prevent, Natl Ctr HIV Hepatitis STD & Prevent, Atlanta, GA 30329 USA. [Kuklenyik, Zsuzsanna; Barr, John R.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30329 USA. [Folks, Thomas M.] SW Fdn Biomed Res, SW Natl Primate Res Ctr, San Antonio, TX 78245 USA. RP Garcia-Lerma, JG (reprint author), Ctr Dis Control & Prevent, Div HIVAIDS Prevent, Natl Ctr HIV Hepatitis STD & Prevent, 1600 Clifton Rd, Atlanta, GA 30329 USA. EM GGarcia-Lerma@cdc.gov NR 36 TC 42 Z9 43 U1 0 U2 7 PU AMER ASSOC ADVANCEMENT SCIENCE PI WASHINGTON PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA SN 1946-6234 J9 SCI TRANSL MED JI Sci. Transl. Med. PD JAN 13 PY 2010 VL 2 IS 14 AR 14ra4 DI 10.1126/scitranslmed.3000391 PG 8 WC Cell Biology; Medicine, Research & Experimental SC Cell Biology; Research & Experimental Medicine GA 590YF UT WOS:000277263700003 PM 20371467 ER PT J AU Patel, P Mackellar, D Simmons, P Uniyal, A Gallagher, K Bennett, B Sullivan, TJ Kowalski, A Parker, MM LaLota, M Kerndt, P Sullivan, PS AF Patel, Pragna Mackellar, Duncan Simmons, Pat Uniyal, Apurva Gallagher, Kathleen Bennett, Berry Sullivan, Timothy J. Kowalski, Alexis Parker, Monica M. LaLota, Marlene Kerndt, Peter Sullivan, Patrick S. CA Ctr Disease Control Prevention Acu TI Detecting Acute Human Immunodeficiency Virus Infection Using 3 Different Screening Immunoassays and Nucleic Acid Amplification Testing for Human Immunodeficiency Virus RNA, 2006-2008 SO ARCHIVES OF INTERNAL MEDICINE LA English DT Article ID PRIMARY HIV-INFECTION; PARTNER NOTIFICATION; SEXUAL TRANSMISSION; UNITED-STATES; HETEROSEXUAL TRANSMISSION; RISK; IDENTIFICATION; SEROCONVERSION; DONORS; TYPE-1 AB Background: The yield of nucleic acid amplification testing (NAAT) after routine screening for human immunodeficiency virus (HIV) antibody to detect acute HIV infection (AHI) may vary with different HIV-antibody assays. Methods: From April 24,2006, through March 28, 2008, patients under-went routine HIV-antibody screening using a first-generation assay at 14 county sexually transmitted disease (STD) clinics and 1 community clinic serving homosexual patients in Los Angeles; using a second-generation rapid test at 3 municipal STD clinics in New York; and using a third-generation assay at 80 public health clinics in Florida. To identify AHI, seronegative specimens were pooled for NAAT, followed by individual NAAT of specimens with positive findings. All AHI samples screened by first- and second-generation assays also underwent third-generation testing. Results: We screened 37 012 persons using NAAT after first-generation testing; 35 AHIs were identified, in-creasing HIV case detection by 8.2%. After a second-generation rapid test, 6547 persons underwent NAAT; 7 AHIs were identified, increasing HIV case detection by 24.1%. After third-generation testing, 54 948 persons underwent NAAT; 12 AHI cases were identified, increasing HIV case detection by 1.4%. Overall, pooled NAAT after negative third-generation test results detected 26 AHI cases, increasing HIV case detection by 2.2%. Most of the AHI cases from Los Angeles (26 of 35 [74%]) were identified at the community clinic where NAAT after third-generation testing increased HIV case detection by 11.9%. Conclusions: Pooled NAAT after third-generation testing increases HIV case detection, especially in venues of high HIV seropositivity. Therefore, targeted AHI screening using pooled NAAT after third-generation testing may be most effective, warranting a cost-benefit analysis. C1 [Patel, Pragna; Mackellar, Duncan] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. [Simmons, Pat; LaLota, Marlene] Bur HIV AIDS, Florida Dept Hlth, Tallahassee, FL USA. [Uniyal, Apurva; Kerndt, Peter] Los Angeles Dept Hlth Serv, Sexually Transmitted Dis Program, Los Angeles, CA USA. [Gallagher, Kathleen; Kowalski, Alexis] Bur Sexually Transmitted Dis Control, New York City Dept Hlth & Mental Hyg, New York, NY USA. [Bennett, Berry] Florida Bur Labs, Retrovirol Sect, Jacksonville, FL USA. [Sullivan, Timothy J.; Parker, Monica M.] Wadsworth Ctr, New York State Dept Hlth, Albany, NY USA. [Sullivan, Patrick S.] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA. RP Patel, P (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, 1600 Clifton Rd,Mail Stop E-45, Atlanta, GA 30333 USA. EM plp3@cdc.gov RI Sullivan, Patrick/A-9436-2009; OI Sullivan, Timothy/0000-0003-3144-9188; Sullivan, Patrick/0000-0002-7728-0587 FU CDC [1 UA1 PS000063] FX Funding/Support: This study was supported by grant 1 UA1 PS000063 from the CDC. NR 53 TC 70 Z9 73 U1 0 U2 4 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0003-9926 J9 ARCH INTERN MED JI Arch. Intern. Med. PD JAN 11 PY 2010 VL 170 IS 1 BP 66 EP 74 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 541PK UT WOS:000273429200012 PM 20065201 ER PT J AU Cox-Singh, J Hiu, J Lucas, SB Divis, PC Zulkarnaen, M Chandran, P Wong, KT Adem, P Zaki, SR Singh, B Krishna, S AF Cox-Singh, Janet Hiu, Jessie Lucas, Sebastian B. Divis, Paul C. Zulkarnaen, Mohammad Chandran, Patricia Wong, Kum T. Adem, Patricia Zaki, Sherif R. Singh, Balbir Krishna, Sanjeev TI Severe malaria - a case of fatal Plasmodium knowlesi infection with post-mortem findings: a case report SO MALARIA JOURNAL LA English DT Article ID FALCIPARUM-MALARIA; CEREBRAL MALARIA; ADHESION MOLECULE-1; ANTIGENIC VARIATION; AFRICAN CHILDREN; VIVAX MALARIA; VAR GENES; PATHOGENESIS; HEMOZOIN; FEATURES AB Background: Zoonotic malaria caused by Plasmodium knowlesi is an important, but newly recognized, human pathogen. For the first time, post-mortem findings from a fatal case of knowlesi malaria are reported here. Case presentation: A formerly healthy 40 year-old male became symptomatic 10 days after spending time in the jungle of North Borneo. Four days later, he presented to hospital in a state of collapse and died within two hours. He was hyponatraemic and had elevated blood urea, potassium, lactate dehydrogenase and amino transferase values; he was also thrombocytopenic and eosinophilic. Dengue haemorrhagic shock was suspected and a postmortem examination performed. Investigations for dengue virus were negative. Blood for malaria parasites indicated hyperparasitaemia and single species P. knowlesi infection was confirmed by nested-PCR. Macroscopic pathology of the brain and endocardium showed multiple petechial haemorrhages, the liver and spleen were enlarged and lungs had features consistent with ARDS. Microscopic pathology showed sequestration of pigmented parasitized red blood cells in the vessels of the cerebrum, cerebellum, heart and kidney without evidence of chronic inflammatory reaction in the brain or any other organ examined. Brain sections were negative for intracellular adhesion molecule-1. The spleen and liver had abundant pigment containing macrophages and parasitized red blood cells. The kidney had evidence of acute tubular necrosis and endothelial cells in heart sections were prominent. Conclusions: The overall picture in this case was one of systemic malaria infection that fit the WHO classification for severe malaria. Post-mortem findings in this case were unexpectedly similar to those that define fatal falciparum malaria, including cerebral pathology. There were important differences including the absence of coma despite petechial haemorrhages and parasite sequestration in the brain. These results suggest that further study of knowlesi malaria will aid the interpretation of, often conflicting, information on malaria pathophysiology in humans. C1 [Cox-Singh, Janet; Krishna, Sanjeev] St Georges Univ London, Div Cellular & Mol Med, Ctr Infect, London SW17 0RE, England. [Cox-Singh, Janet; Divis, Paul C.; Zulkarnaen, Mohammad; Singh, Balbir; Krishna, Sanjeev] Univ Malaysia Sarawak, Malaria Res Ctr, Kuching, Sarawak, Malaysia. [Hiu, Jessie] Queen Elizabeth Hosp, Dept Forens, Kota Kinabalu, Sabah, Malaysia. [Lucas, Sebastian B.] St Thomas Hosp, KCL Sch Med, Dept Histopathol, London, England. [Chandran, Patricia; Wong, Kum T.] Univ Malaya, Dept Pathol, Fac Med, Kuala Lumpur, Malaysia. [Adem, Patricia; Zaki, Sherif R.] Ctr Dis Control & Prevent, Infect Dis Pathol Branch, Atlanta, GA USA. RP Cox-Singh, J (reprint author), St Georges Univ London, Div Cellular & Mol Med, Ctr Infect, London SW17 0RE, England. EM coxsingh@gmail.com RI Wong, Kum Thong/B-2788-2010; OI Singh, Balbir/0000-0002-9143-3965; Krishna, Sanjeev/0000-0003-0066-0634; Cox-Singh, Janet/0000-0003-4878-5188 FU Medical Research Council (UK) [RAA 0033]; Wellcome Trust [078538/Z/05/Z] FX We acknowledge the contributions of Mr Fread Anderios, Microbiologist, Kota Kinabalu Public Health Laboratory, Malaysian Ministry of Health, Drs Ganesan Durairajah and Timothy William Queen Elizabeth Hospital, Sabah. JCS and SK are funded by the Medical Research Council (UK) Grant Number RAA 0033, this work was funded in part by the Wellcome Trust (BS and JCS Grant Number 078538/Z/05/Z). NR 44 TC 64 Z9 66 U1 4 U2 10 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1475-2875 J9 MALARIA J JI Malar. J. PD JAN 11 PY 2010 VL 9 AR 10 DI 10.1186/1475-2875-9-10 PG 7 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA 553PO UT WOS:000274379500001 PM 20064229 ER PT J AU Chang, HGH Smith, PF Tserenpuntsag, B Markey, K Parashar, U Morse, DL AF Chang, Hwa-Gan H. Smith, Perry F. Tserenpuntsag, Bold Markey, Katherine Parashar, Umesh Morse, Dale L. TI Reduction in hospitalizations for diarrhea and rotavirus infections in New York state following introduction of rotavirus vaccine SO VACCINE LA English DT Article DE Diarrhea; Rotavirus; Vaccine; Healthcare costs ID UNITED-STATES; DISEASE BURDEN; CHILDREN AB Objectives: To monitor trends and costs of diarrhea and rotavirus-associated hospitalizations in New York before and after rotavirus vaccine implementation in 2006. To examine rotavirus test results from sentinel hospital-associated laboratories. Methods: Hospital discharge data and laboratory rotavirus testing data were analyzed for children 1 month up to 18 years of age for 10 sentinel and all statewide hospitals from January 1, 2003 through December 31, 2008. Results: Among children 1-23 months of age, a 40% reduction in diarrhea-associated hospitalizations and 85% decrease in rotavirus-coded hospitalizations at the 10 sentinel hospitals was observed in 2008 compared with the average of pre-vaccine seasons from 2003 through 2006. For both sentinel and statewide hospitals, the percent of diarrhea admissions due to rotavirus was reduced at least 83% among children 1-23 months (vaccine eligible) and 70% for older unimmunized children. Statewide hospital costs for rotavirus hospitalizations in children <2 years of age were reduced $10 million. Sentinel hospital laboratory data validated the declining trends seen in hospitalizations. Conclusions: In 2008, New York hospital data showed significant reductions in rotavirus hospitalizations and costs among children aged 1-23 months who were eligible for vaccine. Reductions also occurred among unimmunized older children suggesting the importance of continue monitoring in future seasons to fully assess vaccine impact Published by Elsevier Ltd. C1 [Chang, Hwa-Gan H.] New York State Dept Hlth, Div Epidemiol, Albany, NY 12237 USA. [Parashar, Umesh] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Chang, HGH (reprint author), New York State Dept Hlth, Div Epidemiol, Room 754,Corning Tower Bldg,Empire State Plaza, Albany, NY 12237 USA. FU NCPDCID CDC HHS [U01/CI000311] NR 18 TC 33 Z9 34 U1 0 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD JAN 8 PY 2010 VL 28 IS 3 BP 754 EP 758 DI 10.1016/j.vaccine.2009.10.075 PG 5 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 561YE UT WOS:000275015200022 PM 19896451 ER PT J AU Cho, BH Clark, TA Messonnier, NE Ortega-Sanchez, IR Weintraub, E Messonnier, ML AF Cho, Bo-Hyun Clark, Thomas A. Messonnier, Nancy E. Ortega-Sanchez, Ismael R. Weintraub, Eric Messonnier, Mark L. TI MCV vaccination in the presence of vaccine-associated Guillain-Barre, Syndrome risk: A decision analysis approach SO VACCINE LA English DT Article DE Decision analysis; Meningococcal disease; Guillain-Barre Syndrome; Quality-adjusted life years ID EVENT-REPORTING-SYSTEM; SAFETY DATALINK PROJECT; UNITED-STATES; INFLUENZA VACCINES; VAERS AB The study evaluates the benefits of meningococcal conjugate vaccine (MCV4) vaccination against the burden of vaccine-associated Guillam-Barre Syndrome (GBS) using simulation An 11-year-old cohort was followed over an 8-year period in a simulation model Table 3 Figs. 1 and 2 to estimate health outcomes to assist decision makers in setting policy Applying a 3% discount rate. MCV4 vaccination would save 2397 quality-adjusted life years (QALYs) while vaccine-attributable GBS could result in 5 QALYs lost Based on the result, MCV4 vaccination is strongly favored despite possible vaccine-associated GBS risk (C) 2009 Elsevier Ltd. All rights reserved C1 [Cho, Bo-Hyun] McKing Consulting Corp, Atlanta, GA 30333 USA. [Clark, Thomas A.; Messonnier, Nancy E.; Ortega-Sanchez, Ismael R.; Messonnier, Mark L.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Coordinating Ctr Infect Dis, Atlanta, GA 30333 USA. [Weintraub, Eric] Ctr Dis Control & Prevent, Immunizat Safety Off, Atlanta, GA 30333 USA. RP Cho, BH (reprint author), McKing Consulting Corp, 1600 Clifton Rd,NE MS E-52, Atlanta, GA 30333 USA. NR 37 TC 5 Z9 5 U1 0 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD JAN 8 PY 2010 VL 28 IS 3 BP 817 EP 822 DI 10.1016/j.vaccine.2009.10.050 PG 6 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 561YE UT WOS:000275015200030 PM 19879992 ER PT J AU Guichard, S Hymbaugh, K Burkholder, B Diorditsa, S Navarro, C Ahmed, S Rahman, MM AF Guichard, Stephane Hymbaugh, Karen Burkholder, Brent Diorditsa, Serguei Navarro, Christine Ahmed, Selina Rahman, Mohd. Mahbubur TI Vaccine wastage in Bangladesh SO VACCINE LA English DT Article DE Vaccine wastage; Immunization; Bangladesh AB The Government of Bangladesh and WHO collaborated in a retrospective vaccine wastage study to estimate overall vaccine wastage rates from January to December 2004 for BCG, measles, DTP and TT. Researchers looked at vaccine distribution and usage patterns in randomly selected districts at both fixed (Upazila) and outreach (Ward) service delivery levels. Wastage was similar at both delivery levels but ranged widely among the sites Average rates were highest for BCG (84.9%, range 55-93%) and measles (69.7%, range 28-86%) and lower for TT (35 5%, range 10-73%) and DTP (44 4%, range 16-77%). Wastage resulted primarily from opened vials at the ward level but this was reduced at fixed sites where the multi-dose vial policy is followed. A large proportion (30-38%) of records were excluded from the analytic vaccine-specific databases due to data recording errors, mismatches between Ward and Upazila databases, or missing data. The study's results may provide methodological and programmatic guidance for other countries in addressing vaccine wastage issues Published by Elsevier Ltd. C1 [Hymbaugh, Karen; Burkholder, Brent] Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA 30333 USA. [Guichard, Stephane] WHO, SE Asia Reg Off, New Delhi, India. RP Burkholder, B (reprint author), Ctr Dis Control & Prevent, Global Immunizat Div, 1600 Clifton Rd,MS E05, Atlanta, GA 30333 USA. NR 8 TC 11 Z9 11 U1 1 U2 6 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X J9 VACCINE JI Vaccine PD JAN 8 PY 2010 VL 28 IS 3 BP 858 EP 863 DI 10.1016/j.vaccine.2009.08.035 PG 6 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA 561YE UT WOS:000275015200035 PM 19716458 ER PT J AU Dilantika, C Sedyaningsih, ER Kasper, MR Agtini, M Listiyaningsih, E Uyeki, TM Burgess, TH Blair, PJ Putnam, SD AF Dilantika, Charisma Sedyaningsih, Endang R. Kasper, Matthew R. Agtini, Magdarina Listiyaningsih, Erlin Uyeki, Timothy M. Burgess, Timothy H. Blair, Patrick J. Putnam, Shannon D. TI Influenza virus infection among pediatric patients reporting diarrhea and influenza-like illness SO BMC INFECTIOUS DISEASES LA English DT Article ID A H5N1; UNITED-STATES; CHILDREN; HUMANS; SURVEILLANCE; EXPRESSION; INDONESIA AB Background: Influenza is a major cause of morbidity and hospitalization among children. While less often reported in adults, gastrointestinal symptoms have been associated with influenza in children, including abdominal pain, nausea, vomiting, and diarrhea. Methods: From September 2005 and April 2008, pediatric patients in Indonesia presenting with concurrent diarrhea and influenza-like illness were enrolled in a study to determine the frequency of influenza virus infection in young patients presenting with symptoms less commonly associated with an upper respiratory tract infection (URTI). Stool specimens and upper respiratory swabs were assayed for the presence of influenza virus. Results: Seasonal influenza A or influenza B viral RNA was detected in 85 (11.6%) upper respiratory specimens and 21 (2.9%) of stool specimens. Viable influenza B virus was isolated from the stool specimen of one case. During the time of this study, human infections with highly pathogenic avian influenza A (H5N1) virus were common in the survey area. However, among 733 enrolled subjects, none had evidence of H5N1 virus infection. Conclusions: The detection of influenza viral RNA and viable influenza virus from stool suggests that influenza virus may be localized in the gastrointestinal tract of children, may be associated with pediatric diarrhea and may serve as a potential mode of transmission during seasonal and epidemic influenza outbreaks. C1 [Dilantika, Charisma; Kasper, Matthew R.; Listiyaningsih, Erlin; Burgess, Timothy H.; Blair, Patrick J.; Putnam, Shannon D.] Naval Med Res Unit 2, Jakarta, Indonesia. [Sedyaningsih, Endang R.; Agtini, Magdarina] Natl Inst Hlth Res & Dev, Ctr Biomed & Pharmaceut Res & Dev, Jakarta, Indonesia. [Uyeki, Timothy M.] Ctr Dis Control & Prevent, Epidemiol & Prevent Branch, Influenza Div, Atlanta, GA USA. RP Kasper, MR (reprint author), Naval Med Res Unit 2, Jakarta, Indonesia. EM kaspernamru2@yahoo.com FU Global Emerging Infections Surveillance and Response System, a Division of the Armed Forces Health Surveillance Center; U.S. State Department FX Funding for this study was provided by the Global Emerging Infections Surveillance and Response System, a Division of the Armed Forces Health Surveillance Center and the U.S. State Department's Biosecurity Engagement Program. NR 27 TC 25 Z9 25 U1 0 U2 0 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2334 J9 BMC INFECT DIS JI BMC Infect. Dis. PD JAN 7 PY 2010 VL 10 AR 3 DI 10.1186/1471-2334-10-3 PG 5 WC Infectious Diseases SC Infectious Diseases GA 557IK UT WOS:000274662600001 PM 20053294 ER PT J AU Louie, JK Acosta, M Jamieson, DJ Honein, MA AF Louie, Janice K. Acosta, Meileen Jamieson, Denise J. Honein, Margaret A. CA Calif Pandemic H1N1 Working Grp TI Severe 2009 H1N1 Influenza in Pregnant and Postpartum Women in California SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID A(H1N1) INFECTION; UNITED-STATES; IMMUNIZATION; ADMISSIONS; IMPACT; VIRUS; TESTS AB BACKGROUND Like previous epidemic and pandemic diseases, 2009 pandemic influenza A (H1N1) may pose an increased risk of severe illness in pregnant women. METHODS Statewide surveillance for patients who were hospitalized with or died from 2009 H1N1 influenza was initiated by the California Department of Public Health. We reviewed demographic and clinical data reported from April 23 through August 11, 2009, for all H1N1-infected, reproductive-age women who were hospitalized or died -nonpregnant women, pregnant women, and postpartum women (those who had delivered <= 2 weeks previously). RESULTS Data were reported for 94 pregnant women, 8 postpartum women, and 137 nonpregnant women of reproductive age who were hospitalized with 2009 H1N1 influenza. Rapid antigen tests were falsely negative in 38% of the patients tested (58 of 153). Most pregnant patients (89 of 94 [95%]) were in the second or third trimester, and approximately one third (32 of 93 [34%]) had established risk factors for complications from influenza other than pregnancy. As compared with early antiviral treatment (administered <= 2 days after symptom onset) in pregnant women, later treatment was associated with admission to an intensive care unit (ICU) or death (relative risk, 4.3). In all, 18 pregnant women and 4 postpartum women (total, 22 of 102 [22%]) required intensive care, and 8 (8%) died. Six deliveries occurred in the ICU, including four emergency cesarean deliveries. The 2009 H1N1 influenza-specific maternal mortality ratio (the number of maternal deaths per 100,000 live births) was 4.3. CONCLUSIONS 2009 H1N1 influenza can cause severe illness and death in pregnant and postpartum women; regardless of the results of rapid antigen testing, prompt evaluation and antiviral treatment of influenza-like illness should be considered in such women. The high cause-specific maternal mortality rate suggests that 2009 H1N1 influenza may increase the 2009 maternal mortality ratio in the United States. C1 [Louie, Janice K.; Acosta, Meileen] Calif Dept Publ Hlth, Richmond, CA 94804 USA. [Jamieson, Denise J.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Honein, Margaret A.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. RP Louie, JK (reprint author), Calif Dept Publ Hlth, 850 Marina Bay Pkwy, Richmond, CA 94804 USA. EM janice.louie@cdph.ca.gov NR 24 TC 321 Z9 346 U1 2 U2 14 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 J9 NEW ENGL J MED JI N. Engl. J. Med. PD JAN 7 PY 2010 VL 362 IS 1 BP 27 EP 35 DI 10.1056/NEJMoa0910444 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA 540PA UT WOS:000273345500006 PM 20032319 ER PT J AU Coolen, P Best, S Lima, A Sabel, J Paulozzi, L AF Coolen, P. Best, S. Lima, A. Sabel, J. Paulozzi, L. TI Overdose Deaths Involving Prescription Opioids Among Medicaid Enrollees-Washington, 2004-2007 (Reprinted from MMWR, vol 58, pg 1171-1175, 2009) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Paulozzi, L.] CDC, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. NR 1 TC 1 Z9 1 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JAN 6 PY 2010 VL 303 IS 1 BP 21 EP + PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 539YS UT WOS:000273296900005 ER PT J AU Sharma, AJ Grummer-Strawn, LM Dalenius, K Galuska, D Anandappa, M Borland, E Mackintosh, H Smith, R AF Sharma, A. J. Grummer-Strawn, L. M. Dalenius, K. Galuska, D. Anandappa, M. Borland, E. Mackintosh, H. Smith, R. TI Obesity Prevalence Among Low-Income, Preschool-Aged Children-United States, 1998-2008 (Reprinted from MMWR, vol 58, pg 769-773, 2009) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Sharma, A. J.; Grummer-Strawn, L. M.; Dalenius, K.; Galuska, D.; Anandappa, M.; Borland, E.; Mackintosh, H.; Smith, R.] CDC, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Sharma, AJ (reprint author), CDC, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. NR 1 TC 3 Z9 3 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA SN 0098-7484 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JAN 6 PY 2010 VL 303 IS 1 BP 28 EP + PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA 539YS UT WOS:000273296900006 ER PT J AU Kanny, D Horan, J Melstrom, PC AF Kanny, D. Horan, J. Melstrom, P. C. TI Alcohol Use Among High School Students-Georgia, 2007 (Reprinted from MMWR, vol 58, pg 885-890, 2009) SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Reprint C1 [Melstrom, P. C.] CDC, Atlanta, GA 30333 USA. NR 1 TC 1 Z9 1 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JAN 6 PY 2010 VL 303 IS 1 BP 30 EP 31 DI 10.1001/jama.2009.1860 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 539YS UT WOS:000273296900007 ER PT J AU Lynch, MF Mintz, ED AF Lynch, Michael F. Mintz, Eric D. TI Typhoid Fever in the United States and Antibiotic Choice Reply SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Letter C1 [Lynch, Michael F.; Mintz, Eric D.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Lynch, MF (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. EM mlynch1@cdc.gov NR 6 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JAN 6 PY 2010 VL 303 IS 1 BP 34 EP 35 DI 10.1001/jama.2009.1936 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 539YS UT WOS:000273296900014 ER PT J AU Fiore, AE Neuzil, KM AF Fiore, Anthony E. Neuzil, Kathleen M. TI 2009 Influenza A(H1N1) Monovalent Vaccines for Children SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Editorial Material ID H1N1 INFLUENZA; CALIFORNIA; INFECTION; VIRUS C1 [Fiore, Anthony E.] Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Atlanta, GA 30333 USA. [Neuzil, Kathleen M.] PATH, Seattle, WA USA. RP Fiore, AE (reprint author), Ctr Dis Control & Prevent, Natl Ctr Infect Dis, 1600 Clifton Rd NE,Mailstop G37, Atlanta, GA 30333 USA. EM abf4@cdc.gov NR 21 TC 14 Z9 14 U1 0 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JAN 6 PY 2010 VL 303 IS 1 BP 73 EP 74 DI 10.1001/jama.2009.1929 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA 539YS UT WOS:000273296900025 PM 20026596 ER PT J AU Baker, CJ Pickering, LK Chilton, L Cieslak, P Ehresmann, KR Englund, J Friedman, C Judson, FN Keitel, WA Lett, SM Marcy, MS Meissner, CH Neuzil, K Sawyer, MH Sumaya, CV Temte, J AF Baker, Carol J. Pickering, Larry K. Chilton, Lance Cieslak, Paul Ehresmann, Kristen R. Englund, Janet Friedman, Carol Judson, Franklyn N. Keitel, Wendy A. Lett, Susan M. Marcy, Michael S. Meissner, Cody H. Neuzil, Kathleen Sawyer, Mark H. Sumaya, Ciro Valent Temte, Jonathan CA Advisory Comm Immunization Practic TI Recommended Adult Immunization Schedule: United States, 2010 SO ANNALS OF INTERNAL MEDICINE LA English DT Article C1 [Friedman, Carol] Ctr Dis Control & Prevent, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Baker, Carol J.; Keitel, Wendy A.] Baylor Coll Med, Houston, TX 77030 USA. [Chilton, Lance] Univ New Mexico, Sch Med, Albuquerque, NM 87131 USA. [Cieslak, Paul] Oregon Publ Hlth Div, Portland, OR USA. [Ehresmann, Kristen R.] Minnesota Dept Hlth, St Paul, MN USA. [Englund, Janet] Childrens Hosp, Seattle, WA USA. [Englund, Janet] Reg Med Ctr, Seattle, WA USA. [Judson, Franklyn N.] Univ Colorado, Hlth Sci Ctr, Denver, CO USA. [Lett, Susan M.] Massachusetts Dept Publ Hlth, Jamaica Plain, MA USA. [Marcy, Michael S.] Harbor UCLA Med Ctr, Torrance, CA 90509 USA. [Meissner, Cody H.] Tufts Med Ctr, Boston, MA USA. [Meissner, Cody H.] Tufts Med Ctr, Boston, GA USA. [Neuzil, Kathleen] Univ Washington, Seattle, WA 98195 USA. [Sawyer, Mark H.] Univ Calif San Diego, Sch Med, San Diego, CA USA. [Sawyer, Mark H.] Rady Childrens Hosp San Diego, San Diego, CA USA. [Sumaya, Ciro Valent] Texas A&M Hlth Sci Ctr, College Stn, TX USA. [Temte, Jonathan] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA. RP Friedman, C (reprint author), Ctr Dis Control & Prevent, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE,Mailstop E52, Atlanta, GA 30333 USA. EM cxf7@cdc.gov.gov NR 0 TC 38 Z9 40 U1 0 U2 0 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD JAN 5 PY 2010 VL 152 IS 1 BP 36 EP W8 DI 10.7326/0003-4819-152-1-201001050-00008 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA 543FJ UT WOS:000273556600005 ER PT J AU Smyth, DS McDougal, LK Gran, FW Manoharan, A Enright, MC Song, JH de Lencastre, H Robinson, DA AF Smyth, Davida S. McDougal, Linda K. Gran, Frode W. Manoharan, Anand Enright, Mark C. Song, Jae-Hoon de Lencastre, Herminia Robinson, D. Ashley TI Population Structure of a Hybrid Clonal Group of Methicillin-Resistant Staphylococcus aureus, ST239-MRSA-III SO PLOS ONE LA English DT Article ID LARGE CHROMOSOMAL REPLACEMENTS; RAPID IDENTIFICATION; EVOLUTIONARY HISTORY; MOLECULAR EVOLUTION; GEOGRAPHIC SPREAD; ASIAN COUNTRIES; 2 HOSPITALS; MEC; EPIDEMIC; STRAINS AB The methicillin-resistant Staphylococcus aureus (MRSA) clonal group known as ST239-MRSA-III is notable for its hybrid origin and for causing sustained hospital epidemics worldwide since the late 1970s. We studied the population structure of this MRSA clonal group using a sample of 111 isolates that were collected over 34 years from 29 countries. Genetic variation was assessed using typing methods and novel ascertainment methods, resulting in approximately 15 kb of sequence from 32 loci for all isolates. A single most parsimonious tree, free of homoplasy, partitioned 28 haplotypes into geographically associated clades, including prominent European, Asian, and South American clades. The rate of evolution was estimated to be approximately 100x faster than standard estimates for bacteria, and dated the most recent common ancestor of these isolates to the mid-20th century. Associations were discovered between the ST239 phylogeny and the ccrB and dru loci of the methicillin resistance genetic element, SCCmec type III, but not with the accessory components of the element that are targeted by multiplex PCR subtyping tools. In summary, the evolutionary history of ST239 can be characterized by rapid clonal diversification that has left strong evidence of geographic and temporal population structure. SCCmec type III has remained linked to the ST239 chromosome during clonal diversification, but it has undergone homoplasious losses of accessory components. These results provide a population genetics framework for the precise identification of emerging ST239 variants, and invite a re-evaluation of the markers used for subtyping SCCmec. C1 [Smyth, Davida S.; Robinson, D. Ashley] New York Med Coll, Dept Microbiol & Immunol, Valhalla, NY 10595 USA. [McDougal, Linda K.] Ctr Dis Control & Prevent, Off Antimicrobial Resistance, Atlanta, GA USA. [Gran, Frode W.] Univ Trondheim Hosp, Dept Med Microbiol, Trondheim, Norway. [Manoharan, Anand] Christian Med Coll & Hosp, Dept Med Unit & Infect Dis 1, Vellore, Tamil Nadu, India. [Enright, Mark C.] Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis Epidemiol, London, England. [Song, Jae-Hoon] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Infect Dis, Seoul, South Korea. [de Lencastre, Herminia] Univ Nova Lisboa, Mol Genet Lab, Inst Tecnol Quim & Biol, P-2780156 Oeiras, Portugal. [de Lencastre, Herminia] Rockefeller Univ, Microbiol Lab, New York, NY 10021 USA. RP Smyth, DS (reprint author), Univ Mississippi, Med Ctr, Dept Microbiol, Jackson, MS 39216 USA. EM darobinson@microbio.umsmed.edu RI Song, Jae Hoon/C-9602-2011; OI de Lencastre, Herminia/0000-0001-6816-8932; Enright, Mark/0000-0001-5273-8750 FU American Heart Association; NIH [GM080602] FX This work was supported by a grant from the American Heart Association and by NIH grant GM080602 ( to D. A. R.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 73 TC 40 Z9 41 U1 0 U2 8 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JAN 5 PY 2010 VL 5 IS 1 AR e8582 DI 10.1371/journal.pone.0008582 PG 10 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA 540NE UT WOS:000273338500024 PM 20062529 ER PT J AU Alvarez, P Mattiello, R Rivailler, P Pereda, A Davis, CT Boado, L D'Ambrosio, E Aguirre, S Espinosa, C La Torre, J Donis, R Mattion, N AF Alvarez, Paula Mattiello, Rosana Rivailler, Pierre Pereda, Ariel Davis, Charles T. Boado, Lorena D'Ambrosio, Elisa Aguirre, Sebastian Espinosa, Cora La Torre, Jose Donis, Ruben Mattion, Nora TI First isolation of an H1N1 avian influenza virus from wild terrestrial non-migratory birds in Argentina SO VIROLOGY LA English DT Article DE Avian influenza virus; Red-winged tinamou; Non-migratory birds; Virus evolution ID A VIRUSES; PHYLOGENETIC ANALYSIS; SEQUENCE ALIGNMENT; SOUTHERN CHINA; POULTRY; HEMAGGLUTININ; OUTBREAK; GENES; EVOLUTION; LINEAGES AB A type A avian influenza (AI) virus was isolated from dead or severely ill red-winged tinamous (Rhynchotus rufescens) found in a hunting ground in April 2008 in Argentina. The subtype of A/red-winged tinamou/Argentina/MP1/2008 was determined as H1N1 by sequence analysis. The cleavage site of the viral hemagglutinin corresponded to a low pathogenic influenza virus, although the clinical presentation and pathological studies suggest that the virus was pathogenic for Fed-winged tinamous. Phylogenetic analysis of the viral genome Suggested that while the hemagglutinin and neuraminidase genes were related to AIV from North America, the internal genes were most closely related to other South American isolates. These findings support the postulated South American phylogenetic lineage for AIV PB2, PB1, PA, M and NS genes, and suggest that the evolutionary pathways of HA and NA genes involve exchanges between the Northern and Southern hemispheres. (C) 2009 Elsevier Inc. All rights reserved. C1 [Alvarez, Paula; Boado, Lorena; Aguirre, Sebastian; La Torre, Jose; Mattion, Nora] Consejo Nacl Invest Cient & Tecn, Inst Ciencia & Tecnol Dr Cesar Milstein, Ctr Virol Anim, RA-1440 Buenos Aires, DF, Argentina. [Mattiello, Rosana; D'Ambrosio, Elisa] Univ Buenos Aires, Fac Ciencias Vet, RA-1427 Caba, Argentina. [Rivailler, Pierre; Davis, Charles T.; Donis, Ruben] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA. [Pereda, Ariel] CICVyA, INTA, RA-1708 Moron, Argentina. [Espinosa, Cora] SENASA, RA-1063 Buenos Aires, DF, Argentina. RP Mattion, N (reprint author), Consejo Nacl Invest Cient & Tecn, Inst Ciencia & Tecnol Dr Cesar Milstein, Ctr Virol Anim, Saladillo 2468, RA-1440 Buenos Aires, DF, Argentina. EM nmattioncevan@centromilstein.org.ar OI Mattion, Nora/0000-0001-8625-1780 NR 32 TC 12 Z9 15 U1 2 U2 5 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0042-6822 J9 VIROLOGY JI Virology PD JAN 5 PY 2010 VL 396 IS 1 BP 76 EP 84 DI 10.1016/j.virol.2009.10.009 PG 9 WC Virology SC Virology GA 531EX UT WOS:000272647600009 PM 19896684 ER PT J AU Hooper, TI DeBakey, SF Pearse, L Pratt, S Hoffman, KJ AF Hooper, Tomoko I. DeBakey, Samar F. Pearse, Lisa Pratt, Stephanie Hoffman, Kenneth J. TI The use of electronic pharmacy data to investigate prescribed medications and fatal motor vehicle crashes in a military population, 2002-2006 SO ACCIDENT ANALYSIS AND PREVENTION LA English DT Article DE Automobile driving; Case-control study; Military personnel; Pharmacoepidemiology; Prescription drugs; Traffic accidents ID ROAD-TRAFFIC ACCIDENTS; RISK-FACTORS; BENZODIAZEPINE USE; SERIOUS INJURY; OLDER DRIVERS; GULF-WAR; DRUG-USE; ASSOCIATION; ALCOHOL; DIPHENHYDRAMINE AB The authors examined the association between prescribed medications and fatal motor vehicle crashes (MVCs) in an active duty military population between 2002 and 2006. Using a case-control design. MVC deaths were ascertained using a military mortality registry, and an integrated health system database provided information on health system eligibility, pharmacy transactions, and medical encounters. Cases and controls were matched on comparable observation time outside periods of deployment. Among selected categories, only one, antidepressant medications, was an independent predictor of fatal MVC (odds ratio, 3.19; 95% confidence interval, 1.01-10.07). Male gender, Black race, enlisted rank, service branch (Navy and Marine Corps), and selected co-morbidities were also independent predictors. Unexpectedly, the odds of younger age quartiles (<27 years) and history of deployment were reduced for MVC cases. Although results need to be considered in the context of data limitations, the association between prescribed antidepressants and fatal MVC may reflect unmeasured co-morbidities, such as combined effects of prescribed and over-the-counter medications and/or alcohol or other substance abuse. Younger individuals, representing new military accessions in training or returning from deployment with serious injuries, may have fewer opportunities to operate vehicles, or targeted efforts to reduce MVC following deployment may be showing a positive effect. Published by Elsevier Ltd. C1 [Hooper, Tomoko I.; Hoffman, Kenneth J.] Uniformed Serv Univ Hlth Sci, Dept Prevent Med & Biometr, Bethesda, MD 20814 USA. [DeBakey, Samar F.] Hlth Res & Anal LLC, Rockville, MD 20852 USA. [Pearse, Lisa] Armed Forces Inst Pathol, Mortal Surveillance Div, Rockville, MD 20850 USA. [Pratt, Stephanie] NIOSH, Div Safety Res, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. RP Hooper, TI (reprint author), Uniformed Serv Univ Hlth Sci, Dept Prevent Med & Biometr, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA. EM thooper@usuhs.mil; sdebakey@health-ra.com; lisa.pearse@usuhs.mil; sgp2@cdc.gov; khoffman100@comcast.net FU PHS HHS [05FED06912] NR 42 TC 6 Z9 6 U1 1 U2 6 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0001-4575 J9 ACCIDENT ANAL PREV JI Accid. Anal. Prev. PD JAN PY 2010 VL 42 IS 1 BP 261 EP 268 DI 10.1016/j.aap.2009.07.024 PG 8 WC Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation SC Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation GA 528YE UT WOS:000272482100029 PM 19887166 ER PT J AU Myers, GL Christenson, RH Wilson, PWF Cushman, M Ballantyne, CM Levy, D Rifai, N Cooper, GR Myers, GL AF Myers, Gary L. Christenson, Robert H. Wilson, Peter W. F. Cushman, Mary Ballantyne, Christie M. Levy, Daniel Rifai, Nader Cooper, Gerald R. Myers, Gary L. CA Comite NACB TI Clinical laboratory practical guides Emerging Biomarkers for the primary prevention of cardiovascular disease and cerebrovascular accidents SO ACTA BIOQUIMICA CLINICA LATINOAMERICANA LA Spanish DT Article ID C-REACTIVE PROTEIN; CORONARY-HEART-DISEASE; APPARENTLY HEALTHY-MEN; BLOOD-CELL COUNT; LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE-A2; HORMONE REPLACEMENT THERAPY; PLATELET-ACTIVATING-FACTOR; MIDDLE-AGED MEN; FIBRIN D-DIMER; BEZAFIBRATE INFARCTION PREVENTION C1 [Myers, Gary L.; Cooper, Gerald R.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Christenson, Robert H.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. [Cushman, Mary] Univ Vermont, Colchester, VT USA. [Ballantyne, Christie M.] Baylor Coll Med, Houston, TX 77030 USA. [Levy, Daniel] Framingham Heart Dis Epidemiol Study, Framingham, MA USA. [Rifai, Nader] Childrens Hosp, Boston, MA 02115 USA. [Rifai, Nader] Harvard Univ, Sch Med, Boston, MA USA. [Wilson, Peter W. F.] Emory Univ, Sch Med, Atlanta, GA USA. RP Myers, GL (reprint author), Ctr Dis Control & Prevent, Atlanta, GA USA. NR 153 TC 1 Z9 2 U1 1 U2 1 PU FEDERACION BIOQUIMICA PROVINCIA BUENOS AIRES PI LA PLATA, BUENOS AIRES PA CALLE 6, NO. 1344, 1900 LA PLATA, BUENOS AIRES, ARGENTINA SN 0325-2957 J9 ACTA BIOQUIM CLIN L JI Acta Bioquim. Clin. Latinoam. PD JAN-MAR PY 2010 VL 44 IS 1 BP 75 EP 100 PG 26 WC Medical Laboratory Technology SC Medical Laboratory Technology GA 784XT UT WOS:000292192700011 ER PT J AU Shipitsyna, E Savicheva, A Sokolovskiy, E Ballard, RC Domeika, M Unemo, M Jensen, JS AF Shipitsyna, Elena Savicheva, Alevtina Sokolovskiy, Evgenij Ballard, Ronald C. Domeika, Marius Unemo, Magnus Jensen, Jorgen S. CA EE SRH Network TI Guidelines for the Laboratory Diagnosis of Mycoplasma genitalium Infections in East European Countries SO ACTA DERMATO-VENEREOLOGICA LA English DT Article DE Mycoplasma genitalium; laboratory diagnosis; guidelines; Eastern Europe ID POLYMERASE-CHAIN-REACTION; REAL-TIME PCR; SEXUALLY-TRANSMITTED INFECTIONS; IN-HOUSE PCR; CHLAMYDIA-TRACHOMATIS; NEISSERIA-GONORRHOEAE; UREAPLASMA-UREALYTICUM; QUANTITATIVE DETECTION; CLINICAL SPECIMENS; QUALITY-ASSURANCE AB The present guidelines aim to provide comprehensive information regarding laboratory diagnosis of Myeoplasma genitalium infections in East European countries. These guidelines are intended primarily for laboratory professionals testing specimens from patients at sexual health care clinics, but may also be useful for community-based screening programmes. Diagnosis of M. genitalium infection is performed exclusively using nucleic acid amplification tests (NAATs), owing to the poor and slow growth of the bacterium in culture. Because no internationally validated and approved commercial NAAT for M. genitalium detection is presently available, it is necessary that laboratories performing M. genitalium diagnostics not only carefully evaluate and validate their in-house PCRs before using them routinely, but also use comprehensive internal controls and take part in external quality assessment programmes. The guidelines were elaborated as a consensus document of the Eastern European Sexual and Reproductive Health Network, and comprise one element of a series of guidelines aimed at optimizing, standardizing, and providing guidance on quality laboratory testing for reproductive tract infections. C1 [Unemo, Magnus] Orebro Univ Hosp, Natl Reference Lab Pathogen Neisseria, Dept Lab Med, SE-70185 Orebro, Sweden. [Shipitsyna, Elena; Savicheva, Alevtina] Pavlov State Med Univ, Microbiol Lab, DO Ott Res Inst Obstet & Gynecol, St Petersburg, Russia. [Sokolovskiy, Evgenij] Pavlov State Med Univ, Dept Dermatol & Venerol, St Petersburg, Russia. [Ballard, Ronald C.] Ctr Dis Control & Prevent, Natl Ctr HIV STD & TB Prevent, Atlanta, GA USA. [Domeika, Marius] Uppsala Univ, Dept Med Sci, Uppsala, Sweden. [Jensen, Jorgen S.] Slatens Serum Inst, Mycoplasma Lab, Copenhagen, Denmark. RP Unemo, M (reprint author), Orebro Univ Hosp, Natl Reference Lab Pathogen Neisseria, Dept Lab Med, SE-70185 Orebro, Sweden. EM magnus.unemo@orebroll.se RI Jensen, Jorgen/I-2917-2012; OI Jensen, Jorgen Skov/0000-0002-7464-7435 FU East Europe Committee of the Swedish Health Care Community, Swedish International Development Cooperation Agency (SIDA) FX The present guidelines were written on behalf of the Eastern European Sexual and Reproductive Health (EE SRH) Network, STI Diagnostic Group, which is supported by grants from the East Europe Committee of the Swedish Health Care Community, Swedish International Development Cooperation Agency (SIDA). Project coordinator Marius Domeika. EE SRH Network: K. Babayan, E. Manukyan (Armenia), R. Ismailov (Azerbaijan), I. Shimanskaya, O. Pankratov, N. Kolomiets, O. Kudina (Belarus), K. Chudomirova (Bulgaria), T. Brilene (Estonia), G. Galdava, O. Kvlividze (Georgia), J. Deak (Hungary), G. Askarova, A. Utegenova (Kazakhstan), D. Yusupova, E. A1-Kilani (Kyrgyzstan), A. Rubins (Latvia), V. Kucinskiene (Lithuania), T. Krasnoselskikh, A. Guschin (Russia), A. Kasymov, O. Kasymov (Tajikistan), G. Mavrov, N. Kochetova, G. Bondarenko (Ukraine), S. Ibragimov, O. Izvekova, and T. Nabiev (Uzbekistan). NR 66 TC 8 Z9 12 U1 0 U2 4 PU ACTA DERMATO-VENEREOLOGICA PI UPPSALA PA TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN SN 0001-5555 J9 ACTA DERM-VENEREOL JI Acta Derm.-Venereol. PY 2010 VL 90 IS 5 BP 461 EP 467 DI 10.2340/00015555-0929 PG 7 WC Dermatology SC Dermatology GA 656CC UT WOS:000282302500005 PM 20814619 ER PT S AU Polderman, AM Eberhard, M Baeta, S Gasser, RB van Lieshout, L Magnussen, P Olsen, A Spannbrucker, N Ziem, J Horton, J AF Polderman, A. M. Eberhard, M. Baeta, S. Gasser, Robin B. van Lieshout, L. Magnussen, P. Olsen, A. Spannbrucker, N. Ziem, J. Horton, J. BE Rollinson, D Hay, SI TI The Rise and Fall of Human Oesophagostomiasis SO ADVANCES IN PARASITOLOGY, VOL 71 SE Advances in Parasitology LA English DT Review; Book Chapter ID STRAND CONFORMATION POLYMORPHISM; NECATOR-AMERICANUS INFECTIONS; INDUCED COLONIC PATHOLOGY; INDUCED NODULAR PATHOLOGY; NORTHERN GHANA; HOOKWORM INFECTIONS; NONHUMAN-PRIMATES; BIFURCUM NEMATODA; MASS TREATMENT; ANCYLOSTOMA-DUODENALE AB Until recently, the infections of humans with representatives of the genus Oesophagostomum were thought to be rare and of zoonotic origin. In the 19805, it was recognised that intense transmission associated with the disease was taking place in northern Togo and Ghana. Pathology can be severe and two clinical presentations, called 'Dapaong Tumour' and Multinodular disease', have been described. Lesions can now be efficiently and specifically visualised by ultrasound. The prevalence of infection appeared to be high in many villages, although its distribution was limited and focal. Parasitological diagnosis has been based on the demonstration of third-stage larvae in stool cultures and more recently on PCR. Molecular and epidemiological evidence supports the proposal that Oesophagostomum bifurcum infections of humans in Ghana and Togo represent a distinct genotype from that of non-human primates in the area. Mass treatment, using repeated doses of albendazole rapidly resulted in the effective elimination of human oesophagostomiasis in the affected areas. This review takes a historic perspective on oesophagostomiasis of humans. This chapter discusses how the unexpected success of mass treatment together with aberrant pathogenesis, the severity of pathology in humans and the limited geographic distribution of the parasite all reflect a poor adaptation of the parasite to the human host. C1 [Polderman, A. M.; van Lieshout, L.] Leiden Univ, Med Ctr, Dept Parasitol, Leiden, Netherlands. [Eberhard, M.] CDC, Div Parasit Dis, Atlanta, GA 30333 USA. [Baeta, S.] Univ Lome, Dept Gynecol Obstet, Lome, Togo. [Gasser, Robin B.] Univ Melbourne, Dept Vet Sci, Werribee, Vic 3030, Australia. [Magnussen, P.; Olsen, A.] Univ Copenhagen, Fac Life Sci, DBL Ctr Hlth Res & Dev, Frederiksberg C, Denmark. [Spannbrucker, N.] Board Publ Hlth Neuruppin, Bonn, Germany. [Horton, J.] Univ Dev Studies, Sch Med & Hlth Sci, Tamale, Ghana. RP Polderman, AM (reprint author), Leiden Univ, Med Ctr, Dept Parasitol, Leiden, Netherlands. OI Olsen, Annette/0000-0001-9352-621X NR 110 TC 3 Z9 3 U1 2 U2 9 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA SN 0065-308X BN 978-0-12-381512-5 J9 ADV PARASIT JI Adv.Parasitol. PY 2010 VL 71 BP 93 EP 155 DI 10.1016/S0065-308X(10)71002-2 PG 63 WC Parasitology SC Parasitology GA BOU45 UT WOS:000277632800003 ER PT J AU Kim, SW Raynor, PC AF Kim, Seung Won Raynor, Peter C. TI Optimization of the Design of a Semivolatile Aerosol Dichotomous Sampler SO AEROSOL SCIENCE AND TECHNOLOGY LA English DT Article ID VIRTUAL IMPACTORS; FLOW; EXPOSURE; EVAPORATION; DEPOSITION; MODEL AB This article reports the results of an optimization procedure for a semivolatile aerosol dichotomous sampler (SADS) and experimental confirmation of the instrument's performance with an optimized sampler. Using numerical model results, the relationships between four major design and operating parameters significantly affecting the performance of the SADS and four performance parameters were expressed in log polynomial equations. Utilizing an optimization procedure, values for the major parameters giving the best performance were determined and used as the base model for optimizing minor parameters. Five minor parameters were then investigated for their possible contribution to better performance of the SADS. The optimal dimensions found were as follows: the diameter ratio between the nozzle and the collection probe was 1.30 and the length ratio of the distance between the nozzle and the collection probe divided by the nozzle diameter was 0.6. Among the minor parameters, only the entrance angle of the nozzle made noticeable improvement at 45 degrees. Experimental tests confirmed that the performance of the new sampler was improved although not as much as expected from the numerical simulation. C1 [Kim, Seung Won; Raynor, Peter C.] Univ Minnesota, Sch Publ Hlth, Div Environm Hlth Sci, Minneapolis, MN USA. RP Kim, SW (reprint author), NIOSH, CDC, HELD, 1095 Willowdale Rd,MS 3030, Morgantown, WV 26505 USA. EM seungwon.kim@cdc.hhs.gov RI Kim, Seung Won/G-1843-2010 OI Kim, Seung Won/0000-0003-2960-5866 FU NIOSH-sponsored Midwest Center for Occupational Health and Safety at the University of Minnesota; University of Minnesota Supercomputing Institute FX This study was supported in part by a grant from the Pilot Project Research Training Program of the NIOSH-sponsored Midwest Center for Occupational Health and Safety at the University of Minnesota and in part by the University of Minnesota Supercomputing Institute. NR 32 TC 2 Z9 2 U1 1 U2 5 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA SN 0278-6826 J9 AEROSOL SCI TECH JI Aerosol Sci. Technol. PY 2010 VL 44 IS 2 BP 129 EP 140 DI 10.1080/02786820903426739 PG 12 WC Engineering, Chemical; Engineering, Mechanical; Environmental Sciences; Meteorology & Atmospheric Sciences SC Engineering; Environmental Sciences & Ecology; Meteorology & Atmospheric Sciences GA 551GV UT WOS:000274195900004 ER PT B AU McCree, DH Hogben, M AF McCree, Donna Hubbard Hogben, Matthew BE McCree, DH Jones, KT OLeary, A TI The Contribution to and Context of Other Sexually Transmitted Diseases and Tuberculosis in the HIV/AIDS Epidemic Among African Americans Introduction SO AFRICAN AMERICANS AND HIV/AIDS: UNDERSTANDING AND ADDRESSING THE EPIDEMIC LA English DT Editorial Material; Book Chapter ID RANDOMIZED CONTROLLED-TRIAL; HUMAN-IMMUNODEFICIENCY-VIRUS; HURRICANE KATRINA DISASTER; PREVENTION INTERVENTIONS; SOCIOECONOMIC-STATUS; HEALTH DISPARITIES; RACIAL DISPARITIES; ADOLESCENT GIRLS; RISK BEHAVIORS; HIV-INFECTION C1 [McCree, Donna Hubbard] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. [Hogben, Matthew] Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. RP McCree, DH (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, 1600 Clifton Rd NE,MS E-37, Atlanta, GA 30333 USA. EM zyr1@cdc.gov; zyr1@cdc.gov NR 55 TC 1 Z9 1 U1 0 U2 0 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY BN 978-0-387-78320-8 PY 2010 BP 3 EP 12 DI 10.1007/978-0-387-78321-5_1 PG 10 WC Behavioral Sciences; Public, Environmental & Occupational Health SC Behavioral Sciences; Public, Environmental & Occupational Health GA BRI40 UT WOS:000282770800001 ER PT B AU Johnson, AS Wei, XM Hu, XH Dean, HD AF Johnson, Anna Satcher Wei, Xiangming Hu, Xiaohong Dean, Hazel D. BE McCree, DH Jones, KT OLeary, A TI Epidemiology and Surveillance of HIV Infection and AIDS Among Non-Hispanic Blacks in the United States SO AFRICAN AMERICANS AND HIV/AIDS: UNDERSTANDING AND ADDRESSING THE EPIDEMIC LA English DT Article; Book Chapter C1 [Johnson, Anna Satcher] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Off Infect Dis, Atlanta, GA 30333 USA. RP Johnson, AS (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Off Infect Dis, Mail Stop E-47,1600 Clifton Rd, Atlanta, GA 30333 USA. EM ATS5@cdc.gov NR 17 TC 1 Z9 1 U1 2 U2 2 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY BN 978-0-387-78320-8 PY 2010 BP 15 EP 30 DI 10.1007/978-0-387-78321-5_2 PG 16 WC Behavioral Sciences; Public, Environmental & Occupational Health SC Behavioral Sciences; Public, Environmental & Occupational Health GA BRI40 UT WOS:000282770800002 ER PT B AU Williams, KM Prather, CM AF Williams, Kim M. Prather, Cynthia M. BE McCree, DH Jones, KT OLeary, A TI Racism, Poverty and HIV/AIDS Among African Americans SO AFRICAN AMERICANS AND HIV/AIDS: UNDERSTANDING AND ADDRESSING THE EPIDEMIC LA English DT Article; Book Chapter ID SOUTHERN UNITED-STATES; LOS-ANGELES-COUNTY; HIV PREVENTION; HEALTH DISPARITIES; PUBLIC-HEALTH; ECOLOGICAL PERSPECTIVE; PSYCHOLOGICAL DISTRESS; SOCIOECONOMIC-STATUS; CONTEXTUAL FACTORS; MATERIAL HARDSHIP C1 [Williams, Kim M.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. [Prather, Cynthia M.] USPHS CDC NCHHSTP DHAP IRS PRB, Atlanta, GA 30333 USA. RP Williams, KM (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, 1600 Clifton Rd,MS E-37, Atlanta, GA 30333 USA. EM KWilliams4@cdc.gov NR 138 TC 4 Z9 4 U1 1 U2 3 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY BN 978-0-387-78320-8 PY 2010 BP 31 EP 51 DI 10.1007/978-0-387-78321-5_3 PG 21 WC Behavioral Sciences; Public, Environmental & Occupational Health SC Behavioral Sciences; Public, Environmental & Occupational Health GA BRI40 UT WOS:000282770800003 ER PT B AU Eke, AN Wilkes, AL Gaiter, J AF Eke, Agatha N. Wilkes, Aisha L. Gaiter, Juarlyn BE McCree, DH Jones, KT OLeary, A TI Organized Religion and the Fight Against HIV/AIDS in the Black Community: The Role of the Black Church SO AFRICAN AMERICANS AND HIV/AIDS: UNDERSTANDING AND ADDRESSING THE EPIDEMIC LA English DT Article; Book Chapter ID AFRICAN-AMERICAN COMMUNITY; FAITH COMMUNITIES; HEALTH-PROMOTION; RANDOMIZED-TRIAL; PUBLIC-HEALTH; MENTAL-HEALTH; SPIRITUALITY; HIV; MEDICINE; PROGRAMS C1 [Eke, Agatha N.; Gaiter, Juarlyn] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. [Wilkes, Aisha L.] Ctr Dis Control & Prevent, Prevent Res Branch DHAP NCHHSTP, Atlanta, GA 30333 USA. RP Eke, AN (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, 1600 Clifton Rd,MS E-37, Atlanta, GA 30333 USA. EM AEke@cdc.gov NR 79 TC 11 Z9 11 U1 1 U2 1 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY BN 978-0-387-78320-8 PY 2010 BP 53 EP 68 DI 10.1007/978-0-387-78321-5_4 PG 16 WC Behavioral Sciences; Public, Environmental & Occupational Health SC Behavioral Sciences; Public, Environmental & Occupational Health GA BRI40 UT WOS:000282770800004 ER PT B AU Gaiter, JL O'Leary, A AF Gaiter, Juarlyn L. O'Leary, Ann BE McCree, DH Jones, KT OLeary, A TI Disproportionate Drug Imprisonment Perpetuates the HIV/AIDS Epidemic in African American Communities SO AFRICAN AMERICANS AND HIV/AIDS: UNDERSTANDING AND ADDRESSING THE EPIDEMIC LA English DT Article; Book Chapter ID CONCURRENT SEXUAL PARTNERSHIPS; SOUTHEASTERN UNITED-STATES; HIV-INFECTED PRISONERS; RISK BEHAVIORS; TRANSMITTED-DISEASES; HEALTH DISPARITIES; SUBSTANCE USE; NEW-YORK; INCARCERATION; TRANSMISSION C1 [Gaiter, Juarlyn L.; O'Leary, Ann] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Prevent Res Branch, Atlanta, GA 30333 USA. RP Gaiter, JL (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Prevent Res Branch, 1600 Clifton Rd,NE,MS E-37, Atlanta, GA 30333 USA. EM JGaiter@cdc.gov NR 74 TC 4 Z9 4 U1 1 U2 1 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY BN 978-0-387-78320-8 PY 2010 BP 69 EP 83 DI 10.1007/978-0-387-78321-5_5 D2 10.1007/978-0-387-78321-5 PG 15 WC Behavioral Sciences; Public, Environmental & Occupational Health SC Behavioral Sciences; Public, Environmental & Occupational Health GA BRI40 UT WOS:000282770800005 ER PT B AU Spikes, PS Willis, LA Koenig, LJ AF Spikes, Pilgrim S. Willis, Leigh A. Koenig, Linda J. BE McCree, DH Jones, KT OLeary, A TI Violence, Trauma, and Mental Health Disorders: Are They Related to Higher HIV Risk for African Americans? SO AFRICAN AMERICANS AND HIV/AIDS: UNDERSTANDING AND ADDRESSING THE EPIDEMIC LA English DT Article; Book Chapter ID POSTTRAUMATIC-STRESS-DISORDER; INTIMATE PARTNER VIOLENCE; NATIONAL-COMORBIDITY-SURVEY; CHILDHOOD SEXUAL-ABUSE; INJECTION-DRUG USERS; MAJOR DEPRESSIVE DISORDER; PRIMARY-CARE PATIENTS; UNITED-STATES; PSYCHOLOGICAL DISTRESS; SUBSTANCE USE C1 [Spikes, Pilgrim S.; Koenig, Linda J.] Ctr Dis Control & Prevent, Prevent Res Branch, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. [Willis, Leigh A.] Minor HIV AIDS Res Initiat MARI, Epidemiol Branch, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. RP Spikes, PS (reprint author), Ctr Dis Control & Prevent, Prevent Res Branch, Div HIV AIDS Prevent, 1600 Clifton Rd,Mailstop E-37, Atlanta, GA 30333 USA. EM PSpikes@cdc.gov NR 174 TC 2 Z9 2 U1 3 U2 3 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY BN 978-0-387-78320-8 PY 2010 BP 85 EP 112 DI 10.1007/978-0-387-78321-5_6 PG 28 WC Behavioral Sciences; Public, Environmental & Occupational Health SC Behavioral Sciences; Public, Environmental & Occupational Health GA BRI40 UT WOS:000282770800006 ER PT B AU Marshall, K Crepaz, N O'Leary, A AF Marshall, Khiya Crepaz, Nicole O'Leary, Ann BE McCree, DH Jones, KT OLeary, A TI A Systematic Review of Evidence-Based Behavioral Interventions for African American Youth at Risk for HIV/STI Infection, 1988-2007 SO AFRICAN AMERICANS AND HIV/AIDS: UNDERSTANDING AND ADDRESSING THE EPIDEMIC LA English DT Review; Book Chapter ID RANDOMIZED CONTROLLED-TRIAL; CONDOM AVAILABILITY PROGRAMS; HIV/AIDS PREVENTION RESEARCH; SEXUAL-BEHAVIOR; REDUCTION INTERVENTIONS; FEMALE ADOLESCENTS; BLACK-ADOLESCENTS; LOW-INCOME; BISEXUAL ADOLESCENTS; AIDS EDUCATION C1 [Marshall, Khiya; O'Leary, Ann] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Prevent Res Branch, Atlanta, GA 30333 USA. RP Marshall, K (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Prevent Res Branch, 1600 Clifton Rd,MS E-37, Atlanta, GA 30333 USA. EM kmarshall@cdc.gov NR 86 TC 6 Z9 6 U1 1 U2 4 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY BN 978-0-387-78320-8 PY 2010 BP 151 EP 180 DI 10.1007/978-0-387-78321-5_9 PG 30 WC Behavioral Sciences; Public, Environmental & Occupational Health SC Behavioral Sciences; Public, Environmental & Occupational Health GA BRI40 UT WOS:000282770800009 ER PT B AU Henny, KD Williams, KM Patterson, J AF Henny, Kirk D. Williams, Kim M. Patterson, Jocelyn BE McCree, DH Jones, KT OLeary, A TI HIV Behavioral Interventions for Heterosexual African American Men: A Critical Review of Cultural Competence SO AFRICAN AMERICANS AND HIV/AIDS: UNDERSTANDING AND ADDRESSING THE EPIDEMIC LA English DT Review; Book Chapter ID SEXUALLY-TRANSMITTED-DISEASES; RISK-REDUCTION INTERVENTION; RANDOMIZED CONTROLLED-TRIAL; UNITED-STATES; PREVENTION INTERVENTION; INTERVIEWER GENDER; PRIMARY-CARE; HIV/AIDS; INFECTION; TRANSMISSION C1 [Henny, Kirk D.; Patterson, Jocelyn] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA 30333 USA. [Williams, Kim M.] Ctr Dis Control & Prevent, Prevent Res Branch, Prevent Natl Ctr HIV STD & TB Prevent, Div HIV AIDS, Atlanta, GA 30333 USA. RP Henny, KD (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, 1600 Clifton Rd NE,MS E-37, Atlanta, GA 30333 USA. EM KHenny@cdc.gov OI Henny, Kirk/0000-0002-0886-8651 NR 73 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY BN 978-0-387-78320-8 PY 2010 BP 181 EP 209 DI 10.1007/978-0-387-78321-5_10 PG 29 WC Behavioral Sciences; Public, Environmental & Occupational Health SC Behavioral Sciences; Public, Environmental & Occupational Health GA BRI40 UT WOS:000282770800010 ER PT B AU Jones, KT Wilton, L Millett, G Johnson, WD AF Jones, Kenneth Terrill Wilton, Leo Millett, Gregorio Johnson, Wayne D. BE McCree, DH Jones, KT OLeary, A TI Formulating the Stress and Severity Model of Minority Social Stress for Black Men Who Have Sex with Men SO AFRICAN AMERICANS AND HIV/AIDS: UNDERSTANDING AND ADDRESSING THE EPIDEMIC LA English DT Article; Book Chapter ID AFRICAN-AMERICAN MEN; UNITED-STATES; HIV RISK; RACIAL-DISCRIMINATION; GAY MEN; ETHNIC-IDENTITY; BISEXUAL MEN; YOUNG MEN; PREVENTION INTERVENTION; PSYCHOLOGICAL DISTRESS C1 [Jones, Kenneth Terrill] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. [Johnson, Wayne D.] CDC, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. [Wilton, Leo] CCPA Human Dev, Binghamton, NY 13902 USA. RP Jones, KT (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, 1600 Clifton Rd NE,MS E-37, Atlanta, GA 30333 USA. EM KJones4@cdc.gov NR 104 TC 6 Z9 7 U1 1 U2 3 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY BN 978-0-387-78320-8 PY 2010 BP 223 EP 238 DI 10.1007/978-0-387-78321-5_12 D2 10.1007/978-0-387-78321-5 PG 16 WC Behavioral Sciences; Public, Environmental & Occupational Health SC Behavioral Sciences; Public, Environmental & Occupational Health GA BRI40 UT WOS:000282770800012 ER PT B AU Purcell, DW Mizuno, Y Lyles, CM AF Purcell, David W. Mizuno, Yuko Lyles, Cynthia M. BE McCree, DH Jones, KT OLeary, A TI HIV Prevention Interventions for African American Injection Drug Users SO AFRICAN AMERICANS AND HIV/AIDS: UNDERSTANDING AND ADDRESSING THE EPIDEMIC LA English DT Article; Book Chapter ID EFFECTIVE BEHAVIORAL INTERVENTIONS; RANDOMIZED CONTROLLED-TRIAL; SYRINGE EXCHANGE PROGRAMS; SEXUAL RISK BEHAVIOR; HEPATITIS-C-VIRUS; UNITED-STATES; NEEDLE EXCHANGE; REDUCTION; HIV/AIDS; CARE C1 [Purcell, David W.] Ctr Dis Control, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. [Lyles, Cynthia M.] Ctr Dis Control & Prevent, Prevent Res Branch, Div HIV AIDS Prevent, Ctr HIV STD & TB Prevent, Atlanta, GA 30333 USA. RP Purcell, DW (reprint author), Ctr Dis Control, Div HIV AIDS Prevent, 1600 Clifton Rd,MS E-37, Atlanta, GA 30333 USA. EM dpurcell@cdc.gov OI Purcell, David/0000-0001-8125-5168 NR 54 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY BN 978-0-387-78320-8 PY 2010 BP 239 EP 254 DI 10.1007/978-0-387-78321-5_13 D2 10.1007/978-0-387-78321-5 PG 16 WC Behavioral Sciences; Public, Environmental & Occupational Health SC Behavioral Sciences; Public, Environmental & Occupational Health GA BRI40 UT WOS:000282770800013 ER PT B AU Seal, DW MacGowan, RJ Eldridge, GD Charania, MR Margolis, AD AF Seal, David Wyatt MacGowan, Robin J. Eldridge, Gloria D. Charania, Mahnaz R. Margolis, Andrew D. BE McCree, DH Jones, KT OLeary, A TI HIV Behavioral Interventions for Incarcerated Populations in the United States: A Critical Review SO AFRICAN AMERICANS AND HIV/AIDS: UNDERSTANDING AND ADDRESSING THE EPIDEMIC LA English DT Review; Book Chapter ID RISK-REDUCTION INTERVENTION; AIDS EDUCATION; CASE-MANAGEMENT; YOUNG MEN; SEXUAL-BEHAVIOR; PRISON-INMATES; HEALTH-POLICY; SUBSTANCE USE; TERM IMPACT; DRUG-USERS C1 [Seal, David Wyatt] Med Coll Wisconsin, Ctr AIDS Intervent Res, Dept Psychiat & Behav Med, Milwaukee, WI 53202 USA. [Seal, David Wyatt] Med Coll Wisconsin, Ctr AIDS Intervent Res, Dept Populat Hlth, Milwaukee, WI 53202 USA. [Charania, Mahnaz R.] Ctr Dis Control & Prevent, Res Synth & Translat Team, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Prevent Res Branch,Div HIV AIDS Prevent,PRS Proje, Atlanta, GA 30333 USA. [Eldridge, Gloria D.] Univ Alaska Anchorage, Dept Psychol, Anchorage, AK 99508 USA. [Eldridge, Gloria D.] Univ Alaska Anchorage, Ctr Behav Hlth Res & Serv, Anchorage, AK 99508 USA. [MacGowan, Robin J.; Margolis, Andrew D.] US PHS, Atlanta, GA 30333 USA. [MacGowan, Robin J.; Margolis, Andrew D.] Ctr Dis Control & Prevent, Intervent Res Team, Prevent Res Branch, Div HIV AIDS Prevent,Natl Ctr HIV Viral Hepatitis, Atlanta, GA 30333 USA. RP Seal, DW (reprint author), Med Coll Wisconsin, Ctr AIDS Intervent Res, Dept Psychiat & Behav Med, 2071 N Summit Ave, Milwaukee, WI 53202 USA. EM dseal@mcw.edu NR 70 TC 1 Z9 1 U1 1 U2 1 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY BN 978-0-387-78320-8 PY 2010 BP 271 EP 309 DI 10.1007/978-0-387-78321-5_15 D2 10.1007/978-0-387-78321-5 PG 39 WC Behavioral Sciences; Public, Environmental & Occupational Health SC Behavioral Sciences; Public, Environmental & Occupational Health GA BRI40 UT WOS:000282770800015 ER PT B AU O'Leary, A Jones, KT McCree, DH AF O'Leary, Ann Jones, Kenneth Terrill McCree, Donna Hubbard BE McCree, DH Jones, KT OLeary, A TI The HIV/AIDS Epidemic in the African American Community: Where Do We Go from Here? SO AFRICAN AMERICANS AND HIV/AIDS: UNDERSTANDING AND ADDRESSING THE EPIDEMIC LA English DT Article; Book Chapter ID HIV PREVENTION; RACIAL DISPARITIES; RECOMMENDATIONS; CONSULTATION; STRATEGIES; INFECTION; WOMEN; RISK; MEN; SEX C1 [O'Leary, Ann; McCree, Donna Hubbard] Ctr Dis Control & Prevent, Prevent Res Branch, Div HIV AIDS Prevent,Intervent Res Team, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP O'Leary, A (reprint author), Ctr Dis Control & Prevent, Prevent Res Branch, Div HIV AIDS Prevent,Intervent Res Team, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd,MS E-37, Atlanta, GA 30333 USA. EM aoleary@cdc.gov NR 16 TC 0 Z9 0 U1 0 U2 2 PU SPRINGER-VERLAG BERLIN PI BERLIN PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY BN 978-0-387-78320-8 PY 2010 BP 311 EP 316 DI 10.1007/978-0-387-78321-5_16 PG 6 WC Behavioral Sciences; Public, Environmental & Occupational Health SC Behavioral Sciences; Public, Environmental & Occupational Health GA BRI40 UT WOS:000282770800016 ER PT J AU Joseph, HA Flores, SA Parsons, JT Purcell, DW AF Joseph, Heather A. Flores, Stephen A. Parsons, Jeffrey T. Purcell, David W. TI Beliefs about transmission risk and vulnerability, treatment adherence, and sexual risk behavior among a sample of HIV-positive men who have sex with men SO AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV LA English DT Article DE HAART; sexual risk; MSM; treatment beliefs; treatment adherence ID ACTIVE ANTIRETROVIRAL THERAPY; BISEXUAL MEN; VIRAL LOAD; UNINTENTIONAL NONADHERENCE; COMBINATION THERAPIES; RANDOMIZED-TRIAL; GAY MEN; PERCEPTIONS; MEDICATION; PREVENTION AB Advances in HIV treatment have generated optimistic beliefs about HIV transmission risk and sexually transmitted infection vulnerability, which can influence motivation to practice safer sex. This study sought to better understand the relationships between these beliefs and different types of sexual risk behavior. A second objective was to determine the association between treatment adherence and sexual risk behaviors. Data collected from 842 HIV-positive men who have sex with men on treatment were examined. Eleven questions measured beliefs regarding HIV transmission risk and vulnerability to other infections or negative health outcomes. The main outcomes were concordant and discordant unprotected anal sex with main and non-main male partners. Thirty-four percent reported concordant and 41% reported discordant unprotected anal sex in the past three months: 26% reported discordant insertive unprotected anal sex. In all multivariate logistic regression models predicting sexual risk behaviors, at least one belief item remained statistically significant. Different patterns of associations between beliefs and sexual risk were observed across partner type and serostatus. Compared to transmission risk beliefs, more vulnerability beliefs were associated with sexual risk. Missing at least one treatment dose in the past month was associated with concordant and discordant sexual risk with non-main partners, while intentionally missing a dose was associated with only discordant risk with non-main partners. Post hoc moderator analysis explored potential interaction between beliefs and adherence. The belief that a low viral load lowers transmission risk was positively associated with discordant sex with non-main partners only among those who missed a dose intentionally. These results underscore the complex relationship between HIV transmission risk and vulnerability beliefs and sexual behavior with different types of partners. Prevention programs should carefully consider how to craft and tailor messages about medical advances while at the same time reinforcing the need for continued sexual safety. C1 [Joseph, Heather A.; Flores, Stephen A.; Purcell, David W.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. [Parsons, Jeffrey T.] CUNY Hunter Coll, New York, NY 10021 USA. [Parsons, Jeffrey T.] CUNY, Grad Ctr, New York, NY USA. [Parsons, Jeffrey T.] Ctr HIV Educ Studies & Training, New York, NY USA. RP Joseph, HA (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, 1600 Clifton Rd NE,Mailstop E37, Atlanta, GA 30333 USA. EM HJoseph1@cdc.gov RI Paparello, Joel/F-7521-2011; OI Purcell, David/0000-0001-8125-5168; Parsons, Jeffrey/0000-0002-6875-7566 FU PHS HHS [UR3/CCU216471, U62/CCU913557] NR 39 TC 13 Z9 13 U1 0 U2 7 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0954-0121 J9 AIDS CARE JI Aids Care-Psychol. Socio-Med. Asp. Aids-Hiv PY 2010 VL 22 IS 1 BP 29 EP 39 DI 10.1080/09540120903012627 PG 11 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychology, Multidisciplinary; Respiratory System; Social Sciences, Biomedical SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychology; Respiratory System; Biomedical Social Sciences GA 535YY UT WOS:000273009100004 PM 20390478 ER PT J AU Orban, LA Stein, R Koenig, LJ Conner, LC Rexhouse, EL Lewis, JV LaGrange, R AF Orban, Lisa A. Stein, Renee Koenig, Linda J. Conner, Latoya C. Rexhouse, Erika L. Lewis, Jennifer V. LaGrange, Ricardo TI Coping strategies of adolescents living with HIV: disease-specific stressors and responses SO AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV LA English DT Article DE coping; HIV; AIDS; stressors; adolescents ID PSYCHOLOGICAL ADJUSTMENT; SOCIAL SUPPORT; LIFE STRESS; CHILDREN; PREDICTORS; PATTERNS AB This study examined disease-specific stressors and coping responses employed by youth with HIV. Data were analyzed from Adolescent Impact, a multi-site study of 166 adolescents infected with HIV in three major US cities. Participants identified HIV-related stressors during a face-to-face interview. Coping strategies were measured using the adolescent version of the Kidcope. Emotional and behavioral functioning were assessed with the Youth or Adult Self Report symptom checklists. Medication-related stressors were most common (30%) and reported more often by perinatally infected youth, whereas youth infected through risk behaviors reported more disclosure-related stressors. Passive emotional regulation was perceived as the most used and most helpful coping strategy overall. Youth reporting medication adherence-related stressors used resignation most frequently. A two-factor model (Passive and Active Coping) emerged. The Passive Coping factor included strategies that do not directly approach the problem, whereas Active Coping included strategies that involve an active approach. Youth with moderately advanced disease (CD4 200-500 cells/mm(3)) used a Passive Coping style more often than healthier youth (CD4 > 500 cells/mm(3)). Additionally, Passive Coping was associated with greater emotional and behavioral problems. Youth infected with HIV may benefit from interventions promoting adaptive coping responses to HIV-specific stressors, particularly medication adherence. C1 [Stein, Renee; Koenig, Linda J.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV STD & TB Prevent, Atlanta, GA 30333 USA. [Orban, Lisa A.; Lewis, Jennifer V.] NYU, Sch Med, New York, NY USA. [Conner, Latoya C.] Childrens Natl Med Ctr, Washington, DC 20010 USA. [Rexhouse, Erika L.] New York Presbyterian Hosp, Weill Cornell Med Coll, New York, NY USA. [LaGrange, Ricardo] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. RP Koenig, LJ (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV STD & TB Prevent, Atlanta, GA 30333 USA. EM lek5@cdc.gov OI Lewis, Jennifer V./0000-0002-3573-5125 FU PHS HHS [U64CCU319459, U64CCU319455, U64CCU219448] NR 22 TC 27 Z9 27 U1 1 U2 12 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0954-0121 J9 AIDS CARE JI Aids Care-Psychol. Socio-Med. Asp. Aids-Hiv PY 2010 VL 22 IS 4 BP 420 EP 430 DI 10.1080/09540120903193724 PG 11 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychology, Multidisciplinary; Respiratory System; Social Sciences, Biomedical SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychology; Respiratory System; Biomedical Social Sciences GA 591PJ UT WOS:000277313800004 PM 20146110 ER PT J AU Blacher, RJ Muiruri, P Njobvu, L Mutsotso, W Potter, D Ong'ech, J Mwai, P Degroot, A Zulu, I Bolu, O Stringer, J Kiarie, J Weidle, PJ AF Blacher, Rachel J. Muiruri, Peter Njobvu, Lungowe Mutsotso, Winnie Potter, Dara Ong'ech, John Mwai, Paul Degroot, Alain Zulu, Isaac Bolu, Omotayo Stringer, Jeffrey Kiarie, James Weidle, Paul J. TI How late is too late? Timeliness to scheduled visits as an antiretroviral therapy adherence measure in Nairobi, Kenya and Lusaka, Zambia SO AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV LA English DT Article DE adherence; self-reported adherence; timeliness to visit; virologic failure; antiretroviral; human immunodeficiency virus (HIV); Africa ID RESOURCE-POOR COUNTRIES; HIV DRUG-RESISTANCE; SUB-SAHARAN AFRICA; RISK-FACTORS; FOLLOW-UP; OUTCOMES; APPOINTMENTS; METAANALYSIS; FAILURE; PROGRAM AB Collecting self-reported data on adherence to highly active antiretroviral therapy (HAART) can be complicated by patients' reluctance to report poor adherence. The timeliness with which patients attend visits might be a useful alternative to estimate medication adherence. Among Kenyan and Zambian women receiving twice daily HAART, we examined the relationship between self-reported pill taking and timeliness attending scheduled visits. We analyzed data from 566 Kenyan and Zambian women enrolled in a prospective 48-week HAART-response study. At each scheduled clinic visit, women reported doses missed over the preceding week. Self-reported adherence was calculated by summing the total number of doses reported taken and dividing by the total number of doses asked about at the visit attended. A participant's adherence to scheduled study visits was defined as oon timeo if she arrived early or within three days, omoderately lateo if she was four-seven days late, and oextremely late/missedo if she was more than eight days late or missed the visit altogether. Self-reported adherence was 95% for 29 (10%) of 288 women who were late for at least one study visit vs. 3 (1%) of 278 who were never late for a study visit (odds ratios [OR] 10.3; 95% confidence intervals [95% CI] 2.9, 42.8). Fifty-one (18%) of 285 women who were ever late for a study visit experienced virologic failure vs. 32 (12%) of 278 women who were never late for a study visit (OR 1.7; 95% CI 1.01, 2.8). A multivariate logistic regression model controlling for self-reported adherence found that being extremely late for a visit was associated with virologic failure (OR 2.0; 95% CI 1.2, 3.4). Timeliness to scheduled visits was associated with self-reported adherence to HAART and with risk for virologic failure. Timeliness to scheduled clinic visits can be used as an objective proxy for self-reported adherence and ultimately for risk of virologic failure. C1 [Blacher, Rachel J.; Weidle, Paul J.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. [Blacher, Rachel J.] ICF Macro, Atlanta, GA 30329 USA. [Muiruri, Peter; Ong'ech, John; Mwai, Paul; Kiarie, James] Univ Nairobi, Kenyatta Natl Hosp, Nairobi, Kenya. [Njobvu, Lungowe; Degroot, Alain; Stringer, Jeffrey] CIDRZ, Lusaka, Zambia. [Mutsotso, Winnie] Kenya Govt Med Res Ctr, CDC Kenya, Nairobi, Kenya. [Potter, Dara; Zulu, Isaac] CDC Zambia, Lusaka, Zambia. [Bolu, Omotayo] CDC, Global AIDS Program, NCHHSTP, Atlanta, GA 30333 USA. RP Blacher, RJ (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Mailstop E-30,1600 Clifton Rd, Atlanta, GA 30333 USA. EM Rachel.J.Blacher@macrointernational.com NR 33 TC 6 Z9 6 U1 1 U2 2 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0954-0121 J9 AIDS CARE JI Aids Care-Psychol. Socio-Med. Asp. Aids-Hiv PY 2010 VL 22 IS 11 BP 1323 EP 1331 AR PII 925796676 DI 10.1080/09540121003692235 PG 9 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychology, Multidisciplinary; Respiratory System; Social Sciences, Biomedical SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychology; Respiratory System; Biomedical Social Sciences GA 660YH UT WOS:000282684800003 PM 20711886 ER PT J AU Anderson, M Elam, G Gerver, S Solarin, I Fenton, K Easterbrook, P AF Anderson, Moji Elam, Gillian Gerver, Sarah Solarin, Ijeoma Fenton, Kevin Easterbrook, Philippa TI "It took a piece of me": initial responses to a positive HIV diagnosis by Caribbean people in the UK SO AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV LA English DT Article DE HIV diagnosis; liminality; biographical disruption; black; Caribbean; UK ID NARRATIVES; IDENTITY; CANCER AB How do people respond to the news that they are HIV positive? To date, there have been few published qualitative studies of HIV diagnosis experiences, and none focusing on Caribbean people. Twenty-five HIV-positive Caribbean people in London, UK, related their diagnosis experience and its immediate aftermath in semi-structured interviews. Diagnosis with HIV caused profound shock and distress to participants, as they associated the disease with immediate death and stigmatisation. The respondents struggled with obiographical disruptiono, the radical disjuncture between life before and after diagnosis, which led them into a state of liminality, as they found themselves obetwixt and betweeno established structural and social identities. Respondents were faced with multifaceted loss: of their known self, their present life, their envisioned future and the partner they had expected to play a role in each of these. A minority of accounts suggest that the way in which healthcare practitioners delivered the diagnosis intensified the participants' distress. This research suggests that healthcare practitioners should educate patients in specific aspects of HIV transmission and treatment, and engage closely with them in order to understand their needs and potential reactions to a positive diagnosis. C1 [Anderson, Moji] Univ W Indies, Dept Sociol Psychol & Social Work, Kingston 7, Jamaica. [Elam, Gillian] UCL, Ctr Sexual Hlth & HIV Res, London, England. [Gerver, Sarah] Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis Epidemiol, London, England. [Solarin, Ijeoma] Univ Witwatersrand, Reprod Hlth Res Unit, Johannesburg, South Africa. [Fenton, Kevin] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. [Easterbrook, Philippa] Kings Coll London, Acad Dept HIV GUM, London WC2R 2LS, England. RP Anderson, M (reprint author), Univ W Indies, Dept Sociol Psychol & Social Work, Kingston 7, Jamaica. EM moji.anderson@uwimona.edu.jm FU Medical Research Council [G0200585, G0802431, ] NR 24 TC 12 Z9 12 U1 0 U2 1 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 0954-0121 J9 AIDS CARE JI Aids Care-Psychol. Socio-Med. Asp. Aids-Hiv PY 2010 VL 22 IS 12 BP 1493 EP 1498 AR PII 926625114 DI 10.1080/09540121.2010.482125 PG 6 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychology, Multidisciplinary; Respiratory System; Social Sciences, Biomedical SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychology; Respiratory System; Biomedical Social Sciences GA 693BB UT WOS:000285198500008 PM 20824553 ER PT J AU Wei, XR Liu, X Dobbs, T Kuehl, D Nkengasong, JN Hu, DJ Parekh, BS AF Wei, Xierong Liu, Xin Dobbs, Trudy Kuehl, Debra Nkengasong, John N. Hu, Dale J. Parekh, Bharat S. TI Development of Two Avidity-Based Assays to Detect Recent HIV Type 1 Seroconversion Using a Multisubtype gp41 Recombinant Protein SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Article ID BED-ENZYME-IMMUNOASSAY; SUBTYPE-E INFECTION; ANTIBODY AVIDITY; UNITED-STATES; TESTING STRATEGY; PERFORMANCE-CHARACTERISTICS; SAN-FRANCISCO; VIRUS; SEROINCIDENCE; TRENDS AB Current laboratory methods to detect recent HIV-1 infection for the estimation of incidence have various limitations, including varying performance in different subtypes or populations. Therefore, new methods are needed to detect recent infections with increased specificity. We developed a recombinant protein, rIDR-M, that covered divergent sequences from the immunodominant region (IDR) of gp41 from all major subtypes and recombinants of HIV-1 group M and expressed in Escherichia coli. The rIDR-M protein was highly reactive with HIV antibodies in sera from different subtypes and equivalently detected antibodies to divergent subtypes B and AE from Thailand, in contrast to individual gp41 peptides derived from respective subtypes, suggesting that it can be used for incidence assays. The protein was used in two different assay formats to measure antibody avidity: (1) a two-well avidity index assay (AI-EIA) and (2) a new one-well limiting antigen avidity assay (LAg-avidity EIA), both with a pH 3.0 buffer to dissociate low-avidity antibodies present during early infection. Limiting the amount of antigen allowed detection of recent HIV-1 infection, with or without dissociation buffer, but the detection was most efficient when the pH 3.0 dissociation buffer was included. When a well-characterized 41-member seroincidence panel (20 recent and 21 long-term) was used, both the two-well AI-EIA and one-well LAg-avidity EIA efficiently distinguished recent and long-term infections. The new avidity-based assays using rIDR-M antigen may improve the accuracy of detecting recent HIV-1 infection and allow a better estimation of incidence in diverse HIV-1 subtypes. C1 [Parekh, Bharat S.] Ctr Dis Control & Prevent, Int Lab Branch, Div Global AIDS, Natl Ctr HIV AIDS, Atlanta, GA 30333 USA. Ctr Dis Control & Prevent, Natl Ctr Viral Hepatitis, Atlanta, GA 30333 USA. Ctr Dis Control & Prevent, Natl Ctr STD, Atlanta, GA 30333 USA. Ctr Dis Control & Prevent, Natl Ctr TB Prevent, Atlanta, GA 30333 USA. RP Parekh, BS (reprint author), Ctr Dis Control & Prevent, Int Lab Branch, Div Global AIDS, Natl Ctr HIV AIDS, MS G19,1600 Clifton Rd,Bldg 15-2611, Atlanta, GA 30333 USA. EM bparekh@cdc.gov NR 45 TC 40 Z9 42 U1 1 U2 4 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD JAN PY 2010 VL 26 IS 1 BP 61 EP 71 DI 10.1089/aid.2009.0133 PG 11 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA 551EY UT WOS:000274190700008 PM 20063992 ER PT J AU Zhang, J Kang, DM Fu, JH Sun, XG Lin, B Bi, ZQ Nkengasong, JN Yang, CF AF Zhang, Jing Kang, Dianmin Fu, Jihua Sun, Xiaoguang Lin, Bin Bi, Zhenqiang Nkengasong, John N. Yang, Chunfu TI Surveillance of Transmitted HIV Type 1 Drug Resistance in Newly Diagnosed HIV Type 1-Infected Patients in Shandong Province, China SO AIDS RESEARCH AND HUMAN RETROVIRUSES LA English DT Article ID COUNTRIES AB A survey to measure transmitted HIV-1 drug resistance (DR) was conducted in 2006 following the World Health Organization threshold survey protocol. Dried blood spots (DBS) were prepared from 53 newly HIV-1-diagnosed patients. Protease and reverse transcriptase (RT) gene regions were sequenced using a broadly sensitive genotyping assay and analyses to identify DR mutations and determine phylogeny of the HIV-1 strains were conducted. Forty-six of the 47 successfully genotyped DBS had no transmitted DR mutations; one had an NNRTI mutation (K101E) in the RT region. Phylogenetic analyses revealed 21 (44.7%) were CRF01_AE, 9 (19.1%) B, 6 (12.8%) CRF07_BC, 3 (6.4%) each of CRF08_BC and C, and 2 (4.3%) B/C unique recombinant forms (URF). The remaining three were one each of A/B, A/C, and unclassifiable. Our analyses indicate that the prevalence of transmitted DR in this population is low and the HIV-1 epidemic in the area was characterized by multiple subtypes and recombinant forms. C1 [Yang, Chunfu] Ctr Dis Control & Prevent, Int Lab Branch, Div Global AIDS,NCHHSTP, Natl Ctr HIV AIDS Viral Hepatitis & Sexual Transm, Atlanta, GA 30333 USA. RP Yang, CF (reprint author), Ctr Dis Control & Prevent, Int Lab Branch, Div Global AIDS,NCHHSTP, Natl Ctr HIV AIDS Viral Hepatitis & Sexual Transm, Mail Stop A-11,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM CYang1@cdc.gov RI Yang, Chunfu/G-6890-2013 FU Association of public Health Laboratories (APHL) FX Dr. Jing Zhang is a recipient of the International Emerging Infectious Diseases (EID) Laboratory Fellowship Program sponsored by Association of public Health Laboratories (APHL) and CDC. J. Zhang and D. Kang contributed equally to this article. NR 16 TC 15 Z9 18 U1 1 U2 5 PU MARY ANN LIEBERT INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0889-2229 J9 AIDS RES HUM RETROV JI Aids Res. Hum. Retrovir. PD JAN PY 2010 VL 26 IS 1 BP 99 EP 103 DI 10.1089/aid.2009.0184 PG 5 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA 551EY UT WOS:000274190700012 PM 20121622 ER PT J AU Althoff, KN Gebo, KA Gange, SJ Klein, MB Brooks, JT Hogg, RS Bosch, RJ Horberg, MA Saag, MS Kitahata, MM Eron, JJ Napravnik, S Rourke, SB Gill, MJ Rodriguez, B Sterling, TR Deeks, SG Martin, JN Jacobson, LP Kirk, GD Collier, AC Benson, CA Silverberg, MJ Goedert, JJ McKaig, RG Thorne, J Rachlis, A Moore, RD Justice, AC AF Althoff, Keri N. Gebo, Kelly A. Gange, Stephen J. Klein, Marina B. Brooks, John T. Hogg, Robert S. Bosch, Ronald J. Horberg, Michael A. Saag, Michael S. Kitahata, Mari M. Eron, Joseph J. Napravnik, Sonia Rourke, Sean B. Gill, M. John Rodriguez, Benigno Sterling, Timothy R. Deeks, Steven G. Martin, Jeffrey N. Jacobson, Lisa P. Kirk, Gregory D. Collier, Ann C. Benson, Constance A. Silverberg, Michael J. Goedert, James J. McKaig, Rosemary G. Thorne, Jennifer Rachlis, Anita Moore, Richard D. Justice, Amy C. CA North Amer AIDS Cohort TI CD4 count at presentation for HIV care in the United States and Canada: Are those over 50 years more likely to have a delayed presentation? SO AIDS RESEARCH AND THERAPY LA English DT Article AB We assessed CD4 count at initial presentation for HIV care among >= 50-year-olds from 1997-2007 in 13 US and Canadian clinical cohorts and compared to <50-year-olds. 44,491 HIV-infected individuals in the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) were included in our study. Trends in mean CD4 count (measured as cells/mm(3)) and 95% confidence intervals ([,]) were determined using linear regression stratified by age category and adjusted for gender, race/ethnicity, HIV transmission risk and cohort. From 1997-2007, the proportion of individuals presenting for HIV care who were >= 50-years-old increased from 17% to 27% (p-value < 0.01). The median CD4 count among >= 50 year-olds was consistently lower than younger adults. The interaction of age group and calendar year was significant (p-value < 0.01) with both age groups experiencing modest annual improvements over time (< 50-year-olds: 5[4, 6] cells/mm(3); >= 50-year-olds: 7[5, 9] cells/mm(3)), after adjusting for sex, race/ethnicity, HIV transmission risk group and cohort; however, increases in the two groups were similar after 2000. A greater proportion of older individuals had an AIDS-defining diagnosis at, or within three months prior to, first presentation for HIV care compared to younger individuals (13% vs. 10%, respectively). Due to the increasing proportion, consistently lower CD4 counts, and more advanced HIV disease in adults >= 50-year-old at first presentation for HIV care, renewed HIV testing efforts are needed. C1 [Althoff, Keri N.; Gange, Stephen J.; Jacobson, Lisa P.; Kirk, Gregory D.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA. [Gebo, Kelly A.; Moore, Richard D.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21287 USA. [Klein, Marina B.] McGill Univ, Dept Med, Montreal, PQ H2X 2P4, Canada. [Brooks, John T.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Hogg, Robert S.] British Columbia Ctr Excellence & HIV AIDS, Vancouver, BC V6Z 1Y6, Canada. [Hogg, Robert S.] Simon Fraser Univ, Vancouver, BC V6Z 1Y6, Canada. [Bosch, Ronald J.] Harvard Univ, Dept Biostat, Boston, MA 02115 USA. [Horberg, Michael A.; Silverberg, Michael J.] Kaiser Permanente No Calif, Div Res, Oakland, CA 94612 USA. [Saag, Michael S.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Kitahata, Mari M.; Collier, Ann C.] Univ Washington, Dept Med, Seattle, WA 98104 USA. [Eron, Joseph J.; Napravnik, Sonia] Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA. [Rourke, Sean B.] Univ Toronto, Dept Psychiat, Toronto, ON M5B 1W8, Canada. [Rourke, Sean B.] Univ Toronto, Dept Neurosci, Toronto, ON M5B 1W8, Canada. [Gill, M. John] Univ Calgary, South Alberta HIV Clin, Calgary, AB T2R 0X7, Canada. [Rodriguez, Benigno] Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA. [Sterling, Timothy R.] Vanderbilt Univ, Dept Med, Nashville, TN 37232 USA. [Deeks, Steven G.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94105 USA. [Martin, Jeffrey N.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94107 USA. [Benson, Constance A.] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA. [Goedert, James J.] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA. [McKaig, Rosemary G.] NIAID, Div AIDS, NIH, Bethesda, MD 20892 USA. [Thorne, Jennifer] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD 21205 USA. [Rachlis, Anita] Univ Toronto, Dept Med, Toronto, ON M4N 3M5, Canada. [Justice, Amy C.] Yale Univ, Dept Med, Sch Med, West Haven, CT 06516 USA. [Justice, Amy C.] VA Connecticut Healthcare Syst, West Haven, CT 06516 USA. RP Althoff, KN (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, 615 N Wolfe St, Baltimore, MD 21205 USA. EM kalthoff@jhsph.edu RI Rodriguez, Benigno/C-3365-2009; Gill, John/G-7083-2016; OI Rodriguez, Benigno/0000-0001-9736-7957; Gill, John/0000-0002-8546-8790; Gange, Stephen/0000-0001-7842-512X; Hogg, Robert/0000-0003-3463-5488 FU National Institutes of Health [U01-AI069918, U01-AA013566, U01-AI31834, U01-AI34989, U01-AI34993, U01-AI34994, U01-AI35004, U01-AI35039, U01-AI35040, U01-AI35041, U01-AI35042, U01-AI35043, U01-AI37613, U01-AI37984, U01-AI38855, U01-AI38858, U01-AI42590, U01-AI68634]; Centers for Disease Control [CDC200-2006-18797]; Canadian Institutes for Health Research [CIHR: TGF-96118, HCP-97105, CBR-86906, CBR-94036, KRS-86251, 169621]; Canadian Trials Network [242]; NIH [U01-AI68636, U01-HD32632, M01-RR00071, M01-RR00079, M01-RR00083, M01-RR00722, P30-AI27757, P30-AI27767, P30-AI50410, P30-AI54999, R01-DA04334, R01-DA12568, R01-MH54907, R24-AI067039, Z01-CP010176, AHQ290-01-0012, N02-CP55504]; N.I.H. [R01-DA11602, AI-69432, K01-AI071754, R01-AA16893, K24-00432, K23-AI-61-0320] FX We are grateful to all patients, physicians, investigators, and staff involved in the NA-ACCORD. This work was supported by grants from the National Institutes of Health: U01-AI069918, U01-AA013566, U01-AI31834, U01-AI34989, U01-AI34993, U01-AI34994, U01-AI35004, U01-AI35039, U01-AI35040, U01-AI35041, U01-AI35042, U01-AI35043, U01-AI37613, U01-AI37984, U01-AI38855, U01-AI38858, U01-AI42590, U01-AI68634, U01-AI68636, U01-HD32632, M01-RR00071, M01-RR00079, M01-RR00083, M01-RR00722, P30-AI27757, P30-AI27767, P30-AI50410, P30-AI54999, R01-DA04334, R01-DA12568, R01-MH54907, R24-AI067039, Z01-CP010176, AHQ290-01-0012, N02-CP55504, R01-DA11602, AI-69432, K01-AI071754, R01-AA16893, K24-00432, K23-AI-61-0320. This work was also supported by the Centers for Disease Control (CDC200-2006-18797), the Canadian Institutes for Health Research (CIHR: TGF-96118; HCP-97105; CBR-86906; CBR-94036; KRS-86251; 169621) and the Canadian Trials Network (project number 242). NR 28 TC 29 Z9 30 U1 0 U2 0 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1742-6405 J9 AIDS RES THER JI Aids Res. Ther. PY 2010 VL 7 AR 45 DI 10.1186/1742-6405-7-45 PG 6 WC Infectious Diseases SC Infectious Diseases GA V29JM UT WOS:000208744700045 PM 21159161 ER PT J AU Lampe, F Snyder, S Geller, S AF Lampe, Frank Snyder, Suzanne Geller, Stacie TI STACIE GELLER, PhD: FURTHERING THE ROLE OF WOMEN IN HEALTH CARE SO ALTERNATIVE THERAPIES IN HEALTH AND MEDICINE LA English DT Editorial Material C1 [Geller, Stacie] Univ Illinois, Coll Med, Ctr Res Women & Gender, Chicago, IL 60680 USA. [Geller, Stacie] Ctr Dis Control & Prevent, Assoc Sch Publ Hlth Cooperat Agreement, Atlanta, GA USA. RP Lampe, F (reprint author), Univ Illinois, Coll Med, Ctr Res Women & Gender, Chicago, IL 60680 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU INNOVISION COMMUNICATIONS PI ALISO VIEJO PA 101 COLUMBIA, ALISO VIEJO, CA 92656 USA SN 1078-6791 J9 ALTERN THER HEALTH M JI Altern. Ther. Health Med. PD JAN-FEB PY 2010 VL 16 IS 1 SI SI BP 66 EP 74 PG 9 WC Integrative & Complementary Medicine SC Integrative & Complementary Medicine GA 633GE UT WOS:000280487200011 ER PT J AU Zaback, T Becker, TM Dignan, MB Lambert, WE AF Zaback, Tosha Becker, Thomas M. Dignan, Mark B. Lambert, William E. TI A Program Evaluation of a Summer Research Training Institute for American Indian and Alaska Native Health Professionals SO AMERICAN INDIAN CULTURE AND RESEARCH JOURNAL LA English DT Article C1 [Zaback, Tosha] Oregon Hlth & Sci Univ, Ctr Dis Control & Prevent, Funded Prevent Res Ctr, Ctr Healthy Communities,Dept Publ Hlth & Prevent, Portland, OR 97201 USA. [Dignan, Mark B.] Univ Kentucky, Lucille P Markey Canc Ctr, Lexington, KY 40506 USA. RP Zaback, T (reprint author), Oregon Hlth & Sci Univ, Ctr Dis Control & Prevent, Funded Prevent Res Ctr, Ctr Healthy Communities,Dept Publ Hlth & Prevent, Portland, OR 97201 USA. NR 13 TC 1 Z9 1 U1 0 U2 0 PU U C L A, AMER INDIAN STUDIES CENTER PI LOS ANGELES PA 3220 CAMPBELL HALL, BOX 951548, LOS ANGELES, CA 90095-1548 USA SN 0161-6463 J9 AM INDIAN CULT RES J JI Am. Indian Cult. Res. J. PY 2010 VL 34 IS 3 BP 93 EP 106 PG 14 WC History SC History GA 681EV UT WOS:000284295100005 ER PT J AU Yang, QH Cogswell, ME Hamner, HC Carriquiry, A Bailey, LB Pfeiffer, CM Berry, RJ AF Yang, Quanhe Cogswell, Mary E. Hamner, Heather C. Carriquiry, Alicia Bailey, Lynn B. Pfeiffer, Christine M. Berry, Robert J. TI Folic acid source, usual intake, and folate and vitamin B-12 status in US adults: National Health and Nutrition Examination Survey (NHANES) 2003-2006 SO AMERICAN JOURNAL OF CLINICAL NUTRITION LA English DT Article ID UNITED-STATES; INTAKE DISTRIBUTIONS; POPULATION-LEVEL; DIETARY-FOLATE; BLOOD FOLATE; FORTIFICATION; RACE/ETHNICITY; NUTRIENTS; FOODS; AGE AB Background: US adults have access to multiple sources of folic acid. The contribution of these sources to usual intakes above the tolerable upper intake level (UL) (1000 mu g/d) and to folate and vitamin B-12 status is unknown. Objective: The objective was to estimate usual folic acid intake above the UL and adjusted serum and red blood cell folate, vitamin B-12, methylmalonic acid, and homocysteine concentrations among US adults by 3 major folic acid intake sources-enriched cereal-grain products (ECGP), ready-to-eat cereals (RTE), and supplements (SUP)-categorized into 4 mutually exclusive consumption groups. Design: We used data from the National Health and Nutrition Examination Survey (NHANES) 2003-2006 (n = 8258). Results: Overall, 2.7% (95% CI: 1.9%, 3.5%) of adults consumed more than the UL of folic acid. The proportions of those who consumed folic acid from ECGP only, ECGP+RTE, ECGP+SUP, and ECGP+RTE+SUP were 42%, 18%, 25%, and 15%, respectively. Of 60% of adults who did not consume supplements containing folic acid (ECGP only and ECGP+ RTE), 0% had intakes that exceeded the UL. Of 34% and 6% of adults who consumed supplements with an average of <= 400 and <= 400 mu g folic acid/d, <1% and 47.8% (95% CI: 39.6%, 56.0%), respectively, had intakes that exceeded the UL. Consumption of RTE and/or supplements with folic acid was associated with higher folate and vitamin B-12 and lower homocysteine concentrations, and consumption of supplements with vitamin B-12 was associated with lower methylmalonic acid concentrations (P < 0.001). Conclusion: At current fortification levels, US adults who do not consume supplements or who consume an average of <= 400 mu g folic acid/d from supplements are unlikely to exceed the UL in intake for folic acid. Am J Clin Nutr 2010; 91: 64-72. C1 [Yang, Quanhe] Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA 30333 USA. [Cogswell, Mary E.; Hamner, Heather C.; Berry, Robert J.] Ctr Dis Control & Prevent, Div Birth Defects & Dev Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Bailey, Lynn B.] Univ Florida, Dept Food Sci & Human Nutr, Gainesville, FL 32611 USA. [Carriquiry, Alicia] Iowa State Univ, Dept Stat, Ames, IA USA. [Pfeiffer, Christine M.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. RP Yang, QH (reprint author), Ctr Dis Control & Prevent, Off Publ Hlth Genom, 1600 Clifton Rd NE,MSE-61, Atlanta, GA 30333 USA. EM qay0@cdc.gov OI Berry, Robert/0000-0002-7162-5046 NR 29 TC 74 Z9 77 U1 0 U2 11 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0002-9165 EI 1938-3207 J9 AM J CLIN NUTR JI Am. J. Clin. Nutr. PD JAN PY 2010 VL 91 IS 1 BP 64 EP 72 DI 10.3945/ajcn.2009.28401 PG 9 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 534SM UT WOS:000272917600010 PM 19828716 ER PT J AU Bailey, RL Dodd, KW Gahche, JJ Dwyer, JT McDowell, MA Yetley, EA Sempos, CA Burt, VL Radimer, KL Picciano, MF AF Bailey, Regan L. Dodd, Kevin W. Gahche, Jaime J. Dwyer, Johanna T. McDowell, Margaret A. Yetley, Elizabeth A. Sempos, Christopher A. Burt, Vicki L. Radimer, Kathy L. Picciano, Mary Frances TI Total folate and folic acid intake from foods and dietary supplements in the United States: 2003-2006 SO AMERICAN JOURNAL OF CLINICAL NUTRITION LA English DT Article ID NEURAL-TUBE DEFECTS; MULTIVITAMIN-MULTIMINERAL SUPPLEMENTS; CEREAL-GRAIN PRODUCTS; COMPLEX SURVEY DATA; NUTRIENT INTAKE; INTAKE DISTRIBUTIONS; FORTIFICATION; PREVENTION; ASSOCIATION; NUTRITION AB Background: The term total folate intake is used to represent folate that occurs naturally in food as well as folic acid from fortified foods and dietary supplements. Folic acid has been referred to as a double-edged sword because of its beneficial role in the prevention of neural tube defects and yet possible deleterious effects on certain cancers and cognitive function. Previous monitoring efforts did not include folic acid from dietary supplements and are therefore not complete. Objective: Our objective was to combine data on dietary folate (as measured by two 24-h recalls) and folic acid from dietary supplements (collected with a 30-d frequency questionnaire) with the use of the bias-corrected best power method to adjust for within-person variability. Design: The National Health and Nutrition Examination Survey (NHANES) is a nationally representative, cross-sectional survey. Linear contrasts were constructed to determine differences in dietary and total folate intake for age and racial-ethnic groups by sex; prevalence of inadequate and excessive intakes is presented. Results: In 2003-2006, 53% of the US population used dietary supplements; 34.5% used dietary supplements that contained folic acid. Total folate intake (in dietary folate equivalents) was higher for men (813 +/- 14) than for women (724 +/- 16) and higher for non-Hispanic whites (827 +/- 19) than for Mexican Americans (615 +/- 11) and non-Hispanic blacks (597 +/- 12); 29% of non-Hispanic black women had inadequate intakes. Total folate and folic acid intakes are highest for those aged > 50 y, and 5% exceed the Tolerable Upper Intake Level. Conclusions: Improved total folate intake is warranted in targeted subgroups, which include women of childbearing age and non-Hispanic black women, whereas other population groups are at risk of excessive intake. Am J Clin Nutr 2010;91:231-7. C1 [Bailey, Regan L.; Dwyer, Johanna T.; Yetley, Elizabeth A.; Sempos, Christopher A.; Picciano, Mary Frances] NIH, Off Dietary Supplements, Bethesda, MD 20892 USA. [Dodd, Kevin W.] NCI, NIH, Bethesda, MD 20892 USA. [Gahche, Jaime J.; McDowell, Margaret A.; Burt, Vicki L.; Radimer, Kathy L.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. RP Bailey, RL (reprint author), 6100 Execut Blvd,2B03, Bethesda, MD 20892 USA. EM baileyr@mail.nih.gov OI Dwyer, Johanna/0000-0002-0783-1769 NR 42 TC 108 Z9 115 U1 2 U2 21 PU AMER SOC CLINICAL NUTRITION PI BETHESDA PA 9650 ROCKVILLE PIKE, SUBSCRIPTIONS, RM L-3300, BETHESDA, MD 20814-3998 USA SN 0002-9165 J9 AM J CLIN NUTR JI Am. J. Clin. Nutr. PD JAN PY 2010 VL 91 IS 1 BP 231 EP 237 DI 10.3945/ajcn.2009.28427 PG 7 WC Nutrition & Dietetics SC Nutrition & Dietetics GA 534SM UT WOS:000272917600029 PM 19923379 ER PT J AU Li, J Coates, RJ Gwinn, M Khoury, MJ AF Li, Jun Coates, Ralph J. Gwinn, Marta Khoury, Muin J. TI Steroid 5-alpha-Reductase Type 2 (SRD5a2) Gene Polymorphisms and Risk of Prostate Cancer: A HuGE Review SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Review DE epidemiology; genetic predisposition to disease; genetics; meta-analysis; polymorphism; genetic; prostatic neoplasms; SRD5a2; testosterone 5-alpha-reductase ID SERUM ANDROGEN CONCENTRATIONS; GENOME-WIDE ASSOCIATION; REDUCTASE TYPE-II; MISSENSE SUBSTITUTION; JAPANESE POPULATION; V89L POLYMORPHISM; SEQUENCE VARIANTS; ALLELIC VARIANTS; CYP17; RECEPTOR AB Steroid 5-alpha-reductase type 2 (SRD5a2) is a critical enzyme in androgen metabolism. Two polymorphisms in the SRD5a2 gene, V89L (rs523349) and A49T (rs9282858), have been studied for associations with prostate cancer risk, with conflicting results. The authors conducted a systematic review and meta-analysis (1997-2007) to examine these associations and compared the results with findings from genome-wide association studies of prostate cancer. The meta-analysis included 24 case-control studies (10,088 cases and 10,120 controls for V89L and 4,998 cases and 5,451 controls for A49T). The authors found that prostate cancer was not associated with V89L (L allele vs. V allele: odds ratio = 0.99, 95% confidence interval: 0.94, 1.05) and was probably not associated with A49T (T allele vs. A allele: odds ratio = 1.10, 95% confidence interval: 0.86, 1.40). These results could have been distorted by spectrum-of-disease bias, convenience sampling of cases and controls, genotype misclassification, and/or confounding. Neither V89L nor A49T was included in microarray chips used for published genome-wide association studies. Analysis of well-designed population-based studies with pathway-based arrays containing common genetic variants could be useful for identifying genetic factors in prostate cancer. C1 [Li, Jun] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Li, Jun] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Off Workforce & Career Dev, Atlanta, GA 30341 USA. [Coates, Ralph J.; Gwinn, Marta; Khoury, Muin J.] Ctr Dis Control & Prevent, Natl Off Publ Hlth Genom, Atlanta, GA 30341 USA. RP Li, J (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway,MS K55, Atlanta, GA 30341 USA. EM ffa2@cdc.gov NR 78 TC 20 Z9 21 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD JAN 1 PY 2010 VL 171 IS 1 BP 1 EP 13 DI 10.1093/aje/kwp318 PG 13 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 537KT UT WOS:000273112500001 PM 19914946 ER PT J AU Santibanez, TA Mootrey, GT Euler, GL Janssen, AP AF Santibanez, Tammy A. Mootrey, Gina T. Euler, Gary L. Janssen, Alan P. TI Behavior and Beliefs About Influenza Vaccine Among Adults Aged 50-64 Years SO AMERICAN JOURNAL OF HEALTH BEHAVIOR LA English DT Article DE influenza; vaccination; adults ID PNEUMOCOCCAL VACCINATION; MEDICARE BENEFICIARIES; ELDERLY OUTPATIENTS; UNITED-STATES; SELF-REPORT; DISPARITIES; IMMUNIZATION; COVERAGE; CHILDREN; US AB Objective: To examine demographics and beliefs about influenza disease and vaccine that may be associated with influenza vaccination among 50- to 64-year-olds. Methods: A national sample of adults aged 50-64 years surveyed by telephone. Results: Variables associated with receiving influenza vaccination included age, education level, recent doctor visit, and beliefs about vaccine effectiveness and vaccine safety. Beliefs about influenza vaccination varied by race/ethnicity, age, education, and gender. Conclusion: The finding of demographic differences in beliefs suggests that segmented communication messages designed for specific demographic subgroups may help to increase influenza vaccination coverage. C1 [Santibanez, Tammy A.; Mootrey, Gina T.; Euler, Gary L.; Janssen, Alan P.] Natl Ctr Immunizat & Resp Dis, Ctr Dis Control & Prevent CDC, Atlanta, GA 30033 USA. RP Santibanez, TA (reprint author), Natl Ctr Immunizat & Resp Dis, Ctr Dis Control & Prevent CDC, 1600 Clifton Rd NE,Mailstop E-62, Atlanta, GA 30033 USA. EM afz5@cdc.gov NR 28 TC 24 Z9 27 U1 0 U2 1 PU PNG PUBLICATIONS PI OAK RIDGE PA 2205-K OAK RIDGE RD, #115, OAK RIDGE, NC 27310 USA SN 1087-3244 J9 AM J HEALTH BEHAV JI Am. J. Health Behav. PY 2010 VL 34 IS 1 BP 77 EP 89 PG 13 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 781LB UT WOS:000291932500010 PM 19663755 ER PT J AU Gu, QP Dillon, CF Burt, VL Gillum, RF AF Gu, Qiuping Dillon, Charles F. Burt, Vicki L. Gillum, Richard F. TI Association of Hypertension Treatment and Control With All-Cause and Cardiovascular Disease Mortality Among US Adults With Hypertension SO AMERICAN JOURNAL OF HYPERTENSION LA English DT Article DE antihypertensive agent; blood pressure; cardiovascular disease; hypertension; mortality; NHANES ID DIASTOLIC BLOOD-PRESSURE; LIPID-LOWERING TREATMENT; ATTACK TRIAL ALLHAT; RANDOMIZED-TRIALS; NATIONAL-HEALTH; PULSE PRESSURE; RISK; METAANALYSIS; PREVENTION; BLOCKERS AB BACKGROUND Clinical trials have provided convincing evidence that blood pressure (BP) lowering treatment reduces the risk of cardiovascular disease (CVD) and total mortality. The objective of this study was to examine the association of hypertension treatment, control, and BP indexes with all-cause and cardiovascular mortality among US adults with hypertension. METHODS Persons aged >= 18 years from the Third National Health and Nutrition Examination Survey (NHANES III) were identified as hypertensives based on a BP >= 140/90 mm Hg or current treatment for hypertension. Vital status in 2006 was ascertained by passive follow-up using the National Death Index. Cox regression models were used to assess correlates of survival. RESULTS At baseline, 52% of hypertensive adults reported currently taking prescription medicine for high BP and 38% of treated persons had BP controlled. Compared to treated controlled hypertensives, treated uncontrolled hypertensives had a 1.57-fold (95% confidence interval (CI) 1.28-1.91) and 1.74-fold (95% CI 1.36-2.22) risk of all-cause and cardiovascular mortality; untreated hypertensives had a 1.34-fold (95% CI 1.12-1.62) and 1.37-fold (95% CI 1.04-1.81) risk of all-cause and cardiovascular mortality, respectively. The association persisted after further excluding persons with pre-existing hypertension comorbidities. Mortality risk was linearly increased with systolic BP (SBP), pulse pressure (PP), and mean arterial pressure (MBP), whereas diastolic BP (DBP) was not a significant predictor of cardiovascular mortality overall. No significant associations were observed between drug classes and mortality risk. CONCLUSIONS This study indicates that uncontrolled and untreated hypertension was associated with increased risk of total and cardiovascular mortality among the general hypertensive population. C1 [Gu, Qiuping; Dillon, Charles F.; Burt, Vicki L.; Gillum, Richard F.] Ctr Dis Control & Prevent, Div Hlth & Nutr Examinat Survey, Natl Ctr Hlth Stat, Hyattsville, MD USA. RP Gu, QP (reprint author), Ctr Dis Control & Prevent, Div Hlth & Nutr Examinat Survey, Natl Ctr Hlth Stat, Hyattsville, MD USA. EM qag3@cdc.gov NR 36 TC 32 Z9 37 U1 0 U2 2 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0895-7061 J9 AM J HYPERTENS JI Am. J. Hypertens. PD JAN PY 2010 VL 23 IS 1 BP 38 EP 45 DI 10.1038/ajh.2009.191 PG 8 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA 533NS UT WOS:000272831400007 PM 19851295 ER PT J AU Reichard, AA Jackson, LL AF Reichard, Audrey A. Jackson, Larry L. TI Occupational Injuries Among Emergency Responders SO AMERICAN JOURNAL OF INDUSTRIAL MEDICINE LA English DT Article DE emergency responder; emergency medical services; paramedic; law enforcement; police; sheriff; firefighter; occupational injuries; nonfatal ID FIRE FIGHTERS; PERSONNEL; WORKERS AB Background Emergency responders frequently incur injuries while providing medical, fire, and law enforcement services. National surveillance systems provide fragmented perspectives on responder injuries because they omit specific classes of workers (e.g., government or volunteers); they report only selected injuries; and employment information is incomplete. Methods We characterized injuries among emergency medical services (EMS), fire-fighting, and police occupations by using data from the National Electronic Injury Surveillance System-Occupational Supplement (NEISS-Work)for injuries treated in U.S. hospital emergency departments in 2000-2001. Results Sprains and strains were the leading injury (33-41%) among EMS, firefighter, and police occupations. Police officers and career firefighters had the highest injury rates (8.5 and 7.4 injuries per 100 full-time equivalent workers, respectively). Conclusions The physical demands of emergency response area leading cause of injuries that may benefit from similar interventions across the occupations. To assess risk, improved exposure data need to be acquired, particularly for volunteers. Am. J. Ind. Med. 53:1-11, 2010. Published 2009 Wiley-Liss, Inc.(dagger) C1 [Reichard, Audrey A.] NIOSH, Div Safety Res, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. RP Reichard, AA (reprint author), NIOSH, Div Safety Res, Ctr Dis Control & Prevent, 1095 Willowdale Rd,MS 1808, Morgantown, WV 26505 USA. EM akr5@cdc.gov NR 38 TC 38 Z9 38 U1 1 U2 7 PU WILEY-LISS PI HOBOKEN PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 0271-3586 J9 AM J IND MED JI Am. J. Ind. Med. PD JAN PY 2010 VL 53 IS 1 BP 1 EP 11 DI 10.1002/ajim.20772 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 537XB UT WOS:000273146500001 PM 19894221 ER PT J AU Gilboa, SM Correa, A Botto, LD Rasmussen, SA Waller, DK Hobbs, CA Cleves, MA Riehle-Colarusso, TJ AF Gilboa, Suzanne M. Correa, Adolfo Botto, Lorenzo D. Rasmussen, Sonja A. Waller, D. Kim Hobbs, Charlotte A. Cleves, Mario A. Riehle-Colarusso, Tiffany J. CA Natl Birth Defects Prevention Stud TI Association between prepregnancy body mass index and congenital heart defects SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Article; Proceedings Paper CT 13th Annual Maternal and Child Health Epidemiology Conference CY DEC 10-12, 2007 CL Atlanta, GA DE body mass index; congenital heart defects; gestational diabetes; obesity ID GESTATIONAL DIABETES-MELLITUS; NEURAL-TUBE DEFECTS; BIRTH-DEFECTS; MATERNAL OBESITY; RISK-FACTORS; UNITED-STATES; MALFORMATIONS; PREGNANCY; WEIGHT; POPULATION AB OBJECTIVE: The purpose of this study was to examine associations between prepregnancy body mass index (BMI) and congenital heart defects (CHDs). STUDY DESIGN: These analyses included case infants with CHDs (n = 6440) and liveborn control infants without birth defects (n = 5673) enrolled in the National Birth Defects Prevention Study (1997-2004). RESULTS: Adjusted odds ratios for all CHDs combined were 1.16 (95% confidence interval [CI], 1.05-1.29), 1.15 (95% CI, 1.00-1.32), and 1.31 (95% CI, 1.11-1.56) for overweight status, moderate obesity, and severe obesity, respectively. Phenotypes associated with elevated BMI (>= 25.0 kg/m(2)) were conotruncal defects (tetralogy of Fallot), total anomalous pulmonary venous return, hypoplastic left heart syndrome, right ventricular outflow tract (RVOT) defects (pulmonary valve stenosis), and septal defects (secundum atrial septal defect). CONCLUSION: These results corroborated those of previous studies and suggested new associations between obesity and conotruncal defects and RVOT defects. C1 [Gilboa, Suzanne M.; Correa, Adolfo; Rasmussen, Sonja A.; Riehle-Colarusso, Tiffany J.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Botto, Lorenzo D.] Univ Utah, Sch Med, Dept Pediat, Salt Lake City, UT USA. [Waller, D. Kim] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Houston, TX USA. [Hobbs, Charlotte A.; Cleves, Mario A.] Univ Arkansas Med Sci, Dept Pediat, Birth Defects Res Sect, Little Rock, AR 72205 USA. [Hobbs, Charlotte A.; Cleves, Mario A.] Arkansas Childrens Hosp, Res Inst, Little Rock, AR 72202 USA. RP Gilboa, SM (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. RI Publications, NBDPS/B-7692-2013 NR 51 TC 13 Z9 14 U1 2 U2 8 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD JAN PY 2010 VL 202 IS 1 AR 51.e1 DI 10.1016/j.ajog.2009.08.005 PG 10 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA 536EN UT WOS:000273026200012 PM 19796755 ER PT J AU Baron, RC Melillo, S Rimer, BK Coates, RJ Kerner, J Habarta, N Chattopadhyay, S Sabatino, SA Elder, R Leeks, KJ AF Baron, Roy C. Melillo, Stephanie Rimer, Barbara K. Coates, Ralph J. Kerner, Jon Habarta, Nancy Chattopadhyay, Sajal Sabatino, Susan A. Elder, Randy Leeks, Kimberly Jackson CA Task Force Community Preventive Se TI Intervention to Increase Recommendation and Delivery of Screening for Breast, Cervical, and Colorectal Cancers by Healthcare Providers A Systematic Review of Provider Reminders SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; COMMUNITY-PREVENTIVE-SERVICES; MAINTENANCE ORGANIZATION; COMPUTERIZED REMINDERS; IMPROVING ATTENDANCE; PHYSICIAN COMPLIANCE; REPEAT MAMMOGRAPHY; COST-EFFECTIVENESS; PATIENT REMINDERS; PRIVATE-PRACTICE AB Most major medical organizations recommend routine screening for breast, cervical, and colorectal cancers. Screening can lead to early detection of these cancers, resulting in reduced mortality. Yet, not all people who should be screened are screened regularly or, in some cases, ever. This report presents results of systematic reviews of effectiveness, applicability, economic efficiency, barriers to implementation, and other harms or benefits of provider reminder/recall interventions to increase screening for breast, cervical, and colorectal cancers. These interventions involve using systems to inform healthcare providers when individual clients are due (reminder) or overdue (recall) for specific cancer screening tests. Evidence in this review of studies published from 1986 through 2004 indicates that reminder/recall systems can effectively increase screening with mammography, Pap, fecal occult blood tests, and flexible sigmoidoscopy. Additional research is needed to determine if provider reminder/recall systems are effective in increasing colorectal cancer screening by colonoscopy. Specific areas for further research are also suggested. (Am J Prev Med 2010;38(1):110-117) (C) 2010 Published by Elsevier Inc. on behalf of American journal of Preventive Medicine. C1 [Baron, Roy C.; Melillo, Stephanie; Habarta, Nancy; Chattopadhyay, Sajal; Elder, Randy; Leeks, Kimberly Jackson] Ctr Dis Control & Prevent, Community Guide Branch, Natl Ctr Hlth Mkt, Atlanta, GA 30333 USA. [Coates, Ralph J.; Sabatino, Susan A.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Kerner, Jon] NCI, NIH, Bethesda, MD 20892 USA. [Rimer, Barbara K.] Univ N Carolina, Sch Publ Hlth, Chapel Hill, NC USA. RP Elder, R (reprint author), Ctr Dis Control & Prevent, Community Guide Branch, Natl Ctr Hlth Mkt, 1600 Clifton Rd,MS E-69, Atlanta, GA 30333 USA. EM relder1@cdc.gov RI Stockwell, Tim/B-6662-2012; OI Kerner, Jon/0000-0002-8792-3830 FU PHS HHS [U50/CCU300860] NR 64 TC 66 Z9 66 U1 0 U2 12 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD JAN PY 2010 VL 38 IS 1 BP 110 EP 117 DI 10.1016/j.amepre.2009.09.031 PG 8 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 541KL UT WOS:000273413800016 PM 20117566 ER PT J AU Bullock, SH Jones, BH Gilchrist, J Marshall, SW AF Bullock, Steven H. Jones, Bruce H. Gilchrist, Julie Marshall, Stephen W. TI Prevention of Physical Training-Related Injuries Recommendations for the Military and Other Active Populations Based on Expedited Systematic Reviews SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Review ID ANTERIOR CRUCIATE LIGAMENT; HYDROXY-BETA-METHYLBUTYRATE; OF-THE-LITERATURE; RANDOMIZED CONTROLLED-TRIAL; AUSTRALIAN ARMY RECRUITS; LOWER-EXTREMITY INJURIES; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CARBOHYDRATE-PROTEIN SUPPLEMENT; EXERCISE-RELATED INJURIES; LIMB MUSCLE SYNCHRONY AB Background: The Military Training Task Force of the Defense Safety Oversight Council chartered a joint Services Physical Training Injury Prevention Working Group to: (1) establish the evidence base for making recommendations to prevent injuries; (2) prioritize the recommendations for prevention programs and policies; and (3) substantiate the need for further research and evaluation on interventions and programs likely to reduce physical training-related injuries. Evidence acquisition: A work group was formed to identify, evaluate, and assess the level of scientific evidence for various physical training-related injury prevention strategies through an expedited systematic review process. Of 40 physical training-related injury prevention strategies identified, education, leader support, and surveillance were determined to be essential elements of a successful injury prevention program and not independent interventions. As a result of the expedited systematic reviews, one more essential element (research) was added for a total of four. Six strategies were not reviewed. The remaining 31 interventions were categorized into three levels representing the strength of recommendation: (1) recommended; (2) not recommended; and (3) insufficient evidence to recommend or not recommend. Evidence synthesis: Education, leadership support, injury surveillance, and research were determined to be critical components of any successful injury prevention program. Six interventions (i.e., prevent overtraining, agility-like training, mouthguards, semirigid ankle braces, nutrient replacement, and synthetic socks) had strong enough evidence to become working group recommendations for implementation in the military services. Two interventions (i.e., back braces and pre-exercise administration of anti-inflammatory medication) were not recommended due to evidence of ineffectiveness or harm, 23 lacked sufficient scientific evidence to support recommendations for all military services at this time, and six were not evaluated. Conclusions: Six interventions should be implemented in all four military services immediately to reduce physical training-related injuries. Two strategies should be discouraged by all leaders at all levels. Of particular note, 23 popular physical training-related injury prevention strategies need further scientific investigation, review, and group consensus before they can be recommended to the military services or similar civilian populations. The expedited systematic process of evaluating interventions enabled the working group to bad consensus around those injury prevention strategies that had enough scientific evidence to support a recommendation. (Am J Prev Med 20 10;38(1S):S156-S181) Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Bullock, Steven H.] USA, Ctr Hlth Promot & Prevent Med, Publ Hlth Assessment Program, Aberdeen Proving Ground, MD USA. [Jones, Bruce H.] USA, Ctr Hlth Promot & Prevent Med, Injury Prevent Program, Aberdeen Proving Ground, MD USA. [Gilchrist, Julie] Ctr Dis Control & Prevent, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA. [Marshall, Stephen W.] Univ N Carolina, Injury Prevent Res Ctr, Dept Epidemiol Biostat Core, Chapel Hill, NC USA. RP Bullock, SH (reprint author), 5158 Blackhawk Rd, Aberdeen Proving Ground, MD 21010 USA. EM Steven.H.Bullock@us.army.mil OI Marshall, Stephen/0000-0002-2664-9233 NR 329 TC 42 Z9 44 U1 1 U2 11 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD JAN PY 2010 VL 38 IS 1 BP S156 EP S181 DI 10.1016/j.amepre.2009.10.023 PG 26 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 541KM UT WOS:000273413900017 PM 20117590 ER PT J AU Jones, BH Canham-Chervak, M Sleet, DA AF Jones, Bruce H. Canham-Chervak, Michelle Sleet, David A. TI An Evidence-Based Public Health Approach to Injury Priorities and Prevention Recommendations for the US Military SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Editorial Material ID SERVICES TASK-FORCE; SETTING PRIORITIES; RISK-FACTORS; INTERVENTIONS; SYSTEM; POLICY; CARE AB Injuries are the leading cause of morbidity and mortality confronting U.S. military forces in peacetime or combat operations. Not only are injuries the biggest health problem of the military services, they are also a complex problem. The leading causes of deaths are different from those that result in hospitalization, which are different from those that result in outpatient care. As a consequence, it is not possible to focus on just one level of injury severity if the impact of injuries on military personnel is to be reduced. To effectively reduce the impact of a problem as big and complex as injuries requires a systematic approach. The purpose of this paper is to: (1) review the steps of the public health process for injury prevention; (2) review literature on evaluation of the scientific quality and consistency of information needed to make decisions about prevention policies, programs, and interventions; and (3) summarize criteria for setting objective injury prevention priorities. The review of these topics will serve as a foundation for making recommendations to enhance the effectiveness of injury prevention efforts in the military and similarly large communities. This paper also serves as an introduction to the other articles in this supplement to the American Journal of Preventive Medicine that illustrate the recommended systematic approach. (Aim J Prev Med 20 10;38(1S):S1-S10) Published by Elsevier Inc. on behalf of American journal of Preventive Medicine C1 [Canham-Chervak, Michelle] USA, Ctr Hlth Promot & Prevent Med, Injury Prevent Program, ATTN MCHB TS DI, Aberdeen Proving Ground, MD 21010 USA. [Sleet, David A.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA. RP Canham-Chervak, M (reprint author), USA, Ctr Hlth Promot & Prevent Med, Injury Prevent Program, ATTN MCHB TS DI, Aberdeen Proving Ground, MD 21010 USA. EM michelle.chervak@us.army.mil NR 56 TC 24 Z9 24 U1 0 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD JAN PY 2010 VL 38 IS 1 BP S1 EP S10 DI 10.1016/j.amepre.2009.10.001 PG 10 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 541KM UT WOS:000273413900001 PM 20117582 ER PT J AU Sleet, DA Baldwin, G AF Sleet, David A. Baldwin, Grant TI It Wouldn't Hurt to Create a Safer Military SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Editorial Material C1 [Sleet, David A.; Baldwin, Grant] Ctr Dis Control & Prevent, CDC, Natl Ctr Injury Prevent & Control, Div Unintent Injury Prevent, Atlanta, GA 30341 USA. RP Sleet, DA (reprint author), Ctr Dis Control & Prevent, CDC, Natl Ctr Injury Prevent & Control, Div Unintent Injury Prevent, 4770 Buford Highway NE,F-62, Atlanta, GA 30341 USA. EM dds6@cdc.gov NR 30 TC 3 Z9 3 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 J9 AM J PREV MED JI Am. J. Prev. Med. PD JAN PY 2010 VL 38 IS 1 BP S218 EP S221 DI 10.1016/j.amepre.2009.10.018 PG 4 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA 541KM UT WOS:000273413900024 PM 20117598 ER PT J AU Beitsch, LM Corso, LC AF Beitsch, Leslie M. Corso, Liza C. TI ACCREDITATION AND ACCOUNTABILITY: IS THE CART BEFORE THE HORSE? RESPOND SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Letter ID PUBLIC-HEALTH C1 [Beitsch, Leslie M.] Florida State Univ, Ctr Med & Publ Hlth, Coll Med, Tallahassee, FL 32306 USA. [Corso, Liza C.] Ctr Dis Control & Prevent, Off Chief Publ Hlth Practice, Atlanta, GA USA. RP Beitsch, LM (reprint author), 1115 W Call St, Tallahassee, FL 32306 USA. EM les.beitsch@med.fsu.edu NR 9 TC 0 Z9 0 U1 0 U2 1 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD JAN PY 2010 VL 100 IS 1 BP 5 EP 6 DI 10.2105/AJPH.2009.181347 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 538EK UT WOS:000273166800002 ER PT J AU Arias, E Eschbach, K Schauman, WS Backlund, EL Sortie, PD AF Arias, Elizabeth Eschbach, Karl Schauman, William S. Backlund, Eric L. Sortie, Paul D. TI The Hispanic Mortality Advantage and Ethnic Misclassification on US Death Certificates SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID UNITED-STATES; PARADOX; HEALTH AB Objectives. We tested the data artifact hypothesis regarding the Hispanic mortality advantage by investigating whether and to what degree this advantage is explained by Hispanic origin misclassification on US death certificates. Methods. We used the National Longitudinal Mortality Study, which links Current Population Survey records to death certificates for 1979 through 1998, to estimate the sensitivity, specificity, and net ascertainment of Hispanic ethnicity on death certificates compared with survey classifications. Using national vital statistics mortality data, we estimated Hispanic age-specific and age-adjusted death rates, which were uncorrected and corrected for death certificate misclassification, and produced death rate ratios comparing the Hispanic with the non-Hispanic White population. Results. Hispanic origin reporting on death certificates in the United States is reasonably good. The net ascertainment of Hispanic origin is just 5% higher on survey records than on death certificates. Corrected age-adjusted death rates for Hispanics are lower than those for the non-Hispanic White population by close to 20%. Conclusions. The Hispanic mortality paradox is not explained by an incongruence between ethnic classification in vital registration and population data systems. (Am J Public Health. 2010;100:S171-S177. doi:10.2105/AJPH.2008.135863) C1 [Arias, Elizabeth] Ctr Dis Control & Prevent, Mortal Stat Branch, Div Vital Stat, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Eschbach, Karl] Univ Texas San Antonio, San Antonio, TX USA. [Schauman, William S.; Backlund, Eric L.] US Bur Census, Suitland, MD USA. [Sortie, Paul D.] NHLBI, NIH, Bethesda, MD 20892 USA. RP Arias, E (reprint author), Ctr Dis Control & Prevent, Mortal Stat Branch, Div Vital Stat, Natl Ctr Hlth Stat, 3311 Toledo Rd,Room 7330, Hyattsville, MD 20782 USA. EM earias@cdc.gov FU University of Texas Medical Branch Center for Population Health and Health Disparity [P50CA105631-05] FX Karl Eschbach was supported by the University of Texas Medical Branch Center for Population Health and Health Disparity, P50CA105631-05. NR 27 TC 44 Z9 44 U1 1 U2 9 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PY 2010 VL 100 SU 1 BP S171 EP S177 DI 10.2105/AJPH.2008.135863 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 573TK UT WOS:000275937600032 PM 19762677 ER PT J AU Duran, D Usman, HR Beltrami, J Alvarez, ME Valleroy, L Lyles, CM AF Duran, Denise Usman, Hussain R. Beltrami, John Alvarez, Maria E. Valleroy, Linda Lyles, Cynthia M. TI HIV Counseling and Testing Among Hispanics at CDC-Funded Sites in the United States, 2007 SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID BEHAVIORAL INTERVENTIONS; POPULATIONS; PREVENTION; SYSTEM; HEALTH; TRENDS; RISK AB Objectives. We sought to determine whether Hispanic-White HIV testing disparities exist and to identify characteristics associated with newly diagnosed HIV among Hispanics. Methods. We used 2007 HIV Counseling and Testing System data to compare test-level records of Hispanics and non-Hispanic Whites, and we conducted a multivariate logistic regression analysis to identify characteristics associated with newly diagnosed HIV. Results. Relative to Whites, Hispanics were more likely to have had a positive HIV test result (1.2% versus 0.8%), to have newly diagnosed HIV (0.8% versus 0.6%), and to have test results returned and receive posttest counseling more than 2 weeks after testing (24.3% versus 21.5%). Newly diagnosed HIV among Hispanics was most strongly associated with being a man who has sex with men (MSM; adjusted odds ratio [AOR]=6.8; 95% confidence interval [CI]=6.1, 7.6), being both an MSM and an injection drug user (AOR=3.7; 95% CI=2.6, 5.3), and being aged 40 to 49 years (AOR=6.4; 95% CI=4.9, 8.2). Conclusions, Hispanic-White disparities exist with respect to rates of positive HIV test results and late return of results. HIV prevention strategies such as rapid testing should focus on Hispanic MSM. (Am J Public Health. 2010;100: S152-S158. doi:10.2105/AJPH.2009.166355) C1 [Duran, Denise] Ctr Dis Control & Prevent, Program Evaluat Branch, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP Duran, D (reprint author), Ctr Dis Control & Prevent, Program Evaluat Branch, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd NE,MS E-59, Atlanta, GA 30333 USA. EM dduran@cdc.gov NR 35 TC 8 Z9 8 U1 1 U2 4 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PY 2010 VL 100 SU 1 BP S152 EP S158 DI 10.2105/AJPH.2009.166355 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 573TK UT WOS:000275937600029 PM 20147691 ER PT J AU Kimbrough, LW Fisher, HE Dooley, S AF Kimbrough, Lisa W. Fisher, Holly E. Dooley, Sam TI IDENTIFYING PREVIOUSLY UNDIAGNOSED HIV INFECTIONS USING SOCIAL NETWORKS SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Letter C1 [Kimbrough, Lisa W.; Fisher, Holly E.; Dooley, Sam] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30341 USA. RP Kimbrough, LW (reprint author), Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Phys Act & Hlth Branch, 4770 Buford Highway,MS K-46, Atlanta, GA 30341 USA. EM lbw4@cdc.gov NR 1 TC 1 Z9 1 U1 0 U2 2 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PY 2010 VL 100 SU 1 BP S6 EP S6 DI 10.2105/AJPH.2009.183749 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 573TK UT WOS:000275937600002 ER PT J AU O'Hegarty, M Pederson, LL Thorne, SL Caraballo, RS Evans, B Athey, L McMichael, J AF O'Hegarty, Michelle Pederson, Linda L. Thorne, Stacy L. Caraballo, Ralph S. Evans, Brian Athey, Leslie McMichael, Joseph TI Customizing Survey Instruments and Data Collection to Reach Hispanic/Latino Adults in Border Communities in Texas SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID CIGARETTE-SMOKING AB Objectives. We sought to modify an instrument and to use it to collect information on smoking knowledge, attitudes, beliefs, and behaviors among Hispanics/Latinos, and to adapt survey methods to obtain high participation levels. Methods. Promotoras (outreach workers) conducted face-to-face interviews with 1485 Hispanic adults (July 2007-April 2008). The project team used Geo-Frame field enumeration methods to develop a sampling frame from households in randomly selected colonias (residential areas along the Texas-Mexico border that may lack some basic necessities (e.g. portable water), in El Paso, Texas. Results. The revised questionnaire included 36 unchanged items from the State Adult Tobacco Survey, 7 modified items, and 17 new items focusing on possible culturally specific quitting methods, secondhand smoke issues, and attitudes and knowledge about tobacco use that might be unique for Hispanic/Latino, groups. The eligibility rate was 90.2%, and the conservative combined completed screener and interview response rate was 80.0%. Conclusions. Strategic, targeted, carefully designed methods and surveys can achieve high reach and response rates in hard-to-reach populations. Similar procedures could be used to obtain cooperation of groups who may not be accessible with traditional methods. (Am J Public Health. 2010;100:S159-S164. doi:10.2105/AJPH.2009.167338) C1 [O'Hegarty, Michelle; Pederson, Linda L.; Thorne, Stacy L.; Caraballo, Ralph S.] Ctr Dis Control & Prevent, Off & Smoking & Hlth, Atlanta, GA 30341 USA. [Evans, Brian; Athey, Leslie; McMichael, Joseph] Res Triangle Inst Int, Res Triangle Pk, NC USA. RP O'Hegarty, M (reprint author), Ctr Dis Control & Prevent, Off & Smoking & Hlth, 4770 Buford Highway NE,Mailstop K-50, Atlanta, GA 30341 USA. EM mohegarty@cdc.gov NR 33 TC 2 Z9 2 U1 0 U2 2 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PY 2010 VL 100 SU 1 BP S159 EP S164 DI 10.2105/AJPH.2009.167338 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 573TK UT WOS:000275937600030 PM 20147687 ER PT J AU Rodwell, TC Barnes, RFW Moore, M Strathdee, SA Raich, A Moser, KS Garfein, RS AF Rodwell, Timothy C. Barnes, Richard F. W. Moore, Marisa Strathdee, Steffanie A. Raich, Annie Moser, Kathleen S. Garfein, Richard S. TI HIV-Tuberculosis Coinfection in Southern California: Evaluating Disparities in Disease Burden SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID MULTIDRUG-RESISTANT TUBERCULOSIS; UNITED-STATES; MEXICAN MIGRANTS; RISK-FACTORS; TRENDS; INFECTION; MORTALITY; PREVALENCE; BORDER AB Objectives. We sought to understand tuberculosis (TB) and HIV coinfection trends in San Diego County, California, and to identify associations between sociodemographic risk factors and TB and HIV coinfection. Methods. We analyzed TB surveillance data from 1993 through 2007. TB cases were grouped by HIV status: positive, negative, or unknown. We used Poisson regression to estimate trends and tested associations between TB and HIV coinfection and sociodemographic risk factors with polychotomous logistic regression. Results. Of 5172 TB cases, 8.8% were also infected with HIV. Incidence of coinfected cases did not change significantly over the period studied, but the proportion of cases among Hispanics increased significantly, whereas cases among non-Hispanic Whites and Blacks decreased. TB cases with HIV coinfection were significantly more likely to be Hispanic, male, injection drugs users, and aged 30 to 49 years, relative to cases with TB disease only. Conclusions. The burden of TB and HIV in San Diego has shifted to Hispanics in the last decade. To address this health disparity, binational TB and HIV prevention efforts are needed. (Am J Public Health. 2010;100:S178-S185. doi:10.2105/AJPH.2009.170142) C1 [Rodwell, Timothy C.] Univ Calif San Diego, Dept Med, Div Global Publ Hlth, Sch Med, La Jolla, CA 92093 USA. [Moore, Marisa] Ctr Dis Control & Prevent, TB Control & Refugee Hlth Program, San Diego Cty Hlth & Human Serv Agcy, Atlanta, GA 30333 USA. [Raich, Annie] San Diego State Univ, Sch Publ Hlth, San Diego, CA 92182 USA. RP Rodwell, TC (reprint author), Univ Calif San Diego, Dept Med, Div Global Publ Hlth, Sch Med, 9500 Gilman Dr, La Jolla, CA 92093 USA. EM trodwell@ucsd.edu FU University of California [CF07-SD-302]; National Institutes of Health [T32 DA023356, K01AI083784-01] FX T. C. Rodwell received financial support from the California HIV/AIDS Research Program at the University of California (fellowship CF07-SD-302) and the National Institutes of Health (grants T32 #DA023356 and K01AI083784-01). NR 35 TC 10 Z9 10 U1 0 U2 5 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PY 2010 VL 100 SU 1 BP S178 EP S185 DI 10.2105/AJPH.2009.170142 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 573TK UT WOS:000275937600033 PM 20147681 ER PT J AU Metcalfe, JZ Cattamanchi, A Vittinghoff, E Ho, C Grinsdale, J Hopewelll, PC Kawamura, LM Nahid, P AF Metcalfe, John Z. Cattamanchi, Adithya Vittinghoff, Eric Ho, Christine Grinsdale, Jennifer Hopewelll, Philip C. Kawamura, L. Masae Nahid, Payam TI Evaluation of Quantitative IFN-gamma Response for Risk Stratification of Active Tuberculosis Suspects SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Article DE interferon-gamma release assay; Quantiferon; risk prediction; risk reclassification ID CORONARY-HEART-DISEASE; MYCOBACTERIUM-TUBERCULOSIS; PULMONARY TUBERCULOSIS; RELEASE ASSAY; BLOOD-TEST; SKIN-TEST; DIAGNOSIS; INFECTION; PREDICTION; RECLASSIFICATION AB Rationale The contribution of interferon-gamma release assays (IGRAs) to appropriate risk stratification of active tuberculosis suspects has not been studied. Objectives: To determine whether the addition of quantitative IGRA results to a prediction model incorporating clinical criteria improves risk stratification of smear-negative-tuberculosis suspects. Methods: Clinical data from tuberculosis suspects evaluated by the San Francisco Department of Public Health Tuberculosis Control Clinic from March 2005 to February 2008 were reviewed. We excluded tuberculosis suspects who were acid fast-bacilli smear-positive, HIV-infected, or under 10 years of age. We developed a clinical prediction model for culture-positive disease and examined the benefit of adding quantitative interferon (IFN)-gamma results measured by QuantiFERON-TB Gold (Cellestis, Carnegie, Australia). Measurements and Main Results: Of 660 patients meeting eligibility criteria, 65 (10%) had culture-proven tuberculosis. The odds of active tuberculosis increased by 7% (95% confidence interval [CI], 3-11%) for each doubling of IFN-gamma level. The addition of quantitative IFN-gamma results to objective clinical data significantly improved model performance (c-statistic 0.71 vs. 0.78; P < 0.001) and correctly reclassified 32% of tuberculosis suspects (95% CI, 11-52%; P < 0.001) into higher-risk or lower-risk categories. However, quantitative IFN-gamma results did not significantly improve appropriate risk reclassification beyond that provided by clinician assessment of risk (4%; 95% Cl, -7 to +22%; P = 0.14). Conclusions: Higher quantitative IFN-gamma results were associated with active tuberculosis, and added clinical value to a prediction model incorporating conventional risk factors. Although this benefit may be attenuated within highly experienced centers, the predictive accuracy of quantitative IFN-gamma levels should be evaluated in other settings. C1 [Metcalfe, John Z.; Cattamanchi, Adithya; Hopewelll, Philip C.; Nahid, Payam] San Francisco Gen Hosp, Div Pulm & Crit Care Med, San Francisco, CA 94110 USA. [Vittinghoff, Eric] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Ho, Christine; Grinsdale, Jennifer; Hopewelll, Philip C.; Kawamura, L. Masae; Nahid, Payam] Dept Publ Hlth, TB Control Sect, San Francisco, CA USA. [Ho, Christine] Ctr Dis Control & Prevent, San Francisco, CA USA. RP Metcalfe, JZ (reprint author), Univ Calif San Francisco, Div Pulm & Crit Care Med, 1001 Potrero Ave,Rm 5K1, San Francisco, CA 94110 USA. EM john.metcalfe@ucsf.edu FU National Institutes of Health [T32 HL007185, K23 HL094141, R01 AI034238, K23 HL092629] FX Supported by grants T32 HL007185 (J.Z.M.), K23 HL094141 (A.C.), R01 AI034238 (P.C.H.), and K23 HL092629 (P.N.) from the National Institutes of Health. NR 35 TC 23 Z9 25 U1 0 U2 1 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD JAN 1 PY 2010 VL 181 IS 1 BP 87 EP 93 DI 10.1164/rccm.200906-0981OC PG 7 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA 537XH UT WOS:000273147100016 PM 19797760 ER PT J AU Barraza-Villarreal, A Cadena, LH Escamilla-Nunez, C Monge, JS Sjodin, A Diaz-Barriga, F Romieu, I AF Barraza-Villarreal, A. Hernandez Cadena, L. Escamilla-Nunez, C. Sienra Monge, J. Sjodin, A. Diaz-Barriga, F. Romieu, I. TI Polycyclic Aromatic Hydrocarbons Exposure And Lung Function In Schoolchildren From Mexico City SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract C1 [Barraza-Villarreal, A.; Hernandez Cadena, L.; Escamilla-Nunez, C.; Romieu, I.] Natl Inst Publ Hlth, Cuernavaca, Morelos, Mexico. [Sienra Monge, J.] Hosp Infantil Mexico Dr Federico Gomez, Mexico City, DF, Mexico. [Sjodin, A.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Diaz-Barriga, F.] Univ Autonoma San Luis Potosi, San Luis Potosi, Mexico. EM abarraza@correo.insp.mx NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2010 VL 181 MA A2535 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V29TP UT WOS:000208771001449 ER PT J AU Hirsch-Moverman, Y Wall, K Maiuri, A Khan, A Munk, E Weinfurter, P DeLuca, N AF Hirsch-Moverman, Y. Wall, K. Maiuri, A. Khan, A. Munk, E. Weinfurter, P. DeLuca, N. CA TB Epidemiologic Studies Consortiu TI Acceptability Of Interferon-gamma Release Assays Among Healthcare Workers Who Receive Routine Employee TuBerculosis Testing SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract C1 [Hirsch-Moverman, Y.] Felton Natl TB Ctr, New York, NY USA. [Wall, K.] Denver Hlth & Hosp Author, Denver, CO USA. [Maiuri, A.; Khan, A.; Weinfurter, P.; DeLuca, N.; TB Epidemiologic Studies Consortiu] CDC, Atlanta, GA 30333 USA. [Munk, E.] Johns Hopkins Univ, Baltimore, MD USA. EM yh154@columbia.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2010 VL 181 MA A1762 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V29TP UT WOS:000208771000762 ER PT J AU Larson, T Antao, V Cusack, C Bove, F AF Larson, T. Antao, V. Cusack, C. Bove, F. TI Morbidity In Workers With Libby Amphibole Exposure SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract C1 [Larson, T.; Antao, V.; Cusack, C.; Bove, F.] ATSDR, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2010 VL 181 MA A1741 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V29TP UT WOS:000208771000741 ER PT J AU Larson, T Antao, V Holiday, D Asman, K Bishop, E Thomas, J AF Larson, T. Antao, V. Holiday, D. Asman, K. Bishop, E. Thomas, J. TI The Use Of Digital Radiography For Classifying Pneumoconiotic Pleural Abnormalities SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract C1 [Larson, T.; Antao, V.] ATSDR, Atlanta, GA USA. [Holiday, D.; Asman, K.; Bishop, E.] RTI Int, Atlanta, GA USA. [Thomas, J.] Avia Christi Med Ctr, Wichita, KS USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2010 VL 181 MA A1737 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V29TP UT WOS:000208771000737 ER PT J AU Ortiz, JR Zhou, H Shay, DK Neuzil, KM Goss, CH AF Ortiz, J. R. Zhou, H. Shay, D. K. Neuzil, K. M. Goss, C. H. TI Does Google Influenza Tracking Correlate With Laboratory Tests Positive For Influenza? SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract C1 [Ortiz, J. R.; Goss, C. H.] Univ Washington, Seattle, WA 98195 USA. [Zhou, H.; Shay, D. K.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Neuzil, K. M.] PATH, Seattle, WA USA. EM jrortiz@u.washington.edu NR 0 TC 1 Z9 1 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2010 VL 181 MA A2626 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V29TP UT WOS:000208771001539 ER PT J AU Randolph, AG Guo, C Jouvet, P Ferdinands, J Weiss, ST Flori, H Loftis, L Yoon, G Anas, N Helfaer, M Paden, M Willson, D Hall, M Hollis, BW Dowling, N Sullivan, R Carroll, CL Czaja, A Truemper, E Katyal, C Thomas, N Graciano, A Montgomery, V Markovitz, B Gedeit, R Shay, DK AF Randolph, A. G. Guo, C. Jouvet, P. Ferdinands, J. Weiss, S. T. Flori, H. Loftis, L. Yoon, G. Anas, N. Helfaer, M. Paden, M. Willson, D. Hall, M. Hollis, B. W. Dowling, N. Sullivan, R. Carroll, C. L. Czaja, A. Truemper, E. Katyal, C. Thomas, N. Graciano, A. Montgomery, V. Markovitz, B. Gedeit, R. Shay, D. K. TI Vitamin D Deficiency Is Associated With Mortality In Patients Admitted To The Pediatric Intensive Care Unit With Community-Acquired Influenza Infection SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Meeting Abstract C1 [Randolph, A. G.] Children, Boston, MA USA. [Guo, C.; Yoon, G.; Sullivan, R.] Childrens Hosp, Boston, MA 02115 USA. [Jouvet, P.] CHU St Justine, Montreal, PQ, Canada. [Ferdinands, J.; Dowling, N.] CDC, Atlanta, GA 30333 USA. [Weiss, S. T.] Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA. [Flori, H.] Childrens Hosp Oakland, Oakland, CA USA. [Loftis, L.] Texas Childrens Hosp, Houston, TX 77030 USA. [Anas, N.] Childrens Hosp Orange Cty, Orange, CA 92668 USA. [Helfaer, M.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. [Paden, M.] Childrens Healthcare Atlanta, Atlanta, GA USA. [Willson, D.] Univ Virginia, Charlottesville, VA USA. [Hall, M.] Nationwide Childrens Hosp, Columbus, OH USA. [Hollis, B. W.] Med Univ S Carolina, Charleston, SC 29425 USA. [Carroll, C. L.] Connecticut Childrens Med Ctr, Hartford, CT USA. [Czaja, A.] Childrens Hosp, Aurora, CO USA. [Truemper, E.] Childrens Hosp Nebraska, Omaha, NE USA. [Katyal, C.] Childrens Hosp Montefiore, Bronx, NY USA. [Thomas, N.] Penn State Hershey Childrens Hosp, Hershey, PA USA. [Graciano, A.] Childrens Hosp Cent Calif, Madera, CA USA. [Montgomery, V.] Kosair Childrens Hosp, Louisville, KY USA. [Markovitz, B.] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA. [Gedeit, R.] Childrens Hosp Wisconsin, Milwaukee, WI 53201 USA. [Shay, D. K.] Ctr Dis Control & Prevent, Atlanta, GA USA. EM adrienne.randolph@childrens.harvard.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA SN 1073-449X J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PY 2010 VL 181 MA A6804 PG 1 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA V29TP UT WOS:000208771005422 ER PT J AU Jain, S Sahanoon, OK Blanton, E Schmitz, A Wannemuehler, KA Hoekstra, RM Quick, RE AF Jain, Seema Sahanoon, Osman K. Blanton, Elizabeth Schmitz, Ann Wannemuehler, Kathleen A. Hoekstra, Robert M. Quick, Robert E. TI Sodium Dichloroisocyanurate Tablets for Routine Treatment of Household Drinking Water in Periurban Ghana: A Randomized Controlled Trial SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID POINT-OF-USE; DIARRHEA PREVENTION; GASTROINTESTINAL ILLNESS; FLOCCULANT-DISINFECTANT; DISEASE TRANSMISSION; NADCC TABLETS; SAFE STORAGE; HOME; INTERVENTIONS; METAANALYSIS AB We conducted a randomized, placebo-controlled, triple-blinded trial to determine the health impact of daily use of sodium dichloroisocyanurate (NaDCC) tablets for household drinking water treatment in periurban Ghana. We randomized 240 households (3,240 individuals) to receive either NaDCC or placebo tablets. All households received a 20-liter safe water storace vessel. Over 42 weeks, 446 diarrhea episodes (2.2%) occurred in intervention and 404 (2.0%) in control households (P = 0.38). Residual free chlorine levels indicated appropriate tablet use. Escherichia coli was found in stored water at baseline in 96% of intervention and 88% of control households and at final evaluation in 8% of intervention and 54% of control households (P = 0.002). NaDCC use did not prevent diarrhea but improved water quality. Diarrhea rates were low and water quality improved in both groups. Safe water storage vessels may have been protective. A follow-up health impact study of NaDCC tablets is warranted. C1 [Jain, Seema] Ctr Dis Control & Prevent, Enter Dis Epidemiol Branch, Div Foodborne Bacterial & Mycot Dis, Natl Ctr Zoonot Vector Borne & Enter Dis, Atlanta, GA 30333 USA. Emory Univ, Sch Med, Div Infect Dis, Atlanta, GA USA. Emory Univ, Rollins Sch Publ Hlth, Ctr Global Safe Water, Atlanta, GA 30322 USA. [Sahanoon, Osman K.] NewEnergy, Tamale, Ghana. RP Jain, S (reprint author), Ctr Dis Control & Prevent, Enter Dis Epidemiol Branch, Div Foodborne Bacterial & Mycot Dis, Natl Ctr Zoonot Vector Borne & Enter Dis, 1600 Clifton Rd,MS A-38, Atlanta, GA 30333 USA. EM bwc8@cdc.gov FU United States Agency for International Development; Bureau of Oceans and Environmental Science of the United States Department of State; Medentech Ltd; Chlorine Chemistry Council FX The United States Agency for International Development, the Bureau of Oceans and Environmental Science of the United States Department of State, Medentech Ltd, and the Chlorine Chemistry Council funded the study. Medentech, Ltd provided NaDCC and placebo tablets. NR 37 TC 21 Z9 21 U1 3 U2 7 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD JAN PY 2010 VL 82 IS 1 BP 16 EP 22 DI 10.4269/ajtmh.2010.08-0584 PG 7 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 540VF UT WOS:000273367400005 PM 20064989 ER PT J AU Brown, HE Ettestad, P Reynolds, PJ Brown, TL Hatton, ES Holmes, JL Glass, GE Gage, KL Eisen, RJ AF Brown, Heidi E. Ettestad, Paul Reynolds, Pamela J. Brown, Ted L. Hatton, Elizabeth S. Holmes, Jennifer L. Glass, Gregory E. Gage, Kenneth L. Eisen, Rebecca J. TI Climatic Predictors of the Intra- and Inter-Annual Distributions of Plague Cases in New Mexico Based on 29 Years of Animal-Based Surveillance Data SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID SOUTHWESTERN UNITED-STATES; YERSINIA-PESTIS; BORNE ZOONOSES; OUTBREAKS; RISK; PRECIPITATION; POPULATIONS; DYNAMICS; VECTOR; MODELS AB Within the United States, the majority of human plague cases are reported from New Mexico. We describe climatic factors involved in intra- and inter-annual plague dynamics using animal-based surveillance data from that state. Unlike the clear seasonal pattern observed at lower elevations, cases occur randomly throughout the year at higher elevations. Increasing elevation corresponded with delayed mean time in case presentation. Using local meteorological data (previous year mean annual precipitation, total degrees over 27 degrees C 3 years before and maximum winter temperatures 4 years before) we built a time-series model predicting annual case load that explained 75% of the variance in pet cases between years. Moreover, we found a significant correlation with observed annual human cases and predicted pet cases. Because covariates were time-lagged by at least I year, intensity of case loads can be predicted in advance of a plague season. Understanding associations between environmental and meteorological factors can be useful for anticipating future disease trends. C1 [Brown, Heidi E.; Holmes, Jennifer L.; Gage, Kenneth L.; Eisen, Rebecca J.] CDC, Ctr Dis Control & Prevent, Natl Ctr Zoonot Vector Borne & Enter Dis, Div Vector Borne Infect Dis, Ft Collins, CO 80522 USA. [Ettestad, Paul; Brown, Ted L.; Hatton, Elizabeth S.] New Mexico Dept Hlth, Epidemiol & Response Div, Santa Fe, NM USA. New Mexico Environm Dept, Vector Control Program, Santa Fe, NM USA. [Glass, Gregory E.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. RP Brown, HE (reprint author), CDC, Ctr Dis Control & Prevent, Natl Ctr Zoonot Vector Borne & Enter Dis, Div Vector Borne Infect Dis, 3150 Rampart Rd,Foothills Campus, Ft Collins, CO 80522 USA. EM hebrown@cdc.gov; Paul.Ettestad@state.nm.us; thunderpass@gmail.com; brownlizard2279@msn.com; Elizabeth.Hatton@state.nm.us; JHolmes@cdc.gov; gglass@jhsph.edu; KGage@cdc.gov; RJEisen@cdc.gov OI Brown, Heidi/0000-0001-8578-5510 FU U.S. Department of Energy; CDC FX We acknowledge Gabrielle Dietrich at the CDC-DVBID for her assistance in collecting the data from the New Mexico Department of Health. This research was supported in part by the appointment of Heidi E. Brown to the Research Participation Program at the CDC, NCZVED, DVBID administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and the CDC. NR 45 TC 17 Z9 18 U1 0 U2 5 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD JAN PY 2010 VL 82 IS 1 BP 95 EP 102 DI 10.4269/ajtmh.2010.09-0247 PG 8 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 540VF UT WOS:000273367400018 PM 20065002 ER PT J AU McMorrow, ML Masanja, MI Kahigwa, E Abdulla, SMK Kachur, SP AF McMorrow, Meredith L. Masanja, M. Irene Kahigwa, Elizeus Abdulla, Salim M. K. Kachur, S. Patrick TI Quality Assurance of Rapid Diagnostic Tests for Malaria in Routine Patient Care in Rural Tanzania SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID MANAGEMENT; PNEUMONIA; CHILDREN; OVERLAP AB Histidine-rich protein 11 (HRP2)-based malaria rapid diagnostic tests (RDTs) have shown high sensitivity and specificity for detecting Plasmodium falciparum malaria in a variety of study settings. However, RDTs are susceptible to heat and humidity and variation in individual performance, which may affect their use in field settings. We evaluated sensitivity and specificity of RDTs during routine use for malaria case management in peripheral health facilities. From December 2007 to October 2008, HRP2-based ParaHIT-f RDTs were introduced in 12 facilities without available microscopy in Rufiji District, Tanzania. Health workers received a single day of instruction on how to perform an RDT and thick blood smear. Job aids, Integrated Management of Childhood Illness guidelines, and national malaria treatment algorithms were reviewed. For quality assurance (QA), thick blood smears for reference microscopy were collected for 2 to 3 days per week from patients receiving RDTs; microscopy was not routinely performed at the health facilities. Slides were stained and read centrally within 72 hours of collection by a reference microscopist. When RDT and blood smear results were discordant, blood smears were read by additional reference microscopists blinded to earlier results. Facilities were supervised monthly by the district laboratory supervisor or a member of the study team. Ten thousand six hundred fifty (10,650) patients were tested with RDTs, and 51.5% (5,488/10,650) had a positive test result. Blood smear results were available for 3,914 patients, of whom 40.1% (1,577/3,914) were positive for P. falciparum malaria. Overall RDT sensitivity was 90.7% (range by facility 85.7-96.5%) and specificity was 73.5% (range 50.0-84.3%). Sensitivity increased with increasing parasite density. Successful implementation of RDTs was achieved in peripheral health facilities with adequate training and supervision. Quality assurance is essential to the adequate performance of any laboratory test. Centralized staining and reading of blood smears provided useful monitoring of RDT performance. However, this level of QA may not be sustainable nationwide. C1 [McMorrow, Meredith L.] Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis, Atlanta, GA 30341 USA. Ctr Dis Control & Prevent, US Publ Hlth Serv, Atlanta, GA 30341 USA. [Masanja, M. Irene; Kahigwa, Elizeus; Abdulla, Salim M. K.] Ifakara Hlth Inst, Dar Es Salaam, Tanzania. RP McMorrow, ML (reprint author), Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis, 4770 Buford Highway,Mailstop F-22, Atlanta, GA 30341 USA. EM mmcmorrow@cdc.gov; imasanja@ihi.or.tz; ekahiawa@ihi.or.tz; sabdulla@ihi.or.tz; spk0@cdc.gov FU U.S. Centers for Disease Control and Prevention; U.S. President's Malaria Initiative (PMI) FX This work was financially supported through the U.S. Centers for Disease Control and Prevention and the U.S. President's Malaria Initiative (PMI). NR 14 TC 28 Z9 28 U1 0 U2 1 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD JAN PY 2010 VL 82 IS 1 BP 151 EP 155 DI 10.4269/ajtmh.2010.09-0440 PG 5 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA 540VF UT WOS:000273367400029 PM 20065013 ER PT J AU Monteiro, F Marcet, P Dorn, P AF Monteiro, Fernando Marcet, Paula Dorn, Patricia BE Telleria, J Tibayrenc, M TI Population Genetics of Triatomines SO AMERICAN TRYPANOSOMIASIS CHAGAS DISEASE: ONE HUNDRED YEARS OF RESEARCH SE Elsevier Insights LA English DT Article; Book Chapter ID CHAGAS-DISEASE VECTOR; RURAL NORTHWESTERN ARGENTINA; MULTILOCUS GENOTYPE DATA; TRYPANOSOMA-CRUZI INFECTION; RHODNIUS-PROLIXUS HEMIPTERA; POLYMERASE-CHAIN-REACTION; INFESTANS HEMIPTERA; MICROSATELLITE MARKERS; MITOCHONDRIAL-DNA; DIMIDIATA HEMIPTERA C1 [Monteiro, Fernando] Inst Oswaldo Cruz, Lab Doencas Parasitarias, BR-20001 Rio De Janeiro, Brazil. [Marcet, Paula] Ctr Dis Control & Prevent, Div Parasit Dis, Atlanta, GA 30329 USA. [Dorn, Patricia] Loyola Univ New Orleans, Dept Biol Sci, New Orleans, LA 70118 USA. RP Monteiro, F (reprint author), Inst Oswaldo Cruz, Lab Doencas Parasitarias, BR-20001 Rio De Janeiro, Brazil. EM fam@ioc.fiocruz.br; pvm3@cdc.gov; dorn@loyno.edu OI Marcet, Paula/0000-0002-0676-3020; Dorn, Patricia/0000-0001-8555-7008 NR 130 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS BN 978-0-12-384877-2 J9 ELSEV INSIGHT PY 2010 BP 169 EP 208 DI 10.1016/B978-0-12-384876-5.00008-3 PG 40 WC Infectious Diseases SC Infectious Diseases GA BFE80 UT WOS:000319517200009 ER PT J AU Perez, JJ Harris, GA Chipuk, JE Brodbelt, JS Green, MD Hampton, CY Fernandez, FM AF Perez, Jose J. Harris, Glenn A. Chipuk, Joseph E. Brodbelt, Jennifer S. Green, Michael D. Hampton, Christina Y. Fernandez, Facundo M. TI Transmission-mode direct analysis in real time and desorption electrospray ionization mass spectrometry of insecticide-treated bednets for malaria control SO ANALYST LA English DT Article ID PLANAR CHROMATOGRAPHY; AMBIENT CONDITIONS; ION-SOURCE; NETS; FIELD; ACID; PERMANET((R)); DELTAMETHRIN; SPECTROSCOPY; GENERATION AB Transmission-mode direct analysis in real time (TM-DART) is presented as an alternative sampling strategy to traditional methods of sample introduction for DART MS analysis. A custom-designed sample holder was fabricated to rapidly and reproducibly position insecticide-treated nets normal to the ionizing metastable gas stream, enabling transmission of desorbed analyte ions through the holder cavity and into the MS. Introduction of the sample at this fixed geometry eliminates the need for optimizing sample position and allows spectra based on factors such as metastable gas temperature and flow to be systematically evaluated. The results presented here, supported by computational fluid dynamic simulations, demonstrate the effects of these factors on the resulting mass spectra and the potential of this sampling strategy to be used for qualitative and quantitative analyses. Transmission-mode desorption electrospray ionization (TM-DESI) experiments on similar insecticide-treated nets were performed for comparison purposes. C1 [Perez, Jose J.; Harris, Glenn A.; Hampton, Christina Y.; Fernandez, Facundo M.] Georgia Inst Technol, Sch Chem & Biochem, Atlanta, GA 30332 USA. [Chipuk, Joseph E.; Brodbelt, Jennifer S.] Univ Texas Austin, Dept Chem & Biochem, Austin, TX 78712 USA. [Green, Michael D.] US Ctr Dis Control & Prevent, Div Parasit Dis, Atlanta, GA 30341 USA. RP Fernandez, FM (reprint author), Georgia Inst Technol, Sch Chem & Biochem, Atlanta, GA 30332 USA. EM facundo.fernandez@chemistry.gatech.edu RI Fernandez, Facundo/B-7015-2008 FU NSF CAREER [0645094]; NSF [CHE-0718320]; Welch Foundation [F1155] FX This work was supported by NSF CAREER grant 0645094 to FMF, NSF (CHE-0718320 to JSB), and the Welch Foundation (F1155 to JSB). NR 30 TC 39 Z9 39 U1 2 U2 41 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 0003-2654 J9 ANALYST JI Analyst PY 2010 VL 135 IS 4 BP 712 EP 719 DI 10.1039/b924533b PG 8 WC Chemistry, Analytical SC Chemistry GA 572WN UT WOS:000275865100009 PM 20309445 ER PT J AU Kussrow, A Enders, CS Castro, AR Cox, DL Ballard, RC Bornhop, DJ AF Kussrow, Amanda Enders, Carolyn S. Castro, Arnold R. Cox, David L. Ballard, Ronald C. Bornhop, Darryl J. TI The potential of backscattering interferometry as an in vitro clinical diagnostic tool for the serological diagnosis of infectious disease SO ANALYST LA English DT Article ID SYPHILIS; INDEX; UPDATE AB Backscattering interferometry enables the detection of syphilis antibody-antigen interactions in the presence of human serum, showing promise as a diagnostic tool for the serological diagnosis of infectious disease with potentially quantitative capabilities. C1 [Kussrow, Amanda; Enders, Carolyn S.; Bornhop, Darryl J.] Vanderbilt Univ, Dept Chem, Nashville, TN 37203 USA. [Kussrow, Amanda; Enders, Carolyn S.; Bornhop, Darryl J.] Vanderbilt Univ, Vanderbilt Inst Chem Biol, Nashville, TN USA. [Castro, Arnold R.; Cox, David L.; Ballard, Ronald C.] Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV STD & TB Prevent, Atlanta, GA USA. RP Bornhop, DJ (reprint author), Vanderbilt Univ, Dept Chem, Nashville, TN 37203 USA. EM darryl.bornhop@vanderbilt.edu FU National Institutes for Health [R01 EB003537-01A2]; Centers for Disease Control and Prevention [200-2009-M-29719]; Vanderbilt University Institute of Chemical Biology FX This research was supported in part by a grant from the National Institutes for Health (R01 EB003537-01A2), the Centers for Disease Control and Prevention (200-2009-M-29719), and the Vanderbilt University Institute of Chemical Biology. NR 16 TC 10 Z9 10 U1 0 U2 5 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 0003-2654 J9 ANALYST JI Analyst PY 2010 VL 135 IS 7 BP 1535 EP 1537 DI 10.1039/c0an00098a PG 3 WC Chemistry, Analytical SC Chemistry GA 614ZH UT WOS:000279098000006 PM 20414494 ER PT J AU Hoang, V Tripp, RA Rota, P Dluhy, RA AF Hoang, Vinh Tripp, Ralph A. Rota, Paul Dluhy, Richard A. TI Identification of individual genotypes of measles virus using surface enhanced Raman spectroscopy SO ANALYST LA English DT Article ID OBLIQUE ANGLE DEPOSITION; SINGLE-MOLECULE; SERS; SCATTERING; ELIMINATION; CONCLUSIONS; PERFORMANCE; PATHOGENS; DIAGNOSIS; BACTERIA AB A spectroscopic assay based on surface-enhanced Raman spectroscopy (SERS) has been developed for rapid genotyping of the measles virus (MeV). Silver nanorods fabricated using an oblique angle vapor deposition method acted as the SERS-active substrate. The SERS spectra of four separate MeV genotypes, i.e. A, H1, D4 and D9, and two separate negative media control samples were analyzed using multivariate statistical methods. Principal components analysis (PCA) and hierarchical cluster analysis (HCA) successfully separated three of the four MeV genotypes studied. The MeV genotypes used in this study had >96% sequence similarity as monitored using the MeV hemagglutinin (H) gene, and the clustering seen in PCA and HCA mirrored this sequence diversity. For example, the MeV genotypes with the highest sequence diversity (similar to 3%, A and H1) were the most widely separated in the PCA scores plot and HCA dendogram. Conversely, the MeV genotypes with the lowest sequence diversity (similar to 0.5%, D4 and D9) could not be statistically differentiated. However, a supervised chemometric method, partial least squares-discriminant analysis (PLS-DA) was able to separate each of the four MeV strains, the two negative controls, and the background, with >90% sensitivity and >96% selectivity based solely on their inherent SERS spectra. These results demonstrate that SERS, in combination with multivariate statistical methods, is a highly sensitive and rapid viral identification and classification method that can be applied to MeV genotyping. C1 [Hoang, Vinh; Dluhy, Richard A.] Univ Georgia, Dept Chem, Athens, GA 30602 USA. [Tripp, Ralph A.] Univ Georgia, Dept Infect Dis, Athens, GA 30602 USA. [Rota, Paul] Ctr Dis Control & Prevent, Meales Mumps Rubella & Herpesvirus Lab Branch, Atlanta, GA 30333 USA. RP Dluhy, RA (reprint author), Univ Georgia, Dept Chem, Athens, GA 30602 USA. EM dluhy@uga.edu OI Tripp, Ralph/0000-0002-2924-9956 FU UGA Office of the Vice President for Research through a UGA Faculty of Infectious Disease FX Support for this project was provided by the UGA Office of the Vice President for Research through a UGA Faculty of Infectious Disease - CDC Seed Grant. NR 45 TC 11 Z9 11 U1 3 U2 34 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 0003-2654 J9 ANALYST JI Analyst PY 2010 VL 135 IS 12 BP 3103 EP 3109 DI 10.1039/c0an00453g PG 7 WC Chemistry, Analytical SC Chemistry GA 680VT UT WOS:000284265700013 PM 20838669 ER PT S AU Bucher, D Tumpey, T Lowen, A Gill, J Shaw, M Matthews, J Galarza, J Arroyo, JM Dormitzer, PR AF Bucher, Doris Tumpey, Terrence Lowen, Anice Gill, James Shaw, Michael Matthews, James Galarza, Jose Arroyo, Jennifer Minieri Dormitzer, Philip Ralph GP NYAS TI 2009 H1N1 swine flu: the 2010 perspective SO ANNALS MEETING REPORTS: HIV/AIDS; SWINE FLU; AND AUTISM SE Annals of the New York Academy of Sciences LA English DT Article DE swine flu; outbreak; H1N1; cross-protection; vaccine; pandemic; 1918 influenza ID INFLUENZA; NEUTRALIZATION; INFECTION AB In May 2009, as the H1N1 swine flu outbreak was in the early stages, a conference was held at the New York Academy of Sciences to discuss what was known about the virus and what was being done to stop the outbreak. In May 2010, a follow-up conference was again held at the New York Academy of Sciences, but now to discuss the H1N1 outbreak retrospectively. The report presented here summarizes the 2010 conference proceedings. C1 [Bucher, Doris; Arroyo, Jennifer Minieri] New York Med Coll, Dept Microbiol & Immunol, Valhalla, NY 10595 USA. [Tumpey, Terrence; Shaw, Michael] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [Lowen, Anice] Mt Sinai Sch Med, Dept Microbiol, New York, NY USA. [Gill, James] Off Chief Med Examiner, New York, NY USA. [Matthews, James] Sanofi Pasteur, Commercial Operat US, Washington, DC USA. [Galarza, Jose] TechnoVax Inc, Tarrytown, NY USA. [Dormitzer, Philip Ralph] Novartis Vaccines & Diagnost, Cambridge, MA USA. RP Bucher, D (reprint author), New York Med Coll, Dept Microbiol & Immunol, Basic Sci Bldg, Valhalla, NY 10595 USA. EM doris_bucher@nymc.edu OI Gill, James R./0000-0001-6900-8025 FU organization IFPMA-IVS Taskforce FX D. B. receives research support from influenza vaccine manufacturers through the organization IFPMA-IVS Taskforce. Three coauthors are employed by manufacturers or developers of influenza vaccines: J.M. (Sanofi Pasteur), J.G. (TechnoVax), and P.D. (Novartis Vaccines and Diagnostics). NR 16 TC 1 Z9 1 U1 2 U2 11 PU WILEY-BLACKWELL PI MALDEN PA COMMERCE PLACE, 350 MAIN STREET, MALDEN 02148, MA USA SN 0077-8923 BN 978-1-57331-768-9 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2010 VL 1205 SI S1 DI 10.1111/j.1749-6632.2010.05739.x PG 11 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA BTW52 UT WOS:000288275300002 PM 20860673 ER PT J AU Mueller, MR Smith, PJ Baumbach, JP Palumbo, JP Meek, JI Gershman, K Vandermeer, M Thomas, AR Long, CE Belflower, R Spina, NL Martin, KG Lynfield, R Openo, KP Kirley, PD Pasutti, LE Barnes, BG Schaffner, W Kamimoto, L AF Mueller, Mark R. Smith, Philip J. Baumbach, Joan P. Palumbo, John P. Meek, James I. Gershman, Ken Vandermeer, Meredith Thomas, Ann R. Long, Christine E. Belflower, Ruth Spina, Nancy L. Martin, Karen G. Lynfield, Ruth Openo, Kyle P. Kirley, Pamala D. Pasutti, Lauren E. Barnes, Brenda G. Schaffner, William Kamimoto, Laurie TI Influenza Testing and Antiviral Prescribing Practices Among Emergency Department Clinicians in 9 States During the 2006 to 2007 Influenza Season SO ANNALS OF EMERGENCY MEDICINE LA English DT Article ID RAPID DIAGNOSIS; UNITED-STATES; COST-EFFECTIVENESS; FEBRILE INFANTS; YOUNG-CHILDREN; HEALTHY-ADULTS; OLDER-ADULTS; MANAGEMENT; IMPACT; HOSPITALIZATIONS AB Study objective: Influenza causes significant widespread illness each year. Emergency department (ED) clinicians are often first-line providers to evaluate and make treatment decisions for patients presenting with influenza. We sought to better understand ED clinician testing and treatment practices in the Emerging Infections Program Network, a federal, state, and academic collaboration that conducts active surveillance for influenza-associated hospitalizations. Methods: During 2007, a survey was administered to ED clinicians who worked in Emerging Infections Program catchment area hospitals' EDs. The survey encompassed the role of the clinician, years since completing clinical training, hospital type, influenza testing practices, and use of antiviral medications during the 2006 to 2007 influenza season. We examined factors associated with influenza testing and antiviral use. Results: A total of 1,055 ED clinicians from 123 hospitals responded to the survey. A majority of respondents (85.3%; n=887) reported they had tested their patients for influenza during the 2006 to 2007 influenza season (Emerging Infections Program site range: 59.3 to 100%; P<.0001). When asked about antiviral medications, 55.7% (n=576) of respondents stated they had prescribed antiviral medications to some of their patients in 2006 to 2007 (Emerging Infections Program site range 32.9% to 80.3%; P<.0001). A positive association between influenza testing and prescribing antiviral medications was observed. Additionally, the type of hospital, location in which an ED clinician worked, and the number of years since medical training were associated with prescribing antiviral influenza medications. Conclusion: There is much heterogeneity in clinician-initiated influenza testing and treatment practices. Additional exploration of the role of hospital testing and treatment policies, clinicians' perception of influenza disease, and methods for educating clinicians about new recommendations is needed to better understand ED clinician testing and treatment decisions, especially in an environment of rapidly changing influenza clinical guidelines. Until influenza testing and treatment guidelines are better promulgated, clinicians may continue to test and treat influenza with inconsistency. [Ann Emerg Med. 2010;55:32-39.] C1 [Mueller, Mark R.; Baumbach, Joan P.] New Mexico Dept Hlth, Santa Fe, NM USA. [Palumbo, John P.; Meek, James I.] Yale Univ, Connecticut Emerging Infect Program, New Haven, CT USA. [Gershman, Ken] Colorado Dept Publ Hlth & Environm, Denver, CO USA. [Vandermeer, Meredith; Thomas, Ann R.] Oregon Publ Hlth Div, Portland, OR USA. [Long, Christine E.; Belflower, Ruth] Univ Rochester, Emerging Infect Program, Rochester, NY USA. [Spina, Nancy L.] New York State Dept Hlth, Emerging Infect Program, Albany, NY USA. [Martin, Karen G.; Lynfield, Ruth] Minnesota Dept Hlth, St Paul, MN USA. [Openo, Kyle P.] Emory Univ, Sch Med, Georgia Emerging Infect Program, Atlanta, GA 30322 USA. [Openo, Kyle P.] Atlanta Vet Affairs Med Ctr, Atlanta, GA USA. [Kirley, Pamala D.; Pasutti, Lauren E.] Calif Emerging Infect Program, Oakland, CA USA. [Barnes, Brenda G.; Schaffner, William] Tennessee Dept Hlth, Nashville, TN USA. [Smith, Philip J.] Ctr Dis Control & Prevent, Immunizat Serv Div, Atlanta, GA USA. [Kamimoto, Laurie] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. RP Kamimoto, L (reprint author), CDC, Influenza Div, 1600 Clifton Rd,MS A-32, Atlanta, GA 30333 USA. EM lkamimoto@cdc.gov NR 39 TC 8 Z9 8 U1 0 U2 0 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-0644 J9 ANN EMERG MED JI Ann. Emerg. Med. PD JAN PY 2010 VL 55 IS 1 BP 32 EP 39 DI 10.1016/j.annemergmed.2009.09.019 PG 8 WC Emergency Medicine SC Emergency Medicine GA 544TD UT WOS:000273681300009 PM 20116012 ER PT J AU Miller, TL Mcnabb, SJN Hilsenrath, P Pasipanodya, J Drewyer, G Weis, SE AF Miller, Thaddeus L. Mcnabb, Scott J. N. Hilsenrath, Peter Pasipanodya, Jotam Drewyer, Gerry Weis, Stephen E. TI The Societal Cost of Tuberculosis: Tarrant County, Texas, 2002 SO ANNALS OF EPIDEMIOLOGY LA English DT Article DE Tuberculosis; Cost of illness; Economics ID WILLINGNESS-TO-PAY; NEW-YORK-CITY; HEALTH-CARE; UNITED-STATES; CONCEPTUAL-FRAMEWORK; EPIDEMIC; MEDICINE; LESSONS; SECTOR; RECOMMENDATIONS AB PURPOSE: Cost analyses of tuberculosis (TB) in the United States have not included elements that may be prevented if TB were prevented, such as losses associated with TB-related disability, personal and other costs to society. Unmeasured TB costs lead to underestimates of the benefit of prevention and create conditions that could result in a resurgence of TB. We gathered data from Tarrant County, Texas, for 2002, to estimate the societal cost due to TB. METHODS: We estimated societal costs due to the presence or suspicion of TB using known variable and fixed costs incurred to all parties. These include costs for infrastructure; diagnostics and surveillance; inpatient and outpatient treatment of active, suspected, and latent TB infection (LTBI); epidemiologic activities; personal costs borne by patients and by others for lost time, disability, and death; and the cost of secondary transmission. A discount rate of 3% was used. RESULTS: During 2002, 108 TB cases were confirmed in Tarrant County, costing an estimated $40,574,953. The average societal cost per TB illness was $ 376,255. Secondary transmission created 47% and pulmonary impairment after TB created 35.4% of the total societal cost per illness. CONCLUSIONS: Prior estimates have concluded that treatment costs constitute most (86%) TB-related expenditures. From a societal perspective treatment and other direct costs account for little (3.3%) of the full burden. These data predict that preventing infection through earlier TB diagnosis and treatment of LTBI and expanding treatment of LTBI may be the most feasible strategies to reduce the cost of TB. Ann Epidemiol 2010;20:1-7. (C) 2010 Elsevier Inc. All rights reserved. C1 [Miller, Thaddeus L.; Pasipanodya, Jotam; Weis, Stephen E.] Univ N Texas, Hlth Sci Ctr Ft Worth, Sch Publ Hlth, Ft Worth, TX 76107 USA. [Miller, Thaddeus L.; Pasipanodya, Jotam; Weis, Stephen E.] Univ N Texas, Hlth Sci Ctr Ft Worth, Dept Med, Ft Worth, TX 76107 USA. [Mcnabb, Scott J. N.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Hilsenrath, Peter] Univ Pacific, Eberhardt Sch Business, Stockton, CA 95211 USA. [Hilsenrath, Peter] Univ Pacific, Thomas J Long Sch Pharm, Stockton, CA 95211 USA. [Drewyer, Gerry] Tarrant Cty Publ Hlth Dept, Ft Worth, TX USA. RP Miller, TL (reprint author), Univ N Texas, Hlth Sci Ctr Ft Worth, Sch Publ Hlth, 1101 S Main St, Ft Worth, TX 76107 USA. EM thmiller@hsc.unt.edu FU Centers for Disease Control and Prevention and its Tuberculosis Epidemiologic Studies Consortium FX This project was funded and otherwise supported by the Centers for Disease Control and Prevention and its Tuberculosis Epidemiologic Studies Consortium. NR 54 TC 10 Z9 10 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1047-2797 J9 ANN EPIDEMIOL JI Ann. Epidemiol. PD JAN PY 2010 VL 20 IS 1 BP 1 EP 7 DI 10.1016/j.annepidem.2009.09.004 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 574NS UT WOS:000275997600001 PM 20006270 ER PT J AU Leiss, JK Giles, D Sullivan, KM Mathews, R Sentelle, G Tomashek, KM AF Leiss, Jack K. Giles, Denise Sullivan, Kristin M. Mathews, Rahel Sentelle, Glenda Tomashek, Kay M. TI US Maternally Linked Birth Records May Be Biased for Hispanics and Other Population Groups SO ANNALS OF EPIDEMIOLOGY LA English DT Article DE Bias (epidemiologic); Birth certificates; Epidemiologic methods; Medical record linkage; Validation studies ID LINKING VITAL RECORDS; PRETERM BIRTH; UNITED-STATES; REPRODUCTIVE HISTORIES; CHANGING PATERNITY; PREGNANCY OUTCOMES; WESTERN-AUSTRALIA; INFANT-MORTALITY; NORTH-CAROLINA; RISK AB PURPOSE: We sought to advance understanding of linkage error in U.S. maternally linked datasets and how the error might affect results of studies based on the linked data. METHODS: North Carolina birth and fetal death records for 1988 1997 were maternally linked (n = 1,030,029). The maternal set probability, defined as the probability that all records assigned to the same maternal set do in fact represent events to the same woman, was used to assess differential maternal linkage error across race/ethnic groups. RESULTS: Maternal set probabilities were lower for records specifying Asian or Hispanic race/ethnicity, suggesting greater maternal linkage error for these sets. The lower probabilities for Hispanics were concentrated in women of Mexican origin who were not born in the United States. CONCLUSIONS: Differential linkage error may be a source of bias in studies that use U.S. maternally linked datasets to make comparisons between Hispanics and other groups or among Hispanic subgroups. Methods to quantify and adjust for this potential bias are needed. Ann Epidemiol 2010;20:23-31. (C) 2010 Elsevier Inc. All rights reserved. C1 [Leiss, Jack K.; Sullivan, Kristin M.; Mathews, Rahel] Constella Grp, Ctr Hlth Res, Durham, NC USA. [Giles, Denise; Sentelle, Glenda; Tomashek, Kay M.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA. RP Leiss, JK (reprint author), Cedar Grove Inst Sustainable Communities, Epidemiol Res Program, 6919 Lee St, Mebane, NC 27302 USA. EM jackl@mcmoss.org FU Centers for Disease Control and Prevention [GS-10E-0351 K]; National Institute of Child Health and Human Development [HD35785]; National Cancer Institute [CA88757]; National Center for Health Statistics [UR6/CCU417428] FX This research was supported in part by contract GS-10E-0351 K from the Centers for Disease Control and Prevention and grants HD35785 from the National Institute of Child Health and Human Development, CA88757 from the National Cancer Institute, and UR6/CCU417428 from the National Center for Health Statistics. NR 39 TC 3 Z9 3 U1 2 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1047-2797 J9 ANN EPIDEMIOL JI Ann. Epidemiol. PD JAN PY 2010 VL 20 IS 1 BP 23 EP 31 DI 10.1016/j.annepidem.2009.09.003 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA 574NS UT WOS:000275997600004 PM 20006273 ER PT J AU Freedman, DS Katzmarzyk, PT Dietz, WH Srinivasan, SR Berenson, GS AF Freedman, David S. Katzmarzyk, Peter T. Dietz, William H. Srinivasan, Sathanur R. Berenson, Gerald S. TI The relation of BMI and skinfold thicknesses to risk factors among young and middle-aged adults: The Bogalusa Heart Study SO ANNALS OF HUMAN BIOLOGY LA English DT Article DE BMI; skinfolds; risk factors; lipids; blood pressure; insulin ID BODY-MASS INDEX; CARDIOVASCULAR-DISEASE RISK; FAT-FREE MASS; ALL-CAUSE MORTALITY; METABOLIC RISK; FOLLOW-UP; BIOELECTRICAL-IMPEDANCE; ANTHROPOMETRIC MEASUREMENTS; MEASUREMENT ERROR; BLOOD-PRESSURE AB Objective: Although adverse levels of cardiovascular disease risk factors are related to skinfold thicknesses and BMI among adults, the relative strengths of these associations are unknown. We examine whether the triceps and subscapular skinfold thicknesses are more strongly related to adult levels of lipids, fasting insulin and blood pressure than BMI. Design and subjects: Cross-sectional (n = 3318) and longitudinal (n = 1593) analyses of 18- to 44-year-olds examined in the Bogalusa Heart Study from 1983 to 2002. Principal components analysis was used to derive a summary index of the six examined risk factors (triglycerides, low-and high-density lipoprotein cholesterol, insulin, and systolic and diastolic blood pressures). Results: The magnitudes of the differences were generally small, but all comparisons indicated that BMI was at least as strongly related to adverse risk factor levels as was the sum of subscapular and triceps skinfold thicknesses (SF sum). For example, adjusted cross-sectional associations with the risk factor summary were r = 0.55 (BMI) and r = 0.49 (SF sum), p < 0.001 for difference between correlations. Similar differences were seen in longitudinal analyses, with changes in the risk factor summary being more strongly associated with changes in BMI (r = 0.50) than with changes in the SF sum (r = 0.38). Conclusion: BMI appears to be at least as accurate as skinfold thicknesses in identifying metabolic risk among adults. The advantages of BMI should be considered in the design and interpretation of clinical and epidemiologic studies. C1 [Freedman, David S.; Dietz, William H.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA USA. [Katzmarzyk, Peter T.] Pennington Biomed Res Ctr, Baton Rouge, LA USA. [Srinivasan, Sathanur R.; Berenson, Gerald S.] Tulane Univ, Sch Publ Hlth & Trop Med, Tulane Ctr Cardiovasc Hlth, New Orleans, LA USA. RP Freedman, DS (reprint author), CDC K-26,4770 Buford Highway, Atlanta, GA 30341 USA. EM DXF1@CDC.gov OI Katzmarzyk, Peter/0000-0002-9280-6022 FU National Institutes of Aging [AG-16 592] FX Supported by National Institutes of Aging Grant AG-16 592. The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper. NR 51 TC 12 Z9 12 U1 0 U2 2 PU INFORMA HEALTHCARE PI LONDON PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND SN 0301-4460 J9 ANN HUM BIOL JI Ann. Hum. Biol. PY 2010 VL 37 IS 6 BP 726 EP 737 DI 10.3109/03014461003641849 PG 12 WC Anthropology; Biology; Public, Environmental & Occupational Health SC Anthropology; Life Sciences & Biomedicine - Other Topics; Public, Environmental & Occupational Health GA 669TD UT WOS:000283372200001 PM 20450389 ER PT S AU Sambhara, S Poland, GA AF Sambhara, Suryaprakash Poland, Gregory A. TI H5N1 Avian Influenza: Preventive and Therapeutic Strategies Against a Pandemic SO ANNUAL REVIEW OF MEDICINE SE Annual Review of Medicine LA English DT Review; Book Chapter DE adjuvants; oil-in-water emulsion; antiviral drugs; human monoclonal antibodies; pathogen sensors ID CROSS-REACTIVE IMMUNITY; TO-PERSON TRANSMISSION; A H5N1; MONOCLONAL-ANTIBODY; WHOLE-VIRUS; RECEPTOR SPECIFICITY; VACCINE DEVELOPMENT; RESPIRATORY-TRACT; RANDOMIZED-TRIAL; ANTIGENIC DRIFT AB Avian influenza H5N1 viruses that have spread to a number of countries in Asia, the Middle East, and Africa have the potential to cause a pandemic. The most effective public health intervention strategy is to combine preventive vaccination with nonpharmaceutical intervention strategies and enhanced surveillance activities. H5N1 vaccines are poorly immunogenic even at high doses; an adjuvant is needed for enhancement of immunogenicity and for dose-sparing. Lack of effective, yet safe, adjuvants is the limiting factor for candidate vaccines that utilize egg-dependent or egg-independent manufacturing technologies. Hence, developing novel adjuvants is crucial for pandemic influenza vaccine development. Although the use of antiviral drugs is also an important public health countermeasure for preventing and treating influenza, the emergence of drug-resistant strains of avian H5N1 viruses underscores the need to develop not only new drugs but other novel preventive and therapeutic strategies such as vaccines. C1 [Sambhara, Suryaprakash] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA. [Poland, Gregory A.] Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA. RP Sambhara, S (reprint author), Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA. EM ssambhara@cdc.gov; poland.gregory@mayo.edu NR 77 TC 28 Z9 30 U1 0 U2 7 PU ANNUAL REVIEWS PI PALO ALTO PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0139 USA SN 0066-4219 BN 978-0-8243-0561-1 J9 ANNU REV MED JI Annu. Rev. Med. PY 2010 VL 61 BP 187 EP 198 DI 10.1146/annurev.med.050908.132031 PG 12 WC Medicine, General & Internal SC General & Internal Medicine GA 559WB UT WOS:000274857600013 PM 20059335 ER PT S AU Valdez, R Yoon, PW Qureshi, N Green, RF Khoury, MJ AF Valdez, Rodolfo Yoon, Paula W. Qureshi, Nadeem Green, Ridgely Fisk Khoury, Muin J. BE Fielding, JE Brownson, RC Green, LW TI Family History in Public Health Practice: A Genomic Tool for Disease Prevention and Health Promotion SO ANNUAL REVIEW OF PUBLIC HEALTH, VOL 31 SE Annual Review of Public Health LA English DT Review; Book Chapter DE risk factors; public health tool; screening; risk assessment; health promotion; chronic disease; cancer; cardiovascular disease; diabetes ID CORONARY-HEART-DISEASE; RANDOMIZED CONTROLLED-TRIAL; GENETIC RISK-ASSESSMENT; MIDDLE-AGED ADULTS; PARENTAL CARDIOVASCULAR-DISEASE; AFFECTED 1ST-DEGREE RELATIVES; COMPUTER DECISION-SUPPORT; PEDIATRIC PRIMARY-CARE; BREAST-CANCER; QUEBEC FAMILY AB Family history is a risk factor for many chronic diseases, including cancer, cardiovascular disease, and diabetes. Professional guidelines usually include family history to assess health risk, initiate interventions, and motivate behavioral changes. The advantages of family history over other genomic tools include a lower cost, greater acceptability, and a reflection of shared genetic and environmental factors. However, the utility of family history in public health has been poorly explored. To establish family history as a public health tool, it needs to be evaluated within the ACCE framework (analytical validity; clinical validity; clinical utility; and ethical, legal, and social issues). Currently, private and I public organizations are developing tools to collect standardized family histories of many diseases. Their goal is to create family history tools that have decision support capabilities and are compatible with electronic health records. These advances will help realize the potential of family history as a public health tool. C1 [Valdez, Rodolfo; Khoury, Muin J.] Ctr Dis Control & Prevent, Off Publ Hlth Genom, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Yoon, Paula W.] Ctr Dis Control & Prevent, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Qureshi, Nadeem] Univ Nottingham, Div Primary Care, Nottingham, England. [Green, Ridgely Fisk] Ctr Dis Control & Prevent, Div Birth Defects & Dev Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. RP Valdez, R (reprint author), Ctr Dis Control & Prevent, Off Publ Hlth Genom, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM rvaldez@cdc.gov; pyoon@cdc.gov; nadeem.qureshi@nottingham.ac.uk; rfiskgreen@cdc.gov; mkhoury@cdc.gov OI Qureshi, Nadeem/0000-0003-4909-0644 NR 111 TC 100 Z9 104 U1 1 U2 18 PU ANNUAL REVIEWS PI PALO ALTO PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA SN 0163-7525 BN 978-0-8243-2731-6 J9 ANNU REV PUBL HEALTH JI Annu. Rev. Public Health PY 2010 VL 31 BP 69 EP 87 DI 10.1146/annurev.publhealth.012809.103621 PG 19 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA BOX22 UT WOS:000277908800006 PM 20070206 ER PT S AU Sleet, DA Ballesteros, MF Borse, NN AF Sleet, David A. Ballesteros, Michael F. Borse, Nagesh N. BE Fielding, JE Brownson, RC Green, LW TI A Review of Unintentional Injuries in Adolescents SO ANNUAL REVIEW OF PUBLIC HEALTH, VOL 31 SE Annual Review of Public Health LA English DT Review; Book Chapter DE unintentional injury; trauma; alcohol; prevention; adolescents ID BICYCLE SAFETY HELMETS; UNITED-STATES; PEDIATRIC INJURIES; NONFATAL INJURIES; SCHOOL-STUDENTS; HEAD-INJURIES; US CHILDREN; ALCOHOL; POPULATION; DEATHS AB Unintentional injuries are the largest source of premature morbidity and mortality and the leading cause of death among adolescents 10-19 years of age. Fatal injury rates of males are twice those of females, and racial disparities in injury are pronounced. Transportation is the largest source of these injuries, principally as drivers and passengers, but also as cyclists and pedestrians. Other major causes involve drowning, poisonings, fires, sports and recreation, and work-related injuries. Implementing known and effective prevention strategies such as using seat belts and bicycle and motorcycle helmets, installing residential smoke alarms, reducing misuse of alcohol, strengthening graduated driver licensing laws, promoting policy change, using safety equipment in sports and leisure, and protecting adolescents at work will all contribute to reducing injuries. The frequency, severity, potential for death and disability, and costs of these injuries, together with the high success potential of prevention strategies, make injury prevention a key public health goal to improve adolescent health in the future. C1 [Sleet, David A.; Ballesteros, Michael F.; Borse, Nagesh N.] Ctr Dis Control & Prevent, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA. [Borse, Nagesh N.] Ctr Dis Control & Prevent, Off Workforce & Career Dev, Atlanta, GA 30341 USA. RP Sleet, DA (reprint author), Ctr Dis Control & Prevent, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA. EM dds6@cdc.gov RI Borse, Nagesh/A-9276-2009 NR 113 TC 29 Z9 32 U1 4 U2 26 PU ANNUAL REVIEWS PI PALO ALTO PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA SN 0163-7525 BN 978-0-8243-2731-6 J9 ANNU REV PUBL HEALTH JI Annu. Rev. Public Health PY 2010 VL 31 BP 195 EP 212 DI 10.1146/annurev.publhealth.012809.103616 PG 18 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA BOX22 UT WOS:000277908800014 PM 20235851 ER PT S AU Leviton, LC Khan, LK Rog, D Dawkins, N Cotton, D AF Leviton, Laura C. Khan, Laura Kettel Rog, Debra Dawkins, Nicola Cotton, David BE Fielding, JE Brownson, RC Green, LW TI Evaluability Assessment to Improve Public Health Policies, Programs, and Practices SO ANNUAL REVIEW OF PUBLIC HEALTH, VOL 31 SE Annual Review of Public Health LA English DT Review; Book Chapter DE exploratory evaluation; logic model; performance measurement; public health programs; stakeholders; theory of change AB Evaluability assessment, also commonly known as exploratory evaluation, has assisted the field of public health to improve programs and to develop a pragmatic, practice-based research agenda. Evaluability assessment was originally developed as a low-cost pre-evaluation activity to prepare better for conventional evaluations of programs, practices, and some policies. For public health programs, however, it serves several other important purposes: (a) giving program staff rapid, constructive feedback about program operations; (b) assisting the core public health planning and assurance functions by helping to develop realistic objectives and providing low-cost, rapid feedback on implementation; (c) navigating federal performance measurement requirements; (d) translating research into practice by examining the feasibility, acceptability, and adaptation of evidence-based practices in new settings and populations; and (e) translating practice into research by identifying promising new approaches to achieve public health goals. C1 [Leviton, Laura C.] Robert Wood Johnson Fdn, Princeton, NJ 08543 USA. [Khan, Laura Kettel] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA 30341 USA. [Rog, Debra] Rockville Inst, Rockville, MD 20850 USA. [Rog, Debra] Westat Corp, Rockville, MD 20850 USA. [Dawkins, Nicola; Cotton, David] ICF Macro, Atlanta, GA 30329 USA. RP Leviton, LC (reprint author), Robert Wood Johnson Fdn, Princeton, NJ 08543 USA. EM llevito@rwjf.org; ldk7@cdc.gov; DebraRog@RockvilleInstitute.org; nicola.u.dawkins@orcmacro.com; DCotton@orcmacro.com NR 50 TC 37 Z9 39 U1 1 U2 11 PU ANNUAL REVIEWS PI PALO ALTO PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA SN 0163-7525 BN 978-0-8243-2731-6 J9 ANNU REV PUBL HEALTH JI Annu. Rev. Public Health PY 2010 VL 31 BP 213 EP 233 DI 10.1146/annurev.publhealth.012809.103625 PG 21 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA BOX22 UT WOS:000277908800015 PM 20235852 ER PT S AU Koo, D Miner, K AF Koo, Denise Miner, Kathleen BE Fielding, JE Brownson, RC Green, LW TI Outcome-Based Workforce Development and Education in Public Health SO ANNUAL REVIEW OF PUBLIC HEALTH, VOL 31 SE Annual Review of Public Health LA English DT Review; Book Chapter DE competencies; Dreyfus model; adult learning; instructional systems design ID FOR-DISEASE-CONTROL; INTELLIGENCE SERVICE; APPLIED EPIDEMIOLOGY; MEDICAL-EDUCATION; TRAINING NEEDS; COMPETENCES; PREVENTION; MODEL; PREPAREDNESS; PERSPECTIVE AB The broad scope of the public health mission leads to an increasingly diverse workforce. Given the range of feeder disciplines and the reality that much of the workforce does not have formal training in public health science and practice, a pressing need exists for training and education throughout the workforce. Just as we in public health take a rigorous approach to our science, so too should we take a rigorous, evidence-driven approach to workforce development. In this review, we recommend a framework for workforce education in public health, integrating three critical conceptual approaches: (a) adult learning theory; (b) competency-based education; and (c) the expanded Dreyfus model in public health, an addition to the Dreyfus model of professional skills progression. We illustrate the application of this framework in practice, using the field of applied epidemiology. This framework provides a context for designing and developing high-quality, outcome-based workforce development efforts and evaluating their impact, with implications for academic and public health practice efforts to educate the public health workforce. C1 [Koo, Denise] Ctr Dis Control & Prevent, US Publ Hlth Serv, Off Workforce & Career Dev, Atlanta, GA 30333 USA. [Miner, Kathleen] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. RP Koo, D (reprint author), Ctr Dis Control & Prevent, US Publ Hlth Serv, Off Workforce & Career Dev, Atlanta, GA 30333 USA. EM dkoo@cdc.gov NR 83 TC 31 Z9 32 U1 0 U2 10 PU ANNUAL REVIEWS PI PALO ALTO PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA SN 0163-7525 BN 978-0-8243-2731-6 J9 ANNU REV PUBL HEALTH JI Annu. Rev. Public Health PY 2010 VL 31 BP 253 EP 269 DI 10.1146/annurev.publhealth.012809.103705 PG 17 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA BOX22 UT WOS:000277908800017 PM 20001820 ER PT S AU Sondik, EJ Huang, DT Klein, RJ Satcher, D AF Sondik, Edward J. Huang, David T. Klein, Richard J. Satcher, David BE Fielding, JE Brownson, RC Green, LW TI Progress Toward the Healthy People 2010 Goals and Objectives SO ANNUAL REVIEW OF PUBLIC HEALTH, VOL 31 SE Annual Review of Public Health LA English DT Review; Book Chapter DE leading health indicators; health disparities; determinants of health AB Healthy People 2010 is a comprehensive framework for improving the health of Americans, built on the foundation of several decades of predecessor initiatives. Its two overarching goals, to "[i]ncrease the quality and years of healthy life" and "[e]liminate health disparities," subsume 28 focus areas and comprise 955 objectives and subobjectives. This review evaluates progress toward meeting the Healthy People 2010 program's challenging agenda in the context of leading health indicator (LHI) measures, developed by the Department of Health and Human Services (DHHS), augmented by additional objectives for a total of 31 measures. Our evaluation of progress includes analysis of changes in objective values, including progress toward Healthy People 2010 targets, where appropriate, and analysis of changes in disparities. The Healthy People 2010 LIE measures suggest that although some progress has been made, there is much work to be done toward the Healthy People 2010 targets and both overarching goals. C1 [Sondik, Edward J.; Huang, David T.; Klein, Richard J.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Satcher, David] Morehouse Sch Med, Ctr Excellence Hlth Dispar, Atlanta, GA 30310 USA. RP Sondik, EJ (reprint author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. EM esondik@cdc.gov; dhuang@cdc.gov; rklein@cdc.gov; dsatcher@msm.edu RI Huang, David/A-5358-2009 OI Huang, David/0000-0002-8860-7469 FU NIMHD NIH HHS [U54 MD008173] NR 9 TC 38 Z9 38 U1 1 U2 7 PU ANNUAL REVIEWS PI PALO ALTO PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA SN 0163-7525 BN 978-0-8243-2731-6 J9 ANNU REV PUBL HEALTH JI Annu. Rev. Public Health PY 2010 VL 31 BP 271 EP 281 DI 10.1146/annurev.publhealth.012809.103613 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA BOX22 UT WOS:000277908800018 PM 20070194 ER PT S AU Van Wave, TW Scutchfield, FD Honore, PA AF Van Wave, Timothy W. Scutchfield, F. Douglas Honore, Peggy A. BE Fielding, JE Brownson, RC Green, LW TI Recent Advances in Public Health Systems Research in the United States SO ANNUAL REVIEW OF PUBLIC HEALTH, VOL 31 SE Annual Review of Public Health LA English DT Review; Book Chapter DE infrastructure; health reform; network analysis; capacity building; quality improvement ID EVIDENCE-BASED INTERVENTIONS; PROMOTE PHYSICAL-ACTIVITY; QUALITY IMPROVEMENT; NETWORK ANALYSIS; ORGANIZATIONAL CAPACITY; PERFORMANCE STANDARDS; WORKFORCE DEVELOPMENT; TOBACCO CONTROL; INFRASTRUCTURE; ACCREDITATION AB Recognizing the public's health is the outcome of dynamic, adaptive, and complex systems of agencies; infrastructure, relationships, and interactions that dictate how to improve health outcomes; and reducing health risks in a population is based on systems thinking and evidence. New methods such as network analysis and public health practice based research networks demonstrate the potential for new insight to our understanding of how systems and infrastructure influence population health. We examine advances in public health systems research since 1988 and discuss the relevance of this type of research to public health practice. We assess the current infrastructure for conducting public health systems research, suggest how the research infrastructure can be improved, and conclude with a discussion of how health reform in the United States will require research focused on understanding the adaptive complexity inherent in public health and health care systems and strengthening the systems research infrastructure. C1 [Van Wave, Timothy W.] Ctr Dis Control & Prevent, Off Chief Publ Hlth Practice, Atlanta, GA 30333 USA. [Scutchfield, F. Douglas] Univ Kentucky, Coll Publ Hlth, Dept Hlth Serv Res & Policy, Lexington, KY 40536 USA. [Honore, Peggy A.] Univ So Mississippi, Coll Hlth, N Potomac, MD 20850 USA. RP Van Wave, TW (reprint author), Ctr Dis Control & Prevent, Off Chief Publ Hlth Practice, Atlanta, GA 30333 USA. EM tbv5@cdc.gov; scutch@email.uky.edu; peggy.honore@usm.edu RI Scutchfield, F. Douglas/F-9959-2013 NR 100 TC 26 Z9 26 U1 2 U2 20 PU ANNUAL REVIEWS PI PALO ALTO PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA SN 0163-7525 BN 978-0-8243-2731-6 J9 ANNU REV PUBL HEALTH JI Annu. Rev. Public Health PY 2010 VL 31 BP 283 EP 295 DI 10.1146/annurev.publhealth.012809.103550 PG 13 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA BOX22 UT WOS:000277908800019 PM 20192815 ER PT J AU Fu, WL Forster, T Mayer, O Curtin, JJ Lehman, SM Donlan, RM AF Fu, Weiling Forster, Terri Mayer, Oren Curtin, John J. Lehman, Susan M. Donlan, Rodney M. TI Bacteriophage Cocktail for the Prevention of Biofilm Formation by Pseudomonas aeruginosa on Catheters in an In Vitro Model System SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID ESCHERICHIA-COLI; STAPHYLOCOCCUS-EPIDERMIDIS; PHENOTYPIC VARIATION; PLANKTONIC CELLS; CYSTIC-FIBROSIS; PHAGE; RESISTANCE; SUSCEPTIBILITY; INFECTIONS; MECHANISMS AB Microorganisms develop biofilms on indwelling medical devices and are associated with device-related infections, resulting in substantial morbidity and mortality. This study investigated the effect of pretreating hydrogel-coated catheters with Pseudomonas aeruginosa bacteriophages on biofilm formation by P. aeruginosa in an in vitro model. Hydrogel-coated catheters were exposed to a 10 log(10) PFU ml(-1) lysate of P. aeruginosa phage M4 for 2 h at 37 degrees C prior to bacterial inoculation. The mean viable biofilm count on untreated catheters was 6.87 log(10) CFU cm(-2) after 24 h. The pretreatment of catheters with phage reduced this value to 4.03 log(10) CFU cm(-2) (P < 0.001). Phage treatment immediately following bacterial inoculation also reduced biofilm viable counts (4.37 log(10) CFU cm(-2) reduction; P < 0.001). The regrowth of biofilms on phage-treated catheters occurred between 24 and 48 h, but supplemental treatment with phage at 24 h significantly reduced biofilm regrowth (P < 0.001). Biofilm isolates resistant to phage M4 were recovered from catheters pretreated with phage. The phage susceptibility profiles of these isolates were used to guide the development of a five-phage cocktail from a larger library of P. aeruginosa phages. The pretreatment of catheters with this cocktail reduced the 48-h mean biofilm cell density by 99.9% (from 7.13 to 4.13 log(10) CFU cm(-2); P < 0.001), but fewer biofilm isolates were resistant to these phages. These results suggest the potential of applying phages, especially phage cocktails, to the surfaces of indwelling medical devices for mitigating biofilm formation by clinically relevant bacteria. C1 [Fu, Weiling; Forster, Terri; Mayer, Oren; Curtin, John J.; Lehman, Susan M.; Donlan, Rodney M.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30333 USA. RP Donlan, RM (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Mail Stop C-16,1600 Clifton Rd, Atlanta, GA 30333 USA. EM rld8@cdc.gov FU Association of Public Health Laboratories (APHL); Centers for Disease Control and Prevention; American Society for Microbiology/Coordinating Centers for Disease Control and Prevention Postdoctoral Fellowship FX We acknowledge Janice Carr for scanning electron micrographs. We also thank Ronny Baxter and Michele Davis of C. R. Bard for providing Foley catheters. We acknowledge Jay Ash and the Snapfinger Creek Water Quality Laboratory staff for assistance in the collection of sewage samples and Tyrone Pitt and Mark Granner (Health Protection Agency, United Kingdom) for phage and bacterial stocks.; This research was supported in part by the appointment of W. Fu and O. Mayer to the Emerging Infectious Diseases Laboratory Fellowship Program administered by the Association of Public Health Laboratories (APHL) and funded by the Centers for Disease Control and Prevention. S. M. Lehman is supported by an American Society for Microbiology/Coordinating Centers for Disease Control and Prevention Postdoctoral Fellowship.; The use of trade names and commercial sources is for identification only and does not imply endorsement by the Public Health Service or the U. S. Department of Health and Human Services. NR 45 TC 114 Z9 125 U1 8 U2 38 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD JAN PY 2010 VL 54 IS 1 BP 397 EP 404 DI 10.1128/AAC.00669-09 PG 8 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA 534XQ UT WOS:000272931200052 PM 19822702 ER PT S AU Moore, MR Whitney, CG AF Moore, Matthew R. Whitney, Cynthia G. BE Weber, JT TI Antibiotic Resistance and Community-Acquired Pneumonia during an Influenza Pandemic SO ANTIMICROBIAL RESISTANCE: BEYOND THE BREAKPOINT SE Issues in Infectious Diseases LA English DT Article; Book Chapter ID INVASIVE PNEUMOCOCCAL DISEASE; RESPIRATORY-TRACT INFECTION; IMMUNODEFICIENCY-VIRUS-INFECTION; STAPHYLOCOCCUS-AUREUS PNEUMONIA; STREPTOCOCCUS-PNEUMONIAE; UNITED-STATES; NECROTIZING PNEUMONIA; BACTERIAL PNEUMONIA; ASIAN INFLUENZA; REQUIRING HOSPITALIZATION AB The threat of an influenza pandemic in 2009 stimulated intense interest in pandemic preparedness, including mobilization of local, state, federal and international resources. There were also discussions on non-pharmacologic approaches to containment and implementation of programs to stockpile neuraminidase inhibitors and vaccines against potential strains of pandemic influenza. All of these activities are important components of preparedness in the United States. However, literature published after each of the 20th century influenza pandemics shows that bacterial pneumonia following influenza infection was a major cause of morbidity and mortality. Some key differences between those pandemics and the next one include characteristics of the individual pandemic strains, the availability of antiviral agents, the availability of antibiotics and the prevalence of associated antimicrobial resistance among common bacterial etiologies of community-acquired pneumonia, and the availability of a protein-conjugate vaccine for Haemophilus influenzae type B disease and 2 vaccines that target Streptococcus pneumoniae. A key challenge posed by the next pandemic is how best to use prevention strategies and antibiotics to minimize morbidity and mortality from secondary bacterial pneumonia. Copyright (C) 2010 S. Karger AG, Basel C1 [Moore, Matthew R.; Whitney, Cynthia G.] Ctr Dis Control & Prevent, Resp Dis Branch, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Moore, MR (reprint author), Ctr Dis Control & Prevent, Resp Dis Branch, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd,MS C-23, Atlanta, GA 30333 USA. EM matt.moore@cdc.hhs.gov NR 129 TC 0 Z9 0 U1 0 U2 1 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND SN 1660-1890 BN 978-3-8055-9323-6 J9 ISSUES INFECT DIS JI Issues Infect. Dis. PY 2010 VL 6 BP 51 EP 69 PG 19 WC Infectious Diseases SC Infectious Diseases GA BOP31 UT WOS:000277209100005 ER PT S AU Churcher, TS Kaplan, RM Ardelli, BF Schwenkenbecher, JM Basanez, MG Lammie, PJ AF Churcher, Thomas S. Kaplan, Ray M. Ardelli, Bernadette F. Schwenkenbecher, Jan M. Basanez, Maria-Gloria Lammie, Patrick J. BE Weber, JT TI Mass Treatment of Parasitic Disease: Implications for the Development and Spread of Anthelmintic Resistance SO ANTIMICROBIAL RESISTANCE: BEYOND THE BREAKPOINT SE Issues in Infectious Diseases LA English DT Article; Book Chapter ID HUMAN HOOKWORM INFECTIONS; GATED CHLORIDE CHANNEL; ONCHOCERCA-VOLVULUS; DRUG-RESISTANCE; WUCHERERIA-BANCROFTI; BENZIMIDAZOLE RESISTANCE; HAEMONCHUS-CONTORTUS; GENETIC-VARIABILITY; EGG HATCH; IVERMECTIN AB There has been a dramatic increase in the use of mass drug administration to reduce the morbidity associated with helminth infections of humans, raising the likelihood that anthelmintic resistance may become a public health concern of the future. After highlighting the scope and magnitude of the chemotherapy-based helminth control programs presently in place, this chapter emphasizes the mechanisms of action of the main anthelmintic drugs in use and how resistance may develop. To date, the most established population-based mass drug administration campaigns have been against the filarial parasites which cause human onchocerciasis and lymphatic filariasis. The molecular and parasitological evidence suggesting the presence of drug resistance in human filarial parasites is reviewed and factors influencing the spread of drug resistant parasites are discussed, taking examples from veterinary helminths and the use of mathematical models. In particular, the public health impact of the development of resistance by soil-transmitted helminths, such as hookworm, is a real concern. Implications of the development of anthelmintic resistance are discussed in relation to existing control programs, emphasizing how their monitoring and evaluation is essential to prevent it becoming a major public health concern of the future. Copyright (C) 2010 S. Karger AG, Basel C1 [Churcher, Thomas S.; Basanez, Maria-Gloria] Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis Epidemiol, London W2 1PG, England. [Schwenkenbecher, Jan M.] Univ Aberdeen, Inst Biol & Environm Sci, Aberdeen AB9 1FX, Scotland. [Kaplan, Ray M.] Univ Georgia, Coll Vet Med, Dept Infect Dis, Athens, GA USA. [Lammie, Patrick J.] Ctr Dis Control & Prevent, Div Parasit Dis, Atlanta, GA USA. [Ardelli, Bernadette F.] Brandon Univ, Dept Zool, Brandon, MB R7A 6A9, Canada. RP Churcher, TS (reprint author), Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis Epidemiol, Norfolk Pl, London W2 1PG, England. EM Thomas.churcher@imperial.ac.uk NR 43 TC 4 Z9 4 U1 2 U2 6 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND SN 1660-1890 BN 978-3-8055-9323-6 J9 ISSUES INFECT DIS JI Issues Infect. Dis. PY 2010 VL 6 BP 120 EP 137 PG 18 WC Infectious Diseases SC Infectious Diseases GA BOP31 UT WOS:000277209100009 ER PT S AU Arthington-Skaggs, BA Frade, JP AF Arthington-Skaggs, Beth A. Frade, Joao Pedro BE Weber, JT TI Antifungal Drug Resistance: Clinical Importance, in vitro Detection and Implications for Prophylaxis and Treatment SO ANTIMICROBIAL RESISTANCE: BEYOND THE BREAKPOINT SE Issues in Infectious Diseases LA English DT Article; Book Chapter ID HEMATOPOIETIC STEM-CELL; LIPOSOMAL AMPHOTERICIN-B; BLOOD-STREAM INFECTIONS; SUSCEPTIBILITY TESTING SUBCOMMITTEE; RECEIVING VORICONAZOLE PROPHYLAXIS; INVASIVE FUNGAL-INFECTIONS; CANDIDA-ALBICANS; TRANSPLANT RECIPIENTS; FLUCONAZOLE RESISTANCE; SURVEILLANCE PROGRAM AB Candida species and Aspergillus species are the primary opportunistic fungal pathogens in immunocompromised patients and are associated with high morbidity and mortality. The epidemiology of invasive fungal infections is changing, challenging the therapeutic options. To date, 4 classes of antifungal drugs have been predominantly used to treat and prevent invasive fungal disease: azoles, echinocandins, flucytosine and polyenes. Large-scale surveys of in vitro antifungal drug resistance among clinical fungal pathogens have shown that emerging resistance among naturally-susceptible species is not a widespread problem; however, ongoing surveillance to detect trends in the number of infections caused by species that are intrinsically less susceptible is warranted. Antifungal prophylaxis has been shown to be effective in reducing the incidence in certain patient groups, including hematopoietic stem cell transplant recipients. Continued efforts to define specific risk factors for invasive fungal infections, implement effective prevention strategies, develop new antifungal agents, and improve the clinical utility of in vitro antifungal susceptibility testing will better position us to reduce the clinical impact of antifungal drug resistance. Copyright (C) 2010 S. Karger AG, Basel C1 [Arthington-Skaggs, Beth A.] Ctr Dis Control & Prevent, Global AIDS Program, Maputo, Mozambique. [Frade, Joao Pedro] Ctr Dis Control & Prevent, Mycot Dis Branch, Div Foodborne Bacterial & Mycot Dis, Atlanta, GA USA. RP Arthington-Skaggs, BA (reprint author), Ctr Dis Control & Prevent, Global AIDS Program, JAT Complex,Bldg 4,267 Av Zedequias Manganhela,7t, Maputo, Mozambique. EM skaggsb@mz.cdc.gov NR 98 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND SN 1660-1890 BN 978-3-8055-9323-6 J9 ISSUES INFECT DIS JI Issues Infect. Dis. PY 2010 VL 6 BP 138 EP 153 PG 16 WC Infectious Diseases SC Infectious Diseases GA BOP31 UT WOS:000277209100010 ER PT S AU Bennett, DE AF Bennett, Diane E. BE Weber, JT TI Preparing for HIV Drug Resistance in the Developing World SO ANTIMICROBIAL RESISTANCE: BEYOND THE BREAKPOINT SE Issues in Infectious Diseases LA English DT Article; Book Chapter ID RESOURCE-LIMITED SETTINGS; ACTIVE ANTIRETROVIRAL THERAPY; FIXED-DOSE COMBINATION; PUBLIC-HEALTH APPROACH; TO-CHILD TRANSMISSION; SUB-SAHARAN AFRICA; DYNAMICS IN-VIVO; INFECTED PATIENTS; POOR SETTINGS; SCALING-UP AB HIV drug resistance (HIVDR) inevitably emerges with antiretroviral treatment (ART), because HIV has a high turnover rate and mutates easily, and because ART is lifelong. Inadequate drug pressure leads to quick evolution of resistant HIV. Currently only 42% of eligible individuals in resource-limited countries are receiving ART, but plans for quick ART scale-up are progressing. Their effectiveness could be jeopardized by drug resistance if HIVDR prevention is not incorporated into scale-up plans. ART programs in resource-limited countries are as successful as those in high-income countries. Challenges will come in maintaining high success rates as ART is expanded and decentralized. Most factors associated with treatment interruption and development of resistance are programmatic: costs to the patient associated with care, transport difficulties and interruptions in drug supplies. Optimal regimens and viral load testing to support HIVDR prevention are unavailable to many patients because of their high costs to national programs, and lack of infrastructure. WHO recommends an HIV drug resistance prevention and assessment strategy, emphasizing good ART program practices, continuous drug supplies, support for access and adherence, and planning based on ART program monitoring and drug resistance. If resource-limited countries receive sufficient support and develop an infrastructure for coordinated ART delivery and evidence-based HIVDR prevention, the threat to effective treatment posed by drug resistance can be controlled. Copyright (C) 2010 S. Karger AG, Basel C1 Ctr Dis Control & Prevent, Global AIDS Program, Atlanta, GA 30329 USA. RP Bennett, DE (reprint author), Ctr Dis Control & Prevent, Global AIDS Program, Atlanta, GA 30329 USA. EM dbennett@cdc.gov NR 104 TC 1 Z9 1 U1 1 U2 1 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND SN 1660-1890 BN 978-3-8055-9323-6 J9 ISSUES INFECT DIS JI Issues Infect. Dis. PY 2010 VL 6 BP 154 EP 170 PG 17 WC Infectious Diseases SC Infectious Diseases GA BOP31 UT WOS:000277209100011 ER PT B AU Newton, PN Fernandez, FM Green, MD Primo-Carpenter, J White, NJ AF Newton, Paul N. Fernandez, Facundo M. Green, Michael D. Primo-Carpenter, Joyce White, Nicholas J. BE Sosa, AJ Byarugaba, DK AmabileCuevas, CF Hsueh, PR Kariuki, S Okeke, IN TI Counterfeit and Substandard Anti-infectives in Developing Countries SO ANTIMICROBIAL RESISTANCE IN DEVELOPING COUNTRIES LA English DT Article; Book Chapter ID ANTIMALARIAL-DRUG RESISTANCE; DESORPTION ELECTROSPRAY-IONIZATION; TRAP MASS-SPECTROMETRY; KENYAN RETAIL SECTOR; DAR-ES-SALAAM; QUALITY-CONTROL; SOUTHEAST-ASIA; ANTIMICROBIAL RESISTANCE; CHLOROQUINE RESISTANCE; BACTERIAL-RESISTANCE AB There is considerable interest in optimizing the therapy for important infections in developing countries and in making the best treatments readily available and inexpensive. There is also great concern that resistance to anti-infective drugs is worsening, putting affordable treatments at risk. We argue that an important, but usually neglected aspect of these problems is drug quality. Drugs may be of poor quality if they are counterfeit, substandard or degraded. Few objective data on the prevalence of poor-quality drugs exist but surveys suggest that an alarming proportion of antimalarials and antibiotics in much of the developing world are of poor quality. For individual patients these will increase mortality and morbidity and lead to loss of faith in medicines and health systems. Counterfeit, substandard or degraded drugs with sub-therapeutic concentrations of the active ingredient or the wrong active ingredient are likely to engender the emergence and spread of resistance to these anti-infectives. Although modelling suggests that poor-quality drug should worsen drug resistance, there is sparse evidence from the field, as there has been little research. It will be very difficult to distinguish the effects of poor-drug quality and reduced patient adherence and incorrect health worker prescribing on the spread of resistance. Strengthening drug regulatory authorities, improving quality of drug production and facilitating the availability of relatively inexpensive, good-quality anti-infectives are likely to be key factors in improving drug quality. C1 [Newton, Paul N.; White, Nicholas J.] Mahosot Hosp, Microbiol Lab, Wellcome Trust Mahosot Hosp, Oxford Trop Med Res Collaborat, Vientiane, Lao Pdr, England. [Newton, Paul N.; White, Nicholas J.] Univ Oxford, Churchill Hosp, Ctr Trop Med, Oxford OX1 2JD, England. [Fernandez, Facundo M.] Georgia Inst Technol, Sch Chem & Biochem, Atlanta, GA 30332 USA. [Green, Michael D.] Ctr Dis Control & Prevent, Div Parasit Dis, Atlanta, GA USA. [Primo-Carpenter, Joyce] US Pharmacopeia, Drug Qual & Informat Program, Rockville, MD USA. [White, Nicholas J.] Mahidol Univ, Fac Trop Med, Bangkok, Thailand. RP Newton, PN (reprint author), Mahosot Hosp, Microbiol Lab, Wellcome Trust Mahosot Hosp, Oxford Trop Med Res Collaborat, Vientiane, Lao Pdr, England. EM paul@tropmedres.ac; facundo.fernandez@chemistry.gatech.edu; mgreen@cdc.gov; joypcar@yahoo.com; nickw@tropmedres.ac RI White, Nicholas/I-4629-2012 NR 145 TC 8 Z9 8 U1 0 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES BN 978-0-387-89369-3 PY 2010 BP 413 EP 443 DI 10.1007/978-0-387-89370-9_24 D2 10.1007/978-0-387-89370-9 PG 31 WC Public, Environmental & Occupational Health; Infectious Diseases; Microbiology SC Public, Environmental & Occupational Health; Infectious Diseases; Microbiology GA BLY69 UT WOS:000271458500024 ER PT J AU Teo, CG Locarnini, SA AF Teo, Chong-Gee Locarnini, Stephen A. TI Potential threat of drug-resistant and vaccine-escape HBV mutants to public health SO ANTIVIRAL THERAPY LA English DT Editorial Material ID HEPATITIS-B-VIRUS; SURFACE-ANTIGEN; INFECTED PATIENTS; POLYMERASE GENE; C VIRUS; PREVALENCE; THERAPY; POPULATION; MUTATIONS; NIGERIA AB Immune pressure exerted on HBV by anti-HBV antibodies and long-term therapy with drugs that mutagenize the viral P gene can select for mutations in its S gene, leading to vaccine escape and evasion from serological detection. Although transmissibility of these mutants is poor and their evolution towards heightened virulence appears slow, the situation could change as vaccination coverage increases, and treatment of patients with chronic hepatitis B and those coinfected by HIV and HBV becomes widespread. Enhanced surveillance programmes to track changes in the genotype and phenotype of the mutants are needed. C1 [Teo, Chong-Gee] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA. [Locarnini, Stephen A.] Victorian Infect Dis Reference Lab, Melbourne, Vic, Australia. RP Teo, CG (reprint author), Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA. EM enz0@cdc.gov NR 41 TC 28 Z9 29 U1 0 U2 7 PU INT MEDICAL PRESS LTD PI LONDON PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND SN 1359-6535 J9 ANTIVIR THER JI Antivir. Ther. PY 2010 VL 15 IS 3 BP 445 EP 449 DI 10.3851/IMP1556 PN B PG 5 WC Infectious Diseases; Pharmacology & Pharmacy; Virology SC Infectious Diseases; Pharmacology & Pharmacy; Virology GA 629QS UT WOS:000280215400001 PM 20516564 ER PT J AU Kamili, S AF Kamili, Saleem TI Infectivity and vaccination efficacy studies in animal models of HBV S and pol gene mutants SO ANTIVIRAL THERAPY LA English DT Review ID HEPATITIS-B-VIRUS; INDUCED ESCAPE MUTANT; LAMIVUDINE-RESISTANT MUTANTS; LIVER-TRANSPLANT RECIPIENTS; IMMUNE GLOBULIN PROPHYLAXIS; PERIPHERAL-BLOOD LEUKOCYTES; SURFACE-ANTIGEN VARIANTS; ADEFOVIR DIPIVOXIL; POLYMERASE GENE; IN-VITRO AB Infectious HBV wild-type and mutant clones were produced in vitro with three mutations in pol (rtV173L plus rtL180M plus rtM204V) or with a single mutation in the S gene (sG145R) and inoculated in treatment-naive chimpanzees. Intravenous inoculation of these mutants in chimpanzees resulted in HBV infection; the pol mutations remained stable, whereas the sG145R mutation reverted to wild type during viraemia. Additional hepatitis B vaccine efficacy studies conducted in chimpanzees showed lack of sterilizing immunity against the pol mutant. Whether such mutants can transmit to and infect vaccinated humans requires further investigation. C1 Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP Kamili, S (reprint author), Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. EM skamili@cdc.gov NR 98 TC 6 Z9 6 U1 0 U2 3 PU INT MEDICAL PRESS LTD PI LONDON PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND SN 1359-6535 J9 ANTIVIR THER JI Antivir. Ther. PY 2010 VL 15 IS 3 BP 477 EP 485 DI 10.3851/IMP1520 PN B PG 9 WC Infectious Diseases; Pharmacology & Pharmacy; Virology SC Infectious Diseases; Pharmacology & Pharmacy; Virology GA 629QS UT WOS:000280215400005 PM 20516568 ER PT J AU Khudyakov, Y AF Khudyakov, Yury TI Coevolution and HBV drug resistance SO ANTIVIRAL THERAPY LA English DT Review ID HEPATITIS-B-VIRUS; REGULATORY T-CELLS; CLONAL INTERFERENCE; RNA VIRUSES; NATURAL-HISTORY; C VIRUS; SUPERINFECTION EXCLUSION; HEPADNAVIRUS INFECTION; MUTATIONAL ROBUSTNESS; LAMIVUDINE TREATMENT AB A high rate of mutation sets a strong foundation for the development of resistance to antiviral drugs. However, the ubiquitous presence of drug resistance mutations in the HBV population does not explain variations in the rate and specific types of drug resistance among patients. These variations can be explained by consideration of coevolution among individual sites in the HBV genome, viral variants and subpopulations, as well as coevolution between the entire intrahost HBV population and the host. The concept of coevolution offers a more complete framework for understanding drug resistance. C1 Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA. RP Khudyakov, Y (reprint author), Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA. EM yek0@CDC.gov NR 99 TC 18 Z9 19 U1 0 U2 3 PU INT MEDICAL PRESS LTD PI LONDON PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND SN 1359-6535 J9 ANTIVIR THER JI Antivir. Ther. PY 2010 VL 15 IS 3 BP 505 EP 515 DI 10.3851/IMP1515 PN B PG 11 WC Infectious Diseases; Pharmacology & Pharmacy; Virology SC Infectious Diseases; Pharmacology & Pharmacy; Virology GA 629QS UT WOS:000280215400009 PM 20516572 ER PT J AU Gubareva, LV Trujillo, AA Okomo-Adhiambo, M Mishin, VP Deyde, VM Sleeman, K Nguyen, HT Sheu, TG Garten, RJ Shaw, MW Fry, AM Klimov, AI AF Gubareva, Larisa V. Trujillo, A. Angelica Okomo-Adhiambo, Margaret Mishin, Vasiliy P. Deyde, Varough M. Sleeman, Katrina Nguyen, Ha T. Sheu, Tiffany G. Garten, Rebecca J. Shaw, Michael W. Fry, Alicia M. Klimov, Alexander I. TI Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro SO ANTIVIRAL THERAPY LA English DT Article ID H5N1 AVIAN INFLUENZA; NEURAMINIDASE INHIBITOR; AMANTADINE-RESISTANCE; ADAMANTANE RESISTANCE; ISOLATED WORLDWIDE; A(H1N1) VIRUSES; OSELTAMIVIR; PERAMIVIR; SURVEILLANCE; ZANAMIVIR AB Background: Antiviral drugs are an important option for managing infections caused by influenza viruses. This study assessed the drug susceptibility of 2009 pandemic influenza A (H1N1) viruses collected globally between April 2009 and January 2010. Methods: Virus isolates were tested for adamantane susceptibility, using pyrosequencing to detect the S31N marker of adamantane resistance in the M2 protein and biological assays to assess viral replication in cell culture. To assess neuraminidase (NA) inhibitor (NAI) susceptibility, virus isolates were tested in chemiluminescent NA inhibition assays and by pyrosequencing to detect the H275Y (H274Y in N2 numbering) marker of oseltamivir resistance in the NA. Results: With the exception of three, all viruses that were tested for adamantane susceptibility (n=3,362) were resistant to this class of drugs. All viruses tested for NAI susceptibility (n=3,359) were sensitive to two US Food and Drug Administration-approved NAIs, oseltamivir (mean +/- SD 50% inhibitory concentration (IC(50)] 0.25 +/- 0.12 nM) and zanamivir (mean IC(50) 0.29 +/- 0.09 nM), except 23 (0.7%), which were resistant to oseltamivir, but sensitive to zanamivir. Oseltamivir-resistant viruses had the H275Y mutation in their NA and were detected in patients exposed to the drug through prophylaxis or treatment. NA activity of all viruses was inhibited by the NAls peramivir, laninamivir (R-125489) and A-315675, except for H275Y variants, which exhibited approximately 100-fold reduction in peramivir susceptibility. Conclusions: This report provides data regarding antiviral susceptibility of 2009 pandemic influenza A (H1N1) surveillance viruses, the majority of which were resistant to adamantanes and sensitive to NAls. These findings provide information essential for antiviral resistance monitoring and development of novel diagnostic tests for detecting influenza antiviral resistance. C1 [Gubareva, Larisa V.; Trujillo, A. Angelica; Okomo-Adhiambo, Margaret; Mishin, Vasiliy P.; Deyde, Varough M.; Sleeman, Katrina; Nguyen, Ha T.; Sheu, Tiffany G.; Garten, Rebecca J.; Shaw, Michael W.; Fry, Alicia M.; Klimov, Alexander I.] Ctr Dis Control & Prevent, Virus Surveillance & Diag Branch, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Gubareva, LV (reprint author), Ctr Dis Control & Prevent, Virus Surveillance & Diag Branch, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM lgubareva@cdc.gov FU Atlanta Research and Education Foundation FX The findings and conclusions of this report are those of the authors and do not necessarily represent the views of the CDC. MO-A, HTN and VPM received financial support for this work from the Atlanta Research and Education Foundation. All other authors declare no competing interests. NR 54 TC 63 Z9 65 U1 0 U2 6 PU INT MEDICAL PRESS LTD PI LONDON PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND SN 1359-6535 J9 ANTIVIR THER JI Antivir. Ther. PY 2010 VL 15 IS 8 BP 1151 EP 1159 DI 10.3851/IMP1678 PG 9 WC Infectious Diseases; Pharmacology & Pharmacy; Virology SC Infectious Diseases; Pharmacology & Pharmacy; Virology GA 722KN UT WOS:000287431200010 PM 21149922 ER PT J AU Cong, M Youngpairoj, AS Zheng, Q Aung, W Mitchell, J Hanson, D Hendry, M Dobard, C Heneine, W Garcia-Lerma, JG AF Cong, M. Youngpairoj, A. S. Zheng, Q. Aung, W. Mitchell, J. Hanson, D. Hendry, M. Dobard, C. Heneine, W. Garcia-Lerma, J. G. TI Complete protection against rectal transmission of an emtricitabine (FTC) -resistant SHIV162p3(M184V) mutant by intermittent prophylaxis with Truvada SO ANTIVIRAL THERAPY LA English DT Meeting Abstract CT Workshop on International HIV and Hepatitis Virus Drug Resistance and Curative Strategies CY JUL 08-12, 2010 CL Dubrovnik, CROATIA SP Univ California, Sch Med C1 [Cong, M.; Youngpairoj, A. S.; Zheng, Q.; Aung, W.; Mitchell, J.; Hanson, D.; Hendry, M.; Dobard, C.; Heneine, W.; Garcia-Lerma, J. G.] Ctr Dis Control & Prevent, Branch Lab, Div HIV AIDS Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU INT MEDICAL PRESS LTD PI LONDON PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND SN 1359-6535 J9 ANTIVIR THER JI Antivir. Ther. PY 2010 VL 15 SU 2 BP A39 EP A39 PG 1 WC Infectious Diseases; Pharmacology & Pharmacy; Virology SC Infectious Diseases; Pharmacology & Pharmacy; Virology GA 722KO UT WOS:000287431300035 ER PT J AU Cong, M Youngpairoj, AS Zheng, Q Aung, W Mitchell, J Hanson, D Hendry, M Dobard, C Heneme, W Garcia-Lerma, JG AF Cong, M. Youngpairoj, A. S. Zheng, Q. Aung, W. Mitchell, J. Hanson, D. Hendry, M. Dobard, C. Heneme, W. Garcia-Lerma, J. G. TI Complete protection against rectal transmission of an emtricitabine (FTC)-resistant SHIV162p3(M184V) mutant by intermittent prophylaxis with Truvada SO ANTIVIRAL THERAPY LA English DT Meeting Abstract CT International HIV and Hepatitis Virus Drug Resistance and Curative Strategies Workshop CY JUN 08-12, 2010 CL Dubrovnik, CROATIA C1 [Cong, M.; Youngpairoj, A. S.; Zheng, Q.; Aung, W.; Mitchell, J.; Hanson, D.; Hendry, M.; Dobard, C.; Heneme, W.; Garcia-Lerma, J. G.] Ctr Dis Control & Prevent, Branch Lab, Div HIV AIDS Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU INT MEDICAL PRESS LTD PI LONDON PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND SN 1359-6535 J9 ANTIVIR THER JI Antivir. Ther. PY 2010 VL 15 IS 4 MA 31 BP A39 EP A39 PG 1 WC Infectious Diseases; Pharmacology & Pharmacy; Virology SC Infectious Diseases; Pharmacology & Pharmacy; Virology GA 629QW UT WOS:000280215800050 ER PT J AU Dobard, C Masciotra, S Lipscomb, J Youngpairoj, A Cong, M Sharma, S Johnson, JA Garcia-Lerma, JG Heneine, W AF Dobard, C. Masciotra, S. Lipscomb, J. Youngpairoj, A. Cong, M. Sharma, S. Johnson, J. A. Garcia-Lerma, J. G. Heneine, W. TI Assessing drug resistance emergence in a macaque model of antiretroviral pre-exposure prophylaxis SO ANTIVIRAL THERAPY LA English DT Meeting Abstract CT Workshop on International HIV and Hepatitis Virus Drug Resistance and Curative Strategies CY JUL 08-12, 2010 CL Dubrovnik, CROATIA SP Univ California, Sch Med C1 [Dobard, C.; Masciotra, S.; Lipscomb, J.; Youngpairoj, A.; Cong, M.; Sharma, S.; Johnson, J. A.; Garcia-Lerma, J. G.; Heneine, W.] CDC, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU INT MEDICAL PRESS LTD PI LONDON PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND SN 1359-6535 J9 ANTIVIR THER JI Antivir. Ther. PY 2010 VL 15 SU 2 BP A165 EP A165 PG 1 WC Infectious Diseases; Pharmacology & Pharmacy; Virology SC Infectious Diseases; Pharmacology & Pharmacy; Virology GA 722KO UT WOS:000287431300137 ER EF